1	Interferons	_	_	NNS	O	-1	none	_	_
2	induce	_	_	VBP	O	-1	none	_	_
3	normal	_	_	JJ	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	aberrant	_	_	JJ	O	-1	none	_	_
6	retinoic-acid	_	_	JJ	Protein	9	multitoken	_	_
7	receptors	_	_	NNS	Protein	9	multitoken	_	_
8	type	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	in	_	_	IN	O	-1	none	_	_
11	acute	_	_	JJ	O	-1	none	_	_
12	promyelocytic	_	_	JJ	O	-1	none	_	_
13	leukemia	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	:	_	_	:	O	-1	none	_	_
16	potentiation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	induction	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	retinoid	_	_	NN	O	-1	none	_	_
22	dependent	_	_	JJ	O	-1	none	_	_
23	differentiation	_	_	NN	O	-1	none	_	_
24	markers	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	acute	_	_	JJ	O	-1	none	_	_
5	promyelocytic	_	_	JJ	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	APL	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	line	_	_	NN	O	-1	none	_	_
11	NB4	_	_	NN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	interferon	_	_	NN	O	-1	none	_	_
14	alpha	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	IFN	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	alpha	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	as	_	_	RB	O	-1	none	_	_
23	well	_	_	RB	O	-1	none	_	_
24	as	_	_	IN	O	-1	none	_	_
25	IFN	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	beta	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	gamma	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	results	_	_	VBZ	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	an	_	_	DT	O	-1	none	_	_
35	increased	_	_	JJ	O	-1	none	_	_
36	expression	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	transcripts	_	_	NNS	O	-1	none	_	_
40	coding	_	_	VBG	O	-1	none	_	_
41	for	_	_	IN	O	-1	none	_	_
42	retinoic-acid	_	_	JJ	Protein	45	multitoken	_	_
43	receptor	_	_	NN	Protein	45	multitoken	_	_
44	type	_	_	NN	Protein	45	multitoken	_	_
45	alpha	_	_	NN	Protein	0	root	_	_
46	(	_	_	-LRB-	O	-1	none	_	_
47	RAR	_	_	NN	Protein	50	multitoken	_	_
48	(	_	_	-LRB-	Protein	50	multitoken	_	_
49	alpha	_	_	NN	Protein	50	multitoken	_	_
50	)	_	_	-RRB-	Protein	0	root	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	the	_	_	DT	O	-1	none	_	_
54	leukemia	_	_	NN	Protein	58	multitoken	_	_
55	specific	_	_	JJ	Protein	58	multitoken	_	_
56	retinoic	_	_	JJ	Protein	58	multitoken	_	_
57	acid	_	_	NN	Protein	58	multitoken	_	_
58	receptor	_	_	NN	Protein	0	root	_	_
59	PML-RAR	_	_	NN	Protein	-1	none	_	_
60	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	RAR	_	_	NN	Protein	8	multitoken	_	_
6	(	_	_	-LRB-	Protein	8	multitoken	_	_
7	alpha	_	_	NN	Protein	8	multitoken	_	_
8	)	_	_	-RRB-	Protein	0	root	_	_
9	and	_	_	CC	O	-1	none	_	_
10	PML-RAR	_	_	NN	Protein	-1	none	_	_
11	mRNAs	_	_	NNS	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	rapid	_	_	JJ	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	it	_	_	PRP	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	parallelled	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	increase	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	corresponding	_	_	JJ	O	-1	none	_	_
24	proteins	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Up-regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	RAR	_	_	NN	Protein	6	multitoken	_	_
4	(	_	_	-LRB-	Protein	6	multitoken	_	_
5	alpha	_	_	NN	Protein	6	multitoken	_	_
6	)	_	_	-RRB-	Protein	0	root	_	_
7	and	_	_	CC	O	-1	none	_	_
8	PML-RAR	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	IFN	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	alpha	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	accompanied	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	strong	_	_	JJ	O	-1	none	_	_
21	potentiation	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	induction	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	2	_	_	CD	O	-1	none	_	_
27	retinoid	_	_	NN	O	-1	none	_	_
28	dependent	_	_	JJ	O	-1	none	_	_
29	granulocytic	_	_	JJ	O	-1	none	_	_
30	markers	_	_	NNS	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	i.e.	_	_	FW	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	granulocyte-colony-stimulating	_	_	JJ	Protein	36	multitoken	_	_
35	factor	_	_	NN	Protein	36	multitoken	_	_
36	receptor	_	_	NN	Protein	0	root	_	_
37	mRNA	_	_	NN	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	leukocyte	_	_	NN	Protein	41	multitoken	_	_
40	alkaline	_	_	NN	Protein	41	multitoken	_	_
41	phosphatase	_	_	NN	Protein	0	root	_	_
42	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	IFN	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	alpha	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	does	_	_	VBZ	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	have	_	_	VB	O	-1	none	_	_
10	any	_	_	DT	O	-1	none	_	_
11	effects	_	_	NNS	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	retinoid	_	_	NN	O	-1	none	_	_
15	dependent	_	_	JJ	O	-1	none	_	_
16	regulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	myeloid	_	_	JJ	O	-1	none	_	_
20	surface	_	_	NN	O	-1	none	_	_
21	markers	_	_	NNS	O	-1	none	_	_
22	CD11b	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	CD33	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IFN	_	_	NN	O	-1	none	_	_
3	dependent	_	_	JJ	O	-1	none	_	_
4	increase	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	RAR	_	_	NN	Protein	9	multitoken	_	_
7	(	_	_	-LRB-	Protein	9	multitoken	_	_
8	alpha	_	_	NN	Protein	9	multitoken	_	_
9	)	_	_	-RRB-	Protein	0	root	_	_
10	levels	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	enhancing	_	_	JJ	O	-1	none	_	_
14	effect	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	cytokine	_	_	NN	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	retinoid	_	_	NN	O	-1	none	_	_
20	dependent	_	_	JJ	O	-1	none	_	_
21	granulocytic	_	_	JJ	O	-1	none	_	_
22	markers	_	_	NNS	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	may	_	_	MD	O	-1	none	_	_
25	be	_	_	VB	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	characteristic	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	PML-RAR	_	_	NN	Protein	-1	none	_	_
30	positive	_	_	JJ	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	since	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	phenomena	_	_	NNS	O	-1	none	_	_
36	are	_	_	VBP	O	-1	none	_	_
37	not	_	_	RB	O	-1	none	_	_
38	observed	_	_	VBN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	HL-60	_	_	NN	O	-1	none	_	_
41	promyelocytes	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Interferons	_	_	NNS	O	-1	none	_	_
2	as	_	_	RB	O	-1	none	_	_
3	well	_	_	RB	O	-1	none	_	_
4	as	_	_	IN	O	-1	none	_	_
5	retinoids	_	_	NNS	O	-1	none	_	_
6	inhibit	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	growth	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NB4	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	although	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	2	_	_	CD	O	-1	none	_	_
16	classes	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	compounds	_	_	NNS	O	-1	none	_	_
19	do	_	_	VBP	O	-1	none	_	_
20	not	_	_	RB	O	-1	none	_	_
21	significantly	_	_	RB	O	-1	none	_	_
22	interact	_	_	VBP	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	terms	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	anti-proliferative	_	_	JJ	O	-1	none	_	_
27	activity	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	possible	_	_	JJ	O	-1	none	_	_
6	use	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	combinations	_	_	NNS	O	-1	none	_	_
9	between	_	_	IN	O	-1	none	_	_
10	IFNs	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	retinoic	_	_	JJ	O	-1	none	_	_
13	acid	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	cyto	_	_	NN	O	-1	none	_	_
17	differentiating	_	_	VBG	O	-1	none	_	_
18	treatment	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	APL	_	_	NN	O	-1	none	_	_
21	patients	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Numerous	_	_	JJ	O	-1	none	_	_
2	cellular	_	_	JJ	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	biochemical	_	_	JJ	O	-1	none	_	_
5	abnormalities	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	immune	_	_	JJ	O	-1	none	_	_
8	regulation	_	_	NN	O	-1	none	_	_
9	have	_	_	VBP	O	-1	none	_	_
10	been	_	_	VBN	O	-1	none	_	_
11	described	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	patients	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	systemic	_	_	JJ	O	-1	none	_	_
16	lupus	_	_	NN	O	-1	none	_	_
17	erythematosus	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	SLE	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	including	_	_	VBG	O	-1	none	_	_
23	surface	_	_	NN	O	-1	none	_	_
24	Ag	_	_	NN	O	-1	none	_	_
25	receptor	_	_	NN	O	-1	none	_	_
26	initiated	_	_	VBN	O	-1	none	_	_
27	signaling	_	_	NN	O	-1	none	_	_
28	events	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	lymphokine	_	_	NN	O	-1	none	_	_
31	production	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	NF-kappa	_	_	NN	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	contributes	_	_	VBZ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	numerous	_	_	JJ	O	-1	none	_	_
10	inflammatory	_	_	JJ	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	has	_	_	VBZ	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	shown	_	_	VBN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	molecular	_	_	JJ	O	-1	none	_	_
20	target	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	antiinflammatory	_	_	JJ	O	-1	none	_	_
23	drugs	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	we	_	_	PRP	O	-1	none	_	_
26	sought	_	_	VBD	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	characterize	_	_	VB	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	functional	_	_	JJ	O	-1	none	_	_
31	role	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	NF-kappa	_	_	NN	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	protein	_	_	NN	O	-1	none	_	_
37	complex	_	_	NN	O	-1	none	_	_
38	in	_	_	IN	O	-1	none	_	_
39	lupus	_	_	NN	O	-1	none	_	_
40	T	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Freshly	_	_	RB	O	-1	none	_	_
2	isolated	_	_	VBN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	lupus	_	_	NN	O	-1	none	_	_
7	patients	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	rheumatoid	_	_	JJ	O	-1	none	_	_
10	arthritis	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	RA	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	patients	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	normal	_	_	JJ	O	-1	none	_	_
18	individuals	_	_	NNS	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	activated	_	_	VBN	O	-1	none	_	_
21	physiologically	_	_	RB	O	-1	none	_	_
22	via	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	TCR	_	_	NN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	anti-CD3	_	_	JJ	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	anti-CD28	_	_	JJ	Protein	-1	none	_	_
29	Abs	_	_	NNS	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	assess	_	_	VB	O	-1	none	_	_
32	proximal	_	_	JJ	O	-1	none	_	_
33	membrane	_	_	NN	O	-1	none	_	_
34	signaling	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	with	_	_	IN	O	-1	none	_	_
38	PMA	_	_	NN	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	a	_	_	DT	O	-1	none	_	_
41	calcium	_	_	NN	O	-1	none	_	_
42	ionophore	_	_	NN	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	A23187	_	_	NN	O	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	to	_	_	TO	O	-1	none	_	_
47	bypass	_	_	VB	O	-1	none	_	_
48	membrane	_	_	NN	O	-1	none	_	_
49	mediated	_	_	JJ	O	-1	none	_	_
50	signaling	_	_	NN	O	-1	none	_	_
51	events	_	_	NNS	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	measured	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	extracts	_	_	NNS	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	gel	_	_	NN	O	-1	none	_	_
13	shift	_	_	NN	O	-1	none	_	_
14	analysis	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	compared	_	_	VBN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	normal	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NF-kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	SLE	_	_	NN	O	-1	none	_	_
15	patients	_	_	NNS	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	significantly	_	_	RB	O	-1	none	_	_
18	decreased	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	SLE	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	but	_	_	CC	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	RA	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	patients	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	absent	_	_	JJ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	several	_	_	JJ	O	-1	none	_	_
9	SLE	_	_	NN	O	-1	none	_	_
10	patients	_	_	NNS	O	-1	none	_	_
11	who	_	_	WP	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	receiving	_	_	VBG	O	-1	none	_	_
15	any	_	_	DT	O	-1	none	_	_
16	medication	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	including	_	_	VBG	O	-1	none	_	_
19	corticosteroids	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Also	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	remained	_	_	VBD	O	-1	none	_	_
7	absent	_	_	JJ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	follow-up	_	_	JJ	O	-1	none	_	_
10	studies	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	supershift	_	_	NN	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	using	_	_	VBG	O	-1	none	_	_
5	specific	_	_	JJ	O	-1	none	_	_
6	Abs	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	group	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	SLE	_	_	NN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	who	_	_	WP	O	-1	none	_	_
19	displayed	_	_	VBD	O	-1	none	_	_
20	undetectable	_	_	JJ	O	-1	none	_	_
21	NF-kappa	_	_	NN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	p65	_	_	NN	Protein	-1	none	_	_
26	complexes	_	_	NNS	O	-1	none	_	_
27	were	_	_	VBD	O	-1	none	_	_
28	not	_	_	RB	O	-1	none	_	_
29	formed	_	_	VBN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	immunoblot	_	_	NN	O	-1	none	_	_
4	analysis	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	extracts	_	_	NNS	O	-1	none	_	_
8	showed	_	_	VBD	O	-1	none	_	_
9	decreased	_	_	VBN	O	-1	none	_	_
10	or	_	_	CC	O	-1	none	_	_
11	absent	_	_	JJ	O	-1	none	_	_
12	p65	_	_	NN	Protein	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	levels	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	p65	_	_	NN	Protein	-1	none	_	_
3	complexes	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	transcriptionally	_	_	RB	O	-1	none	_	_
6	active	_	_	JJ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	comparison	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	p50	_	_	NN	Protein	-1	none	_	_
12	homodimer	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	this	_	_	DT	O	-1	none	_	_
15	novel	_	_	JJ	O	-1	none	_	_
16	finding	_	_	NN	O	-1	none	_	_
17	may	_	_	MD	O	-1	none	_	_
18	provide	_	_	VB	O	-1	none	_	_
19	insight	_	_	NN	O	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	origin	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	abnormal	_	_	JJ	O	-1	none	_	_
25	cytokine	_	_	NN	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	other	_	_	JJ	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	SLE	_	_	NN	O	-1	none	_	_
32	patients	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	kinase	_	_	NN	O	-1	none	_	_
5	C	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	elevation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	cAMP	_	_	NN	O	-1	none	_	_
10	interact	_	_	VBP	O	-1	none	_	_
11	synergistically	_	_	RB	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	raise	_	_	VB	O	-1	none	_	_
14	c-Fos	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	AP-1	_	_	NN	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	Jurkat	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	earlier	_	_	RBR	O	-1	none	_	_
4	found	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	Jurkat	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	kinase	_	_	NN	O	-1	none	_	_
13	C	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	PKC	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	enhances	_	_	VBZ	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	cyclic	_	_	JJ	O	-1	none	_	_
20	adenosine	_	_	NN	O	-1	none	_	_
21	monophosphate	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	cAMP	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	accumulation	_	_	NN	O	-1	none	_	_
26	induced	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	adenosine	_	_	NN	O	-1	none	_	_
29	receptor	_	_	NN	O	-1	none	_	_
30	stimulation	_	_	NN	O	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	activation	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	Gs	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	therefore	_	_	RB	O	-1	none	_	_
5	examined	_	_	VBN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	effect	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	phorbol	_	_	NN	O	-1	none	_	_
11	ester	_	_	NN	O	-1	none	_	_
12	PMA	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	phorbol	_	_	NN	O	-1	none	_	_
15	12-myristate	_	_	NN	O	-1	none	_	_
16	13-acetate	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	stimulates	_	_	VBZ	O	-1	none	_	_
20	PKC	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	combination	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	adenosine	_	_	NN	O	-1	none	_	_
27	receptor	_	_	NN	O	-1	none	_	_
28	agonist	_	_	NN	O	-1	none	_	_
29	NECA	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	5	_	_	CD	O	-1	none	_	_
32	'-(	_	_	CD	O	-1	none	_	_
33	N-ethyl	_	_	NN	O	-1	none	_	_
34	)-carboxamido	_	_	JJ	O	-1	none	_	_
35	adenosine	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	forskolin	_	_	NN	O	-1	none	_	_
39	to	_	_	TO	O	-1	none	_	_
40	raise	_	_	VB	O	-1	none	_	_
41	cAMP	_	_	NN	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	on	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	levels	_	_	NNS	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	c-Fos	_	_	NN	Protein	-1	none	_	_
48	and	_	_	CC	O	-1	none	_	_
49	Jun	_	_	NN	Protein	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	on	_	_	IN	O	-1	none	_	_
52	the	_	_	DT	O	-1	none	_	_
53	binding	_	_	NN	O	-1	none	_	_
54	and	_	_	CC	O	-1	none	_	_
55	transcriptional	_	_	JJ	O	-1	none	_	_
56	activity	_	_	NN	O	-1	none	_	_
57	of	_	_	IN	O	-1	none	_	_
58	the	_	_	DT	O	-1	none	_	_
59	transcription	_	_	NN	O	-1	none	_	_
60	factor	_	_	NN	O	-1	none	_	_
61	,	_	_	,	O	-1	none	_	_
62	activator	_	_	NN	O	-1	none	_	_
63	protein-1	_	_	NN	O	-1	none	_	_
64	(	_	_	-LRB-	O	-1	none	_	_
65	AP-1	_	_	NN	O	-1	none	_	_
66	)	_	_	-RRB-	O	-1	none	_	_
67	.	_	_	.	O	-1	none	_	_

1	PMA	_	_	NN	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	caused	_	_	VBD	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	concentration-	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	time	_	_	NN	O	-1	none	_	_
8	dependent	_	_	JJ	O	-1	none	_	_
9	increase	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	c-Fos	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	Jun	_	_	NN	Protein	-1	none	_	_
15	immunoreactivity	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	contrast	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	cAMP	_	_	NN	O	-1	none	_	_
20	elevation	_	_	NN	O	-1	none	_	_
21	that	_	_	WDT	O	-1	none	_	_
22	had	_	_	VBD	O	-1	none	_	_
23	only	_	_	RB	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	slight	_	_	JJ	O	-1	none	_	_
26	effect	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	PMA	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	combination	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	NECA	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	forskolin	_	_	NN	O	-1	none	_	_
10	acted	_	_	VBD	O	-1	none	_	_
11	together	_	_	RB	O	-1	none	_	_
12	either	_	_	RB	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	increase	_	_	VB	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	c-Fos	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	decrease	_	_	VB	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	Jun	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	levels	_	_	NNS	O	-1	none	_	_
25	as	_	_	RB	O	-1	none	_	_
26	well	_	_	RB	O	-1	none	_	_
27	as	_	_	IN	O	-1	none	_	_
28	increasing	_	_	VBG	O	-1	none	_	_
29	AP-1	_	_	NN	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	as	_	_	IN	O	-1	none	_	_
33	judged	_	_	VBN	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	gel-shift	_	_	JJ	O	-1	none	_	_
36	assay	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	AP-1	_	_	NN	O	-1	none	_	_
40	transcriptional	_	_	JJ	O	-1	none	_	_
41	activity	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	there	_	_	EX	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	clear-cut	_	_	JJ	O	-1	none	_	_
6	synergy	_	_	NN	O	-1	none	_	_
7	between	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	PKC	_	_	NN	Protein	-1	none	_	_
10	stimulator	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	cAMP	_	_	NN	O	-1	none	_	_
14	elevating	_	_	VBG	O	-1	none	_	_
15	agents	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	simultaneous	_	_	JJ	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	PKC	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	elevation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	cAMP	_	_	NN	O	-1	none	_	_
14	leads	_	_	VBZ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	an	_	_	DT	O	-1	none	_	_
17	enhanced	_	_	JJ	O	-1	none	_	_
18	AP-1	_	_	NN	O	-1	none	_	_
19	transcriptional	_	_	JJ	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	T-leukemia	_	_	NN	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	line	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	suggesting	_	_	VBG	O	-1	none	_	_
28	that	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	previously	_	_	RB	O	-1	none	_	_
31	observed	_	_	VBN	O	-1	none	_	_
32	interaction	_	_	NN	O	-1	none	_	_
33	between	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	parallel	_	_	JJ	O	-1	none	_	_
36	signal	_	_	NN	O	-1	none	_	_
37	transduction	_	_	NN	O	-1	none	_	_
38	pathways	_	_	NNS	O	-1	none	_	_
39	may	_	_	MD	O	-1	none	_	_
40	have	_	_	VB	O	-1	none	_	_
41	functional	_	_	JJ	O	-1	none	_	_
42	consequences	_	_	NNS	O	-1	none	_	_
43	at	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	level	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	gene	_	_	NN	O	-1	none	_	_
48	transcription	_	_	NN	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	HMG-I	_	_	NNP	Protein	-1	none	_	_
2	binds	_	_	VBZ	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	GATA	_	_	NN	O	-1	none	_	_
5	motifs	_	_	NNS	O	-1	none	_	_
6	:	_	_	:	O	-1	none	_	_
7	implications	_	_	NNS	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	HPFH	_	_	NN	O	-1	none	_	_
11	syndrome	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	examined	_	_	VBN	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	HMG-I	_	_	NN	Protein	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	gamma-globin	_	_	NN	O	-1	none	_	_
14	promoter	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	find	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	HMG-I	_	_	NN	Protein	-1	none	_	_
5	binds	_	_	VBZ	O	-1	none	_	_
6	preferentially	_	_	RB	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	more	_	_	RBR	O	-1	none	_	_
10	3	_	_	CD	O	-1	none	_	_
11	'	_	_	''	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	pair	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	GATA	_	_	NN	O	-1	none	_	_
17	motifs	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	gamma-globin	_	_	NN	O	-1	none	_	_
21	promoter	_	_	NN	O	-1	none	_	_
22	;	_	_	:	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	paired	_	_	JJ	O	-1	none	_	_
25	motif	_	_	NN	O	-1	none	_	_
26	is	_	_	VBZ	O	-1	none	_	_
27	bound	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	erythroid	_	_	JJ	O	-1	none	_	_
31	factor	_	_	NN	O	-1	none	_	_
32	GATA-1	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	naturally	_	_	RB	O	-1	none	_	_
3	occurring	_	_	VBG	O	-1	none	_	_
4	mutation	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	-175	_	_	CD	O	-1	none	_	_
7	T-C	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	area	_	_	NN	O	-1	none	_	_
12	bound	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	HMG-I	_	_	NN	Protein	-1	none	_	_
15	results	_	_	VBZ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	overexpression	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	gamma-globin	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	adult	_	_	JJ	O	-1	none	_	_
22	red	_	_	JJ	O	-1	none	_	_
23	blood	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	HPFH	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	up-regulation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	gamma-globin	_	_	NN	O	-1	none	_	_
33	promoter	_	_	NN	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	in	_	_	FW	O	-1	none	_	_
36	vitro	_	_	FW	O	-1	none	_	_
37	expression	_	_	NN	O	-1	none	_	_
38	assays	_	_	NNS	O	-1	none	_	_
39	;	_	_	:	O	-1	none	_	_
40	HMG-I	_	_	NN	Protein	-1	none	_	_
41	does	_	_	VBZ	O	-1	none	_	_
42	not	_	_	RB	O	-1	none	_	_
43	bind	_	_	VB	O	-1	none	_	_
44	to	_	_	TO	O	-1	none	_	_
45	this	_	_	DT	O	-1	none	_	_
46	mutant	_	_	NN	O	-1	none	_	_
47	sequence	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	survey	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	GATA	_	_	NN	O	-1	none	_	_
5	motifs	_	_	NNS	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	other	_	_	JJ	O	-1	none	_	_
8	globin	_	_	NN	O	-1	none	_	_
9	cis-elements	_	_	NNS	O	-1	none	_	_
10	demonstrates	_	_	VBZ	O	-1	none	_	_
11	HMG-I	_	_	NN	Protein	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	most	_	_	JJS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	them	_	_	PRP	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	implicate	_	_	VBP	O	-1	none	_	_
4	HMG-I	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	HPFH	_	_	NN	O	-1	none	_	_
8	phenotype	_	_	NN	O	-1	none	_	_
9	;	_	_	:	O	-1	none	_	_
10	we	_	_	PRP	O	-1	none	_	_
11	speculate	_	_	VBP	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	it	_	_	PRP	O	-1	none	_	_
14	may	_	_	MD	O	-1	none	_	_
15	participate	_	_	VB	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	formation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	multiprotein	_	_	JJ	O	-1	none	_	_
21	complexes	_	_	NNS	O	-1	none	_	_
22	that	_	_	WDT	O	-1	none	_	_
23	regulate	_	_	VBP	O	-1	none	_	_
24	globin	_	_	NN	O	-1	none	_	_
25	gene	_	_	NN	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Preassociation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	STAT1	_	_	NN	Protein	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	STAT2	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	STAT3	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	separate	_	_	JJ	O	-1	none	_	_
10	signalling	_	_	NN	O	-1	none	_	_
11	complexes	_	_	NNS	O	-1	none	_	_
12	prior	_	_	RB	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	cytokine	_	_	NN	O	-1	none	_	_
15	stimulation	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	variety	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	cytokines	_	_	NNS	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	growth	_	_	NN	O	-1	none	_	_
7	factors	_	_	NNS	O	-1	none	_	_
8	act	_	_	VBP	O	-1	none	_	_
9	through	_	_	IN	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	mediated	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	family	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	latent	_	_	JJ	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	factors	_	_	NNS	O	-1	none	_	_
23	called	_	_	VBN	O	-1	none	_	_
24	STAT	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	signal	_	_	NN	O	-1	none	_	_
27	transducers	_	_	NNS	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	activators	_	_	NNS	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	transcription	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	proteins	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Ligand	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	tyrosine	_	_	NN	O	-1	none	_	_
4	phosphorylation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	STATs	_	_	NNS	O	-1	none	_	_
8	promotes	_	_	VBZ	O	-1	none	_	_
9	their	_	_	PRP$	O	-1	none	_	_
10	homodimer	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	heterodimer	_	_	NN	O	-1	none	_	_
13	formation	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	subsequent	_	_	JJ	O	-1	none	_	_
16	nuclear	_	_	JJ	O	-1	none	_	_
17	translocation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	STAT	_	_	NN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	heterocomplexes	_	_	NNS	O	-1	none	_	_
8	exist	_	_	VBP	O	-1	none	_	_
9	prior	_	_	RB	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	cytokine	_	_	NN	O	-1	none	_	_
12	treatment	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	unstimulated	_	_	JJ	O	-1	none	_	_
3	HeLa	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	ruptured	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	hypotonic	_	_	JJ	O	-1	none	_	_
9	buffer	_	_	NN	O	-1	none	_	_
10	without	_	_	IN	O	-1	none	_	_
11	salt	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	detergent	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	immunoadsorption	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	either	_	_	CC	O	-1	none	_	_
18	STAT1	_	_	NN	Protein	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	STAT2	_	_	NN	Protein	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	resulting	_	_	VBG	O	-1	none	_	_
24	cytosol	_	_	NN	O	-1	none	_	_
25	yields	_	_	NNS	O	-1	none	_	_
26	coimmunoadsorption	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	other	_	_	JJ	O	-1	none	_	_
30	STAT	_	_	NN	O	-1	none	_	_
31	protein	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	STAT1	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	STAT2	_	_	NN	Protein	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	STAT1	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	STAT3	_	_	NN	Protein	-1	none	_	_
8	translated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	reticulocyte	_	_	NN	O	-1	none	_	_
11	lysate	_	_	NN	O	-1	none	_	_
12	spontaneously	_	_	RB	O	-1	none	_	_
13	form	_	_	VBP	O	-1	none	_	_
14	heterocomplexes	_	_	NNS	O	-1	none	_	_
15	when	_	_	WRB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	translation	_	_	NN	O	-1	none	_	_
18	lysates	_	_	NNS	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	mixed	_	_	VBN	O	-1	none	_	_
21	at	_	_	IN	O	-1	none	_	_
22	0	_	_	CD	O	-1	none	_	_
23	degrees	_	_	NNS	O	-1	none	_	_
24	C	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Newly	_	_	RB	O	-1	none	_	_
2	translated	_	_	VBN	O	-1	none	_	_
3	STAT1	_	_	NN	Protein	-1	none	_	_
4	binds	_	_	VBZ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	equilibrium	_	_	NN	O	-1	none	_	_
7	fashion	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	STAT2	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	STAT3	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	show	_	_	VBP	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	STAT2	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	STAT3	_	_	NN	Protein	-1	none	_	_
20	exist	_	_	VBP	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	separate	_	_	JJ	O	-1	none	_	_
23	heterocomplexes	_	_	NNS	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	STAT1	_	_	NN	Protein	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	consistent	_	_	JJ	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	model	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	which	_	_	WDT	O	-1	none	_	_
33	STAT1	_	_	NN	Protein	-1	none	_	_
34	contains	_	_	VBZ	O	-1	none	_	_
35	a	_	_	DT	O	-1	none	_	_
36	common	_	_	JJ	O	-1	none	_	_
37	binding	_	_	NN	O	-1	none	_	_
38	site	_	_	NN	O	-1	none	_	_
39	for	_	_	IN	O	-1	none	_	_
40	other	_	_	JJ	O	-1	none	_	_
41	STAT	_	_	NN	O	-1	none	_	_
42	proteins	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Signal	_	_	NN	O	-1	none	_	_
2	transduction	_	_	NN	O	-1	none	_	_
3	abnormalities	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	patients	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	advanced	_	_	JJ	O	-1	none	_	_
11	renal	_	_	JJ	O	-1	none	_	_
12	carcinoma	_	_	NN	O	-1	none	_	_
13	:	_	_	:	O	-1	none	_	_
14	clinical	_	_	JJ	O	-1	none	_	_
15	relevance	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	effects	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	cytokine	_	_	NN	O	-1	none	_	_
20	therapy	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Studies	_	_	NNS	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	demonstrated	_	_	VBN	O	-1	none	_	_
4	abnormalities	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	CD3	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	T-cell	_	_	NN	O	-1	none	_	_
10	antigen	_	_	NN	O	-1	none	_	_
11	receptor	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	TCR	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	pathways	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	signal	_	_	NN	O	-1	none	_	_
19	transduction	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	from	_	_	IN	O	-1	none	_	_
24	animals	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	patients	_	_	NNS	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	advanced	_	_	JJ	O	-1	none	_	_
29	malignancy	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Diminished	_	_	VBN	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TCRzeta	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	p56	_	_	NN	Protein	9	multitoken	_	_
7	(	_	_	-LRB-	Protein	9	multitoken	_	_
8	lck	_	_	NN	Protein	9	multitoken	_	_
9	)	_	_	-RRB-	Protein	0	root	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	associated	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	TCR	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	reduced	_	_	VBD	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	localization	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	RelA	_	_	NN	Protein	-1	none	_	_
22	containing	_	_	VBG	O	-1	none	_	_
23	nuclear	_	_	JJ	O	-1	none	_	_
24	factor	_	_	NN	O	-1	none	_	_
25	kappaB	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	NFkappaB	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	complexes	_	_	NNS	O	-1	none	_	_
30	have	_	_	VBP	O	-1	none	_	_
31	been	_	_	VBN	O	-1	none	_	_
32	noted	_	_	VBN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	defects	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	described	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	patients	_	_	NNS	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	malignant	_	_	JJ	O	-1	none	_	_
13	melanoma	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	renal	_	_	JJ	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	carcinoma	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	RCC	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	ovarian	_	_	JJ	O	-1	none	_	_
23	cancer	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	colorectal	_	_	JJ	O	-1	none	_	_
27	cancer	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Preliminary	_	_	JJ	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	indicate	_	_	VBP	O	-1	none	_	_
5	possible	_	_	JJ	O	-1	none	_	_
6	correlation	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	clinical	_	_	JJ	O	-1	none	_	_
9	variables	_	_	NNS	O	-1	none	_	_
10	such	_	_	JJ	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	stage	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	selected	_	_	VBN	O	-1	none	_	_
15	instances	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	29	_	_	CD	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	patients	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	levels	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	TCRzeta	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p56	_	_	NN	Protein	14	multitoken	_	_
12	(	_	_	-LRB-	Protein	14	multitoken	_	_
13	lck	_	_	NN	Protein	14	multitoken	_	_
14	)	_	_	-RRB-	Protein	0	root	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	determined	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	Western	_	_	NN	O	-1	none	_	_
19	blots	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	T-cell	_	_	NN	O	-1	none	_	_
22	lysates	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	semiquantitated	_	_	VBN	O	-1	none	_	_
25	using	_	_	VBG	O	-1	none	_	_
26	densitometry	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Relative	_	_	JJ	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	then	_	_	RB	O	-1	none	_	_
5	correlated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	series	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	clinical	_	_	JJ	O	-1	none	_	_
11	variables	_	_	NNS	O	-1	none	_	_
12	including	_	_	VBG	O	-1	none	_	_
13	response	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	therapy	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	performance	_	_	NN	O	-1	none	_	_
18	status	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	survival	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	disease	_	_	NN	O	-1	none	_	_
23	sites	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	age	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	others	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	another	_	_	DT	O	-1	none	_	_
3	group	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	28	_	_	CD	O	-1	none	_	_
6	patients	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	three	_	_	CD	O	-1	none	_	_
9	individuals	_	_	NNS	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	first	_	_	JJ	O	-1	none	_	_
13	group	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	frequency	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	abnormal	_	_	JJ	O	-1	none	_	_
20	NFkappaB	_	_	NN	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	studied	_	_	VBN	O	-1	none	_	_
24	using	_	_	VBG	O	-1	none	_	_
25	electrophoretic	_	_	JJ	O	-1	none	_	_
26	mobility	_	_	NN	O	-1	none	_	_
27	shift	_	_	NN	O	-1	none	_	_
28	assays	_	_	NNS	O	-1	none	_	_
29	after	_	_	IN	O	-1	none	_	_
30	activation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	phorbol	_	_	NN	O	-1	none	_	_
36	myristate	_	_	NN	O	-1	none	_	_
37	acetate	_	_	NN	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	ionomycin	_	_	NN	O	-1	none	_	_
40	or	_	_	CC	O	-1	none	_	_
41	anti-CD3	_	_	JJ	O	-1	none	_	_
42	monoclonal	_	_	JJ	O	-1	none	_	_
43	antibody	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Changes	_	_	NNS	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	signaling	_	_	VBG	O	-1	none	_	_
5	molecules	_	_	NNS	O	-1	none	_	_
6	during	_	_	IN	O	-1	none	_	_
7	cytokine	_	_	NN	O	-1	none	_	_
8	treatment	_	_	NN	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	investigated	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	TCRzeta	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	p56	_	_	NN	Protein	6	multitoken	_	_
4	(	_	_	-LRB-	Protein	6	multitoken	_	_
5	lck	_	_	NN	Protein	6	multitoken	_	_
6	)	_	_	-RRB-	Protein	0	root	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	detected	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	peripheral	_	_	JJ	O	-1	none	_	_
12	blood	_	_	NN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	27	_	_	CD	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	29	_	_	CD	O	-1	none	_	_
19	patients	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	overall	_	_	RB	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	reduced	_	_	VBN	O	-1	none	_	_
25	levels	_	_	NNS	O	-1	none	_	_
26	were	_	_	VBD	O	-1	none	_	_
27	noted	_	_	VBN	O	-1	none	_	_
28	visually	_	_	RB	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	12	_	_	CD	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	29	_	_	CD	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	41	_	_	CD	O	-1	none	_	_
35	%	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	13	_	_	CD	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	29	_	_	CD	O	-1	none	_	_
41	(	_	_	-LRB-	O	-1	none	_	_
42	45	_	_	CD	O	-1	none	_	_
43	%	_	_	NN	O	-1	none	_	_
44	)	_	_	-RRB-	O	-1	none	_	_
45	individuals	_	_	NNS	O	-1	none	_	_
46	,	_	_	,	O	-1	none	_	_
47	respectively	_	_	RB	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	semiquantitated	_	_	VBN	O	-1	none	_	_
5	using	_	_	VBG	O	-1	none	_	_
6	densitometry	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	significant	_	_	JJ	O	-1	none	_	_
9	decreases	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	TCRzeta	_	_	NN	Protein	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	P	_	_	NN	O	-1	none	_	_
14	=	_	_	JJ	O	-1	none	_	_
15	0.029	_	_	CD	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	p56	_	_	NN	Protein	21	multitoken	_	_
19	(	_	_	-LRB-	Protein	21	multitoken	_	_
20	lck	_	_	NN	Protein	21	multitoken	_	_
21	)	_	_	-RRB-	Protein	0	root	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	P	_	_	NN	O	-1	none	_	_
24	=	_	_	JJ	O	-1	none	_	_
25	0.029	_	_	CD	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	but	_	_	CC	O	-1	none	_	_
28	not	_	_	RB	O	-1	none	_	_
29	CD3epsilon	_	_	NN	Protein	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	P	_	_	NN	O	-1	none	_	_
32	=	_	_	JJ	O	-1	none	_	_
33	0.131	_	_	CD	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	compared	_	_	VBN	O	-1	none	_	_
37	with	_	_	IN	O	-1	none	_	_
38	control	_	_	NN	O	-1	none	_	_
39	levels	_	_	NNS	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	were	_	_	VBD	O	-1	none	_	_
42	found	_	_	VBN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	patients	_	_	NNS	O	-1	none	_	_
3	treated	_	_	VBN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IFN	_	_	NN	Protein	8	multitoken	_	_
8	alpha	_	_	NN	Protein	0	root	_	_
9	based	_	_	VBN	O	-1	none	_	_
10	therapy	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	relative	_	_	JJ	O	-1	none	_	_
13	levels	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	TCRzeta	_	_	NN	Protein	-1	none	_	_
16	increased	_	_	VBD	O	-1	none	_	_
17	significantly	_	_	RB	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	P	_	_	NN	O	-1	none	_	_
20	=	_	_	JJ	O	-1	none	_	_
21	0.002	_	_	CD	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	day	_	_	NN	O	-1	none	_	_
25	15	_	_	CD	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	cycle	_	_	NN	O	-1	none	_	_
28	one	_	_	CD	O	-1	none	_	_
29	compared	_	_	VBN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	baseline	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Correlations	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	TCRzeta	_	_	NN	Protein	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	p56	_	_	NN	Protein	8	multitoken	_	_
6	(	_	_	-LRB-	Protein	8	multitoken	_	_
7	lck	_	_	NN	Protein	8	multitoken	_	_
8	)	_	_	-RRB-	Protein	0	root	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	disease	_	_	NN	O	-1	none	_	_
14	variables	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	except	_	_	IN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	lower	_	_	JJR	O	-1	none	_	_
19	TCRzeta	_	_	NN	Protein	-1	none	_	_
20	levels	_	_	NNS	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	P	_	_	NN	O	-1	none	_	_
23	<	_	_	JJR	O	-1	none	_	_
24	0.001	_	_	CD	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	presence	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	bone	_	_	NN	O	-1	none	_	_
31	metastases	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	not	_	_	RB	O	-1	none	_	_
35	found	_	_	VBN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Abnormal	_	_	JJ	O	-1	none	_	_
2	NFkappaB	_	_	NN	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	after	_	_	IN	O	-1	none	_	_
5	stimulation	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	phorbol	_	_	NN	O	-1	none	_	_
8	myristate	_	_	NN	O	-1	none	_	_
9	acetate	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	ionomycin	_	_	NN	O	-1	none	_	_
12	and/or	_	_	CC	O	-1	none	_	_
13	anti-CD3	_	_	JJ	O	-1	none	_	_
14	monoclonal	_	_	JJ	O	-1	none	_	_
15	antibody	_	_	NN	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	found	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	59	_	_	CD	O	-1	none	_	_
20	%	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	patients	_	_	NNS	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	17	_	_	CD	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	28	_	_	CD	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	was	_	_	VBD	O	-1	none	_	_
30	not	_	_	RB	O	-1	none	_	_
31	accounted	_	_	VBN	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	advanced	_	_	JJ	O	-1	none	_	_
36	age	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	study	_	_	NN	O	-1	none	_	_
40	cohort	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NFkappaB	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	peripheral	_	_	JJ	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	inducible	_	_	JJ	O	-1	none	_	_
11	during	_	_	IN	O	-1	none	_	_
12	cytokine	_	_	NN	O	-1	none	_	_
13	therapy	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	four	_	_	CD	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	six	_	_	CD	O	-1	none	_	_
18	individuals	_	_	NNS	O	-1	none	_	_
19	who	_	_	WP	O	-1	none	_	_
20	displayed	_	_	VBD	O	-1	none	_	_
21	impaired	_	_	JJ	O	-1	none	_	_
22	NFkappaB	_	_	NN	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	prior	_	_	RB	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	therapy	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	impaired	_	_	JJ	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	NFkappaB	_	_	NN	O	-1	none	_	_
7	does	_	_	VBZ	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	appear	_	_	VB	O	-1	none	_	_
10	linked	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	reduction	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	TCRzeta	_	_	NN	Protein	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	because	_	_	IN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	five	_	_	CD	O	-1	none	_	_
21	patients	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	normal	_	_	JJ	O	-1	none	_	_
24	TCRzeta	_	_	NN	Protein	-1	none	_	_
25	levels	_	_	NNS	O	-1	none	_	_
26	were	_	_	VBD	O	-1	none	_	_
27	present	_	_	JJ	O	-1	none	_	_
28	although	_	_	IN	O	-1	none	_	_
29	kappaB	_	_	NN	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	was	_	_	VBD	O	-1	none	_	_
32	not	_	_	RB	O	-1	none	_	_
33	inducible	_	_	JJ	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	majority	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	patients	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	advanced	_	_	JJ	O	-1	none	_	_
8	RCC	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	peripheral	_	_	JJ	O	-1	none	_	_
11	blood	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	express	_	_	VBP	O	-1	none	_	_
15	TCRzeta	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	p56	_	_	NN	Protein	20	multitoken	_	_
18	(	_	_	-LRB-	Protein	20	multitoken	_	_
19	lck	_	_	NN	Protein	20	multitoken	_	_
20	)	_	_	-RRB-	Protein	0	root	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	subset	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	reduced	_	_	VBN	O	-1	none	_	_
28	levels	_	_	NNS	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	these	_	_	DT	O	-1	none	_	_
31	TCRzeta	_	_	NN	Protein	-1	none	_	_
32	associated	_	_	VBN	O	-1	none	_	_
33	molecules	_	_	NNS	O	-1	none	_	_
34	are	_	_	VBP	O	-1	none	_	_
35	seen	_	_	VBN	O	-1	none	_	_
36	that	_	_	IN	O	-1	none	_	_
37	may	_	_	MD	O	-1	none	_	_
38	increase	_	_	VB	O	-1	none	_	_
39	during	_	_	IN	O	-1	none	_	_
40	cytokine	_	_	NN	O	-1	none	_	_
41	based	_	_	VBN	O	-1	none	_	_
42	therapy	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Abnormal	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NFkappaB	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	present	_	_	JJ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	>	_	_	JJR	O	-1	none	_	_
10	50	_	_	CD	O	-1	none	_	_
11	%	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	patients	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	also	_	_	RB	O	-1	none	_	_
17	revert	_	_	VB	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	normal	_	_	JJ	O	-1	none	_	_
20	during	_	_	IN	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	IFN	_	_	NN	Protein	24	multitoken	_	_
24	alpha	_	_	NN	Protein	0	root	_	_
25	based	_	_	VBN	O	-1	none	_	_
26	treatment	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	alteration	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	NFkappaB	_	_	NN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	occurred	_	_	VBD	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	presence	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	normal	_	_	JJ	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	TCRzeta	_	_	NN	Protein	-1	none	_	_
15	associated	_	_	JJ	O	-1	none	_	_
16	signaling	_	_	NN	O	-1	none	_	_
17	elements	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	clinical	_	_	JJ	O	-1	none	_	_
3	significance	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	these	_	_	DT	O	-1	none	_	_
6	findings	_	_	NNS	O	-1	none	_	_
7	remains	_	_	VBZ	O	-1	none	_	_
8	unclear	_	_	JJ	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	retinoblastoma	_	_	NN	O	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	product	_	_	NN	O	-1	none	_	_
5	negatively	_	_	RB	O	-1	none	_	_
6	regulates	_	_	VBZ	O	-1	none	_	_
7	transcriptional	_	_	JJ	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	mediated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	cytomegalovirus	_	_	NN	O	-1	none	_	_
14	IE2	_	_	NN	Protein	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IE2	_	_	NN	Protein	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	product	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	cytomegalovirus	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	HCMV	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	one	_	_	CD	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	few	_	_	JJ	O	-1	none	_	_
16	viral	_	_	JJ	O	-1	none	_	_
17	regulatory	_	_	JJ	O	-1	none	_	_
18	proteins	_	_	NNS	O	-1	none	_	_
19	expressed	_	_	VBD	O	-1	none	_	_
20	immediately	_	_	RB	O	-1	none	_	_
21	upon	_	_	IN	O	-1	none	_	_
22	infection	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	host	_	_	NN	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	potent	_	_	JJ	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	activator	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	many	_	_	JJ	O	-1	none	_	_
9	viral	_	_	JJ	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	cellular	_	_	JJ	O	-1	none	_	_
12	promoters	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	found	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	retinoblastoma	_	_	NN	O	-1	none	_	_
6	susceptibility	_	_	NN	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	product	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	Rb	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	dramatically	_	_	RB	O	-1	none	_	_
13	suppressed	_	_	VBD	O	-1	none	_	_
14	this	_	_	DT	O	-1	none	_	_
15	IE2	_	_	NN	Protein	-1	none	_	_
16	transactivation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	various	_	_	JJ	O	-1	none	_	_
19	promoters	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	unlike	_	_	IN	O	-1	none	_	_
4	another	_	_	DT	O	-1	none	_	_
5	tumor	_	_	NN	O	-1	none	_	_
6	suppressor	_	_	NN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	p53	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	Rb	_	_	NN	Protein	-1	none	_	_
12	did	_	_	VBD	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	have	_	_	VB	O	-1	none	_	_
15	any	_	_	DT	O	-1	none	_	_
16	significant	_	_	JJ	O	-1	none	_	_
17	effect	_	_	NN	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	basal	_	_	JJ	O	-1	none	_	_
20	levels	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	suggesting	_	_	VBG	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	Rb	_	_	NN	Protein	-1	none	_	_
27	specifically	_	_	RB	O	-1	none	_	_
28	interacts	_	_	VBZ	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	IE2	_	_	NN	Protein	-1	none	_	_
31	rather	_	_	RB	O	-1	none	_	_
32	than	_	_	IN	O	-1	none	_	_
33	other	_	_	JJ	O	-1	none	_	_
34	cellular	_	_	JJ	O	-1	none	_	_
35	factors	_	_	NNS	O	-1	none	_	_
36	involved	_	_	VBN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	general	_	_	JJ	O	-1	none	_	_
40	transcription	_	_	NN	O	-1	none	_	_
41	machinery	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	found	_	_	VBD	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	protein-affinity	_	_	JJ	O	-1	none	_	_
5	chromatography	_	_	NN	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	Rb	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	extracts	_	_	NNS	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	produced	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	in	_	_	FW	O	-1	none	_	_
15	vitro	_	_	FW	O	-1	none	_	_
16	translation	_	_	NN	O	-1	none	_	_
17	directly	_	_	RB	O	-1	none	_	_
18	bound	_	_	VBD	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	IE2	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Rb	_	_	NN	Protein	-1	none	_	_
6	may	_	_	MD	O	-1	none	_	_
7	regulate	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	life	_	_	NN	O	-1	none	_	_
10	cycle	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	HCMV	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	endemic	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	population	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	data	_	_	NNS	O	-1	none	_	_
5	may	_	_	MD	O	-1	none	_	_
6	provide	_	_	VB	O	-1	none	_	_
7	new	_	_	JJ	O	-1	none	_	_
8	insights	_	_	NNS	O	-1	none	_	_
9	into	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	slow	_	_	JJ	O	-1	none	_	_
12	rate	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	HCMV	_	_	NN	O	-1	none	_	_
15	DNA	_	_	NN	O	-1	none	_	_
16	replication	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	possible	_	_	JJ	O	-1	none	_	_
22	involvement	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	HCMV	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	tumorigenesis	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Overproduction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NFKB2	_	_	NN	Protein	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	lyt-10	_	_	NN	Protein	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	c-Rel	_	_	NN	Protein	-1	none	_	_
9	:	_	_	:	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	mechanism	_	_	NN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	HTLV-I	_	_	NN	O	-1	none	_	_
14	Tax	_	_	NN	Protein	-1	none	_	_
15	mediated	_	_	VBD	O	-1	none	_	_
16	trans-activation	_	_	NN	O	-1	none	_	_
17	via	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	signalling	_	_	NN	O	-1	none	_	_
22	pathway	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Molecular	_	_	JJ	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	biochemical	_	_	JJ	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	epidemiological	_	_	JJ	O	-1	none	_	_
6	evidence	_	_	NN	O	-1	none	_	_
7	implicate	_	_	VBP	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	etiologic	_	_	JJ	O	-1	none	_	_
12	agent	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	adult	_	_	JJ	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	ATL	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Tax	_	_	NN	Protein	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	HTLV-I	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	positive	_	_	JJ	O	-1	none	_	_
9	transcriptional	_	_	JJ	O	-1	none	_	_
10	activator	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	HTLV-I	_	_	NN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	viral	_	_	JJ	O	-1	none	_	_
19	oncogene	_	_	NN	O	-1	none	_	_
20	that	_	_	WDT	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	increases	_	_	VBZ	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	cellular	_	_	JJ	O	-1	none	_	_
26	genes	_	_	NNS	O	-1	none	_	_
27	including	_	_	VBG	O	-1	none	_	_
28	GM-CSF	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	IL-2R	_	_	NN	Protein	31	multitoken	_	_
31	alpha	_	_	NN	Protein	0	root	_	_
32	and	_	_	CC	O	-1	none	_	_
33	IL-2	_	_	NN	Protein	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	cellular	_	_	JJ	O	-1	none	_	_
5	targets	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	trans-activating	_	_	JJ	O	-1	none	_	_
9	effects	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Tax	_	_	NN	Protein	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	NF-kappa	_	_	NN	O	-1	none	_	_
15	B/Rel	_	_	NN	O	-1	none	_	_
16	family	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factors	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	pleiotropic	_	_	JJ	O	-1	none	_	_
22	regulators	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	immunoregulatory	_	_	JJ	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	cytokine	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	viral	_	_	JJ	O	-1	none	_	_
29	gene	_	_	NN	O	-1	none	_	_
30	expression	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	report	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	demonstrate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	NFKB2	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	lyt-10	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	c-Rel	_	_	NN	Protein	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	overexpressed	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	HTLV-I	_	_	NN	O	-1	none	_	_
18	infected	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	Tax	_	_	NN	Protein	-1	none	_	_
21	expressing	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	together	_	_	RB	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	account	_	_	NN	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	majority	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	constitutive	_	_	JJ	O	-1	none	_	_
34	NF-kappa	_	_	NN	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	binding	_	_	NN	O	-1	none	_	_
37	activity	_	_	NN	O	-1	none	_	_
38	in	_	_	IN	O	-1	none	_	_
39	these	_	_	DT	O	-1	none	_	_
40	cells	_	_	NNS	O	-1	none	_	_
41	before	_	_	IN	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	after	_	_	IN	O	-1	none	_	_
44	PMA	_	_	NN	O	-1	none	_	_
45	stimulation	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Most	_	_	RBS	O	-1	none	_	_
2	importantly	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	show	_	_	VBP	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	Tax	_	_	NN	Protein	-1	none	_	_
8	dependent	_	_	JJ	O	-1	none	_	_
9	correlation	_	_	NN	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NFKB2	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	p100	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	processing	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	DNA	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	NFKB2	_	_	NN	Protein	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	p52	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	form	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	induction	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	c-Rel	_	_	NN	Protein	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	trans-activation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	NF-kappa	_	_	NN	O	-1	none	_	_
37	B	_	_	NN	O	-1	none	_	_
38	mediated	_	_	VBN	O	-1	none	_	_
39	gene	_	_	NN	O	-1	none	_	_
40	expression	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NFKB2	_	_	NN	Protein	5	multitoken	_	_
5	precursor	_	_	NN	Protein	0	root	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	physically	_	_	RB	O	-1	none	_	_
8	associated	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	c-Rel	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	Tax	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	HTLV-I	_	_	NN	O	-1	none	_	_
16	infected	_	_	JJ	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	NFKB2	_	_	NN	Protein	-1	none	_	_
5	synthesis	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	processing	_	_	NN	O	-1	none	_	_
8	allows	_	_	VBZ	O	-1	none	_	_
9	continuous	_	_	JJ	O	-1	none	_	_
10	nuclear	_	_	JJ	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	otherwise	_	_	RB	O	-1	none	_	_
15	cytoplasmic	_	_	JJ	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	conjunction	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	overexpression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	c-Rel	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	NFKB2	_	_	NN	Protein	-1	none	_	_
27	alters	_	_	VBZ	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	NF-kappa	_	_	NN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	signalling	_	_	NN	O	-1	none	_	_
32	pathway	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	contributes	_	_	VBZ	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	leukemic	_	_	JJ	O	-1	none	_	_
37	transformation	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	T	_	_	NN	O	-1	none	_	_
40	cells	_	_	NNS	O	-1	none	_	_
41	by	_	_	IN	O	-1	none	_	_
42	HTLV-I	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	controls	_	_	VBZ	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	inhibitor	_	_	NN	O	-1	none	_	_
7	I	_	_	NN	Protein	10	multitoken	_	_
8	kappa	_	_	NN	Protein	10	multitoken	_	_
9	B	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	:	_	_	:	O	-1	none	_	_
12	evidence	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	inducible	_	_	JJ	O	-1	none	_	_
16	autoregulatory	_	_	JJ	O	-1	none	_	_
17	pathway	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	eukaryotic	_	_	JJ	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factor	_	_	NN	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	factor-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	participates	_	_	VBZ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	many	_	_	JJ	O	-1	none	_	_
15	parts	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	genetic	_	_	JJ	O	-1	none	_	_
19	program	_	_	NN	O	-1	none	_	_
20	mediating	_	_	VBG	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	lymphocyte	_	_	NN	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	growth	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	occurs	_	_	VBZ	O	-1	none	_	_
7	after	_	_	IN	O	-1	none	_	_
8	its	_	_	PRP$	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	dissociation	_	_	NN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	its	_	_	PRP$	O	-1	none	_	_
13	cytoplasmic	_	_	JJ	O	-1	none	_	_
14	inhibitor	_	_	NN	O	-1	none	_	_
15	I	_	_	NN	Protein	18	multitoken	_	_
16	kappa	_	_	NN	Protein	18	multitoken	_	_
17	B	_	_	NN	Protein	18	multitoken	_	_
18	alpha	_	_	NN	Protein	0	root	_	_
19	.	_	_	.	O	-1	none	_	_

1	Phorbol	_	_	NN	O	-1	none	_	_
2	ester	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	tumor	_	_	NN	Protein	6	multitoken	_	_
5	necrosis	_	_	NN	Protein	6	multitoken	_	_
6	factor-alpha	_	_	NN	Protein	0	root	_	_
7	induction	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	NF-kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	associated	_	_	VBN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	both	_	_	CC	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	degradation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	performed	_	_	VBN	O	-1	none	_	_
20	I	_	_	NN	Protein	23	multitoken	_	_
21	kappa	_	_	NN	Protein	23	multitoken	_	_
22	B	_	_	NN	Protein	23	multitoken	_	_
23	alpha	_	_	NN	Protein	0	root	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	I	_	_	NN	Protein	31	multitoken	_	_
29	kappa	_	_	NN	Protein	31	multitoken	_	_
30	B	_	_	NN	Protein	31	multitoken	_	_
31	alpha	_	_	NN	Protein	0	root	_	_
32	gene	_	_	NN	O	-1	none	_	_
33	expression	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Transfection	_	_	NN	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	I	_	_	NN	Protein	9	multitoken	_	_
7	kappa	_	_	NN	Protein	9	multitoken	_	_
8	B	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	specifically	_	_	RB	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	65-kilodalton	_	_	JJ	O	-1	none	_	_
17	transactivating	_	_	NN	O	-1	none	_	_
18	subunit	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	NF-kappa	_	_	NN	O	-1	none	_	_
21	B.	_	_	NNP	O	-1	none	_	_
22	Association	_	_	NNP	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	newly	_	_	RB	O	-1	none	_	_
26	synthesized	_	_	VBN	O	-1	none	_	_
27	I	_	_	NN	Protein	30	multitoken	_	_
28	kappa	_	_	NN	Protein	30	multitoken	_	_
29	B	_	_	NN	Protein	30	multitoken	_	_
30	alpha	_	_	NN	Protein	0	root	_	_
31	with	_	_	IN	O	-1	none	_	_
32	p65	_	_	NN	Protein	-1	none	_	_
33	restores	_	_	VBZ	O	-1	none	_	_
34	intracellular	_	_	JJ	O	-1	none	_	_
35	inhibition	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	NF-kappa	_	_	NN	O	-1	none	_	_
38	B	_	_	NN	O	-1	none	_	_
39	DNA	_	_	NN	O	-1	none	_	_
40	binding	_	_	NN	O	-1	none	_	_
41	activity	_	_	NN	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	prolongs	_	_	VBZ	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	survival	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	this	_	_	DT	O	-1	none	_	_
48	labile	_	_	JJ	O	-1	none	_	_
49	inhibitor	_	_	NN	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	show	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	controls	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	I	_	_	NN	Protein	16	multitoken	_	_
14	kappa	_	_	NN	Protein	16	multitoken	_	_
15	B	_	_	NN	Protein	16	multitoken	_	_
16	alpha	_	_	NN	Protein	0	root	_	_
17	by	_	_	IN	O	-1	none	_	_
18	means	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	an	_	_	DT	O	-1	none	_	_
21	inducible	_	_	JJ	O	-1	none	_	_
22	autoregulatory	_	_	JJ	O	-1	none	_	_
23	pathway	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	p16	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	E2F	_	_	NN	O	-1	none	_	_
8	dependent	_	_	JJ	O	-1	none	_	_
9	thymidine	_	_	NN	Protein	10	multitoken	_	_
10	kinase	_	_	NN	Protein	0	root	_	_
11	regulation	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	alterations	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	MTS1	_	_	NN	Protein	-1	none	_	_
8	tumor	_	_	NN	O	-1	none	_	_
9	suppressor	_	_	NN	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	chromosome	_	_	NN	O	-1	none	_	_
13	9p21	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	encodes	_	_	VBZ	O	-1	none	_	_
17	p16	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	inhibitor	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	cyclin-dependent-kinase-4	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	6	_	_	CD	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	tumorigenesis	_	_	NN	O	-1	none	_	_
28	is	_	_	VBZ	O	-1	none	_	_
29	not	_	_	RB	O	-1	none	_	_
30	yet	_	_	RB	O	-1	none	_	_
31	clear	_	_	JJ	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Phosphorylation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	retinoblastoma	_	_	NN	Protein	5	multitoken	_	_
5	protein	_	_	NN	Protein	0	root	_	_
6	by	_	_	IN	O	-1	none	_	_
7	cyclin	_	_	NN	Protein	10	multitoken	_	_
8	dependent	_	_	JJ	Protein	10	multitoken	_	_
9	kinases	_	_	NNS	Protein	10	multitoken	_	_
10	4	_	_	CD	Protein	0	root	_	_
11	and	_	_	CC	O	-1	none	_	_
12	6	_	_	CD	Protein	-1	none	_	_
13	prevents	_	_	VBZ	O	-1	none	_	_
14	its	_	_	PRP$	O	-1	none	_	_
15	interaction	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	E2F	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	which	_	_	WDT	O	-1	none	_	_
23	subsequently	_	_	RB	O	-1	none	_	_
24	promotes	_	_	VBZ	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	S	_	_	NN	O	-1	none	_	_
29	phase	_	_	NN	O	-1	none	_	_
30	regulated	_	_	VBN	O	-1	none	_	_
31	genes	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	such	_	_	JJ	O	-1	none	_	_
34	as	_	_	IN	O	-1	none	_	_
35	thymidine	_	_	NN	Protein	36	multitoken	_	_
36	kinase	_	_	NN	Protein	0	root	_	_
37	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	role	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	p16	_	_	NN	Protein	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	regulation	_	_	NN	O	-1	none	_	_
9	has	_	_	VBZ	O	-1	none	_	_
10	been	_	_	VBN	O	-1	none	_	_
11	presumed	_	_	VBN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	there	_	_	EX	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	no	_	_	DT	O	-1	none	_	_
16	proof	_	_	NN	O	-1	none	_	_
17	so	_	_	RB	O	-1	none	_	_
18	far	_	_	RB	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	loss	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	this	_	_	DT	O	-1	none	_	_
23	tumor	_	_	NN	O	-1	none	_	_
24	suppressor	_	_	NN	O	-1	none	_	_
25	gene	_	_	NN	O	-1	none	_	_
26	really	_	_	RB	O	-1	none	_	_
27	affects	_	_	VBZ	O	-1	none	_	_
28	E2F	_	_	NN	O	-1	none	_	_
29	mediated	_	_	JJ	O	-1	none	_	_
30	regulations	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	regulation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	thymidine	_	_	NN	Protein	7	multitoken	_	_
7	kinase	_	_	NN	Protein	0	root	_	_
8	in	_	_	IN	O	-1	none	_	_
9	phytohemagglutinin	_	_	NN	Protein	-1	none	_	_
10	stimulated	_	_	VBD	O	-1	none	_	_
11	normal	_	_	JJ	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	p16	_	_	NN	Protein	-1	none	_	_
18	negative	_	_	JJ	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	acute	_	_	JJ	O	-1	none	_	_
21	lymphoblastic	_	_	JJ	O	-1	none	_	_
22	leukemia	_	_	NN	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	lines	_	_	NNS	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	MOLT-4	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	CEM	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Compared	_	_	VBN	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	normal	_	_	JJ	O	-1	none	_	_
4	lymphocytes	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	MOLT-4	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	CEM	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	exhibited	_	_	VBD	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	altered	_	_	JJ	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	cycle	_	_	NN	O	-1	none	_	_
15	regulation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	thymidine	_	_	NN	Protein	18	multitoken	_	_
18	kinase	_	_	NN	Protein	0	root	_	_
19	,	_	_	,	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	much	_	_	RB	O	-1	none	_	_
22	higher	_	_	JJR	O	-1	none	_	_
23	intracellular	_	_	JJ	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	this	_	_	DT	O	-1	none	_	_
27	enzyme	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	higher	_	_	JJR	O	-1	none	_	_
31	thymidine	_	_	NN	Protein	32	multitoken	_	_
32	kinase	_	_	NN	Protein	0	root	_	_
33	mRNA	_	_	NN	O	-1	none	_	_
34	expression	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	p16	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	normal	_	_	JJ	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	lymphocytes	_	_	NNS	O	-1	none	_	_
9	caused	_	_	VBD	O	-1	none	_	_
10	arrest	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	G1	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	without	_	_	IN	O	-1	none	_	_
17	effect	_	_	NN	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	growth	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	MOLT-4	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	CEM	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	although	_	_	IN	O	-1	none	_	_
29	all	_	_	DT	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	them	_	_	PRP	O	-1	none	_	_
32	express	_	_	VBP	O	-1	none	_	_
33	functional	_	_	JJ	O	-1	none	_	_
34	retinoblastoma	_	_	NN	Protein	35	multitoken	_	_
35	protein	_	_	NN	Protein	0	root	_	_
36	.	_	_	.	O	-1	none	_	_

1	Nevertheless	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	two	_	_	CD	O	-1	none	_	_
6	leukemia	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	lines	_	_	NNS	O	-1	none	_	_
9	transient	_	_	JJ	O	-1	none	_	_
10	overexpression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	p16	_	_	NN	Protein	-1	none	_	_
13	reestablished	_	_	VBD	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	normal	_	_	JJ	O	-1	none	_	_
16	regulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	thymidine	_	_	NN	Protein	19	multitoken	_	_
19	kinase	_	_	NN	Protein	0	root	_	_
20	,	_	_	,	O	-1	none	_	_
21	paralleled	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	increase	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	underphosphorylated	_	_	JJ	O	-1	none	_	_
28	form	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	retinoblastoma	_	_	NN	Protein	31	multitoken	_	_
31	protein	_	_	NN	Protein	0	root	_	_
32	and	_	_	CC	O	-1	none	_	_
33	decrease	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	free	_	_	JJ	O	-1	none	_	_
36	E2F	_	_	NN	O	-1	none	_	_
37	bound	_	_	VBD	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	its	_	_	PRP$	O	-1	none	_	_
40	motif	_	_	NN	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	thymidine	_	_	NN	Protein	44	multitoken	_	_
44	kinase	_	_	NN	Protein	0	root	_	_
45	promoter	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	loss	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	p16	_	_	NN	Protein	-1	none	_	_
7	causes	_	_	VBZ	O	-1	none	_	_
8	upregulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	precursor	_	_	NN	O	-1	none	_	_
13	pathway	_	_	NN	O	-1	none	_	_
14	enzyme	_	_	NN	O	-1	none	_	_
15	via	_	_	IN	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	E2F	_	_	NN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	mechanism	_	_	NN	O	-1	none	_	_
22	involving	_	_	VBG	O	-1	none	_	_
23	retinoblastoma	_	_	NN	Protein	24	multitoken	_	_
24	protein	_	_	NN	Protein	0	root	_	_
25	.	_	_	.	O	-1	none	_	_

1	CD30	_	_	NN	Protein	-1	none	_	_
2	dependent	_	_	JJ	O	-1	none	_	_
3	degradation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	TRAF2	_	_	NN	Protein	-1	none	_	_
6	:	_	_	:	O	-1	none	_	_
7	implications	_	_	NNS	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	negative	_	_	JJ	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	TRAF	_	_	NN	O	-1	none	_	_
13	signaling	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	control	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	survival	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	CD30	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	cell-surface	_	_	JJ	O	-1	none	_	_
5	receptor	_	_	NN	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	augment	_	_	VB	O	-1	none	_	_
9	lymphocyte	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	survival	_	_	NN	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	its	_	_	PRP$	O	-1	none	_	_
15	ability	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	induce	_	_	VB	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	NF-kappaB	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	CD30	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	however	_	_	RB	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	implicated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	apoptotic	_	_	JJ	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	death	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	lymphocytes	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	one	_	_	CD	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	effects	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	CD30	_	_	NN	Protein	-1	none	_	_
11	signal	_	_	NN	O	-1	none	_	_
12	transduction	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	render	_	_	VB	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	sensitive	_	_	JJ	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	apoptosis	_	_	NN	O	-1	none	_	_
20	induced	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	type	_	_	NN	Protein	28	multitoken	_	_
24	1	_	_	CD	Protein	28	multitoken	_	_
25	tumor	_	_	NN	Protein	28	multitoken	_	_
26	necrosis	_	_	NN	Protein	28	multitoken	_	_
27	factor	_	_	NN	Protein	28	multitoken	_	_
28	receptor	_	_	NN	Protein	0	root	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	TNFR1	_	_	NN	Protein	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	sensitization	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	dependent	_	_	JJ	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	TRAF	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	sites	_	_	NNS	O	-1	none	_	_
10	within	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	CD30	_	_	NN	Protein	-1	none	_	_
13	cytoplasmic	_	_	JJ	O	-1	none	_	_
14	domain	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	proteins	_	_	NNS	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	binds	_	_	VBZ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	sites	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	TRAF2	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	transduction	_	_	NN	O	-1	none	_	_
16	molecule	_	_	NN	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	also	_	_	RB	O	-1	none	_	_
20	utilized	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	TNFR1	_	_	NN	Protein	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	mediate	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	several	_	_	JJ	O	-1	none	_	_
29	downstream	_	_	JJ	O	-1	none	_	_
30	kinases	_	_	NNS	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	transcription	_	_	NN	O	-1	none	_	_
33	factors	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	During	_	_	IN	O	-1	none	_	_
2	CD30	_	_	NN	Protein	-1	none	_	_
3	signal	_	_	NN	O	-1	none	_	_
4	transduction	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	found	_	_	VBD	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	TRAF2	_	_	NN	Protein	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	cytoplasmic	_	_	JJ	O	-1	none	_	_
15	domain	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	CD30	_	_	NN	Protein	-1	none	_	_
18	results	_	_	VBZ	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	rapid	_	_	JJ	O	-1	none	_	_
22	depletion	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	TRAF2	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	associated	_	_	JJ	O	-1	none	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	TRAF1	_	_	NN	Protein	-1	none	_	_
30	by	_	_	IN	O	-1	none	_	_
31	proteolysis	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	model	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	CD30	_	_	NN	Protein	-1	none	_	_
9	limits	_	_	VBZ	O	-1	none	_	_
10	its	_	_	PRP$	O	-1	none	_	_
11	own	_	_	JJ	O	-1	none	_	_
12	ability	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	transduce	_	_	VB	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	survival	_	_	NN	O	-1	none	_	_
17	signals	_	_	NNS	O	-1	none	_	_
18	through	_	_	IN	O	-1	none	_	_
19	signal	_	_	NN	O	-1	none	_	_
20	coupled	_	_	VBN	O	-1	none	_	_
21	depletion	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	TRAF2	_	_	NN	Protein	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Depletion	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	intracellular	_	_	JJ	O	-1	none	_	_
4	TRAF2	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	its	_	_	PRP$	O	-1	none	_	_
7	coassociated	_	_	JJ	O	-1	none	_	_
8	proteins	_	_	NNS	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	increased	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	sensitivity	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	undergoing	_	_	VBG	O	-1	none	_	_
18	apoptosis	_	_	NN	O	-1	none	_	_
19	during	_	_	IN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	death	_	_	NN	O	-1	none	_	_
23	inducing	_	_	VBG	O	-1	none	_	_
24	receptors	_	_	NNS	O	-1	none	_	_
25	such	_	_	JJ	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	TNFR1	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Consistent	_	_	JJ	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	hypothesis	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	dominant	_	_	JJ	O	-1	none	_	_
10	negative	_	_	JJ	O	-1	none	_	_
11	form	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	TRAF2	_	_	NN	Protein	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	found	_	_	VBN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	potentiate	_	_	VB	O	-1	none	_	_
18	TNFR1	_	_	NN	Protein	-1	none	_	_
19	mediated	_	_	VBN	O	-1	none	_	_
20	death	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	provide	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	potential	_	_	JJ	O	-1	none	_	_
6	mechanism	_	_	NN	O	-1	none	_	_
7	through	_	_	IN	O	-1	none	_	_
8	which	_	_	WDT	O	-1	none	_	_
9	CD30	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	as	_	_	RB	O	-1	none	_	_
12	well	_	_	RB	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	other	_	_	JJ	O	-1	none	_	_
15	TRAF	_	_	NN	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	members	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	TNFR	_	_	NN	O	-1	none	_	_
21	superfamily	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	can	_	_	MD	O	-1	none	_	_
24	negatively	_	_	RB	O	-1	none	_	_
25	regulate	_	_	VB	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	survival	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Suppression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-kappaB	_	_	NN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	normal	_	_	JJ	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	supernatant	_	_	JJ	O	-1	none	_	_
11	fluid	_	_	NN	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	renal	_	_	JJ	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	carcinomas	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	T	_	_	NN	O	-1	none	_	_
2	lymphocytes	_	_	NNS	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	patients	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	renal	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	carcinoma	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	RCC	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	show	_	_	VBP	O	-1	none	_	_
13	reduced	_	_	VBN	O	-1	none	_	_
14	immune	_	_	JJ	O	-1	none	_	_
15	function	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	impaired	_	_	JJ	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	factor	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	NF-kappaB	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	determined	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mechanism	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	NF-kappaB	_	_	NN	O	-1	none	_	_
7	suppression	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	RCC	_	_	NN	O	-1	none	_	_
13	patient	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	determined	_	_	VBD	O	-1	none	_	_
16	whether	_	_	IN	O	-1	none	_	_
17	supernatant	_	_	JJ	O	-1	none	_	_
18	fluid	_	_	NN	O	-1	none	_	_
19	from	_	_	IN	O	-1	none	_	_
20	RCC	_	_	NN	O	-1	none	_	_
21	explants	_	_	NNS	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	RCC-S	_	_	NNS	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	induced	_	_	VBD	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	same	_	_	JJ	O	-1	none	_	_
28	phenotype	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	NF-kappaB	_	_	NN	O	-1	none	_	_
31	suppression	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	normal	_	_	JJ	O	-1	none	_	_
34	T	_	_	NN	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	that	_	_	WDT	O	-1	none	_	_
37	is	_	_	VBZ	O	-1	none	_	_
38	observed	_	_	VBN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	patient	_	_	NN	O	-1	none	_	_
41	T	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	pattern	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	kappaB	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	RCC	_	_	NN	O	-1	none	_	_
12	patient	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	altered	_	_	VBN	O	-1	none	_	_
15	as	_	_	IN	O	-1	none	_	_
16	compared	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	that	_	_	DT	O	-1	none	_	_
19	seen	_	_	VBN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	obtained	_	_	VBN	O	-1	none	_	_
24	from	_	_	IN	O	-1	none	_	_
25	normal	_	_	JJ	O	-1	none	_	_
26	volunteers	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	some	_	_	DT	O	-1	none	_	_
3	patients	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	no	_	_	DT	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	RelA	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	NFkappaB1	_	_	NN	Protein	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	detectable	_	_	JJ	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	while	_	_	IN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	others	_	_	NNS	O	-1	none	_	_
19	kappaB	_	_	NN	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	modestly	_	_	RB	O	-1	none	_	_
24	induced	_	_	VBN	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	duration	_	_	NN	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	reduced	_	_	VBN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	degraded	_	_	VBN	O	-1	none	_	_
4	normally	_	_	RB	O	-1	none	_	_
5	following	_	_	VBG	O	-1	none	_	_
6	stimulation	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	both	_	_	CC	O	-1	none	_	_
9	normal	_	_	JJ	O	-1	none	_	_
10	controls	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	RCC	_	_	NN	O	-1	none	_	_
16	patients	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	RCC-S	_	_	NNP	O	-1	none	_	_
2	did	_	_	VBD	O	-1	none	_	_
3	not	_	_	RB	O	-1	none	_	_
4	alter	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	cytoplasmic	_	_	JJ	O	-1	none	_	_
7	levels	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	RelA	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	NF-kappaB1	_	_	NN	Protein	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	did	_	_	VBD	O	-1	none	_	_
14	suppress	_	_	VB	O	-1	none	_	_
15	their	_	_	PRP$	O	-1	none	_	_
16	nuclear	_	_	JJ	O	-1	none	_	_
17	localization	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	inhibited	_	_	VBD	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	RelA	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	NF-kappaB	_	_	NN	Protein	26	multitoken	_	_
26	1	_	_	CD	Protein	0	root	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	complexes	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	RCC-S	_	_	NNS	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	induce	_	_	VB	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	normal	_	_	JJ	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	same	_	_	JJ	O	-1	none	_	_
14	phenotype	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	impaired	_	_	JJ	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	detected	_	_	VBN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	T	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	RCC	_	_	NN	O	-1	none	_	_
27	patient	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	appears	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	NF-kappaB	_	_	NN	O	-1	none	_	_
6	suppression	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	RCC-S	_	_	NNS	O	-1	none	_	_
9	may	_	_	MD	O	-1	none	_	_
10	contribute	_	_	VB	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	immunosuppression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	host	_	_	NN	O	-1	none	_	_
16	immunity	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Role	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cellular	_	_	JJ	O	-1	none	_	_
4	tumor	_	_	NN	O	-1	none	_	_
5	necrosis	_	_	NN	O	-1	none	_	_
6	factor	_	_	NN	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	associated	_	_	VBN	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	NF-kappaB	_	_	NN	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	lymphocyte	_	_	NN	O	-1	none	_	_
15	transformation	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	herpesvirus	_	_	NN	O	-1	none	_	_
18	Saimiri	_	_	NN	O	-1	none	_	_
19	STP	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	STP	_	_	NN	O	-1	none	_	_
3	oncoproteins	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	herpesvirus	_	_	NN	O	-1	none	_	_
7	saimiri	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	HVS	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	subgroup	_	_	NN	O	-1	none	_	_
12	A	_	_	DT	O	-1	none	_	_
13	strain	_	_	NN	O	-1	none	_	_
14	11	_	_	CD	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	subgroup	_	_	NN	O	-1	none	_	_
17	C	_	_	NN	O	-1	none	_	_
18	strain	_	_	NN	O	-1	none	_	_
19	488	_	_	CD	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	now	_	_	RB	O	-1	none	_	_
22	found	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	be	_	_	VB	O	-1	none	_	_
25	stably	_	_	RB	O	-1	none	_	_
26	associated	_	_	VBN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	tumor	_	_	NN	Protein	37	multitoken	_	_
29	necrosis	_	_	NN	Protein	37	multitoken	_	_
30	factor	_	_	NN	Protein	37	multitoken	_	_
31	receptor	_	_	NN	Protein	37	multitoken	_	_
32	associated	_	_	JJ	Protein	37	multitoken	_	_
33	factor	_	_	NN	Protein	37	multitoken	_	_
34	(	_	_	-LRB-	Protein	37	multitoken	_	_
35	TRAF	_	_	NN	Protein	37	multitoken	_	_
36	)	_	_	-RRB-	Protein	37	multitoken	_	_
37	1	_	_	CD	Protein	0	root	_	_
38	,	_	_	,	O	-1	none	_	_
39	2	_	_	CD	Protein	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	or	_	_	CC	O	-1	none	_	_
42	3	_	_	CD	Protein	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Mutational	_	_	JJ	O	-1	none	_	_
2	analyses	_	_	NNS	O	-1	none	_	_
3	identified	_	_	VBD	O	-1	none	_	_
4	residues	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	PXQXT/S	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	STP-A11	_	_	NN	Protein	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	critical	_	_	JJ	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	TRAF	_	_	NN	O	-1	none	_	_
13	association	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	somewhat	_	_	RB	O	-1	none	_	_
6	divergent	_	_	JJ	O	-1	none	_	_
7	region	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	STP-C488	_	_	NN	Protein	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	critical	_	_	JJ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	TRAF	_	_	NN	O	-1	none	_	_
14	association	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Mutational	_	_	JJ	O	-1	none	_	_
2	analysis	_	_	NN	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	revealed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	STP-C488	_	_	NN	Protein	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	NF-kappaB	_	_	NN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	correlated	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	its	_	_	PRP$	O	-1	none	_	_
15	ability	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	associate	_	_	VB	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	TRAFs	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	STP-C488	_	_	NN	Protein	-1	none	_	_
3	P10	_	_	NN	O	-1	none	_	_
4	--	_	_	:	O	-1	none	_	_
5	>	_	_	JJR	O	-1	none	_	_
6	R	_	_	NN	O	-1	none	_	_
7	mutant	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	defective	_	_	JJ	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	Rat-1	_	_	NN	O	-1	none	_	_
13	fibroblast	_	_	NN	O	-1	none	_	_
14	transformation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	fibroblast	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	transformation	_	_	NN	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	blocked	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	TRAF2	_	_	NN	Protein	-1	none	_	_
25	dominant	_	_	JJ	O	-1	none	_	_
26	negative	_	_	JJ	O	-1	none	_	_
27	mutant	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Other	_	_	JJ	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	implicated	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	immortalization	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	common	_	_	JJ	O	-1	none	_	_
9	marmoset	_	_	NN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	lymphocytes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	also	_	_	RB	O	-1	none	_	_
15	be	_	_	VB	O	-1	none	_	_
16	critical	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	transformation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	rodent	_	_	JJ	O	-1	none	_	_
25	fibroblasts	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Fas	_	_	NN	Protein	4	multitoken	_	_
4	ligand	_	_	NN	Protein	0	root	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	death	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	apoptosis	_	_	NN	Protein	13	multitoken	_	_
11	linked	_	_	VBN	Protein	13	multitoken	_	_
12	gene	_	_	NN	Protein	13	multitoken	_	_
13	4	_	_	CD	Protein	0	root	_	_
14	.	_	_	.	O	-1	none	_	_

1	Programmed	_	_	VBN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	death	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	process	_	_	NN	O	-1	none	_	_
7	required	_	_	VBN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	normal	_	_	JJ	O	-1	none	_	_
11	development	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	organism	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	best	_	_	JJS	O	-1	none	_	_
5	understood	_	_	VBN	O	-1	none	_	_
6	apoptotic	_	_	JJ	O	-1	none	_	_
7	pathways	_	_	NNS	O	-1	none	_	_
8	occurs	_	_	VBZ	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	lymphocytes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	mediated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	Fas	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	Fas	_	_	NN	Protein	19	multitoken	_	_
19	ligand	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	FasL	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	interaction	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	During	_	_	IN	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	apoptosis	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cell-receptor	_	_	NN	O	-1	none	_	_
9	engagement	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	we	_	_	PRP	O	-1	none	_	_
12	identified	_	_	VBD	O	-1	none	_	_
13	ALG-4F	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	truncated	_	_	JJ	O	-1	none	_	_
17	transcript	_	_	NN	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	prevents	_	_	VBZ	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cell-receptor-induced	_	_	JJ	O	-1	none	_	_
22	FasL	_	_	NN	Protein	-1	none	_	_
23	upregulation	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	death	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	full-length	_	_	JJ	O	-1	none	_	_
4	ALG-4	_	_	NN	Protein	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	FasL	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	consequently	_	_	RB	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	apoptosis	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	ALG-4	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	necessary	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	sufficient	_	_	JJ	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	FasL	_	_	NN	Protein	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Fas	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	FasL	_	_	NN	Protein	-1	none	_	_
4	interaction	_	_	NN	O	-1	none	_	_
5	initiates	_	_	VBZ	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	death	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	many	_	_	JJ	O	-1	none	_	_
10	other	_	_	JJ	O	-1	none	_	_
11	systems	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	its	_	_	PRP$	O	-1	none	_	_
15	dysregulation	_	_	NN	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	mechanism	_	_	NN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	several	_	_	JJ	O	-1	none	_	_
22	pathologic	_	_	JJ	O	-1	none	_	_
23	conditions	_	_	NNS	O	-1	none	_	_
24	arise	_	_	VBP	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Understanding	_	_	VBG	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	molecular	_	_	JJ	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	FasL	_	_	NN	Protein	-1	none	_	_
7	regulation	_	_	NN	O	-1	none	_	_
8	could	_	_	MD	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	very	_	_	RB	O	-1	none	_	_
11	useful	_	_	JJ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	elucidating	_	_	VBG	O	-1	none	_	_
14	how	_	_	WRB	O	-1	none	_	_
15	these	_	_	DT	O	-1	none	_	_
16	diseases	_	_	NNS	O	-1	none	_	_
17	develop	_	_	VBP	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	identifying	_	_	VBG	O	-1	none	_	_
21	potential	_	_	JJ	O	-1	none	_	_
22	therapeutic	_	_	JJ	O	-1	none	_	_
23	targets	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Sp1	_	_	NN	Protein	-1	none	_	_
4	phosphorylation	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	independent	_	_	JJ	O	-1	none	_	_
9	HIV	_	_	NN	O	-1	none	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	domain	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	stimulated	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	okadaic	_	_	JJ	O	-1	none	_	_
19	acid	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	purely	_	_	RB	O	-1	none	_	_
6	enhancer	_	_	NN	O	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	effect	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	cytokines	_	_	NNS	O	-1	none	_	_
11	such	_	_	JJ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	TNF	_	_	NN	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	HIV	_	_	NN	O	-1	none	_	_
20	regulatory	_	_	JJ	O	-1	none	_	_
21	region	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	LTR	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	we	_	_	PRP	O	-1	none	_	_
27	observed	_	_	VBD	O	-1	none	_	_
28	that	_	_	IN	O	-1	none	_	_
29	okadaic	_	_	JJ	O	-1	none	_	_
30	acid	_	_	NN	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	OKA	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	activates	_	_	VBZ	O	-1	none	_	_
35	HIV	_	_	NN	O	-1	none	_	_
36	transcription	_	_	NN	O	-1	none	_	_
37	through	_	_	IN	O	-1	none	_	_
38	both	_	_	CC	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	enhancer	_	_	NN	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	responding	_	_	VBG	O	-1	none	_	_
43	to	_	_	TO	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	factor	_	_	NN	O	-1	none	_	_
46	NF-kappa	_	_	NN	O	-1	none	_	_
47	B	_	_	NN	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	and	_	_	CC	O	-1	none	_	_
50	the	_	_	DT	O	-1	none	_	_
51	promoter	_	_	NN	O	-1	none	_	_
52	domain	_	_	NN	O	-1	none	_	_
53	of	_	_	IN	O	-1	none	_	_
54	the	_	_	DT	O	-1	none	_	_
55	LTR	_	_	NN	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inducibility	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	HIV	_	_	NN	O	-1	none	_	_
5	LTR	_	_	NN	O	-1	none	_	_
6	driven	_	_	VBN	O	-1	none	_	_
7	luciferase	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	constructs	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	lymphoblastoid	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	stimulated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	OKA	_	_	NN	O	-1	none	_	_
16	depended	_	_	VBD	O	-1	none	_	_
17	on	_	_	IN	O	-1	none	_	_
18	both	_	_	CC	O	-1	none	_	_
19	functional	_	_	JJ	O	-1	none	_	_
20	Sp1	_	_	NN	Protein	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	elements	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	ability	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	TATA	_	_	NN	O	-1	none	_	_
29	box	_	_	NN	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	bind	_	_	VB	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	protein	_	_	NN	O	-1	none	_	_
34	TBP	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	both	_	_	DT	O	-1	none	_	_
3	transformed	_	_	VBN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	normal	_	_	JJ	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	OKA	_	_	NN	O	-1	none	_	_
9	stimulation	_	_	NN	O	-1	none	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	intense	_	_	JJ	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	constitutively	_	_	RB	O	-1	none	_	_
16	expressed	_	_	VBN	O	-1	none	_	_
17	Sp1	_	_	NN	Protein	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	nucleus	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	property	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	OKA	_	_	NN	O	-1	none	_	_
27	not	_	_	RB	O	-1	none	_	_
28	shared	_	_	VBN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	TNF	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	phorbol	_	_	NN	O	-1	none	_	_
33	ester	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	or	_	_	CC	O	-1	none	_	_
36	PHA	_	_	NN	Protein	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	interleukin	_	_	NN	Protein	39	multitoken	_	_
39	2	_	_	CD	Protein	0	root	_	_
40	.	_	_	.	O	-1	none	_	_

1	Responsiveness	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	LTR	_	_	NN	O	-1	none	_	_
4	constructs	_	_	NNS	O	-1	none	_	_
5	deleted	_	_	VBN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	elements	_	_	NNS	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	HIV	_	_	NN	O	-1	none	_	_
12	Tat	_	_	NN	Protein	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	increased	_	_	VBN	O	-1	none	_	_
16	upon	_	_	IN	O	-1	none	_	_
17	OKA	_	_	NN	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	TNF	_	_	NN	O	-1	none	_	_
21	stimulation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	SP1	_	_	NN	Protein	-1	none	_	_
6	phosphorylation	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	OKA	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	selective	_	_	JJ	O	-1	none	_	_
13	inhibitor	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	serine	_	_	NN	O	-1	none	_	_
17	threonine	_	_	NN	O	-1	none	_	_
18	phosphatase	_	_	NN	O	-1	none	_	_
19	PP2A	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	facilitates	_	_	VBZ	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	formation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	complex	_	_	NN	O	-1	none	_	_
28	involving	_	_	VBG	O	-1	none	_	_
29	general	_	_	JJ	O	-1	none	_	_
30	transcription	_	_	NN	O	-1	none	_	_
31	factors	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	HIV	_	_	NN	O	-1	none	_	_
34	Tat	_	_	NN	Protein	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	Sp1	_	_	NN	Protein	-1	none	_	_
38	proteins	_	_	NNS	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	formation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	complex	_	_	NN	O	-1	none	_	_
6	would	_	_	MD	O	-1	none	_	_
7	increase	_	_	VB	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	independently	_	_	RB	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	synergy	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	low	_	_	JJ	O	-1	none	_	_
20	basal	_	_	JJ	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	HIV	_	_	NN	O	-1	none	_	_
25	LTR	_	_	NN	O	-1	none	_	_
26	observed	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	normal	_	_	JJ	O	-1	none	_	_
29	T	_	_	NN	O	-1	none	_	_
30	lymphocytes	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	jun	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	fos	_	_	NN	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	family	_	_	NN	O	-1	none	_	_
9	members	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	12-O-tetradecanoylphorbol-13-acetate	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	hemopoietic	_	_	JJ	O	-1	none	_	_
14	differentiation	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Terminal	_	_	JJ	O	-1	none	_	_
2	differentiation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	leukemic	_	_	JJ	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	lines	_	_	NNS	O	-1	none	_	_
8	U-937	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	HL-60	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	12-O-tetradecanoylphorbol-13-acetate	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	accompanied	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	marked	_	_	JJ	O	-1	none	_	_
17	changes	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	demonstrate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	jun	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	fos	_	_	NN	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	family	_	_	NN	O	-1	none	_	_
16	members	_	_	NNS	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	induced	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	variable	_	_	JJ	O	-1	none	_	_
21	kinetics	_	_	NNS	O	-1	none	_	_
22	during	_	_	IN	O	-1	none	_	_
23	12-O-tetradecanoylphorbol-13-acetate	_	_	NN	O	-1	none	_	_
24	induced	_	_	VBD	O	-1	none	_	_
25	differentiation	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	c-jun	_	_	NN	Protein	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	best	_	_	JJS	O	-1	none	_	_
31	paralleling	_	_	JJ	O	-1	none	_	_
32	differentiation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	generation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	AP-1	_	_	NN	O	-1	none	_	_
5	complexes	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	measured	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	DNA	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	closely	_	_	RB	O	-1	none	_	_
15	parallels	_	_	VBZ	O	-1	none	_	_
16	morphological	_	_	JJ	O	-1	none	_	_
17	differentiation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	ability	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	complexes	_	_	NNS	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	regulate	_	_	VB	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	demonstrated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	increased	_	_	VBN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	an	_	_	DT	O	-1	none	_	_
19	AP-1	_	_	NN	O	-1	none	_	_
20	driven	_	_	VBN	O	-1	none	_	_
21	reporter	_	_	NN	O	-1	none	_	_
22	construct	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	marked	_	_	JJ	O	-1	none	_	_
25	increases	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	endogenous	_	_	JJ	O	-1	none	_	_
31	AP-1	_	_	NN	O	-1	none	_	_
32	regulated	_	_	VBN	O	-1	none	_	_
33	genes	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Differentiation	_	_	NN	O	-1	none	_	_
2	assays	_	_	NNS	O	-1	none	_	_
3	using	_	_	VBG	O	-1	none	_	_
4	water	_	_	NN	O	-1	none	_	_
5	soluble	_	_	JJ	O	-1	none	_	_
6	phorbol	_	_	NN	O	-1	none	_	_
7	esters	_	_	NNS	O	-1	none	_	_
8	reveal	_	_	VBP	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	differentiation	_	_	NN	O	-1	none	_	_
11	becomes	_	_	VBZ	O	-1	none	_	_
12	irreversible	_	_	JJ	O	-1	none	_	_
13	soon	_	_	RB	O	-1	none	_	_
14	after	_	_	IN	O	-1	none	_	_
15	AP-1	_	_	NN	O	-1	none	_	_
16	appears	_	_	VBZ	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	tight	_	_	JJ	O	-1	none	_	_
3	correlation	_	_	NN	O	-1	none	_	_
4	between	_	_	IN	O	-1	none	_	_
5	c-jun	_	_	NN	Protein	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	generation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	AP-1	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	suggests	_	_	VBZ	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	critical	_	_	JJ	O	-1	none	_	_
19	role	_	_	NN	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	this	_	_	DT	O	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	transcriptional	_	_	JJ	O	-1	none	_	_
25	complex	_	_	NN	O	-1	none	_	_
26	during	_	_	IN	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	process	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	stably	_	_	RB	O	-1	none	_	_
8	expressing	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	Tax	_	_	NN	Protein	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	lymphotropic	_	_	JJ	O	-1	none	_	_
17	virus	_	_	NN	O	-1	none	_	_
18	type	_	_	NN	O	-1	none	_	_
19	I	_	_	CD	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	constitutive	_	_	JJ	O	-1	none	_	_
5	Tax	_	_	NN	Protein	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	interaction	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	its	_	_	PRP$	O	-1	none	_	_
15	recognition	_	_	NN	O	-1	none	_	_
16	sequence	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	dependent	_	_	JJ	O	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	examined	_	_	VBN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	lymphoid	_	_	JJ	O	-1	none	_	_
29	Jurkat	_	_	NN	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	lines	_	_	NNS	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	19D	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	9J	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	stably	_	_	RB	O	-1	none	_	_
38	transformed	_	_	VBN	O	-1	none	_	_
39	with	_	_	IN	O	-1	none	_	_
40	a	_	_	DT	O	-1	none	_	_
41	Tax	_	_	NN	Protein	-1	none	_	_
42	expression	_	_	NN	O	-1	none	_	_
43	vector	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Tax	_	_	NN	Protein	-1	none	_	_
2	expressing	_	_	VBG	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	lines	_	_	NNS	O	-1	none	_	_
6	contained	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	constitutive	_	_	JJ	O	-1	none	_	_
9	level	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	detectable	_	_	JJ	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	mobility	_	_	NN	O	-1	none	_	_
19	shift	_	_	NN	O	-1	none	_	_
20	assay	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	uv	_	_	NN	O	-1	none	_	_
23	cross	_	_	VBP	O	-1	none	_	_
24	linking	_	_	VBG	O	-1	none	_	_
25	using	_	_	VBG	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	palindromic	_	_	JJ	O	-1	none	_	_
28	NF-kappa	_	_	NN	O	-1	none	_	_
29	B	_	_	NN	O	-1	none	_	_
30	probe	_	_	NN	O	-1	none	_	_
31	homologous	_	_	JJ	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	interferon	_	_	NN	Protein	35	multitoken	_	_
35	beta	_	_	NN	Protein	0	root	_	_
36	PRDII	_	_	NN	O	-1	none	_	_
37	site	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	Jurkat	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	NC2	_	_	NN	O	-1	none	_	_
5	.10	_	_	CD	O	-1	none	_	_
6	induction	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	phorbol	_	_	NN	O	-1	none	_	_
9	esters	_	_	NNS	O	-1	none	_	_
10	resulted	_	_	VBD	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	appearance	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	new	_	_	JJ	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	proteins	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	85	_	_	CD	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	75	_	_	CD	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	54	_	_	CD	O	-1	none	_	_
26	kDa	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	whereas	_	_	IN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	Tax	_	_	NN	Protein	-1	none	_	_
31	expressing	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	85-kDa	_	_	JJ	O	-1	none	_	_
35	protein	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	92-kDa	_	_	JJ	O	-1	none	_	_
39	DNA	_	_	NN	O	-1	none	_	_
40	binding	_	_	NN	O	-1	none	_	_
41	protein	_	_	NN	O	-1	none	_	_
42	were	_	_	VBD	O	-1	none	_	_
43	constitutively	_	_	RB	O	-1	none	_	_
44	induced	_	_	VBN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Tax	_	_	NN	Protein	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	19D	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	9J	_	_	NN	O	-1	none	_	_
9	resulted	_	_	VBD	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	endogenous	_	_	JJ	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	dependent	_	_	JJ	O	-1	none	_	_
18	granulocyte-macrophage	_	_	JJ	Protein	21	multitoken	_	_
19	colony	_	_	NN	Protein	21	multitoken	_	_
20	stimulating	_	_	NN	Protein	21	multitoken	_	_
21	factor	_	_	NN	Protein	0	root	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	increased	_	_	VBD	O	-1	none	_	_
25	basal	_	_	JJ	O	-1	none	_	_
26	level	_	_	NN	O	-1	none	_	_
27	expression	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	transfected	_	_	VBN	O	-1	none	_	_
30	NF-kappa	_	_	NN	O	-1	none	_	_
31	B	_	_	NN	O	-1	none	_	_
32	regulated	_	_	VBN	O	-1	none	_	_
33	promoters	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Nonetheless	_	_	RB	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	both	_	_	CC	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	endogenous	_	_	JJ	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	transfected	_	_	JJ	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	inducible	_	_	JJ	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	PMA	_	_	NN	O	-1	none	_	_
15	treatment	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Tax	_	_	NN	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	Jurkat	_	_	NN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	may	_	_	MD	O	-1	none	_	_
8	alter	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	stoichiometry	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	proteins	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	thus	_	_	RB	O	-1	none	_	_
19	change	_	_	VB	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	NF-kappa	_	_	NN	O	-1	none	_	_
24	B	_	_	NN	O	-1	none	_	_
25	regulated	_	_	VBN	O	-1	none	_	_
26	promoters	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Nasal	_	_	JJ	O	-1	none	_	_
2	NK-	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	T-cell	_	_	NN	O	-1	none	_	_
5	lymphomas	_	_	NNS	O	-1	none	_	_
6	share	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	same	_	_	JJ	O	-1	none	_	_
9	type	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Epstein-Barr	_	_	JJ	O	-1	none	_	_
12	virus	_	_	NN	O	-1	none	_	_
13	latency	_	_	NN	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	nasopharyngeal	_	_	JJ	O	-1	none	_	_
16	carcinoma	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	Hodgkin	_	_	NN	O	-1	none	_	_
19	's	_	_	POS	O	-1	none	_	_
20	disease	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Nasal	_	_	JJ	O	-1	none	_	_
2	T/NK-cell	_	_	NN	O	-1	none	_	_
3	lymphomas	_	_	NNS	O	-1	none	_	_
4	can	_	_	MD	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	further	_	_	JJ	O	-1	none	_	_
7	separated	_	_	VBN	O	-1	none	_	_
8	into	_	_	IN	O	-1	none	_	_
9	those	_	_	DT	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	natural	_	_	JJ	O	-1	none	_	_
12	killer	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	NK	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	lineage	_	_	NN	O	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	T-cell	_	_	NN	O	-1	none	_	_
21	lineage	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	differences	_	_	NNS	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	cellular	_	_	JJ	O	-1	none	_	_
27	phenotype	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	T-cell	_	_	NN	O	-1	none	_	_
30	receptor	_	_	NN	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	TcR	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	gene	_	_	NN	O	-1	none	_	_
35	rearrangement	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	TcR	_	_	NN	O	-1	none	_	_
38	transcript	_	_	NN	O	-1	none	_	_
39	expression	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	NK-	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	T-cell	_	_	NN	O	-1	none	_	_
5	subtypes	_	_	NNS	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	closely	_	_	RB	O	-1	none	_	_
8	associated	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	Epstein-Barr	_	_	JJ	O	-1	none	_	_
11	virus	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	EBV	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	EBV	_	_	NN	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	determined	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	23	_	_	CD	O	-1	none	_	_
12	cases	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	nasal	_	_	JJ	O	-1	none	_	_
15	lymphoma	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	NL	_	_	NNP	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	in	_	_	FW	O	-1	none	_	_
21	situ	_	_	FW	O	-1	none	_	_
22	hybridisation	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	ISH	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	reverse	_	_	JJ	O	-1	none	_	_
28	transcriptase-polymerase	_	_	NN	O	-1	none	_	_
29	chain	_	_	NN	O	-1	none	_	_
30	reaction	_	_	NN	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	RT-PCR	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	immunohistochemistry	_	_	NN	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	IH	_	_	NN	O	-1	none	_	_
38	)	_	_	-RRB-	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Of	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	23	_	_	CD	O	-1	none	_	_
4	cases	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	19	_	_	CD	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	classified	_	_	VBN	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	NK-cell	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	4	_	_	CD	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	T-cell	_	_	NN	O	-1	none	_	_
15	tumours	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	ISH	_	_	NN	O	-1	none	_	_
2	for	_	_	IN	O	-1	none	_	_
3	EBV	_	_	NN	O	-1	none	_	_
4	encoded	_	_	VBD	O	-1	none	_	_
5	small	_	_	JJ	O	-1	none	_	_
6	non	_	_	JJ	O	-1	none	_	_
7	polyadenylated	_	_	JJ	O	-1	none	_	_
8	RNAs	_	_	NNS	O	-1	none	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	all	_	_	DT	O	-1	none	_	_
12	cases	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	whether	_	_	IN	O	-1	none	_	_
15	NK	_	_	NN	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	harboured	_	_	VBD	O	-1	none	_	_
20	EBV	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	virtually	_	_	RB	O	-1	none	_	_
23	all	_	_	DT	O	-1	none	_	_
24	tumour	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	RT-PCR	_	_	NNP	O	-1	none	_	_
2	demonstrated	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	NL	_	_	NNP	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	both	_	_	DT	O	-1	none	_	_
7	subtypes	_	_	NNS	O	-1	none	_	_
8	expressed	_	_	VBD	O	-1	none	_	_
9	EBNAI	_	_	NN	Protein	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	QUK	_	_	NN	O	-1	none	_	_
13	splice	_	_	NN	O	-1	none	_	_
14	pattern	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	latent	_	_	JJ	O	-1	none	_	_
18	membrane	_	_	NN	O	-1	none	_	_
19	proteins	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	LMP1	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	2	_	_	CD	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	BamHI	_	_	NN	O	-1	none	_	_
27	A	_	_	NN	O	-1	none	_	_
28	rightward	_	_	JJ	O	-1	none	_	_
29	transcripts	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	absence	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	EBNA2	_	_	NN	Protein	-1	none	_	_
35	mRNAs	_	_	NNS	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	compatible	_	_	JJ	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	latency	_	_	NN	O	-1	none	_	_
41	type	_	_	NN	O	-1	none	_	_
42	II	_	_	CD	O	-1	none	_	_
43	pattern	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	2	_	_	CD	O	-1	none	_	_
3	early	_	_	JJ	O	-1	none	_	_
4	lytic	_	_	JJ	O	-1	none	_	_
5	transcripts	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	BZLF1	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	BHRF1	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	detected	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	13	_	_	CD	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	10	_	_	CD	O	-1	none	_	_
18	cases	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	respectively	_	_	RB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	lack	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	ZEBRA	_	_	NN	Protein	-1	none	_	_
26	staining	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	any	_	_	DT	O	-1	none	_	_
29	case	_	_	NN	O	-1	none	_	_
30	indicates	_	_	VBZ	O	-1	none	_	_
31	that	_	_	IN	O	-1	none	_	_
32	these	_	_	DT	O	-1	none	_	_
33	lytic	_	_	JJ	O	-1	none	_	_
34	transcripts	_	_	NNS	O	-1	none	_	_
35	are	_	_	VBP	O	-1	none	_	_
36	most	_	_	RBS	O	-1	none	_	_
37	likely	_	_	RB	O	-1	none	_	_
38	expressed	_	_	VBN	O	-1	none	_	_
39	by	_	_	IN	O	-1	none	_	_
40	rare	_	_	JJ	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	biopsies	_	_	NNS	O	-1	none	_	_
45	entering	_	_	VBG	O	-1	none	_	_
46	lytic	_	_	JJ	O	-1	none	_	_
47	cycle	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	viral	_	_	JJ	O	-1	none	_	_
3	transcriptional	_	_	JJ	O	-1	none	_	_
4	pattern	_	_	NN	O	-1	none	_	_
5	similar	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	that	_	_	DT	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	nasopharyngeal	_	_	JJ	O	-1	none	_	_
10	carcinoma	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	Hodgkin	_	_	NN	O	-1	none	_	_
13	's	_	_	POS	O	-1	none	_	_
14	disease	_	_	NN	O	-1	none	_	_
15	suggests	_	_	VBZ	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	EBV	_	_	NN	O	-1	none	_	_
18	can	_	_	MD	O	-1	none	_	_
19	exploit	_	_	VB	O	-1	none	_	_
20	common	_	_	JJ	O	-1	none	_	_
21	regulatory	_	_	JJ	O	-1	none	_	_
22	mechanisms	_	_	NNS	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	diverse	_	_	JJ	O	-1	none	_	_
28	host	_	_	NN	O	-1	none	_	_
29	cell	_	_	NN	O	-1	none	_	_
30	types	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-AT	_	_	NN	O	-1	none	_	_
4	signal	_	_	NN	O	-1	none	_	_
5	transduction	_	_	NN	O	-1	none	_	_
6	events	_	_	NNS	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	dominant	_	_	JJ	O	-1	none	_	_
10	negative	_	_	JJ	O	-1	none	_	_
11	form	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	calcineurin	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	"	_	_	``	O	-1	none	_	_
5	dominant	_	_	JJ	O	-1	none	_	_
6	negative	_	_	JJ	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	"	_	_	``	O	-1	none	_	_
9	form	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	calcineurin	_	_	NN	Protein	17	multitoken	_	_
13	catalytic	_	_	JJ	Protein	17	multitoken	_	_
14	(	_	_	-LRB-	Protein	17	multitoken	_	_
15	A	_	_	DT	Protein	17	multitoken	_	_
16	)	_	_	-RRB-	Protein	17	multitoken	_	_
17	subunit	_	_	NN	Protein	0	root	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	prepared	_	_	VBN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	lacks	_	_	VBZ	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	calmodulin	_	_	NN	Protein	-1	none	_	_
25	binding	_	_	NN	O	-1	none	_	_
26	domain	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	autoinhibitory	_	_	JJ	O	-1	none	_	_
29	domain	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	most	_	_	JJS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	its	_	_	PRP$	O	-1	none	_	_
34	catalytic	_	_	JJ	O	-1	none	_	_
35	core	_	_	NN	O	-1	none	_	_
36	but	_	_	CC	O	-1	none	_	_
37	possesses	_	_	VBZ	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	regulatory	_	_	JJ	Protein	43	multitoken	_	_
40	(	_	_	-LRB-	Protein	43	multitoken	_	_
41	B	_	_	NN	Protein	43	multitoken	_	_
42	)	_	_	-RRB-	Protein	43	multitoken	_	_
43	subunit	_	_	NN	Protein	0	root	_	_
44	binding	_	_	NN	O	-1	none	_	_
45	domain	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	tested	_	_	VBN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	its	_	_	PRP$	O	-1	none	_	_
5	ability	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	block	_	_	VB	O	-1	none	_	_
8	calcineurin	_	_	NN	O	-1	none	_	_
9	dependent	_	_	JJ	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	Jurkat	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	this	_	_	DT	O	-1	none	_	_
18	"	_	_	``	O	-1	none	_	_
19	B-subunit	_	_	NN	O	-1	none	_	_
20	knock-out	_	_	JJ	O	-1	none	_	_
21	"	_	_	``	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	BKO	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	construct	_	_	NN	O	-1	none	_	_
26	suppressed	_	_	VBD	O	-1	none	_	_
27	reporter	_	_	NN	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	activity	_	_	NN	O	-1	none	_	_
30	driven	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	NF-AT	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	pivotal	_	_	JJ	O	-1	none	_	_
36	promoter	_	_	NN	O	-1	none	_	_
37	element	_	_	NN	O	-1	none	_	_
38	for	_	_	IN	O	-1	none	_	_
39	interleukin	_	_	NN	Protein	43	multitoken	_	_
40	(	_	_	-LRB-	Protein	43	multitoken	_	_
41	IL	_	_	NN	Protein	43	multitoken	_	_
42	)	_	_	-RRB-	Protein	43	multitoken	_	_
43	-2	_	_	CD	Protein	0	root	_	_
44	gene	_	_	NN	O	-1	none	_	_
45	induction	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Immunoprecipitation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	epitope	_	_	NN	O	-1	none	_	_
4	labeled	_	_	VBN	O	-1	none	_	_
5	BKO	_	_	NNP	O	-1	none	_	_
6	demonstrated	_	_	VBD	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	formation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	tight	_	_	JJ	O	-1	none	_	_
13	complex	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	endogenous	_	_	JJ	Protein	17	multitoken	_	_
16	B	_	_	NN	Protein	17	multitoken	_	_
17	subunit	_	_	NN	Protein	0	root	_	_
18	in	_	_	IN	O	-1	none	_	_
19	Jurkat	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	consistent	_	_	JJ	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	an	_	_	DT	O	-1	none	_	_
25	inhibitory	_	_	JJ	O	-1	none	_	_
26	mechanism	_	_	NN	O	-1	none	_	_
27	that	_	_	WDT	O	-1	none	_	_
28	involves	_	_	VBZ	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	sequestration	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	B	_	_	NN	Protein	34	multitoken	_	_
34	subunit	_	_	NN	Protein	0	root	_	_
35	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	sharply	_	_	RB	O	-1	none	_	_
5	reduced	_	_	VBN	O	-1	none	_	_
6	NF-AT	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	produced	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	co-transfecting	_	_	VBG	O	-1	none	_	_
11	BKO	_	_	NNP	O	-1	none	_	_
12	could	_	_	MD	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	"	_	_	''	O	-1	none	_	_
15	rescued	_	_	VBD	O	-1	none	_	_
16	"	_	_	``	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	overexpression	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	transfected	_	_	VBN	O	-1	none	_	_
21	B	_	_	NN	Protein	22	multitoken	_	_
22	subunit	_	_	NN	Protein	0	root	_	_
23	,	_	_	,	O	-1	none	_	_
24	suggesting	_	_	VBG	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	depletion	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	this	_	_	DT	O	-1	none	_	_
29	subunit	_	_	NN	O	-1	none	_	_
30	was	_	_	VBD	O	-1	none	_	_
31	responsible	_	_	JJ	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	inhibition	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	potential	_	_	JJ	O	-1	none	_	_
6	utility	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	agents	_	_	NNS	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	disrupt	_	_	VBP	O	-1	none	_	_
11	calcineurin	_	_	NN	O	-1	none	_	_
12	mediated	_	_	JJ	O	-1	none	_	_
13	signal	_	_	NN	O	-1	none	_	_
14	transduction	_	_	NN	O	-1	none	_	_
15	pathways	_	_	NNS	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	blocking	_	_	VBG	O	-1	none	_	_
18	formation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	catalytically	_	_	RB	O	-1	none	_	_
22	active	_	_	JJ	O	-1	none	_	_
23	dimer	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	calcineurin	_	_	NN	Protein	26	multitoken	_	_
26	A	_	_	NN	Protein	0	root	_	_
27	and	_	_	CC	O	-1	none	_	_
28	B	_	_	NN	Protein	29	multitoken	_	_
29	subunits	_	_	NNS	Protein	0	root	_	_
30	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	pp90rsk	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	early	_	_	JJ	Protein	7	multitoken	_	_
6	growth	_	_	NN	Protein	7	multitoken	_	_
7	response-1	_	_	NN	Protein	0	root	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	pokeweed	_	_	NN	O	-1	none	_	_
12	mitogen	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	examined	_	_	VBN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	effects	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	pokeweed	_	_	NN	O	-1	none	_	_
10	mitogen	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	PWM	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	early	_	_	JJ	Protein	20	multitoken	_	_
19	growth	_	_	NN	Protein	20	multitoken	_	_
20	response-1	_	_	NN	Protein	0	root	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	EGR-1	_	_	NN	Protein	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	normal	_	_	JJ	O	-1	none	_	_
27	human	_	_	NN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	PWM	_	_	NN	O	-1	none	_	_
2	regulates	_	_	VBZ	O	-1	none	_	_
3	EGR-1	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	both	_	_	CC	O	-1	none	_	_
8	transcriptional	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	post-transcriptional	_	_	JJ	O	-1	none	_	_
11	mechanisms	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	transfection	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	EGR-1	_	_	NN	Protein	-1	none	_	_
6	promoter	_	_	NN	O	-1	none	_	_
7	fragments	_	_	NNS	O	-1	none	_	_
8	linked	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	chloramphenicol	_	_	NN	Protein	12	multitoken	_	_
12	acetyltransferase	_	_	NN	Protein	0	root	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	CAT	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	demonstrated	_	_	VBD	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	PWM	_	_	NN	O	-1	none	_	_
20	induced	_	_	VBD	O	-1	none	_	_
21	EGR-1	_	_	NN	Protein	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	conferred	_	_	VBN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	CArG	_	_	NN	O	-1	none	_	_
28	motif	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	C	_	_	NN	O	-1	none	_	_
31	C	_	_	NN	O	-1	none	_	_
32	[	_	_	CD	O	-1	none	_	_
33	AT	_	_	IN	O	-1	none	_	_
34	]	_	_	CD	O	-1	none	_	_
35	6GG	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	EGR-1	_	_	NN	Protein	-1	none	_	_
40	promoter	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	further	_	_	RB	O	-1	none	_	_
4	demonstrated	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	S6	_	_	NN	O	-1	none	_	_
9	kinase	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	pp90rsk	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	evidenced	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	phosphorylation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	S6	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	serum	_	_	NN	Protein	22	multitoken	_	_
21	response	_	_	NN	Protein	22	multitoken	_	_
22	factor	_	_	NN	Protein	0	root	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	SRF	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	peptides	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	PWM	_	_	NN	O	-1	none	_	_
30	treated	_	_	JJ	O	-1	none	_	_
31	B	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	findings	_	_	NNS	O	-1	none	_	_
6	suggest	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	PWM	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	able	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	initiate	_	_	VB	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	intracytoplasmic	_	_	JJ	O	-1	none	_	_
15	signalling	_	_	NN	O	-1	none	_	_
16	cascade	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	EGR-1	_	_	NN	Protein	-1	none	_	_
19	induction	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	normal	_	_	JJ	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Cell	_	_	NN	O	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	bifunctional	_	_	JJ	O	-1	none	_	_
4	role	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Jun	_	_	NN	O	-1	none	_	_
7	oncogene	_	_	NN	O	-1	none	_	_
8	family	_	_	NN	O	-1	none	_	_
9	members	_	_	NNS	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	glucocorticoid	_	_	NN	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Interaction	_	_	NN	O	-1	none	_	_
2	between	_	_	IN	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	kinase	_	_	NN	O	-1	none	_	_
5	C	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	PKC	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	-	_	_	:	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	glucocorticoid	_	_	NN	Protein	12	multitoken	_	_
12	receptor	_	_	NN	Protein	0	root	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	GR	_	_	NN	Protein	-1	none	_	_
15	)-mediated	_	_	JJ	O	-1	none	_	_
16	signaling	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	suggested	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	ability	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	PKC	_	_	NN	O	-1	none	_	_
25	activating	_	_	VBG	O	-1	none	_	_
26	phorbol	_	_	NN	O	-1	none	_	_
27	ester	_	_	NN	O	-1	none	_	_
28	12-O-tetradecanoylphorbol-13-acetate	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	TPA	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	inhibit	_	_	VB	O	-1	none	_	_
34	GR	_	_	NN	Protein	-1	none	_	_
35	dependent	_	_	JJ	O	-1	none	_	_
36	transcription	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	mouse	_	_	NN	O	-1	none	_	_
40	mammary	_	_	JJ	O	-1	none	_	_
41	tumor	_	_	NN	O	-1	none	_	_
42	virus	_	_	NN	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	MMTV	_	_	NN	O	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	long	_	_	JJ	O	-1	none	_	_
47	terminal	_	_	JJ	O	-1	none	_	_
48	repeat	_	_	NN	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	LTR	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	interference	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	specific	_	_	JJ	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	TPA	_	_	NN	O	-1	none	_	_
13	augmented	_	_	VBD	O	-1	none	_	_
14	dexamethasone	_	_	NN	O	-1	none	_	_
15	induced	_	_	VBN	O	-1	none	_	_
16	transcriptional	_	_	JJ	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	MMTV	_	_	NN	O	-1	none	_	_
21	LTR	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	several	_	_	JJ	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	lines	_	_	NNS	O	-1	none	_	_
27	but	_	_	CC	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	inhibitory	_	_	JJ	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	NIH-3T3	_	_	NN	O	-1	none	_	_
32	fibroblasts	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	TPA-GR	_	_	NNP	Protein	-1	none	_	_
2	synergism	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	determined	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	have	_	_	VB	O	-1	none	_	_
7	occurred	_	_	VBN	O	-1	none	_	_
8	at	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	GR	_	_	NN	Protein	-1	none	_	_
11	responsive	_	_	JJ	O	-1	none	_	_
12	element	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	GRE	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	level	_	_	NN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	functional	_	_	JJ	O	-1	none	_	_
19	analysis	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	deletion	_	_	NN	O	-1	none	_	_
22	mutants	_	_	NNS	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	synthetic	_	_	JJ	O	-1	none	_	_
25	GRE	_	_	NN	O	-1	none	_	_
26	oligonucleotides	_	_	NNS	O	-1	none	_	_
27	driving	_	_	VBG	O	-1	none	_	_
28	chloramphenicol	_	_	NN	Protein	29	multitoken	_	_
29	acetyl-transferase	_	_	NN	Protein	0	root	_	_
30	expression	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Synergism	_	_	NN	O	-1	none	_	_
2	required	_	_	VBD	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	intact	_	_	JJ	O	-1	none	_	_
5	GR	_	_	NN	Protein	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	domain	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	whereas	_	_	IN	O	-1	none	_	_
11	amino-	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	carboxyl-terminal	_	_	JJ	O	-1	none	_	_
14	domains	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	dispensable	_	_	JJ	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	abrogated	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	PKC	_	_	NN	O	-1	none	_	_
8	inhibitor	_	_	NN	O	-1	none	_	_
9	staurosporine	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	suggesting	_	_	VBG	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	PKC	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Increased	_	_	VBN	O	-1	none	_	_
2	c-jun	_	_	NN	Protein	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	jun-B	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	jun-D	_	_	NN	Protein	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	above	_	_	IN	O	-1	none	_	_
10	basal	_	_	JJ	O	-1	none	_	_
11	levels	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	increased	_	_	VBD	O	-1	none	_	_
14	transcriptional	_	_	JJ	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	AP-1	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	TPA	_	_	NN	O	-1	none	_	_
20	responsive	_	_	JJ	O	-1	none	_	_
21	elements	_	_	NNS	O	-1	none	_	_
22	fused	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	chloramphenicol	_	_	NN	Protein	25	multitoken	_	_
25	acetyl-transferase	_	_	NN	Protein	0	root	_	_
26	vectors	_	_	NNS	O	-1	none	_	_
27	were	_	_	VBD	O	-1	none	_	_
28	observed	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	treated	_	_	VBN	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	TPA	_	_	NN	O	-1	none	_	_
35	alone	_	_	RB	O	-1	none	_	_
36	or	_	_	CC	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	combination	_	_	NN	O	-1	none	_	_
39	with	_	_	IN	O	-1	none	_	_
40	dexamethasone	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	ability	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Jun	_	_	NN	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	cooperate	_	_	VB	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	GR	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	has	_	_	VBZ	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	investigated	_	_	VBN	O	-1	none	_	_
16	after	_	_	IN	O	-1	none	_	_
17	transfection	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	c-jun	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	jun-B	_	_	NN	Protein	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	jun-D	_	_	NN	Protein	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	vectors	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	which	_	_	WDT	O	-1	none	_	_
29	augmented	_	_	VBD	O	-1	none	_	_
30	GR	_	_	NN	Protein	-1	none	_	_
31	dependent	_	_	JJ	O	-1	none	_	_
32	transcription	_	_	NN	O	-1	none	_	_
33	from	_	_	IN	O	-1	none	_	_
34	either	_	_	CC	O	-1	none	_	_
35	MMTV	_	_	NN	O	-1	none	_	_
36	LTR	_	_	NN	O	-1	none	_	_
37	or	_	_	CC	O	-1	none	_	_
38	GRE	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Conversely	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	c-jun	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	jun-B	_	_	NN	Protein	-1	none	_	_
6	transfection	_	_	NN	O	-1	none	_	_
7	blunted	_	_	VBD	O	-1	none	_	_
8	GR	_	_	NN	Protein	-1	none	_	_
9	dependent	_	_	JJ	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	HeLa	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	presence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	c-fos	_	_	NN	Protein	-1	none	_	_
5	had	_	_	VBD	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	negative	_	_	JJ	O	-1	none	_	_
8	influence	_	_	NN	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	GR	_	_	NN	Protein	-1	none	_	_
11	function	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	correlated	_	_	VBD	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	specific	_	_	JJ	O	-1	none	_	_
18	synergistic	_	_	JJ	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	antagonistic	_	_	JJ	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	Jun	_	_	NN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	respect	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	GR	_	_	NN	Protein	-1	none	_	_
28	;	_	_	:	O	-1	none	_	_
29	high	_	_	JJ	O	-1	none	_	_
30	basal	_	_	JJ	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	c-fos	_	_	NN	Protein	-1	none	_	_
34	as	_	_	RB	O	-1	none	_	_
35	well	_	_	RB	O	-1	none	_	_
36	as	_	_	IN	O	-1	none	_	_
37	AP-1	_	_	NN	O	-1	none	_	_
38	DNA	_	_	NN	O	-1	none	_	_
39	binding	_	_	NN	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	transcriptional	_	_	JJ	O	-1	none	_	_
42	activity	_	_	NN	O	-1	none	_	_
43	were	_	_	VBD	O	-1	none	_	_
44	observed	_	_	VBN	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	HeLa	_	_	NN	O	-1	none	_	_
47	cells	_	_	NNS	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	but	_	_	CC	O	-1	none	_	_
50	not	_	_	RB	O	-1	none	_	_
51	in	_	_	IN	O	-1	none	_	_
52	T	_	_	NN	O	-1	none	_	_
53	cells	_	_	NNS	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	exogenous	_	_	JJ	O	-1	none	_	_
5	c-fos	_	_	NN	Protein	-1	none	_	_
6	has	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	inhibitory	_	_	JJ	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	GR	_	_	NN	Protein	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	GRE	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	Jun	_	_	NN	O	-1	none	_	_
5	plays	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	bifunctional	_	_	JJ	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	GR	_	_	NN	Protein	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	transcriptional	_	_	JJ	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	GRE	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	selecting	_	_	VBG	O	-1	none	_	_
18	either	_	_	CC	O	-1	none	_	_
19	synergistic	_	_	JJ	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	antagonistic	_	_	JJ	O	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	depending	_	_	VBG	O	-1	none	_	_
24	on	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	specific	_	_	JJ	O	-1	none	_	_
28	microenvironment	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	regard	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	intracellular	_	_	JJ	O	-1	none	_	_
6	levels	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	c-fos	_	_	NN	Protein	-1	none	_	_
9	appear	_	_	VBP	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	be	_	_	VB	O	-1	none	_	_
12	influential	_	_	JJ	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Calcineurin	_	_	NN	O	-1	none	_	_
2	acts	_	_	VBZ	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	synergy	_	_	NN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	PMA	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	inactivate	_	_	VB	O	-1	none	_	_
9	I	_	_	NN	O	-1	none	_	_
10	kappa	_	_	NN	O	-1	none	_	_
11	B/MAD3	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	inhibitor	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	interleukin-2	_	_	NN	Protein	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	IL-2	_	_	NN	Protein	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	promoter	_	_	NN	O	-1	none	_	_
7	consists	_	_	VBZ	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	several	_	_	JJ	O	-1	none	_	_
10	independent	_	_	JJ	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	TcR	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	responsive	_	_	JJ	O	-1	none	_	_
18	elements	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	promoters	_	_	NNS	O	-1	none	_	_
5	dependent	_	_	JJ	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	elements	_	_	NNS	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	inhibitable	_	_	JJ	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	immunosuppressants	_	_	NNS	O	-1	none	_	_
14	cyclosporin	_	_	NN	O	-1	none	_	_
15	A	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	CsA	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	tacrolimus	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	FK-506	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Calcineurin	_	_	NN	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	Ca2	_	_	NN	O	-1	none	_	_
5	+/calmodulin-dependent	_	_	JJ	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	phosphatase	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	FK-506-	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	CsA	_	_	NN	O	-1	none	_	_
14	sensitive	_	_	JJ	O	-1	none	_	_
15	enzyme	_	_	NN	O	-1	none	_	_
16	required	_	_	VBN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	TcR	_	_	NN	O	-1	none	_	_
19	mediated	_	_	JJ	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	IL-2	_	_	NN	Protein	-1	none	_	_
24	promoter	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	constitutively	_	_	RB	O	-1	none	_	_
6	active	_	_	JJ	O	-1	none	_	_
7	form	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	calcineurin	_	_	NN	O	-1	none	_	_
10	partially	_	_	RB	O	-1	none	_	_
11	substitutes	_	_	VBZ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	Ca2+	_	_	NN	O	-1	none	_	_
15	co-stimulus	_	_	NN	O	-1	none	_	_
16	required	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	activate	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	promoter	_	_	NN	O	-1	none	_	_
22	elements	_	_	NNS	O	-1	none	_	_
23	IL-2A	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	binds	_	_	VBZ	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	factors	_	_	NNS	O	-1	none	_	_
29	OAP	_	_	NN	Protein	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	Oct-1	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	IL-2E	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	which	_	_	WDT	O	-1	none	_	_
37	binds	_	_	VBZ	O	-1	none	_	_
38	NF-AT	_	_	NN	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	completely	_	_	RB	O	-1	none	_	_
43	substitutes	_	_	VBZ	O	-1	none	_	_
44	for	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	Ca2+	_	_	NN	O	-1	none	_	_
47	co-stimulus	_	_	NN	O	-1	none	_	_
48	required	_	_	VBN	O	-1	none	_	_
49	to	_	_	TO	O	-1	none	_	_
50	stimulate	_	_	VB	O	-1	none	_	_
51	an	_	_	DT	O	-1	none	_	_
52	NF-kappa	_	_	NN	O	-1	none	_	_
53	B	_	_	NN	O	-1	none	_	_
54	dependent	_	_	JJ	O	-1	none	_	_
55	element	_	_	NN	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	Calcineurin	_	_	NN	O	-1	none	_	_
2	stimulates	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	element	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	enhancing	_	_	VBG	O	-1	none	_	_
9	inactivation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	I	_	_	NN	O	-1	none	_	_
12	kappa	_	_	NN	O	-1	none	_	_
13	B/MAD3	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	inhibitor	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	NF-kappa	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	thereby	_	_	RB	O	-1	none	_	_
22	increasing	_	_	VBG	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	amount	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	nuclear	_	_	JJ	O	-1	none	_	_
27	NF-kappa	_	_	NN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	DNA	_	_	NN	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	activity	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	provide	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	first	_	_	JJ	O	-1	none	_	_
6	demonstration	_	_	NN	O	-1	none	_	_
7	in	_	_	FW	O	-1	none	_	_
8	vivo	_	_	FW	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	phosphatase	_	_	NN	O	-1	none	_	_
15	can	_	_	MD	O	-1	none	_	_
16	inactivate	_	_	VB	O	-1	none	_	_
17	I	_	_	NN	O	-1	none	_	_
18	kappa	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	suggest	_	_	VBP	O	-1	none	_	_
23	one	_	_	CD	O	-1	none	_	_
24	possible	_	_	JJ	O	-1	none	_	_
25	explanation	_	_	NN	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	mechanism	_	_	NN	O	-1	none	_	_
28	based	_	_	VBN	O	-1	none	_	_
29	toxicities	_	_	NNS	O	-1	none	_	_
30	associated	_	_	VBN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	FK-506	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	CsA	_	_	NN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	demonstrating	_	_	VBG	O	-1	none	_	_
37	that	_	_	IN	O	-1	none	_	_
38	these	_	_	DT	O	-1	none	_	_
39	drugs	_	_	NNS	O	-1	none	_	_
40	can	_	_	MD	O	-1	none	_	_
41	inhibit	_	_	VB	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	calcineurin	_	_	NN	O	-1	none	_	_
44	dependent	_	_	JJ	O	-1	none	_	_
45	activation	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	a	_	_	DT	O	-1	none	_	_
48	virtually	_	_	RB	O	-1	none	_	_
49	ubiquitous	_	_	JJ	O	-1	none	_	_
50	transcription	_	_	NN	O	-1	none	_	_
51	factor	_	_	NN	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Relationship	_	_	NN	O	-1	none	_	_
2	between	_	_	IN	O	-1	none	_	_
3	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
4	constitutive	_	_	JJ	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	TNFalpha	_	_	NN	Protein	-1	none	_	_
8	synthesis	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	apoptosis	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	EBV	_	_	NN	O	-1	none	_	_
14	infected	_	_	JJ	O	-1	none	_	_
15	lymphoblastoid	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	understand	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	NF-kappaB	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	EBV	_	_	NN	O	-1	none	_	_
11	transformation	_	_	NN	O	-1	none	_	_
12	we	_	_	PRP	O	-1	none	_	_
13	have	_	_	VBP	O	-1	none	_	_
14	established	_	_	VBN	O	-1	none	_	_
15	stably	_	_	RB	O	-1	none	_	_
16	transfected	_	_	VBN	O	-1	none	_	_
17	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
18	into	_	_	IN	O	-1	none	_	_
19	lymphoblastoid	_	_	JJ	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	clones	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	obtained	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	loss	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	correlated	_	_	VBD	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	constitutive	_	_	JJ	O	-1	none	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	transgenic	_	_	JJ	O	-1	none	_	_
21	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Protein	_	_	NN	O	-1	none	_	_
2	latency	_	_	NN	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	determined	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	immunocytochemistry	_	_	NN	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	surface	_	_	NN	O	-1	none	_	_
4	markers	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	intracytoplasmic	_	_	JJ	O	-1	none	_	_
7	content	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	cytokines	_	_	NNS	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	cycle	_	_	NN	O	-1	none	_	_
12	analysis	_	_	NN	O	-1	none	_	_
13	after	_	_	IN	O	-1	none	_	_
14	BrdU	_	_	NN	O	-1	none	_	_
15	incorporation	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	DNA	_	_	NN	O	-1	none	_	_
18	staining	_	_	NN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	propidium	_	_	NN	O	-1	none	_	_
21	iodide	_	_	NN	O	-1	none	_	_
22	were	_	_	VBD	O	-1	none	_	_
23	studied	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	flow	_	_	NN	O	-1	none	_	_
26	cytometry	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Percentage	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	apoptotic	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	determined	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	in-situ	_	_	FW	O	-1	none	_	_
9	labelling	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	strand	_	_	NN	O	-1	none	_	_
13	breaks	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	significative	_	_	JJ	O	-1	none	_	_
3	changes	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	EBV	_	_	NN	O	-1	none	_	_
6	latency	_	_	NN	O	-1	none	_	_
7	nor	_	_	CC	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	surface	_	_	NN	O	-1	none	_	_
11	marker	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	found	_	_	VBN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	intracytoplasmic	_	_	JJ	O	-1	none	_	_
5	TNFalpha	_	_	NN	Protein	-1	none	_	_
6	levels	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	strongly	_	_	RB	O	-1	none	_	_
9	reduced	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	transfected	_	_	VBN	O	-1	none	_	_
12	clones	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	30	_	_	CD	O	-1	none	_	_
4	%	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
7	transfected	_	_	VBN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	apoptotic	_	_	JJ	O	-1	none	_	_
11	after	_	_	IN	O	-1	none	_	_
12	8	_	_	CD	O	-1	none	_	_
13	h	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	TNFalpha	_	_	NN	Protein	-1	none	_	_
16	treatment	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	correlated	_	_	VBD	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	strong	_	_	JJ	O	-1	none	_	_
6	reduction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	BrdU	_	_	NN	O	-1	none	_	_
9	incorporation	_	_	NN	O	-1	none	_	_
10	after	_	_	IN	O	-1	none	_	_
11	24	_	_	CD	O	-1	none	_	_
12	h	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	TNFalpha	_	_	NN	Protein	-1	none	_	_
15	treatment	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	seen	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	non	_	_	JJ	O	-1	none	_	_
7	transfected	_	_	VBN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	transfected	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	control	_	_	NN	O	-1	none	_	_
16	plasmid	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	TNFalpha	_	_	NN	Protein	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	could	_	_	MD	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	one	_	_	CD	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	targets	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	NF-kappaB	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	EBV	_	_	NN	O	-1	none	_	_
18	infected	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	NF-kappaB	_	_	NN	O	-1	none	_	_
23	protects	_	_	VBZ	O	-1	none	_	_
24	EBV	_	_	NN	O	-1	none	_	_
25	infected	_	_	JJ	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	from	_	_	IN	O	-1	none	_	_
28	apoptosis	_	_	NN	O	-1	none	_	_
29	induced	_	_	VBN	O	-1	none	_	_
30	by	_	_	IN	O	-1	none	_	_
31	TNFalpha	_	_	NN	Protein	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	which	_	_	WDT	O	-1	none	_	_
34	may	_	_	MD	O	-1	none	_	_
35	favour	_	_	VB	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	proliferative	_	_	JJ	O	-1	none	_	_
38	effect	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	this	_	_	DT	O	-1	none	_	_
41	cytokine	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	maintenance	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	lymphocyte	_	_	NN	O	-1	none	_	_
5	homeostasis	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	apoptosis	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	critical	_	_	JJ	O	-1	none	_	_
11	regulatory	_	_	JJ	O	-1	none	_	_
12	mechanism	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	normal	_	_	JJ	O	-1	none	_	_
16	immune	_	_	JJ	O	-1	none	_	_
17	system	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Transfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Jurkat	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	NF-kappaB	_	_	NN	O	-1	none	_	_
8	subunits	_	_	NNS	O	-1	none	_	_
9	p50	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p65	_	_	NN	Protein	-1	none	_	_
12	confers	_	_	VBZ	O	-1	none	_	_
13	resistance	_	_	NN	O	-1	none	_	_
14	against	_	_	IN	O	-1	none	_	_
15	Fas	_	_	NN	Protein	-1	none	_	_
16	mediated	_	_	JJ	O	-1	none	_	_
17	apoptosis	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Reciprocally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	inhibition	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	NF-kappaB	_	_	NN	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	soluble	_	_	JJ	O	-1	none	_	_
10	peptide	_	_	NN	O	-1	none	_	_
11	inhibitor	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	dominant	_	_	JJ	O	-1	none	_	_
15	form	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	NF-kappaB	_	_	NN	O	-1	none	_	_
19	inhibitor	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	IkappaB	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	makes	_	_	VBZ	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	more	_	_	RBR	O	-1	none	_	_
27	susceptible	_	_	JJ	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	Fas	_	_	NN	Protein	-1	none	_	_
30	mediated	_	_	JJ	O	-1	none	_	_
31	apoptosis	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	inhibition	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	NF-kappaB	_	_	NN	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	soluble	_	_	JJ	O	-1	none	_	_
10	peptide	_	_	NN	O	-1	none	_	_
11	inhibitor	_	_	NN	O	-1	none	_	_
12	rendered	_	_	VBD	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	hybridoma	_	_	NN	O	-1	none	_	_
17	more	_	_	RBR	O	-1	none	_	_
18	susceptible	_	_	JJ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	TCR	_	_	NN	O	-1	none	_	_
21	mediated	_	_	JJ	O	-1	none	_	_
22	apoptosis	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Correspondingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	transfection	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	p50	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	p65	_	_	NN	Protein	-1	none	_	_
8	provided	_	_	VBD	O	-1	none	_	_
9	considerable	_	_	JJ	O	-1	none	_	_
10	protection	_	_	NN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	TCR	_	_	NN	O	-1	none	_	_
13	mediated	_	_	JJ	O	-1	none	_	_
14	apoptosis	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	corroborated	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	studies	_	_	NNS	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	Fas	_	_	NN	Protein	-1	none	_	_
9	mediated	_	_	VBD	O	-1	none	_	_
10	death	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	primary	_	_	JJ	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Concanavalin	_	_	NN	O	-1	none	_	_
2	A	_	_	NN	O	-1	none	_	_
3	activated	_	_	VBD	O	-1	none	_	_
4	cycling	_	_	NN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	blasts	_	_	NNS	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	mice	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	transgenic	_	_	JJ	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	dominant	_	_	JJ	O	-1	none	_	_
16	IkappaB	_	_	NN	O	-1	none	_	_
17	molecule	_	_	NN	O	-1	none	_	_
18	have	_	_	VBP	O	-1	none	_	_
19	increased	_	_	VBN	O	-1	none	_	_
20	sensitivity	_	_	NN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	Fas	_	_	NN	Protein	-1	none	_	_
23	mediated	_	_	JJ	O	-1	none	_	_
24	apoptosis	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	associated	_	_	VBN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	down-regulation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	NF-kappaB	_	_	NN	O	-1	none	_	_
32	complexes	_	_	NNS	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	nucleus	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	summary	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	provide	_	_	VBP	O	-1	none	_	_
7	compelling	_	_	JJ	O	-1	none	_	_
8	evidence	_	_	NN	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	protects	_	_	VBZ	O	-1	none	_	_
12	against	_	_	IN	O	-1	none	_	_
13	Fas	_	_	NN	Protein	-1	none	_	_
14	mediated	_	_	VBD	O	-1	none	_	_
15	death	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	likely	_	_	JJ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	important	_	_	JJ	O	-1	none	_	_
23	regulator	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	homeostasis	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	tolerance	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Inhibitory	_	_	JJ	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	E3330	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	novel	_	_	JJ	O	-1	none	_	_
8	quinone	_	_	NN	O	-1	none	_	_
9	derivative	_	_	JJ	O	-1	none	_	_
10	able	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	suppress	_	_	VB	O	-1	none	_	_
13	tumor	_	_	NN	Protein	15	multitoken	_	_
14	necrosis	_	_	NN	Protein	15	multitoken	_	_
15	factor-alpha	_	_	NN	Protein	0	root	_	_
16	generation	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	nuclear	_	_	JJ	O	-1	none	_	_
22	factor-kappa	_	_	NN	O	-1	none	_	_
23	B.	_	_	NNP	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	2E	_	_	NN	O	-1	none	_	_
26	)-3-[	_	_	CD	O	-1	none	_	_
27	5-(	_	_	CD	O	-1	none	_	_
28	2,3-Dimethoxy-6-methyl-1	_	_	NN	O	-1	none	_	_
29	,4-benzoquinoyl	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	]-2-nonyl-2-	_	_	NN	O	-1	none	_	_
32	propenoic	_	_	JJ	O	-1	none	_	_
33	acid	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	E3330	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	is	_	_	VBZ	O	-1	none	_	_
39	a	_	_	DT	O	-1	none	_	_
40	novel	_	_	JJ	O	-1	none	_	_
41	agent	_	_	NN	O	-1	none	_	_
42	with	_	_	IN	O	-1	none	_	_
43	hepatoprotective	_	_	JJ	O	-1	none	_	_
44	activity	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	effect	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	E3330	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	transcriptional	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	tumor	_	_	NN	O	-1	none	_	_
12	necrosis	_	_	NN	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	TNF	_	_	NN	O	-1	none	_	_
16	)-alpha	_	_	NN	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	on	_	_	IN	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	NF	_	_	NN	O	-1	none	_	_
24	)-kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	run-on	_	_	JJ	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	E3330	_	_	NN	O	-1	none	_	_
7	decreases	_	_	VBZ	O	-1	none	_	_
8	transcriptional	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	TNF-alpha	_	_	NN	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	lipopolysaccharide	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	LPS	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	stimulation	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	peripheral	_	_	JJ	O	-1	none	_	_
23	monocytes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	investigate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	inhibitory	_	_	JJ	O	-1	none	_	_
5	mechanisms	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	constructed	_	_	VBD	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	secreted-type	_	_	JJ	O	-1	none	_	_
11	placental	_	_	JJ	Protein	13	multitoken	_	_
12	alkaline	_	_	NN	Protein	13	multitoken	_	_
13	phosphatase	_	_	NN	Protein	0	root	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	PLAP	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	reporter	_	_	NN	O	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	whose	_	_	WP$	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	controlled	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	1.4-kb	_	_	JJ	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	TNF-alpha	_	_	NN	Protein	-1	none	_	_
28	promoter	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	stable	_	_	JJ	O	-1	none	_	_
3	transformant	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	PLAP	_	_	NN	Protein	-1	none	_	_
7	reporter	_	_	NN	O	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	derived	_	_	VBN	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	monocytic	_	_	JJ	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	line	_	_	NN	O	-1	none	_	_
15	showed	_	_	VBD	O	-1	none	_	_
16	very	_	_	RB	O	-1	none	_	_
17	little	_	_	JJ	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	on	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	promoter	_	_	NN	O	-1	none	_	_
22	before	_	_	IN	O	-1	none	_	_
23	stimulation	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	whereas	_	_	IN	O	-1	none	_	_
26	LPS	_	_	NN	O	-1	none	_	_
27	stimulation	_	_	NN	O	-1	none	_	_
28	led	_	_	VBD	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	a	_	_	DT	O	-1	none	_	_
31	dramatic	_	_	JJ	O	-1	none	_	_
32	increase	_	_	NN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	PLAP	_	_	NN	Protein	-1	none	_	_
35	activity	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	E3330	_	_	NN	O	-1	none	_	_
2	inhibited	_	_	VBD	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	induced	_	_	JJ	O	-1	none	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	dose	_	_	NN	O	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	manner	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	four	_	_	CD	O	-1	none	_	_
4	putative	_	_	JJ	O	-1	none	_	_
5	NF-kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	sites	_	_	NNS	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	kappa	_	_	NN	O	-1	none	_	_
11	B-1	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	kappa	_	_	NN	O	-1	none	_	_
14	B-2	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	kappa	_	_	NN	O	-1	none	_	_
17	B-3	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	kappa	_	_	NN	O	-1	none	_	_
20	B-4	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	human	_	_	NN	O	-1	none	_	_
24	TNF-alpha	_	_	NN	Protein	-1	none	_	_
25	promoter	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	mutated	_	_	VBN	O	-1	none	_	_
4	promoter-PLAP	_	_	JJ	Protein	-1	none	_	_
5	plasmids	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	established	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	these	_	_	DT	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	were	_	_	VBD	O	-1	none	_	_
15	necessary	_	_	JJ	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	induction	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	TNF-alpha	_	_	NN	Protein	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	on	_	_	IN	O	-1	none	_	_
22	stimulation	_	_	NN	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	LPS	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	gel	_	_	NN	O	-1	none	_	_
3	retardation	_	_	NN	O	-1	none	_	_
4	experiment	_	_	NN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	synthetic	_	_	JJ	O	-1	none	_	_
7	double	_	_	JJ	O	-1	none	_	_
8	stranded	_	_	JJ	O	-1	none	_	_
9	oligonucleotides	_	_	NNS	O	-1	none	_	_
10	showed	_	_	VBD	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	consisting	_	_	VBG	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	p50	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	p65	_	_	NN	Protein	-1	none	_	_
20	heterodimer	_	_	NN	O	-1	none	_	_
21	bound	_	_	VBN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	all	_	_	DT	O	-1	none	_	_
24	four	_	_	CD	O	-1	none	_	_
25	putative	_	_	JJ	O	-1	none	_	_
26	NF-kappa	_	_	NN	O	-1	none	_	_
27	B	_	_	NN	O	-1	none	_	_
28	DNA	_	_	NN	O	-1	none	_	_
29	probes	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	suggesting	_	_	VBG	O	-1	none	_	_
32	that	_	_	IN	O	-1	none	_	_
33	all	_	_	DT	O	-1	none	_	_
34	four	_	_	CD	O	-1	none	_	_
35	putative	_	_	JJ	O	-1	none	_	_
36	NF-kappa	_	_	NN	O	-1	none	_	_
37	B	_	_	NN	O	-1	none	_	_
38	recognition	_	_	NN	O	-1	none	_	_
39	sites	_	_	NNS	O	-1	none	_	_
40	play	_	_	VBP	O	-1	none	_	_
41	an	_	_	DT	O	-1	none	_	_
42	important	_	_	JJ	O	-1	none	_	_
43	role	_	_	NN	O	-1	none	_	_
44	in	_	_	IN	O	-1	none	_	_
45	inducible	_	_	JJ	O	-1	none	_	_
46	TNF-alpha	_	_	NN	Protein	-1	none	_	_
47	expression	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	E3330	_	_	NN	O	-1	none	_	_
2	decreased	_	_	VBD	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	nuclei	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	suggesting	_	_	VBG	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	E3330	_	_	NN	O	-1	none	_	_
12	inhibits	_	_	VBZ	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	and/or	_	_	CC	O	-1	none	_	_
17	translocation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	nuclei	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blotting	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	anti-I	_	_	JJ	Protein	7	multitoken	_	_
6	kappa	_	_	NN	Protein	7	multitoken	_	_
7	B-alpha	_	_	NN	Protein	0	root	_	_
8	antibody	_	_	NN	O	-1	none	_	_
9	indicated	_	_	VBD	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	E3330	_	_	NN	O	-1	none	_	_
12	inhibited	_	_	VBD	O	-1	none	_	_
13	degradation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	I	_	_	NN	Protein	17	multitoken	_	_
16	kappa	_	_	NN	Protein	17	multitoken	_	_
17	B-alpha	_	_	NN	Protein	0	root	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	inhibitory	_	_	JJ	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	NF-kappa	_	_	NN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	LPS	_	_	NN	O	-1	none	_	_
30	stimulated	_	_	VBD	O	-1	none	_	_
31	monocytes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	E3330	_	_	NN	O	-1	none	_	_
2	may	_	_	MD	O	-1	none	_	_
3	suppress	_	_	VB	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	production	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	active	_	_	JJ	O	-1	none	_	_
8	oxygen	_	_	NN	O	-1	none	_	_
9	species	_	_	NNS	O	-1	none	_	_
10	serving	_	_	VBG	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	common	_	_	JJ	O	-1	none	_	_
13	messengers	_	_	NNS	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	activate	_	_	VB	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B.	_	_	NNP	O	-1	none	_	_

1	High	_	_	JJ	O	-1	none	_	_
2	molecular	_	_	JJ	O	-1	none	_	_
3	weight	_	_	NN	O	-1	none	_	_
4	dextran	_	_	NN	O	-1	none	_	_
5	sulfate	_	_	NN	O	-1	none	_	_
6	increases	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NF-kappaB-regulated	_	_	JJ	O	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	monocyte	_	_	NN	O	-1	none	_	_
14	derived	_	_	VBN	O	-1	none	_	_
15	macrophages	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	known	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	sulfated	_	_	JJ	O	-1	none	_	_
6	polysaccharides	_	_	NNS	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	mimic	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	action	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	common	_	_	JJ	O	-1	none	_	_
13	T-cell	_	_	NN	O	-1	none	_	_
14	mitogens	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	investigate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	basis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	mitogenic	_	_	JJ	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	high	_	_	JJ	O	-1	none	_	_
12	molecular	_	_	JJ	O	-1	none	_	_
13	weight	_	_	NN	O	-1	none	_	_
14	dextran	_	_	NN	O	-1	none	_	_
15	sulfate	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	HMDS	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	monocyte	_	_	NN	O	-1	none	_	_
21	derived	_	_	VBN	O	-1	none	_	_
22	macrophages	_	_	NNS	O	-1	none	_	_
23	were	_	_	VBD	O	-1	none	_	_
24	transfected	_	_	VBN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	recombinant	_	_	JJ	O	-1	none	_	_
27	plasmid	_	_	NN	O	-1	none	_	_
28	containing	_	_	VBG	O	-1	none	_	_
29	chloramphenicol	_	_	NN	Protein	31	multitoken	_	_
30	acetyl	_	_	NN	Protein	31	multitoken	_	_
31	transferase	_	_	NN	Protein	0	root	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	CAT	_	_	NN	Protein	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	reporter	_	_	NN	O	-1	none	_	_
36	gene	_	_	NN	O	-1	none	_	_
37	under	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	control	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	HIV-1	_	_	NN	O	-1	none	_	_
43	long	_	_	JJ	O	-1	none	_	_
44	terminal	_	_	JJ	O	-1	none	_	_
45	repeat	_	_	NN	O	-1	none	_	_
46	(	_	_	-LRB-	O	-1	none	_	_
47	LTR	_	_	NN	O	-1	none	_	_
48	)	_	_	-RRB-	O	-1	none	_	_
49	promoter	_	_	NN	O	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	which	_	_	WDT	O	-1	none	_	_
52	is	_	_	VBZ	O	-1	none	_	_
53	regulated	_	_	VBN	O	-1	none	_	_
54	by	_	_	IN	O	-1	none	_	_
55	transcription	_	_	NN	O	-1	none	_	_
56	factor	_	_	NN	O	-1	none	_	_
57	NF-kappaB	_	_	NN	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	observed	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	HMDS	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	similar	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	bacterial	_	_	JJ	O	-1	none	_	_
9	lipopolysaccharide	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	LPS	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	increases	_	_	VBZ	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	CAT	_	_	NN	Protein	-1	none	_	_
19	reporter	_	_	NN	O	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	suggesting	_	_	VBG	O	-1	none	_	_
22	increased	_	_	VBN	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	NF-kappaB	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NF-kappaB	_	_	NN	O	-1	none	_	_
5	correlated	_	_	VBD	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	increased	_	_	JJ	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	B7	_	_	NN	Protein	12	multitoken	_	_
12	.1	_	_	NN	Protein	0	root	_	_
13	molecules	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	postulated	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	NF-kappaB-regulated	_	_	JJ	O	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	might	_	_	MD	O	-1	none	_	_
9	play	_	_	VB	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	role	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	accessory	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	as	_	_	RB	O	-1	none	_	_
20	well	_	_	RB	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	rate	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	replication	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	HIV-1	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	monocyte	_	_	NN	O	-1	none	_	_
30	derived	_	_	VBN	O	-1	none	_	_
31	macrophages	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	interleukin-8	_	_	NN	Protein	-1	none	_	_
3	AP-1	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	like	_	_	IN	O	-1	none	_	_
8	sites	_	_	NNS	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	genetic	_	_	JJ	O	-1	none	_	_
11	end	_	_	NN	O	-1	none	_	_
12	targets	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	FK506	_	_	NN	O	-1	none	_	_
15	sensitive	_	_	JJ	O	-1	none	_	_
16	pathway	_	_	NN	O	-1	none	_	_
17	accompanied	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	calcium	_	_	NN	O	-1	none	_	_
20	mobilization	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	FK506	_	_	NN	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	immunosuppressant	_	_	JJ	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	inhibits	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	production	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	several	_	_	JJ	O	-1	none	_	_
11	cytokines	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	observed	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	FK506	_	_	NN	O	-1	none	_	_
5	suppressed	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	chemotactic	_	_	JJ	O	-1	none	_	_
11	cytokine	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	interleukin-8	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	IL-8	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	line	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	Jurkat	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	activated	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	phorbol	_	_	NN	O	-1	none	_	_
30	12-myristate	_	_	NN	O	-1	none	_	_
31	13-acetate	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	PMA	_	_	NN	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	calcium	_	_	NN	O	-1	none	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	Ca2+	_	_	NN	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	ionophore	_	_	NN	O	-1	none	_	_
41	(	_	_	-LRB-	O	-1	none	_	_
42	ionomycin	_	_	NN	O	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	deleted	_	_	VBN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	mutated	_	_	VBN	O	-1	none	_	_
5	analysis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	IL-8	_	_	NN	Protein	-1	none	_	_
9	promoters	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	AP-1	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	kappa	_	_	NN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	like	_	_	IN	O	-1	none	_	_
17	sites	_	_	NNS	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	identified	_	_	VBN	O	-1	none	_	_
20	as	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	responsive	_	_	JJ	O	-1	none	_	_
23	elements	_	_	NNS	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	PMA	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	ionomycin	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	FK506	_	_	NN	O	-1	none	_	_
2	suppressed	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	transcriptions	_	_	NNS	O	-1	none	_	_
5	through	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	AP-1	_	_	NN	O	-1	none	_	_
8	or	_	_	CC	O	-1	none	_	_
9	kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	like	_	_	IN	O	-1	none	_	_
12	sites	_	_	NNS	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	PMA	_	_	NN	O	-1	none	_	_
16	plus	_	_	CC	O	-1	none	_	_
17	Ca	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	2+	_	_	CD	O	-1	none	_	_
20	)-mobilizing	_	_	JJ	O	-1	none	_	_
21	agents	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	but	_	_	CC	O	-1	none	_	_
24	not	_	_	RB	O	-1	none	_	_
25	those	_	_	DT	O	-1	none	_	_
26	induced	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	Ca	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	2+	_	_	CD	O	-1	none	_	_
31	)-independent	_	_	JJ	O	-1	none	_	_
32	stimuli	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	gel	_	_	NN	O	-1	none	_	_
3	retardation	_	_	NN	O	-1	none	_	_
4	analysis	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	FK506	_	_	NN	O	-1	none	_	_
7	had	_	_	VBD	O	-1	none	_	_
8	little	_	_	JJ	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	AP-1	_	_	NN	O	-1	none	_	_
16	site	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	PMA	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	ionomycin	_	_	NN	O	-1	none	_	_
21	induced	_	_	VBD	O	-1	none	_	_
22	nuclear	_	_	JJ	O	-1	none	_	_
23	factors	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	were	_	_	VBD	O	-1	none	_	_
27	recognized	_	_	VBN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	anti-JunD	_	_	JJ	Protein	-1	none	_	_
30	or	_	_	CC	O	-1	none	_	_
31	c-Fos	_	_	NN	Protein	-1	none	_	_
32	antibody	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	FK506	_	_	NN	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	EGTA	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	Ca2+	_	_	NN	O	-1	none	_	_
9	chelator	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	similarly	_	_	RB	O	-1	none	_	_
12	affected	_	_	VBD	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	formation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	like	_	_	IN	O	-1	none	_	_
19	site	_	_	NN	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	complexes	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	which	_	_	WDT	O	-1	none	_	_
24	were	_	_	VBD	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	recognized	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	any	_	_	DT	O	-1	none	_	_
29	antibodies	_	_	NNS	O	-1	none	_	_
30	against	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	human	_	_	NN	O	-1	none	_	_
33	Rel	_	_	NN	O	-1	none	_	_
34	family	_	_	NN	O	-1	none	_	_
35	proteins	_	_	NNS	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	c-Rel	_	_	NN	Protein	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	p65	_	_	NN	Protein	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	p50	_	_	NN	Protein	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	p49	_	_	NN	Protein	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	confirmed	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	previous	_	_	JJ	O	-1	none	_	_
7	report	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	FK506	_	_	NN	O	-1	none	_	_
10	suppressed	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	PMA	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	ionomycin	_	_	NN	O	-1	none	_	_
15	induced	_	_	VBD	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	through	_	_	IN	O	-1	none	_	_
18	authentic	_	_	JJ	O	-1	none	_	_
19	kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	site	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	immunoglobulin	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	Ig	_	_	NN	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	gene	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	which	_	_	WDT	O	-1	none	_	_
31	NF-kappa	_	_	NN	O	-1	none	_	_
32	B	_	_	NN	O	-1	none	_	_
33	binding	_	_	NN	O	-1	none	_	_
34	was	_	_	VBD	O	-1	none	_	_
35	also	_	_	RB	O	-1	none	_	_
36	decreased	_	_	VBN	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	FK506	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	indicating	_	_	VBG	O	-1	none	_	_
41	that	_	_	IN	O	-1	none	_	_
42	both	_	_	CC	O	-1	none	_	_
43	IL-8	_	_	NN	Protein	-1	none	_	_
44	kappa	_	_	NN	O	-1	none	_	_
45	B	_	_	NN	O	-1	none	_	_
46	like	_	_	IN	O	-1	none	_	_
47	site	_	_	NN	O	-1	none	_	_
48	and	_	_	CC	O	-1	none	_	_
49	Ig	_	_	NN	Protein	51	multitoken	_	_
50	kappa	_	_	NN	Protein	51	multitoken	_	_
51	B	_	_	NN	Protein	0	root	_	_
52	site	_	_	NN	O	-1	none	_	_
53	are	_	_	VBP	O	-1	none	_	_
54	FK506	_	_	NN	O	-1	none	_	_
55	sensitive	_	_	JJ	O	-1	none	_	_
56	in	_	_	IN	O	-1	none	_	_
57	spite	_	_	NN	O	-1	none	_	_
58	of	_	_	IN	O	-1	none	_	_
59	the	_	_	DT	O	-1	none	_	_
60	difference	_	_	NN	O	-1	none	_	_
61	of	_	_	IN	O	-1	none	_	_
62	binding	_	_	NN	O	-1	none	_	_
63	factors	_	_	NNS	O	-1	none	_	_
64	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	only	_	_	RB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	reported	_	_	JJ	O	-1	none	_	_
9	IL-2	_	_	NN	Protein	-1	none	_	_
10	NF-AT	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	NFIL-2A	_	_	NN	Protein	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Ig	_	_	NN	Protein	17	multitoken	_	_
16	kappa	_	_	NN	Protein	17	multitoken	_	_
17	B	_	_	NN	Protein	0	root	_	_
18	site	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	IL-8	_	_	NN	Protein	-1	none	_	_
24	AP-1	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	kappa	_	_	NN	O	-1	none	_	_
27	B	_	_	NN	O	-1	none	_	_
28	like	_	_	IN	O	-1	none	_	_
29	sites	_	_	NNS	O	-1	none	_	_
30	are	_	_	VBP	O	-1	none	_	_
31	terminals	_	_	NNS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	FK506	_	_	NN	O	-1	none	_	_
34	sensitive	_	_	JJ	O	-1	none	_	_
35	pathway	_	_	NN	O	-1	none	_	_
36	involving	_	_	VBG	O	-1	none	_	_
37	Ca2+	_	_	NN	O	-1	none	_	_
38	mobilization	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Cupric	_	_	JJ	O	-1	none	_	_
2	ion	_	_	NN	O	-1	none	_	_
3	blocks	_	_	VBZ	O	-1	none	_	_
4	NF	_	_	NN	O	-1	none	_	_
5	kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	through	_	_	IN	O	-1	none	_	_
9	inhibiting	_	_	VBG	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	signal	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	phosphorylation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	I	_	_	NN	Protein	18	multitoken	_	_
16	kappa	_	_	NN	Protein	18	multitoken	_	_
17	B	_	_	NN	Protein	18	multitoken	_	_
18	alpha	_	_	NN	Protein	0	root	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Deoxycholate	_	_	NN	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	cytoplasmic	_	_	JJ	O	-1	none	_	_
6	extract	_	_	NN	O	-1	none	_	_
7	prepared	_	_	VBN	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	stimulated	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	TNF-alpha	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	presence	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	Cu2+	_	_	NN	O	-1	none	_	_
18	resulted	_	_	VBD	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	release	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	NF	_	_	NN	O	-1	none	_	_
24	kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	from	_	_	IN	O	-1	none	_	_
27	I	_	_	NN	Protein	30	multitoken	_	_
28	kappa	_	_	NN	Protein	30	multitoken	_	_
29	B	_	_	NN	Protein	30	multitoken	_	_
30	alpha	_	_	NN	Protein	0	root	_	_
31	,	_	_	,	O	-1	none	_	_
32	indicating	_	_	VBG	O	-1	none	_	_
33	that	_	_	IN	O	-1	none	_	_
34	Cu2+	_	_	NN	O	-1	none	_	_
35	interferes	_	_	VBZ	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	dissociation	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	NF	_	_	NN	O	-1	none	_	_
42	kappa	_	_	NN	O	-1	none	_	_
43	B-I	_	_	NN	Protein	45	multitoken	_	_
44	kappa	_	_	NN	Protein	45	multitoken	_	_
45	B	_	_	NN	Protein	0	root	_	_
46	complex	_	_	NN	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	Neither	_	_	CC	O	-1	none	_	_
2	phosphorylation	_	_	NN	O	-1	none	_	_
3	nor	_	_	CC	O	-1	none	_	_
4	degradation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	I	_	_	NN	Protein	9	multitoken	_	_
7	kappa	_	_	NN	Protein	9	multitoken	_	_
8	B	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	observed	_	_	VBN	O	-1	none	_	_
12	upon	_	_	IN	O	-1	none	_	_
13	TNF-alpha	_	_	NN	Protein	-1	none	_	_
14	stimulation	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	presence	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	Cu2+	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Cu2+	_	_	NN	O	-1	none	_	_
6	inhibits	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	release	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NF	_	_	NN	O	-1	none	_	_
11	kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	blockade	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	signal	_	_	NN	O	-1	none	_	_
18	leading	_	_	VBG	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	phosphorylation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	I	_	_	NN	Protein	26	multitoken	_	_
24	kappa	_	_	NN	Protein	26	multitoken	_	_
25	B	_	_	NN	Protein	26	multitoken	_	_
26	alpha	_	_	NN	Protein	0	root	_	_
27	.	_	_	.	O	-1	none	_	_

1	Apoptosis	_	_	NN	O	-1	none	_	_
2	resistant	_	_	JJ	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	have	_	_	VBP	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	deficiency	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	NF-kappaB-mediated	_	_	JJ	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	Fas	_	_	NN	Protein	13	multitoken	_	_
13	ligand	_	_	NN	Protein	0	root	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	To	_	_	TO	O	-1	none	_	_
2	gain	_	_	VB	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	better	_	_	JJR	O	-1	none	_	_
5	understanding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	transcriptional	_	_	JJ	O	-1	none	_	_
9	events	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	regulate	_	_	VBP	O	-1	none	_	_
12	this	_	_	DT	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	we	_	_	PRP	O	-1	none	_	_
16	took	_	_	VBD	O	-1	none	_	_
17	advantage	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	our	_	_	PRP$	O	-1	none	_	_
20	previously	_	_	RB	O	-1	none	_	_
21	described	_	_	VBN	O	-1	none	_	_
22	mutant	_	_	NN	O	-1	none	_	_
23	Jurkat	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	deficient	_	_	JJ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	FasL	_	_	NN	Protein	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	apoptosis	_	_	NN	O	-1	none	_	_
10	induced	_	_	VBN	O	-1	none	_	_
11	upon	_	_	IN	O	-1	none	_	_
12	TCR	_	_	NN	O	-1	none	_	_
13	triggering	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	although	_	_	IN	O	-1	none	_	_
16	their	_	_	PRP$	O	-1	none	_	_
17	cytokine	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	IL-2	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	IFN-gamma	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	production	_	_	NN	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	normal	_	_	JJ	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	demonstrate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	inducible	_	_	JJ	O	-1	none	_	_
9	transcriptional	_	_	JJ	O	-1	none	_	_
10	activity	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	FasL	_	_	NN	Protein	-1	none	_	_
14	reporter	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	abolished	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	specific	_	_	JJ	O	-1	none	_	_
19	inhibitors	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	NF-kappaB	_	_	NN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	could	_	_	MD	O	-1	none	_	_
5	trace	_	_	VB	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	deficit	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	mutant	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	inefficient	_	_	JJ	O	-1	none	_	_
15	NF-kappaB	_	_	NN	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	evidencing	_	_	VBG	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	relevant	_	_	JJ	O	-1	none	_	_
21	role	_	_	NN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	NF-kappaB	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	regulation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	FasL	_	_	NN	Protein	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	activated	_	_	VBN	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	our	_	_	PRP$	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	induction	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	FasL	_	_	NN	Protein	-1	none	_	_
11	versus	_	_	CC	O	-1	none	_	_
12	cytokine	_	_	NN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	differentially	_	_	RB	O	-1	none	_	_
17	sensitive	_	_	JJ	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	NF-kappaB	_	_	NN	O	-1	none	_	_
20	deprivation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	NF-X2	_	_	NNP	O	-1	none	_	_
2	that	_	_	WDT	O	-1	none	_	_
3	binds	_	_	VBZ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	DRA	_	_	NN	O	-1	none	_	_
7	X2-box	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	activator	_	_	NN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	1	_	_	CD	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	cloning	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	c-Jun	_	_	NN	Protein	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	class	_	_	NN	O	-1	none	_	_
3	II	_	_	CD	O	-1	none	_	_
4	MHC	_	_	NN	O	-1	none	_	_
5	Ag	_	_	NN	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	family	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	surface	_	_	NN	O	-1	none	_	_
12	glycoproteins	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Their	_	_	PRP$	O	-1	none	_	_
2	constitutive	_	_	JJ	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	limited	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	lymphocytes	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	thymic	_	_	JJ	O	-1	none	_	_
11	epithelial	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	many	_	_	JJ	O	-1	none	_	_
3	other	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	their	_	_	PRP$	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	IFN-gamma	_	_	NN	Protein	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Conserved	_	_	VBN	O	-1	none	_	_
2	upstream	_	_	JJ	O	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	sequences	_	_	NNS	O	-1	none	_	_
5	regulate	_	_	VBP	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	tissue	_	_	NN	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	class	_	_	NN	O	-1	none	_	_
12	II	_	_	CD	O	-1	none	_	_
13	genes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	DRA	_	_	NN	O	-1	none	_	_
4	promoter	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	one	_	_	CD	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	cis	_	_	NN	O	-1	none	_	_
10	acting	_	_	VBG	O	-1	none	_	_
11	regulatory	_	_	JJ	O	-1	none	_	_
12	motifs	_	_	NNS	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	X2-box	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	X2	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	NF-X2	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	binds	_	_	VBZ	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	present	_	_	VBP	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	isolation	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	characterization	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	full-length	_	_	JJ	O	-1	none	_	_
12	cDNA	_	_	NN	O	-1	none	_	_
13	clone	_	_	NN	O	-1	none	_	_
14	encoding	_	_	VBG	O	-1	none	_	_
15	NF-X2	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	cDNA	_	_	NN	O	-1	none	_	_
3	clone	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	isolated	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	cDNA	_	_	NN	O	-1	none	_	_
9	cloning	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	encodes	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	c-Jun	_	_	NN	Protein	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	together	_	_	RB	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	c-Fos	_	_	NN	Protein	-1	none	_	_
22	forms	_	_	VBZ	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	heterodimeric	_	_	JJ	O	-1	none	_	_
25	activator	_	_	NN	O	-1	none	_	_
26	protein-1	_	_	NN	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	complex	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	c-Fos	_	_	NN	Protein	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	c-Jun	_	_	NN	Protein	-1	none	_	_
5	heterodimers	_	_	NNS	O	-1	none	_	_
6	do	_	_	VBP	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	exist	_	_	VB	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	they	_	_	PRP	O	-1	none	_	_
14	form	_	_	VBP	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	bind	_	_	VBP	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	X2-box	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	class	_	_	NN	O	-1	none	_	_
22	II	_	_	CD	O	-1	none	_	_
23	nonexpressing	_	_	JJ	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	c-Fos	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	c-Jun	_	_	NN	Protein	-1	none	_	_
6	heterodimers	_	_	NNS	O	-1	none	_	_
7	might	_	_	MD	O	-1	none	_	_
8	contribute	_	_	VB	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	repression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	DRA	_	_	NN	Protein	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	p53	_	_	NN	Protein	-1	none	_	_
3	paradox	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	pathogenesis	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	tumor	_	_	NN	O	-1	none	_	_
9	progression	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Recent	_	_	JJ	O	-1	none	_	_
2	evidence	_	_	NN	O	-1	none	_	_
3	suggests	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	p53	_	_	NN	Protein	-1	none	_	_
7	molecule	_	_	NN	O	-1	none	_	_
8	appears	_	_	VBZ	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	two	_	_	CD	O	-1	none	_	_
11	different	_	_	JJ	O	-1	none	_	_
12	forms	_	_	NNS	O	-1	none	_	_
13	:	_	_	:	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	mutant	_	_	NN	O	-1	none	_	_
16	p53	_	_	NN	Protein	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	stimulates	_	_	VBZ	O	-1	none	_	_
19	tumor	_	_	NN	O	-1	none	_	_
20	progression	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	wild	_	_	JJ	O	-1	none	_	_
24	type	_	_	NN	O	-1	none	_	_
25	p53	_	_	NN	Protein	-1	none	_	_
26	that	_	_	WDT	O	-1	none	_	_
27	inhibits	_	_	VBZ	O	-1	none	_	_
28	tumor	_	_	NN	O	-1	none	_	_
29	progression	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	it	_	_	PRP	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	established	_	_	VBN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	tumor	_	_	NN	Protein	11	multitoken	_	_
10	necrosis	_	_	NN	Protein	11	multitoken	_	_
11	factor-alpha	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	TNF-alpha	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	can	_	_	MD	O	-1	none	_	_
16	activate	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	wild	_	_	JJ	O	-1	none	_	_
21	type	_	_	NN	O	-1	none	_	_
22	p53	_	_	NN	Protein	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	concert	_	_	NN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	nuclear	_	_	JJ	O	-1	none	_	_
28	transcription	_	_	NN	O	-1	none	_	_
29	factor	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	NF-kappa	_	_	NN	O	-1	none	_	_
32	B.	_	_	NNP	O	-1	none	_	_
33	Both	_	_	CC	O	-1	none	_	_
34	TNF-alpha	_	_	NN	Protein	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	NF-kappa	_	_	NN	O	-1	none	_	_
37	B	_	_	NN	O	-1	none	_	_
38	are	_	_	VBP	O	-1	none	_	_
39	also	_	_	RB	O	-1	none	_	_
40	involved	_	_	VBN	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	stimulation	_	_	NN	O	-1	none	_	_
44	of	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	pathway	_	_	NN	O	-1	none	_	_
47	that	_	_	WDT	O	-1	none	_	_
48	leads	_	_	VBZ	O	-1	none	_	_
49	to	_	_	TO	O	-1	none	_	_
50	the	_	_	DT	O	-1	none	_	_
51	expression	_	_	NN	O	-1	none	_	_
52	of	_	_	IN	O	-1	none	_	_
53	major	_	_	JJ	O	-1	none	_	_
54	histocompatibility	_	_	NN	O	-1	none	_	_
55	complex	_	_	NN	O	-1	none	_	_
56	(	_	_	-LRB-	O	-1	none	_	_
57	MHC	_	_	NN	O	-1	none	_	_
58	)	_	_	-RRB-	O	-1	none	_	_
59	class	_	_	NN	O	-1	none	_	_
60	I	_	_	CD	O	-1	none	_	_
61	molecules	_	_	NNS	O	-1	none	_	_
62	and	_	_	CC	O	-1	none	_	_
63	,	_	_	,	O	-1	none	_	_
64	hence	_	_	RB	O	-1	none	_	_
65	,	_	_	,	O	-1	none	_	_
66	antigen	_	_	NN	O	-1	none	_	_
67	presentation	_	_	NN	O	-1	none	_	_
68	to	_	_	TO	O	-1	none	_	_
69	the	_	_	DT	O	-1	none	_	_
70	T	_	_	NN	O	-1	none	_	_
71	cells	_	_	NNS	O	-1	none	_	_
72	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	paper	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	shall	_	_	MD	O	-1	none	_	_
6	advance	_	_	VB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	hypothesis	_	_	NN	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	:	_	_	:	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	i	_	_	FW	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	TNF-alpha	_	_	NN	Protein	-1	none	_	_
15	indirectly	_	_	RB	O	-1	none	_	_
16	controls	_	_	VBZ	O	-1	none	_	_
17	immune	_	_	JJ	O	-1	none	_	_
18	surveillance	_	_	NN	O	-1	none	_	_
19	;	_	_	:	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	ii	_	_	LS	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	TNF-alpha	_	_	NN	Protein	-1	none	_	_
25	controls	_	_	NNS	O	-1	none	_	_
26	DNA	_	_	NN	O	-1	none	_	_
27	repair	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	tumor	_	_	NN	O	-1	none	_	_
30	suppression	_	_	NN	O	-1	none	_	_
31	through	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	regulation	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	wild	_	_	JJ	O	-1	none	_	_
36	type	_	_	NN	O	-1	none	_	_
37	p53	_	_	NN	Protein	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	hypothesized	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	elevated	_	_	JJ	O	-1	none	_	_
8	TNF-alpha	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	primarily	_	_	RB	O	-1	none	_	_
11	responsible	_	_	JJ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	promoting	_	_	VBG	O	-1	none	_	_
14	tumor	_	_	NN	O	-1	none	_	_
15	progression	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Thymocytes	_	_	NNS	O	-1	none	_	_
2	control	_	_	VBP	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	CD4	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	differently	_	_	RB	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	mature	_	_	JJ	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	lymphocytes	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	analyzed	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	enhancer	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	silencer	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	CD4	_	_	NN	Protein	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	during	_	_	IN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	development	_	_	NN	O	-1	none	_	_
23	using	_	_	VBG	O	-1	none	_	_
24	transgenic	_	_	JJ	O	-1	none	_	_
25	mice	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Immunofluorescence	_	_	NN	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	on	_	_	IN	O	-1	none	_	_
4	thymic	_	_	JJ	O	-1	none	_	_
5	populations	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	mice	_	_	NNS	O	-1	none	_	_
8	carrying	_	_	VBG	O	-1	none	_	_
9	transgenes	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	various	_	_	JJ	O	-1	none	_	_
12	combinations	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	these	_	_	DT	O	-1	none	_	_
15	regulatory	_	_	JJ	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	elements	_	_	NNS	O	-1	none	_	_
18	revealed	_	_	VBD	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	thymocytes	_	_	NNS	O	-1	none	_	_
21	control	_	_	VBP	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	CD4	_	_	NN	Protein	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	different	_	_	JJ	O	-1	none	_	_
28	manner	_	_	NN	O	-1	none	_	_
29	than	_	_	IN	O	-1	none	_	_
30	mature	_	_	JJ	O	-1	none	_	_
31	peripheral	_	_	JJ	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	lymphocytes	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	its	_	_	PRP$	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	becomes	_	_	VBZ	O	-1	none	_	_
6	lower	_	_	JJR	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	double	_	_	JJ	O	-1	none	_	_
10	positive	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	fraction	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	CD4+	_	_	JJ	O	-1	none	_	_
17	CD8int/-	_	_	JJ	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	population	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	indicating	_	_	VBG	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	additional	_	_	JJ	O	-1	none	_	_
25	enhancer	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	located	_	_	JJ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	either	_	_	CC	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	first	_	_	JJ	O	-1	none	_	_
32	or	_	_	CC	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	third	_	_	JJ	O	-1	none	_	_
35	intron	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	CD4	_	_	NN	Protein	-1	none	_	_
39	gene	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	is	_	_	VBZ	O	-1	none	_	_
42	required	_	_	VBN	O	-1	none	_	_
43	for	_	_	IN	O	-1	none	_	_
44	CD4	_	_	NN	Protein	-1	none	_	_
45	gene	_	_	NN	O	-1	none	_	_
46	expression	_	_	NN	O	-1	none	_	_
47	in	_	_	IN	O	-1	none	_	_
48	this	_	_	DT	O	-1	none	_	_
49	population	_	_	NN	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	other	_	_	JJ	O	-1	none	_	_
3	studied	_	_	VBN	O	-1	none	_	_
4	regulatory	_	_	JJ	O	-1	none	_	_
5	element	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	minimal	_	_	JJ	O	-1	none	_	_
9	CD4	_	_	NN	Protein	-1	none	_	_
10	silencer	_	_	NN	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	inhibits	_	_	VBZ	O	-1	none	_	_
13	CD4	_	_	NN	Protein	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	peripheral	_	_	JJ	O	-1	none	_	_
18	CD8	_	_	NN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	lymphocytes	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	silencer	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	inactive	_	_	JJ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	most	_	_	RBS	O	-1	none	_	_
8	immature	_	_	JJ	O	-1	none	_	_
9	DN	_	_	JJ	O	-1	none	_	_
10	thymocytes	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	probably	_	_	RB	O	-1	none	_	_
14	use	_	_	VBP	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	distinct	_	_	JJ	O	-1	none	_	_
17	silencer	_	_	NN	O	-1	none	_	_
18	mechanism	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	down-regulate	_	_	VB	O	-1	none	_	_
21	CD4	_	_	NN	Protein	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Altogether	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	CD4	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	regulated	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	several	_	_	JJ	O	-1	none	_	_
10	positive	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	negative	_	_	JJ	O	-1	none	_	_
13	regulatory	_	_	JJ	O	-1	none	_	_
14	mechanisms	_	_	NNS	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	come	_	_	VBP	O	-1	none	_	_
17	into	_	_	IN	O	-1	none	_	_
18	play	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	developmentally	_	_	RB	O	-1	none	_	_
22	coordinated	_	_	VBN	O	-1	none	_	_
23	manner	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Defective	_	_	JJ	O	-1	none	_	_
2	translocation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	kinase	_	_	NN	O	-1	none	_	_
6	C	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	multidrug	_	_	JJ	O	-1	none	_	_
9	resistant	_	_	JJ	O	-1	none	_	_
10	HL-60	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	confers	_	_	VBZ	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	reversible	_	_	JJ	O	-1	none	_	_
15	loss	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	phorbol	_	_	NN	O	-1	none	_	_
18	ester	_	_	NN	O	-1	none	_	_
19	induced	_	_	VBD	O	-1	none	_	_
20	monocytic	_	_	JJ	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	HL-60	_	_	NN	O	-1	none	_	_
8	myeloid	_	_	JJ	O	-1	none	_	_
9	leukemia	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	differentiate	_	_	VBP	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	response	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	phorbol	_	_	NN	O	-1	none	_	_
16	esters	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	event	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	associated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	induction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	c-jun	_	_	NN	Protein	-1	none	_	_
10	early	_	_	JJ	O	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	appearance	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	monocytic	_	_	JJ	O	-1	none	_	_
18	phenotype	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	examined	_	_	VBN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	effects	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	vincristine	_	_	NN	O	-1	none	_	_
10	selected	_	_	VBN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	multidrug	_	_	JJ	O	-1	none	_	_
13	resistance	_	_	NN	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	12-O-tetradecanoylphorbol-13-acetate	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	TPA	_	_	NN	O	-1	none	_	_
18	)-induced	_	_	JJ	O	-1	none	_	_
19	HL-60	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	multidrug	_	_	JJ	O	-1	none	_	_
6	resistant	_	_	JJ	O	-1	none	_	_
7	HL-60	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	designated	_	_	VBN	O	-1	none	_	_
11	HL-60	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	vinc	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	fail	_	_	VBP	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	respond	_	_	VB	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	TPA	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	increase	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	c-jun	_	_	NN	Protein	-1	none	_	_
25	transcripts	_	_	NNS	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	other	_	_	JJ	O	-1	none	_	_
28	phenotypic	_	_	JJ	O	-1	none	_	_
29	characteristics	_	_	NNS	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	monocytic	_	_	JJ	O	-1	none	_	_
32	differentiation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	HL-60	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	vinc	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	okadaic	_	_	JJ	O	-1	none	_	_
12	acid	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	inhibitor	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	serine/threonine	_	_	NN	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	phosphatases	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	induces	_	_	VBZ	O	-1	none	_	_
22	c-jun	_	_	NN	Protein	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	growth	_	_	NN	O	-1	none	_	_
26	arrest	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	c-fms	_	_	NN	Protein	-1	none	_	_
33	gene	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Studies	_	_	NNS	O	-1	none	_	_
2	were	_	_	VBD	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	performed	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	HL-60	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	vinc	_	_	NN	O	-1	none	_	_
10	revertant	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	HL-60/vinc/R	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	line	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	has	_	_	VBZ	O	-1	none	_	_
17	regained	_	_	VBN	O	-1	none	_	_
18	partial	_	_	JJ	O	-1	none	_	_
19	sensitivity	_	_	NN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	vincristine	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	finding	_	_	NN	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	HL-60/vinc/R	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	respond	_	_	VBP	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	TPA	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	monocytic	_	_	JJ	O	-1	none	_	_
14	phenotype	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	c-jun	_	_	NN	Protein	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	suggests	_	_	VBZ	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	c-jun	_	_	NN	Protein	-1	none	_	_
24	induction	_	_	NN	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	obligatory	_	_	JJ	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	monocytic	_	_	JJ	O	-1	none	_	_
30	differentiation	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Other	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	further	_	_	RB	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	jun-B	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	fra-1	_	_	NN	Protein	-1	none	_	_
10	genes	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	TPA	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	both	_	_	CC	O	-1	none	_	_
17	HL-60	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	vinc	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	HL-60/vinc/R	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	whereas	_	_	IN	O	-1	none	_	_
25	c-fos	_	_	NN	Protein	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	attenuated	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	HL-60	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	vinc	_	_	NN	O	-1	none	_	_
34	line	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	TPA	_	_	NN	O	-1	none	_	_
3	activates	_	_	VBZ	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	kinase	_	_	NN	O	-1	none	_	_
6	C	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	PKC	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	we	_	_	PRP	O	-1	none	_	_
12	examined	_	_	VBD	O	-1	none	_	_
13	translocation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	PKC	_	_	NN	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	cytosol	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	membrane	_	_	NN	O	-1	none	_	_
22	fraction	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	HL-60	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	HL-60/vinc/R	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	demonstrated	_	_	VBD	O	-1	none	_	_
7	translocation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	PKC	_	_	NN	O	-1	none	_	_
10	activity	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	this	_	_	DT	O	-1	none	_	_
13	subcellular	_	_	JJ	O	-1	none	_	_
14	redistribution	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	undetectable	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	HL-60	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	vinc	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Activity	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mitogen	_	_	NN	O	-1	none	_	_
5	activated	_	_	VBN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	family	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	associated	_	_	JJ	O	-1	none	_	_
11	phosphorylation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	c-Jun	_	_	NN	Protein	-1	none	_	_
14	Y-peptide	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	markedly	_	_	RB	O	-1	none	_	_
17	diminished	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	TPA	_	_	NN	O	-1	none	_	_
20	treated	_	_	VBN	O	-1	none	_	_
21	HL-60	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	vinc	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	but	_	_	CC	O	-1	none	_	_
27	not	_	_	RB	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	response	_	_	NN	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	okadaic	_	_	JJ	O	-1	none	_	_
32	acid	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	findings	_	_	NNS	O	-1	none	_	_
6	suggest	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	vincristine	_	_	NN	O	-1	none	_	_
9	resistance	_	_	NN	O	-1	none	_	_
10	confers	_	_	VBZ	O	-1	none	_	_
11	insensitivity	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	TPA	_	_	NN	O	-1	none	_	_
14	induced	_	_	VBD	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	can	_	_	MD	O	-1	none	_	_
18	include	_	_	VB	O	-1	none	_	_
19	defects	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	PKC	_	_	NN	O	-1	none	_	_
22	mediated	_	_	JJ	O	-1	none	_	_
23	signaling	_	_	NN	O	-1	none	_	_
24	events	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	induction	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	jun	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	fos	_	_	NN	O	-1	none	_	_
31	early	_	_	JJ	O	-1	none	_	_
32	response	_	_	NN	O	-1	none	_	_
33	gene	_	_	NN	O	-1	none	_	_
34	expression	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	class	_	_	NN	Protein	4	multitoken	_	_
3	II	_	_	CD	Protein	4	multitoken	_	_
4	trans-activator	_	_	NN	Protein	0	root	_	_
5	CIITA	_	_	NN	Protein	-1	none	_	_
6	interacts	_	_	VBZ	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	TBP	_	_	NN	Protein	-1	none	_	_
10	associated	_	_	VBN	O	-1	none	_	_
11	factor	_	_	NN	O	-1	none	_	_
12	TAFII32	_	_	NN	Protein	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	class	_	_	NN	Protein	5	multitoken	_	_
3	II	_	_	CD	Protein	5	multitoken	_	_
4	trans-	_	_	JJ	Protein	5	multitoken	_	_
5	activator	_	_	NN	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	CIITA	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	main	_	_	JJ	O	-1	none	_	_
12	transcriptional	_	_	JJ	O	-1	none	_	_
13	co-activator	_	_	NN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	MHC	_	_	NN	O	-1	none	_	_
19	class	_	_	NN	O	-1	none	_	_
20	II	_	_	CD	O	-1	none	_	_
21	proteins	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Its	_	_	PRP$	O	-1	none	_	_
2	N-terminal	_	_	JJ	O	-1	none	_	_
3	125	_	_	CD	O	-1	none	_	_
4	amino	_	_	NN	O	-1	none	_	_
5	acids	_	_	NNS	O	-1	none	_	_
6	function	_	_	VBP	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	independent	_	_	JJ	O	-1	none	_	_
10	transcriptional	_	_	JJ	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	domain	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Analyses	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	primary	_	_	JJ	O	-1	none	_	_
5	amino	_	_	NN	O	-1	none	_	_
6	acid	_	_	NN	O	-1	none	_	_
7	sequence	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	domain	_	_	NN	O	-1	none	_	_
12	predict	_	_	VBP	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	presence	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	three	_	_	CD	O	-1	none	_	_
17	alpha-helices	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	each	_	_	DT	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	high	_	_	JJ	O	-1	none	_	_
23	proportion	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	acidic	_	_	JJ	O	-1	none	_	_
26	residues	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	site	_	_	NN	O	-1	none	_	_
3	directed	_	_	JJ	O	-1	none	_	_
4	mutagenesis	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	found	_	_	VBD	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	two	_	_	CD	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	these	_	_	DT	O	-1	none	_	_
12	predicted	_	_	JJ	O	-1	none	_	_
13	alpha-helices	_	_	NNS	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	required	_	_	VBN	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	full	_	_	JJ	O	-1	none	_	_
18	transcriptional	_	_	JJ	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	CIITA	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	CIITA	_	_	NN	Protein	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	both	_	_	CC	O	-1	none	_	_
9	functional	_	_	JJ	O	-1	none	_	_
10	alpha-helices	_	_	NNS	O	-1	none	_	_
11	have	_	_	VBP	O	-1	none	_	_
12	been	_	_	VBN	O	-1	none	_	_
13	deleted	_	_	VBN	O	-1	none	_	_
14	displays	_	_	NNS	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	dominant	_	_	JJ	O	-1	none	_	_
17	negative	_	_	JJ	O	-1	none	_	_
18	phenotype	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	domain	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	CIITA	_	_	NN	Protein	-1	none	_	_
6	interacts	_	_	VBZ	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	32	_	_	CD	O	-1	none	_	_
10	kDa	_	_	NN	O	-1	none	_	_
11	subunit	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	general	_	_	JJ	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	complex	_	_	NN	O	-1	none	_	_
17	TFIID	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	TAFII32	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Decreased	_	_	VBN	O	-1	none	_	_
2	transcriptional	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	N-terminal	_	_	JJ	O	-1	none	_	_
6	deletions	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	correlated	_	_	VBN	O	-1	none	_	_
11	directly	_	_	RB	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	their	_	_	PRP$	O	-1	none	_	_
14	reduced	_	_	VBN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	TAFII32	_	_	NN	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	interactions	_	_	NNS	O	-1	none	_	_
5	between	_	_	IN	O	-1	none	_	_
6	TAFII32	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	responsible	_	_	JJ	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	class	_	_	NN	O	-1	none	_	_
15	II	_	_	CD	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	presence	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	CD4	_	_	NN	Protein	-1	none	_	_
11	cytoplasmic	_	_	JJ	O	-1	none	_	_
12	tail	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	critical	_	_	JJ	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	immunodeficiency	_	_	NN	O	-1	none	_	_
18	virus	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	HIV	_	_	NN	O	-1	none	_	_
21	)-induced	_	_	JJ	O	-1	none	_	_
22	apoptosis	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	J.Corbeil	_	_	NNP	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	M.Tremblay	_	_	NNP	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	D.D.Richman	_	_	NNP	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	J.Exp.Med	_	_	NNP	O	-1	none	_	_
32	.183:39-48,	_	_	CD	O	-1	none	_	_
33	1996	_	_	CD	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	pursued	_	_	VBN	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	investigation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	CD4	_	_	NN	Protein	-1	none	_	_
12	transduction	_	_	NN	O	-1	none	_	_
13	pathway	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	HIV	_	_	NN	O	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	apoptosis	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	do	_	_	VB	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	wild-type	_	_	JJ	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	mutant	_	_	NN	O	-1	none	_	_
8	forms	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	CD4	_	_	NN	Protein	-1	none	_	_
12	cytoplasmic	_	_	JJ	O	-1	none	_	_
13	tail	_	_	NN	O	-1	none	_	_
14	were	_	_	VBD	O	-1	none	_	_
15	stably	_	_	RB	O	-1	none	_	_
16	expressed	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	lymphoblastoid	_	_	JJ	O	-1	none	_	_
20	T-cell	_	_	NN	O	-1	none	_	_
21	line	_	_	NN	O	-1	none	_	_
22	A2	_	_	NN	O	-1	none	_	_
23	.01	_	_	CD	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Apoptosis	_	_	NN	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	prevented	_	_	VBN	O	-1	none	_	_
4	when	_	_	WRB	O	-1	none	_	_
5	CD4	_	_	NN	Protein	-1	none	_	_
6	truncated	_	_	VBN	O	-1	none	_	_
7	at	_	_	IN	O	-1	none	_	_
8	residue	_	_	NN	O	-1	none	_	_
9	402	_	_	CD	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	expressed	_	_	VBN	O	-1	none	_	_
12	;	_	_	:	O	-1	none	_	_
13	however	_	_	RB	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	expressing	_	_	VBG	O	-1	none	_	_
17	mutated	_	_	VBN	O	-1	none	_	_
18	receptors	_	_	NNS	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	do	_	_	VBP	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	associate	_	_	VB	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	p56	_	_	NN	Protein	27	multitoken	_	_
25	(	_	_	-LRB-	Protein	27	multitoken	_	_
26	lck	_	_	NN	Protein	27	multitoken	_	_
27	)	_	_	-RRB-	Protein	0	root	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	mutated	_	_	VBN	O	-1	none	_	_
30	at	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	dicysteine	_	_	NN	O	-1	none	_	_
33	motif	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	truncated	_	_	VBN	O	-1	none	_	_
36	at	_	_	IN	O	-1	none	_	_
37	residue	_	_	NN	O	-1	none	_	_
38	418	_	_	CD	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	but	_	_	CC	O	-1	none	_	_
41	which	_	_	WDT	O	-1	none	_	_
42	conserved	_	_	VBN	O	-1	none	_	_
43	proximal	_	_	JJ	O	-1	none	_	_
44	domains	_	_	NNS	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	the	_	_	DT	O	-1	none	_	_
47	cytoplasmic	_	_	JJ	O	-1	none	_	_
48	tail	_	_	NN	O	-1	none	_	_
49	underwent	_	_	VBD	O	-1	none	_	_
50	apoptosis	_	_	NN	O	-1	none	_	_
51	like	_	_	IN	O	-1	none	_	_
52	wild-	_	_	JJ	O	-1	none	_	_
53	type	_	_	NN	O	-1	none	_	_
54	CD4	_	_	NN	Protein	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	differences	_	_	NNS	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	wild-type	_	_	JJ	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	mutated	_	_	VBN	O	-1	none	_	_
7	receptors	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	apoptosis	_	_	NN	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	related	_	_	VBN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	levels	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	p56	_	_	NN	Protein	22	multitoken	_	_
20	(	_	_	-LRB-	Protein	22	multitoken	_	_
21	lck	_	_	NN	Protein	22	multitoken	_	_
22	)	_	_	-RRB-	Protein	0	root	_	_
23	or	_	_	CC	O	-1	none	_	_
24	NF-	_	_	NN	O	-1	none	_	_
25	kappaB	_	_	NN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Initial	_	_	JJ	O	-1	none	_	_
2	signaling	_	_	NN	O	-1	none	_	_
3	through	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	CD4	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	played	_	_	VBD	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	major	_	_	JJ	O	-1	none	_	_
10	role	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	sensitization	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	HIV	_	_	NN	O	-1	none	_	_
16	infected	_	_	JJ	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	undergo	_	_	VB	O	-1	none	_	_
21	apoptosis	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Incubation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HIV	_	_	NN	O	-1	none	_	_
4	infected	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	monoclonal	_	_	JJ	O	-1	none	_	_
8	antibody	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	MAb	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	13B8-2	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	binds	_	_	VBZ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	CD4	_	_	NN	Protein	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	region	_	_	NN	O	-1	none	_	_
21	critical	_	_	JJ	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	dimerization	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	receptor	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	prevented	_	_	VBD	O	-1	none	_	_
29	apoptosis	_	_	NN	O	-1	none	_	_
30	without	_	_	IN	O	-1	none	_	_
31	inhibiting	_	_	VBG	O	-1	none	_	_
32	HIV	_	_	NN	O	-1	none	_	_
33	replication	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Positive	_	_	JJ	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	negative	_	_	JJ	O	-1	none	_	_
4	regulation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	granulocyte-macrophage	_	_	JJ	Protein	9	multitoken	_	_
7	colony	_	_	NN	Protein	9	multitoken	_	_
8	stimulating	_	_	NN	Protein	9	multitoken	_	_
9	factor	_	_	NN	Protein	0	root	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	AML1	_	_	NN	O	-1	none	_	_
14	related	_	_	JJ	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	factor	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	PEBP2	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	granulocyte-macrophage	_	_	JJ	Protein	5	multitoken	_	_
3	colony	_	_	NN	Protein	5	multitoken	_	_
4	stimulating	_	_	NN	Protein	5	multitoken	_	_
5	factor	_	_	NN	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	GM-CSF	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	contains	_	_	VBZ	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	consensus	_	_	NN	O	-1	none	_	_
14	sequence	_	_	NN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	polyomavirus	_	_	NN	O	-1	none	_	_
18	enhancer	_	_	NN	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	protein	_	_	NN	O	-1	none	_	_
21	2	_	_	CD	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	PEBP2	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	factor	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	which	_	_	WDT	O	-1	none	_	_
29	consists	_	_	VBZ	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	alpha	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	beta	_	_	NN	O	-1	none	_	_
34	subunits	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	at	_	_	IN	O	-1	none	_	_
4	least	_	_	JJS	O	-1	none	_	_
5	two	_	_	CD	O	-1	none	_	_
6	genes	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	alpha	_	_	NN	O	-1	none	_	_
9	A	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	alpha	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	encoding	_	_	VBG	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	alpha	_	_	NN	O	-1	none	_	_
17	subunit	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	alpha	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	mouse	_	_	NN	O	-1	none	_	_
6	homologue	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	AML1	_	_	NN	Protein	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	detected	_	_	VBN	O	-1	none	_	_
12	at	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	breakpoints	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	t	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	8	_	_	CD	O	-1	none	_	_
19	;	_	_	:	O	-1	none	_	_
20	21	_	_	CD	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	t	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	3	_	_	CD	O	-1	none	_	_
26	;	_	_	:	O	-1	none	_	_
27	21	_	_	CD	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	myeloid	_	_	JJ	O	-1	none	_	_
30	leukemias	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	examined	_	_	VBD	O	-1	none	_	_
3	alpha	_	_	NN	Protein	4	multitoken	_	_
4	A1	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	alpha	_	_	NN	O	-1	none	_	_
8	A	_	_	NN	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	product	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	alpha	_	_	NN	Protein	14	multitoken	_	_
14	B1	_	_	NN	Protein	0	root	_	_
15	and	_	_	CC	O	-1	none	_	_
16	alpha	_	_	NN	Protein	17	multitoken	_	_
17	B2	_	_	NN	Protein	0	root	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	two	_	_	CD	O	-1	none	_	_
20	alpha	_	_	NN	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	encoded	_	_	VBN	O	-1	none	_	_
23	isomers	_	_	NNS	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	their	_	_	PRP$	O	-1	none	_	_
27	effects	_	_	NNS	O	-1	none	_	_
28	on	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	GM-CSF	_	_	NN	Protein	-1	none	_	_
31	promoter	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	PEBP2	_	_	NN	Protein	3	multitoken	_	_
2	alpha	_	_	NN	Protein	3	multitoken	_	_
3	A1	_	_	NN	Protein	0	root	_	_
4	,	_	_	,	O	-1	none	_	_
5	alpha	_	_	NN	Protein	6	multitoken	_	_
6	B1	_	_	NN	Protein	0	root	_	_
7	,	_	_	,	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	alpha	_	_	NN	Protein	10	multitoken	_	_
10	B2	_	_	NN	Protein	0	root	_	_
11	proteins	_	_	NNS	O	-1	none	_	_
12	bound	_	_	VBD	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	PEBP2	_	_	NN	O	-1	none	_	_
15	site	_	_	NN	O	-1	none	_	_
16	within	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	mouse	_	_	NN	O	-1	none	_	_
19	GM-CSF	_	_	NN	Protein	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	suppressed	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	alpha	_	_	NN	Protein	11	multitoken	_	_
11	B2	_	_	NN	Protein	0	root	_	_
12	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Jurkat	_	_	NN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	extract	_	_	NN	O	-1	none	_	_
4	contained	_	_	VBD	O	-1	none	_	_
5	PEBP2	_	_	NN	O	-1	none	_	_
6	site	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	s	_	_	NNS	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	cross	_	_	NN	O	-1	none	_	_
14	reacted	_	_	VBD	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	antimouse	_	_	NN	O	-1	none	_	_
17	alpha	_	_	NN	Protein	18	multitoken	_	_
18	A1	_	_	NN	Protein	0	root	_	_
19	antibodies	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	indicated	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	PEBP2	_	_	NN	O	-1	none	_	_
10	alpha	_	_	NN	O	-1	none	_	_
11	A	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	alpha	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	Protein	17	multitoken	_	_
16	AML1	_	_	NN	Protein	17	multitoken	_	_
17	)	_	_	-RRB-	Protein	0	root	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	beta	_	_	NN	O	-1	none	_	_
21	genes	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	Jurkat	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	further	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	required	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	determine	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	precise	_	_	JJ	O	-1	none	_	_
10	role	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	PEBP2	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	GM-CSF	_	_	NN	Protein	-1	none	_	_
16	promoter	_	_	NN	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	present	_	_	JJ	O	-1	none	_	_
21	findings	_	_	NNS	O	-1	none	_	_
22	suggested	_	_	VBD	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	importance	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	relative	_	_	JJ	O	-1	none	_	_
28	ratio	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	different	_	_	JJ	O	-1	none	_	_
31	PEBP2	_	_	NN	O	-1	none	_	_
32	isoforms	_	_	NNS	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	regulating	_	_	VBG	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	levels	_	_	NNS	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	promoter	_	_	NN	O	-1	none	_	_
40	activity	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Autoregulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	transactivator	_	_	NN	O	-1	none	_	_
7	RelA	_	_	NN	Protein	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	p65	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	multiple	_	_	JJ	O	-1	none	_	_
13	cytoplasmic	_	_	JJ	O	-1	none	_	_
14	inhibitors	_	_	NNS	O	-1	none	_	_
15	containing	_	_	VBG	O	-1	none	_	_
16	ankyrin	_	_	NN	O	-1	none	_	_
17	motifs	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	After	_	_	IN	O	-1	none	_	_
2	cellular	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	I	_	_	NN	Protein	8	multitoken	_	_
6	kappa	_	_	NN	Protein	8	multitoken	_	_
7	B	_	_	NN	Protein	8	multitoken	_	_
8	alpha	_	_	NN	Protein	0	root	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	rapidly	_	_	RB	O	-1	none	_	_
11	degraded	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	concert	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	induced	_	_	VBN	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	translocation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	NF-kappa	_	_	NN	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	demonstrates	_	_	VBZ	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	tumor	_	_	NN	Protein	9	multitoken	_	_
7	necrosis	_	_	NN	Protein	9	multitoken	_	_
8	factor	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	degradation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	I	_	_	NN	Protein	16	multitoken	_	_
14	kappa	_	_	NN	Protein	16	multitoken	_	_
15	B	_	_	NN	Protein	16	multitoken	_	_
16	alpha	_	_	NN	Protein	0	root	_	_
17	in	_	_	IN	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	preceded	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	its	_	_	PRP$	O	-1	none	_	_
25	rapid	_	_	JJ	O	-1	none	_	_
26	phosphorylation	_	_	NN	O	-1	none	_	_
27	in	_	_	FW	O	-1	none	_	_
28	vivo	_	_	FW	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	I	_	_	NN	Protein	9	multitoken	_	_
7	kappa	_	_	NN	Protein	9	multitoken	_	_
8	B	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	result	_	_	VBP	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	mobilization	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	only	_	_	RB	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	fraction	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	entire	_	_	JJ	O	-1	none	_	_
21	cytoplasmic	_	_	JJ	O	-1	none	_	_
22	pool	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	RelA	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	thus	_	_	RB	O	-1	none	_	_
4	reveal	_	_	VBP	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	presence	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	second	_	_	JJ	O	-1	none	_	_
10	inducible	_	_	JJ	O	-1	none	_	_
11	autoregulated	_	_	JJ	O	-1	none	_	_
12	inhibitory	_	_	JJ	O	-1	none	_	_
13	pathway	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	helps	_	_	VBZ	O	-1	none	_	_
16	ensure	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	rapid	_	_	JJ	O	-1	none	_	_
19	but	_	_	CC	O	-1	none	_	_
20	transient	_	_	JJ	O	-1	none	_	_
21	action	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	nuclear	_	_	JJ	O	-1	none	_	_
24	NF-kappa	_	_	NN	O	-1	none	_	_
25	B.	_	_	NNP	O	-1	none	_	_

1	Triggering	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	interleukin-6	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	interferon-gamma	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	tumor	_	_	NN	Protein	12	multitoken	_	_
11	necrosis	_	_	NN	Protein	12	multitoken	_	_
12	factor-alpha	_	_	NN	Protein	0	root	_	_
13	in	_	_	IN	O	-1	none	_	_
14	monocytic	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	involves	_	_	VBZ	O	-1	none	_	_
17	cooperation	_	_	NN	O	-1	none	_	_
18	between	_	_	IN	O	-1	none	_	_
19	interferon	_	_	NN	Protein	21	multitoken	_	_
20	regulatory	_	_	JJ	Protein	21	multitoken	_	_
21	factor-1	_	_	NN	Protein	0	root	_	_
22	,	_	_	,	O	-1	none	_	_
23	NF	_	_	NN	O	-1	none	_	_
24	kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	Sp1	_	_	NN	Protein	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	factors	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	basis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	synergistic	_	_	JJ	O	-1	none	_	_
9	induction	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	interferon-gamma	_	_	NN	Protein	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	IFN-gamma	_	_	NN	Protein	-1	none	_	_
14	)/tumor	_	_	NN	Protein	16	multitoken	_	_
15	necrosis	_	_	NN	Protein	16	multitoken	_	_
16	factor-alpha	_	_	NN	Protein	0	root	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	TNF-alpha	_	_	NN	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	interleukin-6	_	_	NN	Protein	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	IL-6	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	gene	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	THP-1	_	_	NN	O	-1	none	_	_
29	monocytic	_	_	JJ	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	compared	_	_	VBN	O	-1	none	_	_
34	it	_	_	PRP	O	-1	none	_	_
35	with	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	basis	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	this	_	_	DT	O	-1	none	_	_
40	induction	_	_	NN	O	-1	none	_	_
41	by	_	_	IN	O	-1	none	_	_
42	lipopolysaccharide	_	_	NN	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	LPS	_	_	NN	O	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	IL-6	_	_	NN	Protein	-1	none	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	demonstrated	_	_	VBD	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	three	_	_	CD	O	-1	none	_	_
9	regions	_	_	NNS	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	targets	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IFN-gamma	_	_	NN	Protein	-1	none	_	_
16	and/or	_	_	CC	O	-1	none	_	_
17	TNF-alpha	_	_	NN	Protein	-1	none	_	_
18	action	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	whereas	_	_	IN	O	-1	none	_	_
21	only	_	_	RB	O	-1	none	_	_
22	one	_	_	CD	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	these	_	_	DT	O	-1	none	_	_
25	regions	_	_	NNS	O	-1	none	_	_
26	seemed	_	_	VBD	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	be	_	_	VB	O	-1	none	_	_
29	implicated	_	_	VBN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	LPS	_	_	NN	O	-1	none	_	_
32	activation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	three	_	_	CD	O	-1	none	_	_
3	regions	_	_	NNS	O	-1	none	_	_
4	concerned	_	_	VBN	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	:	_	_	:	O	-1	none	_	_
7	1	_	_	CD	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	region	_	_	NN	O	-1	none	_	_
11	between	_	_	IN	O	-1	none	_	_
12	-73	_	_	CD	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	-36	_	_	CD	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	minimal	_	_	JJ	O	-1	none	_	_
20	element	_	_	NN	O	-1	none	_	_
21	inducible	_	_	JJ	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	LPS	_	_	NN	O	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	TNF-alpha	_	_	NN	Protein	-1	none	_	_
26	;	_	_	:	O	-1	none	_	_
27	2	_	_	CD	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	element	_	_	NN	O	-1	none	_	_
31	located	_	_	JJ	O	-1	none	_	_
32	between	_	_	IN	O	-1	none	_	_
33	-181	_	_	CD	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	-73	_	_	CD	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	which	_	_	WDT	O	-1	none	_	_
38	appeared	_	_	VBD	O	-1	none	_	_
39	to	_	_	TO	O	-1	none	_	_
40	regulate	_	_	VB	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	response	_	_	NN	O	-1	none	_	_
43	to	_	_	TO	O	-1	none	_	_
44	IFN-gamma	_	_	NN	Protein	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	TNF-alpha	_	_	NN	Protein	-1	none	_	_
47	negatively	_	_	RB	O	-1	none	_	_
48	;	_	_	:	O	-1	none	_	_
49	and	_	_	CC	O	-1	none	_	_
50	3	_	_	CD	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	a	_	_	DT	O	-1	none	_	_
53	distal	_	_	JJ	O	-1	none	_	_
54	element	_	_	NN	O	-1	none	_	_
55	upstream	_	_	JJ	O	-1	none	_	_
56	of	_	_	IN	O	-1	none	_	_
57	-224	_	_	CD	O	-1	none	_	_
58	,	_	_	,	O	-1	none	_	_
59	which	_	_	WDT	O	-1	none	_	_
60	was	_	_	VBD	O	-1	none	_	_
61	inducible	_	_	JJ	O	-1	none	_	_
62	by	_	_	IN	O	-1	none	_	_
63	IFN-gamma	_	_	NN	Protein	-1	none	_	_
64	alone	_	_	RB	O	-1	none	_	_
65	.	_	_	.	O	-1	none	_	_

1	LPS	_	_	NN	O	-1	none	_	_
2	signaling	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	found	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	involve	_	_	VB	O	-1	none	_	_
7	NF	_	_	NN	O	-1	none	_	_
8	kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	p50	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	p65	_	_	NN	Protein	-1	none	_	_
16	heterodimers	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Synergistic	_	_	JJ	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	IL-6	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	IFN-gamma	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	TNF-alpha	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	monocytic	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	involved	_	_	VBN	O	-1	none	_	_
17	cooperation	_	_	NN	O	-1	none	_	_
18	between	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	IRF-1	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	NF	_	_	NN	O	-1	none	_	_
23	kappa	_	_	NN	O	-1	none	_	_
24	B	_	_	NN	O	-1	none	_	_
25	p65	_	_	NN	Protein	-1	none	_	_
26	homodimers	_	_	NNS	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	concomitant	_	_	JJ	O	-1	none	_	_
29	removal	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	negative	_	_	JJ	O	-1	none	_	_
33	effect	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	retinoblastoma	_	_	NN	O	-1	none	_	_
37	control	_	_	NN	O	-1	none	_	_
38	element	_	_	NN	O	-1	none	_	_
39	present	_	_	JJ	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	IL-6	_	_	NN	Protein	-1	none	_	_
43	promoter	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	removal	_	_	NN	O	-1	none	_	_
3	occurred	_	_	VBD	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	constitutive	_	_	JJ	O	-1	none	_	_
9	Sp1	_	_	NN	Protein	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	whose	_	_	WP$	O	-1	none	_	_
13	increased	_	_	VBN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	phosphorylation	_	_	NN	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	mediated	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	IFN-gamma	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Monocyte	_	_	NN	O	-1	none	_	_
2	tethering	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	P-selectin	_	_	NN	Protein	-1	none	_	_
5	regulates	_	_	VBZ	O	-1	none	_	_
6	monocyte	_	_	NN	Protein	8	multitoken	_	_
7	chemotactic	_	_	JJ	Protein	8	multitoken	_	_
8	protein-1	_	_	NN	Protein	0	root	_	_
9	and	_	_	CC	O	-1	none	_	_
10	tumor	_	_	NN	Protein	12	multitoken	_	_
11	necrosis	_	_	NN	Protein	12	multitoken	_	_
12	factor-alpha	_	_	NN	Protein	0	root	_	_
13	secretion	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Signal	_	_	NN	O	-1	none	_	_
2	integration	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	translocation	_	_	NN	O	-1	none	_	_
7	[	_	_	NN	O	-1	none	_	_
8	see	_	_	VB	O	-1	none	_	_
9	comments	_	_	NNS	O	-1	none	_	_
10	]	_	_	CD	O	-1	none	_	_
11	Adhesion	_	_	NN	O	-1	none	_	_
12	molecules	_	_	NNS	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	tether	_	_	VBP	O	-1	none	_	_
15	circulating	_	_	VBG	O	-1	none	_	_
16	leukocytes	_	_	NNS	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	endothelial	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	may	_	_	MD	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	transduce	_	_	VB	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	modulate	_	_	VB	O	-1	none	_	_
25	outside-in	_	_	JJ	O	-1	none	_	_
26	signals	_	_	NNS	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	cellular	_	_	JJ	O	-1	none	_	_
29	activation	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	providing	_	_	VBG	O	-1	none	_	_
32	an	_	_	DT	O	-1	none	_	_
33	initial	_	_	JJ	O	-1	none	_	_
34	regulatory	_	_	JJ	O	-1	none	_	_
35	point	_	_	NN	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	inflammatory	_	_	JJ	O	-1	none	_	_
39	response	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Adhesion	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	monocytes	_	_	NNS	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	P-selectin	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	most	_	_	RBS	O	-1	none	_	_
10	rapidly	_	_	RB	O	-1	none	_	_
11	expressed	_	_	VBD	O	-1	none	_	_
12	endothelial	_	_	JJ	O	-1	none	_	_
13	tethering	_	_	NN	O	-1	none	_	_
14	factor	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	increased	_	_	VBD	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	secretion	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	monocyte	_	_	NN	Protein	22	multitoken	_	_
21	chemotactic	_	_	JJ	Protein	22	multitoken	_	_
22	protein-1	_	_	NN	Protein	0	root	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	MCP-1	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	tumor	_	_	NN	Protein	29	multitoken	_	_
28	necrosis	_	_	NN	Protein	29	multitoken	_	_
29	factor-alpha	_	_	NN	Protein	0	root	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	TNF-alpha	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	leukocytes	_	_	NNS	O	-1	none	_	_
36	when	_	_	WRB	O	-1	none	_	_
37	they	_	_	PRP	O	-1	none	_	_
38	were	_	_	VBD	O	-1	none	_	_
39	stimulated	_	_	VBN	O	-1	none	_	_
40	with	_	_	IN	O	-1	none	_	_
41	platelet	_	_	NN	O	-1	none	_	_
42	activating	_	_	NN	O	-1	none	_	_
43	factor	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Increased	_	_	VBN	O	-1	none	_	_
2	cytokine	_	_	NN	O	-1	none	_	_
3	secretion	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	specifically	_	_	RB	O	-1	none	_	_
6	inhibited	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	G1	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	anti-P-selectin	_	_	JJ	Protein	-1	none	_	_
12	mAb	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	prevents	_	_	VBZ	O	-1	none	_	_
15	P-selectin	_	_	NN	Protein	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	binding	_	_	VBG	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	its	_	_	PRP$	O	-1	none	_	_
20	ligand	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	P-selectin	_	_	NN	Protein	24	multitoken	_	_
23	glycoprotein	_	_	NN	Protein	24	multitoken	_	_
24	ligand-1	_	_	NN	Protein	0	root	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	on	_	_	IN	O	-1	none	_	_
27	myeloid	_	_	JJ	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	tethering	_	_	NN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	P-selectin	_	_	NN	Protein	-1	none	_	_
6	specifically	_	_	RB	O	-1	none	_	_
7	enhanced	_	_	VBD	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	translocation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	factor-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	required	_	_	VBN	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	expression	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	MCP-1	_	_	NN	Protein	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	TNF-alpha	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	other	_	_	JJ	O	-1	none	_	_
32	immediate-early	_	_	JJ	O	-1	none	_	_
33	genes	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	P-selectin	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	through	_	_	IN	O	-1	none	_	_
8	its	_	_	PRP$	O	-1	none	_	_
9	ligands	_	_	NNS	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	monocytes	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	locally	_	_	RB	O	-1	none	_	_
15	regulate	_	_	VB	O	-1	none	_	_
16	cytokine	_	_	NN	O	-1	none	_	_
17	secretion	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	inflamed	_	_	JJ	O	-1	none	_	_
20	tissues	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	MIP1	_	_	NN	O	-1	none	_	_
2	alpha	_	_	NN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	MNP	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	novel	_	_	JJ	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	expressed	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	hematopoietic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	crucial	_	_	JJ	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	MIP-1	_	_	NN	Protein	26	multitoken	_	_
26	alpha	_	_	NN	Protein	0	root	_	_
27	gene	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Murine	_	_	JJ	O	-1	none	_	_
2	macrophage	_	_	NN	Protein	6	multitoken	_	_
3	inflammatory	_	_	JJ	Protein	6	multitoken	_	_
4	protein	_	_	NN	Protein	6	multitoken	_	_
5	1	_	_	CD	Protein	6	multitoken	_	_
6	alpha	_	_	NN	Protein	0	root	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	MIP-1	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	its	_	_	PRP$	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	equivalent	_	_	JJ	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	GOS19	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	LD78	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	AT464	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	are	_	_	VBP	O	-1	none	_	_
24	members	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	-C-C	_	_	NN	O	-1	none	_	_
28	family	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	low-molecular-weight	_	_	JJ	O	-1	none	_	_
31	chemokines	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Secreted	_	_	VBN	O	-1	none	_	_
2	from	_	_	IN	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	macrophages	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	bone	_	_	NN	O	-1	none	_	_
10	marrow	_	_	NN	O	-1	none	_	_
11	derived	_	_	VBN	O	-1	none	_	_
12	MIP-1	_	_	NN	Protein	13	multitoken	_	_
13	alpha	_	_	NN	Protein	0	root	_	_
14	and	_	_	CC	O	-1	none	_	_
15	GOS19	_	_	NN	Protein	-1	none	_	_
16	inhibits	_	_	VBZ	O	-1	none	_	_
17	primitive	_	_	JJ	O	-1	none	_	_
18	hematopoietic	_	_	JJ	O	-1	none	_	_
19	stem	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	appears	_	_	VBZ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	be	_	_	VB	O	-1	none	_	_
25	involved	_	_	VBN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	homeostatic	_	_	JJ	O	-1	none	_	_
29	control	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	stem	_	_	NN	O	-1	none	_	_
32	cell	_	_	NN	O	-1	none	_	_
33	proliferation	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	induces	_	_	VBZ	O	-1	none	_	_
4	chemotaxis	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	inflammatory	_	_	JJ	O	-1	none	_	_
7	responses	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	mature	_	_	JJ	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	types	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	important	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	understand	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	mechanisms	_	_	NNS	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	control	_	_	VBP	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	MIP-1	_	_	NN	Protein	16	multitoken	_	_
16	alpha	_	_	NN	Protein	0	root	_	_
17	and	_	_	CC	O	-1	none	_	_
18	GOS19	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	work	_	_	NN	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	Jurkat	_	_	NN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	set	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	widely	_	_	RB	O	-1	none	_	_
15	expressed	_	_	VBN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	factors	_	_	NNS	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	ICK-1	_	_	NN	O	-1	none	_	_
21	family	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	affect	_	_	VBP	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	GOS19	_	_	NN	Protein	-1	none	_	_
26	promoter	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	member	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	ICK-1A	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	behaves	_	_	VBZ	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	strong	_	_	JJ	O	-1	none	_	_
10	negative	_	_	JJ	O	-1	none	_	_
11	regulator	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	communication	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	provide	_	_	VBP	O	-1	none	_	_
7	evidence	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	pathway	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	macrophage	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	line	_	_	NN	O	-1	none	_	_
18	U937	_	_	NN	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	different	_	_	JJ	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	that	_	_	DT	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	Jurkat	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	ICK-1	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	site	_	_	NN	O	-1	none	_	_
10	does	_	_	VBZ	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	confer	_	_	VB	O	-1	none	_	_
13	negative	_	_	JJ	O	-1	none	_	_
14	regulation	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	U937	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	provide	_	_	VBP	O	-1	none	_	_
3	evidence	_	_	NN	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	additional	_	_	JJ	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	site	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	MIP-1	_	_	NN	O	-1	none	_	_
12	alpha	_	_	NN	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	MNP	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	site	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	overlaps	_	_	VBZ	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	ICK-1	_	_	NN	O	-1	none	_	_
24	site	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Interaction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	extracts	_	_	NNS	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	various	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	lines	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	tissue	_	_	NN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	MNP	_	_	NN	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	leads	_	_	VBZ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	formation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	fast	_	_	JJ	O	-1	none	_	_
21	migrating	_	_	VBG	O	-1	none	_	_
22	protein-DNA	_	_	JJ	O	-1	none	_	_
23	complexes	_	_	NNS	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	similar	_	_	JJ	O	-1	none	_	_
26	but	_	_	CC	O	-1	none	_	_
27	distinct	_	_	JJ	O	-1	none	_	_
28	electrophoretic	_	_	JJ	O	-1	none	_	_
29	mobilities	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	mutation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	MNP	_	_	NN	O	-1	none	_	_
6	site	_	_	NN	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	does	_	_	VBZ	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	abrogate	_	_	VB	O	-1	none	_	_
11	ICK-1	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	inactivates	_	_	VBZ	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	GOS19	_	_	NN	O	-1	none	_	_
16	.1	_	_	NN	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	U937	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	reduces	_	_	VBZ	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	fourfold	_	_	RB	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	Jurkat	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	MNP	_	_	NN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	s	_	_	VBZ	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	at	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	MNP	_	_	NN	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	constitutes	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	novel	_	_	JJ	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	s	_	_	NNS	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	expressed	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	hematopoietic	_	_	JJ	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Modulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	endogenous	_	_	JJ	O	-1	none	_	_
4	IL-1	_	_	NN	Protein	5	multitoken	_	_
5	beta	_	_	NN	Protein	0	root	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IL-1	_	_	NN	Protein	9	multitoken	_	_
8	receptor	_	_	NN	Protein	9	multitoken	_	_
9	antagonist	_	_	NN	Protein	0	root	_	_
10	results	_	_	VBZ	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	opposing	_	_	JJ	O	-1	none	_	_
13	effects	_	_	NNS	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	HIV	_	_	NN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	chronically	_	_	RB	O	-1	none	_	_
19	infected	_	_	JJ	O	-1	none	_	_
20	monocytic	_	_	JJ	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	proportion	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	HIV	_	_	NN	O	-1	none	_	_
5	infected	_	_	JJ	O	-1	none	_	_
6	individuals	_	_	NNS	O	-1	none	_	_
7	experience	_	_	VBP	O	-1	none	_	_
8	episodes	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	localized	_	_	JJ	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	systemic	_	_	JJ	O	-1	none	_	_
13	bacterial	_	_	JJ	O	-1	none	_	_
14	infections	_	_	NNS	O	-1	none	_	_
15	caused	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	Gram	_	_	NN	O	-1	none	_	_
18	negative	_	_	JJ	O	-1	none	_	_
19	bacteria	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Many	_	_	JJ	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	clinical	_	_	JJ	O	-1	none	_	_
5	side	_	_	NN	O	-1	none	_	_
6	effects	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	infections	_	_	NNS	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	associated	_	_	VBN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	proinflammatory	_	_	JJ	O	-1	none	_	_
17	cytokines	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	induced	_	_	VBN	O	-1	none	_	_
22	primarily	_	_	RB	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	LPS	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	constituent	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	bacterial	_	_	JJ	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	wall	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	Gram	_	_	NN	O	-1	none	_	_
35	negative	_	_	JJ	O	-1	none	_	_
36	bacteria	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	examines	_	_	VBZ	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	mechanisms	_	_	NNS	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	LPS	_	_	NN	O	-1	none	_	_
10	mediated	_	_	JJ	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	HIV	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	U1	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	promonocytic	_	_	JJ	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	line	_	_	NN	O	-1	none	_	_
23	chronically	_	_	RB	O	-1	none	_	_
24	infected	_	_	VBN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	HIV	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Stimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	U1	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	alone	_	_	RB	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	minimal	_	_	JJ	O	-1	none	_	_
10	levels	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	HIV	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	significantly	_	_	RB	O	-1	none	_	_
18	enhanced	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	granulocyte-macrophage	_	_	JJ	Protein	23	multitoken	_	_
21	colony	_	_	NN	Protein	23	multitoken	_	_
22	stimulating	_	_	NN	Protein	23	multitoken	_	_
23	factor	_	_	NN	Protein	0	root	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	GM-CSF	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Costimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	U1	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	plus	_	_	CC	O	-1	none	_	_
8	GM-CSF	_	_	NN	Protein	-1	none	_	_
9	resulted	_	_	VBD	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	accumulation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	steady-state	_	_	JJ	O	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	HIV	_	_	NN	O	-1	none	_	_
18	RNA	_	_	NN	O	-1	none	_	_
19	;	_	_	:	O	-1	none	_	_
20	however	_	_	RB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	only	_	_	RB	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	weak	_	_	JJ	O	-1	none	_	_
25	induction	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	HIV	_	_	NN	O	-1	none	_	_
28	long	_	_	JJ	O	-1	none	_	_
29	terminal	_	_	JJ	O	-1	none	_	_
30	repeat	_	_	NN	O	-1	none	_	_
31	driven	_	_	VBN	O	-1	none	_	_
32	transcription	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	which	_	_	WDT	O	-1	none	_	_
35	was	_	_	VBD	O	-1	none	_	_
36	not	_	_	RB	O	-1	none	_	_
37	associated	_	_	VBN	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	activation	_	_	NN	O	-1	none	_	_
41	of	_	_	IN	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	cellular	_	_	JJ	O	-1	none	_	_
44	transcription	_	_	NN	O	-1	none	_	_
45	factor	_	_	NN	O	-1	none	_	_
46	nuclear	_	_	JJ	O	-1	none	_	_
47	factor-kappa	_	_	NN	O	-1	none	_	_
48	B	_	_	NN	O	-1	none	_	_
49	,	_	_	,	O	-1	none	_	_
50	was	_	_	VBD	O	-1	none	_	_
51	noted	_	_	VBN	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Costimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	LPS	_	_	NN	O	-1	none	_	_
6	plus	_	_	CC	O	-1	none	_	_
7	GM-CSF	_	_	NN	Protein	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	production	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	proinflammatory	_	_	JJ	O	-1	none	_	_
13	cytokines	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	IL-8	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	IL-1	_	_	NN	Protein	18	multitoken	_	_
18	beta	_	_	NN	Protein	0	root	_	_
19	and	_	_	CC	O	-1	none	_	_
20	IL-6	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	but	_	_	CC	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	TNF-alpha	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	balance	_	_	NN	O	-1	none	_	_
5	between	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	endogenously	_	_	RB	O	-1	none	_	_
8	produced	_	_	VBN	O	-1	none	_	_
9	viral	_	_	JJ	O	-1	none	_	_
10	inducer	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	IL-1	_	_	NN	Protein	13	multitoken	_	_
13	beta	_	_	NN	Protein	0	root	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	an	_	_	DT	O	-1	none	_	_
17	inhibitor	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	IL-1ra	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	may	_	_	MD	O	-1	none	_	_
22	represent	_	_	VB	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	important	_	_	JJ	O	-1	none	_	_
25	pathway	_	_	NN	O	-1	none	_	_
26	leading	_	_	VBG	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	modulation	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	HIV	_	_	NN	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	from	_	_	IN	O	-1	none	_	_
33	monocytic	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	GM-CSF	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	share	_	_	NN	O	-1	none	_	_
5	common	_	_	JJ	O	-1	none	_	_
6	control	_	_	NN	O	-1	none	_	_
7	mechanisms	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	response	_	_	NN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	costimulatory	_	_	JJ	O	-1	none	_	_
12	signals	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Antigen	_	_	NN	O	-1	none	_	_
2	complexed	_	_	VBD	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	major	_	_	JJ	O	-1	none	_	_
5	histocompatibility	_	_	NN	O	-1	none	_	_
6	complex	_	_	NN	O	-1	none	_	_
7	class	_	_	NN	O	-1	none	_	_
8	I	_	_	CD	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	molecules	_	_	NNS	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	surface	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	antigen	_	_	NN	O	-1	none	_	_
17	presenting	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	interacts	_	_	VBZ	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	receptor	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	TCR	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	on	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	surface	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	initiates	_	_	VBZ	O	-1	none	_	_
36	an	_	_	DT	O	-1	none	_	_
37	activation	_	_	NN	O	-1	none	_	_
38	cascade	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	So	_	_	RB	O	-1	none	_	_
2	called	_	_	VBN	O	-1	none	_	_
3	costimulatory	_	_	JJ	O	-1	none	_	_
4	signals	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	mediated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	other	_	_	JJ	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	surface	_	_	NN	O	-1	none	_	_
11	interactions	_	_	NNS	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	soluble	_	_	JJ	O	-1	none	_	_
14	cytokines	_	_	NNS	O	-1	none	_	_
15	produced	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	antigen	_	_	NN	O	-1	none	_	_
18	presenting	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	also	_	_	RB	O	-1	none	_	_
23	required	_	_	VBN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	complete	_	_	JJ	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	High	_	_	JJ	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	cytokine	_	_	NN	O	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	required	_	_	VBD	O	-1	none	_	_
12	both	_	_	CC	O	-1	none	_	_
13	TCR	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	costimulatory	_	_	JJ	O	-1	none	_	_
16	signals	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	granulocyte-macrophage	_	_	JJ	Protein	5	multitoken	_	_
3	colony	_	_	NN	Protein	5	multitoken	_	_
4	stimulating	_	_	NN	Protein	5	multitoken	_	_
5	factor	_	_	NN	Protein	0	root	_	_
6	requires	_	_	VBZ	O	-1	none	_	_
7	sequences	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	as	_	_	RB	O	-1	none	_	_
12	well	_	_	RB	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	powerful	_	_	JJ	O	-1	none	_	_
16	enhancer	_	_	NN	O	-1	none	_	_
17	located	_	_	JJ	O	-1	none	_	_
18	3kb	_	_	JJ	O	-1	none	_	_
19	upstream	_	_	JJ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	respond	_	_	VB	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	TCR	_	_	NN	O	-1	none	_	_
24	like	_	_	IN	O	-1	none	_	_
25	signals	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	promoter	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	enhancer	_	_	NN	O	-1	none	_	_
5	regions	_	_	NNS	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	mainly	_	_	RB	O	-1	none	_	_
8	activated	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	factor	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	activated	_	_	VBN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	NFAT	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NFAT	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	TCR	_	_	NN	O	-1	none	_	_
7	signals	_	_	NNS	O	-1	none	_	_
8	has	_	_	VBZ	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	well	_	_	RB	O	-1	none	_	_
11	described	_	_	VBN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	interleukin-2	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	IL-4	_	_	NN	Protein	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Costimulatory	_	_	JJ	O	-1	none	_	_
2	signals	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	such	_	_	JJ	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	CD28	_	_	NN	Protein	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	surface	_	_	NN	O	-1	none	_	_
12	molecule	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	lead	_	_	VBP	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	through	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	distinct	_	_	JJ	O	-1	none	_	_
23	region	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	granulocyte-macrophage	_	_	JJ	Protein	29	multitoken	_	_
27	colony	_	_	NN	Protein	29	multitoken	_	_
28	stimulating	_	_	NN	Protein	29	multitoken	_	_
29	factor	_	_	NN	Protein	0	root	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	GM-CSF	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	promoter	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	region	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	termed	_	_	VBN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	CK-1	_	_	NN	O	-1	none	_	_
7	or	_	_	CC	O	-1	none	_	_
8	CD28RE	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	appears	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	bind	_	_	VB	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	members	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	family	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	factors	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HTLV-1	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	infects	_	_	VBZ	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	can	_	_	MD	O	-1	none	_	_
15	lead	_	_	VB	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	increase	_	_	VB	O	-1	none	_	_
18	GM-CSF	_	_	NN	Protein	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	found	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	HTLV-1	_	_	NN	O	-1	none	_	_
7	transactivator	_	_	NN	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	tax	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	acts	_	_	VBZ	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	costimulatory	_	_	JJ	O	-1	none	_	_
16	signal	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	GM-CSF	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	it	_	_	PRP	O	-1	none	_	_
27	can	_	_	MD	O	-1	none	_	_
28	cooperate	_	_	VB	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	TCR	_	_	NN	O	-1	none	_	_
31	signals	_	_	NNS	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	mediate	_	_	VB	O	-1	none	_	_
34	high	_	_	JJ	O	-1	none	_	_
35	level	_	_	NN	O	-1	none	_	_
36	gene	_	_	NN	O	-1	none	_	_
37	expression	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Tax	_	_	NN	Protein	-1	none	_	_
2	activates	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	GM-CSF	_	_	NN	Protein	-1	none	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	through	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	CK-1	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CD28RE	_	_	NN	O	-1	none	_	_
11	region	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	also	_	_	RB	O	-1	none	_	_
14	activates	_	_	VBZ	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	factor-kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	binding	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	this	_	_	DT	O	-1	none	_	_
21	region	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	other	_	_	JJ	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	factors	_	_	NNS	O	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	coactivators	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	required	_	_	VBN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	tax	_	_	NN	Protein	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	these	_	_	DT	O	-1	none	_	_
18	remain	_	_	VBP	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	identified	_	_	VBN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	CK-1	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	CD28RE	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	GM-CSF	_	_	NN	Protein	-1	none	_	_
7	shows	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	high	_	_	JJ	O	-1	none	_	_
10	degree	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	similarity	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	CD28RE	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	IL-3	_	_	NN	Protein	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	contains	_	_	VBZ	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	related	_	_	JJ	O	-1	none	_	_
25	region	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	observation	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	together	_	_	RB	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	fact	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	both	_	_	CC	O	-1	none	_	_
10	GM-CSF	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	IL-2	_	_	NN	Protein	-1	none	_	_
13	respond	_	_	VBP	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	TCR	_	_	NN	O	-1	none	_	_
16	signals	_	_	NNS	O	-1	none	_	_
17	via	_	_	IN	O	-1	none	_	_
18	NFAT	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	implies	_	_	VBZ	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	high	_	_	JJ	O	-1	none	_	_
23	degree	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	conservation	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	regulation	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	cytokine	_	_	NN	O	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	expression	_	_	NN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	T	_	_	NN	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Signaling	_	_	NN	O	-1	none	_	_
2	events	_	_	NNS	O	-1	none	_	_
3	induced	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	lipopolysaccharide	_	_	NN	O	-1	none	_	_
6	activated	_	_	VBD	O	-1	none	_	_
7	toll	_	_	NN	Protein	10	multitoken	_	_
8	like	_	_	IN	Protein	10	multitoken	_	_
9	receptor	_	_	NN	Protein	10	multitoken	_	_
10	2	_	_	CD	Protein	0	root	_	_
11	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	Toll	_	_	NN	Protein	5	multitoken	_	_
3	like	_	_	IN	Protein	5	multitoken	_	_
4	receptor	_	_	NN	Protein	5	multitoken	_	_
5	2	_	_	CD	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	TLR2	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	signaling	_	_	NN	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	responds	_	_	VBZ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	LPS	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	activates	_	_	VBZ	O	-1	none	_	_
19	NF-kappaB	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	investigate	_	_	VBP	O	-1	none	_	_
5	further	_	_	RB	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	events	_	_	NNS	O	-1	none	_	_
8	triggered	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	TLR2	_	_	NN	Protein	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	response	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	LPS	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	TLR2	_	_	NN	Protein	-1	none	_	_
5	associates	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	high-affinity	_	_	JJ	O	-1	none	_	_
9	LPS	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	membrane	_	_	NN	O	-1	none	_	_
13	CD14	_	_	NN	Protein	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	serve	_	_	VB	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	an	_	_	DT	O	-1	none	_	_
18	LPS	_	_	NN	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	complex	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	LPS	_	_	NN	O	-1	none	_	_
25	treatment	_	_	NN	O	-1	none	_	_
26	enhances	_	_	VBZ	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	oligomerization	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	TLR2	_	_	NN	Protein	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Concomitant	_	_	JJ	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	receptor	_	_	NN	O	-1	none	_	_
4	oligomerization	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	IL-1R-associated	_	_	JJ	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	IRAK	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	recruited	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	TLR2	_	_	NN	Protein	-1	none	_	_
17	complex	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Intracellular	_	_	JJ	O	-1	none	_	_
2	deletion	_	_	NN	O	-1	none	_	_
3	variants	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	TLR2	_	_	NN	Protein	-1	none	_	_
6	lacking	_	_	VBG	O	-1	none	_	_
7	C-terminal	_	_	JJ	O	-1	none	_	_
8	13	_	_	CD	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	141	_	_	CD	O	-1	none	_	_
11	aa	_	_	NN	O	-1	none	_	_
12	fail	_	_	VBP	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	recruit	_	_	VB	O	-1	none	_	_
15	IRAK	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	consistent	_	_	JJ	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	inability	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	these	_	_	DT	O	-1	none	_	_
25	mutants	_	_	NNS	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	transmit	_	_	VB	O	-1	none	_	_
28	LPS	_	_	NN	O	-1	none	_	_
29	cellular	_	_	JJ	O	-1	none	_	_
30	signaling	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	both	_	_	DT	O	-1	none	_	_
4	deletion	_	_	NN	O	-1	none	_	_
5	mutants	_	_	NNS	O	-1	none	_	_
6	could	_	_	MD	O	-1	none	_	_
7	still	_	_	RB	O	-1	none	_	_
8	form	_	_	VB	O	-1	none	_	_
9	complexes	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	wild-type	_	_	JJ	O	-1	none	_	_
12	TLR2	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	act	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	dominant	_	_	JJ	O	-1	none	_	_
18	negative	_	_	JJ	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	DN	_	_	JJ	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	fashion	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	block	_	_	VB	O	-1	none	_	_
25	TLR2	_	_	NN	Protein	-1	none	_	_
26	mediated	_	_	JJ	O	-1	none	_	_
27	signal	_	_	NN	O	-1	none	_	_
28	transduction	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	DN	_	_	JJ	O	-1	none	_	_
2	constructs	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	myeloid	_	_	JJ	O	-1	none	_	_
5	differentiation	_	_	NN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	IRAK	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	TNF	_	_	NN	Protein	14	multitoken	_	_
11	receptor	_	_	NN	Protein	14	multitoken	_	_
12	associated	_	_	JJ	Protein	14	multitoken	_	_
13	factor	_	_	NN	Protein	14	multitoken	_	_
14	6	_	_	CD	Protein	0	root	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	NF-kappaB-inducing	_	_	NN	Protein	18	multitoken	_	_
18	kinase	_	_	NN	Protein	0	root	_	_
19	,	_	_	,	O	-1	none	_	_
20	when	_	_	WRB	O	-1	none	_	_
21	coexpressed	_	_	VBN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	TLR2	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	abrogate	_	_	VBP	O	-1	none	_	_
26	TLR2	_	_	NN	Protein	-1	none	_	_
27	mediated	_	_	VBD	O	-1	none	_	_
28	NF-kappaB	_	_	NN	O	-1	none	_	_
29	activation	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	reveal	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	conserved	_	_	JJ	O	-1	none	_	_
6	signaling	_	_	NN	O	-1	none	_	_
7	pathway	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	TLR2	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	IL-1Rs	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	suggest	_	_	VBP	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	molecular	_	_	JJ	O	-1	none	_	_
16	mechanism	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	inhibition	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	TLR2	_	_	NN	Protein	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	DN	_	_	JJ	O	-1	none	_	_
24	variants	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Globin	_	_	NN	O	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	switching	_	_	NN	O	-1	none	_	_
4	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vivo	_	_	FW	O	-1	none	_	_
3	protein-DNA	_	_	JJ	O	-1	none	_	_
4	interactions	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	beta-globin	_	_	NN	Protein	-1	none	_	_
9	locus	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	erythroid	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	expressing	_	_	VBG	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	fetal	_	_	JJ	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	adult	_	_	JJ	O	-1	none	_	_
19	globin	_	_	NN	O	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	program	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	characterize	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	protein-DNA	_	_	JJ	O	-1	none	_	_
5	interactions	_	_	NNS	O	-1	none	_	_
6	important	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	developmental	_	_	JJ	O	-1	none	_	_
10	control	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	beta-globin	_	_	NN	Protein	-1	none	_	_
15	locus	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	we	_	_	PRP	O	-1	none	_	_
18	analyzed	_	_	VBD	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	in	_	_	FW	O	-1	none	_	_
21	vivo	_	_	FW	O	-1	none	_	_
22	dimethyl	_	_	NN	O	-1	none	_	_
23	sulfate	_	_	NN	O	-1	none	_	_
24	footprinting	_	_	NN	O	-1	none	_	_
25	erythroid	_	_	JJ	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	expressing	_	_	VBG	O	-1	none	_	_
28	either	_	_	CC	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	fetal	_	_	JJ	Protein	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	adult	_	_	JJ	Protein	34	multitoken	_	_
34	globin	_	_	NN	Protein	0	root	_	_
35	developmental	_	_	JJ	O	-1	none	_	_
36	program	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	locus	_	_	NN	O	-1	none	_	_
4	control	_	_	NN	O	-1	none	_	_
5	region	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	LCR	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	beta-globin	_	_	NN	Protein	-1	none	_	_
12	locus	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	in	_	_	FW	O	-1	none	_	_
15	vivo	_	_	FW	O	-1	none	_	_
16	footprints	_	_	NNS	O	-1	none	_	_
17	on	_	_	IN	O	-1	none	_	_
18	NF-E2	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	AP-1	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	GATA-1	_	_	NN	Protein	-1	none	_	_
25	motifs	_	_	NNS	O	-1	none	_	_
26	remained	_	_	VBD	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	same	_	_	JJ	O	-1	none	_	_
29	regardless	_	_	RB	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	whether	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	fetal	_	_	JJ	Protein	-1	none	_	_
34	or	_	_	CC	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	adult	_	_	JJ	Protein	38	multitoken	_	_
37	globin	_	_	NN	Protein	38	multitoken	_	_
38	genes	_	_	NNS	Protein	0	root	_	_
39	are	_	_	VBP	O	-1	none	_	_
40	expressed	_	_	VBN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	in	_	_	FW	O	-1	none	_	_
5	vivo	_	_	FW	O	-1	none	_	_
6	footprints	_	_	NNS	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	GT	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	CACCC	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	motifs	_	_	NNS	O	-1	none	_	_
13	differed	_	_	VBD	O	-1	none	_	_
14	between	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	expressing	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	fetal	_	_	JJ	Protein	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	adult	_	_	JJ	Protein	23	multitoken	_	_
23	globin	_	_	NN	Protein	0	root	_	_
24	program	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	promoter	_	_	NN	O	-1	none	_	_
3	regions	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	actively	_	_	RB	O	-1	none	_	_
7	transcribed	_	_	VBN	O	-1	none	_	_
8	genes	_	_	NNS	O	-1	none	_	_
9	demonstrated	_	_	VBD	O	-1	none	_	_
10	extensive	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	consistent	_	_	JJ	O	-1	none	_	_
13	footprints	_	_	NNS	O	-1	none	_	_
14	over	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	canonical	_	_	JJ	O	-1	none	_	_
17	elements	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	such	_	_	JJ	O	-1	none	_	_
20	as	_	_	IN	O	-1	none	_	_
21	CACCC	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	CCAAT	_	_	NN	O	-1	none	_	_
24	motifs	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	adult	_	_	JJ	O	-1	none	_	_
3	globin	_	_	NN	O	-1	none	_	_
4	expressing	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	displayed	_	_	VBD	O	-1	none	_	_
7	more	_	_	RBR	O	-1	none	_	_
8	extensive	_	_	JJ	O	-1	none	_	_
9	footprints	_	_	NNS	O	-1	none	_	_
10	than	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	fetal	_	_	JJ	O	-1	none	_	_
13	globin	_	_	NN	O	-1	none	_	_
14	expressing	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	3	_	_	CD	O	-1	none	_	_
19	'	_	_	''	O	-1	none	_	_
20	regulatory	_	_	JJ	O	-1	none	_	_
21	sequences	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	both	_	_	CC	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	Agamma-	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	beta-globin	_	_	NN	Protein	-1	none	_	_
29	genes	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	suggesting	_	_	VBG	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	role	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	these	_	_	DT	O	-1	none	_	_
36	3	_	_	CD	O	-1	none	_	_
37	'	_	_	''	O	-1	none	_	_
38	elements	_	_	NNS	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	beta-globin	_	_	NN	Protein	-1	none	_	_
41	gene	_	_	NN	O	-1	none	_	_
42	expression	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	bulk	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	protein-DNA	_	_	JJ	O	-1	none	_	_
9	interactions	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	underlies	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	developmental	_	_	JJ	O	-1	none	_	_
14	control	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	globin	_	_	NN	O	-1	none	_	_
17	genes	_	_	NNS	O	-1	none	_	_
18	takes	_	_	VBZ	O	-1	none	_	_
19	place	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	gamma-	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	beta-globin	_	_	NN	Protein	-1	none	_	_
25	gene	_	_	NN	O	-1	none	_	_
26	promoters	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	that	_	_	IN	O	-1	none	_	_
30	GT	_	_	NN	O	-1	none	_	_
31	motifs	_	_	NNS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	beta-globin	_	_	NN	Protein	-1	none	_	_
35	locus	_	_	NN	O	-1	none	_	_
36	LCR	_	_	NN	O	-1	none	_	_
37	may	_	_	MD	O	-1	none	_	_
38	play	_	_	VB	O	-1	none	_	_
39	a	_	_	DT	O	-1	none	_	_
40	role	_	_	NN	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	developmental	_	_	JJ	O	-1	none	_	_
44	regulation	_	_	NN	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	human	_	_	NN	O	-1	none	_	_
47	beta-globin	_	_	NN	Protein	-1	none	_	_
48	gene	_	_	NN	O	-1	none	_	_
49	expression	_	_	NN	O	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	perhaps	_	_	RB	O	-1	none	_	_
52	by	_	_	IN	O	-1	none	_	_
53	increasing	_	_	VBG	O	-1	none	_	_
54	the	_	_	DT	O	-1	none	_	_
55	probability	_	_	NN	O	-1	none	_	_
56	of	_	_	IN	O	-1	none	_	_
57	interaction	_	_	NN	O	-1	none	_	_
58	of	_	_	IN	O	-1	none	_	_
59	the	_	_	DT	O	-1	none	_	_
60	LCR	_	_	NN	O	-1	none	_	_
61	holocomplex	_	_	NN	O	-1	none	_	_
62	with	_	_	IN	O	-1	none	_	_
63	the	_	_	DT	O	-1	none	_	_
64	fetal	_	_	JJ	Protein	-1	none	_	_
65	or	_	_	CC	O	-1	none	_	_
66	the	_	_	DT	O	-1	none	_	_
67	adult	_	_	JJ	Protein	68	multitoken	_	_
68	globin	_	_	NN	Protein	0	root	_	_
69	gene	_	_	NN	O	-1	none	_	_
70	.	_	_	.	O	-1	none	_	_

1	Monoclonal	_	_	JJ	O	-1	none	_	_
2	anti-endothelial	_	_	JJ	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	antibodies	_	_	NNS	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	patient	_	_	NN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	Takayasu	_	_	NN	O	-1	none	_	_
10	arteritis	_	_	NN	O	-1	none	_	_
11	activate	_	_	VBP	O	-1	none	_	_
12	endothelial	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	large	_	_	JJ	O	-1	none	_	_
16	vessels	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	OBJECTIVE	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	To	_	_	TO	O	-1	none	_	_
4	create	_	_	VB	O	-1	none	_	_
5	monoclonal	_	_	JJ	O	-1	none	_	_
6	anti-endothelial	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	antibodies	_	_	NNS	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	mAECA	_	_	NNS	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	patient	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	Takayasu	_	_	NN	O	-1	none	_	_
17	arteritis	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	evaluate	_	_	VB	O	-1	none	_	_
20	their	_	_	PRP$	O	-1	none	_	_
21	ability	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	activate	_	_	VB	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	umbilical	_	_	JJ	O	-1	none	_	_
26	vein	_	_	NN	O	-1	none	_	_
27	endothelial	_	_	JJ	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	HUVEC	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	characterize	_	_	VB	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	mechanism	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	EC	_	_	NN	O	-1	none	_	_
40	activation	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	A	_	_	DT	O	-1	none	_	_
4	panel	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	mAECA	_	_	NNS	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	generated	_	_	VBN	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	peripheral	_	_	JJ	O	-1	none	_	_
11	blood	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	patient	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	Takayasu	_	_	NN	O	-1	none	_	_
18	arteritis	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	using	_	_	VBG	O	-1	none	_	_
21	Epstein-Barr	_	_	JJ	O	-1	none	_	_
22	virus	_	_	NN	O	-1	none	_	_
23	transformation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Activity	_	_	NN	O	-1	none	_	_
2	against	_	_	IN	O	-1	none	_	_
3	macrovascular	_	_	JJ	O	-1	none	_	_
4	EC	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	HUVEC	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	microvascular	_	_	JJ	O	-1	none	_	_
10	EC	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	bone	_	_	NN	O	-1	none	_	_
14	marrow	_	_	NN	O	-1	none	_	_
15	EC	_	_	NN	O	-1	none	_	_
16	immortalized	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	SV40	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	antigens	_	_	NNS	O	-1	none	_	_
21	was	_	_	VBD	O	-1	none	_	_
22	detected	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	enzyme	_	_	NN	O	-1	none	_	_
25	linked	_	_	JJ	O	-1	none	_	_
26	immunosorbent	_	_	JJ	O	-1	none	_	_
27	assay	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	mAECA	_	_	NNS	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	aortic	_	_	JJ	O	-1	none	_	_
9	EC	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	studied	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	immunohistochemistry	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	secretion	_	_	NN	O	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	interleukin-6	_	_	NN	Protein	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	IL-6	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	von	_	_	NN	Protein	12	multitoken	_	_
11	Willebrand	_	_	NN	Protein	12	multitoken	_	_
12	factor	_	_	NN	Protein	0	root	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	vWF	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	were	_	_	VBD	O	-1	none	_	_
17	determined	_	_	VBN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	serve	_	_	VB	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	markers	_	_	NNS	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	EC	_	_	NN	O	-1	none	_	_
25	activation	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activated	_	_	JJ	O	-1	none	_	_
3	EC	_	_	NN	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	examined	_	_	VBN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	adherence	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	monocytic	_	_	JJ	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	line	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	U937	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	as	_	_	RB	O	-1	none	_	_
19	well	_	_	RB	O	-1	none	_	_
20	as	_	_	IN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	vascular	_	_	JJ	Protein	28	multitoken	_	_
25	cell	_	_	NN	Protein	28	multitoken	_	_
26	adhesion	_	_	NN	Protein	28	multitoken	_	_
27	molecule	_	_	NN	Protein	28	multitoken	_	_
28	1	_	_	CD	Protein	0	root	_	_
29	,	_	_	,	O	-1	none	_	_
30	intercellular	_	_	JJ	Protein	33	multitoken	_	_
31	adhesion	_	_	NN	Protein	33	multitoken	_	_
32	molecule	_	_	NN	Protein	33	multitoken	_	_
33	1	_	_	CD	Protein	0	root	_	_
34	,	_	_	,	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	E-selectin	_	_	NN	Protein	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	extracts	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	mAECA	_	_	NNS	O	-1	none	_	_
9	treated	_	_	VBN	O	-1	none	_	_
10	EC	_	_	NNS	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	analyzed	_	_	VBN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	induction	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	translocation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	kappaB	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	NF-kappaB	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	using	_	_	VBG	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	specific	_	_	JJ	O	-1	none	_	_
29	NF-kappaB	_	_	NN	O	-1	none	_	_
30	oligoprobe	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	an	_	_	DT	O	-1	none	_	_
33	electrophoretic	_	_	JJ	O	-1	none	_	_
34	mobility	_	_	NN	O	-1	none	_	_
35	shift	_	_	NN	O	-1	none	_	_
36	assay	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Six	_	_	CD	O	-1	none	_	_
4	mAECA	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	selected	_	_	VBN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	mixture	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	produced	_	_	VBD	O	-1	none	_	_
13	100	_	_	CD	O	-1	none	_	_
14	%	_	_	NN	O	-1	none	_	_
15	inhibition	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	original	_	_	JJ	O	-1	none	_	_
21	IgG	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	from	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	patient	_	_	NN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	Takayasu	_	_	NN	O	-1	none	_	_
28	arteritis	_	_	NN	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	HUVEC	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	All	_	_	DT	O	-1	none	_	_
2	mAECA	_	_	NNS	O	-1	none	_	_
3	possessed	_	_	VBD	O	-1	none	_	_
4	high	_	_	JJ	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	against	_	_	IN	O	-1	none	_	_
7	macrovascular	_	_	JJ	O	-1	none	_	_
8	EC	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	but	_	_	CC	O	-1	none	_	_
11	none	_	_	NN	O	-1	none	_	_
12	had	_	_	VBD	O	-1	none	_	_
13	significant	_	_	JJ	O	-1	none	_	_
14	antimicrovascular	_	_	JJ	O	-1	none	_	_
15	EC	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mAECA	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	but	_	_	CC	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	normal	_	_	JJ	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	IgG	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	had	_	_	VBD	O	-1	none	_	_
11	anti-human	_	_	JJ	O	-1	none	_	_
12	aortic	_	_	JJ	O	-1	none	_	_
13	EC	_	_	NN	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Four	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	6	_	_	CD	O	-1	none	_	_
5	mAECA	_	_	NNS	O	-1	none	_	_
6	activated	_	_	VBD	O	-1	none	_	_
7	EC	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	manifested	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	increased	_	_	VBN	O	-1	none	_	_
12	IL-6	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	vWF	_	_	NN	Protein	-1	none	_	_
15	secretion	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	4	_	_	CD	O	-1	none	_	_
3	mAECA	_	_	NNS	O	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	EC	_	_	NN	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	adhesion	_	_	NN	O	-1	none	_	_
9	molecules	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	increased	_	_	VBD	O	-1	none	_	_
12	adhesion	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	U937	_	_	NN	O	-1	none	_	_
15	monocytic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	EC	_	_	NNP	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	mAECA	_	_	NNS	O	-1	none	_	_
6	stimulated	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	translocation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	NF-kappaB	_	_	NN	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factor	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	CONCLUSION	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Our	_	_	PRP$	O	-1	none	_	_
4	findings	_	_	NNS	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	AECA	_	_	NNS	O	-1	none	_	_
8	may	_	_	MD	O	-1	none	_	_
9	directly	_	_	RB	O	-1	none	_	_
10	stimulate	_	_	VB	O	-1	none	_	_
11	EC	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	Takayasu	_	_	NN	O	-1	none	_	_
14	arteritis	_	_	NN	O	-1	none	_	_
15	through	_	_	IN	O	-1	none	_	_
16	elevation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	adhesion	_	_	NN	O	-1	none	_	_
19	molecule	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	associated	_	_	VBN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	NF-kappaB	_	_	NN	O	-1	none	_	_
24	activation	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	adhesion	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	monocytes	_	_	NNS	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	may	_	_	MD	O	-1	none	_	_
32	therefore	_	_	RB	O	-1	none	_	_
33	play	_	_	VB	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	pathogenic	_	_	JJ	O	-1	none	_	_
36	role	_	_	NN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	development	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	vasculopathy	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	Takayasu	_	_	NN	O	-1	none	_	_
45	arteritis	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Silencing	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	fetal	_	_	JJ	Protein	5	multitoken	_	_
5	globin	_	_	NN	Protein	0	root	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	impaired	_	_	JJ	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	absence	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	adult	_	_	JJ	O	-1	none	_	_
15	beta-globin	_	_	NN	O	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	activator	_	_	NN	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	EKLF	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Globin	_	_	NN	O	-1	none	_	_
2	genes	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	subject	_	_	JJ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	tissue	_	_	NN	O	-1	none	_	_
7	specific	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	developmental	_	_	JJ	O	-1	none	_	_
10	stage	_	_	NN	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	regulation	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Previously	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	others	_	_	NNS	O	-1	none	_	_
5	showed	_	_	VBD	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	targeted	_	_	VBN	O	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	disruption	_	_	NN	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	zinc	_	_	NN	O	-1	none	_	_
13	finger	_	_	NN	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	erythroid	_	_	JJ	Protein	19	multitoken	_	_
17	Kruppel	_	_	NN	Protein	19	multitoken	_	_
18	like	_	_	IN	Protein	19	multitoken	_	_
19	factor	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	EKLF	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	required	_	_	VBN	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	expression	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	beta-globin	_	_	NN	Protein	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	mice	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	presumably	_	_	RB	O	-1	none	_	_
36	through	_	_	IN	O	-1	none	_	_
37	interaction	_	_	NN	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	a	_	_	DT	O	-1	none	_	_
40	high-affinity	_	_	JJ	O	-1	none	_	_
41	binding	_	_	VBG	O	-1	none	_	_
42	site	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	proximal	_	_	JJ	O	-1	none	_	_
46	promoter	_	_	NN	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	examine	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	role	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	EKLF	_	_	NN	Protein	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	developmental	_	_	JJ	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	gamma-globin	_	_	NN	Protein	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	we	_	_	PRP	O	-1	none	_	_
17	interbred	_	_	VBD	O	-1	none	_	_
18	EKLF	_	_	NN	Protein	-1	none	_	_
19	heterozygotes	_	_	NNS	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	+/-)	_	_	CD	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	mice	_	_	NNS	O	-1	none	_	_
24	harboring	_	_	VBG	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	beta-globin	_	_	NN	Protein	-1	none	_	_
28	yeast	_	_	NN	O	-1	none	_	_
29	artificial	_	_	JJ	O	-1	none	_	_
30	chromosome	_	_	NN	O	-1	none	_	_
31	transgene	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	find	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	absence	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	EKLF	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	while	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	beta-globin	_	_	NN	Protein	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	dramatically	_	_	RB	O	-1	none	_	_
16	reduced	_	_	VBN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	gamma-globin	_	_	NN	Protein	-1	none	_	_
19	transcripts	_	_	NNS	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	elevated	_	_	JJ	O	-1	none	_	_
22	approximately	_	_	RB	O	-1	none	_	_
23	5-fold	_	_	RB	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Impaired	_	_	JJ	O	-1	none	_	_
2	silencing	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	gamma-globin	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	identifies	_	_	VBZ	O	-1	none	_	_
7	EKLF	_	_	NN	Protein	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	first	_	_	JJ	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	participating	_	_	VBG	O	-1	none	_	_
14	quantitatively	_	_	RB	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	gamma-globin	_	_	NN	Protein	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	beta-globin	_	_	NN	Protein	-1	none	_	_
20	switch	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	compatible	_	_	JJ	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	competitive	_	_	JJ	O	-1	none	_	_
8	model	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	switching	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	EKLF	_	_	NN	Protein	-1	none	_	_
14	mediates	_	_	VBZ	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	adult	_	_	JJ	O	-1	none	_	_
17	stage	_	_	NN	O	-1	none	_	_
18	specific	_	_	JJ	O	-1	none	_	_
19	interaction	_	_	NN	O	-1	none	_	_
20	between	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	beta-globin	_	_	NN	Protein	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	promoter	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	locus	_	_	NN	O	-1	none	_	_
28	control	_	_	NN	O	-1	none	_	_
29	region	_	_	NN	O	-1	none	_	_
30	that	_	_	WDT	O	-1	none	_	_
31	excludes	_	_	VBZ	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	gamma-globin	_	_	NN	Protein	-1	none	_	_
34	gene	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Cytomegalovirus	_	_	NN	O	-1	none	_	_
2	immediate	_	_	JJ	O	-1	none	_	_
3	early	_	_	JJ	O	-1	none	_	_
4	genes	_	_	NNS	O	-1	none	_	_
5	upregulate	_	_	VBP	O	-1	none	_	_
6	interleukin-6	_	_	NN	Protein	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	immediate	_	_	JJ	O	-1	none	_	_
5	early	_	_	JJ	O	-1	none	_	_
6	genes	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	IE	_	_	JJ	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	cytomegalovirus	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	CMV	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	can	_	_	MD	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	expressed	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	monocytic	_	_	JJ	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	are	_	_	VBP	O	-1	none	_	_
24	known	_	_	VBN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	regulate	_	_	VB	O	-1	none	_	_
27	viral	_	_	JJ	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	cellular	_	_	JJ	O	-1	none	_	_
30	genes	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Interleukin-6	_	_	NNP	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	IL-6	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	plays	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	central	_	_	JJ	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	numerous	_	_	JJ	O	-1	none	_	_
11	inflammatory	_	_	JJ	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	immune	_	_	JJ	O	-1	none	_	_
14	processes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Interleukin-6	_	_	NNP	Protein	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	increased	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	lung	_	_	NN	O	-1	none	_	_
7	transplant	_	_	NN	O	-1	none	_	_
8	patients	_	_	NNS	O	-1	none	_	_
9	clinically	_	_	RB	O	-1	none	_	_
10	diagnosed	_	_	VBD	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	CMV	_	_	NN	O	-1	none	_	_
13	pneumonitis	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IL-6	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	dependent	_	_	JJ	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	various	_	_	JJ	O	-1	none	_	_
9	stimuli	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	include	_	_	VBP	O	-1	none	_	_
12	lipopolysaccharide	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	LPS	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	viruses	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	other	_	_	JJ	O	-1	none	_	_
21	cytokines	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	examined	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	ability	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	CMV	_	_	NN	O	-1	none	_	_
8	IE	_	_	NN	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	products	_	_	NNS	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	modulate	_	_	VB	O	-1	none	_	_
13	IL-6	_	_	NN	Protein	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	THP-1	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	monocytic	_	_	JJ	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	line	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	transfected	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	CMV	_	_	NN	O	-1	none	_	_
16	IE	_	_	JJ	O	-1	none	_	_
17	genes	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Interleukin-6	_	_	NNP	Protein	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	IL-6	_	_	NN	Protein	-1	none	_	_
5	mRNA	_	_	NN	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	measured	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	control	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	CMV	_	_	NN	O	-1	none	_	_
12	immediate	_	_	JJ	O	-1	none	_	_
13	early	_	_	JJ	O	-1	none	_	_
14	transfected	_	_	VBN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Cotransfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	CMV	_	_	NN	O	-1	none	_	_
4	IE	_	_	JJ	O	-1	none	_	_
5	genes	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IL-6	_	_	NN	Protein	-1	none	_	_
8	chloramphenicol	_	_	NN	Protein	10	multitoken	_	_
9	acetyl	_	_	NN	Protein	10	multitoken	_	_
10	transferase	_	_	NN	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	CAT	_	_	NN	Protein	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	IL-6	_	_	NN	Protein	-1	none	_	_
16	luciferase	_	_	NN	O	-1	none	_	_
17	constructs	_	_	NNS	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	used	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	study	_	_	VB	O	-1	none	_	_
22	IL-6	_	_	NN	Protein	-1	none	_	_
23	promoter	_	_	NN	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Interleukin-6	_	_	NN	Protein	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	mRNA	_	_	NN	O	-1	none	_	_
7	production	_	_	NN	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	significantly	_	_	RB	O	-1	none	_	_
10	increased	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	transfected	_	_	VBN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	CMV	_	_	NN	O	-1	none	_	_
17	IE	_	_	JJ	O	-1	none	_	_
18	genes	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	stimulated	_	_	VBN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	LPS	_	_	NN	O	-1	none	_	_
23	compared	_	_	VBN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	LPS	_	_	NN	O	-1	none	_	_
26	stimulated	_	_	VBD	O	-1	none	_	_
27	control	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Cytomegalovirus	_	_	NN	O	-1	none	_	_
2	IE	_	_	NN	O	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	products	_	_	NNS	O	-1	none	_	_
5	significantly	_	_	RB	O	-1	none	_	_
6	enhanced	_	_	VBD	O	-1	none	_	_
7	LPS	_	_	NN	O	-1	none	_	_
8	stimulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	IL-6	_	_	NN	Protein	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	IL-6	_	_	NN	Protein	-1	none	_	_
16	CAT	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	IL-6	_	_	NN	Protein	-1	none	_	_
19	luciferase	_	_	NN	O	-1	none	_	_
20	assays	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	deletion	_	_	NN	O	-1	none	_	_
3	construct	_	_	NN	O	-1	none	_	_
4	that	_	_	WDT	O	-1	none	_	_
5	contains	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	site	_	_	NN	O	-1	none	_	_
10	but	_	_	CC	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	missing	_	_	VBG	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	multiple	_	_	JJ	O	-1	none	_	_
15	response	_	_	NN	O	-1	none	_	_
16	region	_	_	NN	O	-1	none	_	_
17	demonstrated	_	_	VBD	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	continued	_	_	JJ	O	-1	none	_	_
20	increase	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	IL-6	_	_	NN	Protein	-1	none	_	_
23	luciferase	_	_	NN	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	LPS	_	_	NN	O	-1	none	_	_
27	stimulated	_	_	VBD	O	-1	none	_	_
28	CMV	_	_	NN	O	-1	none	_	_
29	transfected	_	_	VBN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	CONCLUSION	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Cytomegalovirus	_	_	NN	O	-1	none	_	_
4	immediate	_	_	JJ	O	-1	none	_	_
5	early	_	_	JJ	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	products	_	_	NNS	O	-1	none	_	_
8	significantly	_	_	RB	O	-1	none	_	_
9	enhanced	_	_	VBD	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	IL-6	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	LPS	_	_	NN	O	-1	none	_	_
15	stimulated	_	_	VBN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	increase	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	IL-6	_	_	NN	Protein	-1	none	_	_
5	luciferase	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	occurs	_	_	VBZ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	absence	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	multiple	_	_	JJ	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	region	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	area	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	IL-6	_	_	NN	Protein	-1	none	_	_
22	promoter	_	_	NN	O	-1	none	_	_
23	responsive	_	_	JJ	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	IL-1	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	TNF	_	_	NN	Protein	28	multitoken	_	_
28	alpha	_	_	NN	Protein	0	root	_	_
29	,	_	_	,	O	-1	none	_	_
30	cyclic	_	_	JJ	O	-1	none	_	_
31	amp	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	phorbol	_	_	NN	O	-1	none	_	_
35	12-myristate	_	_	NN	O	-1	none	_	_
36	13-acetate	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	ability	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	CMV	_	_	NN	O	-1	none	_	_
5	IE	_	_	NN	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	products	_	_	NNS	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	enhance	_	_	VB	O	-1	none	_	_
10	IL-6	_	_	NN	Protein	-1	none	_	_
11	production	_	_	NN	O	-1	none	_	_
12	may	_	_	MD	O	-1	none	_	_
13	play	_	_	VB	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	important	_	_	JJ	O	-1	none	_	_
16	role	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	immune	_	_	JJ	O	-1	none	_	_
19	inflammatory	_	_	JJ	O	-1	none	_	_
20	states	_	_	NNS	O	-1	none	_	_
21	associated	_	_	VBN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	CMV	_	_	NN	O	-1	none	_	_
24	infection	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	overexpression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	IL-1	_	_	NN	O	-1	none	_	_
6	receptor	_	_	NN	O	-1	none	_	_
7	associated	_	_	JJ	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	NFkappaB	_	_	NN	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	stress	_	_	NN	O	-1	none	_	_
17	activated	_	_	VBN	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	kinases	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	murine	_	_	JJ	O	-1	none	_	_
23	T	_	_	NN	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	line	_	_	NN	O	-1	none	_	_
26	EL4	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	association	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	IL-1	_	_	NN	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	associated	_	_	VBN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	IRAK	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	IL-1	_	_	NN	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	complex	_	_	NN	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	one	_	_	CD	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	earliest	_	_	JJS	O	-1	none	_	_
25	events	_	_	NNS	O	-1	none	_	_
26	detectable	_	_	JJ	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	IL-1	_	_	NN	O	-1	none	_	_
29	signal	_	_	NN	O	-1	none	_	_
30	transduction	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	generated	_	_	VBD	O	-1	none	_	_
3	permanent	_	_	JJ	O	-1	none	_	_
4	clones	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	murine	_	_	JJ	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	line	_	_	NN	O	-1	none	_	_
11	EL4	_	_	NN	O	-1	none	_	_
12	6.1	_	_	CD	O	-1	none	_	_
13	overexpressing	_	_	VBG	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	h	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	IRAK	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	evaluate	_	_	VB	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	role	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	this	_	_	DT	O	-1	none	_	_
25	kinase	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	IL-1	_	_	NN	O	-1	none	_	_
28	signaling	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	hIRAK	_	_	NN	O	-1	none	_	_
4	enhanced	_	_	VBD	O	-1	none	_	_
5	IL-1-stimulated	_	_	JJ	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	NFkappaB	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	whereas	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	truncated	_	_	JJ	O	-1	none	_	_
16	form	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	N-IRAK	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	specifically	_	_	RB	O	-1	none	_	_
21	inhibited	_	_	VBD	O	-1	none	_	_
22	IL-1-dependent	_	_	JJ	O	-1	none	_	_
23	NFkappaB	_	_	NN	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	clones	_	_	NNS	O	-1	none	_	_
3	stably	_	_	RB	O	-1	none	_	_
4	overexpressing	_	_	VBG	O	-1	none	_	_
5	hIRAK	_	_	NN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	weak	_	_	JJ	O	-1	none	_	_
8	constitutive	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NFkappaB	_	_	NN	O	-1	none	_	_
12	correlated	_	_	VBD	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	low	_	_	JJ	O	-1	none	_	_
16	basal	_	_	JJ	O	-1	none	_	_
17	IL-2	_	_	NN	Protein	-1	none	_	_
18	production	_	_	NN	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	enhanced	_	_	VBN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	IL-1-dependent	_	_	JJ	O	-1	none	_	_
25	manner	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Compared	_	_	VBN	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	parental	_	_	JJ	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	line	_	_	NN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	dose	_	_	NN	O	-1	none	_	_
9	response	_	_	NN	O	-1	none	_	_
10	curve	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	IL-1-induced	_	_	JJ	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	shifted	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	both	_	_	CC	O	-1	none	_	_
19	potency	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	efficacy	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IRAK	_	_	NN	O	-1	none	_	_
6	directly	_	_	RB	O	-1	none	_	_
7	triggers	_	_	VBZ	O	-1	none	_	_
8	NFkappaB	_	_	NN	O	-1	none	_	_
9	mediated	_	_	JJ	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	EL4	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Qualitatively	_	_	RB	O	-1	none	_	_
2	different	_	_	JJ	O	-1	none	_	_
3	effects	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	IL-1-induced	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	stress	_	_	NN	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	SAP	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	kinases	_	_	NNS	O	-1	none	_	_
18	:	_	_	:	O	-1	none	_	_
19	permanent	_	_	JJ	O	-1	none	_	_
20	overexpression	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	IRAK	_	_	NN	O	-1	none	_	_
23	did	_	_	VBD	O	-1	none	_	_
24	not	_	_	RB	O	-1	none	_	_
25	affect	_	_	VB	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	dose	_	_	NN	O	-1	none	_	_
28	dependence	_	_	NN	O	-1	none	_	_
29	but	_	_	CC	O	-1	none	_	_
30	prolonged	_	_	VBD	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	kinetics	_	_	NNS	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	IL-1-induced	_	_	JJ	O	-1	none	_	_
35	activation	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	SAP	_	_	NN	O	-1	none	_	_
38	kinases	_	_	NNS	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	suggesting	_	_	VBG	O	-1	none	_	_
41	that	_	_	IN	O	-1	none	_	_
42	this	_	_	DT	O	-1	none	_	_
43	signaling	_	_	VBG	O	-1	none	_	_
44	branch	_	_	NN	O	-1	none	_	_
45	may	_	_	MD	O	-1	none	_	_
46	be	_	_	VB	O	-1	none	_	_
47	regulated	_	_	VBN	O	-1	none	_	_
48	by	_	_	IN	O	-1	none	_	_
49	distinct	_	_	JJ	O	-1	none	_	_
50	mechanisms	_	_	NNS	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	Stimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	CD40	_	_	NN	Protein	-1	none	_	_
4	on	_	_	IN	O	-1	none	_	_
5	immunogenic	_	_	JJ	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	malignant	_	_	JJ	O	-1	none	_	_
8	melanomas	_	_	NNS	O	-1	none	_	_
9	augments	_	_	VBZ	O	-1	none	_	_
10	their	_	_	PRP$	O	-1	none	_	_
11	cytotoxic	_	_	JJ	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	lymphocyte	_	_	NN	O	-1	none	_	_
14	mediated	_	_	JJ	O	-1	none	_	_
15	lysis	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	induces	_	_	VBZ	O	-1	none	_	_
18	apoptosis	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	report	_	_	VBP	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	functional	_	_	JJ	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	CD40	_	_	NN	Protein	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	malignant	_	_	JJ	O	-1	none	_	_
13	melanomas	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	MMs	_	_	NNS	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Comparison	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	tumor	_	_	NN	O	-1	none	_	_
4	specimen	_	_	NN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	MM	_	_	NN	O	-1	none	_	_
7	precursor	_	_	NN	O	-1	none	_	_
8	lesions	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	primary	_	_	JJ	O	-1	none	_	_
11	tumors	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	metastases	_	_	NNS	O	-1	none	_	_
15	revealed	_	_	VBD	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	CD40	_	_	NN	Protein	-1	none	_	_
18	surface	_	_	NN	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	down-regulated	_	_	VBN	O	-1	none	_	_
22	during	_	_	IN	O	-1	none	_	_
23	tumor	_	_	NN	O	-1	none	_	_
24	progression	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	CD40	_	_	NN	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	confirmed	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	7	_	_	CD	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	MM	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	lines	_	_	NNS	O	-1	none	_	_
11	established	_	_	VBN	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	immunogenic	_	_	JJ	O	-1	none	_	_
14	primary	_	_	JJ	O	-1	none	_	_
15	tumors	_	_	NNS	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	metastases	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	whereas	_	_	IN	O	-1	none	_	_
20	11	_	_	CD	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	lines	_	_	NNS	O	-1	none	_	_
23	established	_	_	VBN	O	-1	none	_	_
24	from	_	_	IN	O	-1	none	_	_
25	advanced	_	_	JJ	O	-1	none	_	_
26	stages	_	_	NNS	O	-1	none	_	_
27	were	_	_	VBD	O	-1	none	_	_
28	CD40	_	_	NN	Protein	-1	none	_	_
29	negative	_	_	JJ	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	CD40	_	_	NN	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	could	_	_	MD	O	-1	none	_	_
4	be	_	_	VB	O	-1	none	_	_
5	enhanced	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	CD40	_	_	NN	Protein	-1	none	_	_
8	positive	_	_	JJ	O	-1	none	_	_
9	MM	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	stimulation	_	_	NN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	IFN-gamma	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	tumor	_	_	NN	Protein	17	multitoken	_	_
16	necrosis	_	_	NN	Protein	17	multitoken	_	_
17	factor-alpha	_	_	NN	Protein	0	root	_	_
18	but	_	_	CC	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	interleukin	_	_	NN	Protein	24	multitoken	_	_
22	(	_	_	-LRB-	Protein	24	multitoken	_	_
23	IL	_	_	NN	Protein	24	multitoken	_	_
24	)-1beta	_	_	NN	Protein	0	root	_	_
25	or	_	_	CC	O	-1	none	_	_
26	CD40	_	_	NN	Protein	-1	none	_	_
27	triggering	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	CD40	_	_	NN	Protein	-1	none	_	_
2	ligation	_	_	NN	O	-1	none	_	_
3	on	_	_	IN	O	-1	none	_	_
4	MM	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	CD40L	_	_	NN	Protein	-1	none	_	_
7	transfected	_	_	VBN	O	-1	none	_	_
8	murine	_	_	JJ	O	-1	none	_	_
9	L-cells	_	_	NNS	O	-1	none	_	_
10	or	_	_	CC	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	soluble	_	_	JJ	O	-1	none	_	_
14	CD40L	_	_	NN	Protein	-1	none	_	_
15	fusion	_	_	NN	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	up-regulated	_	_	VBD	O	-1	none	_	_
18	their	_	_	PRP$	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	intercellular	_	_	JJ	Protein	23	multitoken	_	_
22	adhesion	_	_	NN	Protein	23	multitoken	_	_
23	molecule-1	_	_	NN	Protein	0	root	_	_
24	and	_	_	CC	O	-1	none	_	_
25	MHC	_	_	NN	O	-1	none	_	_
26	class	_	_	NN	O	-1	none	_	_
27	I	_	_	CD	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	class	_	_	NN	O	-1	none	_	_
30	II	_	_	CD	O	-1	none	_	_
31	molecules	_	_	NNS	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	their	_	_	PRP$	O	-1	none	_	_
34	secretion	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	IL-6	_	_	NN	Protein	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	IL-8	_	_	NN	Protein	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	tumor	_	_	NN	Protein	42	multitoken	_	_
41	necrosis	_	_	NN	Protein	42	multitoken	_	_
42	factor-a	_	_	NN	Protein	0	root	_	_
43	,	_	_	,	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	granulocyte	_	_	NN	Protein	49	multitoken	_	_
46	macrophage	_	_	NN	Protein	49	multitoken	_	_
47	colony	_	_	NN	Protein	49	multitoken	_	_
48	stimulating	_	_	NN	Protein	49	multitoken	_	_
49	factor	_	_	NN	Protein	0	root	_	_
50	and	_	_	CC	O	-1	none	_	_
51	also	_	_	RB	O	-1	none	_	_
52	induced	_	_	VBD	O	-1	none	_	_
53	a	_	_	DT	O	-1	none	_	_
54	rapid	_	_	JJ	O	-1	none	_	_
55	activation	_	_	NN	O	-1	none	_	_
56	of	_	_	IN	O	-1	none	_	_
57	the	_	_	DT	O	-1	none	_	_
58	transcription	_	_	NN	O	-1	none	_	_
59	factor	_	_	NN	O	-1	none	_	_
60	nuclear	_	_	JJ	O	-1	none	_	_
61	factor	_	_	NN	O	-1	none	_	_
62	kappaB	_	_	NN	O	-1	none	_	_
63	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	CD40	_	_	NN	Protein	-1	none	_	_
4	ligation	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	growth	_	_	NN	O	-1	none	_	_
7	inhibition	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	apoptosis	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	MM	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Monocytic	_	_	JJ	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	type	_	_	NN	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	induction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	collagenase	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Interstitial	_	_	JJ	O	-1	none	_	_
2	collagenase	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	MMP-1	_	_	NN	Protein	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	metalloproteinase	_	_	NN	O	-1	none	_	_
9	produced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	resident	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	inflammatory	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	during	_	_	IN	O	-1	none	_	_
16	connective	_	_	JJ	O	-1	none	_	_
17	tissue	_	_	NN	O	-1	none	_	_
18	turnover	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	cleaves	_	_	VBZ	O	-1	none	_	_
21	type	_	_	NN	O	-1	none	_	_
22	I	_	_	CD	O	-1	none	_	_
23	collagen	_	_	NN	O	-1	none	_	_
24	fibrils	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	catalytic	_	_	JJ	O	-1	none	_	_
3	event	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	rate	_	_	NN	O	-1	none	_	_
6	limiting	_	_	VBG	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	remodeling	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	tissues	_	_	NNS	O	-1	none	_	_
11	rich	_	_	JJ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	fibrillar	_	_	NN	O	-1	none	_	_
14	collagen	_	_	NN	O	-1	none	_	_
15	such	_	_	JJ	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	skin	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	lungs	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	collagenase	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	cell-type	_	_	JJ	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	;	_	_	:	O	-1	none	_	_
10	bacterial	_	_	JJ	O	-1	none	_	_
11	LPS	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	zymosan	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	yeast	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	wall	_	_	NN	O	-1	none	_	_
19	derivative	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	potent	_	_	JJ	O	-1	none	_	_
23	inducers	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	collagenase	_	_	NN	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	macrophages	_	_	NNS	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	but	_	_	CC	O	-1	none	_	_
31	do	_	_	VBP	O	-1	none	_	_
32	not	_	_	RB	O	-1	none	_	_
33	alter	_	_	VB	O	-1	none	_	_
34	fibroblast	_	_	NN	O	-1	none	_	_
35	collagenase	_	_	NN	O	-1	none	_	_
36	expression	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	promoter	_	_	NN	O	-1	none	_	_
3	elements	_	_	NNS	O	-1	none	_	_
4	controlling	_	_	VBG	O	-1	none	_	_
5	collagenase	_	_	NN	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	monocytic	_	_	JJ	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	have	_	_	VBP	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	been	_	_	VBN	O	-1	none	_	_
13	previously	_	_	RB	O	-1	none	_	_
14	defined	_	_	VBN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	we	_	_	PRP	O	-1	none	_	_
17	sought	_	_	VBD	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	delineate	_	_	VB	O	-1	none	_	_
20	responsive	_	_	JJ	O	-1	none	_	_
21	cis	_	_	NN	O	-1	none	_	_
22	acting	_	_	VBG	O	-1	none	_	_
23	elements	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	collagenase	_	_	NN	O	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	transiently	_	_	RB	O	-1	none	_	_
30	transfected	_	_	VBN	O	-1	none	_	_
31	human	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	U937	_	_	NN	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	murine	_	_	JJ	O	-1	none	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	J774	_	_	NN	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	monocytic	_	_	JJ	O	-1	none	_	_
41	cell	_	_	NN	O	-1	none	_	_
42	lines	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Deletion	_	_	NN	O	-1	none	_	_
2	constructs	_	_	NNS	O	-1	none	_	_
3	containing	_	_	VBG	O	-1	none	_	_
4	as	_	_	RB	O	-1	none	_	_
5	little	_	_	JJ	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	72	_	_	CD	O	-1	none	_	_
8	bp	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	5	_	_	CD	O	-1	none	_	_
11	'	_	_	''	O	-1	none	_	_
12	-flanking	_	_	JJ	O	-1	none	_	_
13	sequence	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	collagenase	_	_	NN	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	sufficient	_	_	JJ	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	LPS-	_	_	NN	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	zymosan	_	_	NN	O	-1	none	_	_
24	mediated	_	_	VBD	O	-1	none	_	_
25	transcriptional	_	_	JJ	O	-1	none	_	_
26	induction	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	whereas	_	_	IN	O	-1	none	_	_
29	phorbol	_	_	NN	O	-1	none	_	_
30	inducibility	_	_	NN	O	-1	none	_	_
31	exhibited	_	_	VBD	O	-1	none	_	_
32	an	_	_	DT	O	-1	none	_	_
33	absolute	_	_	JJ	O	-1	none	_	_
34	requirement	_	_	NN	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	upstream	_	_	JJ	O	-1	none	_	_
37	elements	_	_	NNS	O	-1	none	_	_
38	including	_	_	VBG	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	polyoma	_	_	NN	O	-1	none	_	_
41	enhancer	_	_	NN	O	-1	none	_	_
42	A	_	_	NN	O	-1	none	_	_
43	binding	_	_	NN	O	-1	none	_	_
44	protein-3	_	_	NN	O	-1	none	_	_
45	site	_	_	NN	O	-1	none	_	_
46	(	_	_	-LRB-	O	-1	none	_	_
47	-83	_	_	CD	O	-1	none	_	_
48	to	_	_	TO	O	-1	none	_	_
49	-91	_	_	CD	O	-1	none	_	_
50	)	_	_	-RRB-	O	-1	none	_	_
51	and	_	_	CC	O	-1	none	_	_
52	TTCA	_	_	NN	O	-1	none	_	_
53	sequence	_	_	NN	O	-1	none	_	_
54	(	_	_	-LRB-	O	-1	none	_	_
55	-102	_	_	CD	O	-1	none	_	_
56	to	_	_	TO	O	-1	none	_	_
57	-105	_	_	CD	O	-1	none	_	_
58	)	_	_	-RRB-	O	-1	none	_	_
59	in	_	_	IN	O	-1	none	_	_
60	both	_	_	CC	O	-1	none	_	_
61	monocytic	_	_	JJ	O	-1	none	_	_
62	cells	_	_	NNS	O	-1	none	_	_
63	and	_	_	CC	O	-1	none	_	_
64	fibroblasts	_	_	NNS	O	-1	none	_	_
65	.	_	_	.	O	-1	none	_	_

1	Mutagenesis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	activator	_	_	NN	O	-1	none	_	_
5	protein-1	_	_	NN	O	-1	none	_	_
6	[	_	_	CD	O	-1	none	_	_
7	AP-1	_	_	NN	O	-1	none	_	_
8	]	_	_	NN	O	-1	none	_	_
9	site	_	_	NN	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	-72	_	_	CD	O	-1	none	_	_
12	abolished	_	_	VBD	O	-1	none	_	_
13	basal	_	_	JJ	O	-1	none	_	_
14	promoter	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	LPS	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	zymosan	_	_	NN	O	-1	none	_	_
20	inducibility	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	while	_	_	IN	O	-1	none	_	_
23	mutagenesis	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	an	_	_	DT	O	-1	none	_	_
26	NF-kappaB-like	_	_	JJ	O	-1	none	_	_
27	site	_	_	NN	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	-20	_	_	CD	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	-10	_	_	CD	O	-1	none	_	_
32	had	_	_	VBD	O	-1	none	_	_
33	no	_	_	DT	O	-1	none	_	_
34	effect	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	extracts	_	_	NNS	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	LPS-	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	zymosan	_	_	NN	O	-1	none	_	_
7	treated	_	_	JJ	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	strong	_	_	JJ	O	-1	none	_	_
11	AP-1	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	gel-shift	_	_	JJ	O	-1	none	_	_
15	analysis	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	supershift	_	_	NN	O	-1	none	_	_
19	analysis	_	_	NN	O	-1	none	_	_
20	showed	_	_	VBD	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	AP-1	_	_	NN	O	-1	none	_	_
23	complexes	_	_	NNS	O	-1	none	_	_
24	contained	_	_	VBD	O	-1	none	_	_
25	specific	_	_	JJ	O	-1	none	_	_
26	members	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	both	_	_	CC	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	jun	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	fos	_	_	NN	O	-1	none	_	_
33	gene	_	_	NN	O	-1	none	_	_
34	families	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	contrast	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	most	_	_	JJS	O	-1	none	_	_
10	LPS	_	_	NN	O	-1	none	_	_
11	effects	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	AP-1	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	but	_	_	CC	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	factor-kappaB	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	mediates	_	_	VBZ	O	-1	none	_	_
21	LPS	_	_	NN	O	-1	none	_	_
22	induction	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	collagenase	_	_	NN	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	macrophagelike	_	_	JJ	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	as	_	_	IN	O	-1	none	_	_
4	compared	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	regulation	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	phorbol	_	_	NN	O	-1	none	_	_
9	ester	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	collagenase	_	_	NN	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	monocytic	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	wall	_	_	NN	O	-1	none	_	_
19	derivatives	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	bacteria	_	_	NNS	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	yeast	_	_	NN	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	largely	_	_	RB	O	-1	none	_	_
26	independent	_	_	JJ	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	upstream	_	_	JJ	O	-1	none	_	_
29	promoter	_	_	NN	O	-1	none	_	_
30	sequences	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Suppression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	MHC	_	_	NN	O	-1	none	_	_
4	class	_	_	NN	O	-1	none	_	_
5	II	_	_	CD	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	class	_	_	NN	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	trans-activator	_	_	NN	O	-1	none	_	_
12	constructs	_	_	NNS	O	-1	none	_	_
13	lacking	_	_	VBG	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	N-terminal	_	_	JJ	O	-1	none	_	_
16	domain	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	class	_	_	NN	Protein	4	multitoken	_	_
3	II	_	_	CD	Protein	4	multitoken	_	_
4	trans-activator	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	CIITA	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	bi-	_	_	JJ	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	multi-functional	_	_	JJ	O	-1	none	_	_
13	domain	_	_	NN	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	plays	_	_	VBZ	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	critical	_	_	JJ	O	-1	none	_	_
19	role	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	MHC	_	_	NN	O	-1	none	_	_
25	class	_	_	NN	O	-1	none	_	_
26	II	_	_	CD	O	-1	none	_	_
27	genes	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	removal	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	N-terminal	_	_	JJ	O	-1	none	_	_
8	151	_	_	CD	O	-1	none	_	_
9	amino	_	_	NN	O	-1	none	_	_
10	acids	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	encompassing	_	_	VBG	O	-1	none	_	_
13	all	_	_	DT	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	acidic	_	_	JJ	O	-1	none	_	_
17	domain	_	_	NN	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	leaving	_	_	VBG	O	-1	none	_	_
20	intact	_	_	JJ	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	proline/serine/threonine	_	_	NN	O	-1	none	_	_
23	rich	_	_	JJ	O	-1	none	_	_
24	domain	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	results	_	_	VBZ	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	mutant	_	_	NN	O	-1	none	_	_
30	protein	_	_	NN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	potent	_	_	JJ	O	-1	none	_	_
33	suppressive	_	_	JJ	O	-1	none	_	_
34	properties	_	_	NNS	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	MHC	_	_	NN	O	-1	none	_	_
37	class	_	_	NN	O	-1	none	_	_
38	II	_	_	CD	O	-1	none	_	_
39	expression	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	HeLa	_	_	NN	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	stably	_	_	RB	O	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	transiently	_	_	RB	O	-1	none	_	_
6	transfected	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	mutant	_	_	NN	O	-1	none	_	_
9	CIITA	_	_	NN	Protein	-1	none	_	_
10	constructs	_	_	NNS	O	-1	none	_	_
11	showed	_	_	VBD	O	-1	none	_	_
12	up	_	_	IN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	99	_	_	CD	O	-1	none	_	_
15	%	_	_	NN	O	-1	none	_	_
16	suppression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	MHC	_	_	NN	O	-1	none	_	_
19	class	_	_	NN	O	-1	none	_	_
20	II	_	_	CD	O	-1	none	_	_
21	antigen	_	_	NN	O	-1	none	_	_
22	induction	_	_	NN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	IFN-gamma	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	marked	_	_	JJ	O	-1	none	_	_
27	suppression	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	HLA-DRA	_	_	NN	O	-1	none	_	_
30	mRNA	_	_	NN	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	transfection	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	lymphoma	_	_	NN	O	-1	none	_	_
7	line	_	_	NN	O	-1	none	_	_
8	resulted	_	_	VBD	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	up	_	_	RB	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	89	_	_	CD	O	-1	none	_	_
13	%	_	_	NN	O	-1	none	_	_
14	reduction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	constitutive	_	_	JJ	O	-1	none	_	_
17	MHC	_	_	NN	O	-1	none	_	_
18	class	_	_	NN	O	-1	none	_	_
19	II	_	_	CD	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	within	_	_	IN	O	-1	none	_	_
22	5	_	_	CD	O	-1	none	_	_
23	days	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	suppression	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	HLA-DRA	_	_	NN	O	-1	none	_	_
28	mRNA	_	_	NN	O	-1	none	_	_
29	synthesis	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	interferon	_	_	NN	Protein	5	multitoken	_	_
3	regulatory	_	_	JJ	Protein	5	multitoken	_	_
4	factor	_	_	NN	Protein	5	multitoken	_	_
5	2	_	_	CD	Protein	0	root	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	.	_	_	.	O	-1	none	_	_

1	Intron-exon	_	_	JJ	O	-1	none	_	_
2	organization	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	functional	_	_	JJ	O	-1	none	_	_
5	analysis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	5	_	_	CD	O	-1	none	_	_
8	'-flanking	_	_	JJ	O	-1	none	_	_
9	region	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Interferon	_	_	NN	Protein	4	multitoken	_	_
2	regulatory	_	_	JJ	Protein	4	multitoken	_	_
3	factor	_	_	NN	Protein	4	multitoken	_	_
4	2	_	_	CD	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	IRF-2	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	transcriptional	_	_	JJ	O	-1	none	_	_
11	regulatory	_	_	JJ	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	terminates	_	_	VBZ	O	-1	none	_	_
15	interferon	_	_	NN	Protein	16	multitoken	_	_
16	beta	_	_	NN	Protein	0	root	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	initiated	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	interferon	_	_	NN	Protein	23	multitoken	_	_
21	regulatory	_	_	JJ	Protein	23	multitoken	_	_
22	factor	_	_	NN	Protein	23	multitoken	_	_
23	1	_	_	CD	Protein	0	root	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	isolated	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	genomic	_	_	JJ	O	-1	none	_	_
9	DNA	_	_	NN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	IRF-2	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	determined	_	_	VBD	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	intron-exon	_	_	JJ	O	-1	none	_	_
18	structure	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	IRF-2	_	_	NN	Protein	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	mapped	_	_	VBD	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	major	_	_	JJ	O	-1	none	_	_
28	transcription	_	_	NN	O	-1	none	_	_
29	initiation	_	_	NN	O	-1	none	_	_
30	site	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	identified	_	_	VBD	O	-1	none	_	_
33	a	_	_	DT	O	-1	none	_	_
34	number	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	potential	_	_	JJ	O	-1	none	_	_
37	regulatory	_	_	JJ	O	-1	none	_	_
38	elements	_	_	NNS	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	5	_	_	CD	O	-1	none	_	_
42	'-flanking	_	_	JJ	O	-1	none	_	_
43	region	_	_	NN	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	localized	_	_	VBD	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	IRF-2	_	_	NN	Protein	-1	none	_	_
49	gene	_	_	NN	O	-1	none	_	_
50	on	_	_	IN	O	-1	none	_	_
51	human	_	_	NN	O	-1	none	_	_
52	chromosome	_	_	NN	O	-1	none	_	_
53	4	_	_	CD	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IRF-2	_	_	NN	Protein	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	region	_	_	NN	O	-1	none	_	_
5	contains	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	CpG	_	_	NN	O	-1	none	_	_
8	island	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	several	_	_	JJ	O	-1	none	_	_
12	GC	_	_	NN	O	-1	none	_	_
13	boxes	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	putative	_	_	JJ	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	CAAT	_	_	NN	O	-1	none	_	_
25	box	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	but	_	_	CC	O	-1	none	_	_
28	no	_	_	DT	O	-1	none	_	_
29	TATA	_	_	NN	O	-1	none	_	_
30	box	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	region	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	linked	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	heterologous	_	_	JJ	O	-1	none	_	_
10	reporter	_	_	NN	O	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	we	_	_	PRP	O	-1	none	_	_
14	found	_	_	VBD	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	region	_	_	NN	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	inducible	_	_	JJ	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	both	_	_	CC	O	-1	none	_	_
23	interferons	_	_	NNS	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	interferon-alpha	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	-gamma	_	_	NN	Protein	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	interferon	_	_	NN	Protein	33	multitoken	_	_
31	regulatory	_	_	JJ	Protein	33	multitoken	_	_
32	factor	_	_	NN	Protein	33	multitoken	_	_
33	1	_	_	CD	Protein	0	root	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	region	_	_	NN	O	-1	none	_	_
3	which	_	_	WDT	O	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	these	_	_	DT	O	-1	none	_	_
6	inductions	_	_	NNS	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	identified	_	_	VBN	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	being	_	_	VBG	O	-1	none	_	_
11	confined	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	40	_	_	CD	O	-1	none	_	_
14	nucleotides	_	_	NNS	O	-1	none	_	_
15	5	_	_	CD	O	-1	none	_	_
16	'	_	_	''	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	major	_	_	JJ	O	-1	none	_	_
20	transcriptional	_	_	JJ	O	-1	none	_	_
21	initiation	_	_	NN	O	-1	none	_	_
22	site	_	_	NN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	testing	_	_	VBG	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	series	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	clones	_	_	NNS	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	truncated	_	_	VBN	O	-1	none	_	_
31	promoter	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	IRF-2	_	_	NN	Protein	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	region	_	_	NN	O	-1	none	_	_
3	contains	_	_	VBZ	O	-1	none	_	_
4	elements	_	_	NNS	O	-1	none	_	_
5	which	_	_	WDT	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	shared	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	transcriptional	_	_	JJ	O	-1	none	_	_
11	enhancers	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	other	_	_	JJ	O	-1	none	_	_
14	genes	_	_	NNS	O	-1	none	_	_
15	including	_	_	VBG	O	-1	none	_	_
16	interferon	_	_	NN	Protein	19	multitoken	_	_
17	regulatory	_	_	JJ	Protein	19	multitoken	_	_
18	factor	_	_	NN	Protein	19	multitoken	_	_
19	1	_	_	CD	Protein	0	root	_	_
20	,	_	_	,	O	-1	none	_	_
21	interferon	_	_	NN	Protein	22	multitoken	_	_
22	beta	_	_	NN	Protein	0	root	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	interferon	_	_	NN	O	-1	none	_	_
26	inducible	_	_	JJ	O	-1	none	_	_
27	genes	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	interferon	_	_	NN	Protein	8	multitoken	_	_
6	regulatory	_	_	JJ	Protein	8	multitoken	_	_
7	factor	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	not	_	_	RB	O	-1	none	_	_
10	only	_	_	RB	O	-1	none	_	_
11	triggers	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	interferon	_	_	NN	O	-1	none	_	_
17	signal	_	_	NN	O	-1	none	_	_
18	transduction	_	_	NN	O	-1	none	_	_
19	pathway	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	also	_	_	RB	O	-1	none	_	_
23	may	_	_	MD	O	-1	none	_	_
24	play	_	_	VB	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	role	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	limiting	_	_	VBG	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	duration	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	this	_	_	DT	O	-1	none	_	_
33	response	_	_	NN	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	activating	_	_	VBG	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	IRF-2	_	_	NN	Protein	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Tissue	_	_	NN	O	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	regulation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	rabbit	_	_	NN	O	-1	none	_	_
7	15-lipoxygenase	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	erythroid	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	transcriptional	_	_	JJ	O	-1	none	_	_
15	silencer	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	15-lipoxygenase	_	_	NN	Protein	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	lox	_	_	NN	Protein	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	tissue	_	_	NN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	manner	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	predominantly	_	_	RB	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	erythroid	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	but	_	_	CC	O	-1	none	_	_
20	also	_	_	RB	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	airway	_	_	NN	O	-1	none	_	_
23	epithelial	_	_	JJ	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	eosinophils	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	report	_	_	NN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	5	_	_	CD	O	-1	none	_	_
9	'	_	_	''	O	-1	none	_	_
10	flanking	_	_	JJ	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	15-lox	_	_	JJ	Protein	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	contains	_	_	VBZ	O	-1	none	_	_
17	sequences	_	_	NNS	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	down-regulate	_	_	VBP	O	-1	none	_	_
20	its	_	_	PRP$	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	variety	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	non	_	_	JJ	O	-1	none	_	_
27	erythroid	_	_	JJ	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	lines	_	_	NNS	O	-1	none	_	_
30	but	_	_	CC	O	-1	none	_	_
31	not	_	_	RB	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	two	_	_	CD	O	-1	none	_	_
34	erythroid	_	_	JJ	O	-1	none	_	_
35	cell	_	_	NN	O	-1	none	_	_
36	lines	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	element	_	_	NN	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	characteristics	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	transcriptional	_	_	JJ	O	-1	none	_	_
8	'	_	_	''	O	-1	none	_	_
9	silencer	_	_	NN	O	-1	none	_	_
10	'	_	_	''	O	-1	none	_	_
11	since	_	_	IN	O	-1	none	_	_
12	it	_	_	PRP	O	-1	none	_	_
13	functions	_	_	VBZ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	both	_	_	CC	O	-1	none	_	_
16	orientations	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	main	_	_	JJ	O	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	silencer	_	_	NN	O	-1	none	_	_
7	has	_	_	VBZ	O	-1	none	_	_
8	been	_	_	VBN	O	-1	none	_	_
9	mapped	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	first	_	_	JJ	O	-1	none	_	_
13	900	_	_	CD	O	-1	none	_	_
14	bp	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	5	_	_	CD	O	-1	none	_	_
17	'	_	_	''	O	-1	none	_	_
18	flanking	_	_	JJ	O	-1	none	_	_
19	DNA	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	contains	_	_	VBZ	O	-1	none	_	_
23	nine	_	_	CD	O	-1	none	_	_
24	binding	_	_	NN	O	-1	none	_	_
25	sites	_	_	NNS	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	nuclear	_	_	JJ	O	-1	none	_	_
29	factor	_	_	NN	O	-1	none	_	_
30	present	_	_	JJ	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	non	_	_	JJ	O	-1	none	_	_
33	erythroid	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	but	_	_	CC	O	-1	none	_	_
36	not	_	_	RB	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	erythroid	_	_	JJ	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	binding	_	_	VBG	O	-1	none	_	_
3	sites	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	similar	_	_	JJ	O	-1	none	_	_
6	sequences	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	multiple	_	_	JJ	O	-1	none	_	_
9	copies	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	confer	_	_	VBP	O	-1	none	_	_
15	tissue	_	_	NN	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	down-regulation	_	_	NN	O	-1	none	_	_
18	when	_	_	WRB	O	-1	none	_	_
19	attached	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	minimal	_	_	JJ	O	-1	none	_	_
23	lox	_	_	NN	Protein	-1	none	_	_
24	promoter	_	_	NN	O	-1	none	_	_
25	fragment	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	5	_	_	CD	O	-1	none	_	_
3	'	_	_	''	O	-1	none	_	_
4	flanking	_	_	JJ	O	-1	none	_	_
5	DNA	_	_	NN	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	contains	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cluster	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	three	_	_	CD	O	-1	none	_	_
12	binding	_	_	VBG	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	GATA	_	_	NN	O	-1	none	_	_
17	family	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factors	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	interaction	_	_	NN	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	two	_	_	CD	O	-1	none	_	_
6	zinc	_	_	NN	O	-1	none	_	_
7	finger	_	_	NN	O	-1	none	_	_
8	domains	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	v-erb	_	_	NN	Protein	12	multitoken	_	_
12	A	_	_	NN	Protein	0	root	_	_
13	oncoprotein	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	v-erb	_	_	NN	Protein	3	multitoken	_	_
3	A	_	_	NN	Protein	0	root	_	_
4	oncogene	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	avian	_	_	JJ	O	-1	none	_	_
7	erythroblastosis	_	_	NN	O	-1	none	_	_
8	virus	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	mutated	_	_	VBN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	virally	_	_	RB	O	-1	none	_	_
14	transduced	_	_	VBN	O	-1	none	_	_
15	copy	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	host	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	encoding	_	_	VBG	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	thyroid	_	_	NN	O	-1	none	_	_
24	hormone	_	_	NN	O	-1	none	_	_
25	receptor	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	expressed	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	v-erb	_	_	NN	Protein	7	multitoken	_	_
7	A	_	_	NN	Protein	0	root	_	_
8	oncogene	_	_	NN	O	-1	none	_	_
9	binds	_	_	VBZ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	acts	_	_	VBZ	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	dominant	_	_	JJ	O	-1	none	_	_
17	negative	_	_	JJ	O	-1	none	_	_
18	inhibitor	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	both	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	thyroid	_	_	NN	O	-1	none	_	_
23	hormone	_	_	NN	O	-1	none	_	_
24	receptor	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	closely	_	_	RB	O	-1	none	_	_
28	related	_	_	JJ	O	-1	none	_	_
29	retinoic	_	_	JJ	Protein	31	multitoken	_	_
30	acid	_	_	NN	Protein	31	multitoken	_	_
31	receptor	_	_	NN	Protein	0	root	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	v-erb	_	_	NN	Protein	3	multitoken	_	_
3	A	_	_	NN	Protein	0	root	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	sustained	_	_	VBN	O	-1	none	_	_
7	two	_	_	CD	O	-1	none	_	_
8	amino	_	_	NN	O	-1	none	_	_
9	acid	_	_	NN	O	-1	none	_	_
10	alterations	_	_	NNS	O	-1	none	_	_
11	within	_	_	IN	O	-1	none	_	_
12	its	_	_	PRP$	O	-1	none	_	_
13	DNA	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	domain	_	_	NN	O	-1	none	_	_
16	relative	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	that	_	_	DT	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	c-erb	_	_	NN	Protein	21	multitoken	_	_
21	A	_	_	NN	Protein	0	root	_	_
22	,	_	_	,	O	-1	none	_	_
23	one	_	_	CD	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	at	_	_	IN	O	-1	none	_	_
28	serine	_	_	NN	O	-1	none	_	_
29	61	_	_	CD	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	known	_	_	VBN	O	-1	none	_	_
33	to	_	_	TO	O	-1	none	_	_
34	be	_	_	VB	O	-1	none	_	_
35	important	_	_	JJ	O	-1	none	_	_
36	for	_	_	IN	O	-1	none	_	_
37	v-erb	_	_	NN	Protein	38	multitoken	_	_
38	A	_	_	NN	Protein	0	root	_	_
39	function	_	_	NN	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	neoplastic	_	_	JJ	O	-1	none	_	_
43	cell	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	second	_	_	JJ	O	-1	none	_	_
7	alteration	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	at	_	_	IN	O	-1	none	_	_
10	threonine	_	_	NN	O	-1	none	_	_
11	78	_	_	CD	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	also	_	_	RB	O	-1	none	_	_
14	plays	_	_	VBZ	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	important	_	_	JJ	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	although	_	_	IN	O	-1	none	_	_
19	more	_	_	JJR	O	-1	none	_	_
20	indirect	_	_	JJ	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	role	_	_	NN	O	-1	none	_	_
23	:	_	_	:	O	-1	none	_	_
24	alteration	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	sequence	_	_	NN	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	threonine	_	_	NN	O	-1	none	_	_
30	78	_	_	CD	O	-1	none	_	_
31	such	_	_	JJ	O	-1	none	_	_
32	that	_	_	IN	O	-1	none	_	_
33	it	_	_	PRP	O	-1	none	_	_
34	resembles	_	_	VBZ	O	-1	none	_	_
35	that	_	_	DT	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	c-erb	_	_	NN	Protein	38	multitoken	_	_
38	A	_	_	NN	Protein	0	root	_	_
39	can	_	_	MD	O	-1	none	_	_
40	act	_	_	VB	O	-1	none	_	_
41	as	_	_	IN	O	-1	none	_	_
42	an	_	_	DT	O	-1	none	_	_
43	intragenic	_	_	JJ	O	-1	none	_	_
44	suppressor	_	_	NN	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	can	_	_	MD	O	-1	none	_	_
47	partially	_	_	RB	O	-1	none	_	_
48	restore	_	_	VB	O	-1	none	_	_
49	function	_	_	NN	O	-1	none	_	_
50	to	_	_	TO	O	-1	none	_	_
51	a	_	_	DT	O	-1	none	_	_
52	v-erb	_	_	NN	Protein	53	multitoken	_	_
53	A	_	_	NN	Protein	0	root	_	_
54	protein	_	_	NN	O	-1	none	_	_
55	rendered	_	_	VBD	O	-1	none	_	_
56	defective	_	_	JJ	O	-1	none	_	_
57	due	_	_	JJ	O	-1	none	_	_
58	to	_	_	TO	O	-1	none	_	_
59	a	_	_	DT	O	-1	none	_	_
60	mutation	_	_	NN	O	-1	none	_	_
61	at	_	_	IN	O	-1	none	_	_
62	position	_	_	NN	O	-1	none	_	_
63	61	_	_	CD	O	-1	none	_	_
64	.	_	_	.	O	-1	none	_	_

1	Threonine	_	_	NN	O	-1	none	_	_
2	78	_	_	CD	O	-1	none	_	_
3	lies	_	_	VBZ	O	-1	none	_	_
4	within	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	D-box	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	v-erb	_	_	NN	Protein	10	multitoken	_	_
10	A	_	_	NN	Protein	0	root	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	region	_	_	NN	O	-1	none	_	_
15	thought	_	_	VBD	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	mediate	_	_	VB	O	-1	none	_	_
18	receptor-receptor	_	_	JJ	O	-1	none	_	_
19	dimerizations	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	physical	_	_	JJ	O	-1	none	_	_
26	proximity	_	_	NN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	serine	_	_	NN	O	-1	none	_	_
30	at	_	_	IN	O	-1	none	_	_
31	position	_	_	NN	O	-1	none	_	_
32	61	_	_	CD	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	therefore	_	_	RB	O	-1	none	_	_
3	appears	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	indirect	_	_	JJ	O	-1	none	_	_
7	interaction	_	_	NN	O	-1	none	_	_
8	occurs	_	_	VBZ	O	-1	none	_	_
9	between	_	_	IN	O	-1	none	_	_
10	these	_	_	DT	O	-1	none	_	_
11	two	_	_	CD	O	-1	none	_	_
12	sites	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	that	_	_	IN	O	-1	none	_	_
15	this	_	_	DT	O	-1	none	_	_
16	interaction	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	crucial	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	v-erb	_	_	NN	Protein	21	multitoken	_	_
21	A	_	_	NN	Protein	0	root	_	_
22	function	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	CIITA	_	_	NN	Protein	-1	none	_	_
2	activates	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	MHC	_	_	NN	O	-1	none	_	_
7	class	_	_	NN	O	-1	none	_	_
8	II	_	_	CD	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	mouse	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	has	_	_	VBZ	O	-1	none	_	_
3	long	_	_	RB	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	puzzle	_	_	NN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	MHC	_	_	NN	O	-1	none	_	_
9	class	_	_	NN	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	molecules	_	_	NNS	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	expressed	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	mouse	_	_	NN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	;	_	_	:	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	believed	_	_	VBN	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	play	_	_	VB	O	-1	none	_	_
33	a	_	_	DT	O	-1	none	_	_
34	role	_	_	NN	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	cell	_	_	NN	O	-1	none	_	_
38	mediated	_	_	JJ	O	-1	none	_	_
39	immune	_	_	JJ	O	-1	none	_	_
40	response	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	MHC	_	_	NN	Protein	6	multitoken	_	_
4	class	_	_	NN	Protein	6	multitoken	_	_
5	II	_	_	CD	Protein	6	multitoken	_	_
6	transactivator	_	_	NN	Protein	0	root	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	has	_	_	VBZ	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	reported	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	major	_	_	JJ	O	-1	none	_	_
17	regulatory	_	_	JJ	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	both	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	constitutive	_	_	JJ	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	IFN	_	_	NN	O	-1	none	_	_
25	inducible	_	_	JJ	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	MHC	_	_	NN	O	-1	none	_	_
29	class	_	_	NN	O	-1	none	_	_
30	II	_	_	CD	O	-1	none	_	_
31	genes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	expressing	_	_	VBG	O	-1	none	_	_
9	MHC	_	_	NN	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	have	_	_	VBP	O	-1	none	_	_
13	CIITA	_	_	NN	Protein	-1	none	_	_
14	transcripts	_	_	NNS	O	-1	none	_	_
15	while	_	_	IN	O	-1	none	_	_
16	MHC	_	_	NN	O	-1	none	_	_
17	class	_	_	NN	O	-1	none	_	_
18	II	_	_	CD	O	-1	none	_	_
19	negative	_	_	JJ	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	mouse	_	_	NN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	do	_	_	VBP	O	-1	none	_	_
28	not	_	_	RB	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	MHC	_	_	NN	O	-1	none	_	_
5	class	_	_	NN	O	-1	none	_	_
6	II	_	_	CD	O	-1	none	_	_
7	genes	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	mouse	_	_	NN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	can	_	_	MD	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	reconstituted	_	_	VBN	O	-1	none	_	_
15	upon	_	_	IN	O	-1	none	_	_
16	transfection	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	CIITA	_	_	NN	Protein	-1	none	_	_
21	cDNA	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	explains	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	lack	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	MHC	_	_	NN	O	-1	none	_	_
18	class	_	_	NN	O	-1	none	_	_
19	II	_	_	CD	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	mouse	_	_	NN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	respectively	_	_	RB	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Potent	_	_	JJ	O	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	regulatory	_	_	JJ	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	antiproliferative	_	_	JJ	O	-1	none	_	_
6	activities	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	20-methyl	_	_	JJ	O	-1	none	_	_
9	analogues	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	1,25	_	_	CD	O	-1	none	_	_
12	dihydroxyvitamin	_	_	NN	O	-1	none	_	_
13	D3	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	biological	_	_	JJ	O	-1	none	_	_
3	active	_	_	JJ	O	-1	none	_	_
4	form	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	vitamin	_	_	NN	O	-1	none	_	_
7	D3	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	1,25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
10	D3	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	VD	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	regulates	_	_	VBZ	O	-1	none	_	_
16	cellular	_	_	JJ	O	-1	none	_	_
17	growth	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	provides	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	hormone	_	_	NN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	interesting	_	_	JJ	O	-1	none	_	_
8	therapeutic	_	_	JJ	O	-1	none	_	_
9	potential	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	hypercalcemia	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	side	_	_	JJ	O	-1	none	_	_
7	effect	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	which	_	_	WDT	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	caused	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	VD	_	_	NN	O	-1	none	_	_
14	's	_	_	POS	O	-1	none	_	_
15	classical	_	_	JJ	O	-1	none	_	_
16	action	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	regulation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	calcium	_	_	NN	O	-1	none	_	_
22	homeostasis	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	made	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	need	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	VD	_	_	NN	O	-1	none	_	_
7	analogues	_	_	NNS	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	selectively	_	_	RB	O	-1	none	_	_
10	increased	_	_	VBN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	regulatory	_	_	JJ	O	-1	none	_	_
13	properties	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Studies	_	_	NNS	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	20-epi	_	_	NN	O	-1	none	_	_
4	analogues	_	_	NNS	O	-1	none	_	_
5	pointed	_	_	VBD	O	-1	none	_	_
6	out	_	_	RP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	importance	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	carbon-20	_	_	NN	O	-1	none	_	_
12	position	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	led	_	_	VBD	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	development	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	20-methyl	_	_	NN	O	-1	none	_	_
20	derivatives	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	VD	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	report	_	_	NN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	biological	_	_	JJ	O	-1	none	_	_
6	properties	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	compounds	_	_	NNS	O	-1	none	_	_
10	ZK161422	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	ZK157202	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	20-methyl-	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	20-methyl-23-eneanalogues	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	respectively	_	_	RB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	have	_	_	VBP	O	-1	none	_	_
23	been	_	_	VBN	O	-1	none	_	_
24	analyzed	_	_	VBN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	comparison	_	_	NN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	VD	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	compounds	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	about	_	_	IN	O	-1	none	_	_
5	2-fold	_	_	RB	O	-1	none	_	_
6	lower	_	_	JJR	O	-1	none	_	_
7	affinity	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	VD	_	_	NN	Protein	11	multitoken	_	_
11	receptor	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	VDR	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	than	_	_	IN	O	-1	none	_	_
16	VD	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	compared	_	_	VBN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	VD	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	their	_	_	PRP$	O	-1	none	_	_
8	antiproliferative	_	_	JJ	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	up	_	_	RB	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	30-fold	_	_	RB	O	-1	none	_	_
14	higher	_	_	JJR	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	peripheral	_	_	JJ	O	-1	none	_	_
18	blood	_	_	NN	O	-1	none	_	_
19	mononuclear	_	_	JJ	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	even	_	_	RB	O	-1	none	_	_
23	up	_	_	IN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	300-fold	_	_	RB	O	-1	none	_	_
26	higher	_	_	JJR	O	-1	none	_	_
27	on	_	_	IN	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	breast	_	_	NN	O	-1	none	_	_
30	cancer	_	_	NN	O	-1	none	_	_
31	MCF-7	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	hypercalcemic	_	_	JJ	O	-1	none	_	_
4	effect	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	ZK157202	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	increased	_	_	VBN	O	-1	none	_	_
10	10-fold	_	_	RB	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	ZK161422	_	_	NN	O	-1	none	_	_
13	has	_	_	VBZ	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	same	_	_	JJ	O	-1	none	_	_
16	calcium	_	_	NN	O	-1	none	_	_
17	mobilizing	_	_	VBG	O	-1	none	_	_
18	potency	_	_	NN	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	VD	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	ZK161422	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	but	_	_	CC	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	ZK157202	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	preference	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	promoter	_	_	NN	O	-1	none	_	_
17	carrying	_	_	VBG	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	VD	_	_	NN	O	-1	none	_	_
20	response	_	_	NN	O	-1	none	_	_
21	element	_	_	NN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	palindromic	_	_	JJ	O	-1	none	_	_
25	arrangement	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	two	_	_	CD	O	-1	none	_	_
28	hexameric	_	_	JJ	O	-1	none	_	_
29	receptor	_	_	NN	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	sites	_	_	NNS	O	-1	none	_	_
32	spaced	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	9	_	_	CD	O	-1	none	_	_
35	nucleotides	_	_	NNS	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	IP9	_	_	NN	O	-1	none	_	_
38	)	_	_	-RRB-	O	-1	none	_	_
39	rather	_	_	RB	O	-1	none	_	_
40	than	_	_	IN	O	-1	none	_	_
41	for	_	_	IN	O	-1	none	_	_
42	activation	_	_	NN	O	-1	none	_	_
43	from	_	_	IN	O	-1	none	_	_
44	a	_	_	DT	O	-1	none	_	_
45	response	_	_	NN	O	-1	none	_	_
46	element	_	_	NN	O	-1	none	_	_
47	formed	_	_	VBN	O	-1	none	_	_
48	by	_	_	IN	O	-1	none	_	_
49	a	_	_	DT	O	-1	none	_	_
50	direct	_	_	JJ	O	-1	none	_	_
51	repeat	_	_	NN	O	-1	none	_	_
52	spaced	_	_	VBN	O	-1	none	_	_
53	by	_	_	IN	O	-1	none	_	_
54	3	_	_	CD	O	-1	none	_	_
55	nucleotides	_	_	NNS	O	-1	none	_	_
56	(	_	_	-LRB-	O	-1	none	_	_
57	DR3	_	_	NN	O	-1	none	_	_
58	)	_	_	-RRB-	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	observation	_	_	NN	O	-1	none	_	_
3	supports	_	_	VBZ	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	model	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	which	_	_	WDT	O	-1	none	_	_
9	promoter	_	_	NN	O	-1	none	_	_
10	selectivity	_	_	NN	O	-1	none	_	_
11	reflects	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	selectively	_	_	RB	O	-1	none	_	_
14	increased	_	_	VBN	O	-1	none	_	_
15	antiproliferative	_	_	JJ	O	-1	none	_	_
16	effect	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	VD	_	_	NN	O	-1	none	_	_
19	analogues	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Impaired	_	_	JJ	O	-1	none	_	_
2	fetal	_	_	JJ	O	-1	none	_	_
3	thymocyte	_	_	NN	O	-1	none	_	_
4	development	_	_	NN	O	-1	none	_	_
5	after	_	_	IN	O	-1	none	_	_
6	efficient	_	_	JJ	O	-1	none	_	_
7	adenovirus	_	_	NN	O	-1	none	_	_
8	mediated	_	_	VBD	O	-1	none	_	_
9	inhibition	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	introduce	_	_	VBP	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	new	_	_	JJ	O	-1	none	_	_
5	experimental	_	_	JJ	O	-1	none	_	_
6	system	_	_	NN	O	-1	none	_	_
7	combining	_	_	VBG	O	-1	none	_	_
8	adenovirus	_	_	NN	O	-1	none	_	_
9	mediated	_	_	VBN	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	transfer	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	fetal	_	_	JJ	O	-1	none	_	_
14	thymic	_	_	JJ	O	-1	none	_	_
15	organ	_	_	NN	O	-1	none	_	_
16	culture	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	FTOC	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	system	_	_	NN	O	-1	none	_	_
3	allowed	_	_	VBD	O	-1	none	_	_
4	us	_	_	PRP	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	efficiently	_	_	RB	O	-1	none	_	_
7	express	_	_	VB	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	developing	_	_	VBG	O	-1	none	_	_
10	thymocytes	_	_	NNS	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	mutant	_	_	NN	O	-1	none	_	_
13	form	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	inhibitor	_	_	NN	O	-1	none	_	_
19	I	_	_	NN	Protein	22	multitoken	_	_
20	kappa	_	_	NN	Protein	22	multitoken	_	_
21	B	_	_	NN	Protein	22	multitoken	_	_
22	alpha	_	_	NN	Protein	0	root	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	mut-I	_	_	NN	Protein	26	multitoken	_	_
25	kappa	_	_	NN	Protein	26	multitoken	_	_
26	B	_	_	NN	Protein	0	root	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	study	_	_	VB	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	maturation	_	_	NN	O	-1	none	_	_
33	defects	_	_	VBZ	O	-1	none	_	_
34	occurring	_	_	VBG	O	-1	none	_	_
35	when	_	_	WRB	O	-1	none	_	_
36	NF-kappa	_	_	NN	O	-1	none	_	_
37	B	_	_	NN	O	-1	none	_	_
38	activation	_	_	NN	O	-1	none	_	_
39	is	_	_	VBZ	O	-1	none	_	_
40	inhibited	_	_	VBN	O	-1	none	_	_
41	during	_	_	IN	O	-1	none	_	_
42	fetal	_	_	JJ	O	-1	none	_	_
43	development	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Proliferation	_	_	NN	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	as	_	_	IN	O	-1	none	_	_
4	measured	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	percentage	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	cycle	_	_	NN	O	-1	none	_	_
12	appeared	_	_	VBD	O	-1	none	_	_
13	normal	_	_	JJ	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	as	_	_	IN	O	-1	none	_	_
16	did	_	_	VBD	O	-1	none	_	_
17	rearrangement	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	TCR	_	_	NN	Protein	23	multitoken	_	_
23	beta-chain	_	_	NN	Protein	0	root	_	_
24	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	apoptosis	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	much	_	_	RB	O	-1	none	_	_
6	higher	_	_	JJR	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	FTOC	_	_	NN	O	-1	none	_	_
9	infected	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	adenovirus	_	_	NN	O	-1	none	_	_
12	containing	_	_	VBG	O	-1	none	_	_
13	mut-I	_	_	NN	O	-1	none	_	_
14	kappa	_	_	NN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	than	_	_	IN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	FTOC	_	_	NN	O	-1	none	_	_
19	infected	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	control	_	_	NN	O	-1	none	_	_
23	virus	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	suggest	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	plays	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	crucial	_	_	JJ	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	ensuring	_	_	VBG	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	differentiation	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	survival	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	thymocytes	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	early	_	_	JJ	O	-1	none	_	_
25	stages	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	their	_	_	PRP$	O	-1	none	_	_
28	development	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Calcineurin	_	_	NN	O	-1	none	_	_
2	activates	_	_	VBZ	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	GM-CSF	_	_	NN	Protein	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	synergy	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	either	_	_	CC	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	kinase	_	_	NN	O	-1	none	_	_
14	C	_	_	NN	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B/AP	_	_	NN	O	-1	none	_	_
18	-1	_	_	CD	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	cis	_	_	NN	O	-1	none	_	_
3	acting	_	_	VBG	O	-1	none	_	_
4	elements	_	_	NNS	O	-1	none	_	_
5	GM-kappa	_	_	NN	O	-1	none	_	_
6	B/GC-box	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	CLE0	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	granulocyte-macrophage	_	_	JJ	Protein	15	multitoken	_	_
13	colony	_	_	NN	Protein	15	multitoken	_	_
14	stimulating	_	_	NN	Protein	15	multitoken	_	_
15	factor	_	_	NN	Protein	0	root	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	GM-CSF	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	required	_	_	VBN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	maximal	_	_	JJ	O	-1	none	_	_
24	induction	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	Jurkat	_	_	NN	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	costimulation	_	_	NN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	phorbol-12-myristate	_	_	NN	O	-1	none	_	_
33	acetate	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	PMA	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	Ca2+	_	_	NN	O	-1	none	_	_
39	ionophore	_	_	NN	O	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	A23187	_	_	NN	O	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	GM-kappa	_	_	NN	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	sequence	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	recognized	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	mainly	_	_	RB	O	-1	none	_	_
14	induced	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	PMA	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	CLE0	_	_	NN	O	-1	none	_	_
3	sequence	_	_	NN	O	-1	none	_	_
4	interacts	_	_	VBZ	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	factors	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	related	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	PMA	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	AP-1	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	PMA	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	A23187	_	_	NN	O	-1	none	_	_
19	induced	_	_	VBD	O	-1	none	_	_
20	NF-AT	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	examined	_	_	VBD	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	signal	_	_	NN	O	-1	none	_	_
5	transducing	_	_	NN	O	-1	none	_	_
6	components	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	activate	_	_	VB	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	GM-CSF	_	_	NN	Protein	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Cotransfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	p50	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	p65	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	-	_	_	:	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	AP-1	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	c-Jun	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	c-Fos	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	-	_	_	:	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	vectors	_	_	NNS	O	-1	none	_	_
21	into	_	_	IN	O	-1	none	_	_
22	Jurkat	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	luciferase	_	_	NN	O	-1	none	_	_
27	reporter	_	_	NN	O	-1	none	_	_
28	containing	_	_	VBG	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	GM-CSF	_	_	NN	Protein	-1	none	_	_
31	promoter	_	_	NN	O	-1	none	_	_
32	did	_	_	VBD	O	-1	none	_	_
33	not	_	_	RB	O	-1	none	_	_
34	stimulate	_	_	VB	O	-1	none	_	_
35	transcription	_	_	NN	O	-1	none	_	_
36	from	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	GM-CSF	_	_	NN	Protein	-1	none	_	_
39	promoter	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	cotransfection	_	_	NN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	combination	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	AP-1	_	_	NN	O	-1	none	_	_
13	significantly	_	_	RB	O	-1	none	_	_
14	augmented	_	_	VBD	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	GM-CSF	_	_	NN	Protein	-1	none	_	_
19	promoter	_	_	NN	O	-1	none	_	_
20	containing	_	_	VBG	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	GM-kappa	_	_	NN	O	-1	none	_	_
23	B/GC-box	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	CLE0	_	_	NN	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	AP-1	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	NF-AT	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	constitutively	_	_	RB	O	-1	none	_	_
5	active	_	_	JJ	O	-1	none	_	_
6	calcineurin	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	CN	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	Ca2	_	_	NN	Protein	15	multitoken	_	_
13	+/calmodulin-dependent	_	_	JJ	Protein	15	multitoken	_	_
14	protein	_	_	NN	Protein	15	multitoken	_	_
15	phosphatase	_	_	NN	Protein	0	root	_	_
16	,	_	_	,	O	-1	none	_	_
17	potentiated	_	_	VBD	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	two	_	_	CD	O	-1	none	_	_
20	fold	_	_	JJ	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	transcriptional	_	_	JJ	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	NF-kappa	_	_	NN	O	-1	none	_	_
26	B/AP-1.	_	_	NN	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	constitutively	_	_	RB	O	-1	none	_	_
3	active	_	_	JJ	O	-1	none	_	_
4	forms	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	CN	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	kinase	_	_	NN	O	-1	none	_	_
10	C	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	PKC	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	synergistically	_	_	RB	O	-1	none	_	_
15	activated	_	_	VBN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	GM-CSF	_	_	NN	Protein	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	cooperation	_	_	NN	O	-1	none	_	_
6	among	_	_	IN	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B-,	_	_	NN	O	-1	none	_	_
9	AP-1-	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	NF-AT-binding	_	_	JJ	O	-1	none	_	_
12	sequences	_	_	NNS	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	required	_	_	VBN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	GM-CSF	_	_	NN	Protein	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	through	_	_	IN	O	-1	none	_	_
22	PKC-	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	Ca2+	_	_	NN	O	-1	none	_	_
25	-	_	_	:	O	-1	none	_	_
26	signaling	_	_	NN	O	-1	none	_	_
27	pathways	_	_	NNS	O	-1	none	_	_
28	downstream	_	_	RB	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	activation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Essential	_	_	JJ	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	alveolar	_	_	JJ	O	-1	none	_	_
5	macrophages	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	intrapulmonary	_	_	JJ	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Acute	_	_	JJ	O	-1	none	_	_
2	inflammatory	_	_	JJ	O	-1	none	_	_
3	injury	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	rat	_	_	NN	O	-1	none	_	_
6	lung	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	deposition	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	immunoglobulin	_	_	NN	O	-1	none	_	_
12	G	_	_	NN	O	-1	none	_	_
13	immune	_	_	JJ	O	-1	none	_	_
14	complexes	_	_	NNS	O	-1	none	_	_
15	requires	_	_	VBZ	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	cytokines	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	chemokines	_	_	NNS	O	-1	none	_	_
21	as	_	_	RB	O	-1	none	_	_
22	well	_	_	RB	O	-1	none	_	_
23	as	_	_	IN	O	-1	none	_	_
24	activation	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factor	_	_	NN	O	-1	none	_	_
29	nuclear	_	_	JJ	O	-1	none	_	_
30	factor	_	_	NN	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	NF	_	_	NN	O	-1	none	_	_
33	)-kappaB	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	little	_	_	JJ	O	-1	none	_	_
4	direct	_	_	JJ	O	-1	none	_	_
5	evidence	_	_	NN	O	-1	none	_	_
6	regarding	_	_	VBG	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	alveolar	_	_	JJ	O	-1	none	_	_
11	macrophages	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	these	_	_	DT	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	events	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	studies	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	rat	_	_	NN	O	-1	none	_	_
7	lungs	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	depleted	_	_	VBN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	alveolar	_	_	JJ	O	-1	none	_	_
12	macrophages	_	_	NNS	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	airway	_	_	NN	O	-1	none	_	_
15	instillation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	liposome	_	_	NN	O	-1	none	_	_
18	encapsulated	_	_	VBD	O	-1	none	_	_
19	dichloromethylene	_	_	NN	O	-1	none	_	_
20	diphosphonate	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	procedures	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	which	_	_	WDT	O	-1	none	_	_
5	greatly	_	_	RB	O	-1	none	_	_
6	reduced	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	number	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	retrievable	_	_	JJ	O	-1	none	_	_
11	alveolar	_	_	JJ	O	-1	none	_	_
12	macrophages	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	suppressed	_	_	VBD	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	lung	_	_	NN	O	-1	none	_	_
18	NF-kappaB	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	inflammatory	_	_	JJ	O	-1	none	_	_
22	model	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	bronchoalveolar	_	_	JJ	O	-1	none	_	_
5	lavage	_	_	NN	O	-1	none	_	_
6	levels	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	tumor	_	_	NN	Protein	10	multitoken	_	_
9	necrosis	_	_	NN	Protein	10	multitoken	_	_
10	factor-alpha	_	_	NN	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	TNF-alpha	_	_	NN	Protein	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	CXC	_	_	NN	O	-1	none	_	_
17	chemokine	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	macrophage	_	_	NN	Protein	21	multitoken	_	_
20	inflammatory	_	_	JJ	Protein	21	multitoken	_	_
21	protein-2	_	_	NN	Protein	0	root	_	_
22	,	_	_	,	O	-1	none	_	_
23	were	_	_	VBD	O	-1	none	_	_
24	substantially	_	_	RB	O	-1	none	_	_
25	reduced	_	_	VBN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	parallel	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	upregulation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	lung	_	_	NN	O	-1	none	_	_
8	vascular	_	_	JJ	O	-1	none	_	_
9	adhesion	_	_	NN	O	-1	none	_	_
10	molecule	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	intercellular	_	_	JJ	Protein	14	multitoken	_	_
13	adhesion	_	_	NN	Protein	14	multitoken	_	_
14	molecule-1	_	_	NN	Protein	0	root	_	_
15	,	_	_	,	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	greatly	_	_	RB	O	-1	none	_	_
18	reduced	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	intrapulmonary	_	_	JJ	O	-1	none	_	_
21	instillation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	phosphonate	_	_	NN	O	-1	none	_	_
24	containing	_	_	VBG	O	-1	none	_	_
25	liposomes	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Neutrophil	_	_	NN	O	-1	none	_	_
2	accumulation	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	development	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	lung	_	_	NN	O	-1	none	_	_
7	injury	_	_	NN	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	substantially	_	_	RB	O	-1	none	_	_
11	diminished	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Lung	_	_	NN	O	-1	none	_	_
2	instillation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TNF-alpha	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	alveolar	_	_	JJ	O	-1	none	_	_
7	macrophage	_	_	NN	O	-1	none	_	_
8	depleted	_	_	VBN	O	-1	none	_	_
9	rats	_	_	NNS	O	-1	none	_	_
10	restored	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	NF-kappaB	_	_	NN	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	whole	_	_	JJ	O	-1	none	_	_
17	lung	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	inflammatory	_	_	JJ	O	-1	none	_	_
9	model	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	initial	_	_	JJ	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	NF-kappaB	_	_	NN	O	-1	none	_	_
15	occurs	_	_	VBZ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	alveolar	_	_	JJ	O	-1	none	_	_
18	macrophages	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	ensuing	_	_	VBG	O	-1	none	_	_
22	production	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	TNF-alpha	_	_	NN	Protein	-1	none	_	_
25	may	_	_	MD	O	-1	none	_	_
26	propagate	_	_	VB	O	-1	none	_	_
27	NF-kappaB	_	_	NN	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	other	_	_	JJ	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	types	_	_	NNS	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	lung	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Role	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	IKK1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	IKK2	_	_	NN	Protein	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	lipopolysaccharide	_	_	NN	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	monocytic	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Mononuclear	_	_	JJ	O	-1	none	_	_
2	phagocytes	_	_	NNS	O	-1	none	_	_
3	play	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	major	_	_	JJ	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	immune	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	inflammatory	_	_	JJ	O	-1	none	_	_
11	responses	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Bacterial	_	_	JJ	O	-1	none	_	_
2	lipopolysaccharide	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	LPS	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	induces	_	_	VBZ	O	-1	none	_	_
7	monocytes	_	_	NNS	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	express	_	_	VB	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	variety	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	genes	_	_	NNS	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	activating	_	_	VBG	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Rel	_	_	NN	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	family	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	reported	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	tumor	_	_	NN	O	-1	none	_	_
9	necrosis	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	interleukin	_	_	NN	O	-1	none	_	_
13	1	_	_	CD	O	-1	none	_	_
14	signaling	_	_	NN	O	-1	none	_	_
15	pathways	_	_	NNS	O	-1	none	_	_
16	activate	_	_	VBP	O	-1	none	_	_
17	two	_	_	CD	O	-1	none	_	_
18	kinases	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	IKK1	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	IKK2	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Phosphorylation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	IkappaB	_	_	NN	O	-1	none	_	_
5	cytoplasmic	_	_	JJ	O	-1	none	_	_
6	inhibitors	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	IkappaBbeta	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	IkappaBepsilon	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	these	_	_	DT	O	-1	none	_	_
17	kinases	_	_	NNS	O	-1	none	_	_
18	triggers	_	_	VBZ	O	-1	none	_	_
19	proteolytic	_	_	JJ	O	-1	none	_	_
20	degradation	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	release	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	NF-kappaB	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	Rel	_	_	NN	O	-1	none	_	_
28	proteins	_	_	NNS	O	-1	none	_	_
29	into	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	nucleus	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	At	_	_	IN	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	role	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	IKKs	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	LPS	_	_	NN	O	-1	none	_	_
11	signaling	_	_	NN	O	-1	none	_	_
12	has	_	_	VBZ	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	investigated	_	_	VBN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	report	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	induces	_	_	VBZ	O	-1	none	_	_
8	IKK	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	THP-1	_	_	NN	O	-1	none	_	_
15	monocytic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	kinetics	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	kinase	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	monocytic	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	relatively	_	_	RB	O	-1	none	_	_
13	slow	_	_	JJ	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	maximal	_	_	JJ	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	observed	_	_	VBN	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	60	_	_	CD	O	-1	none	_	_
20	min	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	which	_	_	WDT	O	-1	none	_	_
23	coincides	_	_	VBZ	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	degradation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	IkappaBs	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	nuclear	_	_	JJ	O	-1	none	_	_
32	translocation	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	NF-kappaB	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	transfection	_	_	NN	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	overexpression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	wild	_	_	JJ	O	-1	none	_	_
8	type	_	_	NN	O	-1	none	_	_
9	IKK1	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	dominant	_	_	JJ	O	-1	none	_	_
13	negative	_	_	JJ	O	-1	none	_	_
14	mutant	_	_	NN	O	-1	none	_	_
15	IKK1	_	_	NN	Protein	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	K44M	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	wild	_	_	JJ	O	-1	none	_	_
22	type	_	_	NN	O	-1	none	_	_
23	IKK2	_	_	NN	Protein	-1	none	_	_
24	did	_	_	VBD	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	affect	_	_	VB	O	-1	none	_	_
27	LPS	_	_	NN	O	-1	none	_	_
28	induced	_	_	VBN	O	-1	none	_	_
29	kappaB	_	_	NN	O	-1	none	_	_
30	dependent	_	_	JJ	O	-1	none	_	_
31	transcription	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	monocytic	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	dominant	_	_	JJ	O	-1	none	_	_
6	negative	_	_	JJ	O	-1	none	_	_
7	mutant	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	IKK2	_	_	NN	Protein	-1	none	_	_
10	inhibited	_	_	VBD	O	-1	none	_	_
11	LPS	_	_	NN	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	kappaB	_	_	NN	O	-1	none	_	_
15	dependent	_	_	JJ	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	dose	_	_	NN	O	-1	none	_	_
20	dependent	_	_	JJ	O	-1	none	_	_
21	manner	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	LPS	_	_	NN	O	-1	none	_	_
6	induction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	kappaB	_	_	NN	O	-1	none	_	_
9	dependent	_	_	JJ	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	monocytic	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	requires	_	_	VBZ	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	IKK2	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Calcium	_	_	NN	O	-1	none	_	_
2	dependent	_	_	JJ	O	-1	none	_	_
3	immediate-early	_	_	JJ	O	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	induction	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	negatively	_	_	RB	O	-1	none	_	_
10	regulated	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	p21Ha-ras	_	_	NN	Protein	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	immediate-early	_	_	JJ	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	IE	_	_	JJ	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	response	_	_	NN	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	such	_	_	JJ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	egr-1	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	c-fos	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	c-jun	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	occurs	_	_	VBZ	O	-1	none	_	_
21	rapidly	_	_	RB	O	-1	none	_	_
22	after	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	activation	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	lymphocytes	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	process	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	involves	_	_	VBZ	O	-1	none	_	_
6	calcium	_	_	NN	O	-1	none	_	_
7	mobilization	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	kinase	_	_	NN	O	-1	none	_	_
13	C	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	PKC	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	phosphorylation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	tyrosine	_	_	NN	O	-1	none	_	_
22	kinases	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	p21	_	_	NN	Protein	4	multitoken	_	_
2	(	_	_	-LRB-	Protein	4	multitoken	_	_
3	ras	_	_	NN	Protein	4	multitoken	_	_
4	)	_	_	-RRB-	Protein	0	root	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	guanine	_	_	NN	O	-1	none	_	_
8	nucleotide	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	mediates	_	_	VBZ	O	-1	none	_	_
13	T-cell	_	_	NN	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	transduction	_	_	NN	O	-1	none	_	_
16	through	_	_	IN	O	-1	none	_	_
17	PKC	_	_	NN	O	-1	none	_	_
18	dependent	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	PKC	_	_	NN	O	-1	none	_	_
21	independent	_	_	JJ	O	-1	none	_	_
22	pathways	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	involvement	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	p21	_	_	NN	Protein	7	multitoken	_	_
5	(	_	_	-LRB-	Protein	7	multitoken	_	_
6	ras	_	_	NN	Protein	7	multitoken	_	_
7	)	_	_	-RRB-	Protein	0	root	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	calcium	_	_	NN	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	signals	_	_	NNS	O	-1	none	_	_
15	has	_	_	VBZ	O	-1	none	_	_
16	been	_	_	VBN	O	-1	none	_	_
17	suggested	_	_	VBN	O	-1	none	_	_
18	through	_	_	IN	O	-1	none	_	_
19	analysis	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	its	_	_	PRP$	O	-1	none	_	_
22	role	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	activation	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	NF-AT	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	investigated	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	inductions	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	IE	_	_	JJ	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	calcium	_	_	NN	O	-1	none	_	_
14	signals	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	Jurkat	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	presence	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	activated	_	_	VBN	O	-1	none	_	_
24	p21	_	_	NN	Protein	27	multitoken	_	_
25	(	_	_	-LRB-	Protein	27	multitoken	_	_
26	ras	_	_	NN	Protein	27	multitoken	_	_
27	)	_	_	-RRB-	Protein	0	root	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	their	_	_	PRP$	O	-1	none	_	_
31	correlated	_	_	VBN	O	-1	none	_	_
32	consequences	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	activated	_	_	VBN	O	-1	none	_	_
5	p21	_	_	NN	Protein	8	multitoken	_	_
6	(	_	_	-LRB-	Protein	8	multitoken	_	_
7	ras	_	_	NN	Protein	8	multitoken	_	_
8	)	_	_	-RRB-	Protein	0	root	_	_
9	negatively	_	_	RB	O	-1	none	_	_
10	regulated	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	IE	_	_	JJ	O	-1	none	_	_
15	genes	_	_	NNS	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	calcium	_	_	NN	O	-1	none	_	_
18	ionophore	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	inhibition	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	calcium	_	_	NN	O	-1	none	_	_
5	activated	_	_	VBD	O	-1	none	_	_
6	IE	_	_	JJ	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	induction	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	reversed	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	treatment	_	_	NN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	cyclosporin	_	_	NN	O	-1	none	_	_
15	A	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	suggesting	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	involvement	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	calcineurin	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	regulation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	later	_	_	JJ	O	-1	none	_	_
3	result	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	inhibition	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	pathway	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	p21	_	_	NN	Protein	13	multitoken	_	_
12	(	_	_	-LRB-	Protein	13	multitoken	_	_
13	ras	_	_	NN	Protein	0	root	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	down-regulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	factor	_	_	NN	O	-1	none	_	_
24	AP-1	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	subsequent	_	_	JJ	O	-1	none	_	_
27	coordinate	_	_	JJ	O	-1	none	_	_
28	reductions	_	_	NNS	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	IL-2	_	_	NN	Protein	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	expression	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	protein	_	_	NN	O	-1	none	_	_
35	production	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	p2l	_	_	NN	Protein	8	multitoken	_	_
6	(	_	_	-LRB-	Protein	8	multitoken	_	_
7	ras	_	_	NN	Protein	8	multitoken	_	_
8	)	_	_	-RRB-	Protein	0	root	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	essential	_	_	JJ	O	-1	none	_	_
12	mediator	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	generating	_	_	VBG	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	only	_	_	RB	O	-1	none	_	_
17	positive	_	_	JJ	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	also	_	_	RB	O	-1	none	_	_
20	negative	_	_	JJ	O	-1	none	_	_
21	modulatory	_	_	JJ	O	-1	none	_	_
22	mechanisms	_	_	NNS	O	-1	none	_	_
23	controlling	_	_	VBG	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	competence	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	response	_	_	NN	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	inductive	_	_	JJ	O	-1	none	_	_
33	stimulations	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	interleukin-1beta	_	_	NN	Protein	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	Epstein-Barr	_	_	JJ	O	-1	none	_	_
7	virus	_	_	NN	O	-1	none	_	_
8	involves	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	number	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	latent	_	_	JJ	O	-1	none	_	_
13	proteins	_	_	NNS	O	-1	none	_	_
14	via	_	_	IN	O	-1	none	_	_
15	their	_	_	PRP$	O	-1	none	_	_
16	interaction	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	RBP	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Epstein-Barr	_	_	NNP	O	-1	none	_	_
2	virus	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	EBV	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	infects	_	_	VBZ	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	resulting	_	_	VBG	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	outgrowth	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	immortalised	_	_	JJ	O	-1	none	_	_
16	lymphoblastoid	_	_	JJ	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	lines	_	_	NNS	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	LCLs	_	_	NNS	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	through	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	use	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	intracellular	_	_	JJ	O	-1	none	_	_
10	staining	_	_	VBG	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	interleukin-1beta	_	_	NN	Protein	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	IL-1beta	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	expressed	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	LCLs	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	investigate	_	_	VB	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	influence	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	individual	_	_	JJ	O	-1	none	_	_
27	latent	_	_	JJ	O	-1	none	_	_
28	proteins	_	_	NNS	O	-1	none	_	_
29	on	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	IL-1beta	_	_	NN	Protein	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	RT-PCR	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	IL-1beta	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	shown	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	up-regulated	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	EBV	_	_	NN	O	-1	none	_	_
12	transformed	_	_	VBN	O	-1	none	_	_
13	LCLs	_	_	NNS	O	-1	none	_	_
14	as	_	_	RB	O	-1	none	_	_
15	well	_	_	RB	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	group	_	_	NN	O	-1	none	_	_
19	III	_	_	CD	O	-1	none	_	_
20	Burkitt	_	_	NN	O	-1	none	_	_
21	's	_	_	POS	O	-1	none	_	_
22	lymphoma	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	BL	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	lines	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	compared	_	_	VBN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	group	_	_	NN	O	-1	none	_	_
32	I	_	_	CD	O	-1	none	_	_
33	BL	_	_	NN	O	-1	none	_	_
34	cell	_	_	NN	O	-1	none	_	_
35	lines	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	up-regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IL-1beta	_	_	NN	Protein	-1	none	_	_
5	message	_	_	NN	O	-1	none	_	_
6	could	_	_	MD	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	mediated	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	latent	_	_	JJ	Protein	13	multitoken	_	_
12	membrane	_	_	NN	Protein	13	multitoken	_	_
13	protein-1	_	_	NN	Protein	0	root	_	_
14	,	_	_	,	O	-1	none	_	_
15	EBV	_	_	NN	Protein	18	multitoken	_	_
16	nuclear	_	_	JJ	Protein	18	multitoken	_	_
17	proteins	_	_	NNS	Protein	18	multitoken	_	_
18	2	_	_	CD	Protein	0	root	_	_
19	,	_	_	,	O	-1	none	_	_
20	3	_	_	CD	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	4	_	_	CD	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	6	_	_	CD	Protein	26	multitoken	_	_
26	genes	_	_	NNS	Protein	0	root	_	_
27	.	_	_	.	O	-1	none	_	_

1	Electrophoretic	_	_	JJ	O	-1	none	_	_
2	mobility	_	_	NN	O	-1	none	_	_
3	shift	_	_	NN	O	-1	none	_	_
4	assays	_	_	NNS	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	EMSAs	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	demonstrated	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	-300	_	_	CD	O	-1	none	_	_
12	region	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-1beta	_	_	NN	Protein	-1	none	_	_
16	promoter	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	contains	_	_	VBZ	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	nuclear	_	_	JJ	O	-1	none	_	_
22	factor-kappaB	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	NF-kappaB	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	binding	_	_	VBG	O	-1	none	_	_
27	site	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	contained	_	_	VBD	O	-1	none	_	_
30	a	_	_	DT	O	-1	none	_	_
31	functional	_	_	JJ	O	-1	none	_	_
32	RBP	_	_	NN	O	-1	none	_	_
33	binding	_	_	NN	O	-1	none	_	_
34	site	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	RBP	_	_	NN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	site	_	_	NN	O	-1	none	_	_
7	could	_	_	MD	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	inhibited	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	addition	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	EBV	_	_	NN	Protein	16	multitoken	_	_
14	nuclear	_	_	JJ	Protein	16	multitoken	_	_
15	proteins	_	_	NNS	Protein	16	multitoken	_	_
16	3	_	_	CD	Protein	0	root	_	_
17	and	_	_	CC	O	-1	none	_	_
18	6	_	_	CD	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	suggesting	_	_	VBG	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	these	_	_	DT	O	-1	none	_	_
23	proteins	_	_	NNS	O	-1	none	_	_
24	displace	_	_	VBP	O	-1	none	_	_
25	RBP	_	_	NN	O	-1	none	_	_
26	from	_	_	IN	O	-1	none	_	_
27	its	_	_	PRP$	O	-1	none	_	_
28	recognition	_	_	NN	O	-1	none	_	_
29	sequence	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	removing	_	_	VBG	O	-1	none	_	_
32	transcriptional	_	_	JJ	O	-1	none	_	_
33	repression	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	allowing	_	_	VBG	O	-1	none	_	_
36	gene	_	_	NN	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	occur	_	_	VB	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	group	_	_	NN	O	-1	none	_	_
3	I	_	_	CD	O	-1	none	_	_
4	BL	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	containing	_	_	VBG	O	-1	none	_	_
8	low	_	_	JJ	O	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappaB	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	only	_	_	RB	O	-1	none	_	_
14	RBP	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	observed	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	EMSAs	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	whereas	_	_	IN	O	-1	none	_	_
22	NF-kappaB	_	_	NN	O	-1	none	_	_
23	binding	_	_	NN	O	-1	none	_	_
24	could	_	_	MD	O	-1	none	_	_
25	be	_	_	VB	O	-1	none	_	_
26	demonstrated	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	EBV	_	_	NN	O	-1	none	_	_
29	transformed	_	_	VBN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	lines	_	_	NNS	O	-1	none	_	_
33	containing	_	_	VBG	O	-1	none	_	_
34	high	_	_	JJ	O	-1	none	_	_
35	levels	_	_	NNS	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	activated	_	_	VBN	O	-1	none	_	_
38	NF-kappaB	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	latent	_	_	JJ	Protein	9	multitoken	_	_
8	membrane	_	_	NN	Protein	9	multitoken	_	_
9	protein-1	_	_	NN	Protein	0	root	_	_
10	led	_	_	VBD	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	NF-kappaB	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	capable	_	_	JJ	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	binding	_	_	VBG	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	IL-1beta	_	_	NN	Protein	-1	none	_	_
22	promoter	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	demonstrates	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	EBV	_	_	NN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	up-regulate	_	_	VB	O	-1	none	_	_
8	IL-1beta	_	_	NN	Protein	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	possibly	_	_	RB	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	using	_	_	VBG	O	-1	none	_	_
14	RBP	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	NF-kappaB	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	both	_	_	DT	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Copyright	_	_	NN	O	-1	none	_	_
2	1998	_	_	CD	O	-1	none	_	_
3	Academic	_	_	NNP	O	-1	none	_	_
4	Press	_	_	NNP	O	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cytokine	_	_	NN	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	leukocytes	_	_	NNS	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	thrombin	_	_	NN	O	-1	none	_	_
11	stimulated	_	_	VBD	O	-1	none	_	_
12	platelets	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Activated	_	_	VBN	O	-1	none	_	_
4	platelets	_	_	NNS	O	-1	none	_	_
5	tether	_	_	VBP	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	activate	_	_	VBP	O	-1	none	_	_
8	myeloid	_	_	JJ	O	-1	none	_	_
9	leukocytes	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	investigate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	potential	_	_	JJ	O	-1	none	_	_
5	relevance	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	mechanism	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	acute	_	_	JJ	O	-1	none	_	_
11	myocardial	_	_	JJ	O	-1	none	_	_
12	infarction	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	AMI	_	_	NNP	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	we	_	_	PRP	O	-1	none	_	_
18	examined	_	_	VBD	O	-1	none	_	_
19	cytokine	_	_	NN	O	-1	none	_	_
20	induction	_	_	NN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	leukocyte-platelet	_	_	JJ	O	-1	none	_	_
23	adhesion	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	occurrence	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	leukocyte-platelet	_	_	JJ	O	-1	none	_	_
29	conjugates	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	patients	_	_	NNS	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	AMI	_	_	NNP	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	AND	_	_	CC	O	-1	none	_	_
3	RESULTS	_	_	NNS	O	-1	none	_	_
4	:	_	_	:	O	-1	none	_	_
5	We	_	_	PRP	O	-1	none	_	_
6	obtained	_	_	VBD	O	-1	none	_	_
7	peripheral	_	_	JJ	O	-1	none	_	_
8	venous	_	_	JJ	O	-1	none	_	_
9	blood	_	_	NN	O	-1	none	_	_
10	samples	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	20	_	_	CD	O	-1	none	_	_
13	patients	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	AMI	_	_	NNP	O	-1	none	_	_
16	before	_	_	IN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	daily	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	5	_	_	CD	O	-1	none	_	_
21	days	_	_	NNS	O	-1	none	_	_
22	after	_	_	IN	O	-1	none	_	_
23	direct	_	_	JJ	O	-1	none	_	_
24	percutaneous	_	_	JJ	O	-1	none	_	_
25	transluminal	_	_	JJ	O	-1	none	_	_
26	coronary	_	_	JJ	O	-1	none	_	_
27	angioplasty	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	PTCA	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	20	_	_	CD	O	-1	none	_	_
34	patients	_	_	NNS	O	-1	none	_	_
35	undergoing	_	_	VBG	O	-1	none	_	_
36	elective	_	_	JJ	O	-1	none	_	_
37	PTCA	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Throughout	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	period	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	CD41	_	_	NN	Protein	-1	none	_	_
7	immunofluorescence	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	leukocytes	_	_	NNS	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	flow	_	_	NN	O	-1	none	_	_
12	cytometry	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	revealed	_	_	VBD	O	-1	none	_	_
15	increased	_	_	VBN	O	-1	none	_	_
16	leukocyte-platelet	_	_	JJ	O	-1	none	_	_
17	adhesion	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	patients	_	_	NNS	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	AMI	_	_	NNP	O	-1	none	_	_
22	compared	_	_	VBN	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	control	_	_	NN	O	-1	none	_	_
25	patients	_	_	NNS	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	mean	_	_	NN	O	-1	none	_	_
28	+/-	_	_	CC	O	-1	none	_	_
29	SE	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	fluorescence	_	_	NN	O	-1	none	_	_
32	[	_	_	NN	O	-1	none	_	_
33	channels	_	_	NNS	O	-1	none	_	_
34	]	_	_	CD	O	-1	none	_	_
35	before	_	_	IN	O	-1	none	_	_
36	PTCA	_	_	NNP	O	-1	none	_	_
37	:	_	_	:	O	-1	none	_	_
38	77	_	_	CD	O	-1	none	_	_
39	+/-	_	_	CC	O	-1	none	_	_
40	16	_	_	CD	O	-1	none	_	_
41	versus	_	_	CC	O	-1	none	_	_
42	35	_	_	CD	O	-1	none	_	_
43	+/-	_	_	CC	O	-1	none	_	_
44	9	_	_	CD	O	-1	none	_	_
45	;	_	_	:	O	-1	none	_	_
46	P	_	_	NN	O	-1	none	_	_
47	=	_	_	JJ	O	-1	none	_	_
48	.003	_	_	CD	O	-1	none	_	_
49	)	_	_	-RRB-	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vitro	_	_	FW	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	thrombin	_	_	NN	Protein	-1	none	_	_
5	stimulated	_	_	VBD	O	-1	none	_	_
6	fixed	_	_	VBN	O	-1	none	_	_
7	platelets	_	_	NNS	O	-1	none	_	_
8	bound	_	_	VBD	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	neutrophils	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Within	_	_	IN	O	-1	none	_	_
2	2	_	_	CD	O	-1	none	_	_
3	hours	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	resulted	_	_	VBD	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	increased	_	_	VBN	O	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	interleukin	_	_	NN	Protein	16	multitoken	_	_
12	(	_	_	-LRB-	Protein	16	multitoken	_	_
13	IL	_	_	NN	Protein	16	multitoken	_	_
14	)	_	_	-RRB-	Protein	16	multitoken	_	_
15	,1	_	_	NN	Protein	16	multitoken	_	_
16	beta	_	_	NN	Protein	0	root	_	_
17	,	_	_	,	O	-1	none	_	_
18	IL-8	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	monocyte	_	_	NN	Protein	27	multitoken	_	_
22	chemoattractant	_	_	NN	Protein	27	multitoken	_	_
23	protein	_	_	NN	Protein	27	multitoken	_	_
24	(	_	_	-LRB-	Protein	27	multitoken	_	_
25	MCP	_	_	NN	Protein	27	multitoken	_	_
26	)	_	_	-RRB-	Protein	27	multitoken	_	_
27	-1	_	_	CD	Protein	0	root	_	_
28	in	_	_	IN	O	-1	none	_	_
29	unfractionated	_	_	JJ	O	-1	none	_	_
30	leukocytes	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	4	_	_	CD	O	-1	none	_	_
3	hours	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	IL-1	_	_	NN	Protein	6	multitoken	_	_
6	beta	_	_	NN	Protein	0	root	_	_
7	and	_	_	CC	O	-1	none	_	_
8	IL-8	_	_	NN	Protein	-1	none	_	_
9	concentration	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	cell-free	_	_	JJ	O	-1	none	_	_
13	supernatant	_	_	NN	O	-1	none	_	_
14	had	_	_	VBD	O	-1	none	_	_
15	increased	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	268	_	_	CD	O	-1	none	_	_
18	+/-	_	_	CC	O	-1	none	_	_
19	36	_	_	CD	O	-1	none	_	_
20	%	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	210	_	_	CD	O	-1	none	_	_
23	+/-	_	_	CC	O	-1	none	_	_
24	7	_	_	CD	O	-1	none	_	_
25	%	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	respectively	_	_	RB	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	cellular	_	_	JJ	O	-1	none	_	_
31	MCP-1	_	_	NN	Protein	-1	none	_	_
32	content	_	_	NN	O	-1	none	_	_
33	had	_	_	VBD	O	-1	none	_	_
34	increased	_	_	VBN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	170	_	_	CD	O	-1	none	_	_
37	+/-	_	_	CC	O	-1	none	_	_
38	8	_	_	CD	O	-1	none	_	_
39	%	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Addition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	platelets	_	_	NNS	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	adherent	_	_	JJ	O	-1	none	_	_
7	monocytes	_	_	NNS	O	-1	none	_	_
8	had	_	_	VBD	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	similar	_	_	JJ	O	-1	none	_	_
11	effect	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	associated	_	_	VBN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	nuclear	_	_	JJ	O	-1	none	_	_
17	factor-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	anti-P	_	_	JJ	Protein	6	multitoken	_	_
6	selectin	_	_	NN	Protein	0	root	_	_
7	antibodies	_	_	NNS	O	-1	none	_	_
8	reduced	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	effect	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	platelets	_	_	NNS	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	cytokine	_	_	NN	O	-1	none	_	_
16	production	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	In	_	_	IN	O	-1	none	_	_
4	patients	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	AMI	_	_	NNP	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	leukocyte-platelet	_	_	JJ	O	-1	none	_	_
9	adhesion	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	increased	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	platelets	_	_	NNS	O	-1	none	_	_
5	induces	_	_	VBZ	O	-1	none	_	_
6	IL-1	_	_	NN	Protein	7	multitoken	_	_
7	beta	_	_	NN	Protein	0	root	_	_
8	,	_	_	,	O	-1	none	_	_
9	IL-8	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	MCP-1	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	leukocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	leukocyte-platelet	_	_	JJ	O	-1	none	_	_
6	adhesion	_	_	NN	O	-1	none	_	_
7	contributes	_	_	VBZ	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	inflammatory	_	_	JJ	O	-1	none	_	_
13	responses	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	AMI	_	_	NNP	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Involvement	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Rel	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	Fos	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	Jun	_	_	NN	Protein	-1	none	_	_
9	proteins	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	promoter	_	_	NN	O	-1	none	_	_
17	CD28	_	_	NN	Protein	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	element/AP	_	_	NN	O	-1	none	_	_
20	-1	_	_	CD	O	-1	none	_	_
21	sequence	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	human	_	_	NN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	CD28	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	important	_	_	JJ	O	-1	none	_	_
5	costimulatory	_	_	JJ	O	-1	none	_	_
6	molecule	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Costimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	through	_	_	IN	O	-1	none	_	_
6	both	_	_	CC	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	Ag	_	_	NN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	CD28	_	_	NN	Protein	-1	none	_	_
12	leads	_	_	VBZ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	high	_	_	JJ	O	-1	none	_	_
15	level	_	_	NN	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	production	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	vital	_	_	JJ	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	development	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	an	_	_	DT	O	-1	none	_	_
27	immune	_	_	JJ	O	-1	none	_	_
28	response	_	_	NN	O	-1	none	_	_
29	in	_	_	FW	O	-1	none	_	_
30	vivo	_	_	FW	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	reports	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	suggested	_	_	VBN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	CD28	_	_	NN	Protein	-1	none	_	_
7	stimulation	_	_	NN	O	-1	none	_	_
8	contributes	_	_	VBZ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	IL-2	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	up-regulating	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	several	_	_	JJ	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	factors	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	including	_	_	VBG	O	-1	none	_	_
26	AP-1	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	nuclear	_	_	JJ	O	-1	none	_	_
29	factor-kappaB	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	NF-kappaB	_	_	NN	O	-1	none	_	_
32	)/Rel	_	_	NN	O	-1	none	_	_
33	family	_	_	NN	O	-1	none	_	_
34	members	_	_	NNS	O	-1	none	_	_
35	as	_	_	RB	O	-1	none	_	_
36	well	_	_	RB	O	-1	none	_	_
37	as	_	_	IN	O	-1	none	_	_
38	an	_	_	DT	O	-1	none	_	_
39	uncharacterized	_	_	JJ	O	-1	none	_	_
40	transcription	_	_	NN	O	-1	none	_	_
41	factor	_	_	NN	O	-1	none	_	_
42	called	_	_	VBN	O	-1	none	_	_
43	CD28	_	_	NN	Protein	-1	none	_	_
44	response	_	_	NN	O	-1	none	_	_
45	complex	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	While	_	_	IN	O	-1	none	_	_
2	several	_	_	JJ	O	-1	none	_	_
3	lines	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	investigation	_	_	NN	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	suggested	_	_	VBN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	NF-kappaB	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Rel	_	_	NN	O	-1	none	_	_
12	family	_	_	NN	O	-1	none	_	_
13	members	_	_	NNS	O	-1	none	_	_
14	make	_	_	VBP	O	-1	none	_	_
15	up	_	_	RP	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	CD28	_	_	NN	Protein	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	complex	_	_	NN	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	other	_	_	JJ	O	-1	none	_	_
24	work	_	_	NN	O	-1	none	_	_
25	has	_	_	VBZ	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	supported	_	_	VBN	O	-1	none	_	_
28	this	_	_	DT	O	-1	none	_	_
29	conclusion	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Recent	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	CD28	_	_	NN	Protein	-1	none	_	_
7	response	_	_	NN	O	-1	none	_	_
8	element	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	CD28RE	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	does	_	_	VBZ	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	function	_	_	VB	O	-1	none	_	_
15	independently	_	_	RB	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	works	_	_	VBZ	O	-1	none	_	_
18	instead	_	_	RB	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	conjunction	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	adjacent	_	_	JJ	O	-1	none	_	_
24	promoter	_	_	NN	O	-1	none	_	_
25	proximal	_	_	JJ	O	-1	none	_	_
26	AP-1-binding	_	_	JJ	O	-1	none	_	_
27	site	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	this	_	_	DT	O	-1	none	_	_
30	hypothesis	_	_	NN	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	confirmed	_	_	VBN	O	-1	none	_	_
33	here	_	_	RB	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Also	_	_	RB	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	current	_	_	JJ	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	CD28RE/AP	_	_	NN	O	-1	none	_	_
12	-1	_	_	CD	O	-1	none	_	_
13	sequence	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	evaluated	_	_	VBN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	four	_	_	CD	O	-1	none	_	_
3	specific	_	_	JJ	O	-1	none	_	_
4	complexes	_	_	NNS	O	-1	none	_	_
5	can	_	_	MD	O	-1	none	_	_
6	be	_	_	VB	O	-1	none	_	_
7	detected	_	_	VBN	O	-1	none	_	_
8	binding	_	_	VBG	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	sequence	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	only	_	_	RB	O	-1	none	_	_
14	one	_	_	CD	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	these	_	_	DT	O	-1	none	_	_
17	complexes	_	_	NNS	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	both	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	CD28RE	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	adjacent	_	_	JJ	O	-1	none	_	_
27	AP-1	_	_	NN	O	-1	none	_	_
28	site	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Of	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	NF-kappaB	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	Rel	_	_	NN	O	-1	none	_	_
6	family	_	_	NN	O	-1	none	_	_
7	members	_	_	NNS	O	-1	none	_	_
8	tested	_	_	VBN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	CD28RE	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	AP-1	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	complex	_	_	NN	O	-1	none	_	_
17	contains	_	_	VBZ	O	-1	none	_	_
18	predominantly	_	_	RB	O	-1	none	_	_
19	c-Rel	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	despite	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	fact	_	_	NN	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	both	_	_	CC	O	-1	none	_	_
26	p50	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	RelA	_	_	NN	Protein	-1	none	_	_
29	can	_	_	MD	O	-1	none	_	_
30	efficiently	_	_	RB	O	-1	none	_	_
31	bind	_	_	VB	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	CD28RE	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	c-Fos	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	c-Jun	_	_	NN	Protein	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	found	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	CD28RE	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	AP-1	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	complex	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	functional	_	_	JJ	O	-1	none	_	_
6	complexes	_	_	NNS	O	-1	none	_	_
7	encompassing	_	_	VBG	O	-1	none	_	_
8	both	_	_	CC	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	CD28RE	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	AP-1-binding	_	_	JJ	O	-1	none	_	_
14	sites	_	_	NNS	O	-1	none	_	_
15	influence	_	_	VBP	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	CD28	_	_	NN	Protein	-1	none	_	_
21	costimulated	_	_	VBN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Synergism	_	_	NN	O	-1	none	_	_
2	between	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	CD3	_	_	NN	O	-1	none	_	_
5	antigen-	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	CD2	_	_	NN	O	-1	none	_	_
8	antigen	_	_	NN	O	-1	none	_	_
9	derived	_	_	VBN	O	-1	none	_	_
10	signals	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Exploration	_	_	NN	O	-1	none	_	_
2	at	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	level	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	induction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	DNA	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	characterization	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	inhibitory	_	_	JJ	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	cyclosporine	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	demonstrated	_	_	VBN	O	-1	none	_	_
4	earlier	_	_	RBR	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	crosslinkage	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	CD3	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	TCR	_	_	NN	O	-1	none	_	_
13	complex	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	CD2	_	_	NN	O	-1	none	_	_
17	antigen	_	_	NN	O	-1	none	_	_
18	results	_	_	VBZ	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	proliferation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	normal	_	_	JJ	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	synergism	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	perceptible	_	_	JJ	O	-1	none	_	_
8	at	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	level	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	process	_	_	NN	O	-1	none	_	_
20	critical	_	_	JJ	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	growth	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	further	_	_	RBR	O	-1	none	_	_
3	understand	_	_	VB	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	molecular	_	_	JJ	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	basis	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	synergism	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	we	_	_	PRP	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	explored	_	_	VBN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	induction	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	DNA	_	_	NN	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	proteins	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	highly	_	_	RB	O	-1	none	_	_
24	purified	_	_	VBN	O	-1	none	_	_
25	normal	_	_	JJ	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	signaled	_	_	VBD	O	-1	none	_	_
30	via	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	CD3	_	_	NN	O	-1	none	_	_
33	and/or	_	_	CC	O	-1	none	_	_
34	CD2	_	_	NN	O	-1	none	_	_
35	proteins	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	transmembrane	_	_	NN	O	-1	none	_	_
5	signaling	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	ionomycin	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and/or	_	_	CC	O	-1	none	_	_
13	sn-1	_	_	NN	O	-1	none	_	_
14	,2	_	_	CD	O	-1	none	_	_
15	dioctanoyl	_	_	NN	O	-1	none	_	_
16	glycerol	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	also	_	_	RB	O	-1	none	_	_
20	determined	_	_	VBN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	emergence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	investigated	_	_	VBN	O	-1	none	_	_
9	using	_	_	VBG	O	-1	none	_	_
10	interleukin-2	_	_	NN	Protein	-1	none	_	_
11	sequence	_	_	NN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	oligonucleotide	_	_	NN	O	-1	none	_	_
14	probes	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	electrophoretic	_	_	JJ	O	-1	none	_	_
18	mobility	_	_	NN	O	-1	none	_	_
19	shift	_	_	NN	O	-1	none	_	_
20	assay	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	first	_	_	JJ	O	-1	none	_	_
7	time	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	CD3	_	_	NN	O	-1	none	_	_
10	antigen	_	_	NN	O	-1	none	_	_
11	derived	_	_	VBN	O	-1	none	_	_
12	signals	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	CD2	_	_	NN	O	-1	none	_	_
15	antigen	_	_	NN	O	-1	none	_	_
16	derived	_	_	VBN	O	-1	none	_	_
17	signals	_	_	NNS	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	synergistic	_	_	JJ	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	inducing	_	_	VBG	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	emergence	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	factors	_	_	NNS	O	-1	none	_	_
27	that	_	_	WDT	O	-1	none	_	_
28	bind	_	_	VBP	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	NF-AT1	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	AP-1	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	NF-kB	_	_	NN	O	-1	none	_	_
37	sites	_	_	NNS	O	-1	none	_	_
38	located	_	_	JJ	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	promoter	_	_	NN	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	enhancer	_	_	NN	O	-1	none	_	_
44	region	_	_	NN	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	the	_	_	DT	O	-1	none	_	_
47	IL-2	_	_	NN	Protein	-1	none	_	_
48	gene	_	_	NN	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	cyclosporine	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	at	_	_	IN	O	-1	none	_	_
6	concentrations	_	_	NNS	O	-1	none	_	_
7	readily	_	_	RB	O	-1	none	_	_
8	accomplished	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	clinical	_	_	JJ	O	-1	none	_	_
11	practice	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	found	_	_	VBN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	inhibit	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	emergence	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	these	_	_	DT	O	-1	none	_	_
21	DNA	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	proteins	_	_	NNS	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	normal	_	_	JJ	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	signaled	_	_	VBD	O	-1	none	_	_
30	via	_	_	IN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	surface	_	_	NN	O	-1	none	_	_
33	proteins	_	_	NNS	O	-1	none	_	_
34	implicated	_	_	VBN	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	antigen	_	_	NN	O	-1	none	_	_
37	dependent	_	_	JJ	O	-1	none	_	_
38	T	_	_	NN	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	activation	_	_	NN	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	T	_	_	NN	O	-1	none	_	_
44	cells	_	_	NNS	O	-1	none	_	_
45	stimulated	_	_	VBN	O	-1	none	_	_
46	by	_	_	IN	O	-1	none	_	_
47	mobilization	_	_	NN	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	cellular	_	_	JJ	O	-1	none	_	_
50	calcium	_	_	NN	O	-1	none	_	_
51	and	_	_	CC	O	-1	none	_	_
52	activation	_	_	NN	O	-1	none	_	_
53	of	_	_	IN	O	-1	none	_	_
54	protein	_	_	NN	O	-1	none	_	_
55	kinase	_	_	NN	O	-1	none	_	_
56	C.	_	_	NN	O	-1	none	_	_

1	Interleukin	_	_	NN	Protein	2	multitoken	_	_
2	10	_	_	CD	Protein	0	root	_	_
3	induced	_	_	VBD	O	-1	none	_	_
4	c-fos	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	divergent	_	_	JJ	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	kinases	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	potent	_	_	JJ	O	-1	none	_	_
5	mediator	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	growth	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	plasma	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	formation	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	signal	_	_	NN	O	-1	none	_	_
4	transduction	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IL-10	_	_	NN	Protein	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	poorly	_	_	RB	O	-1	none	_	_
12	understood	_	_	VBN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effect	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	IL-10	_	_	NN	Protein	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	protooncogene	_	_	NN	O	-1	none	_	_
14	c-fos	_	_	NN	Protein	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	investigated	_	_	VBN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	because	_	_	IN	O	-1	none	_	_
19	Fos	_	_	NN	O	-1	none	_	_
20	plays	_	_	VBZ	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	potential	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	regulation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	cell	_	_	NN	O	-1	none	_	_
30	proliferation	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	differentiation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	B	_	_	NN	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	purified	_	_	VBN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	buffy	_	_	JJ	O	-1	none	_	_
7	coat	_	_	NN	O	-1	none	_	_
8	preparations	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	healthy	_	_	JJ	O	-1	none	_	_
11	blood	_	_	NN	O	-1	none	_	_
12	donors	_	_	NNS	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	positive	_	_	JJ	O	-1	none	_	_
15	selection	_	_	NN	O	-1	none	_	_
16	using	_	_	VBG	O	-1	none	_	_
17	an	_	_	DT	O	-1	none	_	_
18	anti	_	_	JJ	O	-1	none	_	_
19	CD20	_	_	NN	Protein	-1	none	_	_
20	monoclonal	_	_	JJ	O	-1	none	_	_
21	antibody	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	MiniMACS	_	_	NN	O	-1	none	_	_
25	separation	_	_	NN	O	-1	none	_	_
26	unit	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	B	_	_	NN	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	prestimulated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	SAC	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	48	_	_	CD	O	-1	none	_	_
9	hrs	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Then	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	incubated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	medium	_	_	NN	O	-1	none	_	_
8	or	_	_	CC	O	-1	none	_	_
9	IL-10	_	_	NN	Protein	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	100	_	_	CD	O	-1	none	_	_
12	ng/ml	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	10	_	_	CD	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	120	_	_	CD	O	-1	none	_	_
18	min	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	RNA	_	_	NN	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	extracted	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	phenol	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	chloroform	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	c-fos	_	_	NN	Protein	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	analyzed	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	PCR	_	_	NN	O	-1	none	_	_
15	assisted	_	_	JJ	O	-1	none	_	_
16	mRNA	_	_	NN	O	-1	none	_	_
17	assay	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	significant	_	_	JJ	O	-1	none	_	_
3	2-4	_	_	CD	O	-1	none	_	_
4	fold	_	_	JJ	O	-1	none	_	_
5	increase	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	c-fos	_	_	NN	Protein	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	observed	_	_	VBN	O	-1	none	_	_
11	within	_	_	IN	O	-1	none	_	_
12	30	_	_	CD	O	-1	none	_	_
13	min	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	stimulation	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	IL-10	_	_	NN	Protein	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	p	_	_	NN	O	-1	none	_	_
20	<	_	_	JJR	O	-1	none	_	_
21	0.01	_	_	CD	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	2	_	_	CD	O	-1	none	_	_
3	hrs	_	_	NNS	O	-1	none	_	_
4	c-fos	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	declined	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	basal	_	_	JJ	O	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IL-10	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	dose	_	_	NN	O	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	maximum	_	_	NN	O	-1	none	_	_
11	stimulation	_	_	NN	O	-1	none	_	_
12	using	_	_	VBG	O	-1	none	_	_
13	100	_	_	CD	O	-1	none	_	_
14	ng/ml	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	IL-10	_	_	NN	Protein	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IL-10	_	_	NN	Protein	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	on	_	_	IN	O	-1	none	_	_
5	c-fos	_	_	NN	Protein	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	blocked	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	polymyxin	_	_	NN	O	-1	none	_	_
12	B.	_	_	NNP	O	-1	none	_	_
13	Using	_	_	VBG	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	kinase	_	_	NN	O	-1	none	_	_
17	inhibitor	_	_	NN	O	-1	none	_	_
18	genistein	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	10	_	_	CD	O	-1	none	_	_
21	microM	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	complete	_	_	JJ	O	-1	none	_	_
25	inhibition	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	IL-10	_	_	NN	Protein	-1	none	_	_
28	induced	_	_	VBD	O	-1	none	_	_
29	c-fos	_	_	NN	Protein	-1	none	_	_
30	expression	_	_	NN	O	-1	none	_	_
31	was	_	_	VBD	O	-1	none	_	_
32	observed	_	_	VBN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	H-7	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	10	_	_	CD	O	-1	none	_	_
7	microM	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	inhibitor	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	serine/threonine	_	_	NN	O	-1	none	_	_
15	kinases	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	significantly	_	_	RB	O	-1	none	_	_
18	blocked	_	_	VBD	O	-1	none	_	_
19	IL-10	_	_	NN	Protein	-1	none	_	_
20	mediated	_	_	JJ	O	-1	none	_	_
21	c-fos	_	_	NN	Protein	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	p	_	_	NN	O	-1	none	_	_
25	<	_	_	JJR	O	-1	none	_	_
26	0.05	_	_	CD	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	conclusion	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	data	_	_	NNS	O	-1	none	_	_
6	show	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	IL-10	_	_	NN	Protein	-1	none	_	_
9	induces	_	_	VBZ	O	-1	none	_	_
10	c-fos	_	_	NN	Protein	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	B-cells	_	_	NNS	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	tyrosine	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	serine/threonine	_	_	NN	O	-1	none	_	_
21	kinases	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	first	_	_	JJ	O	-1	none	_	_
6	report	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	IL-10	_	_	NN	Protein	-1	none	_	_
9	induced	_	_	VBD	O	-1	none	_	_
10	signal	_	_	NN	O	-1	none	_	_
11	transduction	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	these	_	_	DT	O	-1	none	_	_
14	data	_	_	NNS	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	help	_	_	VB	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	identify	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	intracellular	_	_	JJ	O	-1	none	_	_
21	mechanisms	_	_	NNS	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	which	_	_	WDT	O	-1	none	_	_
24	IL-10	_	_	NN	Protein	-1	none	_	_
25	stimulates	_	_	VBZ	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	B-cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Differential	_	_	JJ	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	4E-BP1	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	4E-BP2	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	two	_	_	CD	O	-1	none	_	_
9	repressors	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	translation	_	_	NN	O	-1	none	_	_
12	initiation	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	during	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	myeloid	_	_	JJ	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	differentiation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	myeloid	_	_	JJ	O	-1	none	_	_
3	differentiation	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	accompanied	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	decrease	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	proliferation	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	translation	_	_	NN	O	-1	none	_	_
4	rate	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	important	_	_	JJ	O	-1	none	_	_
8	determinant	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	proliferation	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	we	_	_	PRP	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	investigated	_	_	VBN	O	-1	none	_	_
16	translation	_	_	NN	O	-1	none	_	_
17	initiation	_	_	NN	O	-1	none	_	_
18	during	_	_	IN	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	myeloid	_	_	JJ	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	differentiation	_	_	NN	O	-1	none	_	_
23	using	_	_	VBG	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	HL-60	_	_	NN	O	-1	none	_	_
26	promyelocytic	_	_	JJ	O	-1	none	_	_
27	leukemia	_	_	NN	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	line	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	U-937	_	_	NN	O	-1	none	_	_
33	monoblastic	_	_	JJ	O	-1	none	_	_
34	cell	_	_	NN	O	-1	none	_	_
35	line	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	decrease	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	translation	_	_	NN	O	-1	none	_	_
6	rate	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	observed	_	_	VBN	O	-1	none	_	_
9	when	_	_	WRB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	differentiate	_	_	VB	O	-1	none	_	_
16	along	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	monocytic	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	macrophage	_	_	NN	O	-1	none	_	_
21	pathway	_	_	NN	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	along	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	granulocytic	_	_	JJ	O	-1	none	_	_
26	pathway	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inhibition	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	synthesis	_	_	NN	O	-1	none	_	_
6	correlates	_	_	VBZ	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	regulation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	two	_	_	CD	O	-1	none	_	_
12	repressors	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	translation	_	_	NN	O	-1	none	_	_
15	initiation	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	4E-BP1	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	4E-BP2	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HL-60	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	U-937	_	_	NN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	differentiation	_	_	NN	O	-1	none	_	_
8	into	_	_	IN	O	-1	none	_	_
9	monocytes	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	macrophages	_	_	NNS	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	IFN-gamma	_	_	NN	Protein	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	PMA	_	_	NN	O	-1	none	_	_
16	results	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	dephosphorylation	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	consequent	_	_	JJ	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	4E-BP1	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Dephosphorylation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	4E-BP1	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	observed	_	_	VBN	O	-1	none	_	_
7	when	_	_	WRB	O	-1	none	_	_
8	U-937	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	induced	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	differentiate	_	_	VB	O	-1	none	_	_
14	into	_	_	IN	O	-1	none	_	_
15	monocytes	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	macrophages	_	_	NNS	O	-1	none	_	_
18	following	_	_	VBG	O	-1	none	_	_
19	treatment	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	retinoic	_	_	JJ	O	-1	none	_	_
22	acid	_	_	NN	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	DMSO	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	HL-60	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	retinoic	_	_	JJ	O	-1	none	_	_
10	acid	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	DMSO	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	results	_	_	VBZ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	granulocytic	_	_	JJ	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	these	_	_	DT	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	decreases	_	_	VBZ	O	-1	none	_	_
25	4E-BP1	_	_	NN	Protein	-1	none	_	_
26	amount	_	_	NN	O	-1	none	_	_
27	without	_	_	IN	O	-1	none	_	_
28	affecting	_	_	VBG	O	-1	none	_	_
29	its	_	_	PRP$	O	-1	none	_	_
30	phosphorylation	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	strongly	_	_	RB	O	-1	none	_	_
33	increases	_	_	VBZ	O	-1	none	_	_
34	4E-BP2	_	_	NN	Protein	-1	none	_	_
35	amount	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	data	_	_	NNS	O	-1	none	_	_
6	provide	_	_	VBP	O	-1	none	_	_
7	evidence	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	differential	_	_	JJ	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	translational	_	_	JJ	O	-1	none	_	_
14	machinery	_	_	NN	O	-1	none	_	_
15	during	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	myeloid	_	_	JJ	O	-1	none	_	_
18	differentiation	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	specific	_	_	JJ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	monocytic	_	_	JJ	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	macrophage	_	_	NN	O	-1	none	_	_
26	pathway	_	_	NN	O	-1	none	_	_
27	or	_	_	CC	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	granulocytic	_	_	JJ	O	-1	none	_	_
31	pathway	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Identification	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	I	_	_	NN	Protein	7	multitoken	_	_
5	kappa	_	_	NN	Protein	7	multitoken	_	_
6	B	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	associated	_	_	VBN	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	kinase	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	monocytic	_	_	JJ	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	line	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	determination	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	its	_	_	PRP$	O	-1	none	_	_
21	phosphorylation	_	_	NN	O	-1	none	_	_
22	sites	_	_	NNS	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	I	_	_	NN	Protein	27	multitoken	_	_
25	kappa	_	_	NN	Protein	27	multitoken	_	_
26	B	_	_	NN	Protein	27	multitoken	_	_
27	alpha	_	_	NN	Protein	0	root	_	_
28	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	stored	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	cytoplasm	_	_	NN	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	inactive	_	_	JJ	O	-1	none	_	_
17	form	_	_	NN	O	-1	none	_	_
18	through	_	_	IN	O	-1	none	_	_
19	interaction	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	I	_	_	NN	O	-1	none	_	_
22	kappa	_	_	NN	O	-1	none	_	_
23	B.	_	_	NNP	O	-1	none	_	_
24	Stimulation	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	leads	_	_	VBZ	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	rapid	_	_	JJ	O	-1	none	_	_
31	phosphorylation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	I	_	_	NN	Protein	36	multitoken	_	_
34	kappa	_	_	NN	Protein	36	multitoken	_	_
35	B	_	_	NN	Protein	36	multitoken	_	_
36	alpha	_	_	NN	Protein	0	root	_	_
37	,	_	_	,	O	-1	none	_	_
38	which	_	_	WDT	O	-1	none	_	_
39	is	_	_	VBZ	O	-1	none	_	_
40	presumed	_	_	VBN	O	-1	none	_	_
41	to	_	_	TO	O	-1	none	_	_
42	be	_	_	VB	O	-1	none	_	_
43	important	_	_	JJ	O	-1	none	_	_
44	for	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	subsequent	_	_	JJ	O	-1	none	_	_
47	degradation	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	recently	_	_	RB	O	-1	none	_	_
4	reported	_	_	VBN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	establishment	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	lipopolysaccharide	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	LPS	_	_	NN	O	-1	none	_	_
12	)-dependent	_	_	JJ	O	-1	none	_	_
13	cell-free	_	_	JJ	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	system	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	association	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	induction	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	I	_	_	NN	Protein	28	multitoken	_	_
26	kappa	_	_	NN	Protein	28	multitoken	_	_
27	B	_	_	NN	Protein	28	multitoken	_	_
28	alpha	_	_	NN	Protein	0	root	_	_
29	phosphorylation	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	identified	_	_	VBN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	kinase	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	extracts	_	_	NNS	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	LPS	_	_	NN	O	-1	none	_	_
16	stimulated	_	_	VBN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	monocytic	_	_	JJ	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	line	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	THP-1	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	that	_	_	WDT	O	-1	none	_	_
25	specifically	_	_	RB	O	-1	none	_	_
26	binds	_	_	VBZ	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	phosphorylates	_	_	VBZ	O	-1	none	_	_
29	I	_	_	NN	Protein	32	multitoken	_	_
30	kappa	_	_	NN	Protein	32	multitoken	_	_
31	B	_	_	NN	Protein	32	multitoken	_	_
32	alpha	_	_	NN	Protein	0	root	_	_
33	.	_	_	.	O	-1	none	_	_

1	LPS	_	_	NN	O	-1	none	_	_
2	stimulation	_	_	NN	O	-1	none	_	_
3	transiently	_	_	RB	O	-1	none	_	_
4	enhanced	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	I	_	_	NN	Protein	9	multitoken	_	_
7	kappa	_	_	NN	Protein	9	multitoken	_	_
8	B	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	bound	_	_	VBD	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	THP-1	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Mutational	_	_	JJ	O	-1	none	_	_
2	analyses	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	I	_	_	NN	Protein	7	multitoken	_	_
5	kappa	_	_	NN	Protein	7	multitoken	_	_
6	B	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	and	_	_	CC	O	-1	none	_	_
9	competition	_	_	NN	O	-1	none	_	_
10	experiments	_	_	NNS	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	synthetic	_	_	JJ	O	-1	none	_	_
14	peptides	_	_	NNS	O	-1	none	_	_
15	identified	_	_	VBD	O	-1	none	_	_
16	major	_	_	JJ	O	-1	none	_	_
17	phosphorylation	_	_	NN	O	-1	none	_	_
18	sites	_	_	NNS	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	bound	_	_	JJ	O	-1	none	_	_
22	kinase	_	_	NN	O	-1	none	_	_
23	as	_	_	IN	O	-1	none	_	_
24	Ser	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	Thr	_	_	NN	O	-1	none	_	_
27	residues	_	_	NNS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	C-terminal	_	_	JJ	O	-1	none	_	_
31	acidic	_	_	JJ	O	-1	none	_	_
32	domain	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	I	_	_	NN	Protein	37	multitoken	_	_
35	kappa	_	_	NN	Protein	37	multitoken	_	_
36	B	_	_	NN	Protein	37	multitoken	_	_
37	alpha	_	_	NN	Protein	0	root	_	_
38	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	peptide	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	corresponding	_	_	VBG	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	C-terminal	_	_	JJ	O	-1	none	_	_
13	acidic	_	_	JJ	O	-1	none	_	_
14	domain	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	I	_	_	NN	Protein	19	multitoken	_	_
17	kappa	_	_	NN	Protein	19	multitoken	_	_
18	B	_	_	NN	Protein	19	multitoken	_	_
19	alpha	_	_	NN	Protein	0	root	_	_
20	,	_	_	,	O	-1	none	_	_
21	blocked	_	_	VBD	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	LPS	_	_	NN	O	-1	none	_	_
24	induced	_	_	VBD	O	-1	none	_	_
25	NF-kappa	_	_	NN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	activation	_	_	NN	O	-1	none	_	_
28	as	_	_	RB	O	-1	none	_	_
29	well	_	_	RB	O	-1	none	_	_
30	as	_	_	IN	O	-1	none	_	_
31	inducible	_	_	JJ	O	-1	none	_	_
32	phosphorylation	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	endogenous	_	_	JJ	O	-1	none	_	_
35	I	_	_	NN	Protein	38	multitoken	_	_
36	kappa	_	_	NN	Protein	38	multitoken	_	_
37	B	_	_	NN	Protein	38	multitoken	_	_
38	alpha	_	_	NN	Protein	0	root	_	_
39	in	_	_	IN	O	-1	none	_	_
40	a	_	_	DT	O	-1	none	_	_
41	cell-free	_	_	JJ	O	-1	none	_	_
42	system	_	_	NN	O	-1	none	_	_
43	using	_	_	VBG	O	-1	none	_	_
44	THP-1	_	_	NN	O	-1	none	_	_
45	cells	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggested	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	bound	_	_	JJ	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	involved	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	signaling	_	_	NN	O	-1	none	_	_
13	pathway	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	LPS	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	inducing	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	phosphorylation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	C-terminal	_	_	JJ	O	-1	none	_	_
23	region	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	I	_	_	NN	Protein	28	multitoken	_	_
26	kappa	_	_	NN	Protein	28	multitoken	_	_
27	B	_	_	NN	Protein	28	multitoken	_	_
28	alpha	_	_	NN	Protein	0	root	_	_
29	and	_	_	CC	O	-1	none	_	_
30	subsequent	_	_	JJ	O	-1	none	_	_
31	dissociation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	NF-kappa	_	_	NN	O	-1	none	_	_
35	B.I	_	_	NN	Protein	38	multitoken	_	_
36	kappa	_	_	NN	Protein	38	multitoken	_	_
37	B	_	_	NN	Protein	38	multitoken	_	_
38	alpha	_	_	NN	Protein	0	root	_	_
39	complex	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	activates	_	_	VBZ	O	-1	none	_	_
6	proenkephalin	_	_	NN	Protein	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	lymphocytes	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Upon	_	_	IN	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	lymphocytes	_	_	NNS	O	-1	none	_	_
6	accumulate	_	_	VBP	O	-1	none	_	_
7	high	_	_	JJ	O	-1	none	_	_
8	levels	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	neuropeptide	_	_	NN	O	-1	none	_	_
12	enkephalin	_	_	NN	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	correlate	_	_	VBP	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	high	_	_	JJ	O	-1	none	_	_
17	levels	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	proenkephalin	_	_	NN	Protein	-1	none	_	_
20	mRNA	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	investigated	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	basis	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	changes	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	proenkephalin	_	_	NN	Protein	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	contains	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	sequence	_	_	NN	O	-1	none	_	_
7	GGGGACGTCCCC	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	named	_	_	VBN	O	-1	none	_	_
10	B2	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	similar	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	sequence	_	_	NN	O	-1	none	_	_
20	GGGGACTTTCC	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	binding	_	_	NN	O	-1	none	_	_
24	site	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factor	_	_	NN	O	-1	none	_	_
29	nuclear	_	_	JJ	O	-1	none	_	_
30	factor	_	_	NN	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	NF	_	_	NN	O	-1	none	_	_
33	)-kappa	_	_	JJ	O	-1	none	_	_
34	B.	_	_	NNP	O	-1	none	_	_
35	Activation	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	T	_	_	NN	O	-1	none	_	_
38	lymphocytes	_	_	NNS	O	-1	none	_	_
39	induces	_	_	VBZ	O	-1	none	_	_
40	an	_	_	DT	O	-1	none	_	_
41	NF-kappa	_	_	NN	O	-1	none	_	_
42	B	_	_	NN	O	-1	none	_	_
43	like	_	_	IN	O	-1	none	_	_
44	binding	_	_	NN	O	-1	none	_	_
45	activity	_	_	NN	O	-1	none	_	_
46	to	_	_	TO	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	B2	_	_	NN	O	-1	none	_	_
49	site	_	_	NN	O	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	concomitant	_	_	JJ	O	-1	none	_	_
52	with	_	_	IN	O	-1	none	_	_
53	activation	_	_	NN	O	-1	none	_	_
54	of	_	_	IN	O	-1	none	_	_
55	the	_	_	DT	O	-1	none	_	_
56	proenkephalin	_	_	NN	Protein	-1	none	_	_
57	promoter	_	_	NN	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	Mutations	_	_	NNS	O	-1	none	_	_
2	at	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	B2	_	_	NN	O	-1	none	_	_
5	site	_	_	NN	O	-1	none	_	_
6	abolish	_	_	VBP	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	transcriptional	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	appears	_	_	VBZ	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	T-cell-specific	_	_	JJ	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	proenkephalin	_	_	NN	Protein	-1	none	_	_
12	promoter	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	mediated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B.	_	_	NNP	O	-1	none	_	_
18	However	_	_	RB	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	as	_	_	IN	O	-1	none	_	_
21	NF-kappa	_	_	NN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	ubiquitous	_	_	JJ	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	transcriptional	_	_	JJ	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	through	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	B2	_	_	NN	O	-1	none	_	_
32	site	_	_	NN	O	-1	none	_	_
33	is	_	_	VBZ	O	-1	none	_	_
34	T	_	_	NN	O	-1	none	_	_
35	cell	_	_	NN	O	-1	none	_	_
36	specific	_	_	JJ	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	yet	_	_	RB	O	-1	none	_	_
39	another	_	_	DT	O	-1	none	_	_
40	T-cell-specific	_	_	JJ	O	-1	none	_	_
41	factor	_	_	NN	O	-1	none	_	_
42	which	_	_	WDT	O	-1	none	_	_
43	synergizes	_	_	VBZ	O	-1	none	_	_
44	with	_	_	IN	O	-1	none	_	_
45	NF-kappa	_	_	NN	O	-1	none	_	_
46	B	_	_	NN	O	-1	none	_	_
47	should	_	_	MD	O	-1	none	_	_
48	be	_	_	VB	O	-1	none	_	_
49	considered	_	_	VBN	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	v-erbA	_	_	NN	Protein	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	required	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	extinguish	_	_	VB	O	-1	none	_	_
7	c-erbA	_	_	NN	Protein	-1	none	_	_
8	function	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	erythroid	_	_	JJ	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	differentiation	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	regulation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	erbA	_	_	NN	O	-1	none	_	_
18	target	_	_	NN	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	CAII	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	v-erbA	_	_	NN	Protein	-1	none	_	_
3	oncoprotein	_	_	NN	O	-1	none	_	_
4	represents	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	retrovirus	_	_	NN	O	-1	none	_	_
7	transduced	_	_	VBN	O	-1	none	_	_
8	oncogenic	_	_	JJ	O	-1	none	_	_
9	version	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	thyroid	_	_	NN	O	-1	none	_	_
13	hormone	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	T3/T4	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	receptor	_	_	NN	O	-1	none	_	_
18	c-erbA	_	_	NN	Protein	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	type	_	_	NN	O	-1	none	_	_
21	alpha	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	contributes	_	_	VBZ	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	erythroleukemia	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	efficiently	_	_	RB	O	-1	none	_	_
9	arresting	_	_	VBG	O	-1	none	_	_
10	differentiation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	red	_	_	JJ	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	progenitors	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	suppressing	_	_	VBG	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	erythrocyte	_	_	NN	O	-1	none	_	_
21	specific	_	_	JJ	O	-1	none	_	_
22	genes	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	v-erbA	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	c-erbA	_	_	NN	Protein	-1	none	_	_
9	bind	_	_	VBP	O	-1	none	_	_
10	directly	_	_	RB	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	sequences	_	_	NNS	O	-1	none	_	_
13	within	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	erythrocyte	_	_	NN	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	carbonic	_	_	JJ	Protein	22	multitoken	_	_
21	anhydrase	_	_	NN	Protein	22	multitoken	_	_
22	II	_	_	CD	Protein	0	root	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	CAII	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	whose	_	_	WP$	O	-1	none	_	_
30	transcription	_	_	NN	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	efficiently	_	_	RB	O	-1	none	_	_
33	suppressed	_	_	VBN	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	v-erbA	_	_	NN	Protein	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	erbA	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	site	_	_	NN	O	-1	none	_	_
5	confers	_	_	VBZ	O	-1	none	_	_
6	thyroid	_	_	NN	O	-1	none	_	_
7	hormone	_	_	NN	O	-1	none	_	_
8	responsiveness	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	heterologous	_	_	JJ	O	-1	none	_	_
12	promoter	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	transient	_	_	JJ	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	experiments	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	target	_	_	NN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	efficient	_	_	JJ	O	-1	none	_	_
23	down-regulation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	CAII	_	_	NN	Protein	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	v-erbA	_	_	NN	Protein	-1	none	_	_
30	oncoprotein	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Likewise	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	T3	_	_	NN	O	-1	none	_	_
4	activated	_	_	VBD	O	-1	none	_	_
5	CAII	_	_	NN	Protein	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	as	_	_	RB	O	-1	none	_	_
8	well	_	_	RB	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	transient	_	_	JJ	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	T3	_	_	NN	O	-1	none	_	_
15	responsive	_	_	JJ	O	-1	none	_	_
16	reporter	_	_	NN	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	containing	_	_	VBG	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	CAII	_	_	NN	Protein	-1	none	_	_
21	specific	_	_	JJ	O	-1	none	_	_
22	erbA	_	_	NN	O	-1	none	_	_
23	binding	_	_	NN	O	-1	none	_	_
24	site	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	overexpression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	v-erbA	_	_	NN	Protein	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	required	_	_	VBN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	its	_	_	PRP$	O	-1	none	_	_
12	function	_	_	NN	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	oncoprotein	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	isotype	_	_	NN	O	-1	none	_	_
3	specific	_	_	JJ	O	-1	none	_	_
4	activator	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	major	_	_	JJ	O	-1	none	_	_
7	histocompatibility	_	_	NN	O	-1	none	_	_
8	complex	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	MHC	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	class	_	_	NN	O	-1	none	_	_
13	II	_	_	CD	O	-1	none	_	_
14	genes	_	_	NNS	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	independent	_	_	JJ	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	class	_	_	NN	Protein	21	multitoken	_	_
20	II	_	_	CD	Protein	21	multitoken	_	_
21	transactivator	_	_	NN	Protein	0	root	_	_
22	.	_	_	.	O	-1	none	_	_

1	Patients	_	_	NNS	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	one	_	_	CD	O	-1	none	_	_
4	type	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	major	_	_	JJ	O	-1	none	_	_
7	histocompatibility	_	_	NN	O	-1	none	_	_
8	complex	_	_	NN	O	-1	none	_	_
9	class	_	_	NN	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	combined	_	_	JJ	O	-1	none	_	_
12	immunodeficiency	_	_	NN	O	-1	none	_	_
13	have	_	_	VBP	O	-1	none	_	_
14	mutations	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	termed	_	_	VBN	O	-1	none	_	_
19	class	_	_	NN	Protein	21	multitoken	_	_
20	II	_	_	CD	Protein	21	multitoken	_	_
21	transactivator	_	_	NN	Protein	0	root	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	CIITA	_	_	NN	Protein	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	which	_	_	WDT	O	-1	none	_	_
27	coordinately	_	_	RB	O	-1	none	_	_
28	controls	_	_	VBZ	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	transcription	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	three	_	_	CD	O	-1	none	_	_
34	major	_	_	JJ	O	-1	none	_	_
35	human	_	_	NN	O	-1	none	_	_
36	class	_	_	NN	O	-1	none	_	_
37	II	_	_	CD	O	-1	none	_	_
38	genes	_	_	NNS	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	HLA-DR	_	_	NN	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	-DQ	_	_	NN	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	-DP	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	experimentally	_	_	RB	O	-1	none	_	_
5	derived	_	_	VBN	O	-1	none	_	_
6	B-lymphoblastoid	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	line	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	clone	_	_	NN	O	-1	none	_	_
11	13	_	_	CD	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	expresses	_	_	VBZ	O	-1	none	_	_
14	high	_	_	JJ	O	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	HLADQ	_	_	NNP	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	absence	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	HLA-DR	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	HLA-DP	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	despite	_	_	IN	O	-1	none	_	_
27	its	_	_	PRP$	O	-1	none	_	_
28	mapping	_	_	NN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	complementation	_	_	NN	O	-1	none	_	_
31	analysis	_	_	NN	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	this	_	_	DT	O	-1	none	_	_
34	group	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	possible	_	_	JJ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	one	_	_	CD	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	clone	_	_	NN	O	-1	none	_	_
9	13	_	_	CD	O	-1	none	_	_
10	CIITA	_	_	NN	Protein	-1	none	_	_
11	alleles	_	_	NNS	O	-1	none	_	_
12	bore	_	_	VBD	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	mutation	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	allowed	_	_	VBD	O	-1	none	_	_
17	HLA-DQ	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	but	_	_	CC	O	-1	none	_	_
20	not	_	_	RB	O	-1	none	_	_
21	HLA-DR	_	_	NN	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	-DP	_	_	NN	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Alternatively	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	another	_	_	DT	O	-1	none	_	_
4	factor	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	distinct	_	_	JJ	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	might	_	_	MD	O	-1	none	_	_
11	control	_	_	VB	O	-1	none	_	_
12	HLA-DQ	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	ectopic	_	_	JJ	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	cDNAs	_	_	NNS	O	-1	none	_	_
10	derived	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	reverse	_	_	JJ	O	-1	none	_	_
13	transcriptase	_	_	NN	O	-1	none	_	_
14	polymerase	_	_	NN	O	-1	none	_	_
15	chain	_	_	NN	O	-1	none	_	_
16	reaction	_	_	NN	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	clone	_	_	NN	O	-1	none	_	_
19	13	_	_	CD	O	-1	none	_	_
20	do	_	_	VBP	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	restore	_	_	VB	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	HLA-DQ	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	another	_	_	DT	O	-1	none	_	_
28	CIITA	_	_	NN	Protein	-1	none	_	_
29	deficient	_	_	JJ	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	line	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	RJ2	_	_	NN	O	-1	none	_	_
34	.2.5	_	_	CD	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	no	_	_	DT	O	-1	none	_	_
5	CIITA	_	_	NN	Protein	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	detectable	_	_	JJ	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	clone	_	_	NN	O	-1	none	_	_
11	13	_	_	CD	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	extracts	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	somatic	_	_	JJ	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	fusion	_	_	NN	O	-1	none	_	_
7	between	_	_	IN	O	-1	none	_	_
8	clone	_	_	NN	O	-1	none	_	_
9	13	_	_	CD	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	RJ2	_	_	NN	O	-1	none	_	_
12	.2.5	_	_	CD	O	-1	none	_	_
13	restored	_	_	VBD	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	HLA-DQ	_	_	NN	O	-1	none	_	_
18	haplotype	_	_	NN	O	-1	none	_	_
19	encoded	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	RJ2	_	_	NN	O	-1	none	_	_
23	.2.5	_	_	CD	O	-1	none	_	_
24	DQB	_	_	NN	O	-1	none	_	_
25	gene	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	data	_	_	NNS	O	-1	none	_	_
6	demonstrate	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	existence	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	HLA-DQ	_	_	NN	O	-1	none	_	_
12	isotype	_	_	NN	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	trans-acting	_	_	JJ	O	-1	none	_	_
15	factor	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	functions	_	_	VBZ	O	-1	none	_	_
19	independently	_	_	RB	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	CIITA	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Sequential	_	_	JJ	O	-1	none	_	_
2	development	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	structural	_	_	JJ	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	functional	_	_	JJ	O	-1	none	_	_
7	alterations	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	tumor	_	_	NN	O	-1	none	_	_
13	bearing	_	_	NN	O	-1	none	_	_
14	mice	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	several	_	_	JJ	O	-1	none	_	_
4	groups	_	_	NNS	O	-1	none	_	_
5	have	_	_	VBP	O	-1	none	_	_
6	described	_	_	VBN	O	-1	none	_	_
7	marked	_	_	JJ	O	-1	none	_	_
8	alterations	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	signal	_	_	NN	O	-1	none	_	_
11	transduction	_	_	NN	O	-1	none	_	_
12	elements	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	cancer	_	_	NN	O	-1	none	_	_
18	patients	_	_	NNS	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	mice	_	_	NNS	O	-1	none	_	_
22	bearing	_	_	VBG	O	-1	none	_	_
23	tumor	_	_	NN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	few	_	_	JJ	O	-1	none	_	_
27	weeks	_	_	NNS	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	>	_	_	JJR	O	-1	none	_	_
30	26	_	_	CD	O	-1	none	_	_
31	days	_	_	NNS	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	sequence	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	which	_	_	WDT	O	-1	none	_	_
5	these	_	_	DT	O	-1	none	_	_
6	alterations	_	_	NNS	O	-1	none	_	_
7	develop	_	_	VBP	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	unknown	_	_	JJ	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	aim	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	explore	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	kinetics	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	development	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	alterations	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	signal	_	_	NN	O	-1	none	_	_
18	transduction	_	_	NN	O	-1	none	_	_
19	molecules	_	_	NNS	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	TCR	_	_	NN	Protein	23	multitoken	_	_
22	zeta	_	_	NN	Protein	23	multitoken	_	_
23	chain	_	_	NN	Protein	0	root	_	_
24	,	_	_	,	O	-1	none	_	_
25	NF	_	_	NN	O	-1	none	_	_
26	kappaB	_	_	NN	O	-1	none	_	_
27	family	_	_	NN	O	-1	none	_	_
28	proteins	_	_	NNS	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	tyrosine	_	_	NN	Protein	36	multitoken	_	_
32	kinase	_	_	NN	Protein	36	multitoken	_	_
33	p56	_	_	NN	Protein	36	multitoken	_	_
34	(	_	_	-LRB-	Protein	36	multitoken	_	_
35	lck	_	_	NN	Protein	36	multitoken	_	_
36	)	_	_	-RRB-	Protein	0	root	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	in	_	_	IN	O	-1	none	_	_
39	mice	_	_	NNS	O	-1	none	_	_
40	bearing	_	_	VBG	O	-1	none	_	_
41	MC38	_	_	NN	O	-1	none	_	_
42	colon	_	_	NN	O	-1	none	_	_
43	adenocarcinoma	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	alterations	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	NF	_	_	NN	O	-1	none	_	_
8	kappaB	_	_	NN	O	-1	none	_	_
9	family	_	_	NN	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	specifically	_	_	RB	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	failure	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	p65	_	_	NN	Protein	-1	none	_	_
17	translocation	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	nucleus	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	occur	_	_	VBP	O	-1	none	_	_
23	earlier	_	_	JJR	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	more	_	_	RBR	O	-1	none	_	_
26	frequently	_	_	RB	O	-1	none	_	_
27	than	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	decrease	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	zeta-chain	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	defects	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	paralleled	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	impaired	_	_	JJ	O	-1	none	_	_
8	ability	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	produce	_	_	VB	O	-1	none	_	_
11	Th1	_	_	NN	O	-1	none	_	_
12	cytokines	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	IL-2	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	IFN-gamma	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	initial	_	_	JJ	O	-1	none	_	_
3	changes	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	followed	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	eventual	_	_	JJ	O	-1	none	_	_
9	loss	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	TCR	_	_	NN	Protein	13	multitoken	_	_
12	zeta	_	_	NN	Protein	13	multitoken	_	_
13	chain	_	_	NN	Protein	0	root	_	_
14	and	_	_	CC	O	-1	none	_	_
15	p56	_	_	NN	Protein	18	multitoken	_	_
16	(	_	_	-LRB-	Protein	18	multitoken	_	_
17	lck	_	_	NN	Protein	18	multitoken	_	_
18	)	_	_	-RRB-	Protein	0	root	_	_
19	and	_	_	CC	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	marked	_	_	JJ	O	-1	none	_	_
22	decrease	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	cytotoxic	_	_	JJ	O	-1	none	_	_
25	function	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	increased	_	_	JJ	O	-1	none	_	_
3	rate	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	lysosomal	_	_	JJ	O	-1	none	_	_
6	degradation	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	one	_	_	CD	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	mechanisms	_	_	NNS	O	-1	none	_	_
12	responsible	_	_	JJ	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	loss	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	zeta-chain	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Abnormal	_	_	JJ	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	lymphocyte	_	_	NN	O	-1	none	_	_
4	development	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	targeted	_	_	VBN	O	-1	none	_	_
8	overexpression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	IkappaB	_	_	NN	Protein	11	multitoken	_	_
11	alpha	_	_	NN	Protein	0	root	_	_
12	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	thymic	_	_	JJ	O	-1	none	_	_
5	maturation	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	factors	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	family	_	_	NN	O	-1	none	_	_
12	has	_	_	VBZ	O	-1	none	_	_
13	long	_	_	RB	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	suspected	_	_	VBN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	but	_	_	CC	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	yet	_	_	RB	O	-1	none	_	_
20	proven	_	_	VBN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Transgenic	_	_	JJ	O	-1	none	_	_
2	mice	_	_	NNS	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	lymphocyte	_	_	NN	O	-1	none	_	_
6	specific	_	_	JJ	O	-1	none	_	_
7	defect	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	NF-kappaB	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	produced	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	targeted	_	_	VBN	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	IkappaB	_	_	NN	Protein	19	multitoken	_	_
19	alpha	_	_	NN	Protein	0	root	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	thymic	_	_	JJ	O	-1	none	_	_
3	cellularity	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	these	_	_	DT	O	-1	none	_	_
6	mice	_	_	NNS	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	significantly	_	_	RB	O	-1	none	_	_
9	decreased	_	_	VBN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	proportion	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	mature	_	_	JJ	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	TCRhigh	_	_	JJ	O	-1	none	_	_
7	thymocytes	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	alphabeta	_	_	NN	O	-1	none	_	_
11	lineage	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	reduced	_	_	VBN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	remaining	_	_	VBG	O	-1	none	_	_
18	TCRhigh	_	_	JJ	O	-1	none	_	_
19	population	_	_	NN	O	-1	none	_	_
20	contained	_	_	VBD	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	unusually	_	_	RB	O	-1	none	_	_
23	high	_	_	JJ	O	-1	none	_	_
24	proportion	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	double	_	_	JJ	O	-1	none	_	_
27	positive	_	_	JJ	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	defect	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	maturation	_	_	NN	O	-1	none	_	_
5	resulted	_	_	VBD	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	transgene	_	_	NN	O	-1	none	_	_
9	dose	_	_	NN	O	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	reduction	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	peripheral	_	_	JJ	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	CD8	_	_	NN	O	-1	none	_	_
20	lineage	_	_	NN	O	-1	none	_	_
21	being	_	_	VBG	O	-1	none	_	_
22	more	_	_	RBR	O	-1	none	_	_
23	severely	_	_	RB	O	-1	none	_	_
24	affected	_	_	VBN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	provide	_	_	VBP	O	-1	none	_	_
4	direct	_	_	JJ	O	-1	none	_	_
5	evidence	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	involvement	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	Rel	_	_	NN	O	-1	none	_	_
13	family	_	_	NN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	late	_	_	JJ	O	-1	none	_	_
17	stages	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	lymphocyte	_	_	NN	O	-1	none	_	_
21	development	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	coincident	_	_	JJ	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	positive	_	_	JJ	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	negative	_	_	JJ	O	-1	none	_	_
28	selection	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	p105	_	_	NN	Protein	-1	none	_	_
4	processing	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	NF-kappaB	_	_	NN	O	-1	none	_	_
7	proteins	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	transiently	_	_	RB	O	-1	none	_	_
10	transfected	_	_	VBN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	NF-kappaB	_	_	NN	O	-1	none	_	_
7	involves	_	_	VBZ	O	-1	none	_	_
8	proteasome	_	_	NN	O	-1	none	_	_
9	mediated	_	_	JJ	O	-1	none	_	_
10	processing	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	NF-kappaB1	_	_	NN	Protein	-1	none	_	_
14	p105	_	_	NN	Protein	-1	none	_	_
15	precursor	_	_	NN	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	generates	_	_	VBZ	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	p50	_	_	NN	Protein	-1	none	_	_
22	subunit	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	NF-kappaB	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	processing	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	p105	_	_	NN	Protein	-1	none	_	_
5	occurs	_	_	VBZ	O	-1	none	_	_
6	constitutively	_	_	RB	O	-1	none	_	_
7	in	_	_	FW	O	-1	none	_	_
8	vivo	_	_	FW	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	be	_	_	VB	O	-1	none	_	_
12	markedly	_	_	RB	O	-1	none	_	_
13	enhanced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	various	_	_	JJ	O	-1	none	_	_
16	cellular	_	_	JJ	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	agents	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	although	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	underlying	_	_	JJ	O	-1	none	_	_
23	regulatory	_	_	JJ	O	-1	none	_	_
24	mechanism	_	_	NN	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	yet	_	_	RB	O	-1	none	_	_
28	clear	_	_	JJ	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	demonstrate	_	_	VBP	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	signal	_	_	NN	O	-1	none	_	_
10	mediated	_	_	JJ	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	p105	_	_	NN	Protein	-1	none	_	_
14	processing	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	associated	_	_	VBN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	de	_	_	FW	O	-1	none	_	_
23	novo	_	_	FW	O	-1	none	_	_
24	synthesis	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	this	_	_	DT	O	-1	none	_	_
27	precursor	_	_	NN	O	-1	none	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	transfection	_	_	NN	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	performed	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	COS7	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	revealed	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	newly	_	_	RB	O	-1	none	_	_
12	synthesized	_	_	VBN	O	-1	none	_	_
13	p105	_	_	NN	Protein	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	appears	_	_	VBZ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	more	_	_	RBR	O	-1	none	_	_
19	rapidly	_	_	RB	O	-1	none	_	_
20	processed	_	_	VBN	O	-1	none	_	_
21	compared	_	_	VBN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	accumulated	_	_	VBN	O	-1	none	_	_
25	form	_	_	NN	O	-1	none	_	_
26	that	_	_	WDT	O	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	already	_	_	RB	O	-1	none	_	_
29	associated	_	_	VBN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	processed	_	_	JJ	O	-1	none	_	_
33	product	_	_	NN	O	-1	none	_	_
34	p50	_	_	NN	Protein	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	processing	_	_	NN	O	-1	none	_	_
5	rate	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	p105	_	_	NN	Protein	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	markedly	_	_	RB	O	-1	none	_	_
10	inhibited	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	co-transfected	_	_	VBN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	p50	_	_	NN	Protein	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	other	_	_	JJ	O	-1	none	_	_
18	NF-kappaB	_	_	NN	O	-1	none	_	_
19	subunits	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	including	_	_	VBG	O	-1	none	_	_
22	RelA	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	c-Rel	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	that	_	_	WDT	O	-1	none	_	_
27	physically	_	_	RB	O	-1	none	_	_
28	interact	_	_	VBP	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	p105	_	_	NN	Protein	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	processing	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	p105	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	subject	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	negative	_	_	JJ	O	-1	none	_	_
13	regulation	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	various	_	_	JJ	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	subunits	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	further	_	_	RB	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	p105	_	_	NN	Protein	-1	none	_	_
6	undergoes	_	_	VBZ	O	-1	none	_	_
7	degradation	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	lipopolysaccharide	_	_	NN	O	-1	none	_	_
10	stimulated	_	_	VBN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	monocytic	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	inducible	_	_	JJ	O	-1	none	_	_
5	degradation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	p105	_	_	NN	Protein	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	coupled	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	generation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	p50	_	_	NN	Protein	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	studies	_	_	NNS	O	-1	none	_	_
5	demonstrate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	processing	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	inducible	_	_	JJ	O	-1	none	_	_
11	degradation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	p105	_	_	NN	Protein	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	differentially	_	_	RB	O	-1	none	_	_
16	regulated	_	_	VBN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Decreased	_	_	VBN	O	-1	none	_	_
2	IL-12	_	_	NN	O	-1	none	_	_
3	production	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	Th1	_	_	NN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	development	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	acetyl	_	_	NN	O	-1	none	_	_
10	salicylic	_	_	JJ	O	-1	none	_	_
11	acid	_	_	NN	O	-1	none	_	_
12	mediated	_	_	VBD	O	-1	none	_	_
13	inhibition	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	NF-kappaB	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	IL-12	_	_	NNP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	75-kDa	_	_	JJ	O	-1	none	_	_
5	heterodimeric	_	_	JJ	O	-1	none	_	_
6	cytokine	_	_	NN	O	-1	none	_	_
7	composed	_	_	VBN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	two	_	_	CD	O	-1	none	_	_
10	covalently	_	_	RB	O	-1	none	_	_
11	linked	_	_	VBN	O	-1	none	_	_
12	p35	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	p40	_	_	NN	Protein	-1	none	_	_
15	chains	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	pro	_	_	JJ	O	-1	none	_	_
3	inflammatory	_	_	JJ	O	-1	none	_	_
4	cytokine	_	_	NN	O	-1	none	_	_
5	plays	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	prominent	_	_	JJ	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	development	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Th1	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	mediated	_	_	JJ	O	-1	none	_	_
16	immune	_	_	JJ	O	-1	none	_	_
17	responses	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Th1	_	_	NN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	mediated	_	_	JJ	O	-1	none	_	_
4	immune	_	_	JJ	O	-1	none	_	_
5	responses	_	_	NNS	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	implicated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	pathogenesis	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	chronic	_	_	JJ	O	-1	none	_	_
14	inflammatory	_	_	JJ	O	-1	none	_	_
15	autoimmune	_	_	JJ	O	-1	none	_	_
16	diseases	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	IL-12	_	_	NN	O	-1	none	_	_
4	appears	_	_	VBZ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	be	_	_	VB	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	critical	_	_	JJ	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	generation	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	maintenance	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	chronic	_	_	JJ	O	-1	none	_	_
17	inflammatory	_	_	JJ	O	-1	none	_	_
18	conditions	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	investigated	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	effects	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	commonly	_	_	RB	O	-1	none	_	_
12	prescribed	_	_	VBN	O	-1	none	_	_
13	anti-inflammatory	_	_	JJ	O	-1	none	_	_
14	drug	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	acetyl	_	_	NN	O	-1	none	_	_
17	salicylic	_	_	JJ	O	-1	none	_	_
18	acid	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	ASA	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	IL-12	_	_	NN	O	-1	none	_	_
25	production	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	Th1	_	_	NN	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	development	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	ASA	_	_	NN	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	found	_	_	VBN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	inhibit	_	_	VB	O	-1	none	_	_
6	secretion	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	IL-12	_	_	NN	O	-1	none	_	_
10	heterodimer	_	_	NN	O	-1	none	_	_
11	as	_	_	RB	O	-1	none	_	_
12	well	_	_	RB	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	p40	_	_	NN	Protein	-1	none	_	_
15	monomer	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	monocytic	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	associated	_	_	VBN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	down-regulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IL-12p40	_	_	NN	Protein	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Addition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	ASA	_	_	NN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	in	_	_	FW	O	-1	none	_	_
7	vitro	_	_	FW	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	helper	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	differentiation	_	_	NN	O	-1	none	_	_
12	system	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	at	_	_	IN	O	-1	none	_	_
15	concentrations	_	_	NNS	O	-1	none	_	_
16	compatible	_	_	JJ	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	plasma	_	_	NN	O	-1	none	_	_
19	levels	_	_	NNS	O	-1	none	_	_
20	reached	_	_	VBN	O	-1	none	_	_
21	during	_	_	IN	O	-1	none	_	_
22	anti-inflammatory	_	_	JJ	O	-1	none	_	_
23	therapy	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	resulted	_	_	VBD	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	reduced	_	_	VBN	O	-1	none	_	_
28	development	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	Th1	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	inhibition	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	NF-kappaB	_	_	NN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	ASA	_	_	NN	O	-1	none	_	_
12	leads	_	_	VBZ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	down-regulation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	IL-12	_	_	NN	O	-1	none	_	_
17	production	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	inhibition	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	Th1	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	development	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Involvement	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	adenylate	_	_	NN	O	-1	none	_	_
4	cyclase	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	p70	_	_	NN	Protein	9	multitoken	_	_
7	(	_	_	-LRB-	Protein	9	multitoken	_	_
8	S6	_	_	NN	Protein	9	multitoken	_	_
9	)-kinase	_	_	NN	Protein	0	root	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	IL-10	_	_	NN	Protein	-1	none	_	_
13	up-regulation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	monocytes	_	_	NNS	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	gp41	_	_	NN	Protein	-1	none	_	_
19	envelope	_	_	NN	O	-1	none	_	_
20	protein	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	immunodeficiency	_	_	NN	O	-1	none	_	_
24	virus	_	_	NN	O	-1	none	_	_
25	type	_	_	NN	O	-1	none	_	_
26	1	_	_	CD	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	previous	_	_	JJ	O	-1	none	_	_
3	results	_	_	NNS	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	recombinant	_	_	JJ	O	-1	none	_	_
7	gp41	_	_	NN	Protein	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	aa565-647	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	extracellular	_	_	JJ	O	-1	none	_	_
14	domain	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	HIV-1	_	_	NN	O	-1	none	_	_
17	transmembrane	_	_	NN	O	-1	none	_	_
18	glycoprotein	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	stimulates	_	_	VBZ	O	-1	none	_	_
21	interleukin-10	_	_	NN	Protein	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	IL-10	_	_	NN	Protein	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	production	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	human	_	_	NN	O	-1	none	_	_
28	monocytes	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	signal	_	_	NN	O	-1	none	_	_
3	cascade	_	_	NN	O	-1	none	_	_
4	transducing	_	_	VBG	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	effect	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	yet	_	_	RB	O	-1	none	_	_
10	clear	_	_	JJ	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	examined	_	_	VBD	O	-1	none	_	_
7	whether	_	_	IN	O	-1	none	_	_
8	gp41	_	_	NN	Protein	-1	none	_	_
9	induced	_	_	VBD	O	-1	none	_	_
10	IL-10	_	_	NN	Protein	-1	none	_	_
11	up-regulation	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	previously	_	_	RB	O	-1	none	_	_
17	described	_	_	VBN	O	-1	none	_	_
18	synergistic	_	_	JJ	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	cAMP	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	NF-kappaB	_	_	NN	O	-1	none	_	_
24	pathways	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	gp41	_	_	NN	Protein	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	cAMP	_	_	NN	O	-1	none	_	_
4	accumulation	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	monocytes	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	time-	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	concentration	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	manner	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	adenylate	_	_	NN	O	-1	none	_	_
17	cyclase	_	_	NN	O	-1	none	_	_
18	inhibitor	_	_	NN	O	-1	none	_	_
19	SQ	_	_	NN	O	-1	none	_	_
20	22536	_	_	CD	O	-1	none	_	_
21	suppressed	_	_	VBD	O	-1	none	_	_
22	gp41	_	_	NN	Protein	-1	none	_	_
23	induced	_	_	VBD	O	-1	none	_	_
24	IL-10	_	_	NN	Protein	-1	none	_	_
25	production	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	monocytes	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	gp41	_	_	NN	Protein	-1	none	_	_
5	failed	_	_	VBD	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	stimulate	_	_	VB	O	-1	none	_	_
8	NF-kappaB	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	activity	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	as	_	_	RB	O	-1	none	_	_
13	much	_	_	JJ	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	no	_	_	DT	O	-1	none	_	_
16	NF-kappaB	_	_	NN	O	-1	none	_	_
17	bound	_	_	VBD	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	main	_	_	JJ	O	-1	none	_	_
21	NF-kappaB-binding	_	_	JJ	O	-1	none	_	_
22	site	_	_	NN	O	-1	none	_	_
23	2	_	_	CD	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	IL-10	_	_	NN	Protein	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	after	_	_	IN	O	-1	none	_	_
29	addition	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	gp41	_	_	NN	Protein	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	examined	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	involvement	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	other	_	_	JJ	O	-1	none	_	_
8	signal	_	_	NN	O	-1	none	_	_
9	transduction	_	_	NN	O	-1	none	_	_
10	pathways	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Specific	_	_	JJ	O	-1	none	_	_
2	inhibitors	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	p70	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	S6	_	_	NN	O	-1	none	_	_
7	)-kinase	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	rapamycin	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Gi	_	_	NN	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	pertussis	_	_	NN	O	-1	none	_	_
17	toxin	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	prevented	_	_	VBD	O	-1	none	_	_
21	induction	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	IL-10	_	_	NN	Protein	-1	none	_	_
24	production	_	_	NN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	gp41	_	_	NN	Protein	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	monocytes	_	_	NNS	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	while	_	_	IN	O	-1	none	_	_
31	inhibitors	_	_	NNS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	phosphatidylinositol	_	_	NN	O	-1	none	_	_
35	3-kinase	_	_	NN	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	PI	_	_	NN	O	-1	none	_	_
38	3-kinase	_	_	NN	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	wortmannin	_	_	NN	O	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	mitogen	_	_	NN	O	-1	none	_	_
45	activated	_	_	JJ	O	-1	none	_	_
46	protein	_	_	NN	O	-1	none	_	_
47	kinase	_	_	NN	O	-1	none	_	_
48	(	_	_	-LRB-	O	-1	none	_	_
49	MAPK	_	_	NN	O	-1	none	_	_
50	)	_	_	-RRB-	O	-1	none	_	_
51	pathway	_	_	NN	O	-1	none	_	_
52	(	_	_	-LRB-	O	-1	none	_	_
53	PD	_	_	NN	O	-1	none	_	_
54	98059	_	_	CD	O	-1	none	_	_
55	)	_	_	-RRB-	O	-1	none	_	_
56	did	_	_	VBD	O	-1	none	_	_
57	not	_	_	RB	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	HIV-1	_	_	NN	O	-1	none	_	_
3	gp41	_	_	NN	Protein	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	IL-10	_	_	NN	Protein	-1	none	_	_
6	up-regulation	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	monocytes	_	_	NNS	O	-1	none	_	_
9	may	_	_	MD	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	involve	_	_	VB	O	-1	none	_	_
12	NF-kappaB	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	MAPK	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	PI	_	_	NN	O	-1	none	_	_
18	3-kinase	_	_	NN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	rather	_	_	RB	O	-1	none	_	_
23	may	_	_	MD	O	-1	none	_	_
24	operate	_	_	VB	O	-1	none	_	_
25	through	_	_	IN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	adenylate	_	_	NN	O	-1	none	_	_
29	cyclase	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	pertussis-toxin-sensitive	_	_	JJ	O	-1	none	_	_
32	Gi/Go	_	_	NN	O	-1	none	_	_
33	protein	_	_	NN	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	effect	_	_	NN	O	-1	none	_	_
36	p70	_	_	NN	O	-1	none	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	S6	_	_	NN	O	-1	none	_	_
39	)-kinase	_	_	NN	O	-1	none	_	_
40	activation	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Yet	_	_	RB	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	same	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	do	_	_	VBP	O	-1	none	_	_
6	initiate	_	_	VB	O	-1	none	_	_
7	early	_	_	RB	O	-1	none	_	_
8	TCR	_	_	NN	O	-1	none	_	_
9	mediated	_	_	JJ	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	events	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	such	_	_	JJ	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	generation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	inositol	_	_	NN	O	-1	none	_	_
18	phosphates	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	increased	_	_	VBN	O	-1	none	_	_
21	intracellular	_	_	JJ	O	-1	none	_	_
22	calcium	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	They	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	display	_	_	VBP	O	-1	none	_	_
4	constitutively	_	_	RB	O	-1	none	_	_
5	high	_	_	JJ	O	-1	none	_	_
6	levels	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	p59fyn	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CD3	_	_	NN	Protein	11	multitoken	_	_
11	zeta	_	_	NN	Protein	0	root	_	_
12	tyrosine	_	_	NN	O	-1	none	_	_
13	phosphorylation	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	generation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	second	_	_	JJ	O	-1	none	_	_
5	messengers	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	normally	_	_	RB	O	-1	none	_	_
10	leads	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	downstream	_	_	JJ	O	-1	none	_	_
13	signaling	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	results	_	_	VBZ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	transcriptional	_	_	JJ	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	therefore	_	_	RB	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	compared	_	_	VBN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	state	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	IL-2	_	_	NN	Protein	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	promoter	_	_	NN	O	-1	none	_	_
14	region	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	freshly	_	_	RB	O	-1	none	_	_
17	isolated	_	_	VBN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	stimulated	_	_	VBN	O	-1	none	_	_
20	Ipr	_	_	NNP	O	-1	none	_	_
21	CD4-8-	_	_	JJ	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	that	_	_	DT	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	normal	_	_	JJ	O	-1	none	_	_
28	T	_	_	NN	O	-1	none	_	_
29	lymphocytes	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Levels	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	octamer	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	p50	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p65	_	_	NN	Protein	-1	none	_	_
12	heterodimer	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	AP-1	_	_	NN	O	-1	none	_	_
17	transcriptional	_	_	JJ	O	-1	none	_	_
18	factors	_	_	NNS	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	constitutively	_	_	RB	O	-1	none	_	_
21	elevated	_	_	JJ	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	freshly	_	_	RB	O	-1	none	_	_
24	isolated	_	_	VBN	O	-1	none	_	_
25	Ipr	_	_	NNP	O	-1	none	_	_
26	CD4-8-	_	_	JJ	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	consistent	_	_	JJ	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	activated	_	_	JJ	O	-1	none	_	_
34	phenotype	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	these	_	_	DT	O	-1	none	_	_
37	cells	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Upon	_	_	IN	O	-1	none	_	_
2	stimulation	_	_	NN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	mitogens	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	formation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	transactivating	_	_	VBG	O	-1	none	_	_
10	complex	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	activated	_	_	VBN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	NF-AT	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	occurs	_	_	VBZ	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	normal	_	_	JJ	O	-1	none	_	_
25	kinetics	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	Ipr	_	_	NNP	O	-1	none	_	_
28	CD4-8-	_	_	JJ	O	-1	none	_	_
29	T	_	_	NN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Yet	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	levels	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	activating	_	_	VBG	O	-1	none	_	_
8	NF-AT	_	_	NN	O	-1	none	_	_
9	complex	_	_	NN	O	-1	none	_	_
10	never	_	_	RB	O	-1	none	_	_
11	reach	_	_	VBP	O	-1	none	_	_
12	those	_	_	DT	O	-1	none	_	_
13	observed	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	similarly	_	_	RB	O	-1	none	_	_
16	stimulated	_	_	VBN	O	-1	none	_	_
17	normal	_	_	JJ	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	extracts	_	_	NNS	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	Ipr	_	_	NNP	O	-1	none	_	_
7	CD4-8-	_	_	JJ	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	display	_	_	VBP	O	-1	none	_	_
11	high	_	_	JJ	O	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	novel	_	_	JJ	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	at	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	NF-AT	_	_	NN	O	-1	none	_	_
22	site	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	which	_	_	WDT	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	present	_	_	JJ	O	-1	none	_	_
27	at	_	_	IN	O	-1	none	_	_
28	much	_	_	RB	O	-1	none	_	_
29	lower	_	_	JJR	O	-1	none	_	_
30	levels	_	_	NNS	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	freshly	_	_	RB	O	-1	none	_	_
33	isolated	_	_	VBN	O	-1	none	_	_
34	normal	_	_	JJ	O	-1	none	_	_
35	T	_	_	NN	O	-1	none	_	_
36	lymphocytes	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Upon	_	_	IN	O	-1	none	_	_
2	mitogenic	_	_	JJ	O	-1	none	_	_
3	stimulation	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	novel	_	_	JJ	O	-1	none	_	_
11	NF-AT-binding	_	_	JJ	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	rapidly	_	_	RB	O	-1	none	_	_
15	down-regulated	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	normal	_	_	JJ	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	persists	_	_	VBZ	O	-1	none	_	_
23	at	_	_	IN	O	-1	none	_	_
24	high	_	_	JJ	O	-1	none	_	_
25	levels	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	Ipr	_	_	NNP	O	-1	none	_	_
28	CD4-8-	_	_	JJ	O	-1	none	_	_
29	T	_	_	NN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	two	_	_	CD	O	-1	none	_	_
3	abnormalities	_	_	NNS	O	-1	none	_	_
4	at	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	NF-AT	_	_	NN	O	-1	none	_	_
7	site	_	_	NN	O	-1	none	_	_
8	provide	_	_	VBP	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	potential	_	_	JJ	O	-1	none	_	_
11	mechanism	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	account	_	_	VB	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	defect	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	IL-2	_	_	NN	Protein	-1	none	_	_
19	production	_	_	NN	O	-1	none	_	_
20	from	_	_	IN	O	-1	none	_	_
21	Ipr	_	_	NNP	O	-1	none	_	_
22	CD4-8-	_	_	JJ	O	-1	none	_	_
23	T	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Vitamin	_	_	NN	O	-1	none	_	_
2	D3-	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	retinoic	_	_	JJ	O	-1	none	_	_
5	acid	_	_	NN	O	-1	none	_	_
6	induced	_	_	VBD	O	-1	none	_	_
7	monocytic	_	_	JJ	O	-1	none	_	_
8	differentiation	_	_	NN	O	-1	none	_	_
9	:	_	_	:	O	-1	none	_	_
10	interactions	_	_	NNS	O	-1	none	_	_
11	between	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	endogenous	_	_	JJ	O	-1	none	_	_
14	vitamin	_	_	NN	Protein	16	multitoken	_	_
15	D3	_	_	NN	Protein	16	multitoken	_	_
16	receptor	_	_	NN	Protein	0	root	_	_
17	,	_	_	,	O	-1	none	_	_
18	retinoic	_	_	JJ	O	-1	none	_	_
19	acid	_	_	NN	O	-1	none	_	_
20	receptors	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	retinoid	_	_	NN	O	-1	none	_	_
24	X	_	_	NN	O	-1	none	_	_
25	receptors	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	U-937	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Retinoic	_	_	JJ	O	-1	none	_	_
2	acid	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	RA	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	1,25	_	_	CD	O	-1	none	_	_
8	alpha-dihydroxycholecalciferol	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	VitD3	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	potent	_	_	JJ	O	-1	none	_	_
14	regulators	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	hematopoletic	_	_	JJ	O	-1	none	_	_
17	differentiation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Yet	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	little	_	_	JJ	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	known	_	_	VBN	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	how	_	_	WRB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	RA	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	VitD3	_	_	NN	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	network	_	_	NN	O	-1	none	_	_
15	operates	_	_	VBZ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	hematopoietic	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	whether	_	_	IN	O	-1	none	_	_
22	receptor	_	_	NN	O	-1	none	_	_
23	interactions	_	_	NNS	O	-1	none	_	_
24	can	_	_	MD	O	-1	none	_	_
25	explain	_	_	VB	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	interplay	_	_	NN	O	-1	none	_	_
28	between	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	RA-	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	VitD3	_	_	NN	O	-1	none	_	_
33	signaling	_	_	NN	O	-1	none	_	_
34	pathways	_	_	NNS	O	-1	none	_	_
35	during	_	_	IN	O	-1	none	_	_
36	differentiation	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	analyzed	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	DNA	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	transcriptional	_	_	JJ	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	endogenous	_	_	JJ	O	-1	none	_	_
17	RA	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	VitD3	_	_	NN	O	-1	none	_	_
20	receptors	_	_	NNS	O	-1	none	_	_
21	[	_	_	VBP	O	-1	none	_	_
22	retinoic	_	_	JJ	O	-1	none	_	_
23	acid	_	_	NN	O	-1	none	_	_
24	receptors	_	_	NNS	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	RARs	_	_	NNS	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	retinoid	_	_	NN	O	-1	none	_	_
30	X	_	_	NN	O	-1	none	_	_
31	receptors	_	_	NNS	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	RXRs	_	_	NNS	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	VitD3	_	_	NN	Protein	38	multitoken	_	_
38	receptor	_	_	NN	Protein	0	root	_	_
39	(	_	_	-LRB-	O	-1	none	_	_
40	VDR	_	_	NN	Protein	-1	none	_	_
41	)	_	_	-RRB-	O	-1	none	_	_
42	]	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	U-937	_	_	NN	O	-1	none	_	_
46	cell	_	_	NN	O	-1	none	_	_
47	line	_	_	NN	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	in	_	_	IN	O	-1	none	_	_
50	which	_	_	WDT	O	-1	none	_	_
51	RA	_	_	NN	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	VitD3	_	_	NN	O	-1	none	_	_
54	induce	_	_	VBP	O	-1	none	_	_
55	distinct	_	_	JJ	O	-1	none	_	_
56	monocytic	_	_	JJ	O	-1	none	_	_
57	differentiation	_	_	NN	O	-1	none	_	_
58	pathways	_	_	NNS	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	VitD3	_	_	NN	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	resulted	_	_	VBD	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	formation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	VDR	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	RXR	_	_	NN	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	complexes	_	_	NNS	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	both	_	_	DT	O	-1	none	_	_
16	VitD3	_	_	NN	O	-1	none	_	_
17	response	_	_	NN	O	-1	none	_	_
18	elements	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	RA	_	_	NN	O	-1	none	_	_
21	response	_	_	NN	O	-1	none	_	_
22	elements	_	_	NNS	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	RAREs	_	_	NNS	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	transcriptional	_	_	JJ	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	only	_	_	RB	O	-1	none	_	_
7	observed	_	_	VBN	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	VitD3	_	_	NN	O	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	element	_	_	NN	O	-1	none	_	_
13	driven	_	_	VBN	O	-1	none	_	_
14	reporter	_	_	NN	O	-1	none	_	_
15	construct	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	DNA	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	complexes	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	detected	_	_	VBN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	RAREs	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	undifferentiated	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Stimulation	_	_	NN	O	-1	none	_	_
2	by	_	_	IN	O	-1	none	_	_
3	RA	_	_	NN	O	-1	none	_	_
4	resulted	_	_	VBD	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	increased	_	_	VBN	O	-1	none	_	_
7	RAR	_	_	NN	Protein	8	multitoken	_	_
8	beta	_	_	NN	Protein	0	root	_	_
9	and	_	_	CC	O	-1	none	_	_
10	RXR	_	_	NN	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	activated	_	_	VBN	O	-1	none	_	_
15	RARE	_	_	NN	O	-1	none	_	_
16	dependent	_	_	JJ	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	increased	_	_	VBD	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	RAR-beta	_	_	NN	Protein	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Concomitant	_	_	JJ	O	-1	none	_	_
2	stimulation	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	VitD3	_	_	NN	O	-1	none	_	_
5	inhibited	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	RA	_	_	NN	O	-1	none	_	_
8	stimulated	_	_	VBD	O	-1	none	_	_
9	formation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	RAR	_	_	NN	Protein	12	multitoken	_	_
12	beta	_	_	NN	Protein	0	root	_	_
13	and	_	_	CC	O	-1	none	_	_
14	RXR	_	_	NN	O	-1	none	_	_
15	heterodimers	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	favoring	_	_	VBG	O	-1	none	_	_
18	VDR	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	RXR	_	_	NN	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	RARE	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Also	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	VitD3	_	_	NN	O	-1	none	_	_
4	inhibited	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	CD23	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CD49f	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	characteristic	_	_	JJ	O	-1	none	_	_
13	markers	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	retinoid	_	_	NN	O	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	U-937	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	neither	_	_	CC	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	RA	_	_	NN	O	-1	none	_	_
7	stimulated	_	_	VBD	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	RARE	_	_	NN	O	-1	none	_	_
10	mediated	_	_	VBD	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	nor	_	_	CC	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	induced	_	_	JJ	O	-1	none	_	_
15	RAR-beta	_	_	NN	Protein	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	suppressed	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	VitD3	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	suggesting	_	_	VBG	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	VitD3	_	_	NN	O	-1	none	_	_
25	selectively	_	_	RB	O	-1	none	_	_
26	inhibited	_	_	VBD	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	retinoid	_	_	NN	O	-1	none	_	_
29	induced	_	_	VBD	O	-1	none	_	_
30	differentiation	_	_	NN	O	-1	none	_	_
31	program	_	_	NN	O	-1	none	_	_
32	but	_	_	CC	O	-1	none	_	_
33	not	_	_	RB	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	RARE	_	_	NN	O	-1	none	_	_
36	mediated	_	_	JJ	O	-1	none	_	_
37	signal	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	complex	_	_	JJ	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	VitD3	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	modifying	_	_	VBG	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	retinoid	_	_	NN	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	pathway	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	may	_	_	MD	O	-1	none	_	_
17	have	_	_	VB	O	-1	none	_	_
18	implications	_	_	NNS	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	differentiation	_	_	NN	O	-1	none	_	_
21	inducing	_	_	VBG	O	-1	none	_	_
22	therapy	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	hematopoietic	_	_	JJ	O	-1	none	_	_
25	tumors	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	TNFalpha	_	_	NN	Protein	-1	none	_	_
2	cooperates	_	_	VBZ	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	kinase	_	_	NN	O	-1	none	_	_
7	A	_	_	NN	O	-1	none	_	_
8	pathway	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	synergistically	_	_	RB	O	-1	none	_	_
11	increase	_	_	VB	O	-1	none	_	_
12	HIV-1	_	_	NN	O	-1	none	_	_
13	LTR	_	_	NN	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	via	_	_	IN	O	-1	none	_	_
16	downstream	_	_	JJ	O	-1	none	_	_
17	TRE	_	_	NN	O	-1	none	_	_
18	like	_	_	IN	O	-1	none	_	_
19	cAMP	_	_	NN	O	-1	none	_	_
20	response	_	_	NN	O	-1	none	_	_
21	elements	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Activating	_	_	VBG	O	-1	none	_	_
2	protein-1	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	AP-1	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	TPA	_	_	NN	O	-1	none	_	_
8	responsive	_	_	JJ	O	-1	none	_	_
9	elements	_	_	NNS	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	TRE	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	located	_	_	JJ	O	-1	none	_	_
15	downstream	_	_	RB	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	initiation	_	_	NN	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	U5	_	_	NN	O	-1	none	_	_
24	region	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	HIV-1	_	_	NN	O	-1	none	_	_
28	long	_	_	JJ	O	-1	none	_	_
29	terminal	_	_	JJ	O	-1	none	_	_
30	repeat	_	_	NN	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	LTR	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	downstream	_	_	JJ	O	-1	none	_	_
3	sequence	_	_	NN	O	-1	none	_	_
4	elements	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	termed	_	_	VBN	O	-1	none	_	_
7	DSE	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	can	_	_	MD	O	-1	none	_	_
10	bind	_	_	VB	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	AP-1	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	CREB	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	ATF	_	_	NN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factors	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrated	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	DSE	_	_	NN	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	cAMP	_	_	NN	O	-1	none	_	_
11	responsive	_	_	JJ	O	-1	none	_	_
12	elements	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	CRE	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	since	_	_	IN	O	-1	none	_	_
18	they	_	_	PRP	O	-1	none	_	_
19	mediated	_	_	VBD	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	signals	_	_	NNS	O	-1	none	_	_
22	elicited	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	cholera	_	_	NN	O	-1	none	_	_
25	toxin	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	Ctx	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	a	_	_	DT	O	-1	none	_	_
31	potent	_	_	JJ	O	-1	none	_	_
32	activator	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	cAMP	_	_	NN	O	-1	none	_	_
36	dependent	_	_	JJ	O	-1	none	_	_
37	protein	_	_	NN	O	-1	none	_	_
38	kinase	_	_	NN	O	-1	none	_	_
39	A	_	_	NN	O	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	PKA	_	_	NN	O	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	signal	_	_	NN	O	-1	none	_	_
44	transduction	_	_	NN	O	-1	none	_	_
45	pathway	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	demonstrate	_	_	VBP	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	HIV-1	_	_	NN	O	-1	none	_	_
11	DSE	_	_	NN	O	-1	none	_	_
12	can	_	_	MD	O	-1	none	_	_
13	mediate	_	_	VB	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	transcriptional	_	_	JJ	O	-1	none	_	_
16	synergy	_	_	NN	O	-1	none	_	_
17	elicited	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	combination	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	Ctx	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	TNFalpha	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Ctx	_	_	NN	O	-1	none	_	_
2	combined	_	_	VBN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	TNFalpha	_	_	NN	Protein	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	IL-1beta	_	_	NN	Protein	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	produce	_	_	VB	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	synergistic	_	_	JJ	O	-1	none	_	_
11	increase	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	p24	_	_	NN	Protein	14	multitoken	_	_
14	antigen	_	_	NN	Protein	0	root	_	_
15	production	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	U1	_	_	NN	O	-1	none	_	_
18	promonocytic	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Transfection	_	_	NN	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	LTR	_	_	NN	O	-1	none	_	_
5	reporter	_	_	NN	O	-1	none	_	_
6	constructs	_	_	NNS	O	-1	none	_	_
7	indicated	_	_	VBD	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	mutation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	DSE	_	_	NN	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	abrogated	_	_	VBD	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	LTR	_	_	NN	O	-1	none	_	_
17	mediated	_	_	VBD	O	-1	none	_	_
18	synergy	_	_	NN	O	-1	none	_	_
19	induced	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	Ctx	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	TNFalpha	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	whereas	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	synergy	_	_	NN	O	-1	none	_	_
28	induced	_	_	VBN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	Ctx	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	IL-1beta	_	_	NN	Protein	-1	none	_	_
33	was	_	_	VBD	O	-1	none	_	_
34	unaffected	_	_	JJ	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	suggesting	_	_	VBG	O	-1	none	_	_
37	TNFalpha	_	_	NN	Protein	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	IL-1beta	_	_	NN	Protein	-1	none	_	_
40	cooperate	_	_	VBP	O	-1	none	_	_
41	differently	_	_	RB	O	-1	none	_	_
42	with	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	cAMP	_	_	NN	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	PKA	_	_	NN	O	-1	none	_	_
47	activation	_	_	NN	O	-1	none	_	_
48	pathway	_	_	NN	O	-1	none	_	_
49	to	_	_	TO	O	-1	none	_	_
50	induce	_	_	VB	O	-1	none	_	_
51	HIV-1	_	_	NN	O	-1	none	_	_
52	expression	_	_	NN	O	-1	none	_	_
53	in	_	_	IN	O	-1	none	_	_
54	U1	_	_	NN	O	-1	none	_	_
55	cells	_	_	NNS	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	DSE	_	_	NN	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	TRE	_	_	NN	O	-1	none	_	_
7	sites	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	we	_	_	PRP	O	-1	none	_	_
10	assessed	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	effect	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	agonist	_	_	NN	O	-1	none	_	_
16	combinations	_	_	NNS	O	-1	none	_	_
17	on	_	_	IN	O	-1	none	_	_
18	AP-1-dependent	_	_	JJ	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	TNFalpha	_	_	NN	Protein	-1	none	_	_
2	as	_	_	RB	O	-1	none	_	_
3	well	_	_	RB	O	-1	none	_	_
4	as	_	_	IN	O	-1	none	_	_
5	IL-1beta	_	_	NN	Protein	-1	none	_	_
6	cooperated	_	_	VBD	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	Ctx	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	produce	_	_	VB	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	synergistic	_	_	JJ	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	AP-1-mediated	_	_	JJ	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	TRE	_	_	NN	O	-1	none	_	_
7	like	_	_	IN	O	-1	none	_	_
8	cAMP	_	_	NN	O	-1	none	_	_
9	responsive	_	_	JJ	O	-1	none	_	_
10	DSE	_	_	NN	O	-1	none	_	_
11	sites	_	_	NNS	O	-1	none	_	_
12	within	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	5	_	_	CD	O	-1	none	_	_
15	'-untranslated	_	_	JJ	O	-1	none	_	_
16	leader	_	_	NN	O	-1	none	_	_
17	can	_	_	MD	O	-1	none	_	_
18	mediate	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	transcriptional	_	_	JJ	O	-1	none	_	_
21	cooperativity	_	_	NN	O	-1	none	_	_
22	between	_	_	IN	O	-1	none	_	_
23	TNFalpha	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	cAMP	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	PKA	_	_	NN	O	-1	none	_	_
29	pathway	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	DSE	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	TRE	_	_	NN	O	-1	none	_	_
6	sites	_	_	NNS	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	bind	_	_	VB	O	-1	none	_	_
10	CREB	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	ATF	_	_	NN	O	-1	none	_	_
13	homodimers	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	we	_	_	PRP	O	-1	none	_	_
16	propose	_	_	VBP	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	mechanism	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	HIV-1	_	_	NN	O	-1	none	_	_
23	DSE	_	_	NN	O	-1	none	_	_
24	bind	_	_	VBP	O	-1	none	_	_
25	heterodimers	_	_	NNS	O	-1	none	_	_
26	composed	_	_	VBN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	both	_	_	CC	O	-1	none	_	_
29	AP-1	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	CREB	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	ATF	_	_	NN	O	-1	none	_	_
34	proteins	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Copyright	_	_	NN	O	-1	none	_	_
2	1997	_	_	CD	O	-1	none	_	_
3	Academic	_	_	NNP	O	-1	none	_	_
4	Press	_	_	NNP	O	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	Differential	_	_	JJ	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	NF-AT	_	_	NN	O	-1	none	_	_
6	complex	_	_	NN	O	-1	none	_	_
7	during	_	_	IN	O	-1	none	_	_
8	restimulation	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	T-cell	_	_	NN	O	-1	none	_	_
14	anergy	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	During	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	induction	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	anergy	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	phenotypically	_	_	RB	O	-1	none	_	_
11	similar	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	responding	_	_	VBG	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	an	_	_	DT	O	-1	none	_	_
17	immunogenic	_	_	JJ	O	-1	none	_	_
18	stimulus	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	amount	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TcR	_	_	NN	O	-1	none	_	_
5	at	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	surface	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	downmodulated	_	_	VBN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	whereas	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	CD2	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	CD25	_	_	NN	O	-1	none	_	_
17	receptors	_	_	NNS	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	increased	_	_	VBN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	restimulated	_	_	VBN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	however	_	_	RB	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	anergic	_	_	JJ	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	fail	_	_	VBP	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	up-regulate	_	_	VB	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	consequence	_	_	NN	O	-1	none	_	_
20	do	_	_	VBP	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	produce	_	_	VB	O	-1	none	_	_
23	IL-2	_	_	NN	Protein	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	compared	_	_	VBN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	ability	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	various	_	_	JJ	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	factors	_	_	NNS	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	bind	_	_	VB	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	their	_	_	PRP$	O	-1	none	_	_
18	appropriate	_	_	JJ	O	-1	none	_	_
19	site	_	_	NN	O	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	DNA	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Factors	_	_	NNS	O	-1	none	_	_
2	were	_	_	VBD	O	-1	none	_	_
3	isolated	_	_	VBN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	nuclei	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	induction	_	_	NN	O	-1	none	_	_
15	phase	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	anergy	_	_	NN	O	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	undergoing	_	_	VBG	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	pattern	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	restimulated	_	_	VBN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	consistent	_	_	JJ	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	pattern	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	has	_	_	VBZ	O	-1	none	_	_
17	previously	_	_	RB	O	-1	none	_	_
18	been	_	_	VBN	O	-1	none	_	_
19	shown	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	regulate	_	_	VB	O	-1	none	_	_
22	T-cell-specific	_	_	JJ	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	IL-2	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	beta	_	_	NN	O	-1	none	_	_
30	chain	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	TcR	_	_	NN	O	-1	none	_	_
34	genes	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	measured	_	_	JJ	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	TCF-1	_	_	NN	Protein	-1	none	_	_
7	site	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	same	_	_	JJ	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	nuclei	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	resting	_	_	VBG	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	activated	_	_	VBN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	anergized	_	_	VBN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inducible	_	_	JJ	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	NK-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	beta	_	_	NN	O	-1	none	_	_
8	E2	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	CD28RC	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	AP-1	_	_	NN	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	expressed	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	resting	_	_	VBG	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	twofold	_	_	RB	O	-1	none	_	_
23	lower	_	_	JJR	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	anergized	_	_	VBN	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	compared	_	_	VBN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	activated	_	_	VBN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	anergic	_	_	JJ	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	express	_	_	VBP	O	-1	none	_	_
8	approximately	_	_	RB	O	-1	none	_	_
9	eightfold	_	_	RB	O	-1	none	_	_
10	lower	_	_	JJR	O	-1	none	_	_
11	amounts	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NF-AT	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	member	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	class	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	inducible	_	_	JJ	O	-1	none	_	_
22	factors	_	_	NNS	O	-1	none	_	_
23	that	_	_	WDT	O	-1	none	_	_
24	regulates	_	_	VBZ	O	-1	none	_	_
25	IL-2	_	_	NN	Protein	-1	none	_	_
26	gene	_	_	NN	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	ABSTRACT	_	_	NN	O	-1	none	_	_
3	TRUNCATED	_	_	VBD	O	-1	none	_	_
4	AT	_	_	IN	O	-1	none	_	_
5	250	_	_	CD	O	-1	none	_	_
6	WORDS	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_

1	Transcription	_	_	NN	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	NF-kappaB	_	_	NN	O	-1	none	_	_
4	regulates	_	_	VBZ	O	-1	none	_	_
5	inducible	_	_	JJ	O	-1	none	_	_
6	Oct-2	_	_	NN	Protein	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	precursor	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	POU	_	_	NN	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factors	_	_	NNS	O	-1	none	_	_
5	Oct-1	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	Oct-2	_	_	NN	Protein	-1	none	_	_
8	regulate	_	_	VBP	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	activity	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	octamer	_	_	NN	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	promoters	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	including	_	_	VBG	O	-1	none	_	_
17	those	_	_	DT	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	direct	_	_	VBP	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	rearranged	_	_	VBN	O	-1	none	_	_
23	immunoglobulin	_	_	NN	O	-1	none	_	_
24	genes	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Unlike	_	_	IN	O	-1	none	_	_
2	Oct-1	_	_	NN	Protein	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	which	_	_	WDT	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	constitutively	_	_	RB	O	-1	none	_	_
7	expressed	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	many	_	_	JJ	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	types	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	Oct-2	_	_	NN	Protein	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	restricted	_	_	JJ	O	-1	none	_	_
17	primarily	_	_	RB	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	lymphocytes	_	_	NNS	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	can	_	_	MD	O	-1	none	_	_
23	be	_	_	VB	O	-1	none	_	_
24	induced	_	_	VBN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	precursor	_	_	NN	O	-1	none	_	_
27	B	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	stimulation	_	_	NN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	bacterial	_	_	JJ	O	-1	none	_	_
33	lipopolysaccharide	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	LPS	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	precise	_	_	JJ	O	-1	none	_	_
5	factors	_	_	NNS	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	mediate	_	_	VBP	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	induction	_	_	NN	O	-1	none	_	_
10	mechanism	_	_	NN	O	-1	none	_	_
11	remain	_	_	VBP	O	-1	none	_	_
12	unknown	_	_	JJ	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	monitored	_	_	VBD	O	-1	none	_	_
8	Oct-2	_	_	NN	Protein	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	arrested	_	_	VBN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	LPS	_	_	NN	O	-1	none	_	_
21	responsive	_	_	JJ	O	-1	none	_	_
22	member	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	Rel	_	_	NN	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	factor	_	_	NN	O	-1	none	_	_
28	family	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	This	_	_	DT	O	-1	none	_	_
2	biochemical	_	_	JJ	O	-1	none	_	_
3	defect	_	_	NN	O	-1	none	_	_
4	correlated	_	_	VBD	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	specific	_	_	JJ	O	-1	none	_	_
8	block	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	Oct-2	_	_	NN	Protein	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	at	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	level	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	whereas	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	Oct-1	_	_	NN	Protein	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	unaffected	_	_	JJ	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	finding	_	_	NN	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	Oct-2	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	under	_	_	IN	O	-1	none	_	_
7	NF-kappaB	_	_	NN	O	-1	none	_	_
8	control	_	_	NN	O	-1	none	_	_
9	highlights	_	_	VBZ	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	important	_	_	JJ	O	-1	none	_	_
12	cross-talk	_	_	NN	O	-1	none	_	_
13	mechanism	_	_	NN	O	-1	none	_	_
14	involving	_	_	VBG	O	-1	none	_	_
15	two	_	_	CD	O	-1	none	_	_
16	distinct	_	_	JJ	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	families	_	_	NNS	O	-1	none	_	_
20	that	_	_	WDT	O	-1	none	_	_
21	regulate	_	_	VBP	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	lymphocyte	_	_	NN	O	-1	none	_	_
24	function	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Triggering	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	T-cell	_	_	NN	O	-1	none	_	_
5	receptor	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	CD3	_	_	NN	O	-1	none	_	_
8	complex	_	_	NN	O	-1	none	_	_
9	activates	_	_	VBZ	O	-1	none	_	_
10	two	_	_	CD	O	-1	none	_	_
11	major	_	_	JJ	O	-1	none	_	_
12	signal	_	_	NN	O	-1	none	_	_
13	cascades	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	lymphocytes	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	i	_	_	FW	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	Ca2	_	_	NN	O	-1	none	_	_
22	+-dependent	_	_	JJ	O	-1	none	_	_
23	signal	_	_	NN	O	-1	none	_	_
24	cascades	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	ii	_	_	LS	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	kinase	_	_	NN	O	-1	none	_	_
31	cascades	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	signal	_	_	NN	O	-1	none	_	_
3	cascades	_	_	NNS	O	-1	none	_	_
4	contribute	_	_	VBP	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	induction	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	interleukin	_	_	NN	Protein	11	multitoken	_	_
11	2	_	_	CD	Protein	0	root	_	_
12	(	_	_	-LRB-	Protein	13	multitoken	_	_
13	IL-2	_	_	NN	Protein	0	root	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	during	_	_	IN	O	-1	none	_	_
17	T-cell	_	_	NN	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Prominent	_	_	JJ	O	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	kinase	_	_	NN	O	-1	none	_	_
4	cascades	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	those	_	_	DT	O	-1	none	_	_
7	that	_	_	WDT	O	-1	none	_	_
8	activate	_	_	VBP	O	-1	none	_	_
9	mitogen	_	_	NN	O	-1	none	_	_
10	activated	_	_	JJ	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	MAP	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	kinases	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	c-Raf	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	at	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	helm	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	classic	_	_	JJ	O	-1	none	_	_
15	MAP-Erk	_	_	JJ	O	-1	none	_	_
16	cascade	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	contributes	_	_	VBZ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	induction	_	_	NN	O	-1	none	_	_
22	through	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	distal	_	_	JJ	O	-1	none	_	_
25	enhancer	_	_	NN	O	-1	none	_	_
26	element	_	_	NN	O	-1	none	_	_
27	spanning	_	_	VBG	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	nucleotides	_	_	NNS	O	-1	none	_	_
30	from	_	_	IN	O	-1	none	_	_
31	positions	_	_	NNS	O	-1	none	_	_
32	-502	_	_	CD	O	-1	none	_	_
33	to	_	_	TO	O	-1	none	_	_
34	-413	_	_	CD	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	front	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	transcriptional	_	_	JJ	O	-1	none	_	_
40	start	_	_	NN	O	-1	none	_	_
41	site	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	IL-2	_	_	NN	Protein	-1	none	_	_
45	gene	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	distal	_	_	JJ	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	enhancer	_	_	NN	O	-1	none	_	_
7	differs	_	_	VBZ	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	induction	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	proximal	_	_	JJ	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	promoter-enhancer	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	since	_	_	IN	O	-1	none	_	_
17	it	_	_	PRP	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	induced	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	phorbol	_	_	NN	O	-1	none	_	_
22	esters	_	_	NNS	O	-1	none	_	_
23	alone	_	_	RB	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	independent	_	_	JJ	O	-1	none	_	_
26	from	_	_	IN	O	-1	none	_	_
27	Ca2+	_	_	NN	O	-1	none	_	_
28	signals	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	DNA	_	_	NN	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	studies	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	detected	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	factors	_	_	NNS	O	-1	none	_	_
14	GABP	_	_	NN	Protein	15	multitoken	_	_
15	alpha	_	_	NN	Protein	0	root	_	_
16	and	_	_	CC	O	-1	none	_	_
17	-beta	_	_	NN	Protein	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	dyad	_	_	JJ	O	-1	none	_	_
21	symmetry	_	_	NN	O	-1	none	_	_
22	element	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	DSE	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	distal	_	_	JJ	O	-1	none	_	_
29	enhancer	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	which	_	_	WDT	O	-1	none	_	_
32	is	_	_	VBZ	O	-1	none	_	_
33	formed	_	_	VBN	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	palindromic	_	_	JJ	O	-1	none	_	_
36	binding	_	_	VBG	O	-1	none	_	_
37	sites	_	_	NNS	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	Ets	_	_	NN	O	-1	none	_	_
40	like	_	_	IN	O	-1	none	_	_
41	factors	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Introduction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	point	_	_	NN	O	-1	none	_	_
4	mutations	_	_	NNS	O	-1	none	_	_
5	suppressing	_	_	VBG	O	-1	none	_	_
6	GABP	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	DSE	_	_	NN	O	-1	none	_	_
11	interfered	_	_	VBD	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	induction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	distal	_	_	JJ	O	-1	none	_	_
18	enhancer	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	entire	_	_	JJ	O	-1	none	_	_
22	IL-2	_	_	NN	Protein	-1	none	_	_
23	promoter-enhancer	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	while	_	_	IN	O	-1	none	_	_
26	overexpression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	both	_	_	CC	O	-1	none	_	_
29	GABP	_	_	NN	O	-1	none	_	_
30	factors	_	_	NNS	O	-1	none	_	_
31	enhanced	_	_	VBD	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	IL-2	_	_	NN	Protein	-1	none	_	_
34	promoter-enhancer	_	_	NN	O	-1	none	_	_
35	induction	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	BXB	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	constitutive	_	_	JJ	O	-1	none	_	_
7	active	_	_	JJ	O	-1	none	_	_
8	version	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	c-Raf	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	further	_	_	JJ	O	-1	none	_	_
15	members	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	Ras-Raf-Erk	_	_	JJ	O	-1	none	_	_
19	signal	_	_	NN	O	-1	none	_	_
20	cascade	_	_	NN	O	-1	none	_	_
21	exerted	_	_	VBD	O	-1	none	_	_
22	an	_	_	DT	O	-1	none	_	_
23	increase	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	GABP	_	_	NN	O	-1	none	_	_
26	mediated	_	_	VBD	O	-1	none	_	_
27	promoter-enhancer	_	_	JJ	O	-1	none	_	_
28	induction	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	coiled-coil	_	_	JJ	O	-1	none	_	_
4	region	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Stat5b	_	_	NN	Protein	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	bait	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	yeast	_	_	NN	O	-1	none	_	_
13	two-hybrid	_	_	JJ	O	-1	none	_	_
14	screen	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	we	_	_	PRP	O	-1	none	_	_
17	identified	_	_	VBD	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	association	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	Nmi	_	_	NN	Protein	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	protein	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	unknown	_	_	JJ	O	-1	none	_	_
27	function	_	_	NN	O	-1	none	_	_
28	previously	_	_	RB	O	-1	none	_	_
29	reported	_	_	VBD	O	-1	none	_	_
30	as	_	_	IN	O	-1	none	_	_
31	an	_	_	DT	O	-1	none	_	_
32	N-Myc	_	_	NN	Protein	33	multitoken	_	_
33	interactor	_	_	NN	Protein	0	root	_	_
34	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	further	_	_	RB	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Nmi	_	_	NN	Protein	-1	none	_	_
6	interacts	_	_	VBZ	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	all	_	_	DT	O	-1	none	_	_
9	STATs	_	_	NNS	O	-1	none	_	_
10	except	_	_	IN	O	-1	none	_	_
11	Stat2	_	_	NN	Protein	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	evaluated	_	_	VBD	O	-1	none	_	_
3	two	_	_	CD	O	-1	none	_	_
4	cytokine	_	_	NN	O	-1	none	_	_
5	systems	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	IFNgamma	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	demonstrate	_	_	VBP	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	Nmi	_	_	NN	Protein	-1	none	_	_
15	augments	_	_	VBZ	O	-1	none	_	_
16	STAT	_	_	NN	O	-1	none	_	_
17	mediated	_	_	JJ	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	response	_	_	NN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	these	_	_	DT	O	-1	none	_	_
23	cytokines	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	our	_	_	PRP$	O	-1	none	_	_
4	data	_	_	NNS	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	only	_	_	RB	O	-1	none	_	_
7	reveal	_	_	VBP	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	Nmi	_	_	NN	Protein	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	potentiate	_	_	VB	O	-1	none	_	_
12	STAT	_	_	NN	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	also	_	_	RB	O	-1	none	_	_
18	suggest	_	_	VBP	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	it	_	_	PRP	O	-1	none	_	_
21	can	_	_	MD	O	-1	none	_	_
22	augment	_	_	VB	O	-1	none	_	_
23	coactivator	_	_	NN	O	-1	none	_	_
24	protein	_	_	NN	O	-1	none	_	_
25	recruitment	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	at	_	_	IN	O	-1	none	_	_
28	least	_	_	JJS	O	-1	none	_	_
29	some	_	_	DT	O	-1	none	_	_
30	members	_	_	NNS	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	group	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	sequence	_	_	NN	O	-1	none	_	_
36	specific	_	_	JJ	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	factors	_	_	NNS	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	jun	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	fos	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	monocytes	_	_	NNS	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	macrophage	_	_	NN	O	-1	none	_	_
14	colony	_	_	NN	O	-1	none	_	_
15	stimulating	_	_	NN	O	-1	none	_	_
16	factor	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	macrophage	_	_	NN	O	-1	none	_	_
3	colony	_	_	NN	O	-1	none	_	_
4	stimulating	_	_	NN	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	M-CSF	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	required	_	_	VBN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	growth	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	mononuclear	_	_	JJ	O	-1	none	_	_
18	phagocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	signaling	_	_	NN	O	-1	none	_	_
5	events	_	_	NNS	O	-1	none	_	_
6	responsible	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	effects	_	_	NNS	O	-1	none	_	_
10	remain	_	_	VBP	O	-1	none	_	_
11	unclear	_	_	JJ	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	examined	_	_	VBN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	effects	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	M-CSF	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	potential	_	_	JJ	O	-1	none	_	_
12	signaling	_	_	NN	O	-1	none	_	_
13	pathways	_	_	NNS	O	-1	none	_	_
14	involving	_	_	VBG	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	jun	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	fos	_	_	NN	Protein	-1	none	_	_
21	early	_	_	JJ	O	-1	none	_	_
22	response	_	_	NN	O	-1	none	_	_
23	genes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Low	_	_	JJ	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	c-jun	_	_	NN	Protein	-1	none	_	_
5	transcripts	_	_	NNS	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	detectable	_	_	JJ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	resting	_	_	VBG	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	peripheral	_	_	JJ	O	-1	none	_	_
12	blood	_	_	NN	O	-1	none	_	_
13	monocytes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	10	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	3	_	_	CD	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	units/ml	_	_	NNS	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	recombinant	_	_	JJ	O	-1	none	_	_
13	M-CSF	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	associated	_	_	VBN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	rapid	_	_	JJ	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	transient	_	_	JJ	O	-1	none	_	_
20	increases	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	c-jun	_	_	NN	Protein	-1	none	_	_
23	mRNA	_	_	NN	O	-1	none	_	_
24	levels	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	run-on	_	_	JJ	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	mRNA	_	_	NN	O	-1	none	_	_
6	stability	_	_	NN	O	-1	none	_	_
7	studies	_	_	NNS	O	-1	none	_	_
8	demonstrated	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	M-CSF	_	_	NN	O	-1	none	_	_
11	regulates	_	_	VBZ	O	-1	none	_	_
12	c-jun	_	_	NN	Protein	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	both	_	_	CC	O	-1	none	_	_
16	an	_	_	DT	O	-1	none	_	_
17	increase	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	rate	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	prolongation	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	half-life	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	c-jun	_	_	NN	Protein	-1	none	_	_
29	transcripts	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	M-CSF	_	_	NNP	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	associated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	rapid	_	_	JJ	O	-1	none	_	_
9	induction	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	jun-B	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	although	_	_	IN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	prolonged	_	_	VBN	O	-1	none	_	_
22	compared	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	that	_	_	DT	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	c-jun	_	_	NN	Protein	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	further	_	_	RB	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	M-CSF	_	_	NN	O	-1	none	_	_
6	increases	_	_	VBZ	O	-1	none	_	_
7	c-fos	_	_	NN	Protein	-1	none	_	_
8	mRNA	_	_	NN	O	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	control	_	_	NN	O	-1	none	_	_
15	at	_	_	IN	O	-1	none	_	_
16	both	_	_	CC	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	transcriptional	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	posttranscriptional	_	_	JJ	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Maximal	_	_	JJ	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	c-fos	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	followed	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	that	_	_	DT	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	fos-B	_	_	NN	Protein	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	M-CSF-induced	_	_	JJ	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	fos	_	_	NN	O	-1	none	_	_
8	related	_	_	JJ	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	fra-1	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	delayed	_	_	VBN	O	-1	none	_	_
15	compared	_	_	VBN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	that	_	_	DT	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	both	_	_	DT	O	-1	none	_	_
20	c-fos	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	fos-B	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	indicate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	M-CSF	_	_	NN	O	-1	none	_	_
9	treatment	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	associated	_	_	VBN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	differential	_	_	JJ	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	multiple	_	_	JJ	O	-1	none	_	_
17	members	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	jun	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	fos	_	_	NN	O	-1	none	_	_
23	family	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	these	_	_	DT	O	-1	none	_	_
29	genes	_	_	NNS	O	-1	none	_	_
30	could	_	_	MD	O	-1	none	_	_
31	contribute	_	_	VB	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	nuclear	_	_	JJ	O	-1	none	_	_
34	signaling	_	_	NN	O	-1	none	_	_
35	mechanisms	_	_	NNS	O	-1	none	_	_
36	that	_	_	WDT	O	-1	none	_	_
37	regulate	_	_	VBP	O	-1	none	_	_
38	a	_	_	DT	O	-1	none	_	_
39	specific	_	_	JJ	O	-1	none	_	_
40	program	_	_	NN	O	-1	none	_	_
41	of	_	_	IN	O	-1	none	_	_
42	monocyte	_	_	NN	O	-1	none	_	_
43	differentiation	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Uncoupling	_	_	VBG	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	dependent	_	_	JJ	O	-1	none	_	_
4	HS1	_	_	NN	Protein	-1	none	_	_
5	phosphorylation	_	_	NN	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	activated	_	_	VBN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	transcriptional	_	_	JJ	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	Jurkat	_	_	NN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	:	_	_	:	O	-1	none	_	_
20	differential	_	_	JJ	O	-1	none	_	_
21	signaling	_	_	NN	O	-1	none	_	_
22	through	_	_	IN	O	-1	none	_	_
23	CD3	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	costimulatory	_	_	JJ	O	-1	none	_	_
27	receptors	_	_	NNS	O	-1	none	_	_
28	CD2	_	_	NN	Protein	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	CD28	_	_	NN	Protein	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	CD3	_	_	NN	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	CD2	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	CD28	_	_	NN	Protein	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	functionally	_	_	RB	O	-1	none	_	_
9	distinct	_	_	JJ	O	-1	none	_	_
10	receptors	_	_	NNS	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Engagement	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	any	_	_	DT	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	these	_	_	DT	O	-1	none	_	_
6	receptors	_	_	NNS	O	-1	none	_	_
7	induces	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	rapid	_	_	JJ	O	-1	none	_	_
10	tyrosine	_	_	NN	O	-1	none	_	_
11	phosphorylation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	shared	_	_	JJ	O	-1	none	_	_
15	group	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	intracellular	_	_	JJ	O	-1	none	_	_
18	signaling	_	_	NN	O	-1	none	_	_
19	proteins	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	including	_	_	VBG	O	-1	none	_	_
22	Vav	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	Cbl	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	p85	_	_	NN	O	-1	none	_	_
27	phosphoinositide	_	_	NN	O	-1	none	_	_
28	3-kinase	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	Src	_	_	NN	Protein	-1	none	_	_
33	family	_	_	NN	O	-1	none	_	_
34	kinases	_	_	NNS	O	-1	none	_	_
35	Lck	_	_	NN	Protein	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	Fyn	_	_	NN	Protein	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Ligation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	CD3	_	_	NN	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	induces	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	tyrosine	_	_	NN	O	-1	none	_	_
8	phosphorylation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	HS1	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	75-kDa	_	_	JJ	O	-1	none	_	_
14	hematopoietic	_	_	JJ	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	intracellular	_	_	JJ	O	-1	none	_	_
18	signaling	_	_	NN	O	-1	none	_	_
19	protein	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	unknown	_	_	JJ	O	-1	none	_	_
22	function	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	examined	_	_	VBN	O	-1	none	_	_
4	changes	_	_	NNS	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	HS1	_	_	NN	Protein	-1	none	_	_
7	phosphorylation	_	_	NN	O	-1	none	_	_
8	after	_	_	IN	O	-1	none	_	_
9	differential	_	_	JJ	O	-1	none	_	_
10	stimulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	CD3	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	CD2	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	CD28	_	_	NN	Protein	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	elucidate	_	_	VB	O	-1	none	_	_
20	its	_	_	PRP$	O	-1	none	_	_
21	role	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	T	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	further	_	_	RB	O	-1	none	_	_
28	delineate	_	_	VB	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	signaling	_	_	NN	O	-1	none	_	_
31	pathways	_	_	NNS	O	-1	none	_	_
32	recruited	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	these	_	_	DT	O	-1	none	_	_
35	receptors	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Unlike	_	_	IN	O	-1	none	_	_
2	ligation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	CD3	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	stimulation	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	anti-CD28	_	_	JJ	Protein	-1	none	_	_
9	mAb	_	_	NN	O	-1	none	_	_
10	or	_	_	CC	O	-1	none	_	_
11	CHO	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	expressing	_	_	VBG	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	CD28	_	_	NN	Protein	-1	none	_	_
16	ligands	_	_	NNS	O	-1	none	_	_
17	CD80	_	_	NN	Protein	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	CD86	_	_	NN	Protein	-1	none	_	_
20	did	_	_	VBD	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	lead	_	_	VB	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	tyrosine	_	_	NN	O	-1	none	_	_
25	phosphorylation	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	HS1	_	_	NN	Protein	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	Jurkat	_	_	NN	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Additionally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	no	_	_	DT	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	phosphorylation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	HS1	_	_	NN	Protein	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	mitogenic	_	_	JJ	O	-1	none	_	_
12	pairs	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	anti-CD2	_	_	JJ	Protein	-1	none	_	_
15	mAbs	_	_	NNS	O	-1	none	_	_
16	capable	_	_	JJ	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	activating	_	_	VBG	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	NFAT	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	nuclear	_	_	JJ	O	-1	none	_	_
25	factor	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	activated	_	_	VBN	O	-1	none	_	_
28	T	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Costimulation	_	_	NN	O	-1	none	_	_
2	through	_	_	IN	O	-1	none	_	_
3	CD28	_	_	NN	Protein	-1	none	_	_
4	and/or	_	_	CC	O	-1	none	_	_
5	CD2	_	_	NN	Protein	-1	none	_	_
6	did	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	modulate	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	CD3	_	_	NN	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	HS1	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vivo	_	_	FW	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	indicated	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	CD3	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	HSI	_	_	NN	Protein	-1	none	_	_
9	phosphorylation	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	upon	_	_	IN	O	-1	none	_	_
13	both	_	_	CC	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	Src	_	_	NN	Protein	-1	none	_	_
16	family	_	_	NN	O	-1	none	_	_
17	tyrosine	_	_	NN	O	-1	none	_	_
18	kinase	_	_	NN	O	-1	none	_	_
19	Lck	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	tyrosine	_	_	NN	O	-1	none	_	_
23	phosphatase	_	_	NN	O	-1	none	_	_
24	CD45	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	did	_	_	VBD	O	-1	none	_	_
27	not	_	_	RB	O	-1	none	_	_
28	require	_	_	VB	O	-1	none	_	_
29	MEK1	_	_	NN	Protein	-1	none	_	_
30	kinase	_	_	NN	O	-1	none	_	_
31	activity	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	was	_	_	VBD	O	-1	none	_	_
35	regulated	_	_	VBN	O	-1	none	_	_
36	by	_	_	IN	O	-1	none	_	_
37	protein	_	_	NN	O	-1	none	_	_
38	kinase	_	_	NN	O	-1	none	_	_
39	C	_	_	NN	O	-1	none	_	_
40	activation	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	although	_	_	IN	O	-1	none	_	_
4	CD3	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	CD28	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	CD2	_	_	NN	Protein	-1	none	_	_
10	activate	_	_	VBP	O	-1	none	_	_
11	many	_	_	JJ	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	same	_	_	JJ	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	molecules	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	they	_	_	PRP	O	-1	none	_	_
19	differed	_	_	VBD	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	their	_	_	PRP$	O	-1	none	_	_
22	capacity	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	induce	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	tyrosine	_	_	NN	O	-1	none	_	_
27	phosphorylation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	HSI	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	dependent	_	_	JJ	O	-1	none	_	_
5	tyrosine	_	_	NN	O	-1	none	_	_
6	phosphorylation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	HS1	_	_	NN	Protein	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	required	_	_	VBN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	NFAT	_	_	NN	O	-1	none	_	_
14	transcriptional	_	_	JJ	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IL-2	_	_	NN	Protein	-1	none	_	_
3	growth	_	_	NN	O	-1	none	_	_
4	hormone	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	major	_	_	JJ	O	-1	none	_	_
8	growth	_	_	NN	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	activated	_	_	VBN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	during	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	developing	_	_	VBG	O	-1	none	_	_
17	immune	_	_	JJ	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	IL-2	_	_	NNP	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	required	_	_	VBN	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	only	_	_	RB	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	cycle	_	_	NN	O	-1	none	_	_
9	progression	_	_	NN	O	-1	none	_	_
10	but	_	_	CC	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	protect	_	_	VB	O	-1	none	_	_
14	Ag	_	_	NN	O	-1	none	_	_
15	activated	_	_	VBN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	from	_	_	IN	O	-1	none	_	_
19	programmed	_	_	VBN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	death	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	several	_	_	JJ	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	types	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	and/or	_	_	CC	O	-1	none	_	_
11	activating	_	_	VBG	O	-1	none	_	_
12	protein-1	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	AP-1	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	has	_	_	VBZ	O	-1	none	_	_
17	been	_	_	VBN	O	-1	none	_	_
18	demonstrated	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	extremely	_	_	RB	O	-1	none	_	_
22	important	_	_	JJ	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	blocking	_	_	VBG	O	-1	none	_	_
25	apoptosis	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	determine	_	_	VB	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	either	_	_	DT	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	both	_	_	DT	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	involved	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	survival	_	_	NN	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	cycle	_	_	NN	O	-1	none	_	_
19	progression	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	response	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	IL-2	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	primary	_	_	JJ	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	responsive	_	_	JJ	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	growth	_	_	NN	O	-1	none	_	_
33	factor	_	_	NN	O	-1	none	_	_
34	were	_	_	VBD	O	-1	none	_	_
35	analyzed	_	_	VBN	O	-1	none	_	_
36	for	_	_	IN	O	-1	none	_	_
37	NF-kappa	_	_	NN	O	-1	none	_	_
38	B	_	_	NN	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	AP-1	_	_	NN	O	-1	none	_	_
41	activation	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	current	_	_	JJ	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	clearly	_	_	RB	O	-1	none	_	_
5	demonstrates	_	_	VBZ	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	does	_	_	VBZ	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	induce	_	_	VB	O	-1	none	_	_
11	I	_	_	NN	Protein	14	multitoken	_	_
12	kappa	_	_	NN	Protein	14	multitoken	_	_
13	B	_	_	NN	Protein	14	multitoken	_	_
14	alpha	_	_	NN	Protein	0	root	_	_
15	degradation	_	_	NN	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	primary	_	_	JJ	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	T	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	that	_	_	WDT	O	-1	none	_	_
26	respond	_	_	VBP	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	IL-2	_	_	NN	Protein	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	entering	_	_	VBG	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	cell	_	_	NN	O	-1	none	_	_
33	cycle	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	avoiding	_	_	VBG	O	-1	none	_	_
36	apoptosis	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Similarly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	neither	_	_	CC	O	-1	none	_	_
5	activates	_	_	VBZ	O	-1	none	_	_
6	JNK	_	_	NN	O	-1	none	_	_
7	nor	_	_	CC	O	-1	none	_	_
8	increases	_	_	VBZ	O	-1	none	_	_
9	AP-1	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	consensus	_	_	NN	O	-1	none	_	_
15	o-tetradecanoylphorbol	_	_	NN	O	-1	none	_	_
16	13-acetate	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	TPA	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	response	_	_	NN	O	-1	none	_	_
21	element	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	other	_	_	JJ	O	-1	none	_	_
4	hand	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	growth	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	does	_	_	VBZ	O	-1	none	_	_
10	induce	_	_	VB	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	STAT3	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	STAT5	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	these	_	_	DT	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	has	_	_	VBZ	O	-1	none	_	_
23	been	_	_	VBN	O	-1	none	_	_
24	previously	_	_	RB	O	-1	none	_	_
25	demonstrated	_	_	VBN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	ETS1	_	_	NN	Protein	-1	none	_	_
2	transactivates	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	GM-CSF	_	_	NN	Protein	-1	none	_	_
6	promoter	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	Jurkat	_	_	NN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	stimulated	_	_	VBN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	PMA	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	ionomycin	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	helper	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	results	_	_	VBZ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	coordinate	_	_	JJ	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	number	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	cytokines	_	_	NNS	O	-1	none	_	_
15	involved	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	differentiation	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	proliferation	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	haematopoietic	_	_	JJ	O	-1	none	_	_
25	system	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Granulocyte-macrophage	_	_	JJ	Protein	4	multitoken	_	_
2	colony	_	_	NN	Protein	4	multitoken	_	_
3	stimulating	_	_	NN	Protein	4	multitoken	_	_
4	factor	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	GM-CSF	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	one	_	_	CD	O	-1	none	_	_
10	such	_	_	JJ	O	-1	none	_	_
11	cytokine	_	_	NN	O	-1	none	_	_
12	whose	_	_	WP$	O	-1	none	_	_
13	increased	_	_	VBN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	results	_	_	VBZ	O	-1	none	_	_
16	partly	_	_	RB	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	increases	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Cis	_	_	NN	O	-1	none	_	_
2	acting	_	_	VBG	O	-1	none	_	_
3	elements	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	NF	_	_	NN	O	-1	none	_	_
6	kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	AP-1	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	ETS	_	_	NN	O	-1	none	_	_
12	like	_	_	IN	O	-1	none	_	_
13	motifs	_	_	NNS	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	been	_	_	VBN	O	-1	none	_	_
16	identified	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	promoter	_	_	NN	O	-1	none	_	_
20	region	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	GM-CSF	_	_	NN	Protein	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	which	_	_	WDT	O	-1	none	_	_
27	are	_	_	VBP	O	-1	none	_	_
28	important	_	_	JJ	O	-1	none	_	_
29	for	_	_	IN	O	-1	none	_	_
30	transcriptional	_	_	JJ	O	-1	none	_	_
31	activity	_	_	NN	O	-1	none	_	_
32	following	_	_	VBG	O	-1	none	_	_
33	PMA	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	ionomycin	_	_	NN	O	-1	none	_	_
36	stimulation	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	number	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	ETS	_	_	NN	O	-1	none	_	_
6	family	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	expressed	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	including	_	_	VBG	O	-1	none	_	_
17	ETS1	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	ELF1	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	describe	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	ability	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	factors	_	_	NNS	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	interact	_	_	VB	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	GM5	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	located	_	_	JJ	O	-1	none	_	_
19	within	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	CLE0	_	_	NN	O	-1	none	_	_
22	element	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	-47	_	_	CD	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	-40	_	_	CD	O	-1	none	_	_
27	upstream	_	_	JJ	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	GM-CSF	_	_	NN	Protein	-1	none	_	_
31	transcription	_	_	NN	O	-1	none	_	_
32	initiation	_	_	NN	O	-1	none	_	_
33	site	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Exogenous	_	_	JJ	O	-1	none	_	_
2	ETS1	_	_	NN	Protein	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	but	_	_	CC	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	ELF1	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	can	_	_	MD	O	-1	none	_	_
9	transactivate	_	_	VB	O	-1	none	_	_
10	GM-CSF	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	through	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	GM5	_	_	NN	O	-1	none	_	_
15	site	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	PMA	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	ionomycin	_	_	NN	O	-1	none	_	_
22	dependent	_	_	JJ	O	-1	none	_	_
23	manner	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Other	_	_	JJ	O	-1	none	_	_
2	unidentified	_	_	JJ	O	-1	none	_	_
3	ETS	_	_	NNS	O	-1	none	_	_
4	like	_	_	IN	O	-1	none	_	_
5	factors	_	_	NNS	O	-1	none	_	_
6	present	_	_	JJ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	Jurkat	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	capable	_	_	JJ	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	binding	_	_	VBG	O	-1	none	_	_
15	GM5	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Mutation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	core	_	_	NN	O	-1	none	_	_
5	ETS	_	_	NN	O	-1	none	_	_
6	binding	_	_	VBG	O	-1	none	_	_
7	site	_	_	NN	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	-GGAA	_	_	NN	O	-1	none	_	_
10	-	_	_	:	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	-GGAT	_	_	NN	O	-1	none	_	_
13	-	_	_	:	O	-1	none	_	_
14	prevents	_	_	VBZ	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	ETS	_	_	NN	O	-1	none	_	_
19	like	_	_	IN	O	-1	none	_	_
20	factors	_	_	NNS	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	exception	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	ETS1	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	GM-CSF	_	_	NN	Protein	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	modified	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	way	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	be	_	_	VB	O	-1	none	_	_
11	ETS1	_	_	NN	Protein	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	fully	_	_	RB	O	-1	none	_	_
16	responsive	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	PMA	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	ionomycin	_	_	NN	O	-1	none	_	_
21	induction	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	addition	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	ETS1	_	_	NN	Protein	-1	none	_	_
27	transactivation	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	presence	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	PMA	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	ionomycin	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	data	_	_	NNS	O	-1	none	_	_
4	suggest	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	ETS1	_	_	NN	Protein	-1	none	_	_
7	may	_	_	MD	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	involved	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	mediating	_	_	VBG	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	increased	_	_	JJ	O	-1	none	_	_
14	GM-CSF	_	_	NN	Protein	-1	none	_	_
15	production	_	_	NN	O	-1	none	_	_
16	associated	_	_	VBN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	nongenomic	_	_	JJ	O	-1	none	_	_
3	mechanism	_	_	NN	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	progesterone	_	_	NN	O	-1	none	_	_
6	mediated	_	_	VBD	O	-1	none	_	_
7	immunosuppression	_	_	NN	O	-1	none	_	_
8	:	_	_	:	O	-1	none	_	_
9	inhibition	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	K+	_	_	NN	O	-1	none	_	_
12	channels	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	Ca2+	_	_	NN	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	which	_	_	WDT	O	-1	none	_	_
5	progesterone	_	_	NN	O	-1	none	_	_
6	causes	_	_	VBZ	O	-1	none	_	_
7	localized	_	_	JJ	O	-1	none	_	_
8	suppression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	immune	_	_	JJ	O	-1	none	_	_
12	response	_	_	NN	O	-1	none	_	_
13	during	_	_	IN	O	-1	none	_	_
14	pregnancy	_	_	NN	O	-1	none	_	_
15	has	_	_	VBZ	O	-1	none	_	_
16	remained	_	_	VBN	O	-1	none	_	_
17	elusive	_	_	JJ	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	lymphocytes	_	_	NNS	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	lines	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	we	_	_	PRP	O	-1	none	_	_
11	show	_	_	VBP	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	progesterone	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	at	_	_	IN	O	-1	none	_	_
16	concentrations	_	_	NNS	O	-1	none	_	_
17	found	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	placenta	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	rapidly	_	_	RB	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	reversibly	_	_	RB	O	-1	none	_	_
25	blocks	_	_	VBZ	O	-1	none	_	_
26	voltage	_	_	NN	O	-1	none	_	_
27	gated	_	_	VBN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	calcium	_	_	NN	O	-1	none	_	_
30	activated	_	_	VBD	O	-1	none	_	_
31	K+	_	_	NN	O	-1	none	_	_
32	channels	_	_	NNS	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	KV	_	_	NN	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	KCa	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	respectively	_	_	RB	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	resulting	_	_	VBG	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	depolarization	_	_	NN	O	-1	none	_	_
44	of	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	membrane	_	_	NN	O	-1	none	_	_
47	potential	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	result	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	Ca2+	_	_	NN	O	-1	none	_	_
6	signaling	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	activated	_	_	VBN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	NF-AT	_	_	NN	O	-1	none	_	_
16	)-driven	_	_	JJ	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	inhibited	_	_	VBN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Progesterone	_	_	NN	O	-1	none	_	_
2	acts	_	_	VBZ	O	-1	none	_	_
3	distally	_	_	RB	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	initial	_	_	JJ	O	-1	none	_	_
7	steps	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	receptor	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	TCR	_	_	NN	O	-1	none	_	_
14	)-mediated	_	_	JJ	O	-1	none	_	_
15	signal	_	_	NN	O	-1	none	_	_
16	transduction	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	since	_	_	IN	O	-1	none	_	_
19	it	_	_	PRP	O	-1	none	_	_
20	blocks	_	_	VBZ	O	-1	none	_	_
21	sustained	_	_	JJ	O	-1	none	_	_
22	Ca2+	_	_	NN	O	-1	none	_	_
23	signals	_	_	NNS	O	-1	none	_	_
24	after	_	_	IN	O	-1	none	_	_
25	thapsigargin	_	_	NN	O	-1	none	_	_
26	stimulation	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	as	_	_	RB	O	-1	none	_	_
29	well	_	_	RB	O	-1	none	_	_
30	as	_	_	IN	O	-1	none	_	_
31	oscillatory	_	_	JJ	O	-1	none	_	_
32	Ca2+	_	_	NN	O	-1	none	_	_
33	signals	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	but	_	_	CC	O	-1	none	_	_
36	not	_	_	RB	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	Ca2+	_	_	NN	O	-1	none	_	_
39	transient	_	_	JJ	O	-1	none	_	_
40	after	_	_	IN	O	-1	none	_	_
41	TCR	_	_	NN	O	-1	none	_	_
42	stimulation	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	K+	_	_	NN	O	-1	none	_	_
2	channel	_	_	NN	O	-1	none	_	_
3	blockade	_	_	NN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	progesterone	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	specific	_	_	JJ	O	-1	none	_	_
8	;	_	_	:	O	-1	none	_	_
9	other	_	_	JJ	O	-1	none	_	_
10	steroid	_	_	NN	O	-1	none	_	_
11	hormones	_	_	NNS	O	-1	none	_	_
12	had	_	_	VBD	O	-1	none	_	_
13	little	_	_	JJ	O	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	no	_	_	DT	O	-1	none	_	_
16	effect	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	although	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	progesterone	_	_	NN	O	-1	none	_	_
21	antagonist	_	_	NN	O	-1	none	_	_
22	RU	_	_	NN	O	-1	none	_	_
23	486	_	_	CD	O	-1	none	_	_
24	also	_	_	RB	O	-1	none	_	_
25	blocked	_	_	VBD	O	-1	none	_	_
26	KV	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	KCa	_	_	NN	O	-1	none	_	_
29	channels	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Progesterone	_	_	NN	O	-1	none	_	_
2	effectively	_	_	RB	O	-1	none	_	_
3	blocked	_	_	VBD	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	broad	_	_	JJ	O	-1	none	_	_
6	spectrum	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	K+	_	_	NN	O	-1	none	_	_
9	channels	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	reducing	_	_	VBG	O	-1	none	_	_
12	both	_	_	DT	O	-1	none	_	_
13	Kv1	_	_	NN	Protein	14	multitoken	_	_
14	.3	_	_	NN	Protein	0	root	_	_
15	and	_	_	CC	O	-1	none	_	_
16	charybdotoxin	_	_	NN	O	-1	none	_	_
17	resistant	_	_	JJ	O	-1	none	_	_
18	components	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	KV	_	_	NN	O	-1	none	_	_
21	current	_	_	JJ	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	KCa	_	_	NN	O	-1	none	_	_
24	current	_	_	JJ	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	as	_	_	RB	O	-1	none	_	_
30	well	_	_	RB	O	-1	none	_	_
31	as	_	_	IN	O	-1	none	_	_
32	blocking	_	_	VBG	O	-1	none	_	_
33	several	_	_	JJ	O	-1	none	_	_
34	cloned	_	_	VBN	O	-1	none	_	_
35	KV	_	_	NN	O	-1	none	_	_
36	channels	_	_	NNS	O	-1	none	_	_
37	expressed	_	_	VBN	O	-1	none	_	_
38	in	_	_	IN	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	lines	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Progesterone	_	_	NN	O	-1	none	_	_
2	had	_	_	VBD	O	-1	none	_	_
3	little	_	_	JJ	O	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	no	_	_	DT	O	-1	none	_	_
6	effect	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cloned	_	_	JJ	O	-1	none	_	_
10	voltage	_	_	NN	O	-1	none	_	_
11	gated	_	_	VBN	O	-1	none	_	_
12	Na+	_	_	NN	O	-1	none	_	_
13	channel	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	inward	_	_	JJ	O	-1	none	_	_
17	rectifier	_	_	NN	O	-1	none	_	_
18	K+	_	_	NN	O	-1	none	_	_
19	channel	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	or	_	_	CC	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	lymphocyte	_	_	NN	O	-1	none	_	_
24	Ca2+	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	Cl-	_	_	NN	O	-1	none	_	_
27	channels	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	direct	_	_	JJ	O	-1	none	_	_
5	inhibition	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	K+	_	_	NN	O	-1	none	_	_
8	channels	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	progesterone	_	_	NN	O	-1	none	_	_
14	contributes	_	_	VBZ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	progesterone	_	_	NN	O	-1	none	_	_
17	induced	_	_	VBD	O	-1	none	_	_
18	immunosuppression	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	appearance	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	binds	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	CD28	_	_	NN	Protein	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	element	_	_	NN	O	-1	none	_	_
12	within	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	interleukin-2	_	_	NN	Protein	-1	none	_	_
15	enhancer	_	_	NN	O	-1	none	_	_
16	correlates	_	_	VBZ	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	interleukin-2	_	_	NN	Protein	-1	none	_	_
19	production	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	lymphocytes	_	_	NNS	O	-1	none	_	_
5	requires	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	combined	_	_	JJ	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	costimulatory	_	_	JJ	O	-1	none	_	_
16	molecules	_	_	NNS	O	-1	none	_	_
17	such	_	_	JJ	O	-1	none	_	_
18	as	_	_	IN	O	-1	none	_	_
19	CD28	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	ability	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	produce	_	_	VB	O	-1	none	_	_
8	interleukin-2	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	critical	_	_	JJ	O	-1	none	_	_
15	control	_	_	NN	O	-1	none	_	_
16	point	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	lymphocyte	_	_	NN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IL-2	_	_	NN	Protein	-1	none	_	_
3	enhancer	_	_	NN	O	-1	none	_	_
4	contains	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	functional	_	_	JJ	O	-1	none	_	_
7	motif	_	_	NN	O	-1	none	_	_
8	named	_	_	VBN	O	-1	none	_	_
9	CD28	_	_	NN	Protein	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	element	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	CD28RE	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	serves	_	_	VBZ	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	role	_	_	NN	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	target	_	_	NN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	mitogenic	_	_	JJ	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	signals	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	CD28RE	_	_	NN	O	-1	none	_	_
3	sequence	_	_	NN	O	-1	none	_	_
4	reveals	_	_	VBZ	O	-1	none	_	_
5	similarity	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	consensus	_	_	NN	O	-1	none	_	_
9	kappaB	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	motif	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	CD28RE	_	_	NN	O	-1	none	_	_
6	binds	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	inducible	_	_	JJ	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	molecular	_	_	JJ	O	-1	none	_	_
13	mass	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	approximately	_	_	RB	O	-1	none	_	_
16	35	_	_	CD	O	-1	none	_	_
17	kDa	_	_	NN	O	-1	none	_	_
18	called	_	_	VBN	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	mitogenic	_	_	JJ	O	-1	none	_	_
23	activated	_	_	VBN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	NF-MATp35	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	that	_	_	WDT	O	-1	none	_	_
30	is	_	_	VBZ	O	-1	none	_	_
31	clearly	_	_	RB	O	-1	none	_	_
32	different	_	_	JJ	O	-1	none	_	_
33	from	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	known	_	_	JJ	O	-1	none	_	_
36	NF-	_	_	NN	O	-1	none	_	_
37	kappaB	_	_	NN	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	Rel	_	_	NN	O	-1	none	_	_
40	family	_	_	NN	O	-1	none	_	_
41	members	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-MATp35	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	depend	_	_	VB	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	de	_	_	FW	O	-1	none	_	_
10	novo	_	_	FW	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	synthesis	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	restricted	_	_	JJ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	received	_	_	VBD	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	mitogenic	_	_	JJ	O	-1	none	_	_
23	combination	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	stimuli	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	not	_	_	RB	O	-1	none	_	_
30	necessarily	_	_	RB	O	-1	none	_	_
31	including	_	_	VBG	O	-1	none	_	_
32	CD28	_	_	NN	Protein	-1	none	_	_
33	signaling	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Nonmitogenic	_	_	JJ	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	stimulation	_	_	NN	O	-1	none	_	_
5	did	_	_	VBD	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	result	_	_	VB	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	appearance	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-MATp35	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	mitogenic	_	_	JJ	O	-1	none	_	_
6	combinations	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	signals	_	_	NNS	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	integrated	_	_	VBN	O	-1	none	_	_
14	at	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	level	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	NF-MATp35	_	_	NN	O	-1	none	_	_
19	induction	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Similar	_	_	JJ	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	its	_	_	PRP$	O	-1	none	_	_
4	effect	_	_	NN	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	production	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	cyclosporin	_	_	NN	O	-1	none	_	_
10	A	_	_	NN	O	-1	none	_	_
11	inhibited	_	_	VBD	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	induction	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	NF-MATp35	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	data	_	_	NNS	O	-1	none	_	_
6	demonstrate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	appearance	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	NF-MATp35	_	_	NN	O	-1	none	_	_
13	shows	_	_	VBZ	O	-1	none	_	_
14	excellent	_	_	JJ	O	-1	none	_	_
15	correlation	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	IL-2	_	_	NN	Protein	-1	none	_	_
18	production	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	unique	_	_	JJ	O	-1	none	_	_
24	characteristic	_	_	NN	O	-1	none	_	_
25	among	_	_	IN	O	-1	none	_	_
26	nuclear	_	_	JJ	O	-1	none	_	_
27	factors	_	_	NNS	O	-1	none	_	_
28	implicated	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	control	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	IL-2	_	_	NN	Protein	-1	none	_	_
34	gene	_	_	NN	O	-1	none	_	_
35	expression	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Salicylates	_	_	NNS	O	-1	none	_	_
2	inhibit	_	_	VBP	O	-1	none	_	_
3	lipopolysaccharide	_	_	NN	O	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	tissue	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	monocytic	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	plasma	_	_	NN	O	-1	none	_	_
4	Factor	_	_	NN	Protein	7	multitoken	_	_
5	VII	_	_	NN	Protein	7	multitoken	_	_
6	and	_	_	CC	Protein	7	multitoken	_	_
7	VIIa	_	_	NN	Protein	0	root	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	tissue	_	_	NN	Protein	15	multitoken	_	_
11	factor	_	_	NN	Protein	15	multitoken	_	_
12	(	_	_	-LRB-	Protein	15	multitoken	_	_
13	TF	_	_	NN	Protein	15	multitoken	_	_
14	)	_	_	-RRB-	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	initiates	_	_	VBZ	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	coagulation	_	_	NN	O	-1	none	_	_
19	protease	_	_	NN	O	-1	none	_	_
20	cascades	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	TF	_	_	NN	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	circulating	_	_	VBG	O	-1	none	_	_
5	monocytes	_	_	NNS	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	associated	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	thrombotic	_	_	JJ	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	inflammatory	_	_	JJ	O	-1	none	_	_
12	complications	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	variety	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	diseases	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	TF	_	_	NN	Protein	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	monocytic	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	exposed	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	bacterial	_	_	JJ	O	-1	none	_	_
14	lipopolysaccharide	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	LPS	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	mediated	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	c-Rel	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	p65	_	_	NN	Protein	-1	none	_	_
26	heterodimers	_	_	NNS	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	kappa	_	_	NN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	site	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	TF	_	_	NN	Protein	-1	none	_	_
35	promoter	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	report	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	family	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	anti-inflammatory	_	_	JJ	O	-1	none	_	_
10	agents	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	known	_	_	VBN	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	salicylates	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	inhibited	_	_	VBD	O	-1	none	_	_
18	LPS	_	_	NN	O	-1	none	_	_
19	induction	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	TF	_	_	NN	Protein	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	TF	_	_	NN	Protein	-1	none	_	_
25	gene	_	_	NN	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	monocytes	_	_	NNS	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	monocytic	_	_	JJ	O	-1	none	_	_
32	THP-1	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	at	_	_	IN	O	-1	none	_	_
35	clinically	_	_	RB	O	-1	none	_	_
36	relevant	_	_	JJ	O	-1	none	_	_
37	doses	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	sodium	_	_	NN	O	-1	none	_	_
4	salicylate	_	_	NN	O	-1	none	_	_
5	blocked	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	LPS	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	proteolytic	_	_	JJ	O	-1	none	_	_
10	degradation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	I	_	_	NN	Protein	15	multitoken	_	_
13	kappa	_	_	NN	Protein	15	multitoken	_	_
14	B	_	_	NN	Protein	15	multitoken	_	_
15	alpha	_	_	NN	Protein	0	root	_	_
16	,	_	_	,	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	prevented	_	_	VBD	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	translocation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	c-Rel	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	p65	_	_	NN	Protein	-1	none	_	_
26	heterodimers	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	other	_	_	JJ	O	-1	none	_	_
6	nonsteroidal	_	_	JJ	O	-1	none	_	_
7	anti-inflammatory	_	_	JJ	O	-1	none	_	_
8	drugs	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	ibuprofen	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	indomethacin	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	did	_	_	VBD	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	inhibit	_	_	VB	O	-1	none	_	_
17	LPS	_	_	NN	O	-1	none	_	_
18	induction	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	TF	_	_	NN	Protein	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	salicylates	_	_	NNS	O	-1	none	_	_
6	inhibited	_	_	VBD	O	-1	none	_	_
7	LPS	_	_	NN	O	-1	none	_	_
8	induction	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	TF	_	_	NN	Protein	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	monocytic	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	preventing	_	_	VBG	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	translocation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	c-Rel	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	p65	_	_	NN	Protein	-1	none	_	_
24	heterodimers	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	clinical	_	_	JJ	O	-1	none	_	_
3	benefits	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	salicylates	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	treatment	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	several	_	_	JJ	O	-1	none	_	_
11	diseases	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	including	_	_	VBG	O	-1	none	_	_
14	atherosclerosis	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	rheumatoid	_	_	JJ	O	-1	none	_	_
17	arthritis	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	may	_	_	MD	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	related	_	_	VBN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	their	_	_	PRP$	O	-1	none	_	_
24	ability	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	reduce	_	_	VB	O	-1	none	_	_
27	monocyte	_	_	NN	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	lymphotropic	_	_	JJ	O	-1	none	_	_
4	virus-I	_	_	NN	O	-1	none	_	_
5	infection	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	lymphocytes	_	_	NNS	O	-1	none	_	_
10	induces	_	_	VBZ	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	beta-galactoside-binding	_	_	JJ	O	-1	none	_	_
15	lectin	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	galectin-3	_	_	NN	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Animal	_	_	NN	O	-1	none	_	_
2	lectins	_	_	NNS	O	-1	none	_	_
3	play	_	_	VBP	O	-1	none	_	_
4	important	_	_	JJ	O	-1	none	_	_
5	roles	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	variety	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	biological	_	_	JJ	O	-1	none	_	_
11	processes	_	_	NNS	O	-1	none	_	_
12	via	_	_	IN	O	-1	none	_	_
13	their	_	_	PRP$	O	-1	none	_	_
14	recognition	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	glycoconjugates	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Galectin-3	_	_	NNP	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	beta-galactoside-binding	_	_	JJ	O	-1	none	_	_
5	lectin	_	_	NN	O	-1	none	_	_
6	previously	_	_	RB	O	-1	none	_	_
7	designated	_	_	VBN	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	epsilon	_	_	NN	Protein	10	multitoken	_	_
10	BP	_	_	NN	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	IgE	_	_	NN	Protein	14	multitoken	_	_
13	binding	_	_	NN	Protein	14	multitoken	_	_
14	protein	_	_	NN	Protein	0	root	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	CBP35	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	Mac-2	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	L-29	_	_	NN	Protein	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	L-34	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	its	_	_	PRP$	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	has	_	_	VBZ	O	-1	none	_	_
30	been	_	_	VBN	O	-1	none	_	_
31	associated	_	_	VBN	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	various	_	_	JJ	O	-1	none	_	_
34	physiological	_	_	JJ	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	pathological	_	_	JJ	O	-1	none	_	_
37	processes	_	_	NNS	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	including	_	_	VBG	O	-1	none	_	_
40	cell	_	_	NN	O	-1	none	_	_
41	growth	_	_	NN	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	tumor	_	_	NN	O	-1	none	_	_
44	transformation	_	_	NN	O	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	metastasis	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	Galectin-3	_	_	NNP	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	widely	_	_	RB	O	-1	none	_	_
4	distributed	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	various	_	_	JJ	O	-1	none	_	_
7	tissues	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	types	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	expressed	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	many	_	_	JJ	O	-1	none	_	_
16	leukocytes	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	notable	_	_	JJ	O	-1	none	_	_
21	exception	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	lymphocytes	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	galectin-3	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	abundantly	_	_	RB	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	number	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lymphotropic	_	_	JJ	O	-1	none	_	_
16	virus	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	HTLV	_	_	NN	O	-1	none	_	_
19	)-I-infected	_	_	JJ	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	lines	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	including	_	_	VBG	O	-1	none	_	_
26	F6T	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	HUT	_	_	NN	O	-1	none	_	_
29	102	_	_	CD	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	K3T	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	MT-2	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	SLB-I	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	but	_	_	CC	O	-1	none	_	_
39	is	_	_	VBZ	O	-1	none	_	_
40	not	_	_	RB	O	-1	none	_	_
41	expressed	_	_	VBN	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	non-HTLV-I-infected	_	_	JJ	O	-1	none	_	_
44	T	_	_	NN	O	-1	none	_	_
45	cell	_	_	NN	O	-1	none	_	_
46	lines	_	_	NNS	O	-1	none	_	_
47	such	_	_	JJ	O	-1	none	_	_
48	as	_	_	IN	O	-1	none	_	_
49	Jurkat	_	_	NN	O	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	CEM	_	_	NN	O	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	and	_	_	CC	O	-1	none	_	_
54	MOLT-4	_	_	NN	O	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	galectin-3	_	_	NN	Protein	-1	none	_	_
6	level	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	markedly	_	_	RB	O	-1	none	_	_
9	increased	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	thymocytes	_	_	NNS	O	-1	none	_	_
13	after	_	_	IN	O	-1	none	_	_
14	infection	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	HTLV-I	_	_	NN	O	-1	none	_	_
17	as	_	_	IN	O	-1	none	_	_
18	compared	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	uninfected	_	_	JJ	O	-1	none	_	_
21	thymocytes	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	up-regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	galectin-3	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	appeared	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	correlate	_	_	VB	O	-1	none	_	_
9	well	_	_	RB	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	HTLV-I	_	_	NN	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	as	_	_	IN	O	-1	none	_	_
16	undetectable	_	_	JJ	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	very	_	_	RB	O	-1	none	_	_
19	low	_	_	JJ	O	-1	none	_	_
20	levels	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	galectin-3	_	_	NN	Protein	-1	none	_	_
23	were	_	_	VBD	O	-1	none	_	_
24	found	_	_	VBN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	S1T	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	ATL-1K	_	_	NN	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	lines	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	which	_	_	WDT	O	-1	none	_	_
34	are	_	_	VBP	O	-1	none	_	_
35	nonproductively	_	_	RB	O	-1	none	_	_
36	infected	_	_	VBN	O	-1	none	_	_
37	with	_	_	IN	O	-1	none	_	_
38	HTLV-I	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	co-transfection	_	_	NN	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	galectin-3	_	_	NN	Protein	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	significantly	_	_	RB	O	-1	none	_	_
10	up-regulated	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	vectors	_	_	NNS	O	-1	none	_	_
14	encoding	_	_	VBG	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	40-kd	_	_	JJ	O	-1	none	_	_
17	Tax	_	_	NN	Protein	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	potent	_	_	JJ	O	-1	none	_	_
22	transactivator	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	HTLV-I	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Analysis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	various	_	_	JJ	O	-1	none	_	_
4	Tax	_	_	NN	Protein	-1	none	_	_
5	mutants	_	_	NNS	O	-1	none	_	_
6	suggested	_	_	VBD	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	galectin-3	_	_	NN	Protein	-1	none	_	_
9	promoter	_	_	NN	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	cyclic-AMP-responsive	_	_	JJ	O	-1	none	_	_
18	element	_	_	NN	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	protein	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	factor	_	_	NN	O	-1	none	_	_
25	family	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factors	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	lesser	_	_	JJR	O	-1	none	_	_
34	extent	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	nuclear	_	_	JJ	O	-1	none	_	_
37	factor-kappa	_	_	NN	O	-1	none	_	_
38	B/Rel	_	_	NN	O	-1	none	_	_
39	induction	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Transfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	promonocytic	_	_	JJ	O	-1	none	_	_
5	U-937	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	HTLV-I	_	_	NN	O	-1	none	_	_
10	Tax	_	_	NN	Protein	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	vector	_	_	NN	O	-1	none	_	_
13	induced	_	_	VBD	O	-1	none	_	_
14	galectin-3	_	_	NN	Protein	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	this	_	_	DT	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	line	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Functionally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	galectin-3	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	activate	_	_	VB	O	-1	none	_	_
8	interleukin-2	_	_	NN	Protein	-1	none	_	_
9	production	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	Jurkat	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	findings	_	_	NNS	O	-1	none	_	_
5	raise	_	_	VBP	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	possibility	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	HTLV-I	_	_	NN	O	-1	none	_	_
10	Tax	_	_	NN	Protein	-1	none	_	_
11	production	_	_	NN	O	-1	none	_	_
12	induces	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	subsequent	_	_	JJ	O	-1	none	_	_
17	synthesis	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	secretion	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	galectin-3	_	_	NN	Protein	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	which	_	_	WDT	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	turn	_	_	NN	O	-1	none	_	_
26	may	_	_	MD	O	-1	none	_	_
27	further	_	_	RB	O	-1	none	_	_
28	activate	_	_	VB	O	-1	none	_	_
29	these	_	_	DT	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	contribute	_	_	VBP	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	altered	_	_	JJ	O	-1	none	_	_
37	properties	_	_	NNS	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	growth	_	_	NN	O	-1	none	_	_
41	found	_	_	VBN	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	adult	_	_	JJ	O	-1	none	_	_
44	T	_	_	NN	O	-1	none	_	_
45	cell	_	_	NN	O	-1	none	_	_
46	leukemia	_	_	NN	O	-1	none	_	_
47	induced	_	_	VBN	O	-1	none	_	_
48	by	_	_	IN	O	-1	none	_	_
49	HTLV-I	_	_	NN	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	cAMP	_	_	NN	O	-1	none	_	_
2	dependent	_	_	JJ	O	-1	none	_	_
3	regulation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	proenkephalin	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	JunD	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	JunB	_	_	NN	Protein	-1	none	_	_
10	:	_	_	:	O	-1	none	_	_
11	positive	_	_	JJ	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	negative	_	_	JJ	O	-1	none	_	_
14	effects	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	AP-1	_	_	NN	O	-1	none	_	_
17	proteins	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	JunD	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	component	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	AP-1	_	_	NN	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	complex	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	activates	_	_	VBZ	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	proenkephalin	_	_	NN	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	fashion	_	_	NN	O	-1	none	_	_
25	that	_	_	WDT	O	-1	none	_	_
26	is	_	_	VBZ	O	-1	none	_	_
27	completely	_	_	RB	O	-1	none	_	_
28	dependent	_	_	JJ	O	-1	none	_	_
29	upon	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	cAMP	_	_	NN	O	-1	none	_	_
32	dependent	_	_	JJ	O	-1	none	_	_
33	protein	_	_	NN	O	-1	none	_	_
34	kinase	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	protein	_	_	NN	O	-1	none	_	_
37	kinase	_	_	NN	O	-1	none	_	_
38	A.	_	_	NN	O	-1	none	_	_
39	Activation	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	proenkephalin	_	_	NN	O	-1	none	_	_
42	transcription	_	_	NN	O	-1	none	_	_
43	by	_	_	IN	O	-1	none	_	_
44	JunD	_	_	NN	Protein	-1	none	_	_
45	is	_	_	VBZ	O	-1	none	_	_
46	dependent	_	_	JJ	O	-1	none	_	_
47	upon	_	_	IN	O	-1	none	_	_
48	a	_	_	DT	O	-1	none	_	_
49	previously	_	_	RB	O	-1	none	_	_
50	characterized	_	_	VBN	O	-1	none	_	_
51	cAMP-,	_	_	NN	O	-1	none	_	_
52	phorbol	_	_	NN	O	-1	none	_	_
53	ester-,	_	_	NN	O	-1	none	_	_
54	and	_	_	CC	O	-1	none	_	_
55	Ca	_	_	NN	O	-1	none	_	_
56	(	_	_	-LRB-	O	-1	none	_	_
57	2+	_	_	CD	O	-1	none	_	_
58	)-inducible	_	_	JJ	O	-1	none	_	_
59	enhancer	_	_	NN	O	-1	none	_	_
60	,	_	_	,	O	-1	none	_	_
61	and	_	_	CC	O	-1	none	_	_
62	JunD	_	_	NN	Protein	-1	none	_	_
63	is	_	_	VBZ	O	-1	none	_	_
64	shown	_	_	VBN	O	-1	none	_	_
65	to	_	_	TO	O	-1	none	_	_
66	bind	_	_	VB	O	-1	none	_	_
67	the	_	_	DT	O	-1	none	_	_
68	enhancer	_	_	NN	O	-1	none	_	_
69	as	_	_	IN	O	-1	none	_	_
70	a	_	_	DT	O	-1	none	_	_
71	homodimer	_	_	NN	O	-1	none	_	_
72	.	_	_	.	O	-1	none	_	_

1	Another	_	_	DT	O	-1	none	_	_
2	component	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	AP-1	_	_	NN	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	complex	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	JunB	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	shown	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	inhibit	_	_	VB	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	mediated	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	JunD	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	homodimer	_	_	NN	O	-1	none	_	_
4	JunB	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	unable	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	bind	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	enhancer	_	_	NN	O	-1	none	_	_
11	;	_	_	:	O	-1	none	_	_
12	however	_	_	RB	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	presence	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	c-Fos	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	high-affinity	_	_	JJ	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	observed	_	_	VBN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	JunD	_	_	NN	Protein	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	activate	_	_	VB	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	genes	_	_	NNS	O	-1	none	_	_
11	linked	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	both	_	_	CC	O	-1	none	_	_
14	cAMP	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	phorbol	_	_	NN	O	-1	none	_	_
17	ester	_	_	NN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	elements	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	protein	_	_	NN	O	-1	none	_	_
23	kinase	_	_	NN	O	-1	none	_	_
24	A	_	_	NN	O	-1	none	_	_
25	dependent	_	_	JJ	O	-1	none	_	_
26	fashion	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	further	_	_	JJ	O	-1	none	_	_
29	blurring	_	_	VBG	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	distinction	_	_	NN	O	-1	none	_	_
32	between	_	_	IN	O	-1	none	_	_
33	these	_	_	DT	O	-1	none	_	_
34	response	_	_	NN	O	-1	none	_	_
35	elements	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	transcriptional	_	_	JJ	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	AP-1-related	_	_	JJ	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	regulated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	cAMP	_	_	NN	O	-1	none	_	_
17	dependent	_	_	JJ	O	-1	none	_	_
18	second-messenger	_	_	NN	O	-1	none	_	_
19	pathway	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	suggest	_	_	VBP	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	JunD	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	other	_	_	JJ	O	-1	none	_	_
26	AP-1-related	_	_	JJ	O	-1	none	_	_
27	proteins	_	_	NNS	O	-1	none	_	_
28	may	_	_	MD	O	-1	none	_	_
29	play	_	_	VB	O	-1	none	_	_
30	an	_	_	DT	O	-1	none	_	_
31	important	_	_	JJ	O	-1	none	_	_
32	role	_	_	NN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	regulation	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	gene	_	_	NN	O	-1	none	_	_
38	expression	_	_	NN	O	-1	none	_	_
39	by	_	_	IN	O	-1	none	_	_
40	cAMP	_	_	NN	O	-1	none	_	_
41	dependent	_	_	JJ	O	-1	none	_	_
42	intracellular	_	_	JJ	O	-1	none	_	_
43	signaling	_	_	NN	O	-1	none	_	_
44	pathways	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Genomic	_	_	JJ	O	-1	none	_	_
2	organization	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	sequence	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	transcriptional	_	_	JJ	O	-1	none	_	_
8	regulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	eotaxin	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Eotaxin	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	eosinophil	_	_	NN	O	-1	none	_	_
5	specific	_	_	JJ	O	-1	none	_	_
6	beta-chemokine	_	_	NN	O	-1	none	_	_
7	assumed	_	_	VBD	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	involved	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	eosinophilic	_	_	JJ	O	-1	none	_	_
13	inflammatory	_	_	JJ	O	-1	none	_	_
14	diseases	_	_	NNS	O	-1	none	_	_
15	such	_	_	JJ	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	atopic	_	_	JJ	O	-1	none	_	_
18	dermatitis	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	allergic	_	_	JJ	O	-1	none	_	_
21	rhinitis	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	asthma	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	parasitic	_	_	JJ	O	-1	none	_	_
26	infections	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Its	_	_	PRP$	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	stimulus-	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	specific	_	_	JJ	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	here	_	_	RB	O	-1	none	_	_
3	describe	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	genomic	_	_	JJ	O	-1	none	_	_
6	organisation	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	3	_	_	CD	O	-1	none	_	_
9	exons	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	132	_	_	CD	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	112	_	_	CD	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	542	_	_	CD	O	-1	none	_	_
16	bp	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	2	_	_	CD	O	-1	none	_	_
19	introns	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	1211	_	_	CD	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	378	_	_	CD	O	-1	none	_	_
24	bp	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	sequence	_	_	NN	O	-1	none	_	_
28	including	_	_	VBG	O	-1	none	_	_
29	3	_	_	CD	O	-1	none	_	_
30	kb	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	DNA	_	_	NN	O	-1	none	_	_
33	from	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	immediate	_	_	JJ	O	-1	none	_	_
36	5	_	_	CD	O	-1	none	_	_
37	'	_	_	''	O	-1	none	_	_
38	upstream	_	_	JJ	O	-1	none	_	_
39	region	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	human	_	_	NN	O	-1	none	_	_
43	eotaxin	_	_	NN	Protein	-1	none	_	_
44	gene	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	hydrophobic	_	_	JJ	O	-1	none	_	_
3	domain	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	Ca2	_	_	NN	Protein	8	multitoken	_	_
6	+-modulating	_	_	JJ	Protein	8	multitoken	_	_
7	cyclophilin	_	_	NN	Protein	8	multitoken	_	_
8	ligand	_	_	NN	Protein	0	root	_	_
9	modulates	_	_	VBZ	O	-1	none	_	_
10	calcium	_	_	NN	O	-1	none	_	_
11	influx	_	_	NN	O	-1	none	_	_
12	signaling	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Ca2	_	_	NN	Protein	4	multitoken	_	_
2	+-modulating	_	_	JJ	Protein	4	multitoken	_	_
3	cyclophilin	_	_	NN	Protein	4	multitoken	_	_
4	ligand	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	CAML	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	originally	_	_	RB	O	-1	none	_	_
10	described	_	_	VBN	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	cyclophilin	_	_	NN	Protein	14	multitoken	_	_
14	B	_	_	NN	Protein	0	root	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	whose	_	_	WP$	O	-1	none	_	_
18	overexpression	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	causes	_	_	VBZ	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	rise	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	intracellular	_	_	JJ	O	-1	none	_	_
27	calcium	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	thus	_	_	RB	O	-1	none	_	_
30	activating	_	_	VBG	O	-1	none	_	_
31	transcription	_	_	NN	O	-1	none	_	_
32	factors	_	_	NNS	O	-1	none	_	_
33	responsible	_	_	JJ	O	-1	none	_	_
34	for	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	early	_	_	JJ	O	-1	none	_	_
37	immune	_	_	JJ	O	-1	none	_	_
38	response	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	reported	_	_	VBN	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	structure-function	_	_	JJ	O	-1	none	_	_
6	analysis	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	CAML	_	_	NN	Protein	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	Jurkat	_	_	NN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	indicates	_	_	VBZ	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	two	_	_	CD	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	CAML	_	_	NN	Protein	-1	none	_	_
20	's	_	_	POS	O	-1	none	_	_
21	putative	_	_	JJ	O	-1	none	_	_
22	membrane	_	_	NN	O	-1	none	_	_
23	spanning	_	_	NN	O	-1	none	_	_
24	domains	_	_	NNS	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	necessary	_	_	JJ	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	sufficient	_	_	JJ	O	-1	none	_	_
29	for	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	modulation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	intracellular	_	_	JJ	O	-1	none	_	_
34	calcium	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	hydrophobic	_	_	JJ	O	-1	none	_	_
6	C-terminal	_	_	JJ	O	-1	none	_	_
7	tail	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	CAML	_	_	NN	Protein	-1	none	_	_
10	forms	_	_	VBZ	O	-1	none	_	_
11	its	_	_	PRP$	O	-1	none	_	_
12	effector	_	_	NN	O	-1	none	_	_
13	domain	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	thus	_	_	RB	O	-1	none	_	_
16	implicating	_	_	VBG	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	N-terminal	_	_	JJ	O	-1	none	_	_
19	hydrophilic	_	_	JJ	O	-1	none	_	_
20	domain	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	regulatory	_	_	JJ	O	-1	none	_	_
24	role	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	define	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	novel	_	_	JJ	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	motif	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	functions	_	_	VBZ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	intracellular	_	_	JJ	O	-1	none	_	_
12	calcium	_	_	NN	O	-1	none	_	_
13	signaling	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Rel	_	_	NN	Protein	-1	none	_	_
2	deficient	_	_	JJ	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	exhibit	_	_	VBP	O	-1	none	_	_
6	defects	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	production	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	interleukin	_	_	NN	Protein	11	multitoken	_	_
11	3	_	_	CD	Protein	0	root	_	_
12	and	_	_	CC	O	-1	none	_	_
13	granulocyte-macrophage	_	_	JJ	Protein	16	multitoken	_	_
14	colony	_	_	NN	Protein	16	multitoken	_	_
15	stimulating	_	_	NN	Protein	16	multitoken	_	_
16	factor	_	_	NN	Protein	0	root	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	c-rel	_	_	NN	Protein	-1	none	_	_
3	protooncogene	_	_	NN	O	-1	none	_	_
4	encodes	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	subunit	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	like	_	_	IN	O	-1	none	_	_
12	family	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	factors	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Mice	_	_	NNS	O	-1	none	_	_
2	lacking	_	_	VBG	O	-1	none	_	_
3	Rel	_	_	NN	Protein	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	defective	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	mitogenic	_	_	JJ	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	display	_	_	VBP	O	-1	none	_	_
16	impaired	_	_	JJ	O	-1	none	_	_
17	humoral	_	_	JJ	O	-1	none	_	_
18	immunity	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	establish	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Rel	_	_	NN	Protein	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	function	_	_	VB	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	activator	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	repressor	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	required	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	lymphocytes	_	_	NNS	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	production	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	IL-3	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	GM-CSF	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	IL-2	_	_	NN	Protein	-1	none	_	_
3	response	_	_	NN	O	-1	none	_	_
4	element	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	11	multitoken	_	_
9	receptor	_	_	NN	Protein	11	multitoken	_	_
10	alpha	_	_	NN	Protein	11	multitoken	_	_
11	chain	_	_	NN	Protein	0	root	_	_
12	promoter	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	composite	_	_	JJ	O	-1	none	_	_
16	element	_	_	NN	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	binds	_	_	VBZ	O	-1	none	_	_
19	Stat5	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	Elf-1	_	_	NN	Protein	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	HMG-I	_	_	NN	Protein	26	multitoken	_	_
24	(	_	_	-LRB-	Protein	26	multitoken	_	_
25	Y	_	_	NN	Protein	26	multitoken	_	_
26	)	_	_	-RRB-	Protein	0	root	_	_
27	and	_	_	CC	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	GATA	_	_	NN	O	-1	none	_	_
30	family	_	_	NN	O	-1	none	_	_
31	protein	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	interleukin-2	_	_	NN	Protein	11	multitoken	_	_
6	(	_	_	-LRB-	Protein	11	multitoken	_	_
7	IL-2	_	_	NN	Protein	11	multitoken	_	_
8	)	_	_	-RRB-	Protein	11	multitoken	_	_
9	receptor	_	_	NN	Protein	11	multitoken	_	_
10	alpha	_	_	NN	Protein	11	multitoken	_	_
11	chain	_	_	NN	Protein	0	root	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	potently	_	_	RB	O	-1	none	_	_
15	upregulated	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	own	_	_	JJ	O	-1	none	_	_
19	ligand	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	characterize	_	_	VBP	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	essential	_	_	JJ	O	-1	none	_	_
9	upstream	_	_	JJ	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	element	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	contains	_	_	VBZ	O	-1	none	_	_
15	both	_	_	CC	O	-1	none	_	_
16	consensus	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	non	_	_	JJ	O	-1	none	_	_
19	consensus	_	_	NN	O	-1	none	_	_
20	GAS	_	_	NN	O	-1	none	_	_
21	motifs	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	two	_	_	CD	O	-1	none	_	_
24	putative	_	_	JJ	O	-1	none	_	_
25	Ets	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	sites	_	_	NNS	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	EBS	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	one	_	_	CD	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	which	_	_	WDT	O	-1	none	_	_
35	overlaps	_	_	VBZ	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	consensus	_	_	NN	O	-1	none	_	_
38	GAS	_	_	NN	O	-1	none	_	_
39	motif	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	a	_	_	DT	O	-1	none	_	_
43	GATA	_	_	NN	O	-1	none	_	_
44	motif	_	_	NN	O	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	which	_	_	WDT	O	-1	none	_	_
47	overlaps	_	_	VBZ	O	-1	none	_	_
48	the	_	_	DT	O	-1	none	_	_
49	non	_	_	JJ	O	-1	none	_	_
50	consensus	_	_	NN	O	-1	none	_	_
51	GAS	_	_	NN	O	-1	none	_	_
52	motif	_	_	NN	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	although	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	individual	_	_	JJ	O	-1	none	_	_
7	components	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	this	_	_	DT	O	-1	none	_	_
10	element	_	_	NN	O	-1	none	_	_
11	do	_	_	VBP	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	respond	_	_	VB	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	together	_	_	RB	O	-1	none	_	_
18	they	_	_	PRP	O	-1	none	_	_
19	form	_	_	VBP	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	composite	_	_	JJ	O	-1	none	_	_
22	element	_	_	NN	O	-1	none	_	_
23	capable	_	_	JJ	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	conferring	_	_	VBG	O	-1	none	_	_
26	IL-2	_	_	NN	Protein	-1	none	_	_
27	responsiveness	_	_	NN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	heterologous	_	_	JJ	O	-1	none	_	_
31	promoter	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Multiple	_	_	JJ	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	including	_	_	VBG	O	-1	none	_	_
4	Stat5	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	Elf-1	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	HMG-I	_	_	NN	Protein	11	multitoken	_	_
9	(	_	_	-LRB-	Protein	11	multitoken	_	_
10	Y	_	_	NN	Protein	11	multitoken	_	_
11	)	_	_	-RRB-	Protein	0	root	_	_
12	and	_	_	CC	O	-1	none	_	_
13	GATA	_	_	NN	O	-1	none	_	_
14	family	_	_	NN	O	-1	none	_	_
15	proteins	_	_	NNS	O	-1	none	_	_
16	bind	_	_	VBP	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	IL-2	_	_	NN	Protein	-1	none	_	_
20	response	_	_	NN	O	-1	none	_	_
21	element	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	mutation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	any	_	_	DT	O	-1	none	_	_
26	one	_	_	CD	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	these	_	_	DT	O	-1	none	_	_
29	binding	_	_	VBG	O	-1	none	_	_
30	sites	_	_	NNS	O	-1	none	_	_
31	diminishes	_	_	VBZ	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	activity	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	this	_	_	DT	O	-1	none	_	_
36	element	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	unidentified	_	_	JJ	O	-1	none	_	_
3	Ets	_	_	NN	O	-1	none	_	_
4	family	_	_	NN	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	binds	_	_	VBZ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	EBS	_	_	NN	O	-1	none	_	_
10	overlapping	_	_	VBG	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	consensus	_	_	NN	O	-1	none	_	_
13	GAS	_	_	NN	O	-1	none	_	_
14	motif	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	appears	_	_	VBZ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	negatively	_	_	RB	O	-1	none	_	_
19	regulate	_	_	VB	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	IL-2R	_	_	NN	Protein	23	multitoken	_	_
23	alpha	_	_	NN	Protein	0	root	_	_
24	promoter	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	tyrosine	_	_	NN	O	-1	none	_	_
4	phosphorylation	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	T-cell	_	_	NN	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	vanadate	_	_	NN	O	-1	none	_	_
10	peroxide	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	inhibitor	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	tyrosine	_	_	NN	O	-1	none	_	_
17	phosphatases	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Rapid	_	_	JJ	O	-1	none	_	_
2	tyrosine	_	_	NN	O	-1	none	_	_
3	phosphorylation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	key	_	_	JJ	O	-1	none	_	_
6	cellular	_	_	JJ	O	-1	none	_	_
7	proteins	_	_	NNS	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	crucial	_	_	JJ	O	-1	none	_	_
11	event	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	transduction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	signals	_	_	NNS	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	T-lymphocytes	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	regulatory	_	_	JJ	O	-1	none	_	_
3	role	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	tyrosine	_	_	NN	O	-1	none	_	_
7	phosphatases	_	_	NNS	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	PTPases	_	_	NNS	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	this	_	_	DT	O	-1	none	_	_
13	process	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	explored	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	studying	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	effects	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	powerful	_	_	JJ	O	-1	none	_	_
23	PTPase	_	_	NN	O	-1	none	_	_
24	inhibitor	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	vanadate	_	_	NN	O	-1	none	_	_
27	peroxide	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	pervanadate	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	on	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	activation	_	_	NN	O	-1	none	_	_
35	cascade	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	Jurkat	_	_	NN	O	-1	none	_	_
38	human	_	_	NN	O	-1	none	_	_
39	leukaemic	_	_	JJ	O	-1	none	_	_
40	T-cells	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Pervanadate	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	tyrosine	_	_	NN	O	-1	none	_	_
7	kinases	_	_	NNS	O	-1	none	_	_
8	lck	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	fyn	_	_	NN	Protein	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	4-	_	_	CD	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	3-fold	_	_	JJ	O	-1	none	_	_
15	respectively	_	_	RB	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	dramatic	_	_	JJ	O	-1	none	_	_
20	increase	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	tyrosine	_	_	NN	O	-1	none	_	_
23	phosphorylation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	cellular	_	_	JJ	O	-1	none	_	_
26	proteins	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	notably	_	_	RB	O	-1	none	_	_
29	phospholipase	_	_	NN	Protein	32	multitoken	_	_
30	C	_	_	NN	Protein	32	multitoken	_	_
31	gamma	_	_	NN	Protein	32	multitoken	_	_
32	1	_	_	CD	Protein	0	root	_	_
33	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	event	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	observed	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	rise	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	intracellular	_	_	JJ	O	-1	none	_	_
11	Ca2+	_	_	NN	O	-1	none	_	_
12	concentration	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	corresponding	_	_	VBG	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	an	_	_	DT	O	-1	none	_	_
17	influx	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	required	_	_	VBD	O	-1	none	_	_
4	surface	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	CD45	_	_	NN	Protein	-1	none	_	_
9	PTPase	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	observed	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	CD45	_	_	NN	Protein	-1	none	_	_
16	deficient	_	_	JJ	O	-1	none	_	_
17	variants	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	Jurkat	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	CD45	_	_	NN	Protein	-1	none	_	_
4	negative	_	_	JJ	O	-1	none	_	_
5	variant	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	effect	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	pervanadate	_	_	NN	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	tyrosine	_	_	NN	O	-1	none	_	_
13	phosphorylation	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	globally	_	_	RB	O	-1	none	_	_
16	decreased	_	_	VBN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	some	_	_	DT	O	-1	none	_	_
19	phosphorylated	_	_	JJ	O	-1	none	_	_
20	substrates	_	_	NNS	O	-1	none	_	_
21	were	_	_	VBD	O	-1	none	_	_
22	specifically	_	_	RB	O	-1	none	_	_
23	missing	_	_	VBG	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Pervanadate	_	_	NN	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	stimulated	_	_	VBD	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	c-fos	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	accumulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	its	_	_	PRP$	O	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	as	_	_	RB	O	-1	none	_	_
15	well	_	_	RB	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	several	_	_	JJ	O	-1	none	_	_
18	other	_	_	JJ	O	-1	none	_	_
19	hallmarks	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	T-lymphocyte	_	_	NN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	such	_	_	JJ	O	-1	none	_	_
24	as	_	_	IN	O	-1	none	_	_
25	surface	_	_	NN	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	CD69	_	_	NN	Protein	-1	none	_	_
30	antigen	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	interleukin	_	_	NN	Protein	36	multitoken	_	_
34	2	_	_	CD	Protein	36	multitoken	_	_
35	receptor	_	_	NN	Protein	36	multitoken	_	_
36	alpha-chain	_	_	NN	Protein	0	root	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	CD25	_	_	NN	Protein	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Pervanadate	_	_	NN	O	-1	none	_	_
2	synergized	_	_	VBD	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	signals	_	_	NNS	O	-1	none	_	_
5	delivered	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	T-cell	_	_	NN	O	-1	none	_	_
8	antigen	_	_	NN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	engagement	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	phorbol	_	_	NN	O	-1	none	_	_
15	ester	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	induce	_	_	VB	O	-1	none	_	_
18	interleukin	_	_	NN	Protein	19	multitoken	_	_
19	2	_	_	CD	Protein	0	root	_	_
20	production	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Pervanadate	_	_	NN	O	-1	none	_	_
2	activated	_	_	VBD	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	shown	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	increase	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	DNA	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	this	_	_	DT	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	thus	_	_	RB	O	-1	none	_	_
3	conclude	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	PTPases	_	_	NNS	O	-1	none	_	_
6	play	_	_	VBP	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	crucial	_	_	JJ	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	negative	_	_	JJ	O	-1	none	_	_
13	regulation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	signal	_	_	NN	O	-1	none	_	_
16	transduction	_	_	NN	O	-1	none	_	_
17	culminating	_	_	VBG	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	T-lymphocyte	_	_	NN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	induction	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	tyrosine	_	_	NN	O	-1	none	_	_
6	phosphorylation	_	_	NN	O	-1	none	_	_
7	appears	_	_	VBZ	O	-1	none	_	_
8	sufficient	_	_	JJ	O	-1	none	_	_
9	per	_	_	FW	O	-1	none	_	_
10	se	_	_	FW	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	initiate	_	_	VB	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	complete	_	_	JJ	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	programme	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Antisense	_	_	JJ	O	-1	none	_	_
2	oligonucleotides	_	_	NNS	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	p65	_	_	NN	Protein	-1	none	_	_
6	subunit	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	block	_	_	NN	O	-1	none	_	_
11	CD11b	_	_	NN	Protein	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	alter	_	_	VB	O	-1	none	_	_
15	adhesion	_	_	NN	O	-1	none	_	_
16	properties	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	differentiated	_	_	VBN	O	-1	none	_	_
19	HL-60	_	_	NN	O	-1	none	_	_
20	granulocytes	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	pleiotropic	_	_	JJ	O	-1	none	_	_
6	regulator	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	variety	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	implicated	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	cellular	_	_	JJ	O	-1	none	_	_
16	response	_	_	NN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	injury	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	function	_	_	NN	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	attributed	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	coordinated	_	_	JJ	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	subunits	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	distinct	_	_	JJ	O	-1	none	_	_
17	regions	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	elements	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	numerous	_	_	JJ	O	-1	none	_	_
24	genes	_	_	NNS	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	including	_	_	VBG	O	-1	none	_	_
27	cytokines	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	growth	_	_	NN	O	-1	none	_	_
30	factor	_	_	NN	O	-1	none	_	_
31	receptors	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	adhesion	_	_	NN	O	-1	none	_	_
35	molecules	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Antisense	_	_	JJ	O	-1	none	_	_
2	phosphorothioate	_	_	NN	O	-1	none	_	_
3	oligonucleotides	_	_	NNS	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	p50	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	p65	_	_	NN	Protein	-1	none	_	_
9	subunits	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	complex	_	_	NN	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	used	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	define	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	physiologic	_	_	JJ	O	-1	none	_	_
21	role	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	factor	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	resting	_	_	VBG	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	stimulated	_	_	VBN	O	-1	none	_	_
30	granulocytes	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	reduction	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	p65	_	_	NN	Protein	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	produced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	treatment	_	_	NN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	phosphorothioate	_	_	NN	O	-1	none	_	_
15	antisense	_	_	JJ	O	-1	none	_	_
16	oligodeoxynucleotide	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	reduction	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	accompanied	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	rapid	_	_	JJ	O	-1	none	_	_
7	changes	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cellular	_	_	JJ	O	-1	none	_	_
11	adhesion	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	dimethyl	_	_	JJ	O	-1	none	_	_
14	sulfoxide	_	_	NN	O	-1	none	_	_
15	differentiated	_	_	VBN	O	-1	none	_	_
16	HL-60	_	_	NN	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	stimulated	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	12-O-tetradecanoylphorbol	_	_	NN	O	-1	none	_	_
22	13-acetate	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	TPA	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	characterized	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	marked	_	_	JJ	O	-1	none	_	_
8	reduction	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	CD11b	_	_	NN	Protein	-1	none	_	_
11	integrin	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	surface	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	treated	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	p65	_	_	NN	Protein	-1	none	_	_
5	antisense	_	_	JJ	O	-1	none	_	_
6	oligomer	_	_	NN	O	-1	none	_	_
7	effectively	_	_	RB	O	-1	none	_	_
8	abolished	_	_	VBD	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	upregulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	CD11b	_	_	NN	Protein	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	produced	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	formyl-met-leu-phe	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	TPA	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	p65	_	_	NN	Protein	-1	none	_	_
5	antisense	_	_	JJ	O	-1	none	_	_
6	phosphorothioate	_	_	NN	O	-1	none	_	_
7	oligodeoxynucleotide	_	_	NN	O	-1	none	_	_
8	had	_	_	VBD	O	-1	none	_	_
9	no	_	_	DT	O	-1	none	_	_
10	significant	_	_	JJ	O	-1	none	_	_
11	effect	_	_	NN	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	reactive	_	_	JJ	O	-1	none	_	_
17	oxygen	_	_	NN	O	-1	none	_	_
18	intermediates	_	_	NNS	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	phagocytosis	_	_	NN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	these	_	_	DT	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	antisense	_	_	JJ	O	-1	none	_	_
6	oligomers	_	_	NNS	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	p65	_	_	NN	Protein	-1	none	_	_
9	can	_	_	MD	O	-1	none	_	_
10	be	_	_	VB	O	-1	none	_	_
11	used	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	define	_	_	VB	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	role	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	pathways	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	neutrophils	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Fas	_	_	NN	Protein	-1	none	_	_
2	mediated	_	_	JJ	O	-1	none	_	_
3	apoptosis	_	_	NN	O	-1	none	_	_
4	plays	_	_	VBZ	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	important	_	_	JJ	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	regulating	_	_	VBG	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	immune	_	_	JJ	O	-1	none	_	_
12	response	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	peripheral	_	_	JJ	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Restimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	blasts	_	_	NNS	O	-1	none	_	_
6	up-regulates	_	_	VBZ	O	-1	none	_	_
7	Fas	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	Fas	_	_	NN	Protein	10	multitoken	_	_
10	ligand	_	_	NN	Protein	0	root	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	subsequent	_	_	JJ	O	-1	none	_	_
15	interaction	_	_	NN	O	-1	none	_	_
16	leading	_	_	VBG	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	death	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Bcl-2	_	_	NN	Protein	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	tumor	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	blocks	_	_	VBZ	O	-1	none	_	_
8	apoptosis	_	_	NN	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	many	_	_	JJ	O	-1	none	_	_
12	stimuli	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	inhibition	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	Fas	_	_	NN	Protein	-1	none	_	_
18	mediated	_	_	VBD	O	-1	none	_	_
19	killing	_	_	NN	O	-1	none	_	_
20	has	_	_	VBZ	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	been	_	_	VBN	O	-1	none	_	_
23	consistently	_	_	RB	O	-1	none	_	_
24	observed	_	_	VBN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	examine	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	behavior	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Bcl-2	_	_	NN	Protein	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	normal	_	_	JJ	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	blasts	_	_	NNS	O	-1	none	_	_
14	were	_	_	VBD	O	-1	none	_	_
15	transiently	_	_	RB	O	-1	none	_	_
16	transfected	_	_	VBN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	Bcl-2	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	related	_	_	JJ	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	products	_	_	NNS	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	determine	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	effect	_	_	NN	O	-1	none	_	_
27	on	_	_	IN	O	-1	none	_	_
28	apoptotic	_	_	JJ	O	-1	none	_	_
29	signaling	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Bcl-2	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	mouse	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	blasts	_	_	NNS	O	-1	none	_	_
12	did	_	_	VBD	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	block	_	_	VB	O	-1	none	_	_
15	Fas	_	_	NN	Protein	-1	none	_	_
16	mediated	_	_	JJ	O	-1	none	_	_
17	apoptosis	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	whereas	_	_	IN	O	-1	none	_	_
20	etoposide-	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	glucocorticoid	_	_	NN	O	-1	none	_	_
23	induced	_	_	VBD	O	-1	none	_	_
24	cytotoxicity	_	_	NN	O	-1	none	_	_
25	was	_	_	VBD	O	-1	none	_	_
26	potently	_	_	RB	O	-1	none	_	_
27	inhibited	_	_	VBN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Bcl-xL	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	adenovirus	_	_	NN	O	-1	none	_	_
6	E1B	_	_	NN	Protein	7	multitoken	_	_
7	19K	_	_	NN	Protein	0	root	_	_
8	did	_	_	VBD	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	interfere	_	_	VB	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	anti-Fas	_	_	JJ	Protein	-1	none	_	_
13	killing	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	interleukin-1beta-converting	_	_	JJ	O	-1	none	_	_
5	enzyme	_	_	NN	O	-1	none	_	_
6	family	_	_	NN	O	-1	none	_	_
7	protease	_	_	NN	O	-1	none	_	_
8	inhibitors	_	_	NNS	O	-1	none	_	_
9	Ac-DEVD-CHO	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	CrmA	_	_	NN	O	-1	none	_	_
12	blocked	_	_	VBD	O	-1	none	_	_
13	Fas	_	_	NN	Protein	-1	none	_	_
14	mediated	_	_	JJ	O	-1	none	_	_
15	apoptosis	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	normally	_	_	RB	O	-1	none	_	_
5	express	_	_	VBP	O	-1	none	_	_
6	Bcl-2	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	Bcl-xL	_	_	NN	Protein	-1	none	_	_
9	following	_	_	VBG	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	their	_	_	PRP$	O	-1	none	_	_
13	inability	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	block	_	_	VB	O	-1	none	_	_
16	Fas	_	_	NN	Protein	-1	none	_	_
17	mediated	_	_	JJ	O	-1	none	_	_
18	apoptosis	_	_	NN	O	-1	none	_	_
19	may	_	_	MD	O	-1	none	_	_
20	allow	_	_	VB	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	elimination	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	self-reactive	_	_	JJ	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	appropriate	_	_	JJ	O	-1	none	_	_
30	regulation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	immune	_	_	JJ	O	-1	none	_	_
33	responses	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Ligand	_	_	NN	O	-1	none	_	_
2	dependent	_	_	JJ	O	-1	none	_	_
3	repression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	erythroid	_	_	JJ	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	GATA-1	_	_	NN	Protein	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	estrogen	_	_	NN	Protein	13	multitoken	_	_
13	receptor	_	_	NN	Protein	0	root	_	_
14	.	_	_	.	O	-1	none	_	_

1	High-dose	_	_	JJ	O	-1	none	_	_
2	estrogen	_	_	NN	O	-1	none	_	_
3	administration	_	_	NN	O	-1	none	_	_
4	induces	_	_	VBZ	O	-1	none	_	_
5	anemia	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	mammals	_	_	NNS	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	chickens	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	estrogens	_	_	NNS	O	-1	none	_	_
5	stimulate	_	_	VBP	O	-1	none	_	_
6	outgrowth	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	bone	_	_	NN	O	-1	none	_	_
9	marrow	_	_	NN	O	-1	none	_	_
10	derived	_	_	VBN	O	-1	none	_	_
11	erythroid	_	_	JJ	O	-1	none	_	_
12	progenitor	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	delay	_	_	VB	O	-1	none	_	_
16	their	_	_	PRP$	O	-1	none	_	_
17	maturation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	delay	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	associated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	down-regulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	many	_	_	JJ	O	-1	none	_	_
9	erythroid	_	_	JJ	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	genes	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	including	_	_	VBG	O	-1	none	_	_
15	alpha-	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	beta-globin	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	band	_	_	NN	O	-1	none	_	_
20	3	_	_	CD	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	band	_	_	NN	O	-1	none	_	_
23	4.1	_	_	CD	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	erythroid	_	_	JJ	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	specific	_	_	JJ	O	-1	none	_	_
30	histone	_	_	NN	O	-1	none	_	_
31	H5	_	_	NN	Protein	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	estrogens	_	_	NNS	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	reduce	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	number	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	erythroid	_	_	JJ	O	-1	none	_	_
12	progenitor	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	primary	_	_	JJ	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	bone	_	_	NN	O	-1	none	_	_
18	marrow	_	_	NN	O	-1	none	_	_
19	cultures	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	address	_	_	VB	O	-1	none	_	_
3	potential	_	_	JJ	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	estrogens	_	_	NNS	O	-1	none	_	_
8	suppress	_	_	VBP	O	-1	none	_	_
9	erythropoiesis	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	we	_	_	PRP	O	-1	none	_	_
12	have	_	_	VBP	O	-1	none	_	_
13	examined	_	_	VBN	O	-1	none	_	_
14	their	_	_	PRP$	O	-1	none	_	_
15	effects	_	_	NNS	O	-1	none	_	_
16	on	_	_	IN	O	-1	none	_	_
17	GATA-1	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	erythroid	_	_	JJ	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	factor	_	_	NN	O	-1	none	_	_
23	that	_	_	WDT	O	-1	none	_	_
24	participates	_	_	VBZ	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	regulation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	majority	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	erythroid	_	_	JJ	O	-1	none	_	_
33	cell	_	_	NN	O	-1	none	_	_
34	specific	_	_	JJ	O	-1	none	_	_
35	genes	_	_	NNS	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	is	_	_	VBZ	O	-1	none	_	_
38	necessary	_	_	JJ	O	-1	none	_	_
39	for	_	_	IN	O	-1	none	_	_
40	full	_	_	JJ	O	-1	none	_	_
41	maturation	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	erythrocytes	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	GATA-1	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	strongly	_	_	RB	O	-1	none	_	_
11	repressed	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	estrogen	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	ER	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	ligand	_	_	NN	O	-1	none	_	_
22	dependent	_	_	JJ	O	-1	none	_	_
23	manner	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	this	_	_	DT	O	-1	none	_	_
27	repression	_	_	NN	O	-1	none	_	_
28	is	_	_	VBZ	O	-1	none	_	_
29	reversible	_	_	JJ	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	presence	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	4-hydroxytamoxifen	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	ER	_	_	NN	Protein	-1	none	_	_
2	mediated	_	_	VBD	O	-1	none	_	_
3	repression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	GATA-1	_	_	NN	Protein	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	occurs	_	_	VBZ	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	artificial	_	_	JJ	O	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	containing	_	_	VBG	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	single	_	_	JJ	O	-1	none	_	_
15	GATA	_	_	NN	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	site	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	as	_	_	RB	O	-1	none	_	_
20	well	_	_	RB	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	context	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	an	_	_	DT	O	-1	none	_	_
27	intact	_	_	JJ	O	-1	none	_	_
28	promoter	_	_	NN	O	-1	none	_	_
29	which	_	_	WDT	O	-1	none	_	_
30	is	_	_	VBZ	O	-1	none	_	_
31	normally	_	_	RB	O	-1	none	_	_
32	regulated	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	GATA-1	_	_	NN	Protein	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	GATA-1	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	ER	_	_	NN	Protein	-1	none	_	_
4	bind	_	_	VBP	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	each	_	_	DT	O	-1	none	_	_
7	other	_	_	JJ	O	-1	none	_	_
8	in	_	_	FW	O	-1	none	_	_
9	vitro	_	_	FW	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	absence	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	coimmunoprecipitation	_	_	NN	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	using	_	_	VBG	O	-1	none	_	_
5	transfected	_	_	VBN	O	-1	none	_	_
6	COS	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	GATA-1	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	ER	_	_	NN	Protein	-1	none	_	_
12	associate	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	ligand	_	_	NN	O	-1	none	_	_
16	dependent	_	_	JJ	O	-1	none	_	_
17	manner	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Mapping	_	_	NN	O	-1	none	_	_
2	experiments	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	GATA-1	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	ER	_	_	NN	Protein	-1	none	_	_
9	form	_	_	NN	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	least	_	_	JJS	O	-1	none	_	_
12	two	_	_	CD	O	-1	none	_	_
13	contacts	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	involve	_	_	VBP	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	finger	_	_	NN	O	-1	none	_	_
19	region	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	N-terminal	_	_	JJ	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	domain	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	GATA-1	_	_	NN	Protein	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	speculate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	estrogens	_	_	NNS	O	-1	none	_	_
5	exert	_	_	VBP	O	-1	none	_	_
6	effects	_	_	NNS	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	erythropoiesis	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	modulating	_	_	VBG	O	-1	none	_	_
11	GATA-1	_	_	NN	Protein	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	interaction	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	ER	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	ABSTRACT	_	_	NN	O	-1	none	_	_
3	TRUNCATED	_	_	VBD	O	-1	none	_	_
4	AT	_	_	IN	O	-1	none	_	_
5	250	_	_	CD	O	-1	none	_	_
6	WORDS	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	CD40	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	CD40	_	_	NN	Protein	4	multitoken	_	_
4	ligand	_	_	NN	Protein	0	root	_	_
5	interactions	_	_	NNS	O	-1	none	_	_
6	play	_	_	VBP	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	key	_	_	JJ	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	immune	_	_	JJ	O	-1	none	_	_
13	responses	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	lymphocytes	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	dendritic	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	signal	_	_	NN	O	-1	none	_	_
3	transduction	_	_	NN	O	-1	none	_	_
4	events	_	_	NNS	O	-1	none	_	_
5	triggered	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	cross	_	_	NN	O	-1	none	_	_
8	linking	_	_	VBG	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	CD40	_	_	NN	Protein	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	have	_	_	VBP	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	widely	_	_	RB	O	-1	none	_	_
16	studied	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	lines	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	but	_	_	CC	O	-1	none	_	_
23	little	_	_	JJ	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	known	_	_	VBN	O	-1	none	_	_
26	about	_	_	IN	O	-1	none	_	_
27	signaling	_	_	NN	O	-1	none	_	_
28	following	_	_	VBG	O	-1	none	_	_
29	CD40	_	_	NN	Protein	-1	none	_	_
30	stimulation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	monocytes	_	_	NNS	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	resting	_	_	VBG	O	-1	none	_	_
35	tonsillar	_	_	JJ	O	-1	none	_	_
36	B	_	_	NN	O	-1	none	_	_
37	cells	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	studied	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	CD40	_	_	NN	Protein	-1	none	_	_
7	pathway	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	highly	_	_	RB	O	-1	none	_	_
10	purified	_	_	VBN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	resting	_	_	VBG	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	CD40	_	_	NN	Protein	-1	none	_	_
3	triggering	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	similar	_	_	JJ	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	AP-1	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	complex	_	_	NN	O	-1	none	_	_
21	occurred	_	_	VBD	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	both	_	_	DT	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	preparations	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	components	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	NF-kappaB	_	_	NN	O	-1	none	_	_
8	complexes	_	_	NNS	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	different	_	_	JJ	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	because	_	_	IN	O	-1	none	_	_
18	p50	_	_	NN	Protein	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	part	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	NF	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	kappaB	_	_	NN	O	-1	none	_	_
26	complex	_	_	NN	O	-1	none	_	_
27	induced	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	CD40	_	_	NN	Protein	-1	none	_	_
30	triggering	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	both	_	_	CC	O	-1	none	_	_
33	monocytes	_	_	NNS	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	whereas	_	_	IN	O	-1	none	_	_
39	p65	_	_	NN	Protein	-1	none	_	_
40	was	_	_	VBD	O	-1	none	_	_
41	only	_	_	RB	O	-1	none	_	_
42	induced	_	_	VBN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	B	_	_	NN	O	-1	none	_	_
45	cells	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	although	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	Janus	_	_	NN	Protein	8	multitoken	_	_
7	kinase	_	_	NN	Protein	8	multitoken	_	_
8	3	_	_	CD	Protein	0	root	_	_
9	tyrosine	_	_	NN	O	-1	none	_	_
10	kinase	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	associated	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	CD40	_	_	NN	Protein	-1	none	_	_
15	molecules	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	both	_	_	CC	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	resting	_	_	VBG	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	Janus	_	_	NN	Protein	26	multitoken	_	_
25	kinase	_	_	NN	Protein	26	multitoken	_	_
26	3	_	_	CD	Protein	0	root	_	_
27	phosphorylation	_	_	NN	O	-1	none	_	_
28	induction	_	_	NN	O	-1	none	_	_
29	was	_	_	VBD	O	-1	none	_	_
30	observed	_	_	VBN	O	-1	none	_	_
31	only	_	_	RB	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	CD40	_	_	NN	Protein	-1	none	_	_
34	activated	_	_	VBN	O	-1	none	_	_
35	monocytes	_	_	NNS	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	with	_	_	IN	O	-1	none	_	_
38	subsequent	_	_	JJ	O	-1	none	_	_
39	induction	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	STAT5a	_	_	NN	Protein	-1	none	_	_
42	DNA	_	_	NN	O	-1	none	_	_
43	binding	_	_	NN	O	-1	none	_	_
44	activity	_	_	NN	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	the	_	_	DT	O	-1	none	_	_
47	nucleus	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	signals	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	monocytes	_	_	NNS	O	-1	none	_	_
14	differ	_	_	VBP	O	-1	none	_	_
15	following	_	_	VBG	O	-1	none	_	_
16	CD40	_	_	NN	Protein	-1	none	_	_
17	stimulation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	observation	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	consistent	_	_	JJ	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	detection	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	normal	_	_	JJ	O	-1	none	_	_
10	CD40	_	_	NN	Protein	-1	none	_	_
11	induced	_	_	VBD	O	-1	none	_	_
12	monocyte	_	_	NN	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	patients	_	_	NNS	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	CD40	_	_	NN	Protein	-1	none	_	_
18	ligand+	_	_	JJ	O	-1	none	_	_
19	hyper	_	_	JJ	O	-1	none	_	_
20	IgM	_	_	NN	O	-1	none	_	_
21	syndrome	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	whom	_	_	WP	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	defect	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	CD40	_	_	NN	Protein	-1	none	_	_
28	induced	_	_	VBD	O	-1	none	_	_
29	B	_	_	NN	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	activation	_	_	NN	O	-1	none	_	_
32	has	_	_	VBZ	O	-1	none	_	_
33	been	_	_	VBN	O	-1	none	_	_
34	reported	_	_	VBN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Active	_	_	JJ	O	-1	none	_	_
2	suppression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	class	_	_	NN	Protein	7	multitoken	_	_
6	II	_	_	CD	Protein	7	multitoken	_	_
7	transactivator	_	_	NN	Protein	0	root	_	_
8	encoding	_	_	VBG	O	-1	none	_	_
9	AIR-1	_	_	NN	O	-1	none	_	_
10	locus	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	responsible	_	_	JJ	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	lack	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	major	_	_	JJ	O	-1	none	_	_
18	histocompatibility	_	_	NN	O	-1	none	_	_
19	complex	_	_	NN	O	-1	none	_	_
20	class	_	_	NN	O	-1	none	_	_
21	II	_	_	CD	O	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	observed	_	_	VBN	O	-1	none	_	_
25	during	_	_	IN	O	-1	none	_	_
26	differentiation	_	_	NN	O	-1	none	_	_
27	from	_	_	IN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	plasma	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	genetic	_	_	JJ	O	-1	none	_	_
6	control	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	major	_	_	JJ	O	-1	none	_	_
9	histocompatibility	_	_	NN	O	-1	none	_	_
10	complex	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	MHC	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	class	_	_	NN	O	-1	none	_	_
15	II	_	_	CD	O	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	during	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	transition	_	_	NN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	plasma	_	_	NN	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	has	_	_	VBZ	O	-1	none	_	_
28	been	_	_	VBN	O	-1	none	_	_
29	analyzed	_	_	VBN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Class	_	_	NN	O	-1	none	_	_
2	II	_	_	CD	O	-1	none	_	_
3	molecules	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	expressed	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	plasma	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	because	_	_	IN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	active	_	_	JJ	O	-1	none	_	_
14	suppression	_	_	NN	O	-1	none	_	_
15	resulting	_	_	VBG	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	abrogation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	class	_	_	NN	O	-1	none	_	_
21	II	_	_	CD	O	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	plasma	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	repressor	_	_	NN	O	-1	none	_	_
10	function	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	designated	_	_	VBN	O	-1	none	_	_
13	SIR	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	suppressor	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	immune	_	_	JJ	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	genes	_	_	NNS	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	does	_	_	VBZ	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	act	_	_	VB	O	-1	none	_	_
25	directly	_	_	RB	O	-1	none	_	_
26	on	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	transcription	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	class	_	_	NN	O	-1	none	_	_
31	II	_	_	CD	O	-1	none	_	_
32	genes	_	_	NNS	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	but	_	_	CC	O	-1	none	_	_
35	instead	_	_	RB	O	-1	none	_	_
36	on	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	transcription	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	AIR-1	_	_	NN	O	-1	none	_	_
42	gene	_	_	NN	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	whose	_	_	WP$	O	-1	none	_	_
45	product	_	_	NN	O	-1	none	_	_
46	,	_	_	,	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	class	_	_	NN	Protein	50	multitoken	_	_
49	II	_	_	CD	Protein	50	multitoken	_	_
50	transactivator	_	_	NN	Protein	0	root	_	_
51	(	_	_	-LRB-	O	-1	none	_	_
52	CIITA	_	_	NN	Protein	-1	none	_	_
53	)	_	_	-RRB-	O	-1	none	_	_
54	,	_	_	,	O	-1	none	_	_
55	is	_	_	VBZ	O	-1	none	_	_
56	fundamental	_	_	JJ	O	-1	none	_	_
57	for	_	_	IN	O	-1	none	_	_
58	the	_	_	DT	O	-1	none	_	_
59	regulation	_	_	NN	O	-1	none	_	_
60	of	_	_	IN	O	-1	none	_	_
61	the	_	_	DT	O	-1	none	_	_
62	constitutive	_	_	JJ	O	-1	none	_	_
63	and	_	_	CC	O	-1	none	_	_
64	inducible	_	_	JJ	O	-1	none	_	_
65	expression	_	_	NN	O	-1	none	_	_
66	of	_	_	IN	O	-1	none	_	_
67	MHC	_	_	NN	O	-1	none	_	_
68	class	_	_	NN	O	-1	none	_	_
69	II	_	_	CD	O	-1	none	_	_
70	genes	_	_	NNS	O	-1	none	_	_
71	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	unambiguously	_	_	RB	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	fact	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	plasmacytoma	_	_	NN	O	-1	none	_	_
10	x	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	hybrids	_	_	NNS	O	-1	none	_	_
14	carrying	_	_	VBG	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	AIR-1	_	_	NN	O	-1	none	_	_
17	locus	_	_	NN	O	-1	none	_	_
18	derived	_	_	VBN	O	-1	none	_	_
19	from	_	_	IN	O	-1	none	_	_
20	CIITA	_	_	NN	Protein	-1	none	_	_
21	expressing	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	do	_	_	VBP	O	-1	none	_	_
24	not	_	_	RB	O	-1	none	_	_
25	express	_	_	VB	O	-1	none	_	_
26	CIITA	_	_	NN	Protein	-1	none	_	_
27	specific	_	_	JJ	O	-1	none	_	_
28	transcripts	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Transfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	cDNA	_	_	NN	O	-1	none	_	_
5	containing	_	_	VBG	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	coding	_	_	VBG	O	-1	none	_	_
10	sequence	_	_	NN	O	-1	none	_	_
11	under	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	control	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	heterologous	_	_	JJ	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	restores	_	_	VBZ	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	MHC	_	_	NN	O	-1	none	_	_
23	class	_	_	NN	O	-1	none	_	_
24	II	_	_	CD	O	-1	none	_	_
25	genes	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	hybrids	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	is	_	_	VBZ	O	-1	none	_	_
31	responsible	_	_	JJ	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	de	_	_	FW	O	-1	none	_	_
34	novo	_	_	FW	O	-1	none	_	_
35	expression	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	mouse	_	_	NN	O	-1	none	_	_
38	MHC	_	_	NN	O	-1	none	_	_
39	class	_	_	NN	O	-1	none	_	_
40	II	_	_	CD	O	-1	none	_	_
41	genes	_	_	NNS	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	both	_	_	CC	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	mouse	_	_	NN	O	-1	none	_	_
46	plasmacytoma	_	_	NN	O	-1	none	_	_
47	cell	_	_	NN	O	-1	none	_	_
48	line	_	_	NN	O	-1	none	_	_
49	and	_	_	CC	O	-1	none	_	_
50	the	_	_	DT	O	-1	none	_	_
51	hybrids	_	_	NNS	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	confirm	_	_	VBP	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	extend	_	_	VBP	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	notion	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	functional	_	_	JJ	O	-1	none	_	_
11	conservation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	AIR-1	_	_	NN	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	product	_	_	NN	O	-1	none	_	_
17	across	_	_	IN	O	-1	none	_	_
18	species	_	_	NNS	O	-1	none	_	_
19	barriers	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	CIITA	_	_	NN	Protein	-1	none	_	_
5	transfected	_	_	VBN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	hybrids	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	surface	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	HLA-DQ	_	_	NN	O	-1	none	_	_
16	heterodimer	_	_	NN	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	observed	_	_	VBN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	result	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	attributable	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	lack	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	HLA-DQ	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	or	_	_	CC	O	-1	none	_	_
12	-DQ	_	_	NN	Protein	13	multitoken	_	_
13	beta	_	_	NN	Protein	0	root	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	because	_	_	IN	O	-1	none	_	_
17	both	_	_	DT	O	-1	none	_	_
18	transcripts	_	_	NNS	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	present	_	_	JJ	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	CIITA	_	_	NN	Protein	-1	none	_	_
24	transfected	_	_	VBN	O	-1	none	_	_
25	hybrids	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	although	_	_	IN	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	reduced	_	_	VBN	O	-1	none	_	_
30	levels	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	further	_	_	RB	O	-1	none	_	_
4	support	_	_	VBP	O	-1	none	_	_
5	our	_	_	PRP$	O	-1	none	_	_
6	previous	_	_	JJ	O	-1	none	_	_
7	observations	_	_	NNS	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	regulation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	HLA-DQ	_	_	NN	O	-1	none	_	_
18	class	_	_	NN	O	-1	none	_	_
19	II	_	_	CD	O	-1	none	_	_
20	subset	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	which	_	_	WDT	O	-1	none	_	_
23	may	_	_	MD	O	-1	none	_	_
24	be	_	_	VB	O	-1	none	_	_
25	thus	_	_	RB	O	-1	none	_	_
26	controlled	_	_	VBN	O	-1	none	_	_
27	at	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	posttranscriptional	_	_	JJ	O	-1	none	_	_
30	level	_	_	NN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	CIITA	_	_	NN	Protein	-1	none	_	_
34	independent	_	_	JJ	O	-1	none	_	_
35	mechanism	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	lymphotoxin	_	_	NN	O	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	stimulated	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	HTLV-I	_	_	NN	O	-1	none	_	_
8	tax	_	_	NN	Protein	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	T-cell	_	_	NN	O	-1	none	_	_
16	lines	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	HTLV-I	_	_	NN	O	-1	none	_	_
3	transcriptional	_	_	JJ	O	-1	none	_	_
4	activator	_	_	NN	O	-1	none	_	_
5	tax	_	_	NN	Protein	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	used	_	_	VBN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	gain	_	_	VB	O	-1	none	_	_
10	insight	_	_	NN	O	-1	none	_	_
11	into	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	mechanism	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	lymphotoxin	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	LT	_	_	NN	O	-1	none	_	_
18	;	_	_	:	O	-1	none	_	_
19	TNF-beta	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	induction	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Tax	_	_	NN	O	-1	none	_	_
2	expressing	_	_	NN	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	lines	_	_	NNS	O	-1	none	_	_
5	produce	_	_	VBP	O	-1	none	_	_
6	LT	_	_	NN	O	-1	none	_	_
7	biologic	_	_	JJ	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	LT	_	_	NN	O	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	LT-293	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	CAT	_	_	NN	Protein	-1	none	_	_
8	construct	_	_	NN	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	contained	_	_	VBD	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	active	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	LT	_	_	JJ	O	-1	none	_	_
20	producing	_	_	VBG	O	-1	none	_	_
21	C81-66-45	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	line	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	contains	_	_	VBZ	O	-1	none	_	_
27	defective	_	_	JJ	O	-1	none	_	_
28	HTLV-I	_	_	NN	O	-1	none	_	_
29	but	_	_	CC	O	-1	none	_	_
30	expresses	_	_	VBZ	O	-1	none	_	_
31	tax	_	_	NN	Protein	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	observation	_	_	NN	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	mutated	_	_	JJ	O	-1	none	_	_
6	LT-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	construct	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	M1-CAT	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	inactive	_	_	JJ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	C81-66-45	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	confirmed	_	_	VBD	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	importance	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	NF-kappa	_	_	NN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	LT	_	_	NN	O	-1	none	_	_
25	gene	_	_	NN	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Tax	_	_	NN	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	transfected	_	_	VBN	O	-1	none	_	_
4	into	_	_	IN	O	-1	none	_	_
5	HTLV-I-negative	_	_	JJ	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	T-cell	_	_	NN	O	-1	none	_	_
8	lines	_	_	NNS	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Jurkat	_	_	NN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	stably	_	_	RB	O	-1	none	_	_
5	expressing	_	_	VBG	O	-1	none	_	_
6	tax	_	_	NN	Protein	-1	none	_	_
7	contained	_	_	VBD	O	-1	none	_	_
8	elevated	_	_	JJ	O	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	directly	_	_	RB	O	-1	none	_	_
15	bound	_	_	VBD	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	LT-kappa	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	JM	_	_	NN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	tax	_	_	NN	Protein	-1	none	_	_
7	induced	_	_	JJ	O	-1	none	_	_
8	LT-293	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	two-	_	_	CD	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	four-fold	_	_	RB	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	though	_	_	IN	O	-1	none	_	_
16	there	_	_	EX	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	no	_	_	DT	O	-1	none	_	_
19	induction	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	M1-CAT	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	increase	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	LT-293	_	_	NN	O	-1	none	_	_
5	CAT	_	_	NN	Protein	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	mirrored	_	_	VBD	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	increase	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	LT	_	_	NN	O	-1	none	_	_
12	biologic	_	_	JJ	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	seen	_	_	VBN	O	-1	none	_	_
15	under	_	_	IN	O	-1	none	_	_
16	these	_	_	DT	O	-1	none	_	_
17	conditions	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	first	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	demonstrate	_	_	VB	O	-1	none	_	_
8	induction	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	LT	_	_	NN	O	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	over	_	_	IN	O	-1	none	_	_
14	basal	_	_	JJ	O	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	indicate	_	_	VBP	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	HTLV-I	_	_	NN	O	-1	none	_	_
20	tax	_	_	NN	Protein	-1	none	_	_
21	causes	_	_	VBZ	O	-1	none	_	_
22	low-level	_	_	JJ	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	both	_	_	DT	O	-1	none	_	_
26	endogenous	_	_	JJ	O	-1	none	_	_
27	LT	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	LT	_	_	NN	O	-1	none	_	_
31	promoter	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	at	_	_	IN	O	-1	none	_	_
34	least	_	_	JJS	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	part	_	_	NN	O	-1	none	_	_
37	through	_	_	IN	O	-1	none	_	_
38	activation	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	NF-kappa	_	_	NN	O	-1	none	_	_
41	B.	_	_	NNP	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	lymphocytes	_	_	NNS	O	-1	none	_	_
10	induces	_	_	VBZ	O	-1	none	_	_
11	caspase	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	apoptosis	_	_	NN	O	-1	none	_	_
14	without	_	_	IN	O	-1	none	_	_
15	detectable	_	_	JJ	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	caspase-1	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	-3	_	_	CD	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	involved	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	transcriptional	_	_	JJ	O	-1	none	_	_
8	control	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	various	_	_	JJ	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	act	_	_	VBP	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	extrinsic	_	_	JJ	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	intrinsic	_	_	JJ	O	-1	none	_	_
18	survival	_	_	NN	O	-1	none	_	_
19	factors	_	_	NNS	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	suppression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	cell-permeable	_	_	JJ	O	-1	none	_	_
12	SN50	_	_	NN	O	-1	none	_	_
13	peptide	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	masks	_	_	VBZ	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	localization	_	_	NN	O	-1	none	_	_
20	sequence	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	NF-kappa	_	_	NN	O	-1	none	_	_
23	B1	_	_	NN	O	-1	none	_	_
24	dimers	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	prevents	_	_	VBZ	O	-1	none	_	_
27	their	_	_	PRP$	O	-1	none	_	_
28	nuclear	_	_	JJ	O	-1	none	_	_
29	localization	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	induces	_	_	VBZ	O	-1	none	_	_
32	apoptosis	_	_	NN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	resting	_	_	VBG	O	-1	none	_	_
35	normal	_	_	JJ	O	-1	none	_	_
36	human	_	_	NN	O	-1	none	_	_
37	PBL	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	resulted	_	_	VBD	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	externalization	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	phosphatidylserine	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	breaks	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	morphological	_	_	JJ	O	-1	none	_	_
19	changes	_	_	NNS	O	-1	none	_	_
20	consistent	_	_	JJ	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	apoptosis	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	DNA	_	_	NN	O	-1	none	_	_
2	fragmentation	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	efficiently	_	_	RB	O	-1	none	_	_
5	blocked	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	caspase	_	_	NN	O	-1	none	_	_
9	inhibitor	_	_	NN	O	-1	none	_	_
10	Z-VAD-fmk	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	partially	_	_	RB	O	-1	none	_	_
13	blocked	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	Ac-DEVD-fmk	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	suggesting	_	_	VBG	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	SN50	_	_	NN	O	-1	none	_	_
20	mediated	_	_	JJ	O	-1	none	_	_
21	apoptosis	_	_	NN	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	caspase	_	_	NN	O	-1	none	_	_
24	dependent	_	_	JJ	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	either	_	_	RB	O	-1	none	_	_
5	low	_	_	JJ	O	-1	none	_	_
6	level	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	required	_	_	VBN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	different	_	_	JJ	O	-1	none	_	_
14	caspases	_	_	NNS	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	involved	_	_	VBN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Preactivation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	resulting	_	_	VBG	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	translocation	_	_	NN	O	-1	none	_	_
11	protected	_	_	VBD	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	SN50	_	_	NN	O	-1	none	_	_
15	induced	_	_	VBD	O	-1	none	_	_
16	apoptosis	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	essential	_	_	JJ	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	survival	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	naive	_	_	JJ	O	-1	none	_	_
14	PBL	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	interleukin-2	_	_	NN	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	its	_	_	PRP$	O	-1	none	_	_
10	receptor	_	_	NN	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	normal	_	_	JJ	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	induces	_	_	VBZ	O	-1	none	_	_
16	nuclear	_	_	JJ	O	-1	none	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	kappaB	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	NF-kappaB	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	IL-2	_	_	NN	Protein	35	multitoken	_	_
30	receptor	_	_	NN	Protein	35	multitoken	_	_
31	(	_	_	-LRB-	Protein	35	multitoken	_	_
32	IL-2R	_	_	NN	Protein	35	multitoken	_	_
33	)	_	_	-RRB-	Protein	35	multitoken	_	_
34	alpha	_	_	NN	Protein	35	multitoken	_	_
35	chain	_	_	NN	Protein	0	root	_	_
36	gene	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	proliferation	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	IL-2R	_	_	NN	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	growth	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	CD8+	_	_	JJ	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	prolymphocytic	_	_	JJ	O	-1	none	_	_
19	leukemia	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	T-PLL	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	has	_	_	VBZ	O	-1	none	_	_
25	been	_	_	VBN	O	-1	none	_	_
26	investigated	_	_	VBN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Flow	_	_	NN	O	-1	none	_	_
2	cytometry	_	_	NN	O	-1	none	_	_
3	revealed	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	primary	_	_	JJ	O	-1	none	_	_
6	leukemia	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	patient	_	_	NN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	CD8+	_	_	JJ	O	-1	none	_	_
13	T-PLL	_	_	NN	O	-1	none	_	_
14	expressed	_	_	VBD	O	-1	none	_	_
15	IL-2Ralpha	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	beta	_	_	NN	Protein	-1	none	_	_
18	chains	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	showed	_	_	VBD	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	proliferative	_	_	JJ	O	-1	none	_	_
26	response	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	an	_	_	DT	O	-1	none	_	_
29	increase	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	IL-2Ralpha	_	_	NN	Protein	-1	none	_	_
32	expression	_	_	NN	O	-1	none	_	_
33	on	_	_	IN	O	-1	none	_	_
34	culture	_	_	NN	O	-1	none	_	_
35	with	_	_	IN	O	-1	none	_	_
36	exogeneous	_	_	JJ	O	-1	none	_	_
37	IL-2	_	_	NN	Protein	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	failed	_	_	VBD	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	detect	_	_	VB	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	mRNA	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	suggesting	_	_	VBG	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	IL-2	_	_	NN	Protein	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	act	_	_	VB	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	paracrine	_	_	JJ	O	-1	none	_	_
18	manner	_	_	NN	O	-1	none	_	_
19	in	_	_	FW	O	-1	none	_	_
20	vivo	_	_	FW	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Electrophoretic	_	_	JJ	O	-1	none	_	_
2	mobility-shift	_	_	JJ	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	revealed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	recombinant	_	_	JJ	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	increased	_	_	VBD	O	-1	none	_	_
9	NF-kappaB	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	extracts	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	Northern	_	_	NN	O	-1	none	_	_
22	blot	_	_	NN	O	-1	none	_	_
23	analysis	_	_	NN	O	-1	none	_	_
24	showed	_	_	VBD	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	IL-2	_	_	NN	Protein	-1	none	_	_
27	increased	_	_	VBD	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	abundance	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	mRNAs	_	_	NNS	O	-1	none	_	_
32	encoding	_	_	VBG	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	NF-kappaB	_	_	NN	O	-1	none	_	_
35	components	_	_	NNS	O	-1	none	_	_
36	c-Rel	_	_	NN	Protein	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	KBF1	_	_	NN	Protein	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	these	_	_	DT	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	IL-2	_	_	NNP	Protein	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	demonstrated	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	markedly	_	_	RB	O	-1	none	_	_
8	increased	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	number	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	low	_	_	JJ	O	-1	none	_	_
13	affinity	_	_	NN	O	-1	none	_	_
14	IL-2Rs	_	_	NNS	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	without	_	_	IN	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	effect	_	_	NN	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	number	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	high-affinity	_	_	JJ	O	-1	none	_	_
28	IL-2Rs	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	capable	_	_	JJ	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	inducing	_	_	VBG	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	NF-kappaB	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	primary	_	_	JJ	O	-1	none	_	_
17	CD8+	_	_	JJ	O	-1	none	_	_
18	T-PLL	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	effect	_	_	NN	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	mediated	_	_	VBN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	least	_	_	JJS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	part	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	at	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	pretranslational	_	_	JJ	O	-1	none	_	_
36	level	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NF-kappaB	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	primary	_	_	JJ	O	-1	none	_	_
7	adult	_	_	JJ	O	-1	none	_	_
8	T-cell	_	_	NN	O	-1	none	_	_
9	leukemia	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	I	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	etiologic	_	_	JJ	O	-1	none	_	_
13	agent	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	adult	_	_	JJ	O	-1	none	_	_
16	T-cell	_	_	NN	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	ATL	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	viral	_	_	JJ	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	Tax	_	_	NN	Protein	-1	none	_	_
5	induces	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	translocalization	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	NF-kappaB	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	proposed	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	play	_	_	VB	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	crucial	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	transformation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	T	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	by	_	_	IN	O	-1	none	_	_
31	HTLV-I	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	HTLV-I	_	_	NN	O	-1	none	_	_
5	genes	_	_	NNS	O	-1	none	_	_
6	including	_	_	VBG	O	-1	none	_	_
7	Tax	_	_	NN	Protein	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	expressed	_	_	VBN	O	-1	none	_	_
11	significantly	_	_	RB	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	primary	_	_	JJ	O	-1	none	_	_
14	leukemic	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	ATL	_	_	NN	O	-1	none	_	_
18	patients	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	examined	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	basis	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	freshly	_	_	RB	O	-1	none	_	_
14	isolated	_	_	VBN	O	-1	none	_	_
15	leukemic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	ATL	_	_	NN	O	-1	none	_	_
19	patients	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	found	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	leukemic	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	ATL	_	_	NN	O	-1	none	_	_
8	patients	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	like	_	_	IN	O	-1	none	_	_
11	HTLV-I-infected	_	_	JJ	O	-1	none	_	_
12	T-cell	_	_	NN	O	-1	none	_	_
13	lines	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	display	_	_	VBP	O	-1	none	_	_
16	constitutive	_	_	JJ	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	DNA	_	_	NN	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	increased	_	_	VBD	O	-1	none	_	_
23	degradation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	an	_	_	DT	O	-1	none	_	_
28	inhibitor	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	NF-kappaB	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	NF-kappaB	_	_	NN	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	Tax	_	_	NN	Protein	-1	none	_	_
8	expressing	_	_	VBG	O	-1	none	_	_
9	T-cell	_	_	NN	O	-1	none	_	_
10	lines	_	_	NNS	O	-1	none	_	_
11	consisted	_	_	VBD	O	-1	none	_	_
12	mostly	_	_	RB	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	p50	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	c-Rel	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	fresh	_	_	JJ	O	-1	none	_	_
19	ATL	_	_	NN	O	-1	none	_	_
20	samples	_	_	NNS	O	-1	none	_	_
21	contained	_	_	VBD	O	-1	none	_	_
22	p50	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	p50	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	p50	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	p65	_	_	NN	Protein	-1	none	_	_
29	heterodimers	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	line	_	_	NN	O	-1	none	_	_
4	derived	_	_	VBN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	ATL	_	_	NN	O	-1	none	_	_
7	leukemic	_	_	JJ	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	TL-Om1	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	displayed	_	_	VBD	O	-1	none	_	_
13	constitutive	_	_	JJ	O	-1	none	_	_
14	NF-kappaB	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	as	_	_	RB	O	-1	none	_	_
18	well	_	_	RB	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	enhanced	_	_	VBN	O	-1	none	_	_
21	degradation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	despite	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	lack	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	detectable	_	_	JJ	O	-1	none	_	_
30	Tax	_	_	NN	Protein	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NF-kappaB	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	TL-Om1	_	_	NN	O	-1	none	_	_
7	consists	_	_	VBZ	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	p50	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p50	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	p50	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	p65	_	_	NN	Protein	-1	none	_	_
16	like	_	_	IN	O	-1	none	_	_
17	that	_	_	DT	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	fresh	_	_	JJ	O	-1	none	_	_
20	primary	_	_	JJ	O	-1	none	_	_
21	leukemic	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	NF-kappaB	_	_	NN	O	-1	none	_	_
8	occurs	_	_	VBZ	O	-1	none	_	_
9	through	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	Tax	_	_	NN	Protein	-1	none	_	_
12	independent	_	_	JJ	O	-1	none	_	_
13	mechanism	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	leukemic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	ATL	_	_	NN	O	-1	none	_	_
19	patients	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	possibly	_	_	RB	O	-1	none	_	_
22	due	_	_	JJ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	differential	_	_	JJ	O	-1	none	_	_
25	NF-kappaB	_	_	NN	O	-1	none	_	_
26	subunit	_	_	NN	O	-1	none	_	_
27	activation	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Intracellular	_	_	JJ	O	-1	none	_	_
2	signals	_	_	NNS	O	-1	none	_	_
3	that	_	_	WDT	O	-1	none	_	_
4	mediate	_	_	VBP	O	-1	none	_	_
5	differentiation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	pluripotent	_	_	JJ	O	-1	none	_	_
8	hemopoietic	_	_	JJ	O	-1	none	_	_
9	progenitors	_	_	NNS	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	dendritic	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	DC	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	largely	_	_	RB	O	-1	none	_	_
18	undefined	_	_	JJ	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	DC	_	_	NN	O	-1	none	_	_
3	characteristics	_	_	NNS	O	-1	none	_	_
4	include	_	_	VBP	O	-1	none	_	_
5	fluid	_	_	JJ	O	-1	none	_	_
6	phase	_	_	NN	O	-1	none	_	_
7	macromolecule	_	_	NN	O	-1	none	_	_
8	uptake	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	FITC-dextran	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	resting	_	_	VBG	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Comparison	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	KG1	_	_	NN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	PMA-unresponsive	_	_	JJ	O	-1	none	_	_
7	subline	_	_	NN	O	-1	none	_	_
8	KG1a	_	_	NN	O	-1	none	_	_
9	reveals	_	_	VBZ	O	-1	none	_	_
10	differences	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	TNF	_	_	NN	Protein	16	multitoken	_	_
15	receptors	_	_	NNS	Protein	16	multitoken	_	_
16	1	_	_	CD	Protein	0	root	_	_
17	and	_	_	CC	O	-1	none	_	_
18	2	_	_	CD	Protein	-1	none	_	_
19	;	_	_	:	O	-1	none	_	_
20	PKC	_	_	NN	Protein	22	multitoken	_	_
21	isoforms	_	_	NNS	Protein	22	multitoken	_	_
22	alpha	_	_	NN	Protein	0	root	_	_
23	,	_	_	,	O	-1	none	_	_
24	beta	_	_	NN	Protein	25	multitoken	_	_
25	I	_	_	CD	Protein	0	root	_	_
26	,	_	_	,	O	-1	none	_	_
27	beta	_	_	NN	Protein	28	multitoken	_	_
28	II	_	_	CD	Protein	0	root	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	mu	_	_	NN	Protein	-1	none	_	_
32	;	_	_	:	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	RelB	_	_	NN	Protein	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	suggesting	_	_	VBG	O	-1	none	_	_
37	that	_	_	IN	O	-1	none	_	_
38	these	_	_	DT	O	-1	none	_	_
39	components	_	_	NNS	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	pathways	_	_	NNS	O	-1	none	_	_
42	are	_	_	VBP	O	-1	none	_	_
43	important	_	_	JJ	O	-1	none	_	_
44	for	_	_	IN	O	-1	none	_	_
45	DC	_	_	NN	O	-1	none	_	_
46	differentiation	_	_	NN	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Homodimerization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	interleukin	_	_	NN	Protein	9	multitoken	_	_
6	4	_	_	CD	Protein	9	multitoken	_	_
7	receptor	_	_	NN	Protein	9	multitoken	_	_
8	alpha	_	_	NN	Protein	9	multitoken	_	_
9	chain	_	_	NN	Protein	0	root	_	_
10	induces	_	_	VBZ	O	-1	none	_	_
11	Cepsilon	_	_	NN	O	-1	none	_	_
12	germline	_	_	NN	O	-1	none	_	_
13	transcripts	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	absence	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	interleukin	_	_	NN	Protein	26	multitoken	_	_
23	2	_	_	CD	Protein	26	multitoken	_	_
24	receptor	_	_	NN	Protein	26	multitoken	_	_
25	gamma	_	_	NN	Protein	26	multitoken	_	_
26	chain	_	_	NN	Protein	0	root	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cytokines	_	_	NNS	O	-1	none	_	_
3	interleukin	_	_	NN	Protein	7	multitoken	_	_
4	(	_	_	-LRB-	Protein	7	multitoken	_	_
5	IL	_	_	NN	Protein	7	multitoken	_	_
6	)	_	_	-RRB-	Protein	7	multitoken	_	_
7	-4	_	_	CD	Protein	0	root	_	_
8	and	_	_	CC	O	-1	none	_	_
9	IL-13	_	_	NN	Protein	-1	none	_	_
10	play	_	_	VBP	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	critical	_	_	JJ	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	inducing	_	_	VBG	O	-1	none	_	_
16	Cepsilon	_	_	NN	O	-1	none	_	_
17	germline	_	_	NN	O	-1	none	_	_
18	transcripts	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	IgE	_	_	NN	O	-1	none	_	_
21	isotype	_	_	NN	O	-1	none	_	_
22	switching	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	IL-4	_	_	NNP	Protein	-1	none	_	_
2	induces	_	_	VBZ	O	-1	none	_	_
3	Cepsilon	_	_	NN	O	-1	none	_	_
4	germline	_	_	NN	O	-1	none	_	_
5	transcripts	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IgE	_	_	NN	O	-1	none	_	_
8	isotype	_	_	NN	O	-1	none	_	_
9	switching	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	patients	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	gammac	_	_	NN	Protein	17	multitoken	_	_
17	chain	_	_	NN	Protein	0	root	_	_
18	deficiency	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Cepsilon	_	_	NN	O	-1	none	_	_
4	germline	_	_	NN	O	-1	none	_	_
5	transcripts	_	_	NNS	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	IL-4	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	lack	_	_	VBP	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	gammac	_	_	NN	Protein	15	multitoken	_	_
15	chain	_	_	NN	Protein	0	root	_	_
16	may	_	_	MD	O	-1	none	_	_
17	involve	_	_	VB	O	-1	none	_	_
18	signaling	_	_	NN	O	-1	none	_	_
19	via	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	IL-13R	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Alternatively	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	IL-4Ralpha	_	_	NN	Protein	5	multitoken	_	_
5	chain	_	_	NN	Protein	0	root	_	_
6	may	_	_	MD	O	-1	none	_	_
7	transduce	_	_	VB	O	-1	none	_	_
8	intracellular	_	_	JJ	O	-1	none	_	_
9	signals	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	lead	_	_	VBP	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	Cepsilon	_	_	NN	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	independently	_	_	RB	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	its	_	_	PRP$	O	-1	none	_	_
19	association	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	other	_	_	JJ	O	-1	none	_	_
22	chains	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	ligand	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	homodimerization	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	chimeric	_	_	JJ	O	-1	none	_	_
9	surface	_	_	NN	O	-1	none	_	_
10	receptors	_	_	NNS	O	-1	none	_	_
11	consisting	_	_	VBG	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	extracellular	_	_	JJ	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	transmembrane	_	_	JJ	O	-1	none	_	_
17	domains	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	erythropoietin	_	_	NN	Protein	-1	none	_	_
21	receptor	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	intracellular	_	_	JJ	O	-1	none	_	_
26	domain	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	IL-4Ralpha	_	_	NN	Protein	-1	none	_	_
29	induces	_	_	VBZ	O	-1	none	_	_
30	Janus	_	_	NN	Protein	32	multitoken	_	_
31	kinase	_	_	NN	Protein	32	multitoken	_	_
32	1	_	_	CD	Protein	0	root	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	Jak1	_	_	NN	Protein	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	activation	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	STAT6	_	_	NN	Protein	-1	none	_	_
39	activation	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	Cepsilon	_	_	NN	O	-1	none	_	_
43	germline	_	_	NN	O	-1	none	_	_
44	transcripts	_	_	NNS	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	human	_	_	NN	O	-1	none	_	_
47	B	_	_	NN	O	-1	none	_	_
48	cell	_	_	NN	O	-1	none	_	_
49	line	_	_	NN	O	-1	none	_	_
50	BJAB	_	_	NN	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	Disruption	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	Jak1	_	_	NN	Protein	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	proline	_	_	NN	O	-1	none	_	_
7	rich	_	_	JJ	O	-1	none	_	_
8	Box1	_	_	NN	O	-1	none	_	_
9	region	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	IL-4Ralpha	_	_	NN	Protein	-1	none	_	_
12	abolished	_	_	VBD	O	-1	none	_	_
13	signaling	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	this	_	_	DT	O	-1	none	_	_
16	chimeric	_	_	JJ	O	-1	none	_	_
17	receptor	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	transfected	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	chimeric	_	_	JJ	Protein	12	multitoken	_	_
9	CD8alpha	_	_	NN	Protein	12	multitoken	_	_
10	and	_	_	CC	Protein	12	multitoken	_	_
11	IL-4Ralpha	_	_	NN	Protein	12	multitoken	_	_
12	receptor	_	_	NN	Protein	0	root	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	expressed	_	_	VBN	O	-1	none	_	_
17	on	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	surface	_	_	NN	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	homodimer	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	constitutively	_	_	RB	O	-1	none	_	_
26	expressed	_	_	VBN	O	-1	none	_	_
27	Cepsilon	_	_	NN	O	-1	none	_	_
28	germline	_	_	NN	O	-1	none	_	_
29	transcripts	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	homodimerization	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	IL-4Ralpha	_	_	NN	Protein	9	multitoken	_	_
9	chain	_	_	NN	Protein	0	root	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	sufficient	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	transduce	_	_	VB	O	-1	none	_	_
14	Jak1	_	_	NN	Protein	-1	none	_	_
15	dependent	_	_	JJ	O	-1	none	_	_
16	intracellular	_	_	JJ	O	-1	none	_	_
17	signals	_	_	NNS	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	lead	_	_	VBP	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	IgE	_	_	NN	O	-1	none	_	_
22	isotype	_	_	NN	O	-1	none	_	_
23	switching	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	p21ras	_	_	NN	Protein	-1	none	_	_
2	initiates	_	_	VBZ	O	-1	none	_	_
3	Rac-1	_	_	NN	Protein	-1	none	_	_
4	but	_	_	CC	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	phosphatidyl	_	_	NN	O	-1	none	_	_
7	inositol	_	_	NN	O	-1	none	_	_
8	3	_	_	CD	O	-1	none	_	_
9	kinase	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	PKB	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	mediated	_	_	JJ	O	-1	none	_	_
14	signaling	_	_	NN	O	-1	none	_	_
15	pathways	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	p21ras	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	antigen	_	_	NN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	TCR	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	then	_	_	RB	O	-1	none	_	_
15	co-ordinates	_	_	VBZ	O	-1	none	_	_
16	important	_	_	JJ	O	-1	none	_	_
17	signaling	_	_	NN	O	-1	none	_	_
18	pathways	_	_	NNS	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	lymphocyte	_	_	NN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Effector	_	_	NN	O	-1	none	_	_
2	pathways	_	_	NNS	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	guanine	_	_	NN	O	-1	none	_	_
6	nucleotide	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	serine/threonine	_	_	NN	O	-1	none	_	_
17	kinase	_	_	NN	O	-1	none	_	_
18	Raf-1	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	Ras	_	_	NN	O	-1	none	_	_
22	related	_	_	JJ	O	-1	none	_	_
23	GTPase	_	_	NN	O	-1	none	_	_
24	Rac-1	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	fibroblasts	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	important	_	_	JJ	O	-1	none	_	_
6	effector	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	Ras	_	_	NN	O	-1	none	_	_
10	oncogene	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	Phosphatidylinositol	_	_	NN	O	-1	none	_	_
13	3-kinase	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	PtdIns	_	_	NN	O	-1	none	_	_
16	3-kinase	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	lipid	_	_	NN	O	-1	none	_	_
5	kinase	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	able	_	_	JJ	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	induce	_	_	VB	O	-1	none	_	_
10	critical	_	_	JJ	O	-1	none	_	_
11	Rac-1	_	_	NN	Protein	-1	none	_	_
12	signaling	_	_	NN	O	-1	none	_	_
13	pathways	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	can	_	_	MD	O	-1	none	_	_
16	couple	_	_	VB	O	-1	none	_	_
17	p21ras	_	_	NN	Protein	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	survival	_	_	NN	O	-1	none	_	_
21	mechanisms	_	_	NNS	O	-1	none	_	_
22	via	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	serine/threonine	_	_	NN	O	-1	none	_	_
25	kinase	_	_	NN	O	-1	none	_	_
26	Akt	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	PKB	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	PtdIns	_	_	NN	O	-1	none	_	_
5	3-kinase	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	Ras	_	_	NN	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	has	_	_	VBZ	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	explored	_	_	VBN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	examined	_	_	VBD	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	ability	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	PtdIns	_	_	NN	O	-1	none	_	_
12	3-kinase	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	initiate	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	Rac-1	_	_	NN	Protein	-1	none	_	_
17	signaling	_	_	NN	O	-1	none	_	_
18	pathways	_	_	NNS	O	-1	none	_	_
19	important	_	_	JJ	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	examined	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	possibility	_	_	NN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	Akt	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	PKB	_	_	NN	Protein	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	regulated	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	Ras	_	_	NN	O	-1	none	_	_
14	signaling	_	_	NN	O	-1	none	_	_
15	pathways	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Ras	_	_	NN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	initiate	_	_	VB	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	Rac-1	_	_	NN	Protein	-1	none	_	_
10	mediated	_	_	JJ	O	-1	none	_	_
11	pathway	_	_	NN	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	regulates	_	_	VBZ	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	transcriptional	_	_	JJ	O	-1	none	_	_
16	function	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	AP-1	_	_	NN	O	-1	none	_	_
19	complexes	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	PtdIns	_	_	NN	O	-1	none	_	_
2	3-kinase	_	_	NN	O	-1	none	_	_
3	signals	_	_	NNS	O	-1	none	_	_
4	can	_	_	MD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	mimic	_	_	VB	O	-1	none	_	_
7	p21ras	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	induce	_	_	VB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	Rac	_	_	NN	O	-1	none	_	_
12	mediated	_	_	VBD	O	-1	none	_	_
13	responses	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	AP-1	_	_	NN	O	-1	none	_	_
16	transcriptional	_	_	JJ	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	neither	_	_	CC	O	-1	none	_	_
4	TCR	_	_	NN	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	Ras	_	_	NN	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	AP-1	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	PtdIns	_	_	NN	O	-1	none	_	_
14	3-kinase	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	PKB	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	response	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	triggering	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	antigen	_	_	NN	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	;	_	_	:	O	-1	none	_	_
15	PtdIns	_	_	NN	O	-1	none	_	_
16	3-kinase	_	_	NN	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	both	_	_	CC	O	-1	none	_	_
20	required	_	_	VBN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	sufficient	_	_	JJ	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	this	_	_	DT	O	-1	none	_	_
25	TCR	_	_	NN	O	-1	none	_	_
26	response	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	p21ras	_	_	NN	Protein	-1	none	_	_
5	signals	_	_	NNS	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	unable	_	_	JJ	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	induce	_	_	VB	O	-1	none	_	_
10	Akt	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	PKB	_	_	NN	Protein	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	nor	_	_	CC	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	Ras	_	_	NN	O	-1	none	_	_
20	function	_	_	NN	O	-1	none	_	_
21	required	_	_	VBN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	Akt	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	PKB	_	_	NN	Protein	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	response	_	_	NN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	TCR	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	data	_	_	NNS	O	-1	none	_	_
4	thus	_	_	RB	O	-1	none	_	_
5	highlight	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	PtdIns	_	_	NN	O	-1	none	_	_
8	3-kinase	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	Akt	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	PKB	_	_	NN	Protein	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	universal	_	_	JJ	O	-1	none	_	_
16	Ras	_	_	NN	O	-1	none	_	_
17	effector	_	_	NN	O	-1	none	_	_
18	molecules	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Ras	_	_	NN	O	-1	none	_	_
2	can	_	_	MD	O	-1	none	_	_
3	initiate	_	_	VB	O	-1	none	_	_
4	Rac-1	_	_	NN	Protein	-1	none	_	_
5	regulated	_	_	JJ	O	-1	none	_	_
6	signaling	_	_	NN	O	-1	none	_	_
7	pathways	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	context	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	antigen	_	_	NN	O	-1	none	_	_
15	receptor	_	_	NN	O	-1	none	_	_
16	function	_	_	NN	O	-1	none	_	_
17	independently	_	_	RB	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	PtdIns	_	_	NN	O	-1	none	_	_
20	3-kinase	_	_	NN	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	oncoprotein	_	_	NN	O	-1	none	_	_
5	latent	_	_	JJ	Protein	8	multitoken	_	_
6	membrane	_	_	NN	Protein	8	multitoken	_	_
7	protein	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	engages	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	tumor	_	_	NN	O	-1	none	_	_
12	necrosis	_	_	NN	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	associated	_	_	VBN	O	-1	none	_	_
16	proteins	_	_	NNS	O	-1	none	_	_
17	TRADD	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	interacting	_	_	NN	O	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	RIP	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	does	_	_	VBZ	O	-1	none	_	_
27	not	_	_	RB	O	-1	none	_	_
28	induce	_	_	VB	O	-1	none	_	_
29	apoptosis	_	_	NN	O	-1	none	_	_
30	or	_	_	CC	O	-1	none	_	_
31	require	_	_	VB	O	-1	none	_	_
32	RIP	_	_	NN	O	-1	none	_	_
33	for	_	_	IN	O	-1	none	_	_
34	NF-kappaB	_	_	NN	O	-1	none	_	_
35	activation	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	site	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	Epstein-Barr	_	_	JJ	O	-1	none	_	_
6	virus	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	EBV	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	transforming	_	_	VBG	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	LMP1	_	_	NN	Protein	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	constitutively	_	_	RB	O	-1	none	_	_
15	associates	_	_	VBZ	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	tumor	_	_	NN	Protein	28	multitoken	_	_
19	necrosis	_	_	NN	Protein	28	multitoken	_	_
20	factor	_	_	NN	Protein	28	multitoken	_	_
21	receptor	_	_	NN	Protein	28	multitoken	_	_
22	1	_	_	CD	Protein	28	multitoken	_	_
23	(	_	_	-LRB-	Protein	28	multitoken	_	_
24	TNFR1	_	_	NN	Protein	28	multitoken	_	_
25	)-associated	_	_	JJ	Protein	28	multitoken	_	_
26	death	_	_	NN	Protein	28	multitoken	_	_
27	domain	_	_	NN	Protein	28	multitoken	_	_
28	protein	_	_	NN	Protein	0	root	_	_
29	TRADD	_	_	NN	Protein	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	mediate	_	_	VB	O	-1	none	_	_
32	NF-kappaB	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	c-Jun	_	_	NN	O	-1	none	_	_
35	N-terminal	_	_	JJ	O	-1	none	_	_
36	kinase	_	_	NN	O	-1	none	_	_
37	activation	_	_	NN	O	-1	none	_	_
38	is	_	_	VBZ	O	-1	none	_	_
39	critical	_	_	JJ	O	-1	none	_	_
40	for	_	_	IN	O	-1	none	_	_
41	long-term	_	_	JJ	O	-1	none	_	_
42	lymphoblastoid	_	_	JJ	O	-1	none	_	_
43	cell	_	_	NN	O	-1	none	_	_
44	proliferation	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	find	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	LMP1	_	_	NN	Protein	-1	none	_	_
6	signaling	_	_	NN	O	-1	none	_	_
7	through	_	_	IN	O	-1	none	_	_
8	TRADD	_	_	NN	Protein	-1	none	_	_
9	differs	_	_	VBZ	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	TNFR1	_	_	NN	Protein	-1	none	_	_
12	signaling	_	_	NN	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	TRADD	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	LMP1	_	_	NN	Protein	-1	none	_	_
2	needs	_	_	VBZ	O	-1	none	_	_
3	only	_	_	RB	O	-1	none	_	_
4	11	_	_	CD	O	-1	none	_	_
5	amino	_	_	NN	O	-1	none	_	_
6	acids	_	_	NNS	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	activate	_	_	VB	O	-1	none	_	_
9	NF-kappaB	_	_	NN	O	-1	none	_	_
10	or	_	_	CC	O	-1	none	_	_
11	synergize	_	_	VB	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	TRADD	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	NF-kappaB	_	_	NN	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	while	_	_	IN	O	-1	none	_	_
19	TNFR1	_	_	NN	Protein	-1	none	_	_
20	requires	_	_	VBZ	O	-1	none	_	_
21	approximately	_	_	RB	O	-1	none	_	_
22	70	_	_	CD	O	-1	none	_	_
23	residues	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Further	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	LMP1	_	_	NN	Protein	-1	none	_	_
4	does	_	_	VBZ	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	require	_	_	VB	O	-1	none	_	_
7	TRADD	_	_	NN	Protein	-1	none	_	_
8	residues	_	_	NNS	O	-1	none	_	_
9	294	_	_	CD	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	312	_	_	CD	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	while	_	_	IN	O	-1	none	_	_
17	TNFR1	_	_	NN	Protein	-1	none	_	_
18	requires	_	_	VBZ	O	-1	none	_	_
19	TRADD	_	_	NN	Protein	-1	none	_	_
20	residues	_	_	NNS	O	-1	none	_	_
21	296	_	_	CD	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	302	_	_	CD	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	LMP1	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	partially	_	_	RB	O	-1	none	_	_
4	blocked	_	_	VBN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	NF-kappaB	_	_	NN	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	TRADD	_	_	NN	Protein	-1	none	_	_
11	mutant	_	_	NN	O	-1	none	_	_
12	consisting	_	_	VBG	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	residues	_	_	NNS	O	-1	none	_	_
15	122	_	_	CD	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	293	_	_	CD	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Unlike	_	_	IN	O	-1	none	_	_
2	TNFR1	_	_	NN	Protein	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	LMP1	_	_	NN	Protein	-1	none	_	_
5	can	_	_	MD	O	-1	none	_	_
6	interact	_	_	VB	O	-1	none	_	_
7	directly	_	_	RB	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	interacting	_	_	NN	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	RIP	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	stably	_	_	RB	O	-1	none	_	_
17	associates	_	_	VBZ	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	RIP	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	EBV	_	_	NN	O	-1	none	_	_
22	transformed	_	_	VBN	O	-1	none	_	_
23	lymphoblastoid	_	_	JJ	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	lines	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Surprisingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	LMP1	_	_	NN	Protein	-1	none	_	_
4	does	_	_	VBZ	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	require	_	_	VB	O	-1	none	_	_
7	RIP	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	NF-kappaB	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Despite	_	_	IN	O	-1	none	_	_
2	constitutive	_	_	JJ	O	-1	none	_	_
3	association	_	_	NN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	TRADD	_	_	NN	Protein	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	RIP	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	LMP1	_	_	NN	Protein	-1	none	_	_
10	does	_	_	VBZ	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	induce	_	_	VB	O	-1	none	_	_
13	apoptosis	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	EBV	_	_	NN	O	-1	none	_	_
16	negative	_	_	JJ	O	-1	none	_	_
17	Burkitt	_	_	NN	O	-1	none	_	_
18	lymphoma	_	_	NN	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	embryonic	_	_	JJ	O	-1	none	_	_
22	kidney	_	_	NN	O	-1	none	_	_
23	293	_	_	CD	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	add	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	different	_	_	JJ	O	-1	none	_	_
6	perspective	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	molecular	_	_	JJ	O	-1	none	_	_
10	interactions	_	_	NNS	O	-1	none	_	_
11	through	_	_	IN	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	LMP1	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	TRADD	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	RIP	_	_	NN	O	-1	none	_	_
19	participate	_	_	VBP	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	B-lymphocyte	_	_	NN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	growth	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	ETS	_	_	NN	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	regulate	_	_	VBP	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	enhancer	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	third	_	_	JJ	O	-1	none	_	_
11	intron	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	TNF-alpha	_	_	NN	Protein	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	describe	_	_	VBP	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	enhancer	_	_	NN	O	-1	none	_	_
5	site	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	third	_	_	JJ	O	-1	none	_	_
9	intron	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	tumor	_	_	NN	O	-1	none	_	_
12	necrosis	_	_	NN	Protein	14	multitoken	_	_
13	factor	_	_	NN	Protein	14	multitoken	_	_
14	alpha	_	_	NN	Protein	0	root	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	TNF-alpha	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	reporter	_	_	NN	O	-1	none	_	_
3	construct	_	_	NN	O	-1	none	_	_
4	containing	_	_	VBG	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	5	_	_	CD	O	-1	none	_	_
7	'-flanking	_	_	JJ	O	-1	none	_	_
8	region	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	mouse	_	_	NN	O	-1	none	_	_
12	TNF-alpha	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	displayed	_	_	VBD	O	-1	none	_	_
15	weak	_	_	JJ	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	when	_	_	WRB	O	-1	none	_	_
18	transfected	_	_	VBN	O	-1	none	_	_
19	into	_	_	IN	O	-1	none	_	_
20	RAW264	_	_	NN	O	-1	none	_	_
21	.7	_	_	CD	O	-1	none	_	_
22	macrophage	_	_	NN	O	-1	none	_	_
23	like	_	_	IN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	third	_	_	JJ	O	-1	none	_	_
6	intron	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	TNF-alpha	_	_	NN	Protein	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	construct	_	_	NN	O	-1	none	_	_
12	resulted	_	_	VBD	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	enhancement	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	CAT	_	_	NN	Protein	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	enhancement	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	eliminated	_	_	VBN	O	-1	none	_	_
5	if	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	conserved	_	_	VBN	O	-1	none	_	_
8	20-bp	_	_	JJ	O	-1	none	_	_
9	sequence	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	removed	_	_	VBN	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	intron	_	_	NN	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	if	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	dominant	_	_	JJ	O	-1	none	_	_
19	negative	_	_	JJ	O	-1	none	_	_
20	ets	_	_	NN	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	factor	_	_	NN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	co-transfected	_	_	VBN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	reporter	_	_	NN	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Mutations	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	site	_	_	NN	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	destroyed	_	_	VBD	O	-1	none	_	_
7	potential	_	_	JJ	O	-1	none	_	_
8	ets	_	_	NN	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	binding	_	_	VBG	O	-1	none	_	_
12	sites	_	_	NNS	O	-1	none	_	_
13	had	_	_	VBD	O	-1	none	_	_
14	reduced	_	_	VBN	O	-1	none	_	_
15	transcriptional	_	_	JJ	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	major	_	_	JJ	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factor	_	_	NN	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	bound	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	oligonucleotide	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	confirmed	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	GABP	_	_	NN	Protein	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	supershift	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	competition	_	_	NN	O	-1	none	_	_
19	analysis	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	RAW264	_	_	NN	O	-1	none	_	_
3	.7	_	_	CD	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	constitutive	_	_	JJ	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	however	_	_	RB	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	bone	_	_	NN	O	-1	none	_	_
15	marrow	_	_	NN	O	-1	none	_	_
16	derived	_	_	VBN	O	-1	none	_	_
17	macrophages	_	_	NNS	O	-1	none	_	_
18	binding	_	_	NN	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	shown	_	_	VBN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	be	_	_	VB	O	-1	none	_	_
24	interferon-gamma	_	_	NN	Protein	-1	none	_	_
25	inducible	_	_	JJ	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	may	_	_	MD	O	-1	none	_	_
3	imply	_	_	VB	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	role	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	ets	_	_	NN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	production	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	TNF-alpha	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Identification	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	characterization	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	leukocyte	_	_	NN	O	-1	none	_	_
7	specific	_	_	JJ	O	-1	none	_	_
8	component	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	body	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	nuclear	_	_	JJ	O	-1	none	_	_
3	body	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	NB	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cellular	_	_	JJ	O	-1	none	_	_
10	organelle	_	_	NN	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	involved	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	pathogenesis	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	acute	_	_	JJ	O	-1	none	_	_
19	promyelocytic	_	_	JJ	O	-1	none	_	_
20	leukemia	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	viral	_	_	JJ	O	-1	none	_	_
23	infection	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NB	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	target	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	antibodies	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	serum	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	patients	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	autoimmune	_	_	JJ	O	-1	none	_	_
17	disease	_	_	NN	O	-1	none	_	_
18	primary	_	_	JJ	O	-1	none	_	_
19	biliary	_	_	JJ	O	-1	none	_	_
20	cirrhosis	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	serum	_	_	NN	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	patient	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	primary	_	_	JJ	O	-1	none	_	_
11	biliary	_	_	JJ	O	-1	none	_	_
12	cirrhosis	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	used	_	_	VBN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	identify	_	_	VB	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	cDNA	_	_	NN	O	-1	none	_	_
19	encoding	_	_	VBG	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	novel	_	_	JJ	O	-1	none	_	_
22	component	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	NB	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	140-kDa	_	_	JJ	O	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	designated	_	_	VBN	O	-1	none	_	_
31	Sp140	_	_	NN	Protein	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	predicted	_	_	JJ	O	-1	none	_	_
3	amino	_	_	NN	O	-1	none	_	_
4	acid	_	_	NN	O	-1	none	_	_
5	sequence	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	amino-terminal	_	_	JJ	O	-1	none	_	_
9	portion	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Sp140	_	_	NN	Protein	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	similar	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	Sp100	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	previously	_	_	RB	O	-1	none	_	_
19	identified	_	_	VBN	O	-1	none	_	_
20	NB	_	_	NN	O	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	carboxyl	_	_	JJ	O	-1	none	_	_
3	portion	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	Sp140	_	_	NN	Protein	-1	none	_	_
6	contained	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	zinc-finger	_	_	JJ	O	-1	none	_	_
9	domain	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	bromodomain	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	motifs	_	_	NNS	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	present	_	_	JJ	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	proteins	_	_	NNS	O	-1	none	_	_
20	regulating	_	_	VBG	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	High	_	_	JJ	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Sp140	_	_	NN	Protein	-1	none	_	_
5	mRNA	_	_	NN	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	detected	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	spleen	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	peripheral	_	_	JJ	O	-1	none	_	_
13	blood	_	_	NN	O	-1	none	_	_
14	leukocytes	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	other	_	_	JJ	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	tissues	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	level	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	SP140	_	_	NN	Protein	-1	none	_	_
5	mRNA	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	myeloid	_	_	JJ	O	-1	none	_	_
8	precursor	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	lines	_	_	NNS	O	-1	none	_	_
11	HL60	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	NB4	_	_	NN	O	-1	none	_	_
14	markedly	_	_	RB	O	-1	none	_	_
15	increased	_	_	VBD	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	response	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	chemically	_	_	RB	O	-1	none	_	_
20	induced	_	_	VBN	O	-1	none	_	_
21	cellular	_	_	JJ	O	-1	none	_	_
22	differentiation	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Immunohistochemical	_	_	JJ	O	-1	none	_	_
2	techniques	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	used	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	demonstrate	_	_	VB	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	SP140	_	_	NN	Protein	-1	none	_	_
9	localized	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	NB	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	differentiated	_	_	VBN	O	-1	none	_	_
15	HL60	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	NB4	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	location	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Sp140	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	NB	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	this	_	_	DT	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	involved	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	host	_	_	NN	O	-1	none	_	_
19	defense	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	suggest	_	_	VBP	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	Sp140	_	_	NN	Protein	-1	none	_	_
24	may	_	_	MD	O	-1	none	_	_
25	be	_	_	VB	O	-1	none	_	_
26	involved	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	pathogenesis	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	acute	_	_	JJ	O	-1	none	_	_
32	promyelocytic	_	_	JJ	O	-1	none	_	_
33	leukemia	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	viral	_	_	JJ	O	-1	none	_	_
36	infection	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	NF-kappaB	_	_	NN	O	-1	none	_	_
2	only	_	_	RB	O	-1	none	_	_
3	partially	_	_	RB	O	-1	none	_	_
4	mediates	_	_	VBZ	O	-1	none	_	_
5	Epstein-Barr	_	_	JJ	O	-1	none	_	_
6	virus	_	_	NN	O	-1	none	_	_
7	latent	_	_	JJ	Protein	10	multitoken	_	_
8	membrane	_	_	NN	Protein	10	multitoken	_	_
9	protein	_	_	NN	Protein	10	multitoken	_	_
10	1	_	_	CD	Protein	0	root	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	latent	_	_	JJ	Protein	5	multitoken	_	_
3	membrane	_	_	NN	Protein	5	multitoken	_	_
4	protein	_	_	NN	Protein	5	multitoken	_	_
5	1	_	_	CD	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	LMP1	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	Epstein-Barr	_	_	JJ	O	-1	none	_	_
11	virus	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	EBV	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	required	_	_	VBN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	EBV	_	_	NN	O	-1	none	_	_
19	induced	_	_	VBD	O	-1	none	_	_
20	immortalization	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	causes	_	_	VBZ	O	-1	none	_	_
27	tumorigenic	_	_	JJ	O	-1	none	_	_
28	transformation	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	lines	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	LMP1	_	_	NN	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	induces	_	_	VBZ	O	-1	none	_	_
4	phenotypic	_	_	JJ	O	-1	none	_	_
5	changes	_	_	NNS	O	-1	none	_	_
6	resembling	_	_	VBG	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	such	_	_	JJ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	size	_	_	NN	O	-1	none	_	_
15	increase	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	up-regulation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	surface	_	_	NN	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	markers	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	LMP1	_	_	NN	Protein	-1	none	_	_
2	contains	_	_	VBZ	O	-1	none	_	_
3	two	_	_	CD	O	-1	none	_	_
4	domains	_	_	NNS	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	activate	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	one	_	_	CD	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	interactions	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	TRAF	_	_	NN	O	-1	none	_	_
17	proteins	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	other	_	_	JJ	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	TRADD	_	_	NN	O	-1	none	_	_
24	protein	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	purpose	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	present	_	_	JJ	O	-1	none	_	_
6	study	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	investigate	_	_	VB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	importance	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	induction	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	up-regulation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	markers	_	_	NNS	O	-1	none	_	_
24	ICAM-1	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	CD71	_	_	NN	Protein	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	LMP1	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	ICAM-1	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	CD71	_	_	NN	Protein	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	nevertheless	_	_	RB	O	-1	none	_	_
6	up-regulated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	LMP1	_	_	NN	Protein	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	primary	_	_	JJ	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	lines	_	_	NNS	O	-1	none	_	_
16	expressing	_	_	VBG	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	dominant	_	_	JJ	O	-1	none	_	_
19	IkappaB	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	LMP1	_	_	NN	Protein	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	size	_	_	NN	O	-1	none	_	_
7	increase	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	primary	_	_	JJ	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	unaffected	_	_	JJ	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	IkappaB	_	_	NN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	concluded	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	even	_	_	RB	O	-1	none	_	_
6	when	_	_	WRB	O	-1	none	_	_
7	LMP1	_	_	NN	Protein	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	unable	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	activate	_	_	VB	O	-1	none	_	_
12	NF-kappaB	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	it	_	_	PRP	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	still	_	_	RB	O	-1	none	_	_
17	capable	_	_	JJ	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	inducing	_	_	VBG	O	-1	none	_	_
20	certain	_	_	JJ	O	-1	none	_	_
21	characteristics	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	activated	_	_	VBN	O	-1	none	_	_
24	B	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	strongly	_	_	RB	O	-1	none	_	_
28	suggesting	_	_	VBG	O	-1	none	_	_
29	that	_	_	IN	O	-1	none	_	_
30	LMP1	_	_	NN	Protein	-1	none	_	_
31	can	_	_	MD	O	-1	none	_	_
32	also	_	_	RB	O	-1	none	_	_
33	activate	_	_	VB	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	independently	_	_	RB	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	NF-kappaB	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	interleukin-2	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	normal	_	_	JJ	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	peripheral	_	_	JJ	O	-1	none	_	_
11	blood	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Convergence	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	costimulatory	_	_	JJ	O	-1	none	_	_
4	signals	_	_	NNS	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	differences	_	_	NNS	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	transformed	_	_	VBN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	study	_	_	VB	O	-1	none	_	_
3	transcriptional	_	_	JJ	O	-1	none	_	_
4	regulation	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	normal	_	_	JJ	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	we	_	_	PRP	O	-1	none	_	_
12	have	_	_	VBP	O	-1	none	_	_
13	optimized	_	_	VBN	O	-1	none	_	_
14	conditions	_	_	NNS	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	transient	_	_	JJ	O	-1	none	_	_
17	transfection	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Interleukin-2	_	_	NNP	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	reporter	_	_	NN	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	behavior	_	_	NN	O	-1	none	_	_
9	closely	_	_	RB	O	-1	none	_	_
10	parallels	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	endogenous	_	_	JJ	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	response	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	costimulatory	_	_	JJ	O	-1	none	_	_
22	signals	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	assessed	_	_	VBN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	mutagenized	_	_	JJ	O	-1	none	_	_
5	promoters	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	most	_	_	RBS	O	-1	none	_	_
9	important	_	_	JJ	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	cis-regulatory	_	_	JJ	O	-1	none	_	_
12	elements	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	proximal	_	_	JJ	O	-1	none	_	_
20	AP-1	_	_	NN	O	-1	none	_	_
21	site	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	NF-	_	_	NN	O	-1	none	_	_
25	kappaB	_	_	NN	O	-1	none	_	_
26	site	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	primary	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	phytohemagglutinin	_	_	NN	Protein	-1	none	_	_
7	or	_	_	CC	O	-1	none	_	_
8	antibodies	_	_	NNS	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	CD3	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	costimulation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	provided	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	pairs	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	CD2	_	_	NN	O	-1	none	_	_
20	antibodies	_	_	NNS	O	-1	none	_	_
21	or	_	_	CC	O	-1	none	_	_
22	B7	_	_	NN	O	-1	none	_	_
23	positive	_	_	JJ	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	or	_	_	CC	O	-1	none	_	_
29	B7	_	_	NN	O	-1	none	_	_
30	negative	_	_	JJ	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	endothelial	_	_	JJ	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	accessory	_	_	NN	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	are	_	_	VBP	O	-1	none	_	_
38	mediated	_	_	VBN	O	-1	none	_	_
39	through	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	same	_	_	JJ	O	-1	none	_	_
42	cis-elements	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	activated	_	_	VBN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	sites	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	much	_	_	RB	O	-1	none	_	_
13	less	_	_	RBR	O	-1	none	_	_
14	important	_	_	JJ	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	normal	_	_	JJ	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	than	_	_	IN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	Jurkat	_	_	NN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	IL-2	_	_	NN	Protein	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	regulation	_	_	NN	O	-1	none	_	_
7	differs	_	_	VBZ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	tumor	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	lines	_	_	NNS	O	-1	none	_	_
12	compared	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	different	_	_	JJ	O	-1	none	_	_
20	costimulatory	_	_	JJ	O	-1	none	_	_
21	signals	_	_	NNS	O	-1	none	_	_
22	converge	_	_	VBP	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	same	_	_	JJ	O	-1	none	_	_
26	cis-elements	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	IL-2	_	_	NN	Protein	-1	none	_	_
30	promoter	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Characterization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	elk-1	_	_	NN	Protein	-1	none	_	_
6	promoter	_	_	NN	O	-1	none	_	_
7	.	_	_	.	O	-1	none	_	_

1	Potential	_	_	JJ	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	downstream	_	_	JJ	O	-1	none	_	_
6	intronic	_	_	JJ	O	-1	none	_	_
7	sequence	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	elk-1	_	_	NN	Protein	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	monocytes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	TATA	_	_	NN	O	-1	none	_	_
3	like	_	_	IN	O	-1	none	_	_
4	motif	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	identified	_	_	VBN	O	-1	none	_	_
7	immediately	_	_	RB	O	-1	none	_	_
8	upstream	_	_	RB	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcriptional	_	_	JJ	O	-1	none	_	_
12	start	_	_	NN	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	analyses	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	DNA	_	_	NN	O	-1	none	_	_
5	fragments	_	_	NNS	O	-1	none	_	_
6	containing	_	_	VBG	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	TATA	_	_	NN	O	-1	none	_	_
9	element	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	identification	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	DNase	_	_	NN	O	-1	none	_	_
16	I-hypersensitive	_	_	JJ	O	-1	none	_	_
17	chromatin	_	_	NN	O	-1	none	_	_
18	site	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	HS	_	_	NN	O	-1	none	_	_
21	1	_	_	CD	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	close	_	_	JJ	O	-1	none	_	_
25	proximity	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	TATA	_	_	NN	O	-1	none	_	_
29	box	_	_	NN	O	-1	none	_	_
30	suggest	_	_	VBP	O	-1	none	_	_
31	that	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	identified	_	_	JJ	O	-1	none	_	_
34	TATA	_	_	NN	O	-1	none	_	_
35	motif	_	_	NN	O	-1	none	_	_
36	is	_	_	VBZ	O	-1	none	_	_
37	important	_	_	JJ	O	-1	none	_	_
38	for	_	_	IN	O	-1	none	_	_
39	elk-1	_	_	NN	Protein	-1	none	_	_
40	transcription	_	_	NN	O	-1	none	_	_
41	in	_	_	FW	O	-1	none	_	_
42	vivo	_	_	FW	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Sequences	_	_	NNS	O	-1	none	_	_
2	upstream	_	_	JJ	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	downstream	_	_	JJ	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	TATA	_	_	NN	O	-1	none	_	_
8	box	_	_	NN	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	found	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	contribute	_	_	VB	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	elk-1	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	second	_	_	JJ	O	-1	none	_	_
3	hypersensitive	_	_	JJ	O	-1	none	_	_
4	site	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	HS	_	_	NN	O	-1	none	_	_
7	2	_	_	CD	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	identified	_	_	VBN	O	-1	none	_	_
11	within	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	first	_	_	JJ	O	-1	none	_	_
14	intron	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	pre-monocytic	_	_	JJ	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	express	_	_	VBP	O	-1	none	_	_
21	Elk-1	_	_	NN	Protein	-1	none	_	_
22	only	_	_	RB	O	-1	none	_	_
23	when	_	_	WRB	O	-1	none	_	_
24	differentiating	_	_	VBG	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	monocytes	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	variety	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	other	_	_	JJ	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	types	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	which	_	_	WDT	O	-1	none	_	_
10	display	_	_	VBP	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	constitutive	_	_	JJ	O	-1	none	_	_
13	Elk-1	_	_	NN	Protein	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	HS	_	_	NN	O	-1	none	_	_
17	2	_	_	CD	O	-1	none	_	_
18	did	_	_	VBD	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	exist	_	_	VB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	suggesting	_	_	VBG	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	inducibility	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	elk-1	_	_	NN	Protein	-1	none	_	_
27	expression	_	_	NN	O	-1	none	_	_
28	is	_	_	VBZ	O	-1	none	_	_
29	associated	_	_	VBN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	presence	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	HS	_	_	NN	O	-1	none	_	_
35	2	_	_	CD	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Egr-1	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	serum	_	_	NN	Protein	6	multitoken	_	_
5	response	_	_	NN	Protein	6	multitoken	_	_
6	factor	_	_	NN	Protein	0	root	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	found	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	interact	_	_	VB	O	-1	none	_	_
11	specifically	_	_	RB	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	intronic	_	_	JJ	O	-1	none	_	_
15	sequence	_	_	NN	O	-1	none	_	_
16	at	_	_	IN	O	-1	none	_	_
17	+265	_	_	CD	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	+448	_	_	CD	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	respectively	_	_	RB	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	Egr-1	_	_	NN	Protein	-1	none	_	_
3	mRNA	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	levels	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	observed	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	increase	_	_	VB	O	-1	none	_	_
11	significantly	_	_	RB	O	-1	none	_	_
12	before	_	_	IN	O	-1	none	_	_
13	induction	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	elk-1	_	_	NN	Protein	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	we	_	_	PRP	O	-1	none	_	_
19	propose	_	_	VBP	O	-1	none	_	_
20	that	_	_	IN	O	-1	none	_	_
21	Egr-1	_	_	NN	Protein	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	important	_	_	JJ	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	regulation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	elk-1	_	_	NN	Protein	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	differentiating	_	_	VBG	O	-1	none	_	_
32	monocytes	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Cytokine	_	_	NN	O	-1	none	_	_
2	rescue	_	_	NN	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	glucocorticoid	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	apoptosis	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	mediated	_	_	VBN	O	-1	none	_	_
12	through	_	_	IN	O	-1	none	_	_
13	inhibition	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	previously	_	_	RB	O	-1	none	_	_
3	reported	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	dexamethasone	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	DEX	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	synthetic	_	_	JJ	O	-1	none	_	_
12	glucocorticoid	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	causes	_	_	VBZ	O	-1	none	_	_
15	apoptosis	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	mature	_	_	JJ	O	-1	none	_	_
18	Th	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	lines	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	this	_	_	DT	O	-1	none	_	_
25	induction	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	death	_	_	NN	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	prevented	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	specific	_	_	JJ	O	-1	none	_	_
33	cytokines	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	namely	_	_	RB	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	IL-2	_	_	NN	Protein	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	Th1	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	by	_	_	IN	O	-1	none	_	_
44	IL-4	_	_	NN	Protein	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	Th2	_	_	NN	O	-1	none	_	_
47	cells	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	differential	_	_	JJ	O	-1	none	_	_
7	rescue	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	specific	_	_	JJ	O	-1	none	_	_
10	cytokines	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	Th	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	correlates	_	_	VBZ	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	level	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
20	that	_	_	WDT	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	regulated	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	DEX	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	cytokines	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	both	_	_	DT	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	types	_	_	NNS	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	cellular	_	_	JJ	O	-1	none	_	_
7	levels	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
10	mRNA	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	evaluated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	DEX	_	_	NN	O	-1	none	_	_
17	treatment	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	DEX	_	_	NN	O	-1	none	_	_
5	mediated	_	_	VBD	O	-1	none	_	_
6	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
7	induction	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	completely	_	_	RB	O	-1	none	_	_
10	inhibited	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	IL-2	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	IL-4	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	Th1	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	while	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	reverse	_	_	JJ	O	-1	none	_	_
25	profile	_	_	NN	O	-1	none	_	_
26	was	_	_	VBD	O	-1	none	_	_
27	seen	_	_	VBN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	Th2	_	_	NN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	both	_	_	DT	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	types	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	cytokine	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	inhibits	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	DEX	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	also	_	_	RB	O	-1	none	_	_
18	rescues	_	_	VBZ	O	-1	none	_	_
19	these	_	_	DT	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	DEX	_	_	NN	O	-1	none	_	_
23	induced	_	_	VBD	O	-1	none	_	_
24	apoptosis	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	although	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	rescue	_	_	NN	O	-1	none	_	_
29	cytokine	_	_	NN	O	-1	none	_	_
30	is	_	_	VBZ	O	-1	none	_	_
31	different	_	_	JJ	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	Th1	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	Th2	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	imply	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	need	_	_	VBP	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	maintain	_	_	VB	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	certain	_	_	JJ	O	-1	none	_	_
12	level	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	NF-kappaB	_	_	NN	O	-1	none	_	_
15	transcriptional	_	_	JJ	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	order	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	survive	_	_	VB	O	-1	none	_	_
21	;	_	_	:	O	-1	none	_	_
22	up-	_	_	RB	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	down-regulation	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	nuclear	_	_	JJ	O	-1	none	_	_
27	NF	_	_	NN	O	-1	none	_	_
28	kappaB	_	_	NN	O	-1	none	_	_
29	through	_	_	IN	O	-1	none	_	_
30	modulation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
33	expression	_	_	NN	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	cytokines	_	_	NNS	O	-1	none	_	_
36	or	_	_	CC	O	-1	none	_	_
37	DEX	_	_	NN	O	-1	none	_	_
38	may	_	_	MD	O	-1	none	_	_
39	lead	_	_	VB	O	-1	none	_	_
40	to	_	_	TO	O	-1	none	_	_
41	cell	_	_	NN	O	-1	none	_	_
42	survival	_	_	NN	O	-1	none	_	_
43	or	_	_	CC	O	-1	none	_	_
44	cell	_	_	NN	O	-1	none	_	_
45	death	_	_	NN	O	-1	none	_	_
46	,	_	_	,	O	-1	none	_	_
47	respectively	_	_	RB	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	primary	_	_	JJ	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	T-lymphocytes	_	_	NNS	O	-1	none	_	_
6	through	_	_	IN	O	-1	none	_	_
7	CD2	_	_	NN	Protein	-1	none	_	_
8	plus	_	_	CC	O	-1	none	_	_
9	CD28	_	_	NN	Protein	-1	none	_	_
10	adhesion	_	_	NN	O	-1	none	_	_
11	molecules	_	_	NNS	O	-1	none	_	_
12	induces	_	_	VBZ	O	-1	none	_	_
13	long-term	_	_	JJ	O	-1	none	_	_
14	nuclear	_	_	JJ	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B.	_	_	NNP	O	-1	none	_	_
19	Stimulation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	highly	_	_	RB	O	-1	none	_	_
22	purified	_	_	VBN	O	-1	none	_	_
23	human	_	_	NN	O	-1	none	_	_
24	T-cells	_	_	NNS	O	-1	none	_	_
25	via	_	_	IN	O	-1	none	_	_
26	CD2	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	CD28	_	_	NN	Protein	-1	none	_	_
29	adhesion	_	_	NN	O	-1	none	_	_
30	molecules	_	_	NNS	O	-1	none	_	_
31	induces	_	_	VBZ	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	maintains	_	_	VBZ	O	-1	none	_	_
34	proliferation	_	_	NN	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	more	_	_	JJR	O	-1	none	_	_
37	than	_	_	IN	O	-1	none	_	_
38	3	_	_	CD	O	-1	none	_	_
39	weeks	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	potent	_	_	JJ	O	-1	none	_	_
3	interleukin	_	_	NN	Protein	4	multitoken	_	_
4	2	_	_	CD	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	)-dependent	_	_	JJ	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	does	_	_	VBZ	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	require	_	_	VB	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	accessory	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Long	_	_	JJ	O	-1	none	_	_
2	lasting	_	_	JJ	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	receptivity	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	associated	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	high-level	_	_	JJ	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	inducible	_	_	JJ	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	16	multitoken	_	_
14	receptor	_	_	NN	Protein	16	multitoken	_	_
15	alpha	_	_	NN	Protein	16	multitoken	_	_
16	chain	_	_	NN	Protein	0	root	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	IL-2R	_	_	NN	Protein	19	multitoken	_	_
19	alpha	_	_	NN	Protein	0	root	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	that	_	_	WDT	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	regulated	_	_	VBN	O	-1	none	_	_
25	at	_	_	IN	O	-1	none	_	_
26	both	_	_	CC	O	-1	none	_	_
27	transcriptional	_	_	JJ	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	posttranscriptional	_	_	JJ	O	-1	none	_	_
30	levels	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Increase	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	IL-2R	_	_	NN	Protein	4	multitoken	_	_
4	alpha	_	_	NN	Protein	0	root	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	involves	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	enhanced	_	_	JJ	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factor	_	_	NN	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	its	_	_	PRP$	O	-1	none	_	_
19	consensus	_	_	NN	O	-1	none	_	_
20	sequence	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	5	_	_	CD	O	-1	none	_	_
24	'-regulatory	_	_	JJ	O	-1	none	_	_
25	region	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	IL-2R	_	_	NN	Protein	29	multitoken	_	_
29	alpha	_	_	NN	Protein	0	root	_	_
30	gene	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	dissect	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	basis	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	unusually	_	_	RB	O	-1	none	_	_
9	persistent	_	_	JJ	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	IL-2R	_	_	NN	Protein	14	multitoken	_	_
14	alpha	_	_	NN	Protein	0	root	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	we	_	_	PRP	O	-1	none	_	_
18	analyzed	_	_	VBD	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	NF-kappa	_	_	NN	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	radiolabeled	_	_	JJ	O	-1	none	_	_
26	IL-2R	_	_	NN	Protein	27	multitoken	_	_
27	alpha	_	_	NN	Protein	0	root	_	_
28	kappa	_	_	NN	O	-1	none	_	_
29	B	_	_	NN	O	-1	none	_	_
30	specific	_	_	JJ	O	-1	none	_	_
31	oligonucleotide	_	_	NN	O	-1	none	_	_
32	probe	_	_	NN	O	-1	none	_	_
33	during	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	time	_	_	NN	O	-1	none	_	_
36	course	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	CD2	_	_	NN	Protein	-1	none	_	_
39	+	_	_	CC	O	-1	none	_	_
40	CD28	_	_	NN	Protein	-1	none	_	_
41	activation	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Resting	_	_	VBG	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	extracts	_	_	NNS	O	-1	none	_	_
5	contained	_	_	VBD	O	-1	none	_	_
6	KBF1	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	p50	_	_	NN	Protein	-1	none	_	_
9	homodimer	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	stimulation	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	new	_	_	JJ	O	-1	none	_	_
6	kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	complexes	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	identified	_	_	VBN	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	p50	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	p65	_	_	NN	Protein	-1	none	_	_
18	heterodimer	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	putative	_	_	JJ	O	-1	none	_	_
21	c-Rel	_	_	NN	Protein	-1	none	_	_
22	homodimer	_	_	NN	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	c	_	_	NN	Protein	26	multitoken	_	_
25	,	_	_	,	Protein	26	multitoken	_	_
26	Rel	_	_	NN	Protein	0	root	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	p65	_	_	NN	Protein	-1	none	_	_
30	heterodimer	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	inducible	_	_	JJ	O	-1	none	_	_
3	complexes	_	_	NNS	O	-1	none	_	_
4	persisted	_	_	VBD	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	at	_	_	IN	O	-1	none	_	_
7	least	_	_	JJS	O	-1	none	_	_
8	3	_	_	CD	O	-1	none	_	_
9	weeks	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Their	_	_	PRP$	O	-1	none	_	_
2	relative	_	_	JJ	O	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	very	_	_	RB	O	-1	none	_	_
6	similar	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	duration	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	proliferation	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	parallel	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	CD2	_	_	NN	Protein	-1	none	_	_
5	+	_	_	CC	O	-1	none	_	_
6	CD28	_	_	NN	Protein	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	triggered	_	_	VBD	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	significant	_	_	JJ	O	-1	none	_	_
11	intracellular	_	_	JJ	O	-1	none	_	_
12	thiol	_	_	NN	O	-1	none	_	_
13	decrease	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	suggesting	_	_	VBG	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	oxygen	_	_	NN	O	-1	none	_	_
18	radicals	_	_	NNS	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	involved	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	signaling	_	_	NN	O	-1	none	_	_
24	pathway	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	adhesion	_	_	NN	O	-1	none	_	_
27	molecules	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	micromolar	_	_	JJ	O	-1	none	_	_
4	amounts	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	pyrrolidine	_	_	NN	O	-1	none	_	_
7	dithiocarbamate	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	oxygen	_	_	NN	O	-1	none	_	_
11	radical	_	_	JJ	O	-1	none	_	_
12	scavenger	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	efficiently	_	_	RB	O	-1	none	_	_
15	blocked	_	_	VBD	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	appearance	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	NF-kappa	_	_	NN	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	T-lymphocytes	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	also	_	_	RB	O	-1	none	_	_
26	inhibited	_	_	VBD	O	-1	none	_	_
27	IL-2	_	_	NN	Protein	-1	none	_	_
28	secretion	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	IL-2R	_	_	NN	Protein	31	multitoken	_	_
31	alpha	_	_	NN	Protein	0	root	_	_
32	cell	_	_	NN	O	-1	none	_	_
33	surface	_	_	NN	O	-1	none	_	_
34	expression	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	T-cell	_	_	NN	O	-1	none	_	_
38	proliferation	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	plays	_	_	VBZ	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	important	_	_	JJ	O	-1	none	_	_
12	role	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	long-term	_	_	JJ	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	primary	_	_	JJ	O	-1	none	_	_
19	T-lymphocytes	_	_	NNS	O	-1	none	_	_
20	via	_	_	IN	O	-1	none	_	_
21	CD2	_	_	NN	Protein	-1	none	_	_
22	+	_	_	CC	O	-1	none	_	_
23	CD28	_	_	NN	Protein	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Initiation	_	_	NN	Protein	3	multitoken	_	_
2	binding	_	_	NN	Protein	3	multitoken	_	_
3	repressor	_	_	NN	Protein	0	root	_	_
4	,	_	_	,	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	factor	_	_	NN	O	-1	none	_	_
7	that	_	_	WDT	O	-1	none	_	_
8	binds	_	_	VBZ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	initiation	_	_	NN	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	histone	_	_	NN	Protein	17	multitoken	_	_
17	h5	_	_	NN	Protein	0	root	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	glycosylated	_	_	JJ	O	-1	none	_	_
23	member	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	family	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	growth	_	_	NN	O	-1	none	_	_
30	regulators	_	_	NNS	O	-1	none	_	_
31	[	_	_	VBP	O	-1	none	_	_
32	corrected	_	_	VBN	O	-1	none	_	_
33	]	_	_	CD	O	-1	none	_	_
34	[	_	_	CD	O	-1	none	_	_
35	published	_	_	VBN	O	-1	none	_	_
36	erratum	_	_	NN	O	-1	none	_	_
37	appears	_	_	VBZ	O	-1	none	_	_
38	in	_	_	IN	O	-1	none	_	_
39	Mol	_	_	NNP	O	-1	none	_	_
40	Cell	_	_	NNP	O	-1	none	_	_
41	Biol	_	_	NNP	O	-1	none	_	_
42	1996	_	_	CD	O	-1	none	_	_
43	Feb	_	_	NNP	O	-1	none	_	_
44	;	_	_	:	O	-1	none	_	_
45	16	_	_	CD	O	-1	none	_	_
46	(	_	_	-LRB-	O	-1	none	_	_
47	2	_	_	CD	O	-1	none	_	_
48	)	_	_	-RRB-	O	-1	none	_	_
49	:735	_	_	CD	O	-1	none	_	_
50	]	_	_	CD	O	-1	none	_	_
51	Initiation	_	_	NN	Protein	53	multitoken	_	_
52	binding	_	_	NN	Protein	53	multitoken	_	_
53	repressor	_	_	NN	Protein	0	root	_	_
54	[	_	_	CD	O	-1	none	_	_
55	corrected	_	_	VBN	O	-1	none	_	_
56	]	_	_	CD	O	-1	none	_	_
57	(	_	_	-LRB-	O	-1	none	_	_
58	IBR	_	_	NN	Protein	-1	none	_	_
59	)	_	_	-RRB-	O	-1	none	_	_
60	is	_	_	VBZ	O	-1	none	_	_
61	a	_	_	DT	O	-1	none	_	_
62	chicken	_	_	NN	O	-1	none	_	_
63	erythrocyte	_	_	NN	O	-1	none	_	_
64	factor	_	_	NN	O	-1	none	_	_
65	(	_	_	-LRB-	O	-1	none	_	_
66	apparent	_	_	JJ	O	-1	none	_	_
67	molecular	_	_	JJ	O	-1	none	_	_
68	mass	_	_	NN	O	-1	none	_	_
69	,	_	_	,	O	-1	none	_	_
70	70	_	_	CD	O	-1	none	_	_
71	to	_	_	TO	O	-1	none	_	_
72	73	_	_	CD	O	-1	none	_	_
73	kDa	_	_	NN	O	-1	none	_	_
74	)	_	_	-RRB-	O	-1	none	_	_
75	that	_	_	WDT	O	-1	none	_	_
76	binds	_	_	VBZ	O	-1	none	_	_
77	to	_	_	TO	O	-1	none	_	_
78	the	_	_	DT	O	-1	none	_	_
79	sequences	_	_	NNS	O	-1	none	_	_
80	spanning	_	_	VBG	O	-1	none	_	_
81	the	_	_	DT	O	-1	none	_	_
82	transcription	_	_	NN	O	-1	none	_	_
83	initiation	_	_	NN	O	-1	none	_	_
84	site	_	_	NN	O	-1	none	_	_
85	of	_	_	IN	O	-1	none	_	_
86	the	_	_	DT	O	-1	none	_	_
87	histone	_	_	NN	Protein	88	multitoken	_	_
88	h5	_	_	NN	Protein	0	root	_	_
89	gene	_	_	NN	O	-1	none	_	_
90	,	_	_	,	O	-1	none	_	_
91	repressing	_	_	VBG	O	-1	none	_	_
92	its	_	_	PRP$	O	-1	none	_	_
93	transcription	_	_	NN	O	-1	none	_	_
94	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	variety	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	other	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	including	_	_	VBG	O	-1	none	_	_
8	transformed	_	_	VBN	O	-1	none	_	_
9	erythroid	_	_	JJ	O	-1	none	_	_
10	precursors	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	do	_	_	VBP	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	have	_	_	VB	O	-1	none	_	_
15	IBR	_	_	NN	Protein	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	referred	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	IBF	_	_	NN	Protein	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	68	_	_	CD	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	70	_	_	CD	O	-1	none	_	_
27	kDa	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	that	_	_	WDT	O	-1	none	_	_
30	recognizes	_	_	VBZ	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	same	_	_	JJ	O	-1	none	_	_
33	IBR	_	_	NN	Protein	-1	none	_	_
34	sites	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	cloned	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	IBR	_	_	NN	Protein	-1	none	_	_
6	cDNA	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	studied	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	relationship	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	IBR	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	IBF	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	IBR	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	503-amino-acid-long	_	_	JJ	O	-1	none	_	_
5	acidic	_	_	JJ	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	99.0	_	_	CD	O	-1	none	_	_
10	%	_	_	NN	O	-1	none	_	_
11	identical	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	recently	_	_	RB	O	-1	none	_	_
15	reported	_	_	VBN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	NRF-1	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	alpha-Pal	_	_	JJ	Protein	20	multitoken	_	_
20	factor	_	_	NN	Protein	0	root	_	_
21	and	_	_	CC	O	-1	none	_	_
22	highly	_	_	RB	O	-1	none	_	_
23	related	_	_	JJ	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	invertebrate	_	_	JJ	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factors	_	_	NNS	O	-1	none	_	_
29	P3A2	_	_	NN	Protein	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	erected	_	_	JJ	Protein	33	multitoken	_	_
32	wing	_	_	NN	Protein	33	multitoken	_	_
33	gene	_	_	NN	Protein	0	root	_	_
34	product	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	EWG	_	_	NN	Protein	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	present	_	_	VBP	O	-1	none	_	_
3	evidence	_	_	NN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IBR	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IBF	_	_	NN	Protein	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	most	_	_	RBS	O	-1	none	_	_
10	likely	_	_	JJ	O	-1	none	_	_
11	identical	_	_	JJ	O	-1	none	_	_
12	proteins	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	differing	_	_	VBG	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	their	_	_	PRP$	O	-1	none	_	_
17	degree	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	glycosylation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	survey	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	genes	_	_	NNS	O	-1	none	_	_
5	potentially	_	_	RB	O	-1	none	_	_
6	regulated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	family	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	factors	_	_	NNS	O	-1	none	_	_
12	primarily	_	_	RB	O	-1	none	_	_
13	revealed	_	_	VBD	O	-1	none	_	_
14	genes	_	_	NNS	O	-1	none	_	_
15	involved	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	growth	_	_	NN	O	-1	none	_	_
18	related	_	_	JJ	O	-1	none	_	_
19	metabolism	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	MHC	_	_	NN	O	-1	none	_	_
3	class	_	_	NN	O	-1	none	_	_
4	II	_	_	CD	O	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	directed	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	carboxyl	_	_	NN	O	-1	none	_	_
11	terminus	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	CIITA	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	one	_	_	CD	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	defective	_	_	JJ	O	-1	none	_	_
19	genes	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	type	_	_	NN	O	-1	none	_	_
22	II	_	_	CD	O	-1	none	_	_
23	MHC	_	_	NN	O	-1	none	_	_
24	combined	_	_	JJ	O	-1	none	_	_
25	immune	_	_	JJ	O	-1	none	_	_
26	deficiency	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Type	_	_	NN	O	-1	none	_	_
2	II	_	_	CD	O	-1	none	_	_
3	major	_	_	JJ	O	-1	none	_	_
4	histocompatibility	_	_	NN	O	-1	none	_	_
5	complex	_	_	NN	O	-1	none	_	_
6	combined	_	_	JJ	O	-1	none	_	_
7	immune	_	_	JJ	O	-1	none	_	_
8	deficiency	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	type	_	_	NN	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	MHC	_	_	NN	O	-1	none	_	_
13	CID	_	_	NN	O	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	bare	_	_	JJ	O	-1	none	_	_
16	lymphocyte	_	_	NN	O	-1	none	_	_
17	syndrome	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	congenital	_	_	JJ	O	-1	none	_	_
22	immunodeficiency	_	_	NN	O	-1	none	_	_
23	disease	_	_	NN	O	-1	none	_	_
24	characterized	_	_	VBN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	absent	_	_	JJ	O	-1	none	_	_
27	MHC	_	_	NN	O	-1	none	_	_
28	class	_	_	NN	O	-1	none	_	_
29	II	_	_	CD	O	-1	none	_	_
30	expression	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Four	_	_	CD	O	-1	none	_	_
2	distinct	_	_	JJ	O	-1	none	_	_
3	complementation	_	_	NN	O	-1	none	_	_
4	groups	_	_	NNS	O	-1	none	_	_
5	have	_	_	VBP	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	identified	_	_	VBN	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	defective	_	_	JJ	O	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	group	_	_	NN	O	-1	none	_	_
8	II	_	_	CD	O	-1	none	_	_
9	type	_	_	NN	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	MHC	_	_	NN	O	-1	none	_	_
12	CID	_	_	NN	O	-1	none	_	_
13	has	_	_	VBZ	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	isolated	_	_	VBN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	termed	_	_	VBN	O	-1	none	_	_
18	CIITA	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	CIITA	_	_	NN	Protein	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	MHC	_	_	NN	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	activator	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	function	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	provided	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	N-terminal	_	_	JJ	O	-1	none	_	_
10	acidic	_	_	JJ	O	-1	none	_	_
11	domain	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	amino	_	_	NN	O	-1	none	_	_
14	acids	_	_	NNS	O	-1	none	_	_
15	26-137	_	_	CD	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	experimentally	_	_	RB	O	-1	none	_	_
21	exchangeable	_	_	JJ	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	heterologous	_	_	JJ	O	-1	none	_	_
25	viral	_	_	JJ	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	activating	_	_	VBG	O	-1	none	_	_
28	domain	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	specificity	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	CIITA	_	_	NN	Protein	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	three	_	_	CD	O	-1	none	_	_
7	major	_	_	JJ	O	-1	none	_	_
8	MHC	_	_	NN	O	-1	none	_	_
9	class	_	_	NN	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	DR	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	DQ	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	DP	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	mediated	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	its	_	_	PRP$	O	-1	none	_	_
23	remaining	_	_	VBG	O	-1	none	_	_
24	C-terminal	_	_	JJ	O	-1	none	_	_
25	residues	_	_	NNS	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	amino	_	_	NN	O	-1	none	_	_
28	acids	_	_	NNS	O	-1	none	_	_
29	317-1130	_	_	CD	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transactivation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	multiple	_	_	JJ	O	-1	none	_	_
5	cis	_	_	NN	O	-1	none	_	_
6	elements	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	especially	_	_	RB	O	-1	none	_	_
9	S	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	X2	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	DR	_	_	NN	Protein	16	multitoken	_	_
16	alpha	_	_	NN	Protein	0	root	_	_
17	proximal	_	_	JJ	O	-1	none	_	_
18	promoter	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	group	_	_	NN	O	-1	none	_	_
21	II	_	_	CD	O	-1	none	_	_
22	CID	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	CIITA	_	_	NN	Protein	-1	none	_	_
26	dependent	_	_	JJ	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	CIITA	_	_	NN	Protein	-1	none	_	_
3	overexpression	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	normal	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	did	_	_	VBD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	increase	_	_	VB	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	propose	_	_	VBP	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	initiation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	CIITA	_	_	NN	Protein	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	serves	_	_	VBZ	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	on-off	_	_	JJ	O	-1	none	_	_
25	switch	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	while	_	_	IN	O	-1	none	_	_
28	availability	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	downstream	_	_	JJ	O	-1	none	_	_
31	interactor	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	s	_	_	VBZ	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	limits	_	_	NNS	O	-1	none	_	_
36	transcription	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Dysregulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	monocytic	_	_	JJ	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	factor-kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	oxidized	_	_	VBN	O	-1	none	_	_
9	low-density	_	_	JJ	O	-1	none	_	_
10	lipoprotein	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	factor-kappa	_	_	NN	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	NF-kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	)/Rel	_	_	NN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	may	_	_	MD	O	-1	none	_	_
11	be	_	_	VB	O	-1	none	_	_
12	involved	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	atherosclerosis	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	as	_	_	RB	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	suggested	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	presence	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	activated	_	_	VBN	O	-1	none	_	_
24	NF-kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	human	_	_	NN	O	-1	none	_	_
28	atherosclerotic	_	_	JJ	O	-1	none	_	_
29	lesions	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	aim	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	present	_	_	JJ	O	-1	none	_	_
6	study	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	investigate	_	_	VB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	effects	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	oxidized	_	_	VBN	O	-1	none	_	_
14	LDL	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	oxLDL	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	NF-kappa	_	_	NN	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	system	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	THP-1	_	_	NN	O	-1	none	_	_
26	monocytic	_	_	JJ	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	as	_	_	RB	O	-1	none	_	_
29	well	_	_	RB	O	-1	none	_	_
30	as	_	_	IN	O	-1	none	_	_
31	adherent	_	_	JJ	O	-1	none	_	_
32	monocytes	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	short-term	_	_	JJ	O	-1	none	_	_
6	incubation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	oxLDL	_	_	NN	O	-1	none	_	_
12	activated	_	_	VBD	O	-1	none	_	_
13	p50	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	p65	_	_	NN	O	-1	none	_	_
16	containing	_	_	VBG	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	dimers	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	induced	_	_	VBD	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	target	_	_	NN	O	-1	none	_	_
27	gene	_	_	NN	O	-1	none	_	_
28	IL-8	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	inhibited	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	antioxidant	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	H2O2	_	_	NN	O	-1	none	_	_
13	scavenger	_	_	NN	O	-1	none	_	_
14	pyrrolidine	_	_	NN	O	-1	none	_	_
15	dithiocarbamate	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	proteasome	_	_	NN	O	-1	none	_	_
19	inhibitor	_	_	NN	O	-1	none	_	_
20	PSI	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	oxLDL	_	_	NN	O	-1	none	_	_
3	induced	_	_	VBD	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	accompanied	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	initial	_	_	JJ	O	-1	none	_	_
12	depletion	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	I	_	_	NN	Protein	16	multitoken	_	_
15	kappa	_	_	NN	Protein	16	multitoken	_	_
16	B-alpha	_	_	NN	Protein	0	root	_	_
17	followed	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	slight	_	_	JJ	O	-1	none	_	_
21	transient	_	_	JJ	O	-1	none	_	_
22	increase	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	level	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	inhibitor	_	_	NN	O	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	long-term	_	_	JJ	O	-1	none	_	_
5	treatment	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	oxLDL	_	_	NN	O	-1	none	_	_
8	prevented	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	lipopolysaccharide	_	_	NN	O	-1	none	_	_
11	induced	_	_	VBD	O	-1	none	_	_
12	depletion	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	I	_	_	NN	Protein	16	multitoken	_	_
15	kappa	_	_	NN	Protein	16	multitoken	_	_
16	B-alpha	_	_	NN	Protein	0	root	_	_
17	,	_	_	,	O	-1	none	_	_
18	accompanied	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	an	_	_	DT	O	-1	none	_	_
21	inhibition	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	both	_	_	CC	O	-1	none	_	_
24	NF-kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	tumor	_	_	NN	Protein	33	multitoken	_	_
32	necrosis	_	_	NN	Protein	33	multitoken	_	_
33	factor-alpha	_	_	NN	Protein	0	root	_	_
34	and	_	_	CC	O	-1	none	_	_
35	interleukin-1	_	_	NN	Protein	36	multitoken	_	_
36	beta	_	_	NN	Protein	0	root	_	_
37	genes	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	provide	_	_	VBP	O	-1	none	_	_
4	additional	_	_	JJ	O	-1	none	_	_
5	evidence	_	_	NN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	oxLDL	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	potent	_	_	JJ	O	-1	none	_	_
11	modulator	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	suggest	_	_	VBP	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	dys	_	_	JJ	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	regulation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	NF-kappa	_	_	NN	O	-1	none	_	_
24	B/Rel	_	_	NN	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	likely	_	_	JJ	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	play	_	_	VB	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	important	_	_	JJ	O	-1	none	_	_
31	role	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	atherogenesis	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Characterization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	cofactor	_	_	NN	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	regulates	_	_	VBZ	O	-1	none	_	_
7	dimerization	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	mammalian	_	_	JJ	O	-1	none	_	_
11	homeodomain	_	_	NN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Dimerization	_	_	NN	O	-1	none	_	_
2	among	_	_	IN	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factors	_	_	NNS	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	become	_	_	VBN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	recurrent	_	_	JJ	O	-1	none	_	_
9	theme	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	regulation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	eukaryotic	_	_	JJ	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Hepatocyte	_	_	NN	Protein	4	multitoken	_	_
2	nuclear	_	_	JJ	Protein	4	multitoken	_	_
3	factor-1	_	_	NN	Protein	4	multitoken	_	_
4	alpha	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	HNF-1	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	homeodomain	_	_	NN	O	-1	none	_	_
12	containing	_	_	VBG	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	functions	_	_	VBZ	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	dimer	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	dimerization	_	_	NN	Protein	6	multitoken	_	_
3	cofactor	_	_	NN	Protein	6	multitoken	_	_
4	of	_	_	IN	Protein	6	multitoken	_	_
5	HNF-1	_	_	NN	Protein	6	multitoken	_	_
6	alpha	_	_	NN	Protein	0	root	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	DCoH	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	identified	_	_	VBN	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	displayed	_	_	VBD	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	restricted	_	_	JJ	O	-1	none	_	_
16	tissue	_	_	NN	O	-1	none	_	_
17	distribution	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	did	_	_	VBD	O	-1	none	_	_
20	not	_	_	RB	O	-1	none	_	_
21	bind	_	_	VB	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	DNA	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	rather	_	_	RB	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	selectively	_	_	RB	O	-1	none	_	_
30	stabilized	_	_	VBD	O	-1	none	_	_
31	HNF-1	_	_	NN	Protein	32	multitoken	_	_
32	alpha	_	_	NN	Protein	0	root	_	_
33	dimers	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	DCoH	_	_	NN	Protein	-1	none	_	_
4	did	_	_	VBD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	confer	_	_	VB	O	-1	none	_	_
7	transcriptional	_	_	JJ	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	GAL4	_	_	NN	O	-1	none	_	_
12	DNA	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	domain	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	DCoH	_	_	NN	Protein	-1	none	_	_
6	regulates	_	_	VBZ	O	-1	none	_	_
7	formation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	transcriptionally	_	_	RB	O	-1	none	_	_
10	active	_	_	JJ	O	-1	none	_	_
11	tetrameric	_	_	JJ	O	-1	none	_	_
12	complexes	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	may	_	_	MD	O	-1	none	_	_
15	contribute	_	_	VB	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	developmental	_	_	JJ	O	-1	none	_	_
19	specificity	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	complex	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factors	_	_	NNS	O	-1	none	_	_
5	belonging	_	_	VBG	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	rel	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	NF-kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	family	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	transdominant	_	_	JJ	O	-1	none	_	_
16	negative	_	_	JJ	O	-1	none	_	_
17	mutant	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	KBF1	_	_	NN	Protein	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	which	_	_	WDT	O	-1	none	_	_
6	binds	_	_	VBZ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	enhancer	_	_	NN	O	-1	none	_	_
10	A	_	_	NN	O	-1	none	_	_
11	located	_	_	JJ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	promoter	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	mouse	_	_	NN	O	-1	none	_	_
18	MHC	_	_	NN	O	-1	none	_	_
19	class	_	_	NN	O	-1	none	_	_
20	I	_	_	CD	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	H-2Kb	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	indistinguishable	_	_	JJ	O	-1	none	_	_
26	from	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	p50	_	_	NN	Protein	-1	none	_	_
29	DNA	_	_	NN	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	subunit	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	transcription	_	_	NN	O	-1	none	_	_
35	factor	_	_	NN	O	-1	none	_	_
36	NF-kappa	_	_	NN	O	-1	none	_	_
37	B	_	_	NN	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	which	_	_	WDT	O	-1	none	_	_
40	regulates	_	_	VBZ	O	-1	none	_	_
41	a	_	_	DT	O	-1	none	_	_
42	series	_	_	NN	O	-1	none	_	_
43	of	_	_	IN	O	-1	none	_	_
44	genes	_	_	NNS	O	-1	none	_	_
45	involved	_	_	VBN	O	-1	none	_	_
46	in	_	_	IN	O	-1	none	_	_
47	immune	_	_	JJ	O	-1	none	_	_
48	and	_	_	CC	O	-1	none	_	_
49	inflammatory	_	_	JJ	O	-1	none	_	_
50	responses	_	_	NNS	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	KBF1	_	_	NN	Protein	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	p50	_	_	NN	Protein	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	binds	_	_	VBZ	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	homodimer	_	_	NN	O	-1	none	_	_
10	but	_	_	CC	O	-1	none	_	_
11	can	_	_	MD	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	form	_	_	VB	O	-1	none	_	_
14	heterodimers	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	products	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	other	_	_	JJ	O	-1	none	_	_
20	members	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	same	_	_	JJ	O	-1	none	_	_
24	family	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	like	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	c-rel	_	_	NN	Protein	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	v-rel	_	_	NN	Protein	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	proto	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	oncogenes	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	dimerization	_	_	NN	O	-1	none	_	_
3	domain	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	KBF1	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	p50	_	_	NN	Protein	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	contained	_	_	VBN	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	amino	_	_	NN	O	-1	none	_	_
12	acids	_	_	NNS	O	-1	none	_	_
13	201	_	_	CD	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	367	_	_	CD	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	mutant	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	KBF1	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	p50	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	delta	_	_	NN	O	-1	none	_	_
9	SP	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	unable	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	bind	_	_	VB	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	but	_	_	CC	O	-1	none	_	_
18	able	_	_	JJ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	form	_	_	VB	O	-1	none	_	_
21	homo-	_	_	JJ	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	heterodimers	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	has	_	_	VBZ	O	-1	none	_	_
26	been	_	_	VBN	O	-1	none	_	_
27	constructed	_	_	VBN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	reduces	_	_	VBZ	O	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	abolishes	_	_	VBZ	O	-1	none	_	_
6	in	_	_	FW	O	-1	none	_	_
7	vitro	_	_	FW	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	DNA	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	wild-type	_	_	JJ	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	same	_	_	JJ	O	-1	none	_	_
18	family	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	KBF1	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	p50	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	c-	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	v-rel	_	_	NN	Protein	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Similarly	_	_	RB	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	basal	_	_	JJ	O	-1	none	_	_
4	as	_	_	RB	O	-1	none	_	_
5	well	_	_	RB	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	TNF	_	_	NN	O	-1	none	_	_
8	or	_	_	CC	O	-1	none	_	_
9	IL1	_	_	NN	O	-1	none	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	MHC	_	_	NN	O	-1	none	_	_
15	class	_	_	NN	O	-1	none	_	_
16	I	_	_	CD	O	-1	none	_	_
17	H-2Kb	_	_	NN	Protein	-1	none	_	_
18	promoter	_	_	NN	O	-1	none	_	_
19	can	_	_	MD	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	inhibited	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	mutant	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	two	_	_	CD	O	-1	none	_	_
27	different	_	_	JJ	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	lines	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	constitute	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	first	_	_	JJ	O	-1	none	_	_
6	formal	_	_	JJ	O	-1	none	_	_
7	demonstration	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	these	_	_	DT	O	-1	none	_	_
10	genes	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	regulated	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	members	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	rel	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	family	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Xenogeneic	_	_	JJ	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	serum	_	_	NN	O	-1	none	_	_
4	promotes	_	_	VBZ	O	-1	none	_	_
5	leukocyte	_	_	NN	O	-1	none	_	_
6	adhesion	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	porcine	_	_	NN	O	-1	none	_	_
9	endothelium	_	_	NN	O	-1	none	_	_
10	under	_	_	IN	O	-1	none	_	_
11	flow	_	_	NN	O	-1	none	_	_
12	conditions	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	possibly	_	_	RB	O	-1	none	_	_
15	through	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	NF-kappa	_	_	NN	O	-1	none	_	_
23	B.	_	_	NNP	O	-1	none	_	_
24	Endothelial	_	_	JJ	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	leukocyte	_	_	NN	O	-1	none	_	_
29	infiltration	_	_	NN	O	-1	none	_	_
30	are	_	_	VBP	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	consistent	_	_	JJ	O	-1	none	_	_
33	feature	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	discordant	_	_	JJ	O	-1	none	_	_
36	xenograft	_	_	NN	O	-1	none	_	_
37	rejection	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	evaluated	_	_	VBD	O	-1	none	_	_
4	whether	_	_	IN	O	-1	none	_	_
5	xenogeneic	_	_	JJ	O	-1	none	_	_
6	serum	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	source	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	xenoreactive	_	_	JJ	O	-1	none	_	_
13	natural	_	_	JJ	O	-1	none	_	_
14	antibodies	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	complement	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	induced	_	_	VBD	O	-1	none	_	_
19	endothelial	_	_	JJ	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	consequent	_	_	JJ	O	-1	none	_	_
24	leukocyte	_	_	NN	O	-1	none	_	_
25	adhesion	_	_	NN	O	-1	none	_	_
26	under	_	_	IN	O	-1	none	_	_
27	flow	_	_	NN	O	-1	none	_	_
28	conditions	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Porcine	_	_	NN	O	-1	none	_	_
2	aortic	_	_	JJ	O	-1	none	_	_
3	endothelial	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	PAEC	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	incubated	_	_	VBN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	1	_	_	CD	O	-1	none	_	_
12	hr	_	_	NN	O	-1	none	_	_
13	30	_	_	CD	O	-1	none	_	_
14	min	_	_	NN	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	5	_	_	CD	O	-1	none	_	_
17	hr	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	10	_	_	CD	O	-1	none	_	_
20	%	_	_	NN	O	-1	none	_	_
21	homologous	_	_	JJ	O	-1	none	_	_
22	porcine	_	_	NN	O	-1	none	_	_
23	serum	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	control	_	_	NN	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	or	_	_	CC	O	-1	none	_	_
28	10	_	_	CD	O	-1	none	_	_
29	%	_	_	NN	O	-1	none	_	_
30	xenogeneic	_	_	JJ	O	-1	none	_	_
31	human	_	_	NN	O	-1	none	_	_
32	serum	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	then	_	_	RB	O	-1	none	_	_
35	perfused	_	_	VBN	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	total	_	_	JJ	O	-1	none	_	_
38	human	_	_	NN	O	-1	none	_	_
39	leukocytes	_	_	NNS	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	a	_	_	DT	O	-1	none	_	_
42	parallel	_	_	JJ	O	-1	none	_	_
43	plate	_	_	NN	O	-1	none	_	_
44	flow	_	_	NN	O	-1	none	_	_
45	chamber	_	_	NN	O	-1	none	_	_
46	under	_	_	IN	O	-1	none	_	_
47	laminar	_	_	NN	O	-1	none	_	_
48	flow	_	_	NN	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	1.5	_	_	CD	O	-1	none	_	_
51	dynes	_	_	NNS	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	cm2	_	_	NN	O	-1	none	_	_
54	)	_	_	-RRB-	O	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	Adherent	_	_	JJ	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	counted	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	digital	_	_	JJ	O	-1	none	_	_
7	image	_	_	NN	O	-1	none	_	_
8	analysis	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Xenogeneic	_	_	JJ	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	serum	_	_	NN	O	-1	none	_	_
4	significantly	_	_	RB	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	P	_	_	NN	O	-1	none	_	_
7	<	_	_	JJR	O	-1	none	_	_
8	0.01	_	_	CD	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	increased	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	number	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	adherent	_	_	JJ	O	-1	none	_	_
15	leukocytes	_	_	NNS	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	compared	_	_	VBN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	porcine	_	_	NN	O	-1	none	_	_
20	serum	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	similar	_	_	JJ	O	-1	none	_	_
3	adhesive	_	_	JJ	O	-1	none	_	_
4	response	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	elicited	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	TNF	_	_	NN	O	-1	none	_	_
9	alpha	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	100	_	_	CD	O	-1	none	_	_
12	U/ml	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	one	_	_	CD	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	most	_	_	RBS	O	-1	none	_	_
19	potent	_	_	JJ	O	-1	none	_	_
20	inducers	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	endothelial	_	_	JJ	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	adhesive	_	_	JJ	O	-1	none	_	_
25	properties	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	here	_	_	RB	O	-1	none	_	_
28	used	_	_	VBN	O	-1	none	_	_
29	as	_	_	IN	O	-1	none	_	_
30	positive	_	_	JJ	O	-1	none	_	_
31	control	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	elucidate	_	_	VB	O	-1	none	_	_
5	possible	_	_	JJ	O	-1	none	_	_
6	mechanisms	_	_	NNS	O	-1	none	_	_
7	underlying	_	_	VBG	O	-1	none	_	_
8	endothelial	_	_	JJ	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	xenogeneic	_	_	JJ	O	-1	none	_	_
13	serum	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	we	_	_	PRP	O	-1	none	_	_
16	focussed	_	_	VBD	O	-1	none	_	_
17	on	_	_	IN	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	NF-kappa	_	_	NN	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	central	_	_	JJ	O	-1	none	_	_
25	regulator	_	_	NN	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	induction	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	different	_	_	JJ	O	-1	none	_	_
31	genes	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	including	_	_	VBG	O	-1	none	_	_
34	adhesive	_	_	JJ	O	-1	none	_	_
35	molecules	_	_	NNS	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	chemoattractants	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	confocal	_	_	JJ	O	-1	none	_	_
3	fluorescence	_	_	NN	O	-1	none	_	_
4	microscopy	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	observed	_	_	VBD	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	positive	_	_	JJ	O	-1	none	_	_
10	staining	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	p65	_	_	NN	Protein	-1	none	_	_
16	subunit	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	nuclei	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	PAEC	_	_	NNP	O	-1	none	_	_
23	exposed	_	_	VBN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	1	_	_	CD	O	-1	none	_	_
26	hr	_	_	NN	O	-1	none	_	_
27	30	_	_	CD	O	-1	none	_	_
28	min	_	_	NN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	human	_	_	NN	O	-1	none	_	_
31	serum	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	which	_	_	WDT	O	-1	none	_	_
34	indicated	_	_	VBD	O	-1	none	_	_
35	NF-kappa	_	_	NN	O	-1	none	_	_
36	B	_	_	NN	O	-1	none	_	_
37	activation	_	_	NN	O	-1	none	_	_
38	in	_	_	IN	O	-1	none	_	_
39	this	_	_	DT	O	-1	none	_	_
40	setting	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	At	_	_	IN	O	-1	none	_	_
2	variance	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	PAEC	_	_	NNP	O	-1	none	_	_
6	incubated	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	homologous	_	_	JJ	O	-1	none	_	_
10	serum	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	strictly	_	_	RB	O	-1	none	_	_
16	localized	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	cytoplasm	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	PAEC	_	_	NNP	O	-1	none	_	_
4	exposed	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	xenogeneic	_	_	JJ	O	-1	none	_	_
7	serum	_	_	NN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	NF-kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	inhibitors	_	_	NNS	O	-1	none	_	_
13	pyrrolidinedithiocarbamate	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	PDTC	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	25	_	_	CD	O	-1	none	_	_
18	microM	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	tosyl-phechloromethylketone	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	TPCK	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	25	_	_	CD	O	-1	none	_	_
26	microM	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	significantly	_	_	RB	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	P	_	_	NN	O	-1	none	_	_
31	<	_	_	JJR	O	-1	none	_	_
32	0.01	_	_	CD	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	reduced	_	_	VBD	O	-1	none	_	_
35	leukocyte	_	_	NN	O	-1	none	_	_
36	adhesion	_	_	NN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	respect	_	_	NN	O	-1	none	_	_
39	to	_	_	TO	O	-1	none	_	_
40	PAEC	_	_	NN	O	-1	none	_	_
41	treated	_	_	VBN	O	-1	none	_	_
42	with	_	_	IN	O	-1	none	_	_
43	human	_	_	NN	O	-1	none	_	_
44	serum	_	_	NN	O	-1	none	_	_
45	alone	_	_	RB	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Findings	_	_	NNS	O	-1	none	_	_
2	that	_	_	WDT	O	-1	none	_	_
3	xenogeneic	_	_	JJ	O	-1	none	_	_
4	serum	_	_	NN	O	-1	none	_	_
5	promotes	_	_	VBZ	O	-1	none	_	_
6	leukocyte-endothelium	_	_	NN	O	-1	none	_	_
7	interaction	_	_	NN	O	-1	none	_	_
8	possibly	_	_	RB	O	-1	none	_	_
9	through	_	_	IN	O	-1	none	_	_
10	NF-kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	might	_	_	MD	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	relevant	_	_	JJ	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	designing	_	_	VBG	O	-1	none	_	_
18	future	_	_	JJ	O	-1	none	_	_
19	therapeutic	_	_	JJ	O	-1	none	_	_
20	strategies	_	_	NNS	O	-1	none	_	_
21	aimed	_	_	VBN	O	-1	none	_	_
22	at	_	_	IN	O	-1	none	_	_
23	prolonging	_	_	VBG	O	-1	none	_	_
24	xenograft	_	_	NN	O	-1	none	_	_
25	survival	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	functions	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	basic	_	_	JJ	O	-1	none	_	_
5	helix-loop-helix	_	_	JJ	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	bHLH	_	_	JJ	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	activating	_	_	VBG	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	linked	_	_	VBN	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	inducing	_	_	VBG	O	-1	none	_	_
20	G1	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	cycle	_	_	NN	O	-1	none	_	_
23	arrest	_	_	NN	O	-1	none	_	_
24	are	_	_	VBP	O	-1	none	_	_
25	negatively	_	_	RB	O	-1	none	_	_
26	regulated	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	members	_	_	NNS	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	Id	_	_	NN	O	-1	none	_	_
32	family	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	HLH	_	_	JJ	O	-1	none	_	_
35	proteins	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	bHLH	_	_	JJ	O	-1	none	_	_
3	antagonists	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	induced	_	_	VBN	O	-1	none	_	_
6	during	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	mitogenic	_	_	JJ	O	-1	none	_	_
9	signalling	_	_	NN	O	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	they	_	_	PRP	O	-1	none	_	_
14	function	_	_	VBP	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	sequestering	_	_	VBG	O	-1	none	_	_
17	their	_	_	PRP$	O	-1	none	_	_
18	bHLH	_	_	JJ	O	-1	none	_	_
19	targets	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	inactive	_	_	JJ	O	-1	none	_	_
22	heterodimers	_	_	NNS	O	-1	none	_	_
23	that	_	_	WDT	O	-1	none	_	_
24	are	_	_	VBP	O	-1	none	_	_
25	unable	_	_	JJ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	bind	_	_	VB	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	specific	_	_	JJ	O	-1	none	_	_
30	gene	_	_	NN	O	-1	none	_	_
31	regulatory	_	_	JJ	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	E	_	_	NN	O	-1	none	_	_
34	box	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	sequences	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	analogous	_	_	JJ	O	-1	none	_	_
7	cell-cycle-regulated	_	_	JJ	O	-1	none	_	_
8	phosphorylation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	Id3	_	_	NN	Protein	-1	none	_	_
11	alters	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	specificity	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	Id3	_	_	NN	Protein	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	abrogating	_	_	VBG	O	-1	none	_	_
18	both	_	_	CC	O	-1	none	_	_
19	E-box-dependent	_	_	JJ	O	-1	none	_	_
20	bHLH	_	_	JJ	O	-1	none	_	_
21	homo-	_	_	JJ	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	heterodimer	_	_	NN	O	-1	none	_	_
24	complex	_	_	NN	O	-1	none	_	_
25	formation	_	_	NN	O	-1	none	_	_
26	in	_	_	FW	O	-1	none	_	_
27	vitro	_	_	FW	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	E-box-dependent	_	_	JJ	O	-1	none	_	_
30	reporter	_	_	NN	O	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	function	_	_	NN	O	-1	none	_	_
33	in	_	_	FW	O	-1	none	_	_
34	vivo	_	_	FW	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	compared	_	_	VBN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	wild-type	_	_	JJ	O	-1	none	_	_
6	Id3	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	Id3	_	_	NN	Protein	-1	none	_	_
10	Asp5	_	_	NN	O	-1	none	_	_
11	mutant	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	mimicking	_	_	VBG	O	-1	none	_	_
14	phosphorylation	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	unable	_	_	JJ	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	promote	_	_	VB	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	cycle	_	_	NN	O	-1	none	_	_
22	S	_	_	NN	O	-1	none	_	_
23	phase	_	_	NN	O	-1	none	_	_
24	entry	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	transfected	_	_	VBN	O	-1	none	_	_
27	fibroblasts	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	whereas	_	_	IN	O	-1	none	_	_
30	an	_	_	DT	O	-1	none	_	_
31	Id3	_	_	NN	Protein	-1	none	_	_
32	Ala5	_	_	NN	O	-1	none	_	_
33	mutant	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	ablating	_	_	VBG	O	-1	none	_	_
36	phosphorylation	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	displays	_	_	VBZ	O	-1	none	_	_
39	an	_	_	DT	O	-1	none	_	_
40	activity	_	_	NN	O	-1	none	_	_
41	significantly	_	_	RB	O	-1	none	_	_
42	greater	_	_	JJR	O	-1	none	_	_
43	than	_	_	IN	O	-1	none	_	_
44	that	_	_	DT	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	wild-type	_	_	JJ	O	-1	none	_	_
47	Id3	_	_	NN	Protein	-1	none	_	_
48	protein	_	_	NN	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	Cdk2	_	_	NN	Protein	-1	none	_	_
2	dependent	_	_	JJ	O	-1	none	_	_
3	phosphorylation	_	_	NN	O	-1	none	_	_
4	therefore	_	_	RB	O	-1	none	_	_
5	provides	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	switch	_	_	NN	O	-1	none	_	_
8	during	_	_	IN	O	-1	none	_	_
9	late	_	_	JJ	O	-1	none	_	_
10	G1-to-S	_	_	JJ	O	-1	none	_	_
11	phase	_	_	NN	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	both	_	_	CC	O	-1	none	_	_
14	nullifies	_	_	VBZ	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	early	_	_	JJ	O	-1	none	_	_
17	G1	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	cycle	_	_	NN	O	-1	none	_	_
20	regulatory	_	_	JJ	O	-1	none	_	_
21	function	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	Id3	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	modulates	_	_	VBZ	O	-1	none	_	_
26	its	_	_	PRP$	O	-1	none	_	_
27	target	_	_	NN	O	-1	none	_	_
28	bHLH	_	_	JJ	O	-1	none	_	_
29	specificity	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	ability	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	Id3	_	_	NN	Protein	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	promote	_	_	VB	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	cycle	_	_	NN	O	-1	none	_	_
14	S	_	_	NN	O	-1	none	_	_
15	phase	_	_	NN	O	-1	none	_	_
16	entry	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	simply	_	_	RB	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	function	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	ability	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	modulate	_	_	VB	O	-1	none	_	_
27	bHLH	_	_	JJ	O	-1	none	_	_
28	heterodimer	_	_	NN	O	-1	none	_	_
29	dependent	_	_	JJ	O	-1	none	_	_
30	gene	_	_	NN	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	establish	_	_	VB	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	biologically	_	_	RB	O	-1	none	_	_
36	important	_	_	JJ	O	-1	none	_	_
37	mechanism	_	_	NN	O	-1	none	_	_
38	through	_	_	IN	O	-1	none	_	_
39	which	_	_	WDT	O	-1	none	_	_
40	Cdk2	_	_	NN	Protein	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	Id-bHLH	_	_	JJ	O	-1	none	_	_
43	functions	_	_	NNS	O	-1	none	_	_
44	are	_	_	VBP	O	-1	none	_	_
45	integrated	_	_	VBN	O	-1	none	_	_
46	in	_	_	IN	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	coordination	_	_	NN	O	-1	none	_	_
49	of	_	_	IN	O	-1	none	_	_
50	cell	_	_	NN	O	-1	none	_	_
51	proliferation	_	_	NN	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	differentiation	_	_	NN	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	Epstein-Barr	_	_	NNP	O	-1	none	_	_
2	virus	_	_	NN	O	-1	none	_	_
3	replicative	_	_	JJ	O	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	transcription	_	_	NN	O	-1	none	_	_
6	during	_	_	IN	O	-1	none	_	_
7	de	_	_	FW	O	-1	none	_	_
8	novo	_	_	FW	O	-1	none	_	_
9	infection	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	thymocytes	_	_	NNS	O	-1	none	_	_
13	:	_	_	:	O	-1	none	_	_
14	simultaneous	_	_	JJ	O	-1	none	_	_
15	early	_	_	JJ	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	BZLF-1	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	its	_	_	PRP$	O	-1	none	_	_
21	repressor	_	_	NN	O	-1	none	_	_
22	RAZ	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Epstein-Barr	_	_	NNP	O	-1	none	_	_
2	virus	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	EBV	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	known	_	_	VBN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	infect	_	_	VB	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	epithelial	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	others	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	EBV	_	_	NN	O	-1	none	_	_
8	can	_	_	MD	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	infect	_	_	VB	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	subset	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	thymocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Infection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	thymocytes	_	_	NNS	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	accompanied	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	appearance	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	linear	_	_	JJ	O	-1	none	_	_
11	EBV	_	_	NN	O	-1	none	_	_
12	genome	_	_	NN	O	-1	none	_	_
13	within	_	_	IN	O	-1	none	_	_
14	8	_	_	CD	O	-1	none	_	_
15	hr	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	infection	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Circularization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	EBV	_	_	NN	O	-1	none	_	_
5	genome	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	detected	_	_	VBN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	contrast	_	_	NN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	infection	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	where	_	_	WRB	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	genome	_	_	NN	O	-1	none	_	_
14	can	_	_	MD	O	-1	none	_	_
15	circularize	_	_	VB	O	-1	none	_	_
16	within	_	_	IN	O	-1	none	_	_
17	24	_	_	CD	O	-1	none	_	_
18	hr	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	infection	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	appearance	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	BamHI	_	_	NN	Protein	6	multitoken	_	_
6	ZLF-1	_	_	NN	Protein	0	root	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	product	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	ZEBRA	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	RT-PCR	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	observed	_	_	VBN	O	-1	none	_	_
17	within	_	_	IN	O	-1	none	_	_
18	8	_	_	CD	O	-1	none	_	_
19	hr	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	infection	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	appearance	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	novel	_	_	JJ	O	-1	none	_	_
6	fusion	_	_	NN	O	-1	none	_	_
7	transcript	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	RAZ	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	comprised	_	_	VBD	O	-1	none	_	_
14	regions	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	BZLF-1	_	_	NN	Protein	-1	none	_	_
18	locus	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	adjacent	_	_	JJ	O	-1	none	_	_
22	BRLF-1	_	_	NN	Protein	-1	none	_	_
23	locus	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	was	_	_	VBD	O	-1	none	_	_
26	detected	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	RT-PCR	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	ZEBRA	_	_	NN	Protein	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	identified	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	infected	_	_	JJ	O	-1	none	_	_
8	thymocytes	_	_	NNS	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	immunoprecipitation	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	demonstrated	_	_	VBD	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	EBNA-1	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	infected	_	_	JJ	O	-1	none	_	_
12	thymocytes	_	_	NNS	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	transcribed	_	_	VBN	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	Fp	_	_	NN	O	-1	none	_	_
18	promoter	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	rather	_	_	RB	O	-1	none	_	_
21	than	_	_	IN	O	-1	none	_	_
22	from	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	Cp/Wp	_	_	NN	O	-1	none	_	_
25	promoter	_	_	NN	O	-1	none	_	_
26	which	_	_	WDT	O	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	used	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	latently	_	_	RB	O	-1	none	_	_
31	infected	_	_	JJ	O	-1	none	_	_
32	B	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Transcripts	_	_	NNS	O	-1	none	_	_
2	encoding	_	_	VBG	O	-1	none	_	_
3	gp350/220	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	major	_	_	JJ	O	-1	none	_	_
7	coat	_	_	NN	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	EBV	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	identified	_	_	VBN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	but	_	_	CC	O	-1	none	_	_
16	we	_	_	PRP	O	-1	none	_	_
17	did	_	_	VBD	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	find	_	_	VB	O	-1	none	_	_
20	any	_	_	DT	O	-1	none	_	_
21	evidence	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	from	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	LMP-2A	_	_	NN	Protein	-1	none	_	_
27	or	_	_	CC	O	-1	none	_	_
28	EBER-1	_	_	NN	Protein	-1	none	_	_
29	loci	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	infected	_	_	JJ	O	-1	none	_	_
32	thymocytes	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	de	_	_	FW	O	-1	none	_	_
6	novo	_	_	FW	O	-1	none	_	_
7	EBV	_	_	NN	O	-1	none	_	_
8	infection	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	thymocytes	_	_	NNS	O	-1	none	_	_
11	differs	_	_	VBZ	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	infection	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	main	_	_	JJ	O	-1	none	_	_
3	difference	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	thymocytes	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	no	_	_	DT	O	-1	none	_	_
10	evidence	_	_	NN	O	-1	none	_	_
11	could	_	_	MD	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	found	_	_	VBN	O	-1	none	_	_
14	that	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	virus	_	_	NN	O	-1	none	_	_
17	ever	_	_	RB	O	-1	none	_	_
18	circularizes	_	_	VBZ	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Rather	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	EBV	_	_	NN	O	-1	none	_	_
4	remains	_	_	VBZ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	linear	_	_	JJ	O	-1	none	_	_
8	configuration	_	_	NN	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	replicative	_	_	JJ	O	-1	none	_	_
12	genes	_	_	NNS	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	transcribed	_	_	VBN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	involvement	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	multiple	_	_	JJ	O	-1	none	_	_
5	tumor	_	_	NN	O	-1	none	_	_
6	necrosis	_	_	NN	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	TNFR	_	_	NN	O	-1	none	_	_
11	)-associated	_	_	JJ	O	-1	none	_	_
12	factors	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	mechanisms	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	receptor	_	_	NN	Protein	21	multitoken	_	_
19	activator	_	_	NN	Protein	21	multitoken	_	_
20	of	_	_	IN	Protein	21	multitoken	_	_
21	NF-kappaB	_	_	NN	Protein	0	root	_	_
22	,	_	_	,	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	member	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	TNFR	_	_	NN	O	-1	none	_	_
28	superfamily	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Receptor	_	_	NN	Protein	4	multitoken	_	_
2	activator	_	_	NN	Protein	4	multitoken	_	_
3	of	_	_	IN	Protein	4	multitoken	_	_
4	NF-kappaB	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	RANK	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	recently	_	_	RB	O	-1	none	_	_
11	identified	_	_	VBN	O	-1	none	_	_
12	member	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	tumor	_	_	NN	O	-1	none	_	_
16	necrosis	_	_	NN	O	-1	none	_	_
17	factor	_	_	NN	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	superfamily	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	expressed	_	_	VBN	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	activated	_	_	VBN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	dendritic	_	_	JJ	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Its	_	_	PRP$	O	-1	none	_	_
2	cognate	_	_	JJ	O	-1	none	_	_
3	ligand	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	RANKL	_	_	NN	Protein	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	plays	_	_	VBZ	O	-1	none	_	_
8	significant	_	_	JJ	O	-1	none	_	_
9	roles	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	dendritic	_	_	JJ	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	function	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	osteoclast	_	_	NN	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	interaction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	RANK	_	_	NN	Protein	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	tumor	_	_	NN	Protein	18	multitoken	_	_
10	necrosis	_	_	NN	Protein	18	multitoken	_	_
11	factor	_	_	NN	Protein	18	multitoken	_	_
12	receptor	_	_	NN	Protein	18	multitoken	_	_
13	associated	_	_	VBN	Protein	18	multitoken	_	_
14	factors	_	_	NNS	Protein	18	multitoken	_	_
15	(	_	_	-LRB-	Protein	18	multitoken	_	_
16	TRAFs	_	_	NNS	Protein	18	multitoken	_	_
17	)	_	_	-RRB-	Protein	18	multitoken	_	_
18	1	_	_	CD	Protein	0	root	_	_
19	,	_	_	,	O	-1	none	_	_
20	2	_	_	CD	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	3	_	_	CD	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	5	_	_	CD	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	6	_	_	CD	Protein	-1	none	_	_
28	both	_	_	CC	O	-1	none	_	_
29	in	_	_	FW	O	-1	none	_	_
30	vitro	_	_	FW	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Mapping	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	structural	_	_	JJ	O	-1	none	_	_
5	requirements	_	_	NNS	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	TRAF	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	RANK	_	_	NN	Protein	-1	none	_	_
10	interaction	_	_	NN	O	-1	none	_	_
11	revealed	_	_	VBD	O	-1	none	_	_
12	multiple	_	_	JJ	O	-1	none	_	_
13	TRAF	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	sites	_	_	NNS	O	-1	none	_	_
16	clustered	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	two	_	_	CD	O	-1	none	_	_
19	distinct	_	_	JJ	O	-1	none	_	_
20	domains	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	RANK	_	_	NN	Protein	-1	none	_	_
24	cytoplasmic	_	_	JJ	O	-1	none	_	_
25	tail	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	TRAF	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	domains	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	shown	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	functionally	_	_	RB	O	-1	none	_	_
10	important	_	_	JJ	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	RANK	_	_	NN	Protein	-1	none	_	_
14	dependent	_	_	JJ	O	-1	none	_	_
15	induction	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	c-Jun	_	_	NN	Protein	-1	none	_	_
20	NH2-terminal	_	_	JJ	O	-1	none	_	_
21	kinase	_	_	NN	O	-1	none	_	_
22	activities	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Site	_	_	NN	O	-1	none	_	_
2	directed	_	_	VBD	O	-1	none	_	_
3	mutagenesis	_	_	NN	O	-1	none	_	_
4	demonstrated	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	TRAF	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	sites	_	_	NNS	O	-1	none	_	_
10	exhibited	_	_	VBD	O	-1	none	_	_
11	selective	_	_	JJ	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	different	_	_	JJ	O	-1	none	_	_
15	TRAF	_	_	NN	O	-1	none	_	_
16	proteins	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	particular	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	TRAF6	_	_	NN	Protein	-1	none	_	_
5	interacted	_	_	VBD	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	membrane	_	_	NN	O	-1	none	_	_
8	proximal	_	_	JJ	O	-1	none	_	_
9	determinants	_	_	NNS	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	those	_	_	DT	O	-1	none	_	_
13	binding	_	_	VBG	O	-1	none	_	_
14	TRAFs	_	_	NNS	Protein	15	multitoken	_	_
15	1	_	_	CD	Protein	0	root	_	_
16	,	_	_	,	O	-1	none	_	_
17	2	_	_	CD	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	3	_	_	CD	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	5	_	_	CD	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	membrane	_	_	NN	O	-1	none	_	_
4	proximal	_	_	JJ	O	-1	none	_	_
5	TRAF6	_	_	NN	Protein	-1	none	_	_
6	interaction	_	_	NN	O	-1	none	_	_
7	domain	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	deleted	_	_	VBN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	RANK	_	_	NN	Protein	-1	none	_	_
12	mediated	_	_	VBD	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	signaling	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	completely	_	_	RB	O	-1	none	_	_
17	inhibited	_	_	VBN	O	-1	none	_	_
18	while	_	_	IN	O	-1	none	_	_
19	c-Jun	_	_	NN	Protein	-1	none	_	_
20	NH2-terminal	_	_	JJ	O	-1	none	_	_
21	kinase	_	_	NN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	partially	_	_	RB	O	-1	none	_	_
25	inhibited	_	_	VBN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	NH2-terminal	_	_	JJ	O	-1	none	_	_
3	truncation	_	_	NN	O	-1	none	_	_
4	mutant	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	TRAF6	_	_	NN	Protein	-1	none	_	_
7	inhibited	_	_	VBD	O	-1	none	_	_
8	RANKL	_	_	NN	Protein	-1	none	_	_
9	mediated	_	_	VBD	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	failed	_	_	VBD	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	affect	_	_	VB	O	-1	none	_	_
17	constitutive	_	_	JJ	O	-1	none	_	_
18	signaling	_	_	NN	O	-1	none	_	_
19	induced	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	receptor	_	_	NN	O	-1	none	_	_
22	overexpression	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	revealing	_	_	VBG	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	selective	_	_	JJ	O	-1	none	_	_
27	role	_	_	NN	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	TRAF6	_	_	NN	Protein	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	ligand	_	_	NN	O	-1	none	_	_
32	induced	_	_	VBD	O	-1	none	_	_
33	activation	_	_	NN	O	-1	none	_	_
34	events	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Differential	_	_	JJ	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	lipopolysaccharide	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	tumor	_	_	NN	O	-1	none	_	_
7	necrosis	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	monocytic	_	_	JJ	O	-1	none	_	_
11	IkappaB	_	_	NN	O	-1	none	_	_
12	kinase	_	_	NN	O	-1	none	_	_
13	signalsome	_	_	JJ	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	IkappaB	_	_	NN	O	-1	none	_	_
17	proteolysis	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inflammatory	_	_	JJ	O	-1	none	_	_
3	mediators	_	_	NNS	O	-1	none	_	_
4	lipopolysaccharide	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	tumor	_	_	NN	O	-1	none	_	_
10	necrosis	_	_	NN	O	-1	none	_	_
11	factor	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	TNF	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	potent	_	_	JJ	O	-1	none	_	_
17	activators	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	NF-kappaB	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	compared	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effect	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	stimuli	_	_	NNS	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	endogenous	_	_	JJ	O	-1	none	_	_
11	IkappaB	_	_	NN	O	-1	none	_	_
12	kinase	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	IKK	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	signalsome	_	_	JJ	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	IkappaB	_	_	NN	O	-1	none	_	_
20	phosphorylation	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	proteolysis	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	monocytic	_	_	JJ	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	investigated	_	_	VBD	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	role	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	signalsome	_	_	JJ	O	-1	none	_	_
34	proteins	_	_	NNS	O	-1	none	_	_
35	IKK-alpha	_	_	NN	Protein	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	IKK-beta	_	_	NN	Protein	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	NF-kappaB-inducing	_	_	NN	Protein	40	multitoken	_	_
40	kinase	_	_	NN	Protein	0	root	_	_
41	(	_	_	-LRB-	O	-1	none	_	_
42	NIK	_	_	NN	Protein	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	IKK-gamma	_	_	NN	Protein	-1	none	_	_
46	(	_	_	-LRB-	O	-1	none	_	_
47	NF-kappaB	_	_	NN	O	-1	none	_	_
48	essential	_	_	JJ	O	-1	none	_	_
49	modulator	_	_	NN	O	-1	none	_	_
50	)	_	_	-RRB-	O	-1	none	_	_
51	,	_	_	,	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	IKK	_	_	NN	Protein	56	multitoken	_	_
54	complex	_	_	NN	Protein	56	multitoken	_	_
55	associated	_	_	VBN	Protein	56	multitoken	_	_
56	protein	_	_	NN	Protein	0	root	_	_
57	.	_	_	.	O	-1	none	_	_

1	Kinase	_	_	NN	O	-1	none	_	_
2	assays	_	_	NNS	O	-1	none	_	_
3	showed	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	TNF	_	_	NN	O	-1	none	_	_
6	elicited	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	rapid	_	_	JJ	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	short	_	_	JJ	O	-1	none	_	_
11	lived	_	_	VBD	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	IKK	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	3-fold	_	_	RB	O	-1	none	_	_
19	greater	_	_	JJR	O	-1	none	_	_
20	effect	_	_	NN	O	-1	none	_	_
21	on	_	_	IN	O	-1	none	_	_
22	IKK-alpha	_	_	NN	Protein	-1	none	_	_
23	than	_	_	IN	O	-1	none	_	_
24	on	_	_	IN	O	-1	none	_	_
25	IKK-beta	_	_	NN	Protein	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	peaking	_	_	VBG	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	5	_	_	CD	O	-1	none	_	_
30	min	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	LPS	_	_	NN	O	-1	none	_	_
5	predominantly	_	_	RB	O	-1	none	_	_
6	stimulated	_	_	VBD	O	-1	none	_	_
7	IKK-beta	_	_	NN	Protein	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	slowly	_	_	RB	O	-1	none	_	_
12	increased	_	_	VBD	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	peaking	_	_	VBG	O	-1	none	_	_
15	at	_	_	IN	O	-1	none	_	_
16	30	_	_	CD	O	-1	none	_	_
17	min	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	second	_	_	JJ	O	-1	none	_	_
3	peak	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	at	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	later	_	_	JJ	O	-1	none	_	_
9	time	_	_	NN	O	-1	none	_	_
10	point	_	_	NN	O	-1	none	_	_
11	following	_	_	VBG	O	-1	none	_	_
12	LPS	_	_	NN	O	-1	none	_	_
13	stimulation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	consisted	_	_	VBD	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	both	_	_	DT	O	-1	none	_	_
19	IKK-alpha	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	-beta	_	_	NN	Protein	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	endogenous	_	_	JJ	O	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	signalsome	_	_	JJ	O	-1	none	_	_
7	components	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	unaffected	_	_	JJ	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	stimulation	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	our	_	_	PRP$	O	-1	none	_	_
4	studies	_	_	NNS	O	-1	none	_	_
5	showed	_	_	VBD	O	-1	none	_	_
6	association	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	IKK	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	alpha	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	beta	_	_	NN	O	-1	none	_	_
15	heterodimer	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	NIK	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	IkappaB-alpha	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	-epsilon	_	_	NN	Protein	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	unstimulated	_	_	JJ	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Exposure	_	_	NN	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	LPS	_	_	NN	O	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	TNF	_	_	NN	O	-1	none	_	_
6	led	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	differential	_	_	JJ	O	-1	none	_	_
9	patterns	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	IkappaB-alpha	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	IkappaB-epsilon	_	_	NN	Protein	-1	none	_	_
14	disappearance	_	_	NN	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	reassembly	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	signalsome	_	_	JJ	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	whereas	_	_	IN	O	-1	none	_	_
23	IKK-alpha	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	IKK-beta	_	_	NN	Protein	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	NIK	_	_	NN	Protein	-1	none	_	_
29	remained	_	_	VBD	O	-1	none	_	_
30	complex	_	_	JJ	O	-1	none	_	_
31	associated	_	_	VBN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	NIK	_	_	NN	Protein	-1	none	_	_
2	can	_	_	MD	O	-1	none	_	_
3	not	_	_	RB	O	-1	none	_	_
4	phosphorylate	_	_	VB	O	-1	none	_	_
5	IkappaB-alpha	_	_	NN	Protein	-1	none	_	_
6	directly	_	_	RB	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	but	_	_	CC	O	-1	none	_	_
9	it	_	_	PRP	O	-1	none	_	_
10	appears	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	functionally	_	_	RB	O	-1	none	_	_
15	important	_	_	JJ	O	-1	none	_	_
16	subunit	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	because	_	_	IN	O	-1	none	_	_
19	mutated	_	_	VBN	O	-1	none	_	_
20	NIK	_	_	NN	Protein	-1	none	_	_
21	inhibited	_	_	VBD	O	-1	none	_	_
22	stimulus	_	_	NN	O	-1	none	_	_
23	induced	_	_	JJ	O	-1	none	_	_
24	kappaB	_	_	NN	O	-1	none	_	_
25	dependent	_	_	JJ	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	more	_	_	RBR	O	-1	none	_	_
28	effectively	_	_	RB	O	-1	none	_	_
29	than	_	_	IN	O	-1	none	_	_
30	mutated	_	_	VBN	O	-1	none	_	_
31	IKK-alpha	_	_	NN	Protein	-1	none	_	_
32	or	_	_	CC	O	-1	none	_	_
33	-beta	_	_	NN	Protein	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	IKK	_	_	NN	O	-1	none	_	_
4	complex	_	_	NN	O	-1	none	_	_
5	associated	_	_	VBN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	inhibited	_	_	VBD	O	-1	none	_	_
8	stimulus	_	_	NN	O	-1	none	_	_
9	mediated	_	_	JJ	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	whereas	_	_	IN	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	essential	_	_	JJ	O	-1	none	_	_
15	modulator	_	_	NN	O	-1	none	_	_
16	enhanced	_	_	VBD	O	-1	none	_	_
17	it	_	_	PRP	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	understanding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	LPS-	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	TNF	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	may	_	_	MD	O	-1	none	_	_
10	allow	_	_	VB	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	development	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	specific	_	_	JJ	O	-1	none	_	_
15	strategies	_	_	NNS	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	treat	_	_	VB	O	-1	none	_	_
18	sepsis	_	_	NN	O	-1	none	_	_
19	associated	_	_	VBN	O	-1	none	_	_
20	disease	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Paternal	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	WT1	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	fibroblasts	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	lymphocytes	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Wilms	_	_	NN	O	-1	none	_	_
3	'	_	_	POS	O	-1	none	_	_
4	tumor	_	_	NN	O	-1	none	_	_
5	suppressor	_	_	NN	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	WT1	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	previously	_	_	RB	O	-1	none	_	_
12	identified	_	_	VBN	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	being	_	_	VBG	O	-1	none	_	_
15	imprinted	_	_	VBN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	frequent	_	_	JJ	O	-1	none	_	_
19	maternal	_	_	JJ	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	placentae	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	fetal	_	_	JJ	O	-1	none	_	_
26	brains	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	examined	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	allele	_	_	NN	O	-1	none	_	_
5	specific	_	_	JJ	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	WT1	_	_	NN	Protein	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	cultured	_	_	VBN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	fibroblasts	_	_	NNS	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	15	_	_	CD	O	-1	none	_	_
15	individuals	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Seven	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	15	_	_	CD	O	-1	none	_	_
4	fibroblast	_	_	NN	O	-1	none	_	_
5	lines	_	_	NNS	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	heterozygous	_	_	JJ	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	polymorphic	_	_	JJ	O	-1	none	_	_
10	alleles	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	patterns	_	_	NNS	O	-1	none	_	_
16	were	_	_	VBD	O	-1	none	_	_
17	variable	_	_	JJ	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	i.e.	_	_	FW	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	equal	_	_	JJ	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	unequal	_	_	JJ	O	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	monoallelic	_	_	JJ	O	-1	none	_	_
26	paternal	_	_	JJ	O	-1	none	_	_
27	expression	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	three	_	_	CD	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	two	_	_	CD	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	two	_	_	CD	O	-1	none	_	_
34	cases	_	_	NNS	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	respectively	_	_	RB	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Exclusive	_	_	JJ	O	-1	none	_	_
2	paternal	_	_	JJ	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	WT1	_	_	NN	Protein	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	shown	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	non	_	_	JJ	O	-1	none	_	_
11	cultured	_	_	VBN	O	-1	none	_	_
12	peripheral	_	_	JJ	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	latter	_	_	JJ	O	-1	none	_	_
17	two	_	_	CD	O	-1	none	_	_
18	individuals	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	allele	_	_	NN	O	-1	none	_	_
3	specific	_	_	JJ	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	profiles	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	other	_	_	JJ	O	-1	none	_	_
8	imprinted	_	_	JJ	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	IGF2	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	H19	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	chromosome	_	_	NN	O	-1	none	_	_
18	11	_	_	CD	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	constant	_	_	JJ	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	consistent	_	_	JJ	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	those	_	_	DT	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	other	_	_	JJ	O	-1	none	_	_
27	tissues	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	unexpected	_	_	JJ	O	-1	none	_	_
3	observations	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	paternal	_	_	JJ	O	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	biallelic	_	_	JJ	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	WT1	_	_	NN	Protein	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	fibroblasts	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	together	_	_	RB	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	previous	_	_	JJ	O	-1	none	_	_
20	findings	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	maternal	_	_	JJ	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	biallelic	_	_	JJ	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	placentae	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	brains	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	suggest	_	_	VBP	O	-1	none	_	_
32	that	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	allele	_	_	NN	O	-1	none	_	_
35	specific	_	_	JJ	O	-1	none	_	_
36	regulatory	_	_	JJ	O	-1	none	_	_
37	system	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	WT1	_	_	NN	Protein	-1	none	_	_
40	is	_	_	VBZ	O	-1	none	_	_
41	unique	_	_	JJ	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	may	_	_	MD	O	-1	none	_	_
44	be	_	_	VB	O	-1	none	_	_
45	controlled	_	_	VBN	O	-1	none	_	_
46	by	_	_	IN	O	-1	none	_	_
47	a	_	_	DT	O	-1	none	_	_
48	putative	_	_	JJ	O	-1	none	_	_
49	tissue-	_	_	NN	O	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	individual	_	_	JJ	O	-1	none	_	_
52	specific	_	_	JJ	O	-1	none	_	_
53	modifier	_	_	NN	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	Regulatory	_	_	JJ	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	interleukin-11	_	_	NN	Protein	-1	none	_	_
5	during	_	_	IN	O	-1	none	_	_
6	acute	_	_	JJ	O	-1	none	_	_
7	lung	_	_	NN	O	-1	none	_	_
8	inflammatory	_	_	JJ	O	-1	none	_	_
9	injury	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	interleukin-11	_	_	NN	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	IL-11	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	evaluated	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	IgG	_	_	NN	O	-1	none	_	_
13	immune	_	_	JJ	O	-1	none	_	_
14	complex	_	_	NN	O	-1	none	_	_
15	model	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	acute	_	_	JJ	O	-1	none	_	_
18	lung	_	_	NN	O	-1	none	_	_
19	injury	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	rats	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	IL-11	_	_	NNP	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	both	_	_	DT	O	-1	none	_	_
7	up-regulated	_	_	VBN	O	-1	none	_	_
8	during	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	course	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	this	_	_	DT	O	-1	none	_	_
13	inflammatory	_	_	JJ	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Exogenously	_	_	RB	O	-1	none	_	_
2	administered	_	_	VBN	O	-1	none	_	_
3	IL-11	_	_	NN	Protein	-1	none	_	_
4	substantially	_	_	RB	O	-1	none	_	_
5	reduced	_	_	VBD	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	dose	_	_	NN	O	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	manner	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	intrapulmonary	_	_	JJ	O	-1	none	_	_
15	accumulation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	neutrophils	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	lung	_	_	NN	O	-1	none	_	_
21	vascular	_	_	JJ	O	-1	none	_	_
22	leak	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	albumin	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	in	_	_	FW	O	-1	none	_	_
3	vivo	_	_	FW	O	-1	none	_	_
4	anti-inflammatory	_	_	JJ	O	-1	none	_	_
5	effects	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	IL-11	_	_	NN	Protein	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	associated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	reduced	_	_	VBN	O	-1	none	_	_
12	NF-kappaB	_	_	NN	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	lung	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	reduced	_	_	VBN	O	-1	none	_	_
18	levels	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	tumor	_	_	NN	Protein	23	multitoken	_	_
21	necrosis	_	_	NN	Protein	23	multitoken	_	_
22	factor	_	_	NN	Protein	23	multitoken	_	_
23	alpha	_	_	NN	Protein	0	root	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	TNF-alpha	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	bronchoalveolar	_	_	JJ	O	-1	none	_	_
29	lavage	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	BAL	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	fluids	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	diminished	_	_	VBD	O	-1	none	_	_
37	up-regulation	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	lung	_	_	NN	O	-1	none	_	_
40	vascular	_	_	JJ	O	-1	none	_	_
41	ICAM-1	_	_	NN	Protein	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	interesting	_	_	JJ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-11	_	_	NN	Protein	-1	none	_	_
6	did	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	affect	_	_	VB	O	-1	none	_	_
9	BAL	_	_	NN	O	-1	none	_	_
10	fluid	_	_	NN	O	-1	none	_	_
11	content	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	CXC	_	_	NN	O	-1	none	_	_
15	chemokines	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	macrophage	_	_	NN	Protein	19	multitoken	_	_
18	inflammatory	_	_	JJ	Protein	19	multitoken	_	_
19	protein-2	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	MIP-2	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	cytokine	_	_	NN	O	-1	none	_	_
25	inducible	_	_	JJ	O	-1	none	_	_
26	neutrophil	_	_	NN	O	-1	none	_	_
27	chemoattractant	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	CINC	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	;	_	_	:	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	presence	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	IL-11	_	_	NN	Protein	-1	none	_	_
36	did	_	_	VBD	O	-1	none	_	_
37	not	_	_	RB	O	-1	none	_	_
38	affect	_	_	VB	O	-1	none	_	_
39	these	_	_	DT	O	-1	none	_	_
40	chemokines	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	BAL	_	_	NN	O	-1	none	_	_
4	content	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	C5a	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	reduced	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	IL-11	_	_	NN	Protein	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-11	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	regulatory	_	_	JJ	O	-1	none	_	_
9	cytokine	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	lung	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	that	_	_	IN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	like	_	_	IN	O	-1	none	_	_
17	other	_	_	JJ	O	-1	none	_	_
18	members	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	this	_	_	DT	O	-1	none	_	_
21	family	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	anti-inflammatory	_	_	JJ	O	-1	none	_	_
25	properties	_	_	NNS	O	-1	none	_	_
26	appear	_	_	VBP	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	be	_	_	VB	O	-1	none	_	_
29	linked	_	_	VBN	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	its	_	_	PRP$	O	-1	none	_	_
32	suppression	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	NF-kappaB	_	_	NN	O	-1	none	_	_
35	activation	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	diminished	_	_	VBN	O	-1	none	_	_
38	production	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	TNF-alpha	_	_	NN	Protein	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	reduced	_	_	VBD	O	-1	none	_	_
44	up-regulation	_	_	NN	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	lung	_	_	NN	O	-1	none	_	_
47	vascular	_	_	JJ	O	-1	none	_	_
48	ICAM-1	_	_	NN	Protein	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	inhibits	_	_	VBZ	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	factor-kappa	_	_	NN	O	-1	none	_	_
5	B/Rel	_	_	NN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	CD3	_	_	NN	O	-1	none	_	_
10	stimulated	_	_	VBN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	peripheral	_	_	JJ	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	markedly	_	_	RB	O	-1	none	_	_
3	reduces	_	_	VBZ	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	NF	_	_	NN	O	-1	none	_	_
8	)-kappa	_	_	NN	O	-1	none	_	_
9	B/Rel	_	_	NN	O	-1	none	_	_
10	nuclear	_	_	JJ	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	PBMC	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	stimulation	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	anti-CD3	_	_	JJ	O	-1	none	_	_
20	mAb	_	_	NN	O	-1	none	_	_
21	OKT3	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inhibition	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	exerted	_	_	VBN	O	-1	none	_	_
5	specifically	_	_	RB	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B/Rel	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	induced	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	mAb	_	_	NN	O	-1	none	_	_
14	OKT3	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	that	_	_	DT	O	-1	none	_	_
19	produced	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	PMA	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	judged	_	_	VBN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	supershifting	_	_	VBG	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	complexes	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	Abs	_	_	NNS	O	-1	none	_	_
11	recognizing	_	_	VBG	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	components	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B/Rel	_	_	NN	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	family	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	p50	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	p65	_	_	NN	Protein	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	Rel	_	_	NN	Protein	27	multitoken	_	_
27	A	_	_	DT	Protein	0	root	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	heterodimeric	_	_	JJ	O	-1	none	_	_
30	form	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	NF-kappa	_	_	NN	O	-1	none	_	_
33	B	_	_	NN	O	-1	none	_	_
34	is	_	_	VBZ	O	-1	none	_	_
35	primarily	_	_	RB	O	-1	none	_	_
36	affected	_	_	VBN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	maximal	_	_	JJ	O	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	at	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	IL-10	_	_	NN	Protein	-1	none	_	_
9	concentration	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	20	_	_	CD	O	-1	none	_	_
12	U/ml	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	exerted	_	_	VBN	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	lymphocytes	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	mediated	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	monocytes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Indeed	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	monocytes	_	_	NNS	O	-1	none	_	_
4	pretreated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	IL-10	_	_	NN	Protein	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	able	_	_	JJ	O	-1	none	_	_
9	so	_	_	RB	O	-1	none	_	_
10	inhibit	_	_	VB	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	purified	_	_	VBN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	stimulated	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	OKT3	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Soluble	_	_	JJ	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	do	_	_	VBP	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	appear	_	_	VB	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	involved	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	mechanism	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	inhibition	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B/Rel	_	_	NN	O	-1	none	_	_
6	inhibition	_	_	NN	O	-1	none	_	_
7	might	_	_	MD	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	ascribed	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	lack	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	cooperation	_	_	NN	O	-1	none	_	_
15	between	_	_	IN	O	-1	none	_	_
16	accessory	_	_	JJ	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	lymphocytes	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	resulting	_	_	VBG	O	-1	none	_	_
23	from	_	_	IN	O	-1	none	_	_
24	down-regulation	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	costimulatory	_	_	JJ	O	-1	none	_	_
28	molecule	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	such	_	_	JJ	O	-1	none	_	_
31	as	_	_	IN	O	-1	none	_	_
32	CD80	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	produced	_	_	VBN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	IL-10	_	_	NN	Protein	-1	none	_	_
37	on	_	_	IN	O	-1	none	_	_
38	activated	_	_	VBN	O	-1	none	_	_
39	monocytes	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-10	_	_	NN	Protein	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	inhibit	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	induction	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B/Rel	_	_	NN	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	CD3	_	_	NN	O	-1	none	_	_
17	stimulated	_	_	VBN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	lymphocytes	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	inappropriate	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	driven	_	_	VBN	O	-1	none	_	_
8	genes	_	_	NNS	O	-1	none	_	_
9	has	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	physiopathologic	_	_	JJ	O	-1	none	_	_
12	role	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	number	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	diseases	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	such	_	_	JJ	O	-1	none	_	_
20	as	_	_	IN	O	-1	none	_	_
21	HIV	_	_	NN	O	-1	none	_	_
22	infection	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	our	_	_	PRP$	O	-1	none	_	_
25	findings	_	_	NNS	O	-1	none	_	_
26	support	_	_	VBP	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	possibility	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	using	_	_	VBG	O	-1	none	_	_
31	this	_	_	DT	O	-1	none	_	_
32	cytokine	_	_	NN	O	-1	none	_	_
33	to	_	_	TO	O	-1	none	_	_
34	suppress	_	_	VB	O	-1	none	_	_
35	an	_	_	DT	O	-1	none	_	_
36	undesirable	_	_	JJ	O	-1	none	_	_
37	activation	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	these	_	_	DT	O	-1	none	_	_
40	transcription	_	_	NN	O	-1	none	_	_
41	factors	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	interleukin	_	_	NN	Protein	5	multitoken	_	_
5	6	_	_	CD	Protein	0	root	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	Mycobacterium	_	_	NN	O	-1	none	_	_
9	tuberculosis	_	_	NN	O	-1	none	_	_
10	or	_	_	CC	O	-1	none	_	_
11	lipopolysaccharide	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	factors	_	_	NNS	O	-1	none	_	_
17	NF-IL6	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	[	_	_	CD	O	-1	none	_	_
22	published	_	_	VBN	O	-1	none	_	_
23	erratum	_	_	NN	O	-1	none	_	_
24	appears	_	_	VBZ	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	Proc	_	_	NNP	O	-1	none	_	_
27	Natl	_	_	NNP	O	-1	none	_	_
28	Acad	_	_	NNP	O	-1	none	_	_
29	Sci	_	_	NNP	O	-1	none	_	_
30	U	_	_	NNP	O	-1	none	_	_
31	S	_	_	NNP	O	-1	none	_	_
32	A	_	_	NNP	O	-1	none	_	_
33	1995	_	_	CD	O	-1	none	_	_
34	Apr	_	_	NNP	O	-1	none	_	_
35	11	_	_	CD	O	-1	none	_	_
36	;	_	_	:	O	-1	none	_	_
37	92	_	_	CD	O	-1	none	_	_
38	(	_	_	-LRB-	O	-1	none	_	_
39	8	_	_	CD	O	-1	none	_	_
40	)	_	_	-RRB-	O	-1	none	_	_
41	:3632	_	_	CD	O	-1	none	_	_
42	]	_	_	CD	O	-1	none	_	_
43	The	_	_	DT	O	-1	none	_	_
44	host	_	_	NN	O	-1	none	_	_
45	response	_	_	NN	O	-1	none	_	_
46	to	_	_	TO	O	-1	none	_	_
47	Mycobacterium	_	_	NN	O	-1	none	_	_
48	tuberculosis	_	_	NN	O	-1	none	_	_
49	includes	_	_	VBZ	O	-1	none	_	_
50	granuloma	_	_	NN	O	-1	none	_	_
51	formation	_	_	NN	O	-1	none	_	_
52	at	_	_	IN	O	-1	none	_	_
53	sites	_	_	NNS	O	-1	none	_	_
54	of	_	_	IN	O	-1	none	_	_
55	infection	_	_	NN	O	-1	none	_	_
56	and	_	_	CC	O	-1	none	_	_
57	systemic	_	_	JJ	O	-1	none	_	_
58	symptoms	_	_	NNS	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	Cytokines	_	_	NNS	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	been	_	_	VBN	O	-1	none	_	_
4	identified	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	immunohistochemistry	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	granulomas	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	animal	_	_	NN	O	-1	none	_	_
11	models	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	bacillus	_	_	FW	O	-1	none	_	_
14	Calmette-Guerin	_	_	FW	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	BCG	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	infection	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	released	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	mononuclear	_	_	JJ	O	-1	none	_	_
24	phagocytes	_	_	NNS	O	-1	none	_	_
25	upon	_	_	IN	O	-1	none	_	_
26	stimulation	_	_	NN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	mycobacterial	_	_	JJ	O	-1	none	_	_
29	proteins	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	regard	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	cytokine	_	_	NN	O	-1	none	_	_
7	interleukin	_	_	NN	Protein	8	multitoken	_	_
8	6	_	_	CD	Protein	0	root	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	IL-6	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	may	_	_	MD	O	-1	none	_	_
13	play	_	_	VB	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	role	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	clinical	_	_	JJ	O	-1	none	_	_
19	manifestations	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	pathological	_	_	JJ	O	-1	none	_	_
22	events	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	tuberculosis	_	_	NN	O	-1	none	_	_
25	infection	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	demonstrated	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	lipoarabinomannan	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	LAM	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	mycobacterial	_	_	JJ	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	wall	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	virtually	_	_	RB	O	-1	none	_	_
18	devoid	_	_	JJ	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	lipopolysaccharide	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	LPS	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	stimulated	_	_	VBN	O	-1	none	_	_
26	mononuclear	_	_	JJ	O	-1	none	_	_
27	phagocytes	_	_	NNS	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	release	_	_	VB	O	-1	none	_	_
30	IL-6	_	_	NN	Protein	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	dose	_	_	NN	O	-1	none	_	_
34	response	_	_	NN	O	-1	none	_	_
35	manner	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	LAM	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	LPS	_	_	NN	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	potent	_	_	JJ	O	-1	none	_	_
6	inducers	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IL-6	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	peripheral	_	_	JJ	O	-1	none	_	_
13	blood	_	_	NN	O	-1	none	_	_
14	monocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	LAM-	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	LPS	_	_	NN	O	-1	none	_	_
5	inducible	_	_	JJ	O	-1	none	_	_
6	IL-6	_	_	NN	Protein	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	localized	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	DNA	_	_	NN	O	-1	none	_	_
14	fragment	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	positions	_	_	NNS	O	-1	none	_	_
17	-158	_	_	CD	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	-49	_	_	CD	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	deletion	_	_	NN	O	-1	none	_	_
23	analysis	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	chloramphenicol	_	_	NN	Protein	26	multitoken	_	_
26	acetyltransferase	_	_	NN	Protein	0	root	_	_
27	assay	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	nuclear	_	_	JJ	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	NF-IL6	_	_	NN	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	positions	_	_	NNS	O	-1	none	_	_
7	-153	_	_	CD	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	-145	_	_	CD	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	-83	_	_	CD	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	-75	_	_	CD	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	one	_	_	CD	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	positions	_	_	NNS	O	-1	none	_	_
23	-72	_	_	CD	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	-63	_	_	CD	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	motifs	_	_	NNS	O	-1	none	_	_
28	are	_	_	VBP	O	-1	none	_	_
29	present	_	_	JJ	O	-1	none	_	_
30	within	_	_	IN	O	-1	none	_	_
31	this	_	_	DT	O	-1	none	_	_
32	fragment	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Site	_	_	NN	O	-1	none	_	_
2	directed	_	_	VBD	O	-1	none	_	_
3	mutagenesis	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	one	_	_	CD	O	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	more	_	_	JJR	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	these	_	_	DT	O	-1	none	_	_
10	motifs	_	_	NNS	O	-1	none	_	_
11	within	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	IL-6	_	_	NN	Protein	-1	none	_	_
14	promoter	_	_	NN	O	-1	none	_	_
15	demonstrated	_	_	VBD	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	each	_	_	DT	O	-1	none	_	_
18	has	_	_	VBZ	O	-1	none	_	_
19	positive	_	_	JJ	O	-1	none	_	_
20	regulatory	_	_	JJ	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	they	_	_	PRP	O	-1	none	_	_
25	could	_	_	MD	O	-1	none	_	_
26	act	_	_	VB	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	function-	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	orientation	_	_	NN	O	-1	none	_	_
32	independent	_	_	JJ	O	-1	none	_	_
33	manner	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Deletion	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	all	_	_	DT	O	-1	none	_	_
4	three	_	_	CD	O	-1	none	_	_
5	elements	_	_	NNS	O	-1	none	_	_
6	abolished	_	_	VBD	O	-1	none	_	_
7	inducibility	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	IL-6	_	_	NN	Protein	-1	none	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	both	_	_	CC	O	-1	none	_	_
14	LAM	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	LPS	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	NF-IL6	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	sites	_	_	NNS	O	-1	none	_	_
10	mediate	_	_	VBP	O	-1	none	_	_
11	IL-6	_	_	NN	Protein	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	both	_	_	CC	O	-1	none	_	_
17	LPS	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	LAM	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	acting	_	_	VBG	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	bacterial	_	_	JJ	O	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	mycobacterial	_	_	JJ	O	-1	none	_	_
26	response	_	_	NN	O	-1	none	_	_
27	elements	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Membrane	_	_	NN	O	-1	none	_	_
2	associated	_	_	VBD	O	-1	none	_	_
3	lymphotoxin	_	_	NN	O	-1	none	_	_
4	on	_	_	IN	O	-1	none	_	_
5	natural	_	_	JJ	O	-1	none	_	_
6	killer	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	activates	_	_	VBZ	O	-1	none	_	_
9	endothelial	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	via	_	_	IN	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	NF-kappaB-dependent	_	_	JJ	O	-1	none	_	_
14	pathway	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Inhibition	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	complement	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	small	_	_	JJ	O	-1	none	_	_
8	animal	_	_	NN	O	-1	none	_	_
9	models	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	xenotransplantation	_	_	NN	O	-1	none	_	_
12	has	_	_	VBZ	O	-1	none	_	_
13	demonstrated	_	_	VBN	O	-1	none	_	_
14	graft	_	_	NN	O	-1	none	_	_
15	infiltration	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	natural	_	_	JJ	O	-1	none	_	_
18	killer	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	NK	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	monocytes	_	_	NNS	O	-1	none	_	_
25	associated	_	_	VBN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	endothelial	_	_	JJ	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	EC	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	activation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	NK	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	activate	_	_	VBP	O	-1	none	_	_
10	porcine	_	_	NN	O	-1	none	_	_
11	EC	_	_	NN	O	-1	none	_	_
12	in	_	_	FW	O	-1	none	_	_
13	vitro	_	_	FW	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	results	_	_	VBZ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	adhesion	_	_	NN	O	-1	none	_	_
19	molecule	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	cytokine	_	_	NN	O	-1	none	_	_
23	secretion	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	used	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	NK	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	line	_	_	NN	O	-1	none	_	_
11	NK92	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	define	_	_	VB	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	molecular	_	_	JJ	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	cellular	_	_	JJ	O	-1	none	_	_
18	basis	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	NK	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	mediated	_	_	JJ	O	-1	none	_	_
23	EC	_	_	NN	O	-1	none	_	_
24	activation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	EC	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	transfected	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	either	_	_	CC	O	-1	none	_	_
8	reporter	_	_	NN	O	-1	none	_	_
9	constructs	_	_	NNS	O	-1	none	_	_
10	containing	_	_	VBG	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	luciferase	_	_	NN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	driven	_	_	VBN	O	-1	none	_	_
15	either	_	_	CC	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	E-selectin	_	_	NN	Protein	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	interleukin	_	_	NN	Protein	23	multitoken	_	_
20	(	_	_	-LRB-	Protein	23	multitoken	_	_
21	IL	_	_	NN	Protein	23	multitoken	_	_
22	)	_	_	-RRB-	Protein	23	multitoken	_	_
23	-8	_	_	CD	Protein	0	root	_	_
24	promoters	_	_	NNS	O	-1	none	_	_
25	or	_	_	CC	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	synthetic	_	_	JJ	O	-1	none	_	_
28	NF-kappaB-dependent	_	_	JJ	O	-1	none	_	_
29	promoter	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	dominant	_	_	JJ	O	-1	none	_	_
6	negative	_	_	JJ	O	-1	none	_	_
7	mutant	_	_	NN	O	-1	none	_	_
8	tumor	_	_	NN	Protein	12	multitoken	_	_
9	necrosis	_	_	NN	Protein	12	multitoken	_	_
10	factor	_	_	NN	Protein	12	multitoken	_	_
11	receptor	_	_	NN	Protein	12	multitoken	_	_
12	I	_	_	PRP	Protein	0	root	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	TNFRI	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	vector	_	_	NN	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	co-transfected	_	_	VBN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	inhibition	_	_	NN	O	-1	none	_	_
22	studies	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Forty-eight	_	_	CD	O	-1	none	_	_
2	hours	_	_	NNS	O	-1	none	_	_
3	after	_	_	IN	O	-1	none	_	_
4	transfection	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	EC	_	_	NN	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	stimulated	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	NK	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	NK	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	membrane	_	_	NN	O	-1	none	_	_
16	extracts	_	_	NNS	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	7	_	_	CD	O	-1	none	_	_
19	hr	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	measured	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	luciferase	_	_	NN	O	-1	none	_	_
27	assay	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Co-culture	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	NK	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	transfected	_	_	VBN	O	-1	none	_	_
9	EC	_	_	NN	O	-1	none	_	_
10	enhanced	_	_	VBD	O	-1	none	_	_
11	E-selectin	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	IL-8	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	NF-kappaB-dependent	_	_	JJ	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	NK	_	_	NN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	membrane	_	_	NN	O	-1	none	_	_
4	extracts	_	_	NNS	O	-1	none	_	_
5	retained	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	capacity	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	activate	_	_	VB	O	-1	none	_	_
10	EC	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	translocation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	NF-kappaB	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	p50	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	p65	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blotting	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NK	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	membrane	_	_	NN	O	-1	none	_	_
8	extracts	_	_	NNS	O	-1	none	_	_
9	detected	_	_	VBD	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	presence	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Lymphotoxin-alpha	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	LTalpha	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	but	_	_	CC	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	tumor	_	_	NN	Protein	21	multitoken	_	_
20	necrosis	_	_	NN	Protein	21	multitoken	_	_
21	factor-alpha	_	_	NN	Protein	0	root	_	_
22	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	LTalpha	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	secreted	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	NK	_	_	NN	O	-1	none	_	_
8	:	_	_	:	O	-1	none	_	_
9	EC	_	_	NNP	O	-1	none	_	_
10	co-cultures	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Co-transfection	_	_	NN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	dominant	_	_	JJ	O	-1	none	_	_
4	negative	_	_	JJ	O	-1	none	_	_
5	mutant	_	_	NN	O	-1	none	_	_
6	TNFRI	_	_	NN	Protein	-1	none	_	_
7	inhibited	_	_	VBD	O	-1	none	_	_
8	EC	_	_	NN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	NK	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	membrane	_	_	NN	O	-1	none	_	_
14	extracts	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	NK	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	80	_	_	CD	O	-1	none	_	_
21	%	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	47	_	_	CD	O	-1	none	_	_
24	%	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	respectively	_	_	RB	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	same	_	_	JJ	O	-1	none	_	_
3	pattern	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	inhibition	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	observed	_	_	VBN	O	-1	none	_	_
8	using	_	_	VBG	O	-1	none	_	_
9	anti-human	_	_	JJ	O	-1	none	_	_
10	LT	_	_	NN	O	-1	none	_	_
11	sera	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Human	_	_	NN	O	-1	none	_	_
4	NK	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	membrane	_	_	NN	O	-1	none	_	_
7	bound	_	_	VBD	O	-1	none	_	_
8	LT	_	_	JJ	O	-1	none	_	_
9	signals	_	_	NNS	O	-1	none	_	_
10	across	_	_	IN	O	-1	none	_	_
11	species	_	_	NNS	O	-1	none	_	_
12	via	_	_	IN	O	-1	none	_	_
13	TNFRI	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	leading	_	_	VBG	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	translocation	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	E-selectin	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	IL-8	_	_	NN	Protein	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	which	_	_	WDT	O	-1	none	_	_
28	results	_	_	VBZ	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	EC	_	_	NN	O	-1	none	_	_
31	activation	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	discrepancy	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	degree	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	inhibition	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	membrane	_	_	NN	O	-1	none	_	_
10	extracts	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	NK	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	mutant	_	_	NN	O	-1	none	_	_
16	TNFRI	_	_	NN	Protein	-1	none	_	_
17	suggests	_	_	VBZ	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	additional	_	_	JJ	O	-1	none	_	_
20	pathways	_	_	NNS	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	utilized	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	NK	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	activate	_	_	VB	O	-1	none	_	_
28	EC	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Second	_	_	JJ	O	-1	none	_	_
2	messenger	_	_	NN	O	-1	none	_	_
3	up-regulation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	androgen	_	_	NN	O	-1	none	_	_
6	receptor	_	_	NN	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	absent	_	_	JJ	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	androgen	_	_	NN	O	-1	none	_	_
13	insensitive	_	_	JJ	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	prostatic	_	_	JJ	O	-1	none	_	_
16	carcinoma	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	lines	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	PC-3	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	DU-145	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	theoretical	_	_	JJ	O	-1	none	_	_
3	pathway	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	regulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	androgen	_	_	NN	Protein	10	multitoken	_	_
10	receptor	_	_	NN	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	AR	_	_	NN	Protein	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	via	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	cAMP	_	_	NN	O	-1	none	_	_
19	response	_	_	NN	O	-1	none	_	_
20	element	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	CRE	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	present	_	_	JJ	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	its	_	_	PRP$	O	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	region	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	-508	_	_	CD	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	-501	_	_	CD	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	20	_	_	CD	O	-1	none	_	_
3	h	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	stimulation	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	8-bromo-cAMP	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	AR	_	_	NN	Protein	-1	none	_	_
10	mRNA	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	upregulated	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	LNCaP	_	_	NN	O	-1	none	_	_
15	but	_	_	CC	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	either	_	_	CC	O	-1	none	_	_
19	PC-3	_	_	NN	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	DU-145	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	lines	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	ability	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	regulate	_	_	VB	O	-1	none	_	_
5	AR	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	via	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	second	_	_	JJ	O	-1	none	_	_
11	messenger	_	_	NN	O	-1	none	_	_
12	pathway	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	lost	_	_	VBN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	PC-3	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	DU-145	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	lines	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	may	_	_	MD	O	-1	none	_	_
3	be	_	_	VB	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	important	_	_	JJ	O	-1	none	_	_
6	primary	_	_	JJ	O	-1	none	_	_
7	mechanism	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	androgen	_	_	NN	O	-1	none	_	_
10	insensitivity	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	prostate	_	_	NN	O	-1	none	_	_
13	cancer	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Interactions	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	transcriptional	_	_	JJ	O	-1	none	_	_
5	activator	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	env	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	mouse	_	_	NN	O	-1	none	_	_
13	mammary	_	_	JJ	O	-1	none	_	_
14	tumor	_	_	NN	O	-1	none	_	_
15	virus	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	dependent	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	specific	_	_	JJ	O	-1	none	_	_
23	transacting	_	_	VBG	O	-1	none	_	_
24	factors	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mouse	_	_	NN	O	-1	none	_	_
3	mammary	_	_	JJ	O	-1	none	_	_
4	tumor	_	_	NN	O	-1	none	_	_
5	virus	_	_	NN	O	-1	none	_	_
6	env	_	_	NN	Protein	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	contains	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	transcriptional	_	_	JJ	O	-1	none	_	_
11	activator	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	META	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	can	_	_	MD	O	-1	none	_	_
17	control	_	_	VB	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	adjacent	_	_	JJ	O	-1	none	_	_
22	long	_	_	JJ	O	-1	none	_	_
23	terminal	_	_	JJ	O	-1	none	_	_
24	repeat	_	_	NN	O	-1	none	_	_
25	region	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	control	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	META	_	_	NN	O	-1	none	_	_
5	parallels	_	_	VBZ	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	several	_	_	JJ	O	-1	none	_	_
9	lymphokine	_	_	NN	O	-1	none	_	_
10	genes	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	being	_	_	VBG	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	dependent	_	_	JJ	O	-1	none	_	_
19	on	_	_	IN	O	-1	none	_	_
20	their	_	_	PRP$	O	-1	none	_	_
21	activation	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	inhibited	_	_	VBN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	immunosuppressive	_	_	JJ	O	-1	none	_	_
28	drug	_	_	NN	O	-1	none	_	_
29	cyclosporine	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	CsA	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	DNase	_	_	NN	Protein	2	multitoken	_	_
2	I	_	_	CD	Protein	0	root	_	_
3	footprinting	_	_	NN	O	-1	none	_	_
4	indicated	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	factors	_	_	NNS	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	activated	_	_	VBN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	lymphocytes	_	_	NNS	O	-1	none	_	_
12	bound	_	_	VBD	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	promoter	_	_	NN	O	-1	none	_	_
15	proximal	_	_	JJ	O	-1	none	_	_
16	site	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	META	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	P	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	promoter-distal	_	_	JJ	O	-1	none	_	_
26	site	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	META	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	D+	_	_	JJ	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	within	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	400-base	_	_	JJ	O	-1	none	_	_
36	pair	_	_	NN	O	-1	none	_	_
37	META	_	_	NN	O	-1	none	_	_
38	region	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	unstimulated	_	_	JJ	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	but	_	_	CC	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	activated	_	_	VBN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	bound	_	_	VBD	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	META	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	D-)	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	adjacent	_	_	JJ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	META	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	D+	_	_	JJ	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	META	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	D+	_	_	JJ	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	directed	_	_	VBD	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	linked	_	_	JJ	O	-1	none	_	_
10	luciferase	_	_	NN	O	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	gel	_	_	NN	O	-1	none	_	_
15	shift	_	_	NN	O	-1	none	_	_
16	analysis	_	_	NN	O	-1	none	_	_
17	revealed	_	_	VBD	O	-1	none	_	_
18	binding	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	inducible	_	_	JJ	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	CsA	_	_	NN	O	-1	none	_	_
23	sensitive	_	_	JJ	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	factors	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	parallel	_	_	NN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	transfection	_	_	NN	O	-1	none	_	_
32	results	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Authentic	_	_	JJ	O	-1	none	_	_
2	NFAT	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	NF-kappaB	_	_	NN	O	-1	none	_	_
5	targets	_	_	NNS	O	-1	none	_	_
6	did	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	compete	_	_	VB	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	META	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	D+	_	_	JJ	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	factor	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	s	_	_	NNS	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	SV40	_	_	NN	Protein	-1	none	_	_
3	core	_	_	NN	O	-1	none	_	_
4	sequence	_	_	NN	O	-1	none	_	_
5	competed	_	_	VBD	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	META	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	D+	_	_	JJ	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	factors	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	META	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	D+	_	_	JJ	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	failed	_	_	VBD	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	compete	_	_	VB	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	complexes	_	_	NNS	O	-1	none	_	_
25	obtained	_	_	VBN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	SV40	_	_	NN	Protein	-1	none	_	_
29	probe	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	taken	_	_	VBN	O	-1	none	_	_
5	together	_	_	RB	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	indicate	_	_	VBP	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	META	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	D+	_	_	JJ	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	novel	_	_	JJ	O	-1	none	_	_
16	transcriptional	_	_	JJ	O	-1	none	_	_
17	enhancer	_	_	NN	O	-1	none	_	_
18	element	_	_	NN	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	similar	_	_	JJ	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	cell-type	_	_	JJ	O	-1	none	_	_
25	specificity	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	activation	_	_	NN	O	-1	none	_	_
28	dependence	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	CsA	_	_	NN	O	-1	none	_	_
32	sensitivity	_	_	NN	O	-1	none	_	_
33	to	_	_	TO	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	NFAT	_	_	NN	O	-1	none	_	_
36	element	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	may	_	_	MD	O	-1	none	_	_
3	be	_	_	VB	O	-1	none	_	_
4	relevant	_	_	JJ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	MMTV	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Mls	_	_	NN	O	-1	none	_	_
14	antigens	_	_	NNS	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	induction	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	lymphomas	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Lipopolysaccharide	_	_	NN	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	tumor	_	_	NN	Protein	7	multitoken	_	_
6	necrosis	_	_	NN	Protein	7	multitoken	_	_
7	factor-alpha	_	_	NN	Protein	0	root	_	_
8	promoter	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	monocytic	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	by	_	_	IN	O	-1	none	_	_
3	Egr-1	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	c-Jun	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	NF-kappaB	_	_	NN	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Biosynthesis	_	_	NNP	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	tumor	_	_	NN	Protein	5	multitoken	_	_
4	necrosis	_	_	NN	Protein	5	multitoken	_	_
5	factor-alpha	_	_	NN	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	TNF-alpha	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	predominantly	_	_	RB	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	monocytic	_	_	JJ	O	-1	none	_	_
16	lineage	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	examined	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	role	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	various	_	_	JJ	O	-1	none	_	_
8	cis	_	_	NN	O	-1	none	_	_
9	acting	_	_	VBG	O	-1	none	_	_
10	regulatory	_	_	JJ	O	-1	none	_	_
11	elements	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	lipopolysaccharide	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	LPS	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	induction	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	TNF-alpha	_	_	NN	Protein	-1	none	_	_
23	promoter	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	monocytic	_	_	JJ	O	-1	none	_	_
28	lineage	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	analysis	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	monocytic	_	_	JJ	O	-1	none	_	_
5	THP-1	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	transfected	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	plasmids	_	_	NNS	O	-1	none	_	_
10	containing	_	_	VBG	O	-1	none	_	_
11	various	_	_	JJ	O	-1	none	_	_
12	lengths	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	TNF-alpha	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	localized	_	_	JJ	O	-1	none	_	_
17	enhancer	_	_	NN	O	-1	none	_	_
18	elements	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	region	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	-182	_	_	CD	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	-37	_	_	CD	O	-1	none	_	_
26	base	_	_	NN	O	-1	none	_	_
27	pairs	_	_	NNS	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	bp	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	that	_	_	WDT	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	required	_	_	VBN	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	optimal	_	_	JJ	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	TNF-alpha	_	_	NN	Protein	-1	none	_	_
41	gene	_	_	NN	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	response	_	_	NN	O	-1	none	_	_
44	to	_	_	TO	O	-1	none	_	_
45	LPS	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	regions	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	identified	_	_	VBN	O	-1	none	_	_
5	:	_	_	:	O	-1	none	_	_
6	region	_	_	NN	O	-1	none	_	_
7	I	_	_	PRP	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	-182	_	_	CD	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	-162	_	_	CD	O	-1	none	_	_
12	bp	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	contained	_	_	VBD	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	overlapping	_	_	VBG	O	-1	none	_	_
17	Sp1	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Egr	_	_	NN	Protein	20	multitoken	_	_
20	-1	_	_	CD	Protein	0	root	_	_
21	site	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	region	_	_	NN	O	-1	none	_	_
25	II	_	_	CD	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	-119	_	_	CD	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	-88	_	_	CD	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	contained	_	_	VBD	O	-1	none	_	_
32	CRE	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	NF-kappaB	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	designated	_	_	VBN	O	-1	none	_	_
37	kappaB3	_	_	NN	O	-1	none	_	_
38	)	_	_	-RRB-	O	-1	none	_	_
39	sites	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	unstimulated	_	_	JJ	O	-1	none	_	_
3	THP-1	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	CRE	_	_	NN	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	lesser	_	_	JJR	O	-1	none	_	_
13	extent	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	c-Jun	_	_	NN	Protein	-1	none	_	_
16	complexes	_	_	NNS	O	-1	none	_	_
17	were	_	_	VBD	O	-1	none	_	_
18	found	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	bind	_	_	VB	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	CRE	_	_	NN	O	-1	none	_	_
24	site	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	LPS	_	_	NN	O	-1	none	_	_
5	stimulation	_	_	NN	O	-1	none	_	_
6	induced	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	cognate	_	_	JJ	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	factors	_	_	NNS	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	Egr-1	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	kappaB3	_	_	NN	O	-1	none	_	_
18	sites	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	were	_	_	VBD	O	-1	none	_	_
22	identified	_	_	VBN	O	-1	none	_	_
23	as	_	_	IN	O	-1	none	_	_
24	Egr-1	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	p50	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	p65	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	respectively	_	_	RB	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	CRE	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	kappaB3	_	_	NN	O	-1	none	_	_
5	sites	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	region	_	_	NN	O	-1	none	_	_
8	II	_	_	CD	O	-1	none	_	_
9	together	_	_	RB	O	-1	none	_	_
10	conferred	_	_	VBD	O	-1	none	_	_
11	strong	_	_	JJ	O	-1	none	_	_
12	LPS	_	_	NN	O	-1	none	_	_
13	responsiveness	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	heterologous	_	_	JJ	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	whereas	_	_	IN	O	-1	none	_	_
20	individually	_	_	RB	O	-1	none	_	_
21	they	_	_	PRP	O	-1	none	_	_
22	failed	_	_	VBD	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	provide	_	_	VB	O	-1	none	_	_
25	transcriptional	_	_	JJ	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	increasing	_	_	VBG	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	spacing	_	_	NN	O	-1	none	_	_
6	between	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	CRE	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	kappaB3	_	_	NN	O	-1	none	_	_
12	sites	_	_	NNS	O	-1	none	_	_
13	completely	_	_	RB	O	-1	none	_	_
14	abolished	_	_	VBD	O	-1	none	_	_
15	LPS	_	_	NN	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	suggesting	_	_	VBG	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	cooperative	_	_	JJ	O	-1	none	_	_
21	interaction	_	_	NN	O	-1	none	_	_
22	between	_	_	IN	O	-1	none	_	_
23	c-Jun	_	_	NN	Protein	-1	none	_	_
24	complexes	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	p50	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	p65	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	maximal	_	_	JJ	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	induction	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	TNF-alpha	_	_	NN	Protein	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	concerted	_	_	JJ	O	-1	none	_	_
16	participation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	least	_	_	JJS	O	-1	none	_	_
20	two	_	_	CD	O	-1	none	_	_
21	separate	_	_	JJ	O	-1	none	_	_
22	cis	_	_	NN	O	-1	none	_	_
23	acting	_	_	VBG	O	-1	none	_	_
24	regulatory	_	_	JJ	O	-1	none	_	_
25	elements	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	AP-1	_	_	NN	O	-1	none	_	_
3	site	_	_	NN	O	-1	none	_	_
4	at	_	_	IN	O	-1	none	_	_
5	-150	_	_	CD	O	-1	none	_	_
6	bp	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	but	_	_	CC	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	likely	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	represent	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	major	_	_	JJ	O	-1	none	_	_
21	target	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	kinase	_	_	NN	O	-1	none	_	_
25	C	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	interleukin	_	_	NN	Protein	29	multitoken	_	_
29	2	_	_	CD	Protein	0	root	_	_
30	promoter	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Stimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	antigen	_	_	NN	O	-1	none	_	_
7	results	_	_	VBZ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	several	_	_	JJ	O	-1	none	_	_
12	kinases	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	including	_	_	VBG	O	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	kinase	_	_	NN	O	-1	none	_	_
17	C	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	PKC	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	that	_	_	WDT	O	-1	none	_	_
23	may	_	_	MD	O	-1	none	_	_
24	mediate	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	later	_	_	JJ	O	-1	none	_	_
27	induction	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	activation	_	_	NN	O	-1	none	_	_
30	related	_	_	JJ	O	-1	none	_	_
31	genes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	examined	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	potential	_	_	JJ	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	PKC	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	interleukin	_	_	NN	Protein	14	multitoken	_	_
14	2	_	_	CD	Protein	0	root	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	stimulated	_	_	VBN	O	-1	none	_	_
23	through	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	receptor	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	CD3	_	_	NN	O	-1	none	_	_
30	complex	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	prolonged	_	_	JJ	O	-1	none	_	_
7	treatment	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	untransformed	_	_	JJ	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	clone	_	_	NN	O	-1	none	_	_
14	Ar-5	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	phorbol	_	_	NN	O	-1	none	_	_
17	esters	_	_	NNS	O	-1	none	_	_
18	results	_	_	VBZ	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	downmodulation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	alpha	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	beta	_	_	NN	O	-1	none	_	_
26	isozymes	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	PKC	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	abrogates	_	_	VBZ	O	-1	none	_	_
32	induction	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	IL-2	_	_	NN	Protein	-1	none	_	_
35	mRNA	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	protein	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	phorbol	_	_	NN	O	-1	none	_	_
6	ester	_	_	NN	O	-1	none	_	_
7	treatment	_	_	NN	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	abolishes	_	_	VBZ	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	chloramphenicol	_	_	NN	Protein	13	multitoken	_	_
13	acetyltransferase	_	_	NN	Protein	0	root	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	Ar-5	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	transfected	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	plasmid	_	_	NN	O	-1	none	_	_
22	containing	_	_	VBG	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	IL-2	_	_	NN	Protein	-1	none	_	_
25	promoter	_	_	NN	O	-1	none	_	_
26	linked	_	_	VBN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	this	_	_	DT	O	-1	none	_	_
29	reporter	_	_	NN	O	-1	none	_	_
30	gene	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IL-2	_	_	NN	Protein	-1	none	_	_
3	promoter	_	_	NN	O	-1	none	_	_
4	contains	_	_	VBZ	O	-1	none	_	_
5	binding	_	_	VBG	O	-1	none	_	_
6	sites	_	_	NNS	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	including	_	_	VBG	O	-1	none	_	_
11	NFAT-1	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	Oct	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	AP-1	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	are	_	_	VBP	O	-1	none	_	_
23	all	_	_	DT	O	-1	none	_	_
24	potentially	_	_	RB	O	-1	none	_	_
25	sensitive	_	_	JJ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	activation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	PKC	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	induction	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	trimer	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	NFAT	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	Oct	_	_	NN	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	sensitive	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	phorbol	_	_	NN	O	-1	none	_	_
19	ester	_	_	NN	O	-1	none	_	_
20	treatment	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	mutations	_	_	NNS	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	NF-kappa	_	_	NN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	site	_	_	NN	O	-1	none	_	_
30	have	_	_	VBP	O	-1	none	_	_
31	no	_	_	DT	O	-1	none	_	_
32	effect	_	_	NN	O	-1	none	_	_
33	on	_	_	IN	O	-1	none	_	_
34	inducibility	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	IL-2	_	_	NN	Protein	-1	none	_	_
38	promoter	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	mutations	_	_	NNS	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	AP-1	_	_	NN	O	-1	none	_	_
8	site	_	_	NN	O	-1	none	_	_
9	located	_	_	JJ	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	-150	_	_	CD	O	-1	none	_	_
12	bp	_	_	NN	O	-1	none	_	_
13	almost	_	_	RB	O	-1	none	_	_
14	completely	_	_	RB	O	-1	none	_	_
15	abrogate	_	_	VBP	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	IL-2	_	_	NN	Protein	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	appearance	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	an	_	_	DT	O	-1	none	_	_
26	inducible	_	_	JJ	O	-1	none	_	_
27	nuclear	_	_	JJ	O	-1	none	_	_
28	factor	_	_	NN	O	-1	none	_	_
29	binding	_	_	NN	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	this	_	_	DT	O	-1	none	_	_
32	site	_	_	NN	O	-1	none	_	_
33	is	_	_	VBZ	O	-1	none	_	_
34	sensitive	_	_	JJ	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	PKC	_	_	NN	O	-1	none	_	_
37	depletion	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	cotransfections	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	c-fos	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	c-jun	_	_	NN	Protein	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	plasmids	_	_	NNS	O	-1	none	_	_
10	markedly	_	_	RB	O	-1	none	_	_
11	enhance	_	_	VBP	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	promoter	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	minimally	_	_	RB	O	-1	none	_	_
19	stimulated	_	_	VBN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	AP-1	_	_	NN	O	-1	none	_	_
7	site	_	_	NN	O	-1	none	_	_
8	at	_	_	IN	O	-1	none	_	_
9	-150	_	_	CD	O	-1	none	_	_
10	bp	_	_	NN	O	-1	none	_	_
11	represents	_	_	VBZ	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	major	_	_	JJ	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	if	_	_	IN	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	only	_	_	RB	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	PKC	_	_	NN	O	-1	none	_	_
23	responsiveness	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	IL-2	_	_	NN	Protein	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Involvement	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	N-terminal	_	_	JJ	O	-1	none	_	_
5	region	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	mineralocorticoid	_	_	NN	Protein	10	multitoken	_	_
10	receptor	_	_	NN	Protein	0	root	_	_
11	hormone	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	domain	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	agonist	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	antagonist	_	_	NN	O	-1	none	_	_
18	binding	_	_	NN	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	revealed	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	new	_	_	JJ	O	-1	none	_	_
24	monoclonal	_	_	JJ	O	-1	none	_	_
25	antibody	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	gain	_	_	VB	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	better	_	_	JJR	O	-1	none	_	_
5	understanding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	mechanism	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	binding	_	_	VBG	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	mineralocorticoid	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	hMR	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	we	_	_	PRP	O	-1	none	_	_
21	developed	_	_	VBD	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	new	_	_	JJ	O	-1	none	_	_
24	monoclonal	_	_	JJ	O	-1	none	_	_
25	antibody	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	mAb	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	raised	_	_	VBN	O	-1	none	_	_
30	against	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	hormone	_	_	NN	O	-1	none	_	_
33	binding	_	_	NN	O	-1	none	_	_
34	domain	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	HBD	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	For	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	purpose	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	mice	_	_	NNS	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	immunized	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	fusion	_	_	NN	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	including	_	_	VBG	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	sequence	_	_	NN	O	-1	none	_	_
15	Thr729-Lys984	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	hMR	_	_	NN	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	ELISA	_	_	NN	O	-1	none	_	_
3	screening	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	mAb	_	_	NN	O	-1	none	_	_
6	18C7	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	selected	_	_	VBN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	its	_	_	PRP$	O	-1	none	_	_
11	specificity	_	_	NN	O	-1	none	_	_
12	towards	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	HBD	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	antibody	_	_	NN	O	-1	none	_	_
3	recognized	_	_	VBD	O	-1	none	_	_
4	both	_	_	CC	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	denatured	_	_	JJ	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	native	_	_	JJ	O	-1	none	_	_
9	MR	_	_	NN	Protein	-1	none	_	_
10	forms	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	as	_	_	RB	O	-1	none	_	_
13	well	_	_	RB	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	hetero-oligomeric	_	_	JJ	O	-1	none	_	_
17	MR	_	_	NN	Protein	-1	none	_	_
18	form	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	transformed	_	_	JJ	O	-1	none	_	_
22	MR	_	_	NN	Protein	-1	none	_	_
23	state	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	several	_	_	JJ	O	-1	none	_	_
4	HBD	_	_	NN	O	-1	none	_	_
5	subfragments	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	mAb	_	_	NN	O	-1	none	_	_
9	18C7	_	_	NN	O	-1	none	_	_
10	epitope	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	located	_	_	JJ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	N-terminal	_	_	JJ	O	-1	none	_	_
16	region	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	HBD	_	_	NN	O	-1	none	_	_
20	from	_	_	IN	O	-1	none	_	_
21	Thr729	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	Leu765	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	then	_	_	RB	O	-1	none	_	_
3	studied	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effect	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	antibody	_	_	NN	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	aldosterone	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	progesterone	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	hMR	_	_	NN	Protein	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	18C7	_	_	NNP	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	incubated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	liganded	_	_	VBN	O	-1	none	_	_
7	MR	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	it	_	_	PRP	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	able	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	partly	_	_	RB	O	-1	none	_	_
14	displace	_	_	VB	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	20	_	_	CD	O	-1	none	_	_
17	%	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	hormone	_	_	NN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	its	_	_	PRP$	O	-1	none	_	_
23	binding	_	_	NN	O	-1	none	_	_
24	site	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	18C7	_	_	NNP	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	incubated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	MR	_	_	NN	Protein	-1	none	_	_
7	before	_	_	IN	O	-1	none	_	_
8	aldosterone	_	_	NN	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	progesterone	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	antibody	_	_	NN	O	-1	none	_	_
14	inhibited	_	_	VBD	O	-1	none	_	_
15	75-80	_	_	CD	O	-1	none	_	_
16	%	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	18C7	_	_	NNP	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	similar	_	_	JJ	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	hormones	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	sucrose	_	_	NN	O	-1	none	_	_
3	gradient	_	_	NN	O	-1	none	_	_
4	analysis	_	_	NN	O	-1	none	_	_
5	indicated	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	simultaneous	_	_	JJ	O	-1	none	_	_
8	presence	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	two	_	_	CD	O	-1	none	_	_
11	kinds	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	complexes	_	_	NNS	O	-1	none	_	_
15	:	_	_	:	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	steroid-MR	_	_	JJ	Protein	-1	none	_	_
18	complex	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	antibody-MR	_	_	JJ	Protein	-1	none	_	_
22	complex	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	its	_	_	PRP$	O	-1	none	_	_
3	associated	_	_	JJ	O	-1	none	_	_
4	proteins	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	especially	_	_	RB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	heat-shock	_	_	JJ	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	hsp90	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	had	_	_	VBD	O	-1	none	_	_
13	been	_	_	VBN	O	-1	none	_	_
14	cross	_	_	JJ	O	-1	none	_	_
15	linked	_	_	VBN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	hMR	_	_	NN	Protein	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	dimethylpimelimidate	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	18C7	_	_	NNP	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	still	_	_	RB	O	-1	none	_	_
25	able	_	_	JJ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	react	_	_	VB	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	receptor	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	epitope	_	_	NN	O	-1	none	_	_
7	recognized	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	18C7	_	_	NNP	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	directly	_	_	RB	O	-1	none	_	_
12	implicated	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	hormone	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	lack	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	steroid	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	HBD	_	_	NN	O	-1	none	_	_
8	mutants	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	Thr729-Leu765	_	_	NN	O	-1	none	_	_
12	sequence	_	_	NN	O	-1	none	_	_
13	deleted	_	_	VBN	O	-1	none	_	_
14	[	_	_	CD	O	-1	none	_	_
15	Jalaguier	_	_	NNP	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	Mesnier	_	_	NNP	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	Leger	_	_	NNP	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	Auzou	_	_	NNP	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	1996	_	_	CD	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	J.Steroid	_	_	NNP	O	-1	none	_	_
26	Biochem.Mol.Biol	_	_	NNP	O	-1	none	_	_
27	.57	_	_	CD	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	43-50	_	_	CD	O	-1	none	_	_
30	]	_	_	NN	O	-1	none	_	_
31	supports	_	_	VBZ	O	-1	none	_	_
32	this	_	_	DT	O	-1	none	_	_
33	hypothesis	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	similar	_	_	JJ	O	-1	none	_	_
5	behaviours	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	aldosterone	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	progesterone	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	we	_	_	PRP	O	-1	none	_	_
12	conclude	_	_	VBP	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	N-terminal	_	_	JJ	O	-1	none	_	_
16	Thr729-Leu765	_	_	NN	O	-1	none	_	_
17	region	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	HBD	_	_	NN	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	similarly	_	_	RB	O	-1	none	_	_
23	involved	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	both	_	_	CC	O	-1	none	_	_
29	hormones	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	c-Myb	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	Ets	_	_	NN	O	-1	none	_	_
4	proteins	_	_	NNS	O	-1	none	_	_
5	synergize	_	_	VBP	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	overcome	_	_	VB	O	-1	none	_	_
8	transcriptional	_	_	JJ	O	-1	none	_	_
9	repression	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	ZEB	_	_	NN	Protein	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Zfh	_	_	NN	O	-1	none	_	_
3	family	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	zinc	_	_	NN	O	-1	none	_	_
6	finger	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	homeodomain	_	_	NN	O	-1	none	_	_
9	proteins	_	_	NNS	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	first	_	_	RB	O	-1	none	_	_
12	identified	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	Drosophila	_	_	FW	O	-1	none	_	_
15	where	_	_	WRB	O	-1	none	_	_
16	it	_	_	PRP	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	required	_	_	VBN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	differentiation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	tissues	_	_	NNS	O	-1	none	_	_
23	such	_	_	JJ	O	-1	none	_	_
24	as	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	central	_	_	JJ	O	-1	none	_	_
27	nervous	_	_	JJ	O	-1	none	_	_
28	system	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	muscle	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	ZEB	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	vertebrate	_	_	JJ	O	-1	none	_	_
5	homolog	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	Zfh-1	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	binds	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	subset	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	E	_	_	NN	O	-1	none	_	_
14	boxes	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	blocks	_	_	VBZ	O	-1	none	_	_
17	myogenesis	_	_	NN	O	-1	none	_	_
18	through	_	_	IN	O	-1	none	_	_
19	transcriptional	_	_	JJ	O	-1	none	_	_
20	repression	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	muscle	_	_	NN	O	-1	none	_	_
23	genes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	present	_	_	VBP	O	-1	none	_	_
3	evidence	_	_	NN	O	-1	none	_	_
4	here	_	_	RB	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	ZEB	_	_	NN	Protein	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	has	_	_	VBZ	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	important	_	_	JJ	O	-1	none	_	_
11	role	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	controlling	_	_	VBG	O	-1	none	_	_
14	hematopoietic	_	_	JJ	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	families	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	factors	_	_	NNS	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	required	_	_	VBN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	normal	_	_	JJ	O	-1	none	_	_
11	hematopoiesis	_	_	NN	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	c-Myb	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Ets	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	act	_	_	VBP	O	-1	none	_	_
4	synergistically	_	_	RB	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	activate	_	_	VB	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	synergy	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	required	_	_	VBN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	at	_	_	IN	O	-1	none	_	_
18	least	_	_	JJS	O	-1	none	_	_
19	several	_	_	JJ	O	-1	none	_	_
20	important	_	_	JJ	O	-1	none	_	_
21	hematopoietic	_	_	JJ	O	-1	none	_	_
22	genes	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	ZEB	_	_	NN	Protein	-1	none	_	_
2	blocks	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	c-Myb	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	Ets	_	_	NN	O	-1	none	_	_
9	individually	_	_	RB	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	together	_	_	RB	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	synergize	_	_	VBP	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	resist	_	_	VB	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	repression	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Such	_	_	JJ	O	-1	none	_	_
2	repression	_	_	NN	O	-1	none	_	_
3	imposes	_	_	VBZ	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	requirement	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	both	_	_	DT	O	-1	none	_	_
8	c-Myb	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	Ets	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	transcriptional	_	_	JJ	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	providing	_	_	VBG	O	-1	none	_	_
16	one	_	_	CD	O	-1	none	_	_
17	explanation	_	_	NN	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	why	_	_	WRB	O	-1	none	_	_
20	synergy	_	_	NN	O	-1	none	_	_
21	between	_	_	IN	O	-1	none	_	_
22	these	_	_	DT	O	-1	none	_	_
23	factors	_	_	NNS	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	important	_	_	JJ	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	balance	_	_	NN	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	repression	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	ZEB	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	transcriptional	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	c-Myb	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Ets	_	_	NN	O	-1	none	_	_
14	provides	_	_	VBZ	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	flexible	_	_	JJ	O	-1	none	_	_
17	regulatory	_	_	JJ	O	-1	none	_	_
18	mechanism	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	controlling	_	_	VBG	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	hematopoietic	_	_	JJ	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	one	_	_	CD	O	-1	none	_	_
5	target	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	positive	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	negative	_	_	JJ	O	-1	none	_	_
11	regulation	_	_	NN	O	-1	none	_	_
12	in	_	_	FW	O	-1	none	_	_
13	vivo	_	_	FW	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	alpha4	_	_	NN	Protein	17	multitoken	_	_
17	integrin	_	_	NN	Protein	0	root	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	play	_	_	VBP	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	key	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	normal	_	_	JJ	O	-1	none	_	_
26	hematopoiesis	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	function	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	mature	_	_	JJ	O	-1	none	_	_
31	leukocytes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Triggering	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HLA-DR	_	_	NN	O	-1	none	_	_
4	antigens	_	_	NNS	O	-1	none	_	_
5	differentially	_	_	RB	O	-1	none	_	_
6	modulates	_	_	VBZ	O	-1	none	_	_
7	tumor	_	_	NN	Protein	10	multitoken	_	_
8	necrosis	_	_	NN	Protein	10	multitoken	_	_
9	factor	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	release	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	at	_	_	IN	O	-1	none	_	_
16	distinct	_	_	JJ	O	-1	none	_	_
17	stage	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	maturation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Triggering	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HLA	_	_	NN	O	-1	none	_	_
4	class	_	_	NN	O	-1	none	_	_
5	II	_	_	CD	O	-1	none	_	_
6	antigens	_	_	NNS	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	anti-HLA-DR	_	_	JJ	O	-1	none	_	_
10	monoclonal	_	_	JJ	O	-1	none	_	_
11	antibody	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	mAb	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	L243	_	_	NN	O	-1	none	_	_
16	significantly	_	_	RB	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	P	_	_	NN	O	-1	none	_	_
19	<	_	_	JJR	O	-1	none	_	_
20	0.05	_	_	CD	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	differentially	_	_	RB	O	-1	none	_	_
24	enhanced	_	_	VBD	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	release	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	tumor	_	_	NN	Protein	31	multitoken	_	_
29	necrosis	_	_	NN	Protein	31	multitoken	_	_
30	factor	_	_	NN	Protein	31	multitoken	_	_
31	alpha	_	_	NN	Protein	0	root	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	TNF-alpha	_	_	NN	Protein	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	non	_	_	JJ	O	-1	none	_	_
38	Hodgkin	_	_	NN	O	-1	none	_	_
39	's	_	_	POS	O	-1	none	_	_
40	lymphoma	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	Ri-I	_	_	NN	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	Ci-I	_	_	NN	O	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	Sc-I	_	_	NN	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	which	_	_	WDT	O	-1	none	_	_
50	are	_	_	VBP	O	-1	none	_	_
51	at	_	_	IN	O	-1	none	_	_
52	a	_	_	DT	O	-1	none	_	_
53	distinct	_	_	JJ	O	-1	none	_	_
54	stage	_	_	NN	O	-1	none	_	_
55	of	_	_	IN	O	-1	none	_	_
56	B-cell	_	_	NN	O	-1	none	_	_
57	differentiation	_	_	NN	O	-1	none	_	_
58	,	_	_	,	O	-1	none	_	_
59	and	_	_	CC	O	-1	none	_	_
60	by	_	_	IN	O	-1	none	_	_
61	the	_	_	DT	O	-1	none	_	_
62	more	_	_	RBR	O	-1	none	_	_
63	mature	_	_	JJ	O	-1	none	_	_
64	Burkitt	_	_	NN	O	-1	none	_	_
65	lymphoma	_	_	NN	O	-1	none	_	_
66	cell	_	_	NN	O	-1	none	_	_
67	Raji	_	_	NN	O	-1	none	_	_
68	;	_	_	:	O	-1	none	_	_
69	in	_	_	IN	O	-1	none	_	_
70	contrast	_	_	NN	O	-1	none	_	_
71	,	_	_	,	O	-1	none	_	_
72	it	_	_	PRP	O	-1	none	_	_
73	did	_	_	VBD	O	-1	none	_	_
74	not	_	_	RB	O	-1	none	_	_
75	induce	_	_	VB	O	-1	none	_	_
76	TNF-alpha	_	_	NN	Protein	-1	none	_	_
77	release	_	_	NN	O	-1	none	_	_
78	by	_	_	IN	O	-1	none	_	_
79	the	_	_	DT	O	-1	none	_	_
80	pre-B	_	_	JJ	O	-1	none	_	_
81	leukemia	_	_	NN	O	-1	none	_	_
82	cells	_	_	NNS	O	-1	none	_	_
83	Nalm-6	_	_	NN	O	-1	none	_	_
84	and	_	_	CC	O	-1	none	_	_
85	BV173	_	_	NN	O	-1	none	_	_
86	.	_	_	.	O	-1	none	_	_

1	TNF-alpha	_	_	NN	Protein	-1	none	_	_
2	release	_	_	NN	O	-1	none	_	_
3	peaked	_	_	VBD	O	-1	none	_	_
4	at	_	_	IN	O	-1	none	_	_
5	24	_	_	CD	O	-1	none	_	_
6	h	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	decreased	_	_	VBD	O	-1	none	_	_
9	thereafter	_	_	RB	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	it	_	_	PRP	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	dose	_	_	NN	O	-1	none	_	_
15	dependent	_	_	JJ	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	preceded	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	increase	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	TNF-alpha	_	_	NN	Protein	-1	none	_	_
23	mRNA	_	_	NN	O	-1	none	_	_
24	detectable	_	_	JJ	O	-1	none	_	_
25	after	_	_	IN	O	-1	none	_	_
26	3	_	_	CD	O	-1	none	_	_
27	h	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	stimulation	_	_	NN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	mAb	_	_	NN	O	-1	none	_	_
32	L243	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	released	_	_	VBN	O	-1	none	_	_
5	TNF-alpha	_	_	NN	Protein	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	responsible	_	_	JJ	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	homotypic	_	_	JJ	O	-1	none	_	_
12	aggregation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	Ri-I	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	Ci-I	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	Sc-I	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	Raji	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	induced	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	mAb	_	_	NN	O	-1	none	_	_
26	L243	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	it	_	_	PRP	O	-1	none	_	_
30	did	_	_	VBD	O	-1	none	_	_
31	not	_	_	RB	O	-1	none	_	_
32	affect	_	_	VB	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	proliferation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	B	_	_	NN	O	-1	none	_	_
37	cells	_	_	NNS	O	-1	none	_	_
38	investigated	_	_	VBN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Altogether	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	our	_	_	PRP$	O	-1	none	_	_
4	data	_	_	NNS	O	-1	none	_	_
5	demonstrate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	:	_	_	:	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	ability	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	release	_	_	VB	O	-1	none	_	_
18	TNF-alpha	_	_	NN	Protein	-1	none	_	_
19	after	_	_	IN	O	-1	none	_	_
20	triggering	_	_	VBG	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	HLA-DR	_	_	NN	O	-1	none	_	_
23	antigens	_	_	NNS	O	-1	none	_	_
24	depends	_	_	VBZ	O	-1	none	_	_
25	on	_	_	IN	O	-1	none	_	_
26	their	_	_	PRP$	O	-1	none	_	_
27	stage	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	differentiation	_	_	NN	O	-1	none	_	_
30	;	_	_	:	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	b	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	levels	_	_	NNS	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	released	_	_	VBN	O	-1	none	_	_
37	TNF-alpha	_	_	NN	Protein	-1	none	_	_
38	seem	_	_	VBP	O	-1	none	_	_
39	to	_	_	TO	O	-1	none	_	_
40	correlate	_	_	VB	O	-1	none	_	_
41	with	_	_	IN	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	stage	_	_	NN	O	-1	none	_	_
44	of	_	_	IN	O	-1	none	_	_
45	B-cell	_	_	NN	O	-1	none	_	_
46	maturation	_	_	NN	O	-1	none	_	_
47	but	_	_	CC	O	-1	none	_	_
48	do	_	_	VBP	O	-1	none	_	_
49	not	_	_	RB	O	-1	none	_	_
50	correlate	_	_	VB	O	-1	none	_	_
51	with	_	_	IN	O	-1	none	_	_
52	the	_	_	DT	O	-1	none	_	_
53	amounts	_	_	NNS	O	-1	none	_	_
54	of	_	_	IN	O	-1	none	_	_
55	cell	_	_	NN	O	-1	none	_	_
56	surface	_	_	NN	O	-1	none	_	_
57	HLA-DR	_	_	NN	O	-1	none	_	_
58	antigens	_	_	NNS	O	-1	none	_	_
59	;	_	_	:	O	-1	none	_	_
60	(	_	_	-LRB-	O	-1	none	_	_
61	c	_	_	NN	O	-1	none	_	_
62	)	_	_	-RRB-	O	-1	none	_	_
63	secreted	_	_	VBN	O	-1	none	_	_
64	TNF-alpha	_	_	NN	Protein	-1	none	_	_
65	regulates	_	_	VBZ	O	-1	none	_	_
66	the	_	_	DT	O	-1	none	_	_
67	levels	_	_	NNS	O	-1	none	_	_
68	of	_	_	IN	O	-1	none	_	_
69	expression	_	_	NN	O	-1	none	_	_
70	of	_	_	IN	O	-1	none	_	_
71	NF-kappa	_	_	NN	O	-1	none	_	_
72	B	_	_	NN	O	-1	none	_	_
73	and	_	_	CC	O	-1	none	_	_
74	AP-1	_	_	NN	O	-1	none	_	_
75	by	_	_	IN	O	-1	none	_	_
76	an	_	_	DT	O	-1	none	_	_
77	autocrine	_	_	JJ	O	-1	none	_	_
78	loop	_	_	NN	O	-1	none	_	_
79	;	_	_	:	O	-1	none	_	_
80	and	_	_	CC	O	-1	none	_	_
81	(	_	_	-LRB-	O	-1	none	_	_
82	d	_	_	NN	O	-1	none	_	_
83	)	_	_	-RRB-	O	-1	none	_	_
84	intracellular	_	_	JJ	O	-1	none	_	_
85	signals	_	_	NNS	O	-1	none	_	_
86	mediating	_	_	VBG	O	-1	none	_	_
87	TNF-alpha	_	_	NN	Protein	-1	none	_	_
88	release	_	_	NN	O	-1	none	_	_
89	by	_	_	IN	O	-1	none	_	_
90	B	_	_	NN	O	-1	none	_	_
91	cells	_	_	NNS	O	-1	none	_	_
92	are	_	_	VBP	O	-1	none	_	_
93	distinct	_	_	JJ	O	-1	none	_	_
94	from	_	_	IN	O	-1	none	_	_
95	those	_	_	DT	O	-1	none	_	_
96	regulating	_	_	VBG	O	-1	none	_	_
97	homotypic	_	_	JJ	O	-1	none	_	_
98	aggregation	_	_	NN	O	-1	none	_	_
99	and	_	_	CC	O	-1	none	_	_
100	proliferation	_	_	NN	O	-1	none	_	_
101	.	_	_	.	O	-1	none	_	_

1	Characterization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	peripheral	_	_	JJ	O	-1	none	_	_
4	blood	_	_	NN	O	-1	none	_	_
5	T-lymphocytes	_	_	NNS	O	-1	none	_	_
6	transduced	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	Tax	_	_	NN	Protein	-1	none	_	_
10	mutants	_	_	NNS	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	different	_	_	JJ	O	-1	none	_	_
13	trans-activating	_	_	JJ	O	-1	none	_	_
14	phenotypes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Tax1	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	transcriptional	_	_	JJ	O	-1	none	_	_
5	trans-activator	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	Human	_	_	NN	O	-1	none	_	_
9	T-cell	_	_	NN	O	-1	none	_	_
10	leukemia	_	_	NN	O	-1	none	_	_
11	virus	_	_	NN	O	-1	none	_	_
12	type	_	_	NN	O	-1	none	_	_
13	I	_	_	CD	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	HTLV-I	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	induces	_	_	VBZ	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	many	_	_	JJ	O	-1	none	_	_
23	cellular	_	_	JJ	O	-1	none	_	_
24	genes	_	_	NNS	O	-1	none	_	_
25	through	_	_	IN	O	-1	none	_	_
26	interaction	_	_	NN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	least	_	_	JJS	O	-1	none	_	_
30	three	_	_	CD	O	-1	none	_	_
31	distinct	_	_	JJ	O	-1	none	_	_
32	cellular	_	_	JJ	O	-1	none	_	_
33	transcription	_	_	NN	O	-1	none	_	_
34	factors	_	_	NNS	O	-1	none	_	_
35	;	_	_	:	O	-1	none	_	_
36	CREB	_	_	NN	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	ATF	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	NF-kappaB	_	_	NN	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	SRF	_	_	NN	Protein	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	Tax1	_	_	NN	Protein	-1	none	_	_
3	induced	_	_	VBD	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	cellular	_	_	JJ	O	-1	none	_	_
7	genes	_	_	NNS	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	considered	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	be	_	_	VB	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	critical	_	_	JJ	O	-1	none	_	_
14	event	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	T-cell	_	_	NN	O	-1	none	_	_
17	transformation	_	_	NN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	HTLV-I	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	elucidate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	role	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	each	_	_	DT	O	-1	none	_	_
7	Tax1	_	_	NN	Protein	-1	none	_	_
8	inducible	_	_	JJ	O	-1	none	_	_
9	transcriptional	_	_	JJ	O	-1	none	_	_
10	pathway	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	T-cell	_	_	NN	O	-1	none	_	_
13	transformation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	we	_	_	PRP	O	-1	none	_	_
16	introduced	_	_	VBD	O	-1	none	_	_
17	Tax1	_	_	NN	Protein	-1	none	_	_
18	mutants	_	_	NNS	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	different	_	_	JJ	O	-1	none	_	_
21	trans-activating	_	_	JJ	O	-1	none	_	_
22	phenotypes	_	_	NNS	O	-1	none	_	_
23	into	_	_	IN	O	-1	none	_	_
24	peripheral	_	_	JJ	O	-1	none	_	_
25	blood	_	_	NN	O	-1	none	_	_
26	lymphocytes	_	_	NNS	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	PBL	_	_	NN	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	by	_	_	IN	O	-1	none	_	_
31	retroviral	_	_	JJ	O	-1	none	_	_
32	vectors	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Analysis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	PBLs	_	_	NNS	O	-1	none	_	_
5	revealed	_	_	VBD	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	NF-kappaB	_	_	NN	O	-1	none	_	_
11	pathway	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	sufficient	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	promote	_	_	VB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	growth	_	_	NN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Extinction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	immunoglobulin	_	_	NN	O	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	upon	_	_	IN	O	-1	none	_	_
10	fusion	_	_	NN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	HeLa	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	preceded	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	rapid	_	_	JJ	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	depletion	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	essential	_	_	JJ	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	factors	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	accompanied	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	widespread	_	_	JJ	O	-1	none	_	_
29	inactivation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	genes	_	_	NNS	O	-1	none	_	_
32	expressed	_	_	VBN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	cell	_	_	NN	O	-1	none	_	_
37	specific	_	_	JJ	O	-1	none	_	_
38	manner	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	immunoglobulin	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	Ig	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	expressing	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	fused	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	non	_	_	JJ	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	Ig	_	_	NN	O	-1	none	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	rapidly	_	_	RB	O	-1	none	_	_
20	suppressed	_	_	VBN	O	-1	none	_	_
21	at	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	level	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	phenomenon	_	_	NN	O	-1	none	_	_
29	termed	_	_	VBN	O	-1	none	_	_
30	extinction	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	fusion	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	HeLa	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	either	_	_	CC	O	-1	none	_	_
11	diploid	_	_	JJ	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	tetraploid	_	_	JJ	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	Daudi	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	results	_	_	VBZ	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	widespread	_	_	JJ	O	-1	none	_	_
22	extinction	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	several	_	_	JJ	O	-1	none	_	_
25	other	_	_	JJ	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	encoded	_	_	VBN	O	-1	none	_	_
29	genes	_	_	NNS	O	-1	none	_	_
30	that	_	_	WDT	O	-1	none	_	_
31	are	_	_	VBP	O	-1	none	_	_
32	expressed	_	_	VBN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	cell	_	_	NN	O	-1	none	_	_
37	specific	_	_	JJ	O	-1	none	_	_
38	manner	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	controls	_	_	NNS	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	unaffected	_	_	JJ	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	molecular	_	_	JJ	O	-1	none	_	_
6	mechanism	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	s	_	_	NNS	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	underlying	_	_	VBG	O	-1	none	_	_
11	Ig	_	_	NN	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	extinction	_	_	NN	O	-1	none	_	_
14	can	_	_	MD	O	-1	none	_	_
15	be	_	_	VB	O	-1	none	_	_
16	explained	_	_	VBN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	least	_	_	JJS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	part	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	lack	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factors	_	_	NNS	O	-1	none	_	_
29	that	_	_	WDT	O	-1	none	_	_
30	are	_	_	VBP	O	-1	none	_	_
31	essential	_	_	JJ	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	Ig	_	_	NN	O	-1	none	_	_
34	gene	_	_	NN	O	-1	none	_	_
35	transcription	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	either	_	_	RB	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	produced	_	_	VBN	O	-1	none	_	_
8	due	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	block	_	_	VB	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	their	_	_	PRP$	O	-1	none	_	_
15	respective	_	_	JJ	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	Oct-2	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	OBF-1	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	PU	_	_	NN	Protein	23	multitoken	_	_
23	.1	_	_	CD	Protein	0	root	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	are	_	_	VBP	O	-1	none	_	_
28	rendered	_	_	VBN	O	-1	none	_	_
29	inactive	_	_	JJ	O	-1	none	_	_
30	posttranslationally	_	_	RB	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	NF-kappa	_	_	NN	O	-1	none	_	_
33	B	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	E47	_	_	NN	Protein	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	isolating	_	_	VBG	O	-1	none	_	_
3	Daudi	_	_	NN	O	-1	none	_	_
4	x	_	_	NN	O	-1	none	_	_
5	HeLa	_	_	NN	O	-1	none	_	_
6	heterokaryons	_	_	NNS	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	few	_	_	JJ	O	-1	none	_	_
9	hours	_	_	NNS	O	-1	none	_	_
10	after	_	_	IN	O	-1	none	_	_
11	fusion	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	we	_	_	PRP	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	studied	_	_	VBN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	initial	_	_	JJ	O	-1	none	_	_
18	fate	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	two	_	_	CD	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	specific	_	_	JJ	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	factors	_	_	NNS	O	-1	none	_	_
26	involved	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	Ig	_	_	NN	O	-1	none	_	_
29	gene	_	_	NN	O	-1	none	_	_
30	transcription	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	Oct-2	_	_	NN	Protein	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	NF-kappa	_	_	NN	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	report	_	_	NN	O	-1	none	_	_
3	provides	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	first	_	_	JJ	O	-1	none	_	_
6	demonstration	_	_	NN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	upon	_	_	IN	O	-1	none	_	_
9	fusion	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	HeLa	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	contents	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	expressed	_	_	VBD	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	factors	_	_	NNS	O	-1	none	_	_
23	are	_	_	VBP	O	-1	none	_	_
24	depleted	_	_	VBN	O	-1	none	_	_
25	within	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	few	_	_	JJ	O	-1	none	_	_
28	hours	_	_	NNS	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	kinetics	_	_	NNS	O	-1	none	_	_
31	that	_	_	WDT	O	-1	none	_	_
32	are	_	_	VBP	O	-1	none	_	_
33	as	_	_	IN	O	-1	none	_	_
34	fast	_	_	JJ	O	-1	none	_	_
35	or	_	_	CC	O	-1	none	_	_
36	faster	_	_	RBR	O	-1	none	_	_
37	than	_	_	IN	O	-1	none	_	_
38	that	_	_	DT	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	Ig	_	_	NN	O	-1	none	_	_
41	gene	_	_	NN	O	-1	none	_	_
42	extinction	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	extinguishing	_	_	VBG	O	-1	none	_	_
5	mechanism	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	effective	_	_	JJ	O	-1	none	_	_
8	very	_	_	RB	O	-1	none	_	_
9	early	_	_	RB	O	-1	none	_	_
10	after	_	_	IN	O	-1	none	_	_
11	fusion	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	suggest	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	extinction	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Ig	_	_	NN	O	-1	none	_	_
7	genes	_	_	NNS	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	part	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	global	_	_	JJ	O	-1	none	_	_
13	mechanism	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	suppresses	_	_	VBZ	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	differentiation	_	_	NN	O	-1	none	_	_
18	program	_	_	NN	O	-1	none	_	_
19	foreign	_	_	JJ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	HeLa	_	_	NN	O	-1	none	_	_
23	phenotype	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	lysosomal	_	_	JJ	Protein	6	multitoken	_	_
5	acid	_	_	NN	Protein	6	multitoken	_	_
6	lipase	_	_	NN	Protein	0	root	_	_
7	in	_	_	IN	O	-1	none	_	_
8	differentiating	_	_	VBG	O	-1	none	_	_
9	monocytes	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	mediated	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	Sp1	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	AP-2	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	lysosomal	_	_	JJ	Protein	4	multitoken	_	_
3	acid	_	_	NN	Protein	4	multitoken	_	_
4	lipase	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	LAL	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	hydrolase	_	_	NN	O	-1	none	_	_
11	required	_	_	VBN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	cleavage	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cholesteryl	_	_	NN	O	-1	none	_	_
17	esters	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	triglycerides	_	_	NNS	O	-1	none	_	_
20	derived	_	_	VBN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	plasma	_	_	NN	O	-1	none	_	_
23	lipoproteins	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	shown	_	_	VBN	O	-1	none	_	_
4	here	_	_	RB	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	during	_	_	IN	O	-1	none	_	_
7	monocyte	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	macrophage	_	_	NN	O	-1	none	_	_
10	differentiation	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	LAL	_	_	NN	Protein	-1	none	_	_
16	mRNA	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	induced	_	_	VBN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	dependent	_	_	JJ	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	C	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	synthesis	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	type	_	_	NN	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	increase	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	LAL	_	_	NN	Protein	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	further	_	_	RB	O	-1	none	_	_
11	investigated	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	THP-1	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	line	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	respect	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	transcriptional	_	_	JJ	O	-1	none	_	_
21	regulation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	monocytic	_	_	JJ	O	-1	none	_	_
4	leukemia	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	line	_	_	NN	O	-1	none	_	_
7	THP-1	_	_	NN	O	-1	none	_	_
8	differentiates	_	_	VBZ	O	-1	none	_	_
9	into	_	_	IN	O	-1	none	_	_
10	macrophage	_	_	NN	O	-1	none	_	_
11	like	_	_	IN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	when	_	_	WRB	O	-1	none	_	_
14	treated	_	_	VBN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	phorbol	_	_	NN	O	-1	none	_	_
17	esters	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	determine	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	cis	_	_	NN	O	-1	none	_	_
7	acting	_	_	VBG	O	-1	none	_	_
8	elements	_	_	NNS	O	-1	none	_	_
9	necessary	_	_	JJ	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	basal	_	_	JJ	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	phorbol	_	_	NN	O	-1	none	_	_
15	12-myristate-13	_	_	JJ	O	-1	none	_	_
16	acetate	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	PMA	_	_	NN	O	-1	none	_	_
19	)-enhanced	_	_	JJ	O	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	we	_	_	PRP	O	-1	none	_	_
24	performed	_	_	VBD	O	-1	none	_	_
25	deletion	_	_	NN	O	-1	none	_	_
26	analysis	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	reporter	_	_	NN	O	-1	none	_	_
29	gene	_	_	NN	O	-1	none	_	_
30	assays	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	PMA	_	_	NN	O	-1	none	_	_
3	responsive	_	_	JJ	O	-1	none	_	_
4	element	_	_	NN	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	identified	_	_	VBN	O	-1	none	_	_
8	between	_	_	IN	O	-1	none	_	_
9	-182	_	_	CD	O	-1	none	_	_
10	bp	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	-107	_	_	CD	O	-1	none	_	_
13	bp	_	_	NN	O	-1	none	_	_
14	upstream	_	_	JJ	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	major	_	_	JJ	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	start	_	_	NN	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Gel	_	_	NN	O	-1	none	_	_
2	mobility	_	_	NN	O	-1	none	_	_
3	shift	_	_	NN	O	-1	none	_	_
4	assays	_	_	NNS	O	-1	none	_	_
5	demonstrated	_	_	VBD	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	Sp1	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	AP-2	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	LAL	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	increased	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	PMA	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	THP-1	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Co-transfections	_	_	NNS	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	plasmids	_	_	NNS	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	Sp1	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	AP-2	_	_	NN	O	-1	none	_	_
9	further	_	_	RB	O	-1	none	_	_
10	emphasized	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	important	_	_	JJ	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	these	_	_	DT	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	factors	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	both	_	_	CC	O	-1	none	_	_
20	basal	_	_	JJ	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	PMA	_	_	NN	O	-1	none	_	_
23	enhanced	_	_	VBD	O	-1	none	_	_
24	LAL	_	_	NN	Protein	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	differentiation	_	_	NN	O	-1	none	_	_
6	dependent	_	_	JJ	O	-1	none	_	_
7	increase	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	lysosomal	_	_	JJ	Protein	11	multitoken	_	_
10	acid	_	_	NN	Protein	11	multitoken	_	_
11	lipase	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	LAL	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	THP-1	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	mediated	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	concerted	_	_	JJ	O	-1	none	_	_
24	action	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	Sp1	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	AP-2	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	monocytic	_	_	JJ	O	-1	none	_	_
4	differentiation	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	like	_	_	IN	O	-1	none	_	_
9	activities	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	immunodeficiency	_	_	NN	O	-1	none	_	_
13	virus	_	_	NN	O	-1	none	_	_
14	1	_	_	CD	O	-1	none	_	_
15	infection	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	myelomonoblastic	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	immunodeficiency	_	_	NN	O	-1	none	_	_
6	virus	_	_	NN	O	-1	none	_	_
7	1	_	_	CD	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	HIV-1	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	infection	_	_	NN	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	cellular	_	_	JJ	O	-1	none	_	_
14	differentiation	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	DNA	_	_	NN	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	have	_	_	VBP	O	-1	none	_	_
22	been	_	_	VBN	O	-1	none	_	_
23	investigated	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	new	_	_	JJ	O	-1	none	_	_
27	model	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	myeloid	_	_	JJ	O	-1	none	_	_
30	differentiation	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	PLB-985	_	_	NNP	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	represent	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	bipotential	_	_	JJ	O	-1	none	_	_
6	myelomonoblastic	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	population	_	_	NN	O	-1	none	_	_
9	capable	_	_	JJ	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	either	_	_	CC	O	-1	none	_	_
12	granulocytic	_	_	JJ	O	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	monocytic	_	_	JJ	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	after	_	_	IN	O	-1	none	_	_
17	induction	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	appropriate	_	_	JJ	O	-1	none	_	_
20	inducers	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	virtue	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	presence	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	CD4	_	_	NN	Protein	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	surface	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	PLB-985	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	chronically	_	_	RB	O	-1	none	_	_
17	infected	_	_	VBN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	HIV-1	_	_	NN	O	-1	none	_	_
20	strain	_	_	NN	O	-1	none	_	_
21	IIIB	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	PLB-IIIB	_	_	NNP	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	clearly	_	_	RB	O	-1	none	_	_
4	possessed	_	_	VBD	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	more	_	_	RBR	O	-1	none	_	_
7	monocytic	_	_	JJ	O	-1	none	_	_
8	phenotype	_	_	NN	O	-1	none	_	_
9	than	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	parental	_	_	JJ	O	-1	none	_	_
12	myeloblasts	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	determined	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	differential	_	_	JJ	O	-1	none	_	_
18	staining	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	increased	_	_	VBN	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	myeloid	_	_	JJ	O	-1	none	_	_
25	specific	_	_	JJ	O	-1	none	_	_
26	surface	_	_	NN	O	-1	none	_	_
27	markers	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	transcription	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	c-fms	_	_	NN	Protein	-1	none	_	_
34	proto-oncogene	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	inducible	_	_	JJ	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	tumor	_	_	NN	O	-1	none	_	_
9	necrosis	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	phorbol	_	_	NN	O	-1	none	_	_
13	myristate	_	_	NN	O	-1	none	_	_
14	acetate	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	PLB-985	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	PLB-IIIB	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	constitutive	_	_	JJ	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	novel	_	_	JJ	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	complex	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	detected	_	_	VBN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	composed	_	_	VBN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	proteins	_	_	NNS	O	-1	none	_	_
21	ranging	_	_	VBG	O	-1	none	_	_
22	between	_	_	IN	O	-1	none	_	_
23	70	_	_	CD	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	110	_	_	CD	O	-1	none	_	_
26	kD	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	proteins	_	_	NNS	O	-1	none	_	_
3	interacted	_	_	VBD	O	-1	none	_	_
4	specifically	_	_	RB	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	symmetric	_	_	JJ	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	site	_	_	NN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	interferon	_	_	NN	Protein	14	multitoken	_	_
14	beta	_	_	NN	Protein	0	root	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	IFN-beta	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	promoter	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Mutations	_	_	NNS	O	-1	none	_	_
2	affecting	_	_	VBG	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	5	_	_	CD	O	-1	none	_	_
5	'	_	_	''	O	-1	none	_	_
6	guanine	_	_	JJ	O	-1	none	_	_
7	residues	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	site	_	_	NN	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	unable	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	compete	_	_	VB	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	these	_	_	DT	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	related	_	_	JJ	O	-1	none	_	_
22	proteins	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Inducibility	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	endogenous	_	_	JJ	O	-1	none	_	_
4	IFN-beta	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	IFN-alpha	_	_	NN	Protein	-1	none	_	_
7	RNA	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	increased	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	PLB-IIIB	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	HIV-1	_	_	NN	O	-1	none	_	_
6	infection	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	myelomonoblastic	_	_	JJ	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	may	_	_	MD	O	-1	none	_	_
11	select	_	_	VB	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	more	_	_	RBR	O	-1	none	_	_
15	mature	_	_	JJ	O	-1	none	_	_
16	monocytic	_	_	JJ	O	-1	none	_	_
17	phenotype	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	unique	_	_	JJ	O	-1	none	_	_
21	subunit	_	_	NN	O	-1	none	_	_
22	associations	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	NF-kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	DNA	_	_	NN	O	-1	none	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	proteins	_	_	NNS	O	-1	none	_	_
29	may	_	_	MD	O	-1	none	_	_
30	contribute	_	_	VB	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	differential	_	_	JJ	O	-1	none	_	_
33	NF-kappa	_	_	NN	O	-1	none	_	_
34	B	_	_	NN	O	-1	none	_	_
35	mediated	_	_	VBN	O	-1	none	_	_
36	gene	_	_	NN	O	-1	none	_	_
37	expression	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Coexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B/Rel	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	Sp1	_	_	NN	Protein	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factors	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	immunodeficiency	_	_	NN	O	-1	none	_	_
12	virus	_	_	NN	O	-1	none	_	_
13	1	_	_	CD	O	-1	none	_	_
14	induced	_	_	VBN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	dendritic	_	_	JJ	O	-1	none	_	_
17	cell-T-cell	_	_	NN	O	-1	none	_	_
18	syncytia	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Productive	_	_	JJ	O	-1	none	_	_
2	infection	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	immunodeficiency	_	_	NN	O	-1	none	_	_
9	virus	_	_	NN	O	-1	none	_	_
10	1	_	_	CD	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	HIV-1	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	typically	_	_	RB	O	-1	none	_	_
15	requires	_	_	VBZ	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	stimulated	_	_	VBN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	antigens	_	_	NNS	O	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	mitogens	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	requirement	_	_	NN	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	attributed	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	synergizes	_	_	VBZ	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	constitutive	_	_	JJ	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	factor	_	_	NN	O	-1	none	_	_
23	Sp1	_	_	NN	Protein	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	drive	_	_	VB	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	HIV-1	_	_	NN	O	-1	none	_	_
28	promoter	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	vigorous	_	_	JJ	O	-1	none	_	_
8	replication	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	HIV-1	_	_	NN	O	-1	none	_	_
11	takes	_	_	VBZ	O	-1	none	_	_
12	place	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	nonactivated	_	_	JJ	O	-1	none	_	_
15	memory	_	_	NN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	syncytium	_	_	NN	O	-1	none	_	_
20	formation	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	dendritic	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	DCs	_	_	NNS	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	syncytia	_	_	NNS	O	-1	none	_	_
3	lack	_	_	VBP	O	-1	none	_	_
4	activated	_	_	VBN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	determined	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	absence	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	staining	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	Ki-67	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	cycle	_	_	NN	O	-1	none	_	_
17	antigen	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	Sp1	_	_	NN	Protein	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	therefore	_	_	RB	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	analyzed	_	_	VBN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	isolated	_	_	VBN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	DCs	_	_	NNS	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	humans	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	mice	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	used	_	_	VBN	O	-1	none	_	_
4	immunolabeling	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	Western	_	_	NN	O	-1	none	_	_
7	blot	_	_	NN	O	-1	none	_	_
8	analysis	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	electrophoretic	_	_	JJ	O	-1	none	_	_
12	mobility	_	_	NN	O	-1	none	_	_
13	shift	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	supershift	_	_	NN	O	-1	none	_	_
16	assays	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	T	_	_	NN	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	lack	_	_	VBP	O	-1	none	_	_
4	active	_	_	JJ	O	-1	none	_	_
5	NF-kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	but	_	_	CC	O	-1	none	_	_
8	express	_	_	VBP	O	-1	none	_	_
9	Sp1	_	_	NN	Protein	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	expected	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	DCs	_	_	NNS	O	-1	none	_	_
2	express	_	_	VBP	O	-1	none	_	_
3	high	_	_	JJ	O	-1	none	_	_
4	levels	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	all	_	_	DT	O	-1	none	_	_
7	known	_	_	JJ	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Rel	_	_	NN	O	-1	none	_	_
12	proteins	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	residing	_	_	VBG	O	-1	none	_	_
17	primarily	_	_	RB	O	-1	none	_	_
18	within	_	_	IN	O	-1	none	_	_
19	RelB	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	p50	_	_	NN	Protein	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	p65	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	DCs	_	_	NNS	O	-1	none	_	_
4	lack	_	_	VBP	O	-1	none	_	_
5	Sp1	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	may	_	_	MD	O	-1	none	_	_
9	explain	_	_	VB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	failure	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	HIV-1	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	replicate	_	_	VB	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	purified	_	_	VBN	O	-1	none	_	_
18	DCs	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Coexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	Sp1	_	_	NN	Protein	-1	none	_	_
7	occurs	_	_	VBZ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	heterologous	_	_	JJ	O	-1	none	_	_
11	DC-T-cell	_	_	NN	O	-1	none	_	_
12	syncytia	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	induced	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	HIV-1	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	HIV-1-induced	_	_	JJ	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	fusion	_	_	NN	O	-1	none	_	_
6	brings	_	_	VBZ	O	-1	none	_	_
7	together	_	_	RB	O	-1	none	_	_
8	factors	_	_	NNS	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	upregulate	_	_	VBP	O	-1	none	_	_
11	virus	_	_	NN	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	DCs	_	_	NNS	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	memory	_	_	NN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	frequently	_	_	RB	O	-1	none	_	_
8	traffic	_	_	VBP	O	-1	none	_	_
9	together	_	_	RB	O	-1	none	_	_
10	in	_	_	FW	O	-1	none	_	_
11	situ	_	_	FW	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	these	_	_	DT	O	-1	none	_	_
14	unusual	_	_	JJ	O	-1	none	_	_
15	heterologous	_	_	JJ	O	-1	none	_	_
16	syncytia	_	_	NN	O	-1	none	_	_
17	could	_	_	MD	O	-1	none	_	_
18	develop	_	_	VB	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	infected	_	_	JJ	O	-1	none	_	_
21	individuals	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	lead	_	_	VB	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	chronic	_	_	JJ	O	-1	none	_	_
26	HIV-1	_	_	NN	O	-1	none	_	_
27	replication	_	_	NN	O	-1	none	_	_
28	without	_	_	IN	O	-1	none	_	_
29	ostensible	_	_	JJ	O	-1	none	_	_
30	immune	_	_	JJ	O	-1	none	_	_
31	stimulation	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Costimulation	_	_	NN	O	-1	none	_	_
2	requirement	_	_	NN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	AP-1	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transcriptional	_	_	JJ	O	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	requires	_	_	VBZ	O	-1	none	_	_
9	T-cell	_	_	NN	O	-1	none	_	_
10	costimulation	_	_	NN	O	-1	none	_	_
11	delivered	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	TCR	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	auxiliary	_	_	NN	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	CD28	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	participate	_	_	VBP	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	among	_	_	IN	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	AP-1-like	_	_	JJ	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B.	_	_	NNP	O	-1	none	_	_
18	Protein	_	_	NN	O	-1	none	_	_
19	phosphorylation	_	_	NN	O	-1	none	_	_
20	has	_	_	VBZ	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	important	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	regulation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	these	_	_	DT	O	-1	none	_	_
29	two	_	_	CD	O	-1	none	_	_
30	factors	_	_	NNS	O	-1	none	_	_
31	:	_	_	:	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	1	_	_	CD	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	it	_	_	PRP	O	-1	none	_	_
36	induces	_	_	VBZ	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	transactivating	_	_	VBG	O	-1	none	_	_
39	capacity	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	AP-1	_	_	NN	O	-1	none	_	_
43	protein	_	_	NN	O	-1	none	_	_
44	c-Jun	_	_	NN	Protein	-1	none	_	_
45	;	_	_	:	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	(	_	_	-LRB-	O	-1	none	_	_
48	2	_	_	CD	O	-1	none	_	_
49	)	_	_	-RRB-	O	-1	none	_	_
50	it	_	_	PRP	O	-1	none	_	_
51	is	_	_	VBZ	O	-1	none	_	_
52	involved	_	_	VBN	O	-1	none	_	_
53	in	_	_	IN	O	-1	none	_	_
54	the	_	_	DT	O	-1	none	_	_
55	release	_	_	NN	O	-1	none	_	_
56	of	_	_	IN	O	-1	none	_	_
57	the	_	_	DT	O	-1	none	_	_
58	cytoplasmic	_	_	JJ	O	-1	none	_	_
59	inhibitor	_	_	NN	O	-1	none	_	_
60	,	_	_	,	O	-1	none	_	_
61	I	_	_	NN	O	-1	none	_	_
62	kappa	_	_	NN	O	-1	none	_	_
63	B	_	_	NN	O	-1	none	_	_
64	,	_	_	,	O	-1	none	_	_
65	from	_	_	IN	O	-1	none	_	_
66	NF-kappa	_	_	NN	O	-1	none	_	_
67	B	_	_	NN	O	-1	none	_	_
68	,	_	_	,	O	-1	none	_	_
69	allowing	_	_	VBG	O	-1	none	_	_
70	translocation	_	_	NN	O	-1	none	_	_
71	of	_	_	IN	O	-1	none	_	_
72	the	_	_	DT	O	-1	none	_	_
73	latter	_	_	JJ	O	-1	none	_	_
74	into	_	_	IN	O	-1	none	_	_
75	the	_	_	DT	O	-1	none	_	_
76	nucleus	_	_	NN	O	-1	none	_	_
77	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	recently	_	_	RB	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	both	_	_	CC	O	-1	none	_	_
7	phosphorylation	_	_	NN	O	-1	none	_	_
8	processes	_	_	NNS	O	-1	none	_	_
9	require	_	_	VBP	O	-1	none	_	_
10	T-cell	_	_	NN	O	-1	none	_	_
11	costimulation	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	activated	_	_	VBN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	kinetics	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	two	_	_	CD	O	-1	none	_	_
13	phosphorylation	_	_	NN	O	-1	none	_	_
14	events	_	_	NNS	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	essentially	_	_	RB	O	-1	none	_	_
17	similar	_	_	JJ	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	According	_	_	VBG	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	our	_	_	PRP$	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	however	_	_	RB	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	kinases	_	_	NNS	O	-1	none	_	_
10	responsible	_	_	JJ	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	two	_	_	CD	O	-1	none	_	_
14	processes	_	_	NNS	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	distinct	_	_	JJ	O	-1	none	_	_
17	entities	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	TPCK	_	_	NN	O	-1	none	_	_
3	inhibits	_	_	VBZ	O	-1	none	_	_
4	phosphorylation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	I	_	_	NN	O	-1	none	_	_
7	kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	consequently	_	_	RB	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	it	_	_	PRP	O	-1	none	_	_
19	markedly	_	_	RB	O	-1	none	_	_
20	enhances	_	_	VBZ	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	JNK	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	MAP	_	_	NN	O	-1	none	_	_
28	kinase	_	_	NN	O	-1	none	_	_
29	related	_	_	JJ	O	-1	none	_	_
30	kinase	_	_	NN	O	-1	none	_	_
31	that	_	_	WDT	O	-1	none	_	_
32	phosphorylates	_	_	VBZ	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	transactivation	_	_	NN	O	-1	none	_	_
35	domain	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	c-Jun	_	_	NN	Protein	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	therefore	_	_	RB	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	propose	_	_	VBP	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	scheme	_	_	NN	O	-1	none	_	_
9	presented	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	FIGURE	_	_	NN	O	-1	none	_	_
12	3	_	_	CD	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	T-cell	_	_	NN	O	-1	none	_	_
15	costimulation	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Costimulation	_	_	NN	O	-1	none	_	_
2	results	_	_	VBZ	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	pathway	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	leads	_	_	VBZ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	simultaneous	_	_	JJ	O	-1	none	_	_
15	induction	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	two	_	_	CD	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factors	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	AP-1	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	NF-kappa	_	_	NN	O	-1	none	_	_
25	B.	_	_	NNP	O	-1	none	_	_
26	Integration	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	signals	_	_	NNS	O	-1	none	_	_
30	generated	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	TCR	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	CD28	_	_	NN	Protein	-1	none	_	_
35	engagement	_	_	NN	O	-1	none	_	_
36	occurs	_	_	VBZ	O	-1	none	_	_
37	along	_	_	IN	O	-1	none	_	_
38	this	_	_	DT	O	-1	none	_	_
39	pathway	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	which	_	_	WDT	O	-1	none	_	_
42	then	_	_	RB	O	-1	none	_	_
43	bifurcates	_	_	VBZ	O	-1	none	_	_
44	to	_	_	TO	O	-1	none	_	_
45	induce	_	_	VB	O	-1	none	_	_
46	I	_	_	NN	O	-1	none	_	_
47	kappa	_	_	NN	O	-1	none	_	_
48	B	_	_	NN	O	-1	none	_	_
49	phosphorylation	_	_	NN	O	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	NF-kappa	_	_	NN	O	-1	none	_	_
52	B	_	_	NN	O	-1	none	_	_
53	activation	_	_	NN	O	-1	none	_	_
54	on	_	_	IN	O	-1	none	_	_
55	the	_	_	DT	O	-1	none	_	_
56	one	_	_	CD	O	-1	none	_	_
57	hand	_	_	NN	O	-1	none	_	_
58	,	_	_	,	O	-1	none	_	_
59	and	_	_	CC	O	-1	none	_	_
60	JNK	_	_	NN	O	-1	none	_	_
61	activation	_	_	NN	O	-1	none	_	_
62	and	_	_	CC	O	-1	none	_	_
63	c-Jun	_	_	NN	Protein	-1	none	_	_
64	phosphorylation	_	_	NN	O	-1	none	_	_
65	on	_	_	IN	O	-1	none	_	_
66	the	_	_	DT	O	-1	none	_	_
67	other	_	_	JJ	O	-1	none	_	_
68	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	currently	_	_	RB	O	-1	none	_	_
4	engaged	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	defining	_	_	VBG	O	-1	none	_	_
7	where	_	_	WRB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	two	_	_	CD	O	-1	none	_	_
10	signals	_	_	NNS	O	-1	none	_	_
11	integrate	_	_	VBP	O	-1	none	_	_
12	along	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	AP-1	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	pathway	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Anti-CD2	_	_	NNP	Protein	-1	none	_	_
2	receptor	_	_	NN	O	-1	none	_	_
3	antibodies	_	_	NNS	O	-1	none	_	_
4	activate	_	_	VBP	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	HIV	_	_	NN	O	-1	none	_	_
7	long	_	_	JJ	O	-1	none	_	_
8	terminal	_	_	JJ	O	-1	none	_	_
9	repeat	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	CD2	_	_	NN	Protein	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	lymphocyte	_	_	NN	O	-1	none	_	_
5	glycoprotein	_	_	NN	O	-1	none	_	_
6	surface	_	_	NN	O	-1	none	_	_
7	molecule	_	_	NN	O	-1	none	_	_
8	mediates	_	_	VBZ	O	-1	none	_	_
9	both	_	_	DT	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	adhesion	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	two	_	_	CD	O	-1	none	_	_
20	processes	_	_	NNS	O	-1	none	_	_
21	that	_	_	WDT	O	-1	none	_	_
22	are	_	_	VBP	O	-1	none	_	_
23	involved	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	spread	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	HIV	_	_	NN	O	-1	none	_	_
29	infection	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	chronically	_	_	RB	O	-1	none	_	_
4	HIV	_	_	NN	O	-1	none	_	_
5	infected	_	_	JJ	O	-1	none	_	_
6	PBMC	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	anti-CD2	_	_	JJ	Protein	-1	none	_	_
9	mAb	_	_	NN	O	-1	none	_	_
10	has	_	_	VBZ	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	shown	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	induce	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	infectious	_	_	JJ	O	-1	none	_	_
19	virus	_	_	NN	O	-1	none	_	_
20	from	_	_	IN	O	-1	none	_	_
21	these	_	_	DT	O	-1	none	_	_
22	cultures	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	investigated	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	mechanisms	_	_	NNS	O	-1	none	_	_
8	whereby	_	_	WRB	O	-1	none	_	_
9	anti-CD2	_	_	JJ	Protein	-1	none	_	_
10	antibodies	_	_	NNS	O	-1	none	_	_
11	stimulate	_	_	VBP	O	-1	none	_	_
12	viral	_	_	JJ	O	-1	none	_	_
13	production	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	transiently	_	_	RB	O	-1	none	_	_
7	transfected	_	_	VBN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	lymphocytes	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	anti-CD2	_	_	JJ	Protein	-1	none	_	_
12	antibodies	_	_	NNS	O	-1	none	_	_
13	results	_	_	VBZ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	HIV	_	_	NN	O	-1	none	_	_
19	long	_	_	JJ	O	-1	none	_	_
20	terminal	_	_	JJ	O	-1	none	_	_
21	repeat	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	CAT	_	_	NN	Protein	-1	none	_	_
4	assays	_	_	NNS	O	-1	none	_	_
5	using	_	_	VBG	O	-1	none	_	_
6	mutated	_	_	VBN	O	-1	none	_	_
7	HIV	_	_	NN	O	-1	none	_	_
8	long	_	_	JJ	O	-1	none	_	_
9	terminal	_	_	JJ	O	-1	none	_	_
10	repeat-CAT	_	_	NN	Protein	-1	none	_	_
11	constructs	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	gel	_	_	NN	O	-1	none	_	_
14	shift	_	_	NN	O	-1	none	_	_
15	assays	_	_	NNS	O	-1	none	_	_
16	demonstrate	_	_	VBP	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	dependent	_	_	JJ	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	NF-kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	enhancer	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	interaction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	CD2	_	_	NN	Protein	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	its	_	_	PRP$	O	-1	none	_	_
10	natural	_	_	JJ	O	-1	none	_	_
11	ligand	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	LFA-3	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	play	_	_	VB	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	role	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	regulation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	HIV	_	_	NN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Possible	_	_	JJ	O	-1	none	_	_
2	differences	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	mechanism	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	s	_	_	VBZ	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	action	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	different	_	_	JJ	O	-1	none	_	_
13	glucocorticoid	_	_	NN	O	-1	none	_	_
14	hormone	_	_	NN	O	-1	none	_	_
15	compounds	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Different	_	_	JJ	O	-1	none	_	_
2	glucocorticoid	_	_	NN	O	-1	none	_	_
3	hormones	_	_	NNS	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	GCH	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	show	_	_	VBP	O	-1	none	_	_
8	differences	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	intensity	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	kinetics	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	their	_	_	PRP$	O	-1	none	_	_
18	immunomodulating	_	_	JJ	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	s	_	_	VBZ	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	action	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	GCH	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	under	_	_	IN	O	-1	none	_	_
12	investigation	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	has	_	_	VBZ	O	-1	none	_	_
17	been	_	_	VBN	O	-1	none	_	_
18	noted	_	_	VBN	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	they	_	_	PRP	O	-1	none	_	_
21	exert	_	_	VBP	O	-1	none	_	_
22	immune	_	_	JJ	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	via	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	genomic	_	_	JJ	O	-1	none	_	_
27	pathway	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	studied	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effects	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	prednisone	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	PDN	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	deflazacort	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	DFC	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	dexamethasone	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	DXM	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	production	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	cytokines	_	_	NNS	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	IL-2	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	IL-6	_	_	NN	Protein	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	TNF-alpha	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	IL-10	_	_	NN	Protein	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	by	_	_	IN	O	-1	none	_	_
37	peripheral	_	_	JJ	O	-1	none	_	_
38	T	_	_	NN	O	-1	none	_	_
39	lymphocytes	_	_	NNS	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	effects	_	_	NNS	O	-1	none	_	_
44	on	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	inhibition	_	_	NN	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	NF-kB	_	_	NN	O	-1	none	_	_
49	DNA	_	_	NN	O	-1	none	_	_
50	binding	_	_	NN	O	-1	none	_	_
51	activity	_	_	NN	O	-1	none	_	_
52	by	_	_	IN	O	-1	none	_	_
53	activated	_	_	VBN	O	-1	none	_	_
54	Jurkat	_	_	NN	O	-1	none	_	_
55	cell	_	_	NN	O	-1	none	_	_
56	line	_	_	NN	O	-1	none	_	_
57	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	obtained	_	_	VBN	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	three	_	_	CD	O	-1	none	_	_
8	GCH	_	_	NN	O	-1	none	_	_
9	molecules	_	_	NNS	O	-1	none	_	_
10	exert	_	_	VBP	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	immunosuppression	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	cytokine	_	_	NN	O	-1	none	_	_
15	production	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	strong	_	_	JJ	O	-1	none	_	_
22	decrease	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	nuclear	_	_	JJ	O	-1	none	_	_
26	translocation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	NF-kB	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	Jurkat	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	;	_	_	:	O	-1	none	_	_
33	moreover	_	_	RB	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	a	_	_	DT	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	not	_	_	RB	O	-1	none	_	_
39	all	_	_	PDT	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	cytokines	_	_	NNS	O	-1	none	_	_
42	investigated	_	_	VBN	O	-1	none	_	_
43	were	_	_	VBD	O	-1	none	_	_
44	affected	_	_	VBN	O	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	not	_	_	RB	O	-1	none	_	_
48	with	_	_	IN	O	-1	none	_	_
49	the	_	_	DT	O	-1	none	_	_
50	same	_	_	JJ	O	-1	none	_	_
51	intensity	_	_	NN	O	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	by	_	_	IN	O	-1	none	_	_
54	the	_	_	DT	O	-1	none	_	_
55	three	_	_	CD	O	-1	none	_	_
56	GCH	_	_	NN	O	-1	none	_	_
57	and	_	_	CC	O	-1	none	_	_
58	(	_	_	-LRB-	O	-1	none	_	_
59	b	_	_	NN	O	-1	none	_	_
60	)	_	_	-RRB-	O	-1	none	_	_
61	DXM	_	_	NN	O	-1	none	_	_
62	inhibited	_	_	VBD	O	-1	none	_	_
63	the	_	_	DT	O	-1	none	_	_
64	binding	_	_	NN	O	-1	none	_	_
65	activity	_	_	NN	O	-1	none	_	_
66	of	_	_	IN	O	-1	none	_	_
67	NF-kB	_	_	NN	O	-1	none	_	_
68	less	_	_	RBR	O	-1	none	_	_
69	than	_	_	IN	O	-1	none	_	_
70	that	_	_	DT	O	-1	none	_	_
71	of	_	_	IN	O	-1	none	_	_
72	DFC	_	_	NN	O	-1	none	_	_
73	and	_	_	CC	O	-1	none	_	_
74	PDN	_	_	NN	O	-1	none	_	_
75	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	agreement	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	concept	_	_	NN	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	different	_	_	JJ	O	-1	none	_	_
11	GCH	_	_	NN	O	-1	none	_	_
12	compounds	_	_	NNS	O	-1	none	_	_
13	might	_	_	MD	O	-1	none	_	_
14	differ	_	_	VB	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	their	_	_	PRP$	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	affinity	_	_	NN	O	-1	none	_	_
20	properties	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	tissue	_	_	NN	O	-1	none	_	_
23	specific	_	_	JJ	O	-1	none	_	_
24	metabolism	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	interaction	_	_	NN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	factor	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	which	_	_	WDT	O	-1	none	_	_
5	early	_	_	JJ	O	-1	none	_	_
6	lymphoid	_	_	JJ	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	selectively	_	_	RB	O	-1	none	_	_
10	transformed	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	v-Abl	_	_	NN	Protein	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	currently	_	_	RB	O	-1	none	_	_
15	unknown	_	_	JJ	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	constitutive	_	_	JJ	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IL-4	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	IL-7	_	_	NN	Protein	-1	none	_	_
11	signaling	_	_	NN	O	-1	none	_	_
12	pathways	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	measured	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	Janus	_	_	NN	Protein	25	multitoken	_	_
20	protein	_	_	NN	Protein	25	multitoken	_	_
21	kinase	_	_	NN	Protein	25	multitoken	_	_
22	(	_	_	-LRB-	Protein	25	multitoken	_	_
23	JAK	_	_	NN	Protein	25	multitoken	_	_
24	)	_	_	-RRB-	Protein	25	multitoken	_	_
25	1	_	_	CD	Protein	0	root	_	_
26	,	_	_	,	O	-1	none	_	_
27	JAK3	_	_	NN	Protein	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	STAT5	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	STAT6	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	pre-B	_	_	JJ	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	transformed	_	_	VBN	O	-1	none	_	_
38	by	_	_	IN	O	-1	none	_	_
39	v-Abl	_	_	NN	Protein	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	determine	_	_	VB	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	cytokine	_	_	NN	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	pathways	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	v-Abl	_	_	NN	Protein	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	important	_	_	JJ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	cellular	_	_	JJ	O	-1	none	_	_
17	events	_	_	NNS	O	-1	none	_	_
18	induced	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	Abelson	_	_	NN	O	-1	none	_	_
22	murine	_	_	JJ	O	-1	none	_	_
23	leukemia	_	_	NN	O	-1	none	_	_
24	virus	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	effects	_	_	NNS	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	IL-4	_	_	NN	Protein	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	IL-7	_	_	NN	Protein	-1	none	_	_
32	on	_	_	IN	O	-1	none	_	_
33	pre-B	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	transformed	_	_	VBN	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	temperature	_	_	NN	O	-1	none	_	_
39	sensitive	_	_	JJ	O	-1	none	_	_
40	v-Abl	_	_	NN	Protein	-1	none	_	_
41	mutant	_	_	NN	O	-1	none	_	_
42	were	_	_	VBD	O	-1	none	_	_
43	examined	_	_	VBN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	IL-4	_	_	NN	Protein	-1	none	_	_
3	had	_	_	VBD	O	-1	none	_	_
4	little	_	_	JJ	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	no	_	_	DT	O	-1	none	_	_
7	effect	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	IL-7	_	_	NN	Protein	-1	none	_	_
10	delayed	_	_	VBD	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	apoptosis	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	cycle	_	_	NN	O	-1	none	_	_
17	arrest	_	_	NN	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	occur	_	_	VBP	O	-1	none	_	_
20	upon	_	_	IN	O	-1	none	_	_
21	v-Abl	_	_	NN	O	-1	none	_	_
22	kinase	_	_	NN	O	-1	none	_	_
23	inactivation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	IL-7	_	_	NNP	Protein	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	delayed	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	decreases	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	levels	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	c-Myc	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	Bcl-2	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Bcl-xL	_	_	NN	Protein	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	occur	_	_	VBP	O	-1	none	_	_
18	upon	_	_	IN	O	-1	none	_	_
19	loss	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	v-Abl	_	_	NN	O	-1	none	_	_
22	kinase	_	_	NN	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	identify	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	potential	_	_	JJ	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	IL-7	_	_	NN	Protein	-1	none	_	_
9	signaling	_	_	NN	O	-1	none	_	_
10	pathways	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	transformation	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	v-Abl	_	_	NN	Protein	-1	none	_	_
15	while	_	_	IN	O	-1	none	_	_
16	demonstrating	_	_	VBG	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	combination	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	IL-4	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	IL-7	_	_	NN	Protein	-1	none	_	_
24	signaling	_	_	NN	O	-1	none	_	_
25	can	_	_	MD	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	substitute	_	_	VB	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	active	_	_	JJ	O	-1	none	_	_
31	v-Abl	_	_	NN	Protein	-1	none	_	_
32	kinase	_	_	NN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	transformed	_	_	VBN	O	-1	none	_	_
35	pre-B	_	_	JJ	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NF-kappaB	_	_	NN	O	-1	none	_	_
5	transcription	_	_	NN	O	-1	none	_	_
6	factor	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	T-lymphocytic	_	_	JJ	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	line	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	hypochlorous	_	_	JJ	O	-1	none	_	_
14	acid	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Reactive	_	_	JJ	O	-1	none	_	_
2	oxygen	_	_	NN	O	-1	none	_	_
3	species	_	_	NNS	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	ROS	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	such	_	_	JJ	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	hydrogen	_	_	NN	O	-1	none	_	_
10	peroxide	_	_	NN	O	-1	none	_	_
11	serve	_	_	VBP	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	second	_	_	JJ	O	-1	none	_	_
14	messengers	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	induction	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	NF-kappaB	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	hence	_	_	RB	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	replication	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	human	_	_	NN	O	-1	none	_	_
33	immunodeficiency	_	_	NN	O	-1	none	_	_
34	virus	_	_	NN	O	-1	none	_	_
35	type	_	_	NN	O	-1	none	_	_
36	1	_	_	CD	O	-1	none	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	HIV-1	_	_	NN	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	human	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	During	_	_	IN	O	-1	none	_	_
2	inflammatory	_	_	JJ	O	-1	none	_	_
3	reactions	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	many	_	_	JJ	O	-1	none	_	_
6	oxidative	_	_	JJ	O	-1	none	_	_
7	species	_	_	NNS	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	produced	_	_	VBN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	one	_	_	CD	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	hypochlorous	_	_	JJ	O	-1	none	_	_
16	acid	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	HOCl	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	responsible	_	_	JJ	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	microbicidal	_	_	JJ	O	-1	none	_	_
27	effects	_	_	NNS	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	activated	_	_	VBN	O	-1	none	_	_
30	human	_	_	NN	O	-1	none	_	_
31	polymorphonuclear	_	_	JJ	O	-1	none	_	_
32	leukocytes	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	T-lymphocytic	_	_	JJ	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	line	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	micromolar	_	_	JJ	O	-1	none	_	_
9	concentrations	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	HOCl	_	_	NN	O	-1	none	_	_
12	promoted	_	_	VBD	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	appearance	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	factor	_	_	NN	O	-1	none	_	_
18	NF-kappaB	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	heterodimer	_	_	NN	O	-1	none	_	_
22	p50	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	p65	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	nucleus	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	even	_	_	RB	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	absence	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	de	_	_	FW	O	-1	none	_	_
39	novo	_	_	FW	O	-1	none	_	_
40	protein	_	_	NN	O	-1	none	_	_
41	synthesis	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	NF-kappaB	_	_	NN	O	-1	none	_	_
7	inhibitory	_	_	JJ	O	-1	none	_	_
8	subunits	_	_	NNS	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	IkappaB	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	demonstrated	_	_	VBD	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	IkappaB-alpha	_	_	NN	Protein	-1	none	_	_
16	proteolysis	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	p105	_	_	NN	Protein	-1	none	_	_
19	processing	_	_	NN	O	-1	none	_	_
20	were	_	_	VBD	O	-1	none	_	_
21	induced	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	treatment	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	NF-kappaB	_	_	NN	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	very	_	_	RB	O	-1	none	_	_
5	effective	_	_	JJ	O	-1	none	_	_
6	when	_	_	WRB	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	subjected	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	hyperthermia	_	_	NN	O	-1	none	_	_
12	before	_	_	IN	O	-1	none	_	_
13	being	_	_	VBG	O	-1	none	_	_
14	treated	_	_	VBN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	HOCl	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Various	_	_	JJ	O	-1	none	_	_
2	antioxidants	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	such	_	_	JJ	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	pyrrolidine	_	_	NN	O	-1	none	_	_
7	dithiocarbamate	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	p-bromophenacyl-bromide	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	nordihydroguaiaretic	_	_	JJ	O	-1	none	_	_
12	acid	_	_	NN	O	-1	none	_	_
13	could	_	_	MD	O	-1	none	_	_
14	strongly	_	_	RB	O	-1	none	_	_
15	reduce	_	_	VB	O	-1	none	_	_
16	NF-kappaB	_	_	NN	O	-1	none	_	_
17	translocation	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	demonstrating	_	_	VBG	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	importance	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	oxidative	_	_	JJ	O	-1	none	_	_
24	species	_	_	NNS	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	transduction	_	_	NN	O	-1	none	_	_
28	mechanism	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	ACH-2	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	treated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	HOCl	_	_	NN	O	-1	none	_	_
8	or	_	_	CC	O	-1	none	_	_
9	H2O2	_	_	NN	O	-1	none	_	_
10	released	_	_	VBN	O	-1	none	_	_
11	tumour	_	_	NN	Protein	13	multitoken	_	_
12	necrosis	_	_	NN	Protein	13	multitoken	_	_
13	factor-alpha	_	_	NN	Protein	0	root	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	TNF-alpha	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	supernatants	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	importance	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TNF-alpha	_	_	NN	Protein	-1	none	_	_
5	release	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	NF-kappaB	_	_	NN	O	-1	none	_	_
8	induction	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	HOCl	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	H2O2	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	demonstrated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	fact	_	_	NN	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	:	_	_	:	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	1	_	_	CD	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	nuclear	_	_	JJ	O	-1	none	_	_
25	appearance	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	NF-kappaB	_	_	NN	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	promoted	_	_	VBN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	untreated	_	_	JJ	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	;	_	_	:	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	2	_	_	CD	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	synergism	_	_	NN	O	-1	none	_	_
39	between	_	_	IN	O	-1	none	_	_
40	TNF-alpha	_	_	NN	Protein	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	HOCl	_	_	NN	O	-1	none	_	_
43	was	_	_	VBD	O	-1	none	_	_
44	detected	_	_	VBN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Collectively	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	HOCl	_	_	NN	O	-1	none	_	_
8	should	_	_	MD	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	considered	_	_	VBN	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	oxidative	_	_	JJ	O	-1	none	_	_
14	species	_	_	NNS	O	-1	none	_	_
15	capable	_	_	JJ	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	inducing	_	_	VBG	O	-1	none	_	_
18	NF-kappaB	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	T-lymphocytic	_	_	JJ	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	line	_	_	NN	O	-1	none	_	_
24	through	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	transduction	_	_	NN	O	-1	none	_	_
27	mechanism	_	_	NN	O	-1	none	_	_
28	involving	_	_	VBG	O	-1	none	_	_
29	ROS	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	having	_	_	VBG	O	-1	none	_	_
33	a	_	_	DT	O	-1	none	_	_
34	long-distance	_	_	JJ	O	-1	none	_	_
35	effect	_	_	NN	O	-1	none	_	_
36	through	_	_	IN	O	-1	none	_	_
37	subsequent	_	_	JJ	O	-1	none	_	_
38	TNF-alpha	_	_	NN	Protein	-1	none	_	_
39	release	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	oncogene	_	_	NN	O	-1	none	_	_
5	product	_	_	NN	O	-1	none	_	_
6	latent	_	_	JJ	Protein	9	multitoken	_	_
7	membrane	_	_	NN	Protein	9	multitoken	_	_
8	protein	_	_	NN	Protein	9	multitoken	_	_
9	1	_	_	CD	Protein	0	root	_	_
10	engages	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	tumor	_	_	NN	Protein	15	multitoken	_	_
13	necrosis	_	_	NN	Protein	15	multitoken	_	_
14	factor	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	associated	_	_	VBN	O	-1	none	_	_
17	death	_	_	NN	O	-1	none	_	_
18	domain	_	_	NN	O	-1	none	_	_
19	protein	_	_	NN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	mediate	_	_	VB	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	lymphocyte	_	_	NN	O	-1	none	_	_
24	growth	_	_	NN	O	-1	none	_	_
25	transformation	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	activate	_	_	VBP	O	-1	none	_	_
28	NF-kappaB	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	latent	_	_	JJ	Protein	7	multitoken	_	_
5	membrane	_	_	NN	Protein	7	multitoken	_	_
6	protein	_	_	NN	Protein	7	multitoken	_	_
7	1	_	_	CD	Protein	0	root	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	LMP1	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	essential	_	_	JJ	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	transformation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	into	_	_	IN	O	-1	none	_	_
20	lymphoblastoid	_	_	JJ	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	lines	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	consistent	_	_	JJ	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	model	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	LMP1	_	_	NN	Protein	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	constitutively	_	_	RB	O	-1	none	_	_
13	activated	_	_	VBN	O	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	transduces	_	_	VBZ	O	-1	none	_	_
17	signals	_	_	NNS	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	transformation	_	_	NN	O	-1	none	_	_
20	through	_	_	IN	O	-1	none	_	_
21	its	_	_	PRP$	O	-1	none	_	_
22	carboxyl-terminal	_	_	JJ	O	-1	none	_	_
23	cytoplasmic	_	_	JJ	O	-1	none	_	_
24	tail	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	transformation	_	_	NN	O	-1	none	_	_
3	effector	_	_	NN	O	-1	none	_	_
4	site	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	TES1	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	located	_	_	JJ	O	-1	none	_	_
10	within	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	membrane	_	_	NN	O	-1	none	_	_
13	proximal	_	_	JJ	O	-1	none	_	_
14	45	_	_	CD	O	-1	none	_	_
15	residues	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	cytoplasmic	_	_	JJ	O	-1	none	_	_
19	tail	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	constitutively	_	_	RB	O	-1	none	_	_
22	engages	_	_	VBZ	O	-1	none	_	_
23	tumor	_	_	NN	O	-1	none	_	_
24	necrosis	_	_	NN	O	-1	none	_	_
25	factor	_	_	NN	O	-1	none	_	_
26	receptor	_	_	NN	O	-1	none	_	_
27	associated	_	_	VBN	O	-1	none	_	_
28	factors	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Signals	_	_	NNS	O	-1	none	_	_
2	from	_	_	IN	O	-1	none	_	_
3	TES1	_	_	NN	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	sufficient	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	drive	_	_	VB	O	-1	none	_	_
8	initial	_	_	JJ	O	-1	none	_	_
9	proliferation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	infected	_	_	JJ	O	-1	none	_	_
12	resting	_	_	VBG	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	most	_	_	JJS	O	-1	none	_	_
18	lymphoblastoid	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	infected	_	_	VBN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	virus	_	_	NN	O	-1	none	_	_
24	that	_	_	WDT	O	-1	none	_	_
25	does	_	_	VBZ	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	express	_	_	VB	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	155	_	_	CD	O	-1	none	_	_
30	residues	_	_	NNS	O	-1	none	_	_
31	beyond	_	_	IN	O	-1	none	_	_
32	TES1	_	_	NN	O	-1	none	_	_
33	fail	_	_	VBP	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	grow	_	_	VB	O	-1	none	_	_
36	as	_	_	IN	O	-1	none	_	_
37	long-term	_	_	JJ	O	-1	none	_	_
38	cell	_	_	NN	O	-1	none	_	_
39	lines	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	find	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	mutating	_	_	VBG	O	-1	none	_	_
6	two	_	_	CD	O	-1	none	_	_
7	tyrosines	_	_	NNS	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	isoleucine	_	_	NN	O	-1	none	_	_
11	at	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	carboxyl	_	_	NN	O	-1	none	_	_
14	end	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	cytoplasmic	_	_	JJ	O	-1	none	_	_
18	tail	_	_	NN	O	-1	none	_	_
19	cripples	_	_	NNS	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	ability	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	EBV	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	cause	_	_	VB	O	-1	none	_	_
26	lymphoblastoid	_	_	JJ	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	outgrowth	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	thereby	_	_	RB	O	-1	none	_	_
31	marking	_	_	VBG	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	second	_	_	JJ	O	-1	none	_	_
34	transformation	_	_	NN	O	-1	none	_	_
35	effector	_	_	NN	O	-1	none	_	_
36	site	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	TES2	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	yeast	_	_	NN	O	-1	none	_	_
3	two-hybrid	_	_	JJ	O	-1	none	_	_
4	screen	_	_	NN	O	-1	none	_	_
5	identified	_	_	VBD	O	-1	none	_	_
6	TES2	_	_	NN	O	-1	none	_	_
7	interacting	_	_	VBG	O	-1	none	_	_
8	proteins	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	including	_	_	VBG	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	tumor	_	_	NN	Protein	19	multitoken	_	_
13	necrosis	_	_	NN	Protein	19	multitoken	_	_
14	factor	_	_	NN	Protein	19	multitoken	_	_
15	receptor	_	_	NN	Protein	19	multitoken	_	_
16	associated	_	_	VBN	Protein	19	multitoken	_	_
17	death	_	_	NN	Protein	19	multitoken	_	_
18	domain	_	_	NN	Protein	19	multitoken	_	_
19	protein	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	TRADD	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	TRADD	_	_	NN	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	only	_	_	JJ	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	interacted	_	_	VBD	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	wild-type	_	_	JJ	O	-1	none	_	_
10	TES2	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	isoleucine	_	_	NN	O	-1	none	_	_
15	mutated	_	_	VBN	O	-1	none	_	_
16	TES2	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	TRADD	_	_	NN	Protein	-1	none	_	_
2	associated	_	_	VBN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	wild-type	_	_	JJ	O	-1	none	_	_
5	LMP1	_	_	NN	Protein	-1	none	_	_
6	but	_	_	CC	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	isoleucine	_	_	NN	O	-1	none	_	_
10	mutated	_	_	VBN	O	-1	none	_	_
11	LMP1	_	_	NN	Protein	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	mammalian	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	TRADD	_	_	NN	Protein	-1	none	_	_
18	constitutively	_	_	RB	O	-1	none	_	_
19	associated	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	LMP1	_	_	NN	Protein	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	EBV	_	_	NN	O	-1	none	_	_
24	transformed	_	_	VBN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	transfection	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	TRADD	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	TES2	_	_	NN	Protein	-1	none	_	_
8	synergistically	_	_	RB	O	-1	none	_	_
9	mediated	_	_	VBD	O	-1	none	_	_
10	high-level	_	_	JJ	O	-1	none	_	_
11	NF-kappaB	_	_	NN	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	LMP1	_	_	NN	Protein	-1	none	_	_
6	appropriates	_	_	VBZ	O	-1	none	_	_
7	TRADD	_	_	NN	Protein	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	enable	_	_	VB	O	-1	none	_	_
10	efficient	_	_	JJ	O	-1	none	_	_
11	long-term	_	_	JJ	O	-1	none	_	_
12	lymphoblastoid	_	_	JJ	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	outgrowth	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	High-level	_	_	JJ	O	-1	none	_	_
2	NF-kappaB	_	_	NN	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	appears	_	_	VBZ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	critical	_	_	JJ	O	-1	none	_	_
10	component	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	long-term	_	_	JJ	O	-1	none	_	_
13	outgrowth	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_
